{"title": "PDF", "author": "PDF", "url": "https://minerva.usc.es/xmlui/bitstream/10347/9787/1/rep_575.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a01 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \nUNIVERSIDAD DE SANTIAGO DE COMPOSTELA \n \nFacultad de Farmacia \nDepartamento de Qu\u00edmica Org\u00e1nica \n \n \n \n \n \nCumarinas: Versatilidad estructural y \naplicaciones en Qu\u00edmica Farmac\u00e9utica  \n \nColaboraci\u00f3n con el Departamento de Qu\u00edmica y Bioqu\u00edmica de la Facultad de \nCiencias de la Universidad de Porto \u2013 Portugal \n \n \n \n \nMemoria para optar al t\u00edtulo de \nDoctora en Farmacia presenta \n \nMaria Jo\u00e3o Correia Pinto Carvalho de Matos Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a03 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0D. Maria Fernanda Martins Borges, Profesora Asociada de Qu\u00edmica Org\u00e1nica \nde la Universidad de Porto y D. Eugenio Uriarte Villares, Catedr\u00e1tico de \nQu\u00edmica Org\u00e1nica de la Universidad de Santiago de Compostela  \nCERTIFICAN \n \nQue la  Memoria titulada \u201cCumarinas: Versatilidad estructural y aplicaciones \nen Qu\u00edmica Farmac\u00e9utica\u201d, que para optar al grado de Doctora en Farmacia presenta MARIA JO\u00c3O CORREIA PINTO CARVALHO DE MATOS, ha sido \nrealizada bajo nuestra direcci\u00f3n, en el Departamento de Qu\u00edmica y Bioqu\u00edmica \nde la Facultad de Ciencias de la Universidad de Porto y en el Departamento de \nQu\u00edmica Org\u00e1nica de la Facultad de Farmacia de la Universidad de Santiago \nde Compostela. \n \nY considerando que el trabajo constituye tema y labor de Tesis Doctoral, \nautorizamos su presentaci\u00f3n en la Universidad de Santiago de Compostela.  \n \nY para que conste, expedimos el presente certificado en Santiago de \nCompostela a 27 de mayo de dos mil trece.  \n                     \n  \n  \nFdo. Maria Fernanda Martins Borges         Fdo. Eugenio Uriarte Villares  \n Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a05 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n \n \n  \n \n \n \n \n \n \n \n \n \n \n \nA mis queridos padres  \ny a mi querido Jose  Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a07 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n \n \n \n    \n \n   \n \n   \n \n   \n \n   \n \n \n\"A ci\u00eancia desenha a onda;  \na poesia enche-a de \u00e1gua.\"  \n \nTeixeira de Pascoaes  \n(1877 -1952) \n Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a09 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Agradecimientos  \n \n\u201cI'm a great believer in luck, and I find the harder I work the more I have of it.\u201d  \nThomas Jefferson  \n \nCuando he empezado esta aventura, no ten\u00eda ni idea de lo bonito que iba a \nser recorrer este camino\u2026 ni tampoco de todo aquello que iba a significar para \nm\u00ed a nivel profesional y personal. A Lourdes y Eugenio, que han dado todo el \napoyo a mi proyecto, tengo que darles las gracias por estar ah\u00ed en todo el \nmomento\u2026 pero sobre todo por el cari\u00f1o y amistad con que me han acogido desde el primer d\u00eda. A Profesora Fer nanda por apoyar este proyecto y por su \ndinamismo y sus consejos.  Por todas las agradables reuniones gastron\u00f3micas \nen la frontera, tambi\u00e9n compartidas con Alexandra.  Al Profesor Gianni Podda \npor la oportunidad de realizar una parte de este trabajo en su gr upo y por su \ndisponibilidad en el tiempo que he pasado en Italia. A mis compa\u00f1eros de \nlaboratorio, en particular a Andr\u00e9, Carmen Picciau  (por todos los buenos \nmomentos que pasamos juntas en Cagliari) ,  Chachy, Eduardo, El\u00edas, Fran, \nHumber, Gabriele, Giovanna (por todos los buenos momentos que pasamos \njuntas en Cagliari) , Giovanni, Giulio, Javi, Jose, Ricci, Santi, Silvia, Silvana \u2026, \nque han estado ah\u00ed todos los d\u00edas. Una palabra especial para Saleta, amiga y compa\u00f1era de viajes, de charlas en el caf\u00e9, de  debates cient\u00edficos y de todos \nlos d\u00edas. Recuerdo tambi\u00e9n con mucho cari\u00f1o todos los j\u00f3venes investigadores que han trabajado conmigo en sus proyectos de tesina, de master y doctorado: \nVeronika, Carla, Carmen, Jo\u00e3o, Juliana, Eleonora, Alessandra, Mar\u00eda, R ita, \nNiccol\u00f2, Andrea \u2026 por todo el esfuerzo y dedicaci\u00f3n. Todo este proyecto no \npodr\u00eda existir sin los compa\u00f1eros de Farmacolog\u00eda, y de una forma muy \nespecial Dolo (adem\u00e1s de por su amistad, por los ensayos biol\u00f3gicos y por la \nvaliosa ayuda en la parte farmacol\u00f3gica) y Paco Orallo ( en memoria), por tanto \n\u00e1nimo que ha dado a este proyecto. Tambi\u00e9n merecen especial referencia todos los profesores que proporcionaron sus medios para colaborar con nosotros en los ensayos biol\u00f3gicos: Prof. Ysa Santos y Prof. Angeles Mu\u00f1oz, \nProf. Marcella Corda y Prof. Antonella Fais, Prof. Ana Maria Brett, Prof. Claudio Olea y Prof. Karl-Norbert Klotz. Un agradecimiento especial a los amigos de \nCuba, Kike y Estela, por todo el cari\u00f1o y amistad y por el trabajo compartido. \n9Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a010 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Merece tambi\u00e9n un agradecimiento especial Xos\u00e9, nuestro t\u00e9cnico, que \nsiempre ha tenido disponibilidad para todo el apoyo t\u00e9cnico que hemos \nnecesitado al largo de este proyecto.  \nPor todo el apoyo, cari\u00f1o, \u00e1nimo y amor, un agradecimiento muy especial a \nJose, por estar ah\u00ed siempre\u2026 Nada hubiese sido igual sin los amigos. Los que \nhan estado m\u00e1s cerca, y aquellos que de lejos han dado todo su \u00e1nimo a este \nproyecto. Por Santiago han estado Tati, mi compa\u00f1era de piso, de fiestas, de \ntrabajo, de todos los momentos y mi AMI GA. Sin ella nada hubiese sido lo \nmismo. Tambi\u00e9n Rosa, mi dulce amiga de siempre, de todos los momentos . Y \nAna Carro, con su sonrisa dulce y sus palabras amigas. Tambi\u00e9n son parte fundamental de este proyecto muchos otros amigos especiales que descubr\u00ed en Santiago\u2026 mi Ana Mag\u00e1n y mi Calili, por todos los buenos momentos juntos\u2026 Tambi\u00e9n Pili y su peque\u00f1o Noel, Marga, Esteban, Graciela, Valentina, Cris, \nJoana, Carmen y Santi, Sofia y Bruno, Pedro, Luchi y Bego (\u2026) y tantos, tantos \notros que han hecho parte de mi camino todos estos a\u00f1os\u2026 Y con especial \ncari\u00f1o a mis compa\u00f1eras de danza y claqu\u00e9, Salom\u00e9 (adem\u00e1s de tantas otras \ncosas, compartimos tambi\u00e9n esta pasi\u00f3n), Pilar, Natalia, Yana, Leo, Archana,  \nMarta, y mi querida Gail. A todos los compa\u00f1eros de las clases de fotograf\u00eda y \ndel fotoforum, por lo bien que lo pasamos.  En especial Paola, Mino, Marcos y \nManuel, los MMMM&P. Y del curso de innovaci\u00f3n, por los proyectos y \naventuras en que no metimos. Un poco m\u00e1s lejos, pero siempre cerca, mis \nni\u00f1as: Rita, Raquel y su peque\u00f1a Pipa, Isa, Vanessa, Daniela, Cristina, \nCarolina, Diana, Mariana, Aninhas, Eva y Catarina. Las amigas para quien no hay distancia ni ausencia\u2026 Y los ni\u00f1os: Miguel, Helder, J o\u00e3o, Tiago,  Pedro, \nZ\u00e9\u2026 \nUno de los principales apoyos todos estos a\u00f1os han sido mi madre Maria \nCristina y mi padre Manuel Jo\u00e3o, que son quienes m\u00e1s sienten y valoran todas \nmis peque\u00f1as victorias. Es por ellos todo el esfuerzo y toda la dedicaci\u00f3n. Tambi\u00e9n merecen todo mi agradecimiento mi hermana Ana (ahora doblemente \npor nuestro peque\u00f1o Bernardo , mi ahijado m\u00e1s lindo! ), que siempre ha sido mi \nejemplo, mi hermano peque\u00f1o Henrique, que es la luz de mis ojos y el abrazo \nm\u00e1s dulce, y mi cu\u00f1ado Z\u00e9. Por tanto amor\u2026 Y  mis queridos abuelos y \npadrinos Mil\u00fa y Edgardo ( en memoria), por el amor que me han dado toda mi \nvida... y por los buenos momentos que pasamos juntos cuando compartimos \n10Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a011 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0piso en algunos de mis a\u00f1os de facultad\u2026 Tambi\u00e9n mi abuelo Jorge ( en \nmemoria), un ejemplo de fuerza y alegr\u00eda de vivir. A mis primas Mafalda y \nRaquel, y mis t\u00edos, Luisa y Pedro, por tanto cari\u00f1o y amistad. Y Margarida y \nAng\u00e9lica, porque tambi\u00e9n son mi familia. Tambi\u00e9n formaron parte de este \nproyecto mi nueva familia de Santiago: Carmen y Ram\u00f3n, mi s cu\u00f1adas Marta, \nEva y Silvia y mis cu\u00f1ados Alberto, Carlos y Tito, y mis dos sobris m\u00e1s lindos Ahinara y Hugo. Una referencia especial a mis primeros amigos espa\u00f1oles  \nGolla, Nano, Gloria y Fernando, porque tambi\u00e9n ellos son mi familia.  \nNo puedo olvidar mis compa\u00f1eros de carrera de Coimbra y de Porto\u2026 por \ntodos los buenos momentos que pasamos juntos. Y todos mis viejos y nuevos \namigos, que han estado siempre presentes y me han apoya do en todas mis \naventuras!\u2026 Esta tesis tiene un poco de todos aquellos que l lenaron mi vida y \nhan dado sentido a todo este proyecto\u2026 en Santiago, en Cagliari, en \nEsposende, en Coimbra, en Porto y por todos los sitios donde deje un poco de \naquello que hoy soy.  \nPor ultimo, un agradecimiento muy especia l a la Funda\u00e7\u00e3o para a Ci\u00eancia e \nTecnologia por haber financiado este proyecto (SFRH/BD/61262/2009). \n \n11Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a013 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Resumen  \nEn esta Memoria se describe un trabajo de dise\u00f1o, s\u00edntesis y evaluaci\u00f3n \nfarmacol\u00f3gica de derivados cumarin\u00edcos de diferente complejidad, mostrando  la \nversatilidad qu\u00edmica de este esqueleto y algunas de sus aplicaciones en la \nQu\u00edmica Farmac\u00e9utica. En esta Memoria se hace una selecci\u00f3n del trabajo \nglobal realizado, mostrando un conjunto de 134  compuestos que han sido los \npublicados hasta este momento de un total de m\u00e1s de 500. Todos ellos \nincorporan en una sola estructura el n\u00facleo de la cumarina y del estilbeno, o \nbien de la cumarina y funciones de tipo \u00e9ster, amida o carbamato. \nModificaciones sencillas de estos esqueletos han permitido adem\u00e1s la obtenci\u00f3n de compuestos con diferentes sustituyentes (\u00e1tomos de bromo o \ncloro, y/o grupos metilo, metoxilo, etoxilo, hidroxilo, nitro, amino, etc) en \ndiversas posiciones de las mol\u00e9culas. La s\u00edntesis de estos compuestos, con \npureza y en cantidad suficiente par a sus ensayos farmacol\u00f3gicos, se ha \nrealizado utilizando metodolog\u00edas directas, eficientes y generalizables. Se presentan los resultados obtenidos en la posterior evaluaci\u00f3n farmacol\u00f3gica de \nestos derivados como inhibidores enzim\u00e1 ticos (MAO-A, MAO-B, AChE y \ntirosinasa), ligandos de adenosina, antioxidantes y antimicrobianos. La \nselecci\u00f3n de los mismos se hizo teniendo en cuenta el conocimiento previo ayudado por herramientas de dise\u00f1o racional (QSAR y docking) y se obtuvieron \nmuy buenos resultados en todos los campos estudiados.  \n   \n \n   \n \n   \n13Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a015 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Summary  \nThis Report describes a work of design, synthesis and pharmacological \nevaluation of coumarin derivatives of varying complexity, showing the chemical \nversatility of this skeleton and some of its applications i n Pharmaceutical \nChemistry. In this Report it was made a selection of the overall work done, \nshowing a set  of 134 compounds that have been published so far, of a total of \nmore than 500 compounds. All incorporated in a single structure the core of the \ncoumarin and the stilbene, or the core of the coumarin and ester, amide or \ncarbamate functions. Simple modifications of t hese skeletons have also allowed  \nthe preparation of compounds with different substituents  (chlorine or bromine \natoms and/or methyl, methoxy, ethoxy, hydroxyl, nitro and amino groups, etc.) \nin different positions of the molecules. The synthesis of these compounds, in \npurity and in sufficient quant ity to its pharmacological evaluation,  was performed \nusing direct, efficient, and generalizable  methodologies . In this Report there are \npresented the results of the subsequent pharmacological evaluation of these \nderivatives as enzyme inhib itors (MAO-A MAO-B, AChE and tyrosinase), \nadenosine ligands, antioxidants and antimicrobials. The selection of these derivatives was made taking into account prior knowl edge helped by rational \ndesign tools (QSAR and docking) and there were obtained very good results in \nall the studied areas. \n     \n \n   \n \n   \n15Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a017 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n \n   \n \n   \n \n   \n \n   \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nI. \u00cdndice  Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a019 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a01. Introducci\u00f3n 21 \n1.1. Estructuras qu\u00edmicas 26 \n1.1.1. Las cumarinas  26 \n1.1.1.1. Actividad biol\u00f3gica de las cumarinas 29 \n1.1.1.2. S\u00edntesis de cumarina 34 \n1.1.2. Los estilbenos (resveratrol) 37 \n1.2. Enfermedades neurodegenerativas 41 \n1.2.1. Enfermedad de Parkinson (EP) 42 \n1.2.2. Enfermedad de Alzheimer (EA) 46 \n1.3. Principal diana farmacol\u00f3gica en la Memoria - MAOs 47 \n1.3.1. Cumarinas y las MAOs  52 \n2. Antecedentes y objetivos 57 \n2.1. Antecedentes 59 \n2.2. Objetivos 61 \n3. Discusi\u00f3n de resultados 65 \n3.1. S\u00edntesis 68 \n3.1.1. Preparaci\u00f3n de los esqueletos cumar\u00ednicos 68 \n3.1.1.1. Reacci\u00f3n de Perkin y Perkin-Oglialoro  68 \n3.1.1.2. Reacci\u00f3n de acoplamiento con paladio 69 \n3.1.2. Transformaciones funcionales 69 \n3.1.2 .1. Reacci\u00f3n de hidr\u00f3lisis de grupos \u00e9ter o \u00e9ster 69 \n3.1.2.2. Reacci\u00f3n de halogenaci\u00f3n  70 \n3.1.2.3. Reacci\u00f3n de formaci\u00f3n de arilaminas 71 \n3.1.2.4. Reacci\u00f3n de alquilaci\u00f3n \u2013 reacci\u00f3n de Williamson  72 \n3.1.2.5. Preparaci\u00f3n de amidas, \u00e9steres y carbamatos 73 \n3.1.3. Series de compuestos sintetizados 73 \n3.2. Estudio biol\u00f3gico y relaci\u00f3n estructura-actividad (REA) 79 \n3.3. Aportaciones estructurales y te\u00f3ricas 81 \n4. Parte experimental 83 \n4.1. Art\u00edculos publicados 85 \n4.2. Art\u00edculos en fase de publicaci\u00f3n 87 \n6. Concl usiones  \u0016\u0015\u0018\n7. Bibliograf\u00eda \u0016\u0015\u001c \n19Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a021 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n \n \n1. Introducci\u00f3n Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a023 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Desde siempre el Hombre ha intentado solucionar los  problemas que iban \nsurgiendo en su vida cotidiana. Con  la necesidad de curar las enfermedades \nque le han afectado, el Hombre ha desarrollado preparaciones \nmedicamentosas utilizando a lo largo de los tiempos aquellas estrategias que \nmejor serv\u00edan este objetivo. Hasta el siglo XVIII, la conocida como \u201cera de los \nbot\u00e1nicos\u201d,1 las preparaciones de uso farmac\u00e9utico eran, en la gran mayor\u00eda de \nlos casos, obtenidas de plantas, en forma de pociones. El descubrimiento de \nnuevas drogas y tratamientos estaba basado en la utilizaci\u00f3n de esas mismas \nplantas y otros productos naturales seg\u00fan la intuici\u00f3n y la observaci\u00f3n emp\u00edrica, siendo el \u201cazar\u201d el principal factor de \u00e9xito. M\u00e1s tarde, siglo XIX, \npuede entenderse como el comienzo de la era de los medicamentos, se \nempezaron a aislar, purificar e identificar las  sustancias activas como las \nentidades responsables de la acci\u00f3n de los extractos naturales y \nposteriormente la \u201cera industrial\u201d ha transformado la producci\u00f3n de nuevos f\u00e1rmacos. El siglo XX, se inicia con la intro ducci\u00f3n del salvars\u00e1n o \u201cbala \nm\u00e1gica\u201d de Paul Ehrlich en el tratamiento de la s\u00edfilis, y con la utilizaci\u00f3n de la aspirina en terap\u00e9utica. La introducci\u00f3n de nuevas t\u00e9cnicas de elucidaci\u00f3n \nestructural ha permitido el desarrollo de nuevas metodolog\u00edas de s\u00ed ntesis como \nestrategia para el descubrimiento de nuevos f\u00e1rmacos y da paso a la denominada \u201cedad de oro\u201d de los medicamentos durante el per\u00edodo 1940 -1960 \ngracias a la introducci\u00f3n de una gran mayor\u00eda de clases f\u00e1rmaco -terap\u00e9uticas \nque hoy d\u00eda constituyen f \u00e1rmacos de gran inter\u00e9s tales como los antibi\u00f3ticos y \njunto con ellos el concepto de medicina preventiva y la vacunaci\u00f3n. Las Ciencias Farmac\u00e9uticas se separaron de las Ciencias M\u00e9dicas y surgieron nuevas \u00e1reas de conocimiento que transformaron la Farmacia  en un conjunto \nmultidisciplinar de saberes. El crecimiento ha sido exponencial y \u00e1reas como la \nFarmacolog\u00eda, la Biolog\u00eda,  la Fisiolog\u00eda, la Biolog\u00eda Molecular, la Gen\u00e9tica y la \nQu\u00edmica pasaron a coordinarse en un intento de dilucidar los mecanismos de \nacci\u00f3n de los f\u00e1rmacos y establecer las relaciones la estructura y la actividad farmacol\u00f3gica de los mismos. La modificaci\u00f3n estructural sobre un compuesto \ncabeza de serie y/o la b\u00fasqueda de nuevos prototipos pas\u00f3 a ser uno de los \naspectos m\u00e1s estudiados\n2 con un objetivo claro: mejorar el \u00edndice terap\u00e9utico \nde los f\u00e1rmacos, es decir aumentar la actividad y/o disminuir su toxicidad y efectos adversos. \n23Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a024 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0El desarrollo de metodolog\u00edas sint\u00e9ticas, de an\u00e1lisis estructural o te\u00f3ricas \ncomo el QSAR y el docking, entre otras, han a\u00f1adido un valor adicional a las \nCiencias Farmac\u00e9uticas permitiendo un dise\u00f1o m\u00e1s racional de f\u00e1rmacos y la \nproducci\u00f3n a gran escala.3 La expansi\u00f3n tecnol\u00f3gica y el recurso a medios de \ninformaci\u00f3n r\u00e1pidos y asequibles, han tra\u00eddo progresos incre \u00edbles a un \u00e1rea \nconocida por su dinamismo.  \nR\u00e1pidamente se ha percibido un cambio radical en la industria farmac\u00e9utica, \nque es hoy en d\u00eda una de las que m\u00e1s presupuesto invierte a nivel  mundial. La \ninnovaci\u00f3n se ha transformado en el objetivo n\u00famero uno de las empresas: \nideas que sean rentables y sostenibles. Todo esto conlleva sin duda ventajas  y \ndesventajas. Existen muchos casos de las conocidas como enfermedades \nolvidadas que afectan a millones de personas y que, por su bajo aporte econ\u00f3mico versus elevado gasto en investigaci\u00f3n y desarrollo, son tambi\u00e9n \nolvidadas por la industria farmac\u00e9utica. En su mayor\u00eda se trata de \nenfermedades tropicales infecciosas que afectan fundament almente a la \npoblaci\u00f3n m\u00e1s empobrecida , como por ejemplo la leishmaniosis, la \ntuberculosis, la enfermedad del sue\u00f1o, la malaria o  la enfermedad de Chagas, \nque generan un impacto devastador en la humanidad.  \nEl descubrimiento de f\u00e1rmacos se considera una actividad compleja y lenta. \nSin embargo, en las \u00faltimas d\u00e9cadas, se est\u00e1n desarrolla ndo nuevos enfoques \ny m\u00e9todos con la intenci\u00f3n de descubrir nuevas entidades qu\u00edmicas de  un \nmodo nuevo y m\u00e1s eficiente nuevos paradigmas han tomado fuerza, como el conocimiento claro de la relaci\u00f3n mol\u00e9cula -receptor, de mecanismos \nmoleculares/celulares implicados en las enfermedades o de modelos \nprecl\u00ednicos que mimetizan de forma m\u00e1s real los procesos bioqu\u00edmicos y patol\u00f3gicos o de marcadores que monitorizan los efectos terap\u00e9uticos . Todas \nestas herramientas constituyen un buen soporte para la obtenci\u00f3n m\u00e1s  eficaz \nde nuevos f\u00e1rmacos m\u00e1s eficaces y seguros.\n4 Los qu\u00edmicos farmac\u00e9uticos, o \nqu\u00edmicos medicinales, presentan un  papel importante en todo este proceso de \ncambio. Est\u00e1 en sus manos el conocimiento general de diferentes \u00e1reas que \npermiten el desarrollo de nuevos f\u00e1rmacos. Y su principal ventaja viene de la \ncapacidad de adaptaci\u00f3n que los caracteriza.5 Por otro lado, tambi\u00e9n la \norganizaci\u00f3n de la forma de trabajo de los investigadores viene cambiando en los \u00faltimos a\u00f1os. Muchos cient\u00edficos est\u00e1n trabajando  en fundaciones para la \n24Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a025 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0investigaci\u00f3n, centros paralelos a la universidad y compa\u00f1\u00edas virtuales, y  han \nsurgido nuevas colaboraciones entre grupos de trabajo de universidades e \nindustria. Este aumento de la \u201clibertad de trabajo\u201d y de movilidad hace emerger \nimportantes expectativas para el desarrollo de f\u00e1rmacos. Por otra parte, se \nest\u00e1n llevando a cabo inversiones significativas en cuanto a espacios \nmodernos, nuevos equipamientos, y personal, en el sentido de aprovechar todo \nsu potencial.4 \nSin embargo, esta tendencia positiva de cambios en investigaci\u00f3n y \ndesarrollo de f\u00e1rmacos no se extiende de forma global a la industria \nfarmac\u00e9utica, y la cada vez m\u00e1s baja productividad medida en funci\u00f3n del \nn\u00famero de nuevos f\u00e1rmacos aprobados por la FDA, limitan de manera muy notable la contrataci\u00f3n de nuevos investigadores.\n6 \n \n25Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a026 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a01.1. Estruc turas qu\u00edmicas  \n \n1.1.1.  Las cumarinas  \n \nLas cumarinas son una gran clase de lactonas, de origen natural o s int\u00e9tico, \nconstituidas por un anillo de benceno condensado a una anillo \u03b1-pirona (Figura \n1), y esencialmente poseen un sistema \u03c0-\u03c0 conjugado rico en electrones, que \nposee buenas propiedades de transporte de carga.7,8 \nEl primer representante de esta familia ha sido aislado por Vogel en el a\u00f1o \nde 1820, del haba de la tonka,  cuyo nombre com\u00fan en Caribe es cumaru, que  \nha dado nombre a esta familia de compu estos. Esta especie de haba es \ndesignada en el sistema binominal por Coumarona odorata Aube (tambi\u00e9n \nconocida por Dipteryx odorata Willd) .8 Dicha estructura qu\u00edmica es denominada \nseg\u00fan la IUPAC como 2H-cromen-2-ona.  \n \nO O234 5\n6\n7\n8\n \nFigura 1. 2H-1-benzopiran- 2-ona o 2H -cromen -2-ona (cumarina).  \n \nLas cumarinas se producen de forma natural en plantas y microorganismos, \ny se han aislado aproximadamente 1000 derivados de m\u00e1s de 800 especies \n(ejemplos en la Figura 2).  \n \n     \n  \nFigura 2. Angelica archangelica  L. y Psoralea corylifolia. \t\r \u00a0\n \n26Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a027 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0En la naturaleza las cumarinas pueden encontrar se en ra\u00edces, hojas, flores o \nfrutos de diferentes familias de las Angiospermas, tales  como Apiaceae, \nRutaceae, Asteraceae, Umbelliferae, entre otras (Figura 3).7 \n \n \nFigura 3. Cumarinas existentes en las principales familias de  Angiospermas. \t\r \u00a0\n \nEl esqueleto cumar\u00ednico se originan biosint\u00e9ticamente por lactonizaci\u00f3n del \n\u00e1cido cumar\u00ednico (2-hidroxi-Z-cin\u00e1mico), seg\u00fan la v\u00eda s int\u00e9tica descrita en la \nFigura 4.8 La bios\u00edntesis de cumarinas en las plantas superiores empieza con \nuna reacci\u00f3n de 2- o bien 2,4-hidroxilaci\u00f3n del \u00e1cido cin\u00e1mico. Los \nhidroxicin\u00e1micos formados son posteriormente glucosilados y como tal se \nisomerizan posteriormente a los is\u00f3meros E. La ciclaci\u00f3n posterior de los \nmismos origina finalmente la cumarina o  su 7-hidroxi derivado, la umbeliferona. \nOtros derivados de la cumarina, tales como esculetina (6,7 -dihidroxicumarina) o \nescopoletina (7-hidroxi-6-metoxicumarina) parecen derivar de la o xidaci\u00f3n de la \numbeliferona y no a partir del correspond iente derivado de \u00e1cido \nhidroxicum\u00e1rico. (Figura 4).9 \n \nCOOH COOH\n\u00c1cido trans -cinamicoOH\n\u00c1cido o-cumaricoCOOH\nO-Glu\nGluc\u00f3 sido do \u00e1 cido o-cumarico\nO-Glu\nGluc\u00f3 sido do \u00e1 cido o-cumaricoCOOH\nO O\nCumarina  \nFigura 4. Esquema general de la bios\u00edntesis de la cumarina.  \n \n27Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a028 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Las cumarinas son, en general, solubles en alcoholes y disolventes \norg\u00e1nicos. Son lactonas y como tales en un medio alcalino sufren hidr\u00f3lisis con \nformaci\u00f3n de sales y solubilizaci\u00f3n de la misma.  Pueden someterse de nuevo \nal cierre del anillo de pirona en condiciones \u00e1cidas. Presentan un espectro \nultravioleta (UV) caracter\u00edstico, que es fuertemente influenciado por sus \nsustituyentes. Presentan fluorescencia a la luz UV de coloraciones entre azul, \namarillo o morado y que se intensifican en presencia de vapor es de \namon\u00edaco.10  \nLa diversidad estructural de los compuestos derivados de las cumarinas \npermite su clasificaci\u00f3n en cumarinas simples, o bien en cumarinas m\u00e1s complejas en general condensadas con otros heterociclos: furocumarinas, piranocumarinas, biscumarinas, cumarinolignanos y triscumarinas.\n11 \nEn cualquier caso, sobre  la estructura base de la cumarina se pueden \nintroducir sustituyentes de distinta naturaleza, lo que lleva a que existan \ncumarinas12 que pueden ser utilizadas, seg\u00fan el tipo de sustituyentes que \nposeen, con diversas finalidades: aditivos alimentarios, perfumes, cosm\u00e9ticos, productos agroqu\u00edmicos o bien como f\u00e1rmacos con la finalidad de estudiar, \nmejorar y ampliar el espectro de su actividad terap\u00e9utica.\n13,14,15,16 \nEl anillo cumar\u00ednico tiene la capacidad de establecer diverso tipo de \ninteracciones no covalentes  que incluyen interacciones hidr\u00f3fobas, \u03c0-\u03c0 y \nelectrost\u00e1ticas, as\u00ed como enlaces de hidr\u00f3geno, fuerzas de van der Waals, \nentre otras, con otras mol\u00e9culas activas y el sitio de activo en diferentes dianas \nde organismos vivos. As\u00ed, estas mol\u00e9culas presentan eficacia en una amplia \ngama de actividades biol\u00f3gicas. Las cumarinas  presentan inter\u00e9s \nfarmacol\u00f3gico como anticoagulantes, antioxidant es, antivirales, inhibidores \nenzim\u00e1ticos y antibacterianos. Adem\u00e1s, la caracter\u00edstica \u00fanica de contener \nox\u00edgeno en el anillo de lactona tambi\u00e9n puede hacer de estas mol\u00e9culas un tipo \nde ligandos ideales para producir ensamblaje supramolecular y, por lo tan to, \nnaturalmente, ser empleado en el dise\u00f1o racional y la s\u00edntesis de supramol\u00e9culas como agentes medicinales, en particular en los campos \nantibacteriano y antif\u00fangico, en que han demostrado ya un papel importante al \nque se ha prestado mucha atenci\u00f3n en lo s \u00faltimos a\u00f1os.  Adem\u00e1s, las \nexcelentes capacidades fluorescentes de los compuestos derivados de la cumarina basadas en las propiedades de riqueza en electrones y las \n28Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a029 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0propiedades de un buen transporte de carga favorecidas por un sistema \nconjugado \u03c0-\u03c0, las hace interesantes como receptores  artificiales de iones, \nsondas fluorescentes para especies biol\u00f3gicamente importantes y marcadores \nbiol\u00f3gicos para supervisar la actividad de enzimas, complejos eventos biol\u00f3gicos, as\u00ed como detectores de propiedades farmacol \u00f3gicas y \nfarmacocin\u00e9ticas precisas.\n17 \n \n1.1.1 .1. Actividad biol\u00f3gica de las cumarinas  \n \nComo ya ha sido referido, desde hace mucho tiempo el estudio de diferentes \ngrupos de trabajo se ha dirigido a la separaci\u00f3n y purificaci\u00f3n de cumarinas de \norigen natural, a partir de una gran variedad de plantas, animales y \nmicroorganismos, as\u00ed como hacia la s\u00edntesis de nuevos derivados de las \ncumarinas con el objetivo de explorar un amplio espectro de actividades farmacol\u00f3gicas.\n18  \nDerivados de las cumarinas se encuentran en casi todas las categor\u00edas \nf\u00e1rmaco-terap\u00e9uticas. Algunas cumarinas han sido estudiada s por sus \npropiedades como cardioprotectores (anticoagulantes y/o vasodilatadores).19,20 \nUno de los casos m\u00e1s conocidos son la warfarina y el a cenocumarol, \nampliamente utilizados  en cl\u00ednica como anticoagulante s. El carbocromeno, \ntambi\u00e9n disponible en la terap\u00e9utica actual, es otro ejemplo de una conocida cumarina con actividad cardioprotectora , debido a su acci\u00f3n vasodilatadora\n e \ninhibidora de la agregaci\u00f3n plaquetaria (Figura 5 ).18 \nPor otra parte, la modulaci\u00f3n del anillo cumar\u00ednico, permite obtener \ninteresantes f\u00e1rmacos antiinflamatorios21,22 y/o antioxidantes23, sobre todo \ncuando sobre dicho anillo se introduce un anillo heteroarom\u00e1tico tipo pirazol  \n(Figura 5).24,25,26  \n \n29Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a030 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0O ONH3C\nCH3\nO\nOO H3C\nO OOHO\nCH3\nCarbocromeno\nCardioprotectores\nO ONNPh\nAr\nOHO O\nNHN\nAr\nAnti-inflamatorios y/o antioxidantesR = H  Warfarina\nR = NO 2 AcenocumarolR\n \nFigura 5.\t\r \u00a0Ejemplos de cumarinas con importancia terap\u00e9utica  como cardioprotectores, \nantiinflamatorios y antioxidantes . \n \nLos derivados hidroxilados de cumarinas y flavonoides, tales como la \numbeliferona y la esculetina (Figura 6 ), han sido descritos como inhibidores de \nla 5\u03b1 -reductasa y de la tirosinasa.27,28 \n \nO O HOR\nR = H  Umbeliferona\nR = OH  Esculetina  \nFigura 6. Estructuras de la umbeliferona y de la esculetina . \n \nEn otros casos, las cumarinas se han revelado como agentes antivirales. \nAs\u00ed, ha sido descrita una interesante actividad antivi ral HVC en cumarinas 3- \ny/o 4 -substituidas29,30,31,32,33,34 y m\u00e1s recientemente en sus  ribonucle\u00f3sidos \nconjugados.35 Por su parte, la condensaci\u00f3n de un anillo  pir\u00e1nico en el enlace h \nha permitido el dise\u00f1o de cumarinas an\u00e1logas de la suksdorfina, compuesto \nnatural con actividad anti-HIV  (Figura 7).36 \n \n30Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a031 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0OOO\nO\nON\nNNN\nO\nHOOHS\nHOO O\nOO\nSuksdorfinaAntivirales\nanti-HIVO OOH\nHOR\nR\n \nFigura 7. Cumarinas 3/4-sustituidas y an\u00e1logos tric\u00edclicos , compuestos con actividad antiviral. \t\r \u00a0 \n \nOtro campo farmacol\u00f3gico en el que destaca cada vez m\u00e1s el n\u00facleo \ncumar\u00ednico es en el de la terapia anti-c\u00e1ncer. La geiparvarina (Figura 8) es uno \nde los ejemplos de compuestos cumar\u00ednicos con inter\u00e9s en dicha \u00e1rea. Es un derivado natural aislado de la Geijera parvioflora Lindl, conocido por su \nactividad citost\u00e1tica en ensayos in vitro. El n\u00facleo furano de esta mol\u00e9cula ha \nprobado ser esencial para su actividad.  Por su parte, cumarinas tambi\u00e9n en \neste caso 3 y/o 4-aril/heteroaril substituidas se han descrito como buenos inhibidores de la tubulina.\n37,38 \nM\u00e1s recientemente, a partir de la importancia del  antimicrobiano \nnovobiocina,  se han desarrollado los primeros an\u00e1log os con actividad anti-\nc\u00e1ncer (Figura 8).39,40  \n \nOO OS\nO O OH\nN\nOAntineopl\u00e1 sicos\nO O OOO\nGeiparvarinaOCH 3\nOCH 3\nH3CNH3CO\nO\nAntimicrobianoHN\nOOH\nO OOHO\nOONH2\nNovobiocinaO OOH\n \nFigura 8. Geiparvarina y otros compuestos a nti-c\u00e1ncer . \n \n31Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a032 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Las propiedades antibacterianas de las cumarinas han sido descritas por \nprimera vez en 1945 por Goth y col. cuando se estudi\u00f3 el dicumarol.41 Es de \ndestacar la actividad antimicrobiana encontrada para diversas cumarinas tales \ncomo la ya mencionada novobiocina (Figura 8) y sus an\u00e1logos, la clorobiocina \ny la cumermicina A 1. La novobiocina, aislada de Streptomyces niveus, es \nprincipalmente activa frente a bacterias Gram -positivas, si bien no se utiliza en \nla cl\u00ednica debido sobre todo a sus  efectos secundarios y la dif\u00edcil solubilidad en \nagua.42 Por otro lado, estos tres ejemplos son antibi\u00f3ticos que presentan \nactividad contra Staphylococcus aureus  (S. aureus) resistente a meticilina \n(MRSA).43 El n\u00famero de bacterias resistentes a m\u00faltiples f\u00e1rmacos es cada vez \nmayor y de especial importancia es el caso de las bacterias Gram -positivas \nMRSA. La capacidad de muchas especies tales como el de S. aureus para \ndesarrollar resistencia a pr\u00e1cticamente todos los antibi\u00f3ticos es una \npreocupaci\u00f3n importante.44 Ello ha provocado el estudio de nuevos \nantimicrobianos sobre nuevas dianas terap\u00e9uticas y en este campo  han \nemergido estructuras cumar\u00ednicas que interaccionan con la DNA helicasa,45,46 y \nque son activas frente a cepas resistentes a la ciprofloxacina.47  \nAlgunos derivados de la cumarina han demostrado adem\u00e1s de  las \nactividades antibacterianas, actividades antif\u00fangicas .48 Un estudio de los \nderivados cumar\u00ednicos sustituidos en el anillo pirona (derivados 3 -carboxilados) \nmuestran tambi\u00e9n importantes actividades.49 Diferentes cumarinas 4-\nsustituidas, tal como las 4-clorocumarinas, mostraron tambi\u00e9n un interesante \nperfil antimicrobiano.50 \nPor otra parte, es tambi\u00e9n conocida la actividad antiparasitaria de \nestructuras derivadas de este anillo, y la creciente demanda de nuevos antiprotozoarios ha provocado la s\u00ed ntesis de nuevos f\u00e1rmacos de estructura \nflavonoide de lo s que destacamos la 8-(3-furil)cumarina, compuesto natural con \nactividad antileishmania,\n51 o las 3-cinamoilcumarinas con actividad \nantimalaria.52 En otros casos, aunque menos frecuentes, se han desarrollado 4 -\narilsulfonilmetilcumarinas con mar cada actividad tuberculost\u00e1tica (Figura 9).53,54 \n \n32Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a033 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0O\nOO\nO OO OH\nR\nAntimal\u00e1 ricos Antileismania Tuberculost\u00e1 ticosO OSO2\nAr\nR\n \nFigura 9. Mol\u00e9culas con actividad antimicrobiana.   \n \nAdem\u00e1s de las actividades farmacol\u00f3gicas mencionadas, merece una \nespecial consideraci\u00f3n la importancia del anillo cumar\u00ednico como prototipo estructural en el dise\u00f1o de nuevos inhibidores de sistemas enzim\u00e1ticos muy \ndirectamente implicados en el desarrollo las enfermedades \nneurodegenerativas.\n55,56 En 2006, se describi\u00f3 la actividad inhibidora de \ndiversas 6-amidocumarinas (Figura 10 ) sobre la \u03b2-secretasa (generalmente \nreferenciada como BACE 1) y su potencial uso en la terapia de la enfermedad de Alzheimer (EA).\n57 En el mismo a\u00f1o, se sintetizaron diver sas 8-\nsulfooxicumarinas (Figura 10) que parecen ser \u00fatiles en el tratamiento del \nestr\u00e9s oxidativo.58 Los inhibidores de la acetilcolinesterasa (AChE) han sido \ntambi\u00e9n ampliamente estudiados por el elevado inter\u00e9s de las cumarinas en enfermedades neurodegenerativas, en especial la EA.\n59 \n \nO OX\nNO\nN\nO O\nOSO 3HHOHO\n \nFigura 10. 6-Amidocumarinas y 8-sulfooxicumarinas, compuestos con  actividad como \ninhibidores enzim\u00e1tico s.  \n \nEn otros casos se han descr ito derivados cumar\u00ednicos multidiana con \nactividad inhibidora de la BACE 1 y de la AChE, ambas dianas de inter\u00e9s en la \nterapia de la EA (Figura 11).60 \n \n33Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a034 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0O OO\nO O H3COH3CON\nCH2CH3\nN\nHO\nF F\nN\nCH2CH3\n \nFigura 11. Compuestos multidiana  (BACE 1 y AChE).  \n \nComo ya ha sido descrito, son muchas m\u00e1s las aplicaciones relacionadas \ncon esta familia de mol\u00e9culas, sin embargo, la actividad farmacol\u00f3gica de las \ncumarinas m\u00e1s directamente relacionada con el presente trabajo es su acci\u00f3n \ninhibidora selectiva de la monoamino oxidasa B (MAO -B)59,60 y sus posibles \naplicaciones terap\u00e9uticas,61,62 encontr\u00e1ndose en los \u00faltimos a\u00f1os una \ninteresante actividad inhibidora de la MAO (IMAO) en algunos an\u00e1logos cumar\u00ednicos,\n63 an\u00e1logos a los que nos referiremos m\u00e1s adelante.  \nTeniendo en mente la etiolog\u00eda compleja de las enfermedades \nneurodegenerativas, y las diferentes dianas implicadas en ellas, tambi\u00e9n dedicaremos especial atenci\u00f3n en esta Memoria a la actividad inhibitoria dual MAO/AChE y a las propiedades antioxidantes de  las cumarinas. Tambi\u00e9n se \nhar\u00e1 una breve referencia a las cumarinas como ligandos de adenosina.  \n \n1.1.1 .2. S\u00edntesis de  cumarina  \n \nLa s\u00edntesis de cumarinas y de sus derivados es un \u00e1rea de gran y \npermanente inter\u00e9s por el gran n\u00famero de compuestos de esta familia y el \namplio espectro de actividades biol\u00f3gicas que presentan, tal y como se ha descrito anteriormente. En otros casos son muchas veces utilizadas como productos intermediarios en la s\u00edntesis de compuestos con po tencial inter\u00e9s \nfarmacol\u00f3gico\n64 tales como piranocumarinas,65 furocumarinas o 2-acil-\nresorcinoles.66,67  \nCl\u00e1sicamente han sido estudiados varios procesos de s\u00edntesis para la \nobtenci\u00f3n de estos derivados,68,69 y si bien los primeros m\u00e9todos presentaban \ndemasiados pasos y en general bajos rendimientos,70 hoy en d\u00eda las rutas \n34Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a035 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0sint\u00e9ticas m\u00e1s utilizadas recurren a reacciones de condensaci\u00f3n de \nPechmann, Perkin, Knoevenagel , Reformatsky o Wittig (Figura 12).71,72,73,74 \nLa primera es, sin duda, la m\u00e1s usada por la simplicida d de los materiales de \npartida y por los moderados rendimientos obtenidos  en la utilizaci\u00f3n de \ndeterminados substratos.75,76 \nO O\nO O\nO OPechmann\nKnoevenagel\nPerkinOHRO\nCO2R1R\nR\nOH\nRCHO\nOHR1OO O\nOR1R\nRO\nOO\u00c1cido\nBase\nNaOAcR1\nReformatsky\nO ORCOR 1\nOHRO\nOZnCHO\nWittig\nO ORCHO\nOHREt2NPhPh3P=CHCO 2EtBrR1\n \nFigura 12. M\u00e9todos m\u00e1s com\u00fanmente empleados en la s\u00edntesis de las cumarinas.  \n \nHoy en d\u00eda, sin embargo, es cada vez mayor la utilizaci\u00f3n de la \u201c Green \nChemistry\u201d que tiende a disminuir el uso de solventes potencialmente t\u00f3xicos \ny/o caros, recurriendo a la utilizaci\u00f3n de zeolitas,  resinas etc. en las reacciones \nde Knoevenagel y Wittig,77 as\u00ed como a t\u00e9cnicas de irradiaci\u00f3n con microondas o \nla utilizaci\u00f3n de l\u00edquidos i\u00f3nicos, no detalladas en esta Memoria.78,79,80 \nEn general, las cumarinas son obtenidas por condensaci\u00f3n de fenoles con \u03b2-\ncetoesteres, en presencia de un catalizador \u00e1cido. Esta reacci\u00f3n, conocida \ncomo reacci\u00f3n de Pechmann,  cursa con la formaci\u00f3n intermedia del \u00e9ster \nfen\u00f3lico y su posterior ciclaci\u00f3n en medio \u00e1cido. Esta v\u00eda sint\u00e9tica es muy utilizada para la obtenci\u00f3n de cumarinas naturales y otras benzopironas de inter\u00e9s biol\u00f3gico o industrial.\n81 \nLa reacci\u00f3n de Perkin consiste en la formaci\u00f3n de una cumarina mediante \ncondensaci\u00f3n ald\u00f3lica entre un orto-hidroxibenzaldeh\u00eddo y el anh\u00eddrido de un \n\u00e1cido o el \u00e1cido, en presencia de la sal alcalina del mismo \u00e1cido.82 En un primer \n35Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a036 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0paso, el m\u00e1s r\u00e1pido de la reacci\u00f3n, la base genera el ani\u00f3n enolato del \nanh\u00eddrido que reac ciona con el aldeh\u00eddo (Figura 13 ).83  \n \nO\nH\nOHO\nOHO\nOO\nO\nOO\nOO O\nOHO\nOO\nH2O\nOHOH\nO\nO O \nFigura 13. Mecanismo general de la reacci\u00f3n de Perkin.  \n \nEn estos casos, el objetivo es mejorar las condiciones de reacci\u00f3n, \ndisminuyendo el uso de reactivos, el tiempo de reacci\u00f3n, aumentando a la vez \nel rendimiento de la misma. Cambios de temperatura han sido muy favorables \na esta reacci\u00f3n. Temperaturas muy ba jas llevaban a reacciones incompletas, y \ntemperaturas muy altas a mezclas de reacci\u00f3n muy complejas y de dif\u00edcil purificaci\u00f3n. La utilizaci\u00f3n de la N,N\u2019-diciclohexilcarbodiimida (DCC), en \ndimetilsulf\u00f3xido (DMSO), favorece la ciclaci\u00f3n posterior para formar  el anillo \ncumar\u00ednico. Esta v\u00eda permite la reacci\u00f3n one-pot  de una serie de cumarinas \nsusceptibles de una s\u00edntesis en paralelo.  \nEn el caso particular  del trabajo realizado en esta Memoria, las reacciones \nse llevaron a cabo por condensaci\u00f3n de salicilaldeh\u00ed dos sustituidos con los \n\u00e1cidos ac\u00e9ticos apropiados, usando DCC como agente deshidratante. Esta es una reacci\u00f3n muy vers\u00e1til proporcionando diferentes fam ilias de cumarinas \nsustituidas. \nEn particular, los derivados acetoxilados de la cumarina se han sintetizado \nmediante la reacci\u00f3n de Perkin -Oglialoro de los derivados del \u00e1cido ac\u00e9tico con \nlos respectivos salicilaldeh\u00eddos, en anh\u00eddrido ac\u00e9tico (Ac\n2O) y acetato pot\u00e1sico \n(CH 3COOK). La reacci\u00f3n de Perkin-Oglialoro es de hecho la modificaci\u00f3n m\u00e1s \nimportante de la reacci\u00f3n tradicional de Perkin, donde se desarrolla la condensaci\u00f3n de aldeh\u00eddos arom\u00e1ticos con \u00e1cidos \u03b1-arilac\u00e9ticos en anh\u00eddrido \nac\u00e9tico y en presencia de una base d\u00e9bil (a trav\u00e9s de anh\u00eddridos mixtos generados in situ) para obtener \u00e1cidos \u03b1-arilcin\u00e1micos.\n84 \n36Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a037 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a01.1.2.  Los estilbenos (resveratrol ) \n \nEl resveratrol85 es un compuesto de origen natural presente en especies de \nespermatofitas, como las vides, en respuesta a un da\u00f1o externo o interno, por \nejemplo una infecci\u00f3n por hongos o exposici\u00f3n a la radiaci\u00f3n UV.86 Su \npresencia depende mucho del origen geogr\u00e1fico, de la especie o de la forma de \ncultivo de las vides, entre otros factores.87 Dado que se encuentra en la piel de \nla uva y no en la pulpa, existe en mayor concentraci\u00f3n en el vino tinto que en el vino blanco (donde el tiempo de contacto con la piel de la uva en la \nfermentaci\u00f3n es mucho m\u00e1s grande \u2013 mayor tiempo de maceraci\u00f3n).\n88 Fue por \nprimera vez detectado en la especie Vitis vin\u00edfera (Figura 14), en 1976, por \nLangcake y Pryce89 y en el vino tinto, en 1992, por Siemann y Creasy.90  \n \n \nFigura 14. Vitis vin\u00edfera.  \n \nEl inter\u00e9s por este compuesto y sus derivados se increment\u00f3 cuando los \nestudios epidemiol\u00f3gicos establecieron una relaci\u00f3n inversa entre el consumo \nde vino tinto y la incidencia de enfermedades cardiovasculares (paradoja \nfrancesa),91 adem\u00e1s de las propiedades hemost\u00e1ticas y del aumento del HDL \ncirculante descrita para el etanol.92  \nEstructuralmente el resveratrol es el 3,4\u2019,5-trihidroxiestilbeno que, debido a la \npresencia del doble enlace, puede asumir las dos formas isom\u00e9ricas trans y cis \n(Figura 15). \n \n37Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a038 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0HOOH\nOH OHHO\nOH\n \nFigura 15. Formas isom\u00e9ricas del resveratrol (trans - y cis-resveratrol).  \n \nLa forma trans del resveratrol, parece ser la responsable de las principales \npropiedades farmacol\u00f3gicas de esta mol\u00e9cula. Es, hoy en d\u00eda, un producto \ncomercial com\u00fan, a partir del que se puede obtener por irradiaci\u00f3n UV la forma \ncis. El distinto comportamiento de estos dos is\u00f3meros depende de su estructura \ntridimensional.  \nLa extracci\u00f3n del resveratrol y productos similares de las fuentes naturales \nes costosa en t\u00e9rminos de tiempo, dinero y bajos rendimientos, por lo que su extenso estudio y proyecci\u00f3n solo han sido posib les despu\u00e9s de su s\u00edntesis en \nlaboratorio. Hoy en d\u00eda est\u00e1 bastante bien caracterizado, siendo sus bandas de \nUV (m\u00e1xima absorbancia a 307 nm para la forma trans y 280 nm para la forma \ncis) y absorci\u00f3n IR (banda de 2800 a 3500 cm\n-1 para el grupo hidroxilo y 965 \ncm-1 para el doble enlace en su forma trans) bien definidas.93 \nPor su gran inter\u00e9s farmacol\u00f3gico, el re sveratrol ha sido muy ampliamente \nestudiado en los \u00faltimos a\u00f1os.94,95 Presenta un gran n\u00famero de actividades \ndestacando sobre todo sus propiedades antineopl\u00e1sicas,96 antiinflamatorias,97 \ncardioprotectoras (vasodilatador e inhibidor de la agregaci\u00f3n plaquetaria )98 y \nantioxidantes,99 mostrando ser muy eficiente convenientemente funcionalizado, \ncomo captador de radicales libres.96,100 Por otra parte, se ha comprobado la \nactividad inhibidora de la MAO en los is\u00f3meros cis y trans del resveratrol, \nsiendo el cis-resveratrol menos efectivo que el trans-resveratrol, sobre dicha \nenzima.101  \nEste interesante perfil farmacol\u00f3gico hace del resveratrol un importante \nprototipo a partir del cual se ha iniciado la b\u00fasqueda de an\u00e1logos capaces de mejorar y/o incrementar su perfil farmacol\u00f3gico sobre todo en lo que respecta a \nsu potencial aplicaci\u00f3n en enfermedades relacionadas con la edad , sobre todo \nlas neurodegenerativas\n.102 Por este motivo, en la presente Memoria hemos \nincorporado dicha estructura a las ya mencionadas cumarinas con las que \ncomparte en gran medida el mismo espectro ter ap\u00e9utico.  \n38Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a039 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0A partir de este cabeza de serie, se han desarrollado nuevos polifenoles casi \nsiempre mediante modificaciones muy sencillas del prototipo pero para los que \nse han encontrado una interesante actividad biol\u00f3gica  (Figura 16). De ellas, \nseguramente la mas estudiada es la actividad antioxidante.103,104 \nRecientemente se ha llevado a cabo un estudio que establece la relaci\u00f3n entre \ndicha actividad antioxidante y su relaci\u00f3n con  la quimioprevenci\u00f3n del \nc\u00e1ncer,100,105 mediante variaci\u00f3n del n\u00famero y/o posici\u00f3n de los grupos hidroxilo  \nsobre el esqueleto estilbenico .106 Un estudio QSAR sobre dicho compuesto \ncorrobora a su vez la influencia de fac tores est\u00e9ricos, de tama\u00f1o y forma, de \nlos sustituyentes sobre el esqueleto estilb\u00e9nico.107 \nPor su parte, la introducci\u00f3n de sustituyentes  sencillos tales como grupos \nmetoxilo, amino, sulfato o \u00e1tomos de hal\u00f3genos, confiere al estilbeno  diversas \nactividades tales como la antioxidante y neuroprotectora (debido a su actividad \ninhibidora de la agregaci\u00f3n amiloide) , encontrada tambi\u00e9n para los metabolitos \nsulfato conjugados a los que hemos aludido.104,108 \nRecientemente, se ha encontrado una interesante actividad antineopl\u00e1sica \nde an\u00e1logos polimetoxilados, actividad que sin embargo desaparece en los \nan\u00e1logos  hidroxilados.109 Por su parte, la introducci\u00f3n de \u00e1tomos de fl\u00faor, as\u00ed \ncomo los grupos amino parecen incrementar dicha activ idad.110 \n \n(OH)n\n(OH)nH/SO 3H\nH/SO 3HH/SO 3H\nAtrapadores de radicales Antioxidantes\nHO\nHONH\nAntioxidantes e inhibidores de la \nagregacion amiloide\nH3CO\nH3COOCH 3H3CO\nAntineolp\u00e1 sicosN(CH 3)2F\nF\n \nFigura 16. Modificaciones sencillas de la mol\u00e9cula del resveratrol ( variaci\u00f3n de sustituyentes \nsobre la estructura trans -estilb\u00e9nica).  \n \n39Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a040 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Modificaciones m\u00e1s dr\u00e1sticas sobre el resveratrol implican la obtenci\u00f3n de \nimino an\u00e1logos mediante  la substituci\u00f3n isost\u00e9rica del doble enlace etil\u00e9nico, \nque conservan la actividad anti oxidante,111 y para los que se encontr\u00f3 una \ninteresante actividad inhibidora de la agregaci\u00f3n \u03b2-amiloide (\u03b2A) (Figura 17).112 \n \nN\nAtrapamiento de radicales libresH/OH/OCH 3HO\nN\nInhibici\u00f3 n de la agregaci\u00f3 n amiloideHNCl OH SO2\nCH3Cl\nCl\n \nFigura 17. Substituci\u00f3n isost\u00e9rica del doble enlace etil\u00e9nico.  \n \nOtra interesante modificaci\u00f3n sobre el estilbeno, supone la sustituci\u00f3n de \nuno de los dos anillos benc\u00e9nicos por un anillo het eroc\u00edclico m\u00e1s o menos \ncomplejo o la condensaci\u00f3n de este con otros ciclos, modificaciones que han \npermitido la preparac i\u00f3n de inhibidores enzim\u00e1ticos MAO -B como en el caso de \nlos derivados de la estiril-cafe\u00edna113 o de la estiril-isatina (Figura 18).114  \n \nN\nNNNO\nON\nHO\nO\nEstiril-isatina\nInhibidores MAOCloro-estiril-cafeinaCl\n \nFigura 18. Substituci\u00f3n  de uno de los dos anillos benc\u00e9n icos por biciclos . \n \nA su vez, la introducci\u00f3n de anillos heteroarom\u00e1ticos del tipo tiofeno  o \nbenzotiazol (Figura 19), permite la s\u00edntesis de estilbenoides capaces de actuar, \npor sus propiedades fluorescentes, como pru ebas de detecci\u00f3n de las placas  \n\u03b2A en la diagnosis de la EA.115 El an\u00e1logo pirid\u00ednico Amyvid  (Figura 19) es uno \nde los cuatro agentes utilizados en el diagn\u00f3stico de la EA en humanos.116  \n \n40Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a041 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0ArAr\nS RN\nSNMe 2S\nNH3CHN\nOF\n3\nAmyvid  \nFigura 19. Introducci\u00f3n de anillos heteroarom\u00e1ticos de tipo tiofeno,  benzotiazol  o piridina . \n \n1.2. Enfermedades neurodegenerativas  \n \nLas enfermedades neurodegenerativas son cada vez m\u00e1s frecuentes con el \nenvejecimiento general de la poblaci\u00f3n mundial. El siglo XX fue testigo de un importante cambio demogr\u00e1fico en la poblaci\u00f3n humana del mundo \nindustrializado que se ha seguido de un cambio similar de la esperanza de vida \na edades superiores en Asia, \u00c1frica y Am\u00e9rica Central y del Sur. La calidad de \nvida de la poblaci\u00f3n de edad avanzada en la sociedad de hoy es, en gran medida, determinada por el proceso normal de envejecimiento de las neuronas en el sistema nervioso central (SNC) y especialmente por la aparici\u00f3n de \nenfermedades caracterizadas por la p\u00e9rdida neuronal acelerada, que \ntradicionalmente son designadas como enfermedades neurodegenerativas. Estas enfermedades son las principales causas de morbilid ad y discapacidad \nen todo el mundo.  \nLa EA es la m\u00e1s prevalente enfermedad neurodegenerativa  seguida de la \nenfermedad de Parkinson (EP). La EA es la causa m\u00e1s com\u00fan de demencia senil, que afecta a aproximadamente el 3% de la poblaci\u00f3n entre las edades de 65-74 a\u00f1os y casi el 50% de las personas de 85 a\u00f1os o m\u00e1s.\n117,118 La \nesclerosis lateral amiotr\u00f3fica (ELA) y la enfermedad de Huntington afectan a un n\u00famero menor de pacientes, pero tienen consecuencias devastadoras. Un gran n\u00famero de enfermedades neurodegenerativas raras tienen similares efectos en los pacientes y sus familias que est\u00e1n tambi\u00e9n afecta das por estas \nenfermedades. La investigaci\u00f3n sobre la patog\u00e9nesis y el tratamiento de estos \ntrastornos est\u00e1 creciendo de manera exponencial. En gran medida esto ha sido \n41Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a042 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0fomentado por importantes avances en la gen\u00e9tica, ya que ahora sabemos que \nlas mutaciones se asocian con un gran n\u00famero de estas enfermedades . Esto \nincluye formas familiares de la EA, EP, la demencia fronto -temporal, ELA, \nenfermedad de Huntington y una variedad de ataxias. La mayor parte de los \ncasos espor\u00e1dicos de las neurodegeneraciones co munes, tales como EA, EP y \nELA parecen ser de origen polig\u00e9nica y son influenciados por factores \nambientales todav\u00eda mal caracterizados. El objetivo final del diagnostico y \nterap\u00e9utica es prevenir estas enfermedades , ya sea en individuos en riesgo , \nantes de la aparici\u00f3n de manifestaciones cl\u00ednicas o para desarrollar eficaces \nterapias neuroprotectoras que retardan o detienen la progresi\u00f3n de la \nenfermedad en las primeras etapas.  \nLas enfermedades neurodegenerativas son consideradas como uno de los \nretos m\u00e1s importantes de la medicina de hoy en d\u00eda debido a su complejidad, la \nfrecuencia de aparici\u00f3n y el desarrollo progresivo. Las  enfermedades \nneurodegenerativas son procesos patol\u00f3gicos que se caracterizan por \ndegeneraci\u00f3n y muerte de las neuronas como consecu encia de la acumulaci\u00f3n \nde prote\u00ednas anormales en su interior, resultado de la desregulaci\u00f3n de \ndiferentes neurotransmisores. Los procesos que generan este ac\u00famulo de \nprote\u00ednas son sumamente complejos y en la actualidad a\u00fan no son totalmente conocidos. En funci\u00f3n del estado de evoluci\u00f3n del paciente este va a presentar \ns\u00edntomas concretos que con el paso del tiempo se van acentuando. Por lo \ntanto, si las neuronas afectadas pertenecen al hipocampo, zona relacionada \ncon la memoria, el paciente perder\u00e1 memoria y si el cuadro progresa \ndesarrollar\u00e1 EA. Si la p\u00e9rdida neuronal se localiza en la sustancia negra, el \npaciente desarrollar\u00e1 EP por tratarse de un \u00e1rea relacionada con el \nmovimiento; y si lo que se afectan son las neuronas motrices el paciente \ndesarrollar\u00e1 ELA, que se caracteriza por causar una debilidad progresiva.  \nDiferentes caracter\u00edsticas y procesos bioqu\u00edmicos tienen en com\u00fan generar \nprocesos patol\u00f3gicos tr\u00e1gicos y devastadores, siendo necesaria una gran \ninversi\u00f3n en la investigaci\u00f3n para aliviar el sufrimiento humano causado por \nestas enfermedades.\n117,118,119 \n \n1.2.1 . Enfermedad de Parkinson (EP)  \n42Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a043 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \nLa principal aplicaci\u00f3n terap\u00e9utica de los inhibidores de la MAO -B es el \ntratamiento de la EP,  un trastorno neurodegenerativo cr\u00f3nico y progresivo, \ncaracterizado por una sintomatolo g\u00eda predominantemente motora acompa\u00f1ada \ncasi siempre de s\u00edntomas no motores como depresi\u00f3n y ansiedad, y que es debido a una disminuci\u00f3n de los niveles de dopamina (DOPA) en el estriado \npor disfunci\u00f3n progresiva de neuronas nigroestriadas.\n120  \nEsta enfermedad ha sido descrita por primera vez en 1817, por James \nParkinson, en el \"An Essay on the Shaking Pulse\", como un desorden \nneurol\u00f3gico severo. Es una de las enfermedades de mayor incidencia en \nancianos (prevalencia estimada en 1% de la poblaci\u00f3n por encima d e los 60 \na\u00f1os de edad) y es caracterizada por cuatro se\u00f1ales esenciales: rigidez, \ntemblor, bradicinesia e inestabilidad postural.121 Desde un punto de vista \npatol\u00f3gico, la EP se caracteriza por la p\u00e9rdida de las neuronas dopamin\u00e9rgicas de la v\u00eda nigroestriada, que se proyectan desde la zona compacta de la sustancia negra (SNC) hasta el estriado. Los s\u00edntomas de la EP aparecen cuando se ha destruido en torno al 80% de las neuronas dopamin\u00e9rgicas de \nesta v\u00eda. Adem\u00e1s de esta p\u00e9rdida neuronal, en la neurofisiopatolog\u00eda de la EP tambi\u00e9n aparecen cuerpos de Lewy, inclusiones de prote\u00ednas citoplasm\u00e1ticas, que no s\u00f3lo est\u00e1n presentes en neurona s dopamin\u00e9rgicas, sino tambi\u00e9n en \nsistemas noradren\u00e9rgicos ( locus coeruleus), seroton\u00e9rgicos (rafe), y \ncolin\u00e9rgicos (n\u00facleo basal de Meynert). Los cuerpos de Lewy est\u00e1n compuestos por distintas prote\u00ednas como la \u03b1-sinucle\u00edna, la parkina, y la \nubiquitina. N o son exclusivos de la EP, pudiendo  encontrarse tambi\u00e9n, por \nejemplo en la EA, o en la demencia de cuerpos de Lewy. El papel que desempa\u00f1an los cuerpos de Lewy en la EP  no est\u00e1 todav\u00eda esclarecido.  \nLa etiolog\u00eda de esta enfermedad est\u00e1 todav\u00eda por esclarece r completamente \ndebido a la complejidad y variedad de  los factores implicados en su desarrollo. \nSon posibles causas de la EP la acci\u00f3n de neurotoxinas ambientales, producci\u00f3n de radicales libres, anomal\u00edas mitocondriales, predisposici\u00f3n \ngen\u00e9tica, envejecimiento cerebral, o incluso una asociaci\u00f3n de m\u00e1s de uno de \nestos factores. En lo que se refiere a la patog\u00e9nesis hay abiertas varias \nhip\u00f3tesis de investigaci\u00f3n, que incluyen distintos mecanismos que parecen estar implicados en el desarrollo de la enfermedad  tales como el estr\u00e9s \n43Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a044 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0oxidativo, uno de los primeros factores de los que se pens\u00f3 que pod\u00eda \ncontribuir al desarrollo de esta enfermedad. Basado fundamentalmente en la \nformaci\u00f3n de especies reactivas de oxigeno (ROS) a partir del metabolismo \noxidativo de la  DOPA, provocando un aumento de los niveles de hierro y una \ndisminuci\u00f3n de los niveles del glutati\u00f3n reducido. Hay evidencias de que la \ninflamaci\u00f3n es otro proceso que podr\u00eda estar implicado en la patog\u00e9nesis de la \nEP. Tambi\u00e9n la excitotoxicidad, un proceso patol\u00f3gico que es capaz de da\u00f1ar a \nlas neuronas y en el que aumenta la concentraci\u00f3n de glutamato, que a trav\u00e9s de radicales libres acaba provocando la muerte de las c\u00e9lulas por distintos \nmecanismos: apoptosis y autofagia. Por estos motivos, es necesario un gran \nesfuerzo en el estudio y nuevas alternativas terap\u00e9uticas de dicha enfermedad, alternativas que hoy en d\u00eda, tratan de paliar los s\u00edntomas de la EP, a la vez de otras que inhiben la evoluci\u00f3n del proceso neurodegenerativo. En otros casos, \nse recurre a terapias que act\u00faan en m\u00e1s de una diana, produciendo beneficios sintom\u00e1ticos y neuroprotectores, terapias que suelen ser m\u00e1s efectivas en el tratamiento de esta compleja enfermedad.\n122 \nEn los a\u00f1os 50, Arvid Carlsson demostr\u00f3 que la DOPA era un \nneurotransmisor y sus niveles en los ganglios basales eran bajos en modelos animales de parkinsonismo. Sus trabajos fueron la base para el desarrollo de distintos ensayos con levodopa (L -DOPA). Gracias a los buenos resultados del \nprimer ensayo controlado de L -DOPA frente a placebo, publicados por Yahr y \ncol. en 1969, este f\u00e1rmaco se convirti\u00f3 en fundamental para el tratamiento de la EP. La principal estrategia actual para el tratamiento de la EP est \u00e1 enfocada a \nla restauraci\u00f3n de la funci\u00f3n dopamin\u00e9rgica en el tejido estriado del cerebro.\n123 \nEl principal objetivo de esta terapia es aumentar/mantener los niveles normales de DOPA a nivel del SNC, donde existe un d\u00e9ficit de la inervaci\u00f3n \ndopamin\u00e9rgica, como consecuencia de le degeneraci\u00f3n de las neuronas \ndopamin\u00e9rgicas nigroestriales y consiguiente bajada de las reservas de DOPA.\n124  \nDesde hace muchos a\u00f1os el aumento de los niveles de DOPA se consigue \nmediante administraci\u00f3n de L -DOPA,125 el intermediario metab\u00f3lico precursor \nde la DOPA, en combinaci\u00f3n con inhibidores de la dopa descarboxilasa perif\u00e9rica (DDC). Al mismo tiempo son administrados f\u00e1rmacos agonistas \ndopamin\u00e9rgicos que mimetizan los neurotransmisores mediadores de la \n44Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a045 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0DOPA.91 Esta estrategia es la metodolog\u00eda com\u00fan para el tratamiento de la \nenfermedad. As\u00ed, el aumento de los niveles de DOPA se puede conseguir con \ndiversas estrategias:  \n \n\u2022 Facilitando la s\u00edntesis de la DOPA; \n\u2022 Favoreciendo la liberaci\u00f3n de la DOPA de los dep\u00f3sitos presin\u00e1pticos; \n\u2022 Disminuyendo la recaptaci\u00f3n de la DOPA ; \n\u2022 Inhibiendo el catabolismo de la DOPA;  \n\u2022 Estimulando los receptores dopamin\u00e9rgicos.  \n \nEstas terapias dopamin\u00e9rgicas ofrecen un ef ectivo alivio de los efectos \nmotores asociados con la enfermedad, especialmente en estados poco \navanzados de la misma. Sin embargo, la restituci\u00f3n de los niveles de la DOPA no evita la progresi\u00f3n neurodegenerativa de la EP y con el tiempo progresa la \np\u00e9rdida neuronal y la eficacia de los f\u00e1rmacos si va disminuyendo.\n92 \nPor este motivo, en los \u00faltimos a\u00f1os han surgido nuevas alternativas \nterap\u00e9uticas como la utilizaci\u00f3n de inhibidores de la catecol -o-metiltransferasa \n(COMT), como el caso de la entacapona, y de inhibidores selectivos de la \nMAO-B,126,127 de los cuales est\u00e1n comercializados en Espa\u00f1a la selegilina128 y \nla rasagilina (adem\u00e1s de su efecto inhibidor de la MAO -B, es tambi\u00e9n un \nimportante neuroprotector)129 y a las que haremos alusi\u00f3n mas adelante.  \nLa selegilina ha sido el primer IMAO -B que se utiliz\u00f3 en cl\u00ednica. Administrada \nconjuntamente con L-DOPA permit\u00eda reducir la dosis a administrar de \u00e9sta. En monoterapia en pacientes con EP en estadios tempranos pod\u00eda retasar el \ncomienzo del tratamiento con L -DOPA. La selegilina se metaboliza a derivados \nanfetam\u00ednicos, responsables de sus efectos secundarios y de la reducci\u00f3n del \nefecto neuroprotector. Uno de ellos, la metanfetamina es neurot\u00f3xica e interfiere con la acci\u00f3n neuroprotectora de la misma.  \nLa rasagilina es otro IMAO -B, m\u00e1s potente y selectivo, su principal diferencia \nrespecto a la selegilina es que no se metaboliza en anfetamina o metanfetamina. Se metaboliza dando un \u00fanico compuesto que, a diferencia de lo que ocurre con los metabolitos de la selegi lina, el 1 -aminoindano ha \nmostrado actividad neuroprotectora.  \n \n45Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a046 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a01.2.2 . Enfermedad de Alzheimer (EA)  \n \nLa EA, como dicho anteriormente, es una enfermedad neurodegenerativa y \nprogresiva, que supone la causa m\u00e1s com\u00fan  de demencia senil.130 La \ndemencia es un trastorno cerebral que afecta gravemente la capacidad de una \npersona de llevar a cabo sus actividades cotidianas. La enfermedad debe su \nnombre al Dr. Alois Alzheimer que la ha descrito por primera vez en 1906. Sus \ns\u00edntomas incluyen p\u00e9rdida de la memoria, problemas de lenguaje y comportamiento impredecible.  La EA comienza lentamente y progresa al largo \ndel tiempo, primero afectando las partes del cerebro que controlan el \npensamiento, la memoria y el lenguaje.  La repercusi\u00f3n de esta enfermedad es \ntal, que se calcula entre 18 y 22 000 000 de personas afectadas a nivel \nmundial, con una prevalencia media entre el 3 y el 15% y una incidencia anual entre 0,3 y 0,7%. \nEl desarrollo de la EA, est\u00e1 muy relacionado con los cambios \nhistopatol\u00f3gicos que ocurren en el cerebro de estos pacientes. Estos cambios \nneuropatol\u00f3gicos, entre los que se citan: la p\u00e9rdida de neuronas y sinapsis, la angiopat\u00eda amiloidea, la placa senil, el cambio neurofibrilar de Alzheimer y el \ndescubrimiento m\u00e1s reciente de las placas no amiliodes \"AMY plaque\", ocurren \no se inician antes del comienzo de la declinaci\u00f3n cognitiva propia de la \nenfermedad (Figura 20).  \nExisten evidencias, en pacientes con EA, de  atrofia del hipocampo, \nliberaci\u00f3n de la prote\u00edna Tau por las neuronas lesionadas, uso de sustratos como energ\u00eda alternativa, dep\u00f3sito excesivo de la prote\u00edna \u03b2A, presencia del \nalelo de la apolipoprote\u00edna E4 y mutaciones en los genes del precursor de la prote\u00edna amiloide (PPA) (cromosoma 21) y la presenilina 1 y 2 (cromosomas 14 y 1 respectivamente).\n131 \nAunque esta patolog\u00eda tiene como hemos indicado una etiolog\u00eda m\u00faltiple, \nparece ser fundamentalmente debida a la acumulaci\u00f3n de  placas \u03b2A en el \ncerebro, lo cual puede promover la degeneraci\u00f3n o atrofia de las neuronas colin\u00e9rgicas, fundamentalmente en la corteza cerebral y en el hipocampo. En \nconsecuencia, cl\u00e1sicamente se ha recurrido al uso de los inhibidores de la \nAChE para su tratamiento farmacol\u00f3gico.\n132,133 \n46Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a047 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n \nFigura 20. Algunas de las caracter\u00edsticas m\u00e1s comunes de la EA.  \n \nEn la actualidad, sin embargo, se est\u00e1n generando nuevas expectativas al \ntener en cuenta otros aspectos relacionados con la etiolog\u00eda de la enfermedad \ntales como la disminuci\u00f3n en los niveles de DOPA, noradrenalina (NA) y \nserotonina o 5-hidroxitriptamina (5-HT), o bien el aumento de la actividad MAO -\nB cerebral, lo que origina un incremento de radicales libres, responsables del estr\u00e9s oxidativo y muerte celular, as\u00ed como del desarrollo de las placas \u03b2A en \nlos enfermos que padecen de EA.\n134 Aunque se requieren m\u00e1s estudios para \nsu clarificaci\u00f3n, se cree que el efecto beneficioso de los inhibidores selectivos \nde la MAO-B como la selegilina es debido a un doble efecto: reduc ci\u00f3n en la \nformaci\u00f3n de radicales libres  y de incremento en los niveles de monoaminas en \nel cerebro de dichos enfermos.135  \nPor la complejidad de la etiolog\u00eda de esta enfermedad, la terap\u00e9utica actual \nse encamina al desarrollo de f\u00e1rmacos mutidiana en concreto a la obtenci\u00f3n de \nmol\u00e9culas que incorporan fragmentos estructurales responsables de una \ninhibici\u00f3n de las diferentes enzimas implicadas BACE, MAO -B, y/o de \nAChE136,137 y que adicionalmente confieran a las mol\u00e9culas caracter\u00edsticas \nantioxidantes .138,139,140,141 Esta es como indicamos una de las metodolog\u00edas \nm\u00e1s prometedoras y en la que nuestro grupo de investigaci\u00f3n est\u00e1 trabajando.  \n \n1.3. Principal d iana farmacol\u00f3gica  en la Memoria - MAO s \n \n47Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a048 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0La MAO (E.C 1.4.3.4) fue descubierta por Mary Hare en 1928 y la denomin\u00f3 \ntiramina oxidasa. Posteriormente se vio que la oxidaci\u00f3n tambi\u00e9n afectaba a \nvarias etilaminas como la DOPA, NA, adrenalina (A), 5 -HT y entonces se \nreconoci\u00f3 como MAO. Al tener como sustratos a ne urotransmisores tan \nimportantes como estos, parece clara la influencia que tendr\u00e1 esta enzima en \ndistintas funciones y patolog\u00edas cerebrales.142  \nLas MAO son una familia heterog\u00e9nea de flavoenzimas que catalizan la \ndesaminaci\u00f3n de neurotransmisores y aminas ex\u00f3genas.143,144,145 Las MAO \ntienen unido de forma covalente el cofactor FAD.146 Las MAO est\u00e1n presentes \nen las membranas externas de las mitocondrias de c\u00e9lulas neuronales de la \ngl\u00eda, entre otras.147 La distribuci\u00f3n de las MAO no se restringe al SNC sino que \ntambi\u00e9n est\u00e1n presentes en la periferia. La MAO -A predomina en h\u00edgado y \ntracto gastrointestinal y la MAO -B en las plaquetas, en el cerebro y en menor \ncantidad en el h\u00edgado. Ambas isoformas est\u00e1n p resentes en el cerebro, aunqu e \nen distinta proporci\u00f3n (75 -80% de MAO-B) y con diferente distribuci\u00f3n, la MAO -\nB es la forma mayoritaria en los ganglios basales y predomina en neuronas seroton\u00e9rgicas y c\u00e9lulas de la gl\u00eda, a diferencia de la MAO -A que abunda en \nneuronas adren\u00e9rgicas, dopamin\u00e9rgicas y catecolamin\u00e9rgicas.\n148,149 \nComo catalizadores de la desaminaci\u00f3n oxidativa de las monoaminas, las \nMAO utilizan el ox\u00edgeno para eliminar un grupo amino de una mol\u00e9cula, \nresultando el correspondiente aldeh\u00eddo  y amoniaco, con la generaci\u00f3n de \nper\u00f3xido de hidr\u00f3geno (Figura 21). Los aldeh\u00eddos se metabolizan r\u00e1pidamente \na los correspondientes \u00e1cidos. Las MAO catalizan la desaminaci\u00f3n oxidativa de neurotransmisores y aminas bi\u00f3genas, actuando sobre aminas primarias, y \ntambi\u00e9n en algunas secundarias y terciarias. En  esta reacci\u00f3n son formadas \nespecies reactivas de oxigeno (ROS), siendo que compuestos capaces de \ndesarrollar mecanismos antioxidantes de destoxificaci\u00f3n pueden ser \ninteresantes adyuvantes en la t erap\u00e9utica.  \n!CH\nHR NH2+O2+H2O CH\nR O+NH3+H2O2\n \nFigura 21. Reacci\u00f3n de desaminaci\u00f3n de neurotransmisores por las MAO.  \n \n48Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a049 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Las dos isoformas denominadas MAO -A y MAO-B (Figura 22)150,151 han sido \nidentificadas en base a su secuencia de amino\u00e1cidos, su estructura \ntridimensional y la preferencia por determinados sustratos e inhibidores espec\u00edficos.\n152 Aunque compartan 70% de la identidad de sus secuencias de \namino\u00e1cidos,153 la MAO-A tiene mayor afinidad por 5-HT, A y NA154,155 mientras \nque la MAO-B desamina preferentemente la \u03b2-feniletilamina y la \nbencilamina.156,157 Estas propiedades determinan la importancia cl\u00ednica de los \ninhibidores de la MAO158 como promisores f\u00e1rmacos para el tratamiento de \nenfermedades neurodegenerativas, depresi\u00f3n y/o obesidad.159 Existen \nevidencias de que con el paso de los a\u00f1os, a medida que progresa el envejecimiento aumenta la actividad cerebral de la MAO -B pero no la de la \nMAO-A. Los mayores aumentos aparecen en los ganglios bas ales y en el \nt\u00e1lamo, seguidos de la corteza frontal y en menor medida, cerebelo y cortezas parietal y temporal.\n160 \n \n!\n ! \nFigura 22. Diagrama virtual de los sitios activos de las isoformas MAO -A y MAO -B con un \nligando 3 -arilcumar\u00ednico  (im\u00e1genes del trabajo descrito en esta Maemoria) . \nEl centro activo de las MAOs, donde se unir\u00e1 el sustrato, es una gran \ncavidad que se extiende desde el sitio de uni\u00f3n del FAD en el centro de la \nenzima a la superficie de la prote\u00edna en el lado opuesto del  anillo de adenosina. \nEsta cavidad es de mayor tama\u00f1o en la isoforma MAO -B que en la MAO-A y en \nrealidad, se compone de dos espacios separados: la cavidad del sustrato y la \ncavidad de entrada, la segunda frente al bucle 99 -112. El centro activo de la \nMAO-B es un ejemplo de flexibilidad ya que puede ser una gran cavidad \u00fanica \no una cavidad dividida en dos seg\u00fan la conformaci\u00f3n del amino\u00e1cido Ile 199. \n49Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a050 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Otro amino\u00e1cido que tambi\u00e9n est\u00e1 implicado, aunque no directamente, en la \ndivisi\u00f3n en dos cavidades es el Tyr  326. De hecho, este par de residuos de \namino\u00e1cidos junto con los Phe 208 -Ile 335 en el caso de la MAO -A determinan \ndiferencias espec\u00edficas entre sustratos e inhibidores de ambas enzimas.161 \nLos primeros inhibidores de la MAO tales como la isoniazida y iproniazida \neran no selectivos pero tras el descubrimiento de las distintas  isoformas de la \nMAO comenzaron a desarrollarse inhibidores relativamente espec\u00edficos.  Los \ninhibidores MAO -A selectivos (IMAO-A) como la clorgilina o la moclobemida \nson utilizados en el tratamiento del des\u00f3rdenes neurol\u00f3gicos tales como la \ndepresi\u00f3n, mientras que los IMAO -B selectivos, tales como la selegilina y la \nrasagilina, son de utilidad y est\u00e1n autorizados en Espa\u00f1a para el tratamiento de \nla EP.162,163 Estos dos f\u00e1rmacos inhiben de forma selectiva e irreversible a la \nMAO-B, as\u00ed que no presentan los efectos no deseados de los inhibidores no \nselectivos. Al inhibir a la MAO -B, incrementan el tiempo de DOPA en el espacio \nsin\u00e1ptico, ya que entorno al 80% de la DOPA es metabolizada por esta enzima. \nPierden la selectividad por la MAO -B a dosis altas, aumentando las reacciones \nadversas. Si se administran conjuntamente con L -DOPA pueden aparecer \ns\u00edntomas de hiperactividad dopamin\u00e9rgica que se solucionan disminuye ndo la \ndosis de L-DOPA administrada.  Estos f\u00e1rmacos se pueden utilizar en estadios \ntempranos de la enfermedad por su posible efecto neuroprotector, ya que \ndurante el metabolismo normal de la DOPA por la MAO -B se pueden generan \nradicales libres y tambi\u00e9n pa ra tratar los fen\u00f3menos de p\u00e9rdida de respuesta a \nL-DOPA. \nLa selegilina fue el primer IMAO -B que se utiliz\u00f3 en el tratamiento de la EP. \nEs un derivado de propargilamina que inhibe de forma irreversible a la enzima. La absorci\u00f3n a trav\u00e9s del tracto gastroin testinal y la distribuci\u00f3n son r\u00e1pidas. \nCruza la barrera hematoencef\u00e1lica y se acumula en regiones cerebrales ricas en MAO-B. Se metaboliza a N-desmetilselegilina, L-metanfetamina y L -\nanfetamina.  \nLa rasagilina tiene eficacia mejorada ya que presenta propiedades \nneuroprotectoras y tiene la ventaja de que se metabo liza en metabolitos no \nt\u00f3xicos. Al igual que la selegilina, es un derivado de propargilamina que inhibe a la enzima de forma irreversible. Se comporta como un inhibidor suicida y la interacci\u00f3n tiene lugar entre el N del grupo propargil y el N -5 del anillo de \n50Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a051 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0isoaloxazina del FAD. Se metaboliza por N -desalquilaci\u00f3n a nivel hep\u00e1tico, \ndando un \u00fanico compuesto no t\u00f3xico el 1 -(R)-aminoindano. A diferencia de lo \nque ocurre con los metabolitos de la selegilina, el 1-aminoindano ha mostrado \nactividad neuroprotectora.164 El perfil farmacol\u00f3gico de los IMAO -B no se limita \na la inhibici\u00f3n de esta enzima sino que pueden tener un efecto neuroprotector, \nefecto antioxidante, protecci\u00f3n frente a neurotoxinas, aumento de  la liberaci\u00f3n \nde DOPA, etc. Algunos de los inhibidores (MAO -A y MAO-B) de referencia \nest\u00e1n recopilados en la Figura 23.  \n \nN\nO N\nHHNCH3\nCH3\nIproniazida (I) (A/B)NCH3\nCH3 H\nSelegilina (I) (B)N\nPargilina (I) (A/B)CH3Cl\nClO N\nCH3\nClorgilina (I) (A)\nH\nN\nN\nHO\nN\nO\nH3C\nIsocarboxazida (I) (A/B)NHN\nMoclobemida (R) (A)ClO O\nH3CO\nBrONH\nBrofaromina (R) (A)H3C NOO\nOH\nToloxatona (R) (A)\nNH\nRasagilina (I) (B)N\nClO\nNHNH2\nLazabemida (R) (B)\n \nFigura 23. Inhibidores MAO -A y MAO -B reversibles (R) e irreversible (I).  \n \nLa reacci\u00f3n de desanimaci\u00f3n oxidativa catalizada por las MAO -A y MAO-B \nparece ser el mecanismo mayoritario sufrido por la DOPA  a nivel del estriado \n(Figura 24). Inhibiendo estas enzimas a nivel central, se consigue inhibir la \ndepleci\u00f3n de los niveles de la DOPA y elevar los niveles de DOPA end\u00f3gena y \nde DOPA producida por administraci\u00f3n de L -DOPA ex\u00f3gena.165 \n \n51Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a052 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0NH2 HO\nHO\nDopamina\nHO\nHO\n3,4-dihidroxifenil-\nacetaldeh\u00ed doCHOMAO\nAldeh\u00ed do\ndeshidrogenasa\nHO\nHO\n\u00c1cido 3,4-dihidroxi-\nfenilacet\u00ed co (DOPAC)COOHCOMT\nCOMTNH2 H3CO\nHO\n3-metoxitiramina\nH3CO\nHO\n3-metoxi-4-hidroxi-\nfenilacetaldeh\u00ed doCHOMAO\nAldeh\u00ed do\ndeshidrogenasa\nH3CO\nHO\n\u00c1cido homovan\u00ed lico (AHV)COOH\n \nFigura 24. Metabolismo de la DOPA.  \n \n1.3.1 . Cumarinas y las MAOs \n \nEn 1981 se encontr\u00f3 por primera vez una  interesante actividad IMAO del \nn\u00facleo de las cumarinas, cuando un grupo organofosforado fue unido al anillo \nde la umbeliferona.166 Pero no fue hasta el 1990 cuando el n\u00facleo de las \ncumarinas ha sido convertido en un prometedor esqueleto con propiedades inhibidoras de las MAOs.\n167,168 En particular, algunas cumarinas aisladas de \nPsoralea corylifolia L., Peucedanum japonicum L. y Monascus anka K. han sido \ndescritas como IMAOs.169 Aunque las cumarinas naturales, en general, \nmuestran baja potencia inhibidora de las MA Os, modificaciones sobre estas \ncumarinas naturales han llevado a la obtenci\u00f3n de productos que han sido \ncaracterizados como potentes y selectivos IMAOs. Por ejemplo, el an\u00e1logo  \ndesmetilado de la ya mencionada geiparvarina , una cumarina natural 7-\nsubstituida, extra\u00edda de las hojas de Geijera parviflora L., exhibe una potente y \nselectiva inhibici\u00f3n de la MAO -B (Figura 25).170 \n \nO O O\nO\nOO O OP\nROROA\nA = S o O\n \nFigura 25. Derivados de la umbeliferona y de la geiparvarina.  \n52Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a053 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \nVarios grupos de investigaci\u00f3n han explorado la importancia del n\u00famero y \nposici\u00f3n de los diferentes sustituyentes en el n\u00facleo de cumarina , teniendo en \ncuenta el volumen est\u00e9rico, lipofilia  y/o propiedades electr\u00f3nicas, con el fin de \nmejorar la actividad y la selectividad (Figura 26).  \n \nO OR'O\nR\nO OO ONO\nO OH\nN O\nR'O OO OHeterociclo\nOO\nO\nRR'R\nR'R\nO O R7R3R4\nO O ORO OO OOR'O\nRR4\nR'\nR''\nR8ROR'R6\nRR7\n \nFigura 26. Estructuras qu\u00edmicas de cumarinas estudiadas como IMAOs  (parte de las \nestructuras pertenecen al trabajo descrito en esta Maemoria) . \n \nAunque las posiciones 3 y 7 del anillo de cumarina han sido las m\u00e1s \nestudiadas, todas las posibilidades de sustituci\u00f3n se han tenido en cuenta y \nhan sido sintetizados y evaluados  un gran n\u00famero de derivados de la cumarina \ncomo IMAOs, siendo la mayor\u00eda de ellos activos y selectivos frente a la isoenzima MAO-B.\n171 \nLos primeros estudios de relaci\u00f3n estructura -actividad (REA) sobre \nderivados de las cumarinas han sugerido que la selectividad viene determinada principalmente por la naturaleza de la uni\u00f3n entre la c umarina y el grupo \n53Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a054 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0sustituyente en la posici\u00f3n 7. Una serie de 7 -hidroxicumarinas con \nsustituyentes de tipo \u00e9ter, \u00e9ster o carbamato en la posici\u00f3n 7, con tama\u00f1o \nvariable y diferente lipofilia, han sido investigados por su actividad inhibidora de las MAO-A y MAO-B. La mayor\u00eda de estos compuestos result\u00f3 ser \npreferentemente IMAO -B. Estudios de REA tambi\u00e9n han demostrado que la \nlipofilia es una propiedad importante para modular la potencia de inhibici\u00f3n de la MAO-B de las cumarinas anteriormente mencionadas. L a presencia de un \ngrupo benciloxi en posici\u00f3n 7 result\u00f3 favorecer la uni\u00f3n de las cumarinas a la MAO-B, mientras que un anillo de fenilo \u03c0-pobre en electrones  en esa misma \nposici\u00f3n si bien parece  mejorar tanto la actividad inhibitoria MAO -A como MAO-\nB, dando lugar a inhibidores menos selectivos. Por otra parte, se ha demostrado que un grupo alquilsulfoniloxi en la posici\u00f3n 7 proporciona actividad IMAO-A, como es el caso de la esuprona. Este efecto es a\u00fan m\u00e1s \npronunciado en los grupos fenilsulfonatos, en que  la sustituci\u00f3n con grupos \naceptores de electrones conduce a m\u00e1s potentes y altamente selectivos IMAO -\nA. Tambi\u00e9n, B. Rendenbach-Mueller y col. han sintetizado y estudiado el \npotencial de derivados de \u00e9teres y \u00e9ster es de \u00e1cido sulf\u00f3nico (Figura 27 ), \ncomprobando que la introducci\u00f3n de un enlace \u00e9ster sulf\u00f3nico, en lugar del \npuente \u00e9ter, cambia dr\u00e1sticamente el perfil de actividad de los nuevos compuestos.\n51 \n \nO O O O O O O O OR3R4\nR6R4\nR3 R6\nO2\nS\nZH3CH2CO2SR\nEsuprona Z = Ph/anel heteroaromatico (Substituido o no) \nFigura 27. Derivados cumar\u00ednicos 7- alkiloxi y sulfoniloxi substituidos.   \n \nSustituciones en las posiciones 3 y/o 4 del n\u00facleo de cumarina tambi\u00e9n \ncontribuyen a modular la actividad inhibidora y la selectividad MAO -B de los \nderivados anteriormente descritos. Se puede inferir que el sitio de uni\u00f3n de la \nMAO-B debe aceptar sustituyentes lipof\u00edlicos de tama\u00f1o limitado en las posiciones 3 y/o 4 del n\u00facleo de cumarina, mientras que los grupos hidr\u00f3fobos, \nhidr\u00f3filos y/o m\u00e1s grandes, no son bien tolerados. Sin embargo, los derivados \nde 7-benziloxicumarinas, teniendo sustituyentes polares debidamente \n54Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a055 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0seleccionados en la posici\u00f3n 4, condujeron a nuevos IMAO -B con un mejor \nperfil farmacocin\u00e9tico.172 \nB. Rendenbach-M\u00fcller y col. tambi\u00e9n han  explorado la importancia de la \npresencia de un grupo heteroarilalcoxi en la posici\u00f3n 7 del esqueleto de \ncumarina para modular la actividad contra las isoformas de la MAO. En este \nestudio, los peque\u00f1os grupos tipo alquilo, fenilo o hal\u00f3geno se introdujeron  en \nlas posiciones 3 y 4 del esqueleto. Los mismos autores han evaluado y descrito \nheteroarilalcoxicumarinas como p otentes y selectivos IMAO -B123,173 en los que \nse introdujeron peque\u00f1os sustituyentes , como grupos metilo, en las posiciones \n3 y 4 de este n\u00facleo de cumarina.  \nDesde el trabajo pionero de H. A. Kadir y col., y el descubrimient o del \npotencial del esqueleto de la cumarina  frente a ambas isoformas de la MAO, \nhan sido sintetizadas nuevas generaciones de mol\u00e9culas diferentemente \nsustituidos y evaluadas in vitro en ensayos farmacol\u00f3gicos. Algunos de los \nderivados descritos son compuestos muy activos y selectivos, con CI50 en el \nrango nanoMolar. Sobre la base de estos importantes estudios, hay varios \nproyectos en curso para el dise\u00f1o racional de f\u00e1rmacos basado en la estructura \nde las nuevas mol\u00e9culas.174 Estos descubrimientos sin duda facilitar\u00e1n  la \nobtenci\u00f3n de nuevas terap\u00e9uticas eficaces y seguras de un problema creciente \ne importante de los pa\u00edses desarrollados: las e nfermedades \nneurodegenerativas.  \n \n55Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a057 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a02. Antecedentes y objetivos Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a059 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a02.1. Antecedentes \n \nEn los \u00faltimos a\u00f1os se ha hecho un gran esfuerzo por conocer el mecanismo \nmolecular de la interacci\u00f3n de los IMAO con los receptores de las MAO y ello \nha originado un elevado n\u00famero de compuestos con esta actividad. \nNuestro grupo ha elaborado una base de datos con la actividad I MAO \nexperimental de m\u00e1s de 1000 compuestos entre los que hab\u00eda algunas \nestructuras cumar\u00ednicas preparadas en nuestro laboratorio ( Figura 28).  No solo \nse encontraron algunos compuestos de inter\u00e9s y con cierta selectividad MAO -\nA, sino que adem\u00e1s se  ha podido establecer un modelo QSAR  capaz de \npredecir la actividad de actividad IMAO nuevas mol\u00e9culas.178,179 \n \nO O OO\nO O OO\nCn \nIMAO -A   IMAO -B \nFigura 28. Algunos derivados preparados previamente en el laboratorio.  \n \nDesde su origen nuestro grupo de investigaci\u00f3n viene estudiando el \nesqueleto cumar\u00ednico y su modificaci\u00f3n estructural dirigida a diferentes \nintereses farmacol\u00f3gicos,18,56,175,176,177,178,179 habiendo realizados varias \nrevisiones recientes sobre este tema.11,15 \nAdem\u00e1s de los referidos estudios de actividad IMAO, realizados en \ncolaboraci\u00f3n con el Laboratorio de Farmacolog\u00eda de nuestra Facultad, \nest\u00e1bamos tambi\u00e9n colaborando en el estudio de otros prototipos cumar\u00ednicos , \ncomo potenciales cardioprotectoresy/o vasodilatadores .15 El destacado \ninvestigador de este grupo, Francisco Orallo, trabajaba  desde hace tiempo en \neste campo obteniendo excelentes resultados y de manera muy destacada  con \nel resveratrol, demostrando que posee una interesante actividad vasodilatadora \ne inhibidora de la agregaci\u00f3n plaquetaria, propiedades que permiten considerar \nal mismo como un interesante cardioprotector.55,87 \nA lo largo del trabajo presentado en esta Memoria hemos tambi\u00e9n tenido en \ncuenta como referencia para el dise\u00f1o de algunos de los compuestos estudiados como neuroprotectores, las estructuras de la sele gilina o la \n59Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a060 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0rasagilina como IMAO -B, o de la AP2238 o la fenserina como inhibidores de \nAChE (Figura 29), incorporando sobre el esqueleto cumar\u00ednico o 3 -\narilcumar\u00ednico partes estructurales de estos compuestos buscando, en alg\u00fan \ncaso, f\u00e1rmacos multidiana.  \n \nNCH3\nSelegilina\nMAOI-B\nCl N\nHO\nON\nNR\nR'\nFenserina\nAChEIO OH3CO\nH3CON\nAP2238\nAChEI - inhibidor de la \u03b1\u03b2-agregaci\u00f3 nPhNH\nRasagilina\nMAOI-B/neuroprotectorCH3H\n \nFigura 29. Algunos de los compuestos de referencia usados en el dise\u00f1o de los nuevo s \ncompuestos descritos en esta M emoria.  \n \nUtilizamos tambi\u00e9n como estructuras de referencia la umbeliferona, conocida \ncomo inhibidor de la tirosinasa  o la novobiocina, conocida como antibacteriano. \nTambi\u00e9n las estructuras de la quercetina y de la catequina, importantes \nantioxidantes cumar\u00ednicos, han sido fuente de inspiraci\u00f3n para los estudios \nelectroqu\u00edmicos y de capacidad antioxidante de nuestras mol \u00e9culas. \n \n60Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a061 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a02.2. Objetivos  \n \nDebido a las propiedades encontradas en el resveratrol y algunas \ncumarinas,178 nos ha parecido muy interesante dise\u00f1ar y sintetizar compuestos \nque incorporasen en su esqueleto estas dos estructuras  y que a su vez pueden \nconsiderarse an\u00e1logos estructurales de las citadas  3,4-benzocumarinas en las \nque el anillo benc\u00e9nico es introducido en la p osici\u00f3n 3 de la misma (Figura 30).  \n \nO O\nO O  \nFigura 30. Derivados h\u00edbridos cumarina- resveratrol.  \n \nAs\u00ed pues hemos planteado el estudio exhaustivo de estas nuevas estructuras \nh\u00edbridas, 3-arilcumarinas, en las cuales el anillo cumar\u00ednico comparte el anillo \nbenc\u00e9nico y el doble enlace con el resveratrol de forma que este queda \nbloqueado como is\u00f3mero trans.179 Adem\u00e1s se pens\u00f3 en ampliar el estudio a \nh\u00edbridos donde la posici\u00f3n 3 estuviese sustituida por diferentes heterociclos \n(Figura 31). \n \nO ORR'\nO ORR'S\nO ON\nRR'\n \nFigura 31. Prototipo estructural  del esqueleto de la s 3-aril y 3-heteroaril cumarina s (R y R\u2019 \npueden ser \u00e1tomos de bromo o cloro, o bien grupos alquilo, alcoxi, hidroxilo, nitro, amino, etc).  \n \nSe intentar\u00eda la s\u00edntesis de estas seri es utilizando metodolog\u00edas lo m\u00e1 s \ndirectas y vers\u00e1tiles posible intentado estrategias de alta eficacia, que nos \npermitiesen obtener los diferentes compuestos con alta pureza y en cantidad \nsuficiente para los ensayos farmacol\u00f3gicos previstos.  \nEl estudio farmacol\u00f3gico inicial supon\u00eda observar la eficacia de serie s \nseleccionadas de estos compuestos sobre determinadas dianas con inter\u00e9s en \n61Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a062 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0problemas relacionados con la edad y en particular con trastornos \nneurodegenerativos. Especialmente MAO y AChE , implicadas de manera muy \nfundamental en enfermedades tales como la EP o la EA respectivamente.  \nAdem\u00e1s, se pretend\u00eda asociar a estas propiedades mas espec\u00edficas, otras \nque pudiesen coadyuvar como son las propiedades antioxidantes.  \nLa selecci\u00f3n de estas series  se realizar\u00eda con dos visiones complementarias: \na) introducir sustituyentes de diferente naturaleza en distinto n\u00famero y posici\u00f3n, \natendiendo fundamentalmente a variabilidad est\u00e9rica, electr\u00f3nica  y/o de lipofilia  \n(\u00e1tomos de cloro o bromo, grupos arilo, alquilo, alcoxilo, hidroxilo, nitro, amino \ny/o combinaciones de varios de estos \u00e1tomos y/o grupos , utilizado el diagrama \nde Craig) y b) utilizando datos precedentes y la l\u00f3gica bioqu\u00edmica, adem\u00e1s de \nla ayuda que pudi\u00e9semos obtener por el uso de metodolog\u00edas computacionales \ntanto de QSAR como de modelado molecular . \nEn otras series, la posici\u00f3n 3 de la cumarina se substituy\u00f3 por  puentes de \ntipo \u00e9ster, amida y carbamato, incorporando rasgos estructurales espec\u00edficos \npresentes en mol\u00e9culas de utilidad cl\u00ednica. En el sentido de explotar diferencias \nde reactividad y de actividad, los mismos sustituyentes han sido introducidos en \ndiferentes posiciones del n\u00facleo cumar\u00ednico  (Figura 32). \n \nO O O ORH\nN O\nR'\nOHN\nOR'\nR\nO OO\nORR\n \nFigura 32. Prototipo estructural de diferentes derivados sintetizados y estu diados (R y R\u2019 \npueden ser diferentes grupos ).  \n \nFue tambi\u00e9n un marcado objetivo intentar explorar con estas series o con \nmodificaciones espec\u00edficas de las mismas en algunos casos, otras dianas farmacol\u00f3gicas o intereses terap\u00e9uticos. As\u00ed, se pens\u00f3 en explorar actividades \nquimioter\u00e1picas de diferente tipo, otras inhibiciones enzim\u00e1ticas como la \ntirosinasa, o interacci\u00f3n con otros receptores como los de adenosina\u2026 y esta \nes todav\u00eda una tarea inacabada.  \nEl objetivo global de la Tesis fue realizar un exhaustivo estudio de REA en \neste grupo de cumarinas y su inter\u00e9s en trastornos neurodegenerativos, siguiendo una metodolog\u00eda c\u00edclica de s\u00edntesis, evaluaci\u00f3n farmacol\u00f3gica, dise\u00f1o y de nuevo s\u00edntesis, intentando conocer mejor los procesos involucrados \n62Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a063 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0y obtener mol\u00e9culas de alto inter\u00e9s como nuevos f \u00e1rmacos. Un objetivo \ncolateral pero no olvidado fue tambi\u00e9n explorar el valor de estas estructuras o \nan\u00e1logos muy pr\u00f3ximos , con intereses farmacol\u00f3gicos diferentes.  \n \n63Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a065 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a03. Discusi\u00f3n de resultados Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a067 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0El trabajo descrito en esta Memoria incluye la s\u00edntesis de series \nseleccionadas de compuestos y su caracterizaci\u00f3n estructural con la pureza y \nla calidad necesarias para su estudio farmacol\u00f3gico. Adem\u00e1s, incluye estudios \nte\u00f3ricos de las mismas. Parte de estos estudios son fruto de interesantes \ncolaboraciones con grupos de la Universidad de Santiago de Compostela (en \ncolaboraci\u00f3n con el Prof. Francisco Orallo y la Prof. Dolores Vi\u00f1a han sido \nrealizados estudios de inhibici\u00f3n de la MAO -A, MAO-B, AChE y estudios de \nneuroprotecci\u00f3n, y en colaboraci\u00f3n con la Prof. Ysabel Santos y la Prof. \nAngeles Mu\u00f1oz han sido realizados estudios  antibacterianos), de la \nUniversidad de Cagliari (en colaboraci\u00f3n con la Prof. Marcella Corda han sido \nrealizados estudios de inhibici\u00f3n de la tirosinasa), de la Universidad de Coimbra (en colaboraci\u00f3n con la Prof. Ana Maria Brett han sido realizados estudios electroqu\u00edmicos), de la Universidad de Santiago de Chile (en \ncolaboraci\u00f3n con el Prof. Claudio Olea han sido realizados estudios de \nevaluaci\u00f3n de la capacidad antioxidante) y de la Universidad de W\u00fcrzburg (en colaboraci\u00f3n con el Prof. Karl-Norbert Klotz han sido realizados estudios en \nreceptores de adenosina). Para tratar d e explicar los datos experimentales \nobtenidos, y extraer informaci\u00f3n de los ensayos in vitro y in vivo, han sido \nrealizados estudios de docking y estudios te\u00f3ricos de capacidad de paso de \nmembranas y otros par\u00e1metros de ADME (en colaboraci\u00f3n con Santiago V ilar y \nGiulio Ferino). Sin el esfuerzo conjunto no habr\u00edamos llevado a cabo todos \nestos proyectos ni hab\u00edamos obtenido los resultados presentes en esta \nMemoria. \nEstos estudios interdisciplinares demue stran que algunos de los compuestos \nevaluados son m\u00e1s activos y m\u00e1s selectivos que los compuestos de referencia frente a diferentes dianas farmacol\u00f3gicas. Adem\u00e1s, nos han permitido \nestablecer interesantes REAs que nos permiten un dise\u00f1o racional de nuevos \nf\u00e1rmacos basados en las estructuras de los receptores y en las estructuras de \nlos ligandos de los mismos.  \nComo ha sido descrito en la I ntroducci\u00f3n, a lo largo del trabajo experimental \npresentado en esta Memoria, hemos utilizado la versatilidad de diferentes v\u00edas sint\u00e9ticas para obtener las amplias familias de derivados que han sido posteriormente caracterizados y estudiados. Hemos buscado las rutas sint\u00e9ticas m\u00e1s r\u00e1pidas y cuyos reactivos, preferencialment e de bajo coste, se \n67Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a068 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0adaptaban mejor a nuestras necesidades. A continuaci\u00f3n son brevemente  \ndescritas las reacciones m\u00e1s utilizadas en el trabajo  experimental de esta \nMemoria.  \n \n3.1. S\u00edntesis \n \n3.1.1.  Preparaci\u00f3n de los esqueletos cumar\u00ednicos  \n \n3.1.1.1 . Reacci\u00f3n de Perkin y Perkin -Oglialoro  \n \nLa etapa clave del planteamiento sint\u00e9tico para la obtenci\u00f3n de las 3-aril y 3-\nheteroarilcumarinas ha sido una reacci\u00f3n de tipo Perkin180 entre un aldeh\u00eddo \nsalic\u00edlico (orto-hydroxybenzaldeh\u00eddo) y un \u00e1cido aril /heteroarilac\u00e9tico, ambos \nconvenientemente substituidos, en presencia de la sal s\u00f3dica del \u00e1cido.181 Las \ncondiciones de esta reacci\u00f3n son sencillas, y el rendimiento muy \nsatisfactorio.182 La versatilidad de esta reacci\u00f3n permiti\u00f3 obtener varias  familia s \nde compuestos cuyos rendimientos var\u00edan entre 45 y 80%, dependiendo de los \nsustituyentes de los reactivos de partida. Los productos de reacci\u00f3n obtenidos \nse purificaron f\u00e1cilmente por cromatograf\u00eda de columna.   \nEn el caso de la preparaci\u00f3n de la s cumarinas planteadas para este trabajo, \nla s\u00edntesis v\u00eda Perkin ha sido llevada a cabo en presencia de DCC, usada  como \nagente des hidratante, en DMSO a 110 \u00baC. Estas condiciones  han sido la mejor \nsoluci\u00f3n para la preparaci\u00f3n de todos los derivados, con excepci\u00f3n a los derivados con sustituyentes hidroxilo y los nitro derivados. Los derivados \nhidroxilados han sido prepa rados v\u00eda hidr\u00f3lisis de los respectivos derivados \nmetoxilados, etoxilados o acetoxilados.  \nLos derivados de tipo \u201cacetoxilo\u201d han sido preparados usando una reacci\u00f3n \nde Perkin modificada, tipo Perkin -Oglialoro, entre los salicilaldeh\u00eddos y los \n\u00e1cidos arilac\u00e9ticos, en anh\u00eddrido ac\u00e9tico (Ac\n2O) y acetato pot\u00e1sico (CH 3COOK).  \nLos derivados de tipo \u201cnitro\u201d se obtuvieron a trav\u00e9s de una reacci\u00f3n de \nPerkin modificada con nuevas condiciones, utilizando un salicilaldeh\u00eddo y un \n\u00e1cido arilac\u00e9tico, en presencia de hidru ro s\u00f3dico (NaH) en anh\u00eddrido ac\u00e9tico, \npor 20 horas.183 \n68Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a069 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0La presencia de los anillos arom\u00e1ticos de las cumarinas preparadas es muy \nclara en los espectros de 1H RMN. Los protones arom\u00e1ticos aparecen en el \nespectro alrededor de 6.5-8 ppm, siendo H-4 el prot\u00f3n m\u00e1s desapantallado y el \nm\u00e1s f\u00e1cilmente identificable ya que es un singlete debido a la presencia de un \ngrupo arilo en posici\u00f3n 3 de la cumarina.  \n \n3.1.1.2 . Reacci\u00f3n de acoplamiento con paladio  \n \nAl largo del trabajo experimental hemos desarrollado alternativas a las v\u00edas \nsint\u00e9ticas tradicionales para la obtenci\u00f3n de nuestros compuestos. Un protocolo novedoso para la r\u00e1pida y eficiente s\u00edntesis de las 3 -arilcumarinas ha sido \nllevado a cabo, utilizando una reacci\u00f3n de cross-coupling catalizada por paladio \nen la forma de un complejo de paladio. Con esta metodolog\u00eda  hemos preparado \ndiferentes derivados a partir de \u00e1cidos bor\u00f3 nicos y 3-halogenocumarinas. La \nreacci\u00f3n se ha realizado en presencia de carbonato s\u00f3di co y una mezcla de \nDMF/H\n2O (1:1), a 110 oC, por 120-180 minutos. Los rendimientos de reacci\u00f3n \nson del orden del 60%. Este m\u00e9todo directo tiene la desventaja de la limitaci\u00f3n \nde los reactivos de partida. Por esta raz\u00f3n lo hemos utilizado simplemente \ncomo v\u00eda alternativa a las reacciones que tradicional ven\u00edamos utilizando.184 \n \n3.1.2.  Transformaciones funcionales  \n \n3.1.2.1 . Reacci \u00f3n de hidr\u00f3lisis de grupos \u00e9ter o \u00e9ster  \n Todos los derivados mono- o poli-metoxilados y/o etoxilados y/o acetoxilados \nhan sido hidrolizados para la obtenci\u00f3n de los correspon dientes derivados \nhidroxilados.  \nLos m\u00e9todos m\u00e1s comunes para esta transformaci\u00f3n recurren a reacciones \nen la presencia de un \u00e1cido de Lewis como el MgI\n2,185 el AlCl 3,186 el BBr 3187 o el \nAlBr 3. Como fuentes de protones son utilizados \u00e1cidos o alcoholes, siendo de \nuso com\u00fan el HCl, el MeOH o el EtOH. Estas reacciones se llevan a cabo, en su gran mayor\u00eda, utilizando como disolventes diclorometano, acetonitrilo, \nacetona, tetrahidrofurano o piridin a.  \n69Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a070 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Otra forma de hidrolizar los derivados preparad os, utilizada por nuestro \ngrupo, es la reacci\u00f3n con el \u00e1cido yodh\u00eddrico, en presencia de \u00e1cido ac\u00e9tico y \nanh\u00eddrido ac\u00e9tico. Esta reacci\u00f3n se llev\u00f3 a cabo a reflujo, durante 4 -5 horas. \nLos productos de reacci\u00f3n han sido de dif\u00edcil purificaci\u00f3n, pero con \nrendimientos  muy satisfactorios. La caracterizaci\u00f3n de los compuestos \nobtenidos  es muy clara por 1H RMN, ya que  el/los picos de los grupos \u2013OCH 3 \ndesaparecen claramente de la zona entre 3-4 ppm, apareciendo uno o m\u00e1s \npicos/bandas muy caracter\u00edsticos en la regi\u00f3n de los 10 ppm.  \nLos compuestos acetoxilados originaron  los correspondientes derivados \nhidroxilados mediante la desacetilaci\u00f3n en presencia de una soluci\u00f3n acuosa \nde HCl 2N y metanol, en reflujo, por 4 horas.  As\u00ed, cuando el objetivo del trabajo \nse centraba en los derivados hidroxilados y no en los metoxilados precursores, \nseguimos fundamentalmente esta v\u00eda porque te trata de una reacci\u00f3n  m\u00e1s \nlimpia y m\u00e1s f\u00e1cil de procesar.  \n \n3.1.2.2 . Reacci\u00f3n de halogenaci\u00f3n \n La halogenaci\u00f3n de compuestos arom\u00e1ticos y heteroarom\u00e1ticos es una \nimportante reacci\u00f3n en s\u00edntesis org\u00e1nica.\n188 Derivados de bromuros de arilo y \nheteroarilo pueden ser potenciales antioxidantes, antibacterianos o agentes \nantitumorales.189,190 Adem\u00e1s, la introducci\u00f3n de hal\u00f3genos en las 3 -\narilcumarinas hace de estas mol\u00e9culas precursores interesantes para  muchos \notros derivados sustituidos. Esto hace de la bromaci\u00f3n una reacci\u00f3n muy \nvers\u00e1til y, por lo tanto, ampliamente estudiada. Habitualmente  son utilizados \ncomo agentes de bromaci\u00f3n el tribromuro del tetraalquilamonio,191 el tribromuro \nde hexametilenotetramina192 y la N-bromosuccinimida (NBS).193,194 Sin \nembargo, debido a su disponibilidad y el f\u00e1cil manejo, este \u00faltimo es el principal \nagente de bromaci\u00f3n. En fase s\u00f3lida195 o en reacciones tradicionales, el uso de \nNBS es un m\u00e9todo de monobromaci\u00f3n eficaz y vers\u00e1til de arom\u00e1ticos y sus derivados, como son las cumarinas.\n196,197 Las condiciones de reacci\u00f3n, la \nsimplicidad y la velocidad del proceso son las vent ajas de este m\u00e9todo, llevado \na cabo con rendimientos muy buenos. La bromaci\u00f3n sobre el n\u00facleo de la \ncumarina no substituida ocurre preferentemente en el C-3. Como en las 3-\n70Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a071 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0arilcumarinas esta posici\u00f3n se encuentra bloqueada por un arilo, la posici\u00f3n de \nbromaci\u00f3n sobre estas mol\u00e9c ulas depender\u00e1 de la naturaleza de los \nsustituyentes presentes en los  anillos arom\u00e1ticos.198  \nEn nuestro caso todos los derivados han sido preparados mediante una \nreacci\u00f3n de bromaci\u00f3n cl\u00e1sica, con NBS y una cantidad catal\u00edtica de azobisisobutironitrilo (AIBN), en tetracloruro de carbono (CCl\n4). Las reacci\u00f3n se \nmantuvo a reflujo 24 horas, y los productos obtenidos han sido separados por \ncromatograf\u00eda en columna. Los rendimientos de reacci\u00f3n var\u00edan entre 40 y el \n60%. Siempre que la 3-arilcumarina no presentaba  sustituyentes en el grupo 3-\narilo, y ten\u00eda un metilo en cualquiera de los otros dos anillos, la bromaci\u00f3n \nocurri\u00f3 en este grupo metilo, permitiendo la obtenci\u00f3n de un derivado \nbromometilado. As\u00ed, en el caso de la 6-metil -3-fenilcumarina, tuvo lugar la \nbromaci\u00f3n benc\u00edlica, lo que ha permitido la obtenci\u00f3n de la 6-bromometil-3-\nfenilcumarina.199 \nEn el caso de los derivados con sustituyentes activantes (por ejemplo grupos \nmetoxilo) en el 3-arilo la bromaci\u00f3n tuvo lugar en una posici\u00f3n orto respecto a \nlos mismos. La reacci\u00f3n descrita ha permitido la obtenci\u00f3n de un gran n\u00famero \nde derivados halogenados en diferentes posiciones del n\u00fac leo de la cumarina. \nEstos pudieron ser, adem\u00e1s de nuevos productos, importantes precursor es \npara otros derivados, ya que es posible su substituici\u00f3n.  \n \n3.1.2 .3. Reacci\u00f3n de formaci\u00f3n de arilaminas  \n \n\u2022 Por aminaci\u00f3n de derivados halogenados \n \nLas arilaminas primarias pueden tener inter\u00e9s biol\u00f3gico por si mismas y son \nadem\u00e1s importantes intermediarios de reacci\u00f3n en la s\u00edntesis de nuevos \nf\u00e1rmacos. Cuando se obtienen a partir de los correspondientes haluros de arilo \nse realiza utilizando amoniaco como nucle\u00f3filo.200 Los principales problemas de \nesta reacci\u00f3n son la necesidad de presi\u00f3n y temperatura elevadas, y que l os \narinos intermediarios son muy inestables, haciendo esta reacci\u00f3n muy \ncomplicada. Por este motivo, la utilizaci\u00f3n de catalizadores de cobre y otros \nmetales de transici\u00f3n ha sido ampliamente estudiada , pero a\u00fan asi sus \n71Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a072 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0condiciones de presi\u00f3n y temperatura son bastante elevadas y la reacci\u00f3n es \ncompatible con muy pocos grupos funcionales.201 Para evitar estos \ninconvenientes ha sido desarrollado un m\u00e9todo sus tituyendo el amoniaco por \ntrifluoracetamida. En est e caso el grupo trifluoracetilo se puede eliminar \nf\u00e1cilmente en condiciones suaves. El punto clave de esta reacci\u00f3n es el acoplamiento cruzado entre la amida y los haluros de arilo.  Distintos ligandos \nhan sido probados para promover el acoplamien to cruzado catalizado por \ncobre, siendo la N,N\u2019-dimetiletilenodiamina (DMEMA) la que mejores \nrendimientos presenta.\n202 En presencia de un yoduro de arilo necesita apenas \nde 45  \u00baC para que la reacci\u00f3n ocurra , si bien, en nuestro caso, los bromuros de \narilo necesitaron de una temperatura de 75 \u00baC para optimizar la reacci\u00f3n. El \nmejor sistema catal\u00edtico ha mostrado ser el CuI/DMEDA y la reacci\u00f3n ha sido \noptimizada mediante tubo sellado a presi\u00f3n. Los bromuros de arilo han pudido \nser convertidos en los productos deseados co n rendimientos aceptables  entre \n60-80 %) . \nEl grupo trifluoracetilo formado e n la reacci\u00f3n pudo ser eliminado de forma \nsencilla a\u00f1adiendo una mezcla de metanol/agua en el tubo de reacci\u00f3n. El  \u00e9xito \nde la reacci\u00f3n tambi\u00e9n fue  debido a la presencia de carbona to de potasio \n(K2CO 3) en el paso de amidaci\u00f3n, que promovi\u00f3  la hidr\u00f3lisis del grupo \ntrifluoracetilo cuando el agua fue  a\u00f1adida. Teniendo en cuenta todos estos \nfactores, la reacci\u00f3n ha sido llevada a cabo seg\u00fan este nuevo m\u00e9todo one-pot  \nde s\u00edntesis de arilaminas primarias partiendo de haluros de arilo, sin necesidad de aislar intermediarios de reacci\u00f3n.\n203 \n \n\u2022 Por reducci\u00f3n de grupo s nitro \n \nLas 3-aminocumarinas se prepararon a partir de las 3 -nitrocumarinas \npreviamente sintetizadas o comerciales, en etanol, con Pd/C como catalizador \nen atm\u00f3sfera de hidrogeno (H 2). La reacci\u00f3n se ha llevado a cabo a \ntemperatura ambiente por 5 horas. El rendimiento es del orden del  92-98%.  \n \n3.1.2.4 . Reacci\u00f3n de alquilaci\u00f3n  \u2013 reacci\u00f3n de Williamson  \n \n72Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a073 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Uno de los objetivos de este trabajo ha sido estudiar la presencia de distintos \ngrupos sustituyentes para estudios de REA para lo que interes\u00f3  introducir en \nlos compuestos diferentes cadenas alqu\u00edlicas. Algunos de los derivados \nhidroxilados han sido transformados en \u00e9teres  de forma sencilla y eficaz \nutilizando la reacci\u00f3n de Williamson.204 \nLa utilizaci\u00f3n de una clorocetona como halogenuro de partida ha permitido la \npreparaci\u00f3n numerosos derivados con sustituyentes en las posiciones \ndeseadas. Los datos de 1H RMN permitieron claramente observar la formaci\u00f3n \nde los \u03b2-ceto\u00e9teres deseados. En todos los casos se ha visto claramente la \ndesaparici\u00f3n del prot\u00f3n hidrox\u00edlico. Y la aparici\u00f3n de nuestros grupos a diferentes ppm.  \nLa versatilidad de esta reacci\u00f3n ha permitido introducir en la mol\u00e9cula \nalcanos, cicloalcanos (en nuestro caso particular de cinco o seis \u00e1tomos) o bien \nhaloalcanos m\u00e1s o menos grandes.  \n \n3.1.2.5 . Preparaci\u00f3n de amidas , \u00e9steres  y carbamatos \n \nLa segunda parte de los objetivo s del trabajo descrito en esta Memoria ha \nsido la s\u00edntesis de cumarinas con funciones amida , \u00e9ster o carbamato partiendo \nde las correspondientes aminocumarinas o hidroxicumarinas  precursoras. \nHemos recurrido a aminocumarinas comerciales sencillas o nitrocumarinas que han sido previamente reducidas. Una reacci\u00f3n de acilac i\u00f3n de las \namino/hidroxicumarinas con un cloruro de \u00e1cido convenientemente sustituido, \nutilizando piridina y diclorometano, a la temperatura ambiente, durante tres \nhoras, nos permiti\u00f3 obtener las diferentes cumarinas substituidas, con muy \nbuenos rendimientos (80-95%).  \n3.1.3.  Series de compuestos sintetizados  \n \nEn las siguientes tablas est\u00e1n reunidas todas las estructuras qu\u00edmicas de las \nmol\u00e9culas descritas en la publicaciones presentadas en esta Memoria.  \n Tabla 1. Cumarinas sencillas. \n73Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a074 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0O OR3\nR8R7R4\nR6\n \nCompuesto R3 R4 R6 R7 R8 \n1 NO 2 H H H H \n2 NO 2 H H OCH 3 H \n3 NO 2 H H H OCH 3 \n4 NO 2 H CH 3 H H \n5 NO 2 H H H CH 3 \n6 NO 2 H OCH 3 H H \n7 NO 2 H H OCH 3 H \n8 NH 2 H H H H \n9 NH 2 H OCH 3 H H \n10 NH 2 H H OCH 3 H \n11 NH 2 H H H OCH 3 \n12 NH 2 H H OH H \n13 NH 2 H H H OH \n14 NH 2 OH H H H \n \nTabla 2. 3-Arilcumarinas.  \nO OR6\nR8R2'R3'\nR4'\nR5'\n \nCompuesto R6 R8 R2\u2019 R3\u2019 R4\u2019 R5\u2019 \n15 H H H H H H \n16 H H H OCH 3 H H \n17 H H H H OCH 3 H \n18 H H H OH H H \n19 H H H NO 2 H H \n20 H H H H NO 2 H \n21 H H H NH 2 H H \n22 H H H H CH 3 H \n74Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a075 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a023 H H H H Cl H \n24 CH 3 H H H H H \n25 CH 3 H H CH 3 H H \n26 CH 3 H H H CH 3 H \n27 CH 3 H OCH 3 H H H \n28 CH 3 H H OCH 3 H H \n29 CH 3 H H H OCH 3 H \n30 CH 3 H H OCH 3 H OCH 3 \n31 CH 3 H H OCH 3 OCH 3 H \n32 CH 3 H H OCH 3 OCH 3 OCH 3 \n33 CH 3 H H Br OCH 3 H \n34 CH 3 H H OCH 3 Br H \n35 CH 3 H Br OCH 3 H OCH 3 \n36 CH 3 H Br OCH 3 OCH 3 OCH 3 \n37 CH 3 H OH H H H \n38 CH 3 H H OH H H \n39 CH 3 H H H OH H \n40 CH 3 H H OH OH H \n41 CH 3 H Br H H H \n42 CH 3 H H Br H H \n43 CH 3 H H H Br H \n44 CH 3 H H C2H5O2 H H \n45 CH 3 H H H NO 2 H \n46 CH 3 H H NH 2 H H \n47 CH 3 H H H NH 2 H \n48 OCH 3 H H H H H \n49 OCH 3 H H CH 3 H H \n50 OCH 3 H H H CH 3 H \n51 OCH 3 H H H OCH 3 H \n52 OCH 3 H H NO 2 H H \n53 OCH 3 H H H NO 2 H \n54 OCH 3 H H Br H H \n55 OCH 3 H H H Br H \n75Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a076 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a056 OH H H H H H \n57 OH H H H CH 3 H \n58 OH H H Br H H \n59 OH H H H Br H \n60 C2H5O2 H H H CH 3 H \n61 C2H5O2 H H Br H H \n62 C2H5O2 H H H Br H \n63 C5H9O H H H CH 3 H \n64 C5H9O H H Br H H \n65 C5H9O H H H Br H \n66 C2H2O2Cl H H Br H H \n67 C2H2O2Cl H H H Br H \n68 NO 2 H H NO 2 H H \n69 NO 2 H H H NO 2 H \n70 NO 2 H H OCH 3 H H \n71 NO 2 H H H OCH 3 H \n72 NO 2 H H CH 3 H H \n73 NO 2 H H H CH 3 H \n74 NO 2 H H Br H H \n75 NH 2 H H H H H \n76 NH 2 H H NH 2 H H \n77 Br H H H OCH 3 H \n78 BrCH 3 H H H H H \n79 CH 3 Br H H H H \n80 CH 3 Br H H OCH 3 H \n81 CH 3 Br H OCH 3 H OCH 3 \n82 CH 3 Br H OCH 3 OCH 3 OCH 3 \n83 Br OCH 3 H H H H \n84 Br OCH 3 H H OCH 3 H \n85 Br OCH 3 H H CH 3 H \n86 Br OH H H H H \n87 Br OH H H OH H \n88 Br OH H H CH 3 H \n76Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a077 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a089 NH 2 OCH 3 H H H H \n90 H OCH 3 H H H H \n91 H OCH 3 H H Br H \n92 H OCH 3 H H OCH 3 H \n93 H CH 3 H H H H \n94 H CH 3 H H OCH 3 H \n95 H CH 3 H H CH 3 H \n96 H CH 3 H H Br H \n97 H CH 3 H OH OH H \n98 H CH 3 H OH OH OH \n99 H CH 3 H OH H OH \n100 H OCH 2CH 3 H H H H \n101 H OCH 2CH 3 H H OCH 3 H \n102 H OCH 2CH 3 H H CH 3 H \n103 H OH H H H H \n104 H OH H H OH H \n105 H OH H H CH 3 H \n \nTabla 3. 3-Heteroarilcumarinas.  \nO OH3C R3\n \nCompuesto R3 \n106 N Cl\n \n107 S\n \n108 S\nBr\n \n109 S\nNH2\n \n \nTabla 4. (Cumarin-3-il)-4-metilbenzoato.  \n110 \nO OO\nOCH3\n \n77Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a078 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \nTabla 5. 3-Amidocumarinas. \nO OH\nN\nOR1' R6R4\n \nCompuesto R4 R6 R1\u2019 \n111 H H CH 3 \n112 OH H CH 3 \n113 H H CH 2Br \n114 H H CH 2Cl \n115 H CH 3 CH3\n \n116 H H \n \n117 H H CH3\n \n118 H H OCH3\n \n119 H H Cl\n \n120 H H NO2\n \n121 H H OCH3\nOCH3 \n122 H H OCH3\nOCH3OCH3\n \n123 H H Cl\nCl \n124 H H \n \n \nTabla 6. 3-Carbamatocumarinas.  \nO OH\nN O\nR1'\nOR4\n \nCompuesto R4 R1\u2019 \n78Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a079 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0125 H CH 3 \n126 H CH 2CH 3 \n127 H CH(CH 3)2 \n128 H CH 2CH(CH 3)2 \n129 H CH 2Cl \n130 H CH 2CH 2Br \n131 H \n \n132 H  \n133 OH CH 2CH 3 \n134 OH CH 2CH(CH 3)2 \n \n3.2. Estudio biol\u00f3gico y relaci\u00f3n estructura -actividad (REA)  \n \nDespu\u00e9s de realizados diferentes ensayos biol\u00f3gicos in vitro y en algunos \ncasos in vivo, y de un estudio REA m\u00e1s detallado, ha  sido posible establecer  \nimportantes conclusiones de la relaci\u00f3n estructura/actividad de los compuestos \npreparados. En general los  compuestos descritos son potentes inhibidores \nselectivos de la MAO -B,205 la diana m\u00e1s estudiada en este trabajo , siendo los \nque presentan el esqueleto 3 -arilcumarina los que demostraron ser los m\u00e1s \ninteresantes.206,207 De todas las posiciones estudiadas, es muy favorable la \nintroducci\u00f3n de grupos poco voluminosos (por ejemplo metilo, bromo o \nmetoxilo) tanto en posici\u00f3n 6 y/o 8 como en las posiciones 3\u2019 y/o 4\u2019 del n\u00facleo \nde la 3 -arilcumarina.208 Grupos de diferente tama\u00f1o,  como otros anillos o \ndiferentes \u00e9teres, han demostrado bajar en gran  escala la actividad de dichas \nmol\u00e9culas. La 3-arilcumarina por si sola tampoco presenta una actividad \nnotable. Los estudios de docking han corroborado la informaci\u00f3n obtenida \nexperimentalmente. La cavidad de la enzima tiene las dimensiones ideales \npara nuestras 3-arilcumarinas cuando presentan peque\u00f1os sustituyentes en su esqueleto base. A mayores, experimentalmente y a trav\u00e9s de dichos estudios \nte\u00f3ricos, tambi\u00e9n hemos sido capaces de con cretar las posiciones del anillo en \n3 que mejor favorecen la interacci\u00f3n con el receptor. Las posiciones meta  y \npara, como dicho anteriormente, han demostrado ser las ideales. Los valores \n79Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a080 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0de CI50 de estos compuestos son, en muchos casos, del rango de bajo nano y \npicoMolar. Hemos encontrado que la 3-(3\u2019-bromofenil)-6-metilcumarina \n(compuesto 42) es m\u00e1s de 6000 veces m\u00e1s activo ( CI50 = 134.04 pM)  y m\u00e1s de \n200 veces m\u00e1s selectivo que la selegilina, usada como compuesto de \nreferencia. Estos datos nos han incent ivado a seguir estudiando este tipo de \nderivados frente a esta diana.  \nHemos realizado diferentes estudios electroqu\u00edmicos209 y de capacidad \nantioxidante de algunas de las 3 -arilcumarinas hidroxiladas.210 Los resultados \nhan sido estimulantes , ya que los potenciales de oxidaci\u00f3n de estos \ncompuestos son bajos y los ORAC-FL bastante elevados con respecto al trolox, el compuesto de referencia. El compuesto m\u00e1s interes ante de la serie \nestudiada, la 3-(4\u2019-hidroxifenil)-8-hidroxicumarina (compuesto 104), ha \npresentado un valor de ORAC-FL de 13,5, conjuntamente al m\u00e1s bajo potencial \nde oxidaci\u00f3n y el 100% de atrapamiento de radicales hidroxilo. La asociaci\u00f3n de este tipo de actividad con la ya mencionada actividad IMAO es una importante estrategia en la obtenci\u00f3n de f\u00e1rmacos con actividades m\u00faltiples.  \nAvanzando un poco m\u00e1s en el estudio, hemos encontrado algunas 3 -\namidocumarinas con actividad inhibitoria dual de MAO -B y AChE.\n211 El perfil de \nestos derivados nos ha abierto un camino en el estudio de inhibidores duales y multi-diana. Los derivados con grupos metilo y clorofenil adjuntos al enlace \nam\u00eddico han sido los m\u00e1s interesantes frente a las dos enzimas.  \nEn un estudio posterior algunos de los derivados tipo carbamato han \nmejorado las actividades IMAO -B obtenidas para las amidas correspondientes, \nperdiendo algunos de ellos la actividad inhibidora de la AChE. As\u00ed que el mejor compuesto de esta serie (bencil(cumarin-3-il)carbamato (compuesto 132), CI\n50 \nMAO-B = 45 nM) fue estudiado in vivo y los resultados han sido muy \nesperanzadores.212 De estas dos series, y buscando ligandos de receptores de \nadenosina implicados en enfermedades neurodegenerativas, hemos encontrado compuestos con actividades moderadas que nos han incentivado a un estudio m\u00e1s profundo en esta \u00e1rea.\n213 \nEstudios antibacterianos han sido realizados en diferentes familias de las \ncumarinas sintetizadas.214,215 Los resultados frente a bacterias humanas m\u00e1s \ninteresantes han sido obtenidos con cumarinas sencillas y algunas 3 -\narilcumarinas nitro-sustituidas. De todas las l\u00edneas  bacterianas estudiadas los \n80Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a081 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0resultados m\u00e1s relevantes han sido encontrados frente a S. aureus y E. coli, \ndos de las bacterias m\u00e1s comunes en patolog\u00edas. Alguna  de las mol\u00e9culas \nestudiadas ha pr esentado resultados comparables a los compuestos de \nreferencia, y nos han permitido establecer importantes REAs.  En particular, la \n3-(3\u2019-metilfenil) -6-nitrocumarina (compuesto 72) ha presentado un halo de \ninhibici\u00f3n frente a S. aureus de 32 mm y un MIC de 8 \u00b5g/mL, valores \ncomparables con la ampicilina (hal o = 32 mm y MIC = 2 \u00b5g/mL), usada como \ncompuesto de referencia.215 \nAlgunas cumarinas sencillas estructuralmente parecidas a la tirosina y \nalgunas 3-arilcumarinas con \u00e1tomos de bromo en diferentes posiciones han \nprobado tener inter\u00e9s en estudios de inhibici\u00f3n  de tirosinasa. Estos compuestos \nhan presentado interesantes perfiles cuando comparados con la umbeliferona, el compuesto de referencia. El compuesto 6 -bromo-3-(4\u00b4-hidroxifenil)-8-\nhidroxicumarina (compuesto 87) ha presentado un valor de inhibici\u00f3n de la \ntirosinasa inferior a la umbeliferona, pero fue la 3 -amino-7-hidroxicumarina \n(compuesto 12) el compuesto m\u00e1s activo de todos los estudiados ( CI\n50 = 0.05 \nmM). Este compuesto es 8 veces m\u00e1s activo que el compuesto de \nreferencia.216,217 \nLas rutas sint\u00e9ticas utilizadas, la caracterizaci\u00f3n de los compuestos, los \nensayos farmacol\u00f3gicos y electroqu\u00edmicos, y los estudios te\u00f3ricos y de REA \nest\u00e1n presentados y discutidos en los respectivos manuscritos, incluidos en el  \napartado experimental de esta Memoria.  \n \n3.3. Aportaciones estructurales y te\u00f3ricas  \n \nA lo largo del trabajo descrito, diferentes estudios te\u00f3ricos (modelizaci\u00f3n y \nsemi-emp\u00edricos) han aportado informaci\u00f3n clave de apoyo a los estudios de \nREA de los compuestos evaluados . Han sido realizados estudios de docking \nrecurriendo al uso de los programas MAESTRO  y MOE, usando como \nreferencia para la validaci\u00f3n de los estudios las estructuras cristalinas de las prote\u00ednas encontradas en el PDB.  \nSimulaciones de docking se han realizado utilizando el protocolo Quantum \nMechanical Polarized Ligand  Docking (QPLD), implementado  en \n81Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a082 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Schrodinger.218 El algoritmo ha utilizado la metodolog\u00eda ab initio para calcular \nlas cargas del ligando dentro del entorno de prote\u00edna. En nuestro protocolo \nQPLD, despu\u00e9s de la preparaci\u00f3n del ligando y de la prote\u00edna, el Glide realiz\u00f3 \nel primer c\u00e1lculo de docking, con la generaci\u00f3n de las carga s iniciales con \nm\u00e9todos semiemp\u00edricos. En el segundo paso, la teor\u00eda funcional de densidad  \n(DFT), con Jaguar, fue aplicado para el  tratamiento completo de la mec\u00e1nica \ncu\u00e1ntica del ligando (QM). Un re-docking de los ligandos mediante el uso de las \ncargas calculadas por Jaguar y,  por \u00faltimo, el algoritmo de QPLD llevaron a la \nobtenci\u00f3n de las poses  energ\u00e9ticamente m\u00e1s favorables para cada ligando. \nUna minimizaci\u00f3n utilizando el P rimer MM-GBSA se llev\u00f3 a cabo con el \u00fanico \nobjetivo de minimizar las poses derivadas  del QPLD, teniendo en cuenta  la \nflexibilidad de los residuos del bolsillo de uni\u00f3n dentro de una distancia  de 5 \u00c5 a \nlos ligando. La metodolog\u00eda de docking mencionada ha demostrado ser muy \u00fatil \npara proponer poses de uni\u00f3n de los derivados estudiados , destacando la \nimportancia de las sustituciones en las posiciones 3, 6 y 8 de la cumarina, bien \ncomo de las posiciones meta  y para del anillo arom\u00e1tico en posici\u00f3n 3 de la 3 -\narilcumarina.205,208 \nEstudios semi-emp\u00edricos como el AM1 y el PM3 han sido llevados a cabo \npara comparar los resultados de los rayos X con los obtenidos por el an\u00e1lisis \nconformacional seguido por  estas metodo log\u00edas. Los c\u00e1lculos te\u00f3ricos dieron \nresultados que reprodujeron eficazmente la estructura tridimensional (3D) de \nlas mol\u00e9culas estudiadas por rayos X, lo cual significa que la determinaci\u00f3n \nestructural te\u00f3rica en la fa se gaseosa puede ser extrapolada .219 \n82Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a083 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n \n4. Parte experimental Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a085 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a04.1. Art\u00edculos publicados  \n1. \u201cRegioselective synthesis of different bromo substituted 3 -arylcoumarins\u201d \n(Matos, M.J.*; Delogu, G.; Podda, G.; Santana, L.; Uriarte, E. ) \u2013 Synthesis \n2010, 16, 2763 -2766.  \n2. \u201cSynthesis of 3-arylcoumarins via Suzuki-cross-coupling reactions of 3-\nchlorocoumarin\u201d (Matos, M.J.*; Vazquez-Rodriguez, S.; Borges, F.; Santana, L.; \nUriarte, E.) \u2013 Tetrahedron Letters 2011, 52, 1225 -1227.  \n3. \u201cImproved synthesis of 3-(aminoaryl)coumarins\u201d (Matos, M.J.*; Gaspar, A.; \nBorges, F.; Uriarte, E.; Santana, L.) \u2013 Organic Preparations and Procedures \nInternational 2012, 44, 522 -526.  \n4. \u201c3-Phenylcoumarin\u201d (Matos, M.J.*; Santana, L.; Uriarte, E.) \u2013 Acta \nCrystallographica 2012, E68, o2645.   \n5. \u201cN-(2-Oxo-2H-chromen-3-yl)cyclohexanecarboxamide \u201d (Matos, M.J.*; \nSantana, L.; Uriarte, E.) \u2013 Acta Crystallographica 2012, E68, o3447-o3448.  \n6. \u201cSynthesis, NMR characterization, X-ray structural analysis and theoretical \ncalculations of  amide and ester derivatives of the coumarin scaffold\u201d ( Matos, \nM.J.*; Uriarte, E.; Santana, L.; Vilar, S.) \u2013 Journal of Molecular Structure 2013, \n1041, 144 -150.  \n7. \u201cA new series of 3-phenylcoumarins as potent and selective MAO -B \ninhibitors\u201d (Matos, M.J.*; Vi\u00f1a, D.;  Quezada, E.; Picciau, C.; Delogu, G.; Orallo, \nF.; Santana, L.; Uriarte, E.) \u2013 Bioorganic & Medicinal Chemistry Le tters 2009,  \n19, 3268 -3270.  \n8. \u201cSynthesis and evaluation of 6 -methyl -3-phenylcoumarins as potent and \nselective MAO-B inhibitors\u201d (Matos, M.J.*; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; \nSantana, L.; Uriarte, E.) \u2013 Bioorganic & Medicinal Chemistry Letters  2009, 19, \n5053-5055.  \n9. \u201cNew halogenated 3-phenylcoumarins as potent and selective MAO -B \ninhibitors\u201d (Matos, M.J.*; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, \nE.) \u2013 Bioorganic & Medicinal Chemistry Letters  2010, 20, 5157 -5160.  \n85Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a086 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a010. \u201cMAO inhibitory activity modulation: 3 -phenylcoumarins versus 3-\nbenzoylcoumarins\u201d (Matos, M.J.; V\u00e1zquez -Rodriguez, S.; Uriarte, E.; Santana, \nL.; Vi\u00f1a, D.*) \u2013 Bioorganic & Medicinal Chemistry Letters 2011, 21, 4224 -4227.  \n11. \u201cSynthesis and study of a series of 3 -arylcoumarins as potent an d selective \nmonoamine oxidase B inhibitors\u201d  (Matos, M.J.*; Ter\u00e1n, C.; P\u00e9rez-Castillo, Y.; \nUriarte, E.; Santana, L.; Vi\u00f1a, D.*) \u2013 Journal of Medicinal Chemistry  2011, 54, \n7127-7137.  \n12. \u201c8-Substituted-3-arylcoumarins as potent and selective MAO -B inhibitors: \nsynthesis, pharmacological evaluation and docking studies\u201d  (Vi\u00f1a, D.; Matos, \nM.J.*; Ferino, G.*; Cadoni, E.; Laguna, R.; Borges, F.; Uriarte, E.; Santana, L.) \u2013 \nChemMedChem  2012, 7, 464 -470.  \n13. \u201cFocusing on new monoamine oxidase inhibitors: differently substituted \ncoumarins as an interesting scaffold\u201d (Matos, M.J.; Vi\u00f1a, D.; Vazquez -\nRodriguez, S.; Uriarte, E.; Santana, L.*) \u2013 Current Topics in Medicinal \nChemistry 2012, 12, 2210 -2239.  \n14. \u201cNovel (coumarin-3-yl)carbamates as selective MAO -B inhibitors: synthesis, \nin vitro and in vivo assays, theoretical evaluation of ADME properties and \ndocking study\u201d (Matos, M.J.*; Vilar , S.; Gonzalez-Franco, R.M.; Uriarte, E.; \nSantana, L.; Friedman, C.; Tatonetti , N.P.; Vi\u00f1a, D.; Fontenla, J.A.) \u2013 European \nJournal of Medicinal Chemistry  2013, 63, 151 -161. \n15. \u201c3-Substituted coumarins as dual inhibitors of AChE and MAO for the \ntreatment of Alzheimer\u00b4s disease\u201d (Vi\u00f1a, D.; Matos, M.J.*; Y\u00e1\u00f1ez, M.; Santana, \nL.; Uriarte, E.) \u2013 MedChemComm  2012, 3, 213 -218.  \n16. \u201cNew halogenated phenylcoumarins as tyrosinase inhibitors\u201d  (Matos, M.J.*; \nSantana, L.; Uriarte, E.; Delogu, G.; Corda, M.; Fadda, M.B.; Era, B.; Fais, A.) \u2013 \nBioorganic & Medicinal Chemistry Letters  2011, 21, 3342 -3345.  \n17. \u201cTyrosine-like condensed derivatives as tyrosinase inhibitors\u201d (Matos, M.J.*; \nSantana, L.; Uriarte, E.; Serra, S.; Corda, M.; Fadda, M.B.; Era, B.; Fais, A.) \u2013 \nJournal of Pharmacy and Pharmacology 2012, 64, 742 -746.  \n18. \u201cTargeting adenosine receptors with coumarins: synthesis and binding \nactivities of amide and carbamate derivatives\u201d  (Matos, M.J.*; Gaspar, A.; \n86Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a087 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0Kachler, S.; Klotz, K.-N.; Borges, F.; Santana, L.; Uriarte, E.) \u2013 Journal of \nPharmacy & Pharmacology  2013, 65, 30 -34. \n19. \u201cLooking for new targets: simple coumarins as antibacterial agents\u201d  (Matos, \nM.J.*; Vazquez-Rodriguez, S.; Santana, L.; Uriarte, E.; Fuentes -Edfuf, C.; \nSantos, Y.; Mu\u00f1oz-Crego, A.) \u2013 Medicinal Chemistry 2012, 8, 1140 -1145.  \n20. \u201cSynthesis and structure-activity relationships of novel amino/nitro \nsubstituted 3-arylcoumarins as antibacterial agents\u201d (Matos, M.J.*; Vazquez -\nRodriguez, S.; Santana, L.; Uriarte, E.; Fuentes -Edfuf, C.; Santos, Y.; Mu\u00f1oz-\nCrego, A.) \u2013 Molecules 2013, 18, 1394-1404.  \n21. \u201cNew hydroxylated 3-arylcoumarins, synthesis and electrochemical study\u201d \n(Janeiro, P.; Matos, M.J.; Santana, L.; Uriarte, E.; Oliveira-Brett, A.M.*) \u2013 \nJournal of Electroanalytical Chemistry 2013, 689, 243 -251.  \n\u201cRemarkable antioxidant properties of a series of hydroxy -3-arylcoumarins\u201d \n(Matos, M.J.*; P\u00e9rez-Cruz, F.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L.; \nBorges, F.; Olea-Azar, C.) \u2013 Bioorganic & Medicinal Chemistry  2013, 21, 3900 -\n3906.  \n4.2. Art\u00edculos en fase de publicaci\u00f3n  \n22. New Insights into Functional and Structural Properties of 3 -Arylcoumarins \nas an Interesting Scaffold in MAO -B Inhibition (Matos, M.J.*; Vilar, S.*; Garc\u00eda-\nMorales, V.; Friedman, C.; Uriarte, E.; Santana, L.; Vi\u00f1a, D.), enviado. \n23. Synthesis and adenosine receptors binding affinities of a series of 3 -\narylcoumarins (Matos, M.J.*; Hogger, V.; Gaspar, A.; Kachler, S.; Borges, F.; \nUriarte, E.; Santana, L.; Klotz, K.-N.) \u2013 Journal of Pharmacy & Pharmacology  \n2013, aceptado. \n \n \n87PAPER 2763\nRegioselective Synthesis of Bromo-Substituted 3-Arylcoumarins\nRegioselective Synthesis of Bromo-Substituted 3-ArylcoumarinsMaria Jo\u00e3o Matos,*a Giovanna Delogu,b Gianni Podda,b Lourdes Santana,a Eugenio Uriartea\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, \nSpain\nFax +34(981)594912; E-mail: mariacmatos@gmail.com\nbDipartimento Farmaco Chimico Tecnologico, Universit\u00e0 degli Studi di Cagliari, 09124 Cagliari, Italy\nReceived 4 March 2010; revised 6 May 2010\nSYNTHESIS 2010, No. 16, pp 2763\u20132766 xx .x x.2 01 0\nAdvanced online publication: 25.06.2010\nDOI: 10.1055/s-0029-1218835; Art ID: T05010SS\n\u00a9 Georg Thieme Verlag Stuttgart \u00b7 New YorkAbstract: Regioselective syntheses of 3-arylcoumarins possessing\na bromine substituent either on the 3-aryl ring, the coumarin moiety\nor on a lateral chain of a coumarin is reported. The regioselectivity\nis influenced by the substituents present in the substrates. Two dif-\nferent bromination methods are described and compared. Perkin\ncondensation of 5-methylsalicylaldehyde and phenylacetic acid orpara -methoxyphenylacetic acid affords the desired coumarins.\nThree different bromine substitution patterns are accessed startingfrom 5-methylsalicylaldehyde.\nKey words: natural products, halogenation, bromine, regioselec-\ntivity, coumarins\nPhenylcoumarins are synthetic compounds in which an\nadditional phenyl ring is present as a substituent at anyposition on the coumarin nucleus. They are easily pre-pared using two general methods: 1) coumarin phenyl-ation,\n1 or 2) via construction of the coumarin nucleus with\nthe aryl ring already in place, e.g., by way of Perkin,2\nPechmann,3,4 Mukaiyama,5 Knoevenagel6 or Perkin\u2013\nOglialoro7 reactions. In the present work we utilize the\nsecond method, and specifically the classical Perkin con-densation.\n8 This represents a direct and general method\nfor preparing 3-phenylcoumarins.\nA number of natural products and synthetic analogues\nfeaturing the coumarin struct ural motif display a broad\nspectrum of biological activity.9 Structurally, 3-phenyl-\ncoumarins can be considered as coumarin\u2013resveratrol hy-brids (Figure 1); these are very important molecularframeworks and are synthetically versatile.\n10 The C3\u2013C4\ndouble bond of the coumarin nucleus fixes the trans  dis-\nposition of the t-resveratrol-type double bond.3 The inter-\nesting pharmacological properties of trans -resveratrol has\nled to increased interest in synthetic studies toward its an-alogues.\n3,10\nFigure 1 6,8-Dihydroxy-3-(4 \u00a2-hydroxyphenyl)coumarin (a couma-\nrin\u2013resveratrol hybrid)Halogenation of aromatic and heteroaromatic compoundsis an important reaction in synthetic organic chemistry.\n11\nAryl and heteroaryl bromides are potential antioxidant,antibacterial and antitumor agents.\n12 They also represent\ninteresting precursors to many substituted analogues.Hence, bromination reactions are versatile and have been\nstudied extensively. Brominating agents such as tetraalkyl-\nammonium tribromide,\n13 1,8-diazabicyclo[5.4.0]undec-7-\nene hydrobromide perbromide (DBUHBr3),14 hexameth-\nylenetetramine tribromide15 and N-bromosuccinimide\n(NBS)16,17 are known to facilitate monobromination of\naromatic compounds and their derivatives. However, as aresult of its ready availability and ease of handling, the lat-ter reagent is the most commonly used brominating agent.The use of N-bromosuccinimide in the solid state,\n18 or in\ntraditional solution reactions, enables efficient monobro-\nmination of aromatics and derivatives such as cou-\nmarins.19,20 N-Bromosuccinimide has been used for\nbromination and/or oxidation reactions.21\u201324 It is also used\nfor the conversion of benzaldehydes into the correspond-ing benzoyl bromides and for bromolactonization of un-saturated acids and their derivatives.\n25\u201327 Mild reaction\nconditions, good yields, and simple, rapid reactions aresome of the advantages of using N-bromosuccinimide. It\nhas been reported that bromination of coumarins occurs\nmainly at C-3, leading to the corresponding monobromoderivatives.\n17 In the present compounds this position is\nblocked by a phenyl ring leading to a change in the reac-\ntivity of the coumarin. Side-chain bromination in benzylor allylic systems can be mediated by free radical initia-tors, while aromatic bromination requires a catalyst.\n28\nElectron-rich aromatic compounds are easily brominated\nusing N-bromosuccinimide.18 Several studies on regiose-\nlective bromination of coumarins have been performed\nwith the aim of synthesizing bioactive natural prod-ucts.\n29,30\nAs part of our research on 3-arylcoumarins, we previouslyreported the synthesis of 6-met hyl-3-arylcoumarins with\nthe aryl ring being mono- (compound 2), di- or tri-meth-\noxy-substituted.\n10 The 3-phenylcoumarins demonstrated\nimportant roles in monoamine oxidase (MAO) enzymatic\ninhibition.10 We found that the presence of a methoxy\ngroup on the 3-phenyl ring was important, especially apara -methoxy group, in order to improve the monoamine\noxidase inhibitor (MAOI) activity.\nIn this paper, we report the direct and selective synthesis\nof various bromo-substituted  6-alkyl-3-arylcoumarins.\nO O\nHOOH\nOH\nDownloaded by: UNIVERSIDAD DE SANTIAGO DE COMPOSTELA. Copyrighted material.\n892764 M. J. Matos et al. PAPER\nSynthesis 2010, No. 16, 2763\u20132766 \u00a9 Thieme Stuttgart \u00b7 New YorkThe bromine atom can be installed on the 3-phenyl ring\n(compound 3) or on the aromatic ring of the coumarin\n(compound 5). In addition, conditions which allow the\nbromine atom to be substituted on a lateral chain (com-pound 7) are described.\n3-Arylcoumarins with different substitution patterns wereprepared via a direct synthetic route involving the classi-cal Perkin procedure.\n8,10,31\u201333 The reactions were accom-\nplished by condensation of appropriately substituted\nsalicylaldehydes with phenylacetic or p-methoxyphenyl-\nacetic acids, using N, N\u00a2-dicyclohexylcarbodiimide (DCC)\nas the dehydrating agent, in dimethyl sulfoxide, at 110 \u00baC\nfor 24 hours (Scheme 1).8,31,32 Coumarins 210 and 5  were\nobtained in yields of 61% and 50%, respectively, by reac-tion of salicylaldehydes 1 and 4\n8,31,32 with p-methoxyphen-\nylacetic acid.\nTreatment of 6-methyl-3-(4 \u00a2-methoxyphenyl)coumarin\n(2) with N-bromosuccinimide, at reflux in carbon tetra-\nchloride, using 2,2 \u00a2-azobis(isobutyronitrile) (AIBN) as\nthe catalyst, afforded brominated phenylcoumarin 3 in a\nyield of 41%. The regioselective formation of 3 occurred\nas a result of activation of the ortho  position in substrate 2\nby the electron-donating methoxy group. Under these\nconditions, the 6-methyl group was not sufficiently acti-vating to direct bromination onto the coumarin moiety.\n3-Bromo-2-hydroxy-5- methylbenzaldehyde ( 4),\n31\u201333 the\nbrominated precursor of coumarin 5, was prepared from 1\nin 44% yield, using the same brominating conditions asdescribed above (Scheme 1). The ortho  position relative\nto the hydroxy substituent, and meta  to the aldehyde, was\nthe most active, and as such was the position at which bro-\nmination occurred.\n5-Bromomethyl-2-hydroxybenzaldehyde ( 6) was ob-\ntained in 34% yield via irradiation of precursor 1 and bro-\nmine in carbon tetrachloride using a tungsten light source.\nThe ability to brominate salicylaldehyde 1, regioselective-\nly, enabled the synthesis of 3-arylcoumarins 5  (from 4 )\nand 7 (from 6), via the classical Perkin condensation, in\n50% and 60% yields, respectively. Thus, bromination of 1\nusing different reaction conditions allowed the position ofthe bromine atom in the final coumarin product to be var-ied.\nIt is interesting to note that with compounds 1 and 2 ,\nwhich both possess benzylic protons, treatment with N-\nbromosuccinimide using conditions (b) did not afford the\ncorresponding bromomethyl derivatives. These substratescontain a strong electron-donating group, and hence aro-matic substitution occurs instead of benzylic substitution.\nOn the other hand, unsubsituted 3-phenylcoumarin\n34 was\nprepared and then treated with N-bromosuccinimide using\nthe above-mentioned conditions, however, no bromo de-\nrivative was obtained. The absence of an activating sub-stituent prevents the electrophilic aromatic substitutionoccurring. Thus, in a substrate without strong activatinggroups, the presence of an alkyl substituent could lead to\nbenzylic halogenation instead of aromatic substitution.\nScheme 1 Reagents and conditions : (a) phenylacetic acid or p-methoxyphenylacetic acid (1.25 equiv), DCC (1.56 equiv), DMSO, 110 \u00baC, 24\nh; (b) NBS (1.2 equiv), AIBN (cat.), CCl4, reflux, 18 h; (c) Br2 (1.4 equiv), tungsten light source, CCl4, 8 h.\nCHOOHO O\nOMeCHOOHBrO O\nOMeBr\n(b)\n(a)25\n4O O\nOMeBr3\nCHOOH\nBrH 2C6\nO OO O\nBr\n87\n(a) (a)\n(a)(b)\n(b) (c)\n161%41%50%\n49\u201360%\n68%34%44%\nDownloaded by: UNIVERSIDAD DE SANTIAGO DE COMPOSTELA. Copyrighted material.\n90PAPER Regioselective Synthesis of Bromo-Substituted 3-Arylcoumarins 2765\nSynthesis 2010, No. 16, 2763\u20132766 \u00a9 Thieme Stuttgart \u00b7 New York6-Methyl-3-phenylcoumarin ( 8),10 with no substituent on\nthe 3-phenyl ring, was reacted under the same brominat-\ning conditions to afford 6-bromomethyl-3-phenylcou-marin (7 ) in a yield of 49%  (Scheme 1). In this case, with\nno sufficiently strong activating group for aromatic bro-\nmination, the bromine atom was instead directed to the\nlateral chain. This reaction sequence represents anothermethod to obtain bromoalkylcoumarin 7.\nComparing the formation of arylcoumarins 3 and 7 from\n6-methyl-3-arylcoumarins 2 and 8, respectively, the pres-\nence of a methoxy group results in bromination on the 3-\naryl ring, whilst the absence of a methoxy group leads tobromine substitution on the lateral chain. Introduction ofa bromine atom on the coumarin ring is possible by aro-matic bromination of the precursor salicylaldehyde. Inthis specific case, the hydroxy substituent on the benzenering directs substitution of the bromine atom at the appro-priate position.\nIn conclusion, convenient procedures have been devel-\noped starting from the 5-methylsalicylaldehyde ( 1), that\nenable bromination on the aryl, methyl or coumarin moi-eties in differently substituted arylcoumarins. The 3-aryl-coumarin products can be used as precursors for othermolecules and for pharmacological evaluation.\nMelting points were obtained using a Reichert Kofler Thermophan\nor in capillary tubes with a B\u00fcchi 510 apparatus and are uncorrect-\ned. 13C (75 MHz) and 1H NMR (300 MHz) spectra were recorded on\na Bruker AMX 300 MHz spectrometer. Chemical shifts ( d, J in Hz)\nare reported in ppm relative to TMS as the internal standard. Mass\nspectra were obtained using a Hewlett-Packard 5988A spectrome-ter. Elemental analyses were recorded on a Perkin-Elmer 240B mi-\ncroanalyzer. Silica gel (Merck 60, 230\u2013400 mesh) was used for\nflash chromatography. Analytical TLC was performed on plates\nprecoated with silica gel (Merck 60 F254, 0.25 mm).\n3-(3\u00a2 -Bromo-4 \u00a2-methoxyphenyl)-6-methylcoumarin (3)\nA soln of 6-methyl-3-(4 \u00a2-methoxyphenyl)coumarin ( 2) (1.0 g, 3.76\nmmol), NBS (0.80 g, 4.51 mmol) and AIBN (cat.) in CCl\n4 (5.0 mL)\nwas stirred under reflux for 18 h. The resulting soln was filtered to\nremove succinimide. The solvent was evaporated under vacuum\nand purified by flash chromatography (hexane\u2013EtOAc, 95:5) to\ngive compound 3.\nWhite solid; yield: 41%; mp 206\u2013207 \u00b0C.\n1H NMR (CDCl3): d= 2.42 (s, 3 H, CH3), 3.94 (s, 3 H, OCH3), 6.97\n(d, J= 8.7 Hz, 1 H, H-5 \u00a2), 7.23\u20137.35 (m, 3 H, H-2 \u00a2, H-6 \u00a2, H-5),\n7.69\u20137.74 (m, 2 H, H-7, H-8), 7.89 (s, 1 H, H-4).\n13C NMR (CDCl3): d= 20.8, 56.3, 111.5, 111.6, 116.1, 119.3,\n126.3, 127.6, 128.5, 129.0, 132.5, 133.1, 134.2, 139.1, 151.5, 156.2,160.6.\nMS (EI): m/z (%) = 347 (18), 346 (98), 345 (19), 344 (100) [M\n+],\n303 (45), 301 (45), 275 (11), 250 (17), 222 (13), 194 (11), 178 (13),\n165 (58), 163 (11), 139 (15), 132 (42), 82 (18), 76 (14), 63 (19), 50\n(14).\nAnal. Calcd for C17H13BrO3: C, 59.15; H, 3.80. Found: C, 59.10; H,\n3.71.\n8-Bromo-3-(4 \u00a2-methoxyphenyl)-6-methylcoumarin (5)\nA soln of 3-bromo-2-hydroxy-5-methylbenzaldehyde ( 4) (0.25 g,\n1.16 mmol), p-methoxyphenylacetic acid (0.24 g, 1.45 mmol) andDCC (0.37 g, 1.81 mmol), in DMSO (2.0 mL), was heated at 100\u2013\n110 \u00b0C in an oil bath for 24 h. Ice (20 g) and AcOH (3.0 mL) wereadded and the mixture was stirred at r.t. for 2 h, and then extracted\nwith Et\n2O (3 \u00d7  25 mL). The combined organic layer was washed\nwith 5% aq NaHCO3 soln (50 mL) and H2O (20 mL), and dried\n(Na2SO4). The solvent was evaporated under vacuum and the resi-\ndue was purified by flash chromatography (hexane\u2013EtOAc, 9:1) to\ngive coumarin 5.\nWhite solid; yield: 50%; mp 144\u2013145 \u00b0C.\n1H NMR (CDCl3): d= 2.41 (s, 3 H, CH3), 3.86 (s, 3 H, OCH3), 6.98\n(d, J= 7.1 Hz, 2 H, H-3 \u00a2, H-5 \u00a2), 7.26 (s, 1 H, H-7), 7.56 (s, 1 H, H-\n5), 7.65\u20137.69 (m, 3 H, H-2 \u00a2, H-6 \u00a2, H-4).\n13C NMR (CDCl3): d= 20.5, 55.4, 109.3, 114.0, 120.7, 126.7,\n126.9, 128.5, 129.9, 135.2, 137.8, 148.1, 159.9, 160.3.\nMS (EI): m/z (%) = 346 (99), 345 (15), 344 (100) [M+], 303 (53),\n301 (54), 275 (15), 207 (15), 166 (17), 165 (72), 138 (17), 89 (13),\n76 (14), 58 (41).\nAnal. Calcd for C17H13BrO3: C, 59.15; H, 3.80. Found: C, 59.27; H,\n3.82.\n5-Bromomethylsalicylaldehyde (6)\nTo a soln of 5-methylsalicylaldehyde ( 1) (2.0 g, 14.69 mmol) in\nCCl4 (23.0 mL), under reflux and with tungsten light irradiation\n(300 W, Philips Reflector R125 35\u00b0), was added Br2 (3.29 g, 20.57\nmmol) over a period of 3 h. The soln was stirred at r.t. for a further\n15 h and the resulting precipitate was filtered and washed with CCl4\nto give aldehyde 6.\nWhite solid; yield: 34%; mp 148 \u00b0C.\n1H NMR (CDCl3): d= 4.43 (s, 2 H, CH2), 6.96 (d, J = 8.4 Hz, 1 H,\nH-3), 7.49\u20137.53 (m, 2 H, H-4, H-6), 9.88 (s, 1 H, CHO), 10.21 (s, 1\nH, OH).\n13C NMR (CDCl3): d= 33.2, 115.2, 128.4, 130.9, 131.0, 136.4,\n162.0, 191.4.\nMS (EI): m/z (%) = 216 (14), 215 (61), 214 (100) [M+], 184 (17),\n168 (12), 121 (15), 17 (10).\nAnal. Calcd for C8H7BrO2: C, 44.68; H, 3.28. Found: C, 44.66; H,\n3.23.\n6-Bromomethyl-3-phenylcoumarin (7)\nCoumarin 7 was obtained in 60% yield starting from 5-bromometh-\nylsalicylaldehyde ( 6), according to the procedure described for the\nsynthesis of compound 5. The same product was also obtained in\n49% yield starting from coumarin 8 using an identical method to\nthat described for the preparation of 3.\nWhite solid; mp 174\u2013175 \u00b0C.\n1H NMR (CDCl3): d= 4.56 (s, 2 H, CH2), 7.34\u20137.72 (m, 8 H, H-2 \u00a2,\nH-3\u00a2, H-4 \u00a2, H-5 \u00a2, H-6 \u00a2, H-5, H-7, H-8), 7.79 (s, 1 H, H-4).\n13C NMR (CDCl3): d= 32.1, 117.0, 119.7, 128.2, 128.5, 128.9,\n129.0, 132.0, 134.3, 134.4, 139.2, 153.1, 160.2.\nMS (EI): m/z (%) = 315 (23), 314 (100), 179 (21), 176 (40), 152\n(12), 118 (19), 89 (15), 76 (16).Anal. Calcd for C\n16H11BrO2: C, 60.98; H, 3.52. Found: C, 60.89; H,\n3.47.\nAcknowledgment\nThe authors thank the Spanish Ministry (PI061457 and P509/\n00501) and Xunta da Galicia (PXIB20304PR) for financial support.\nM.J.M. thanks Funda\u00e7\u00e3o de Ci\u00eancia e Tecnologia for the SFRH/\nBD/61262/2009 scholarship.\nDownloaded by: UNIVERSIDAD DE SANTIAGO DE COMPOSTELA. Copyrighted material.\n912766 M. J. Matos et al. PAPER\nSynthesis 2010, No. 16, 2763\u20132766 \u00a9 Thieme Stuttgart \u00b7 New YorkReferences\n(1) Chen, G.; Tokunaga, N.; Hayashi, T. Org. Lett. 2005 , 7, \n2285.\n(2) Perkin, W. H. J. Chem. Soc. 1868 , 21, 53.\n(3) Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Y\u00e1nez, M.; \nFraiz, N.; Alcaide, C.; Cano, E.; Orallo, F. Bioorg. Med. \nChem. Lett. 2006 , 16, 257.\n(4) Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; \nY\u00e1\u00f1ez, M.; Vi\u00f1a, D.; Orallo, F. J. Med. Chem. 2008 , 51, \n6740.\n(5) Mukaiyama, T. Angew. Chem., Int. Ed. Engl. 1979, 18, 707.\n(6) Bogdal, D. J. Chem. Res., Synop. 1998, 468.\n(7) Bakhchinian, R.; Terrier, F.; Kirkiacharian, S.; Resche-\nRigon, M.; Bouchoux, F.; Cerede, E. Farmaco 2003 , 58, \n1201.\n(8) Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. Indian J. \nChem., Sect. B: Org. Chem. Incl. Med. Chem. 1996 , 35, \n1159.\n(9) Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. \nCurr. Med. Chem. 2005 , 12, 887.\n(10) Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; \nOrallo, F.; Santana, L.; Uriarte, E. Bioorg. Med. Chem. Lett. \n2009, 19, 3268.\n(11) Larock, R. C. Comprehensive Organic Transformations: A \nGuide to Functional Group Preparations ; Wiley-VCH: New \nYork, 1997 .\n(12) Butler, A.; Walker, J. V. Chem. Rev. 1993, 93 , 1937.\n(13) Kajigaeshi, S.; Kakinami, T.; Okamoto, T.; Nakamura, H.; \nFujikama, M. Bull. Chem. Soc. Jpn. 1987 , 60, 4187.\n(14) Muathen, H. A. J. Org. Chem. 1992 , 57, 2740.\n(15) Bisarya, S. C.; Rao, R. Synth. Commun. 1993 , 23, 779.\n(16) Konishi, H.; Aritomi, K.; Okano, T.; Kiji, J. Bull. Chem. Soc. \nJpn\n. 1989 , 62, 591.(17) Das, B.; Venkateswarlu, K.; Krishnaiah, M.; Holla, H. \nTetrahedron Lett. 2006 , 47, 8693.\n(18) Sarma, J. A. R. P.; Nagaraju, A.; Majumdar, K. K.; Samuel, \nP. M.; Das, I.; Roy, S.; McGhie, A. J. J. Chem. Soc., Perkin \nTrans. 2 2000 , 1119.\n(19) Xiao, S.; Yi, T.; Li, F.; Huang, C. Tetrahedron Lett. 2005, \n46, 9009.\n(20) Xie, L.; Yu, D.; Wild, C.; Allaway, G.; Turpin, J.; Smith, P. \nC.; Lee, K.-H. J. Med. Chem. 2004 , 47, 756.\n(21) Organic Solid State Chemistry ; Desiraju, G. R., Ed.; \nElsevier: Amsterdam, 1987.\n(22) Seebach, D. Angew. Chem., Int. Ed. Engl. 1990, 29, 1320.\n(23) Goud, B. S.; Desiraju, G. R. J. Chem. Res., Synop. 1995 , \n244.\n(24) Sarma, J. A.; Nagaraju, A. J. Chem. Soc., Perkin Trans. 2 \n2000, 1113.\n(25) Cheung, Y.-F. Tetrahedron Lett. 1979 , 20, 3809.\n(26) Pearson, A. J.; Ray, T. Tetrahedron Lett. 1986, 27, 111.\n(27) Dai, W.; Katzenellenbogen, J. A. J. Org. Chem. 1991, 56, \n6893.\n(28) Schmid, H. Helv. Chim. Acta 1946 , 29, 1144.\n(29) Maes, D.; Vervisch, S.; Debenedetti, S.; Davio, C.; \nMangelinckx, S.; Giubellina, N.; De Kimpe, N. Tetrahedron \n2005, 61, 2505.\n(30) Riveiro, M. E.; Maes, D. Bioorg. Med. Chem. 2009 , 17, \n6547.\n(31) Mohanty, S.; Makrandi, J. K.; Grover, S. K. Indian J. Chem., \nSect. B: Org. Chem. Incl. Med. Chem. 1989 , 28, 766.\n(32) Kamat, S. P.; D\u2019Souza, A. M.; Paknikar, S. K.; Beauchamp, \nP. S. J. Chem. Res., Synop. 2002, 24 2.\n(33) Adams, R. J. Am. Chem. Soc. 1919 , 41, 247.\n(34) Wang, L.; Jing, H.; Bu, X.; Chang, T.; Jin, L.; Liang, Y. \nCatal. Commun. 2007, 8 , 80.\nDownloaded by: UNIVERSIDAD DE SANTIAGO DE COMPOSTELA. Copyrighted material.\n92Synthesis of 3-arylcoumarins via Suzuki-cross-coupling reactions\nof 3-chlorocoumarin\nMaria Joao Matosa,b,\u21d1, Saleta Vazquez-Rodrigueza, Fernanda Borgesb, Lourdes Santanaa, Eugenio Uriartea\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbCIQUP/Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, Portugal\narticle info\nArticle history:\nReceived 15 November 2010\nRevised 5 January 2011Accepted 12 January 2011\nAvailable online 18 January 2011\nKeywords:\n3-Arylcoumarins\nSuzuki reaction\n3-Chlorocoumarin\nN,N\n0-Bis(salicylidene)-ethylenediamino-\npalladium catalystabstract\nA convenient, new, and effective protocol for a rapid synthesis of different substituted 3-arylcoumarins is\nreported. The developed synthetic route involves Pd-catalyzed cross-coupling reaction, using a catalytic\ncomplex Pd-salen. Under these conditions, a series of different substituted boronic acids have been suc-\ncessfully reacted with a coumarin halide to afford the coupling products in good yields.\n/C2112011 Elsevier Ltd. All rights reserved.\nCoumarins are an important class of benzopyrones that are\nfound in the vegetable kingdom, either in free or combined state.1\nThey occupy an important place in the realm of natural products\nand synthetic organic chemistry. The diverse biological and phar-\nmaceutical properties of natural and synthetic coumarins as anti-\noxidants,2anti-HIV,3anticancer,4vasorelaxants5or enzymatic\ninhibitors6are well-known.1In the last few years our research\ngroup has been engaged in the synthesis of new biologically active\ncoumarins. In particular, the 3-phenylcoumarin\u2019s scaffold has been\nthe focal point of our most recent studies. In fact we have demon-\nstrated that some 3-phenylcoumarins play an important role in the\nmonoamino oxidase (MAO) enzymatic inhibition.7\u20139Accordingly,\nthe interesting application potential of the 3-arylcoumarins in\nthe Health Sciences promotes their preparation as an interesting\ntopic in synthetic organic chemistry.\nTwo different strategies can be used to obtain the phenylcouma-\nrins. One is the construction of the coumarin nucleus by condensa-\ntion\u2013cyclization-type reactions. Wittig,10Pechmann,5,7,11,12\nPerkin8,9,13\u201317or Knoevenagel18,19reactions are some of the syn-\nthetic routes frequently described to prepare 3-arylcoumarins, start-\ning from phenols or aromatic carbonyl compounds. The classical\nPerkin condensation is perhaps the most direct and simple method\nknown for the preparation of 3-arylcoumarins.16Although this\nmethod is often used, it has some drawbacks such as the application\nof strong acids and high temperatures and sometimes the request of\nmulti-step reactions.An alternative strategy consists in the direct 3-arylation of the\ncoumarin scaffold by metal cross-coupling reactions. In recentyears, palladium-catalyzed coupling reactions have been develop-\ning into a versatile and ef\ufb01cient method for the C\u2013C bond forma-\ntion. Suzuki\n20,21and Stille have described simple synthetic routes\nto obtain C\u2013C liaisons throughout the coupling arylboronic or\norganotin compounds with organic halides catalyzed by a palla-\ndium-complex. In these reactions, Pd complexes are used as cata-\nlysts in which the ligands are P and/or N lone pairs donors or\nactive Pd complexes are generated in situ.22In the \ufb01rst case, some\nof these ligands are expensive, toxic, and sensitive to air and a ma-\njor challenge lies in the separation of product from the expensive\ncatalyst, much to the dismay of large-scale producers.22Ionic liq-\nuids,23free of organic solvent systems or phase-transfer catalysts24\nhave been used to provide a green alternative chemistry to the\nconventional organic methodologies, but they are not devoid of\ntoxicity. In turn, phosphine ligands25had played an important role\nin C\u2013C bond formation, in homogeneous reaction medium. Several\nefforts have been made in order to discover air and moisture-stable\npalladium ligands.25However, these ligands are air- and moisture-\nsensitive and the P\u2013C bond degradation frequently occurs at ele-\nvated temperature.26The degradation of the catalyst strongly af-\nfects conversion and selectivity of the derivatives.27So, different\nmethods using phosphine-free ligands have been explored for\napplication in this kind of reactions.28\nBecause of its versatility, palladium catalyzed coupling reac-\ntions were widely used to synthesize different arylcoumarins.\nThe arylation in 4-position of the coumarin nucleus is usually\nachieved by arylation of 4-hydroxycoumarins with arylboronic\n0040-4039/$ - see front matter /C2112011 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.tetlet.2011.01.048\u21d1Corresponding author.\nE-mail address: mariacmatos@gmail.com (M.J. Matos).Tetrahedron Letters 52 (2011) 1225\u20131227\nContents lists available at ScienceDirect\nTetrahedron Letters\njournal homepage: www.elsevier.com/locate/tetlet\n93acids via C\u2013OH bond activation.29Accordingly, the 4-hydroxy\ngroup is converted in pseudo halides, such as tri\ufb02ates or tosylates\nwhich are used instead of halides in a coupling reaction with aryl-\nboronic acids (via a Suzuki type reaction). In other cases, the aryl\nsubstituents have been successfully incorporated in 4-position of\nthe hydroxycoumarin using organostannanes30or organozinc com-\npounds31under Stille or Negishi conditions, respectively.\nHowever, the formation of the aryl C\u2013C bond using coumarin as\nstarting material is till now an uncommon subject.32,33To our\nknowledge, few papers have been published so far concerning the\n3-arylation of coumarin nucleus by direct coupling under Suzuki\nconditions: in all these cases, the halide was 3-bromocoumarin.\nAnd the catalysts were the classic palladium acetate (Pd(OAc) 2), tet-\nrakis(triphenylphosphine)palladium (0) Pd(PPh3) 434,35, and [1,10-\nbis(diphenylphosphino)ferrocene]palladium(II) dichloride.36,37\nSalen ligand has been found to be a highly active catalyst for the Su-\nzuki reaction performed with aryl iodides, bromides, and chlorides,\ngiving excellent yields, in a short reaction time.38,39Salen ligand is a\nbright yellow solid, soluble in polar organic solvents, and effective inC\u2013C bond forming reactions with high selectivity. This symmetrical\npalladium(II) complex was a product of the reaction of the Salen li-\ngand with palladium acetate (for 20 h at room temperature) in a\ngood yield. This complex promotes a catalytic activity in a low con-\ncentration (0.5 mol %).\n40Noteworthy to mention that Salen is a che-\nlating ligand generally used in coordination chemistry and\nhomogeneous catalysis.41\nAlthough signi\ufb01cant advances have been performed in the metal-\ncatalyzed synthesis, the palladium-catalyzed cross-couplingreaction using 3-chlorocoumarin to afford 3-arylcoumarins has\nnever been described. This constraint encourages us to explore this\nsynthetic strategy. Accordingly, preliminary experiments were done\nto examine the effect of various ligands for Pd-based coupling.42,43\nThe most promising one was N,N0-bis(salicylidene)-ethylenediami-\nno-palladium (salen-Pd). In fact, Pd(OAc) 2-salen couple in presence\nof a Na 2CO3in DMF/H 2O (1:1) was found to be an ef\ufb01cient catalytic\nsystem to obtain a variety of 3-arylcoumarin derivatives (Scheme\n1).40As coumarins are sensitive substrates to alkaline conditions,\nand may result in the cleavage of the lactone ring, the solvent, andbase for the coupling reaction were carefully studied. To optimize\nthe reaction the in\ufb02uence of the palladium source in the catalytic\nactivity was also performed. Pd(OAc)\n2was found to be the best op-\ntion.40After reaction optimization, the in\ufb02uence of the Pd-salen\ncomplex in the Suzuki reaction involving cross-coupling of a couma-\nrin halide and different arylboronic acids was investigated. The Su-\nzuki reaction developed herein was found to be effective when\nusing arylboronic acids with a variety of functional groups. Further-\nmore the reaction works with iodo-, bromo- or chloro-coumarin\nsubstrates. Different reaction times are required for each coumarin\nhalide type. Although it is well-known that in Suzuki reaction the\nchloride derivatives are less reactive than the bromide or the iodide\nones, the use of the 3-chlorocoumarin as starting material in the\nreaction is related with its commercial availability. The synthesis\nof 3-iodocoumarin and 3-bromocoumarin involves the introduction\nof other synthetic steps in the overall reaction.\nComparing the synthetic route herein proposed with the classic\none, previously reported by us,7,8one can verify that both are easy\nand not too expensive methodologies. The main advantage of thisnew synthetic approach is that it can afford 3-arylcoumarins with\ndifferent substitution patterns. By means of the traditional meth-\nodology, hydroxyl and nitro derivatives could not be obtained\nand/or puri\ufb01ed. The reaction was not clean and the obtained crude\nproduct was a complex mixture with several sub-products and the\npuri\ufb01cation process was worthless. The reaction versatility is the\nmain advantage of this synthetic strategy comparing to the classic\nPerkin reaction. Compounds 4\u20137\n44\u201346and1047are exclusively pre-\npared by the Suzuki methodology while compounds 1\u20133,8, and 9\ncan be prepared by both methods (Table 1 ).48\u201350The proposed syn-\nthetic strategy operates from micro- to macro-scale and avoids the\nformation of undesired sub-products. The palladium complex can\nbe easily and almost totally recuperated at the end of the process.\nThe catalyst is recovered from the reaction mixture when the prod-\nuct is puri\ufb01ed by \ufb02ash chromatography and it is ready to be reused.\nThis subject has great interest because of the toxicity and the cost\nof palladium complexes.\nIn conclusion, a novel and versatile route for the synthesis of 3-\narylcoumarins is proposed. The palladium cross-coupling reaction\ncan be applied to obtain a series of different functionalized deriv-\natives. In addition, we have shown that N,N0-bis(salicylidene)-eth-\nylenediamino-palladium proved to be a good catalyst for theSuzuki reaction of heterocyclic activated chlorides with arylbo-\nronic acids, under aerobic conditions. This methodology is an ef\ufb01-\ncient synthetic route for obtaining different 3-arylcoumarins.\nAcknowledgments\nThe authors thank the Spanish Ministry (PS0900501) and Xunta\nda Galicia (INCITE09E2R203035ES and PGIDIT09CSA030203PR) for\nthe \ufb01nancial support. M.J.M. thanks Funda\u00e7\u00e3o de Ci\u00eancia e Tecno-\nlogia for the SFRH/BD/61262/2009 scholarship.\nReferences and notes\n1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem.\n2005 ,12, 887\u2013916.OO OOCl\n1-9\n(a)R\nOON\n10\n60 %Cl 1:R=H\n2:R=p-OMe\n3:R=m-OMe\n4:R=m-OH\n5:R=p-NO2\n6:R=m-NO2\n7:R=m-NH2\n8:R=p-Me\n9:R=p-Cl(a)\n61 %\n58 %\n56 %\n64 %\n65 %\n55 %\n59 %\n63 %\n61 %\nScheme 1. Synthesis of 3-arylcoumarin derivatives. Reagents and conditions: (a) 3-\nchlorocoumarin (1.0 equiv), phenylboronic acid/2-chloro-5-pyridineboronic acid\n(1.25 equiv), sodium carbonate (2.0 equiv), palladium complex (0.5 mol %), DMF/\nH2O (1:1), 110 /C176C, 120\u2013180 min.\nTable 1\nSynthesis of 3-arylcoumarins ( 1\u201310) by Perkin reaction and/or via Suzuki-cross-\ncoupling reaction\nCompounds Perkin reactionaSuzuki reactionb\nTime (min) Yield (%) Time (min) Yield (%)\n1 1440 60 120 61\n2 1440 65 120 58\n3 1440 68 120 56\n4 \u2044\u2044 180 64\n5 \u2044\u2044 160 65\n6 \u2044\u2044 160 55\n7 \u2044\u2044 160 59\n8 1440 70 120 63\n9 2160 63 140 61\n10 \u2044\u2044 140 60\n*Compounds 4\u20137and10are exclusively prepared by the Suzuki methodology.\naConditions: phenylacetic acids, DCC, DMSO, 110 /C176C, 24\u201336 h.\nbReactions with 3-chlorocoumarin. Compound 1was synthesized using 3-bro-\nmocoumarin\u2014reaction time: 100 min; yield: 70%.1226 M. J. Matos et al. / Tetrahedron Letters 52 (2011) 1225\u20131227\n942. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Enzyme Inhib. Med. Chem. 2003 ,18,\n63\u201369.\n3. Spino, C.; Dodier, M.; Sotheeswaran, S. Bioorg. Med. Chem. Lett. 1998 ,8, 3475\u2013\n3478.\n4. Kempen, I.; Papapostolou, D.; Thierry, N.; Pochet, L.; Counerotte, S.; Masereel,\nB.; Foidart, J. M.; Reboud-Ravaux, M. J.; Noel, A.; Pirotte, B. Br. J. Cancer 2003 ,88,\n1111\u20131118.\n5. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Yanez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257\u2013261.\n6. Quezada, E.; Delogu, G.; Picciau, C.; Santana, L.; Podda, G.; Borges, F.; Garcia-\nMoraes, V.; Vina, D.; Orallo, F. Molecules 2010 ,15, 270\u2013279.\n7. Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, M.; Vi\u00f1a, D.;\nOrallo, F. J. Med. Chem. 2008 ,51, 6740\u20136751.\n8. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;\nUriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268\u20133270.\n9. Matos, M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053\u20135055.\n10. Mali, R. S.; Joshi, P. P. Synth. Commun. 2001 ,31, 2753\u20132767.\n11. Ming, Y.; Boykin, D. W. Heterocycles 1987 ,26, 3229\u20133231.\n12. Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. Indian J. Chem., Sect B 1996 ,11,\n1159\u20131162.\n13. Khiri, C.; Ladhar, F.; El Gharbi, R.; Le Bigot, Y. Synth. Commun. 1999 ,29, 1451\u2013\n1461.\n14. Mohanty, S.; Makrandi, J. K.; Grove, S. K. Indian J. Chem., Sect B 1989 ,28B, 766\u2013\n769.\n15. Langmuir, M. E.; Yang, J. R.; Moussa, A. M.; Laura, R.; Lecompte, K. A.\nTetrahedron Lett. 1995 ,36, 3989\u20133992.\n16. Mashraqui, S.; Vashi, D.; Mistry, H. D. Synth. Commun. 2004 ,34, 3129\u20133134.\n17.\nKabeya, L. M.; de Marchi, A. A.; Kanashiro, A.; Lopes, N. P.; da Silva, C. H. Bioorg.\nMed. Chem. 2007 ,15, 1516\u20131524.\n18. Bogdal, D. J. Chem. Res. (S) 1998 , 468\u2013469.\n19. Mali, R. S.; Tilve, S. G. Synth. Commun. 1990 ,20, 1781\u20131791.\n20. Suzuki, A. J. Organomet. Chem. 2002 ,653, 83\u201390.\n21. Wang, J.; Meng, F.; Zhang, L. Organometallics 2009 ,28, 2334\u20132337.\n22. Cobert, J. P.; Mignani, G. Chem. Rev. 2006 ,106, 2651\u20132710.\n23. Dupont, J.; de Souza, R. F.; Suarez, A. Z. Chem. Rev. 2002 ,102, 3667\u20133691.\n24. Paetzold, E.; Oehme, G. J. Mol. Catal. A: Chem. 2000 ,152, 69\u201376.\n25. Genet, J. P.; Savignac, M. J. Organomet. Chem. 1999 ,576, 305\u2013317.\n26. Sa\ufb01n, D. A.; Babashkina, M. G. Catal. Lett. 2009 ,130, 679\u2013682.\n27. Mingji, D.; Liang, B.; Wang, C.; You, Z.; Xiang, J.; Dog, G.; Chen, J.; Yang, Z. Adv.\nSynth. Catal. 2004 ,346, 1669\u20131673.\n28. Farina, V. Adv. Synth. Catal. 2004 ,346, 1553\u20131582.\n29. Luo, Y.; Wu, J. Tetrahedron Lett. 2009 ,50, 2103\u20132105.\n30. Schio, L.; Chatreaux, F.; Klich, M. Tetrahedron Lett. 2000 ,41, 1543\u20131547.\n31. Wu, J.; Liao, Y.; Yang, Z. J. Org. Chem. 2001 ,66, 3642\u20133645.\n32. Nemeryuk, M. P.; Dimitrova, V. D.; Sedov, A. L.; Anisimova, O. S.; Traven, V. F.\nChem. Heterocycl. Compd. 2002 ,38, 249\u2013250.\n33. Martins, S.; Branco, P. S.; de la Torre, M. C.; Sierra, M. A.; Pereira, A. Synlett\n2010 ,19, 2918\u20132922.\n34. Schiedel, M.-S.; Briehn, C. A.; Bauerle, P. Angew. Chem., Int. Ed. 2001 ,40, 4677\u2013\n4680.\n35. Chen, L.; Hu, T.-S.; Yao, Z.-J. Eur. J. Org. Chem. 2008 ,36, 6175\u20136182.36. Guo, H.-M.; Tanaka, F. J. Org. Chem. 2009 ,74, 2417\u20132424.\n37. Zhang, L.; Meng, T.; Fan, R.; Wu, J. J. Org. Chem. 2007 ,72, 7279\u20137286.\n38. Miller, K. J.; Baag, J. H.; Abu-Omar, M. M. Inorg. Chem. 1999 ,38, 4510\u20134514.\n39. Audisio, D.; Messaoudi, S.; Peyrat, J. F.; Alami, M. Tetrahedron Lett. 2007 ,48,\n6928\u20136932.\n40. Borhade, S. R.; Waghmode, S. B. Tetrahedron Lett. 2008 ,49, 3423\u20133429.\n41. Bahkerad, M.; Keivanloo, A.; Bahramian, B.; Hashemi, M. Tetrahedron Lett. 2009 ,\n50, 1557\u20131559.\n42. Crociani, B.; Antonaroli, S.; Burattini, M.; Benetollo, F.; Scrivanti, A.; Bertoldini,\nM.J. Organomet. Chem. 2008 ,693, 3932\u20133938.\n43. Blug, M.; Guibert, C.; Le Goff, X.; M\u00e9zailles, N. Chem. Commun. 2009 ,2, 201\u2013\n203.\n44. Leitao, A.; Andricopulo, A. D.; Oliva, G.; Pupo, M. T.; de Marchi, A. A.; Vieira, P.\nC.; da Silva, M. F.; Ferreira, V. F.; de Souza, M. C.; Sa, M. M.; Moraes, V.;\nMontanari, C. A. Bioorg. Med. Chem. Lett. 2004 ,14, 2199\u20132204.\n45. Mashraqui, S. H.; Vashi, D.; Mistry, H. D. Synth. Commun. 2004 ,34, 3129\u20133134.\n46. General method to prepare 3-arylcoumarins : To a 20 mL two neck round-\nbottomed \ufb02ask was added a solution of 3-chlorocoumarin (0.83 mmol), aryl\nboronic acid (1.04 mmol), Na 2CO3(1.66 mmol), and Pd-salen complex\n(0.5 mol %) in DMF/H 2O (1:1). The reaction mixture was heated at 110 /C176C for\n120\u2013180 min. The reaction was monitored by chromatography. After the\ncompletion of the reaction, the mixture was extracted with ethyl acetate\n(3/C220 mL). The organic extracts were dried over anhydrous sodium sulphate,\n\ufb01ltrated, and the solvent was evaporated under vacuum. The obtained crude\nproduct was puri\ufb01ed by column chromatography (hexane/ethyl acetate 9:1) to\ngive the coumarins ( 1\u20139).3-(30-Nitrophenyl)coumarin (6): yellow solid, yield\n55%; mp 252\u20133 /C176C.1H NMR (CDCl 3):d= 7.17\u20137.22 (m, 2H, H-7, H-8), 7.39\u20137.48\n(m, 3H, H-5, H-6, H-50), 7.52\u20137.54 (m, 1H, H-60), 7.60\u20137.71 (m, 2H, H-4, H-40),\n8.44 (s, 1H, H-20).13C NMR (CDCl 3):d= 110.0, 114.2, 116.7, 117.6, 119.3, 122.8,\n125.5, 128.5, 131.1, 132.6, 132.7, 141.4, 149.1, 152.8, 158.6. MS: m/z(%) = 268\n(26), 267 (M+, 100), 239 (24), 221 (38), 193 (17) 165 (52), 164 (16), 163 (19),\n139 (12), 82 (11). Anal. calcd. for C 15H9NO 4(267.24): C, 67.42; H, 3.39. Found:\nC, 67.38; H, 3.36. 3-(30-aminophenyl)coumarin (7): white solid, yield 59%; mp\n154\u20135 /C176C.1H NMR (CDCl 3):d= 4.12 (s, 2H, \u2013NH 2), 7.27\u20137.38 (m, 4H, H-20, H-40,\nH-60, H-8), 7.47 (dd, 2H, H-6, H-7, J= 7.74, J= 1.31), 7.53\u20137.58 (m, 2H, H-5, H-\n50), 7.88 (s, 1H, H-4).13C NMR (CDCl 3):d= 116.8, 118.8, 122.4, 125.0, 125.2,\n127.2, 127.8, 128.7, 131.9, 133.3, 140.1, 152.6, 155.2, 157.3, 158.8. MS: m/z\n(%) = 239 (10), 238 (19), 237 (M+, 100), 182 (36), 181 (12), 152 (50), 124 (18),\n89 (45), 63 (28), 62 (18). Anal. calcd. for C 15H11NO 2(237.25): C, 75.94; H, 4.67.\nFound: C, 76.00; H, 4.72.\n47. 3-(40-Chloropyridin-30-yl)coumarin (10): white solid, yield 60%; mp 234\u20135 /C176C.\n1H NMR (CDCl 3):d= 7.32\u20137.37 (m, 2H, H-50, H-8), 7.46 (d, 2H, H-6, H-7,\nJ= 7.51), 7.52\u20137.58 (m, 2H, H-5, H-60), 7.88 (s, 1H, H-4), 8.58 (s, 1H, H-20).13C\nNMR (CDCl 3):d= 116.8, 118.8, 122.3, 124.7, 125.0, 125.2, 127.2, 131.8, 137.0,\n140.0, 147.7, 149.6, 152.7, 157.3. MS: m/z(%) = 260 (5), 259 (32), 258 (15), 257\n(M+, 100), 223 (18), 182 (34), 152 (44) 123 (13), 89 (40), 85 (23), 71 (30), 63\n(18), 57 (35). Anal. calcd. for C 14H8ClNO 2(257.57): C, 65.26; H, 3.13. Found: C,\n65.24; H, 3.10.\n48. Castaneda, F. Rendiconti Istituto Superiore di Sanita (Italian Edition) 1964 ,27, 99.\n49. Sabitha, G.; Rao, A. V. Synth. Commun. 1987 ,17, 341\u2013354.\n50. Archer, J. F.; Grimshaw, J. J. Chem. Soc., Sect B: Phys. Org. 1969 ,3, 266\u2013270.M. J. Matos et al. / Tetrahedron Letters 52 (2011) 1225\u20131227 1227\n95This article was downloaded by: [University of Santiago de Compostela], [Dr Maria Jo\u00e3o\nMatos]On: 05 November 2012, At: 07:48Publisher: Taylor & FrancisInforma Ltd Registered in England and Wales Registered Number: 1072954 Registeredoffice: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK\nOrganic Preparations and ProceduresInternational: The New Journal forOrganic Synthesis\nPublication details, including instructions for authors andsubscription information:http://www.tandfonline.com/loi/uopp20\nImproved Synthesis of 3-(Aminoaryl)coumarins\nMaria Jo\u00e3o Matos a b , Alexandra Gaspar a , Fernanda Borges a ,\nEugenio Uriarte b & Lourdes Santana b\na CIQUP/Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de\nCi\u00eancias, Universidade do Porto, 4169-007, Porto, Portugal\nb Departamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia,\nUniversidad de Santiago de Compostela, Santiago de Compostela,15782, Spain\nTo cite this article: Maria Jo\u00e3o Matos, Alexandra Gaspar, Fernanda Borges, Eugenio Uriarte & LourdesSantana (2012): Improved Synthesis of 3-(Aminoaryl)coumarins, Organic Preparations and ProceduresInternational: The New Journal for Organic Synthesis, 44:6, 522-526\nTo link to this article:  http://dx.doi.org/10.1080/00304948.2012.730937\nPLEASE SCROLL DOWN FOR ARTICLE\nFull terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions\nThis article may be used for research, teaching, and private study purposes. Any\nsubstantial or systematic reproduction, redistribution, reselling, loan, sub-licensing,systematic supply, or distribution in any form to anyone is expressly forbidden.\nThe publisher does not give any warranty express or implied or make any representation\nthat the contents will be complete or accurate or up to date. The accuracy of anyinstructions, formulae, and drug doses should be independently verified with primarysources. The publisher shall not be liable for any loss, actions, claims, proceedings,demand, or costs or damages whatsoever or howsoever caused arising directly orindirectly in connection with or arising out of the use of this material.\n97Organic Preparations and Procedures International , 44:522\u2013526, 2012\nCopyright \u00a9 Taylor & Francis Group, LLC\nISSN: 0030-4948 print / 1945-5453 onlineDOI: 10.1080/00304948.2012.730937\nOPPI BRIEFS\nImproved Synthesis of 3-(Aminoaryl)coumarins\nMaria Jo \u02dcao Matos,1,2Alexandra Gaspar,1Fernanda Borges,1\nEugenio Uriarte,2and Lourdes Santana2\n1CIQUP/Departamento de Qu \u00b4\u0131mica e Bioqu \u00b4\u0131mica, Faculdade de Ci \u02c6encias,\nUniversidade do Porto, 4169-007 Porto, Portugal\n2Departamento de Qu \u00b4\u0131mica Org \u00b4anica, Facultad de Farmacia, Universidad de\nSantiago de Compostela, Santiago de Compostela, 15782 Spain\nCoumarins(benzopyrones) are widely distributed in the vegetable kingdom, either in\nfree or combined state,1and occupy an important place in the realm of natural prod-\nucts and synthetic organic chemistry.2They have been used as antioxidants,2anti-HIV ,3\nanti-cancer,4vasorelaxants,5or enzymatic inhibitors.6Over the last few years, our research\ngroup has paid special attention to the synthesis of new biologically active coumarins\nas enzymatic inhibitors;7\u201312in particular, 3-arylcoumarins have been the focal point of\nour recent studies13,14as they play an important role in the monoamino oxidase (MAO)\ninhibition.7\u201310Various strategies have been used to obtain arylcoumarins,14e. g. ,t h e\nWittig,15Pechmann,6,7,16Perkin,6\u201313,17\u201321or Knoevenagel22,23reactions starting from phe-\nnols or aromatic carbonyl compounds. We now describe the synthesis of aminoarylcoumarins 4a\u2013e\n24by the previously unreported copper-catalyzed C-N cross-coupling of\nbromoaryl coumarins with tri\ufb02uoroacetamide (TFA).\nPerkin condensation of differently substituted 2-hydroxybenzaldehydes ( 1) with aryl-\nacetic acids (2) afforded the corresponding coumarins ( 3a\u2013e )10,12,25in 59%\u201369% yields;\nbrominated compound 3ehad to be prepared by the NBS bromination of the Perkin con-\ndensation product 3f, since the required (4-bromothien-3-yl)acetic acid is not commer-\ncially available for the direct Perkin reaction. Since previous studies26,27indicated N,N/prime-\ndimethylethylenediamine (DMEDA) to be the best ligand to catalyze the CuI coupling ofthe coumarinyl aryl bromides\n10,12with TFA, the CuI/DMEDA catalytic system was used\nto promote the amination of 3a\u2013e with TFA and potassium carbonate in dioxane at 70\u25e6C\nto give aminoaryl coumarins 4a\u2013e in 88%\u201394% yields. It is likely that this method using\nTFA could be useful for the amination of other aryl bromides.\nReceived March 9, 2012.\nAddress correspondence to Maria Jo \u02dcao Matos, Departamento de Qu \u00b4\u0131mica Org \u00b4anica, Facultad de\nFarmacia, Universidad de Santiago de Compostela, Santiago de Compostela, 15782 Spain. E-mail:\nmariacmatos@gmail.comDownloaded by [University of Santiago de Compostela], [Dr Maria Jo\u00e3o Matos] at 07:48 05 November 2012 \n98Synthesis of 3-(Aminoaryl)coumarins 523\nO OAr\nOHCHO R\nR\n1R1\nArCH 2CO 2H\n2i\n3a-eR1iii\nO OAr' R\n4a-eR1\nScheme 1\nIn conclusion, a novel and versatile route for the synthesis of 3-(aminoaryl)coumarins\nhas been developed. The advantage of Cu-catalyzed cross-coupling method compared\nwith classical cross-coupling reactions28\u201331is its versatility, allowing the preparation of\ndifferently functionalized derivatives in addition to the use of tri\ufb02uoroacetamide as a goodammonia substitute and of CuI/DMEDA as an effective catalytic system for the aminationreaction of activated bromides, under mild conditions.\nExperimental Section\nMelting points were obtained using a Reichert Ko\ufb02er-Thermophan or in capillary tubeswith a B \u00a8uchi 510 apparatus and are uncorrected.\n13C (75.4 MHz) and1H NMR (300 MHz)\nspectra were recorded on a Bruker AMX 300 MHz spectrometer. Chemical shifts ( \u03b4,J\nin Hz) are reported in ppm relative to TMS as the internal standard. Mass spectra wereobtained using a Hewlett-Packard 5988A spectrometer. Elemental analyses were carried\nout on a Perkin-Elmer 240B microanalyzer. Silica gel (Merck 60, 230\u2013400 mesh) was usedDownloaded by [University of Santiago de Compostela], [Dr Maria Jo\u00e3o Matos] at 07:48 05 November 2012 \n99524 Matos et al.\nfor \ufb02ash chromatography. Analytical TLC was performed on plates precoated with silica\ngel (Merck 60 F254, 0.25 mm). The preparation and characterization of 3c,3d, and 3fhave\nbeen described in references 10, 12, and 25.\nGeneral Procedure for the Preparation of 3-Arylcoumarins 3a, 3b, and 3e . A solution\nof the substituted 2-hydroxybenzaldehyde (1, 7.34 mmol), the corresponding arylacetic acid\n(2, 9.18 mmol) and N,N-dicyclohexylcarbodiimide (DCC, 2.36 g, 11.46 mmol), in DMSO\n(5 ml), was heated at 110\u25e6C in an oil bath for 24 h. Ice (20 g) and AcOH (10 ml) were\nadded and the mixture was stirred at r.t. for 2 h, and then extracted with Et 2O( 3\u00d725 ml).\nThe combined organic layer was washed with 5% aq. NaHCO 3solution (50 ml) and H 2O\n(20 ml), and dried (Na 2SO4). The solvent was evaporated under vacuum and the residue\nwas puri\ufb01ed by \ufb02ash chromatography (hexane/EtOAc, 9:1) to give the desired coumarins.\n3-(4-Bromophenyl)-6-methylcoumarin (3a). Colorless solid, 62% yield, mp.\n197\u25e6C\u2013198\u25e6C.1HN M R( C D C l 3):\u03b42.44 (s, 3H, CH 3), 7.24 (dd, J=7.9, 1.6 Hz, 1H,\nH-7), 7.36 (dd, J=7.9, 1.7 Hz, 2H, H-5, H-8), 7.56\u20137.62 (m, 4H, H-2/prime,H - 3/prime,H - 5/prime,H - 6/prime),\n7.78 (s, 1H, H-4).13CN M R( C D C l 3):\u03b420.8, 116.2, 119.2, 123.0, 127.7, 130.1, 131.6,\n132.8, 133.7, 134.3, 139.9, 151.7, 160.5. MS (EI): m/z(%)=317 (18), 316 (99), 315 (19),\n314 (100) [M+], 288 (34), 287 (22), 286 (34), 285 (17), 179 (17), 178 (36), 152 (9), 118\n(14), 89 (11), 76 (12).\nAnal. Calcd for C 16H11BrO 2: C, 60.98; H, 3.52. Found: C, 61.00; H, 3.56.\n3-(2-Bromophenyl)-6-methylcoumarin (3b). Colorless solid, 59% yield, mp.\n141\u25e6C\u2013142\u25e6C.1HN M R( C D C l 3):\u03b42.45 (s, 3H, CH 3), 7.26\u20137.29 (m, 1H, H-4/prime), 7.31\u20137.39\n(m, 2H, H-7, H-8); 7.32\u20137.49 (m, 3H, H-5, H-5/prime,H - 6/prime); 7.69 (d, J=7.8, 1H, H-3/prime); 7.71\n(s, 1H, H-4).13CN M R( C D C l 3):\u03b420.8, 116.4, 118.7, 123.6, 127.4, 127.9, 128.6, 130.1,\n131.3, 132.9, 133.0, 134.3, 135.9, 142.6, 152.0, 160.0. MS (EI): m/z(%)=316 (5), 315\n(38), 314 (100) [M+], 236 (32), 235 (80), 178 (22), 117 (7), 89 (7), 76 (9).\nAnal . Calcd for C 16H11BrO 2: C, 60.98; H, 3.52. Found: C, 60.93; H, 3.48.\nPreparation of the 3-(4-Bromothien-3-yl)-6-methylcoumarin (3e). A solution of 6-\nmethyl-3-(thien-3-yl)coumarin 3f(1.0 g, 3.76 mmol), NBS (0.8 g, 4.51 mmol), and AIBN\n(cat.) in CCl 4(5 ml) was stirred under re\ufb02ux for 18 h. The resulting suspension was \ufb01ltered\nto remove succinimide. The solvent was evaporated under vacuum and puri\ufb01ed by \ufb02ash\nchromatography (hexane/EtOAc, 95:5) to give the desired bromo derivative 3e(1.0 g, 75%)\nas a colorless solid, mp. 175\u25e6C\u2013176\u25e6C.1HN M R( C D C l 3):\u03b42.43 (s, 3H, CH 3), 7.25\u20137.37\n(m, 5H, H-5, H-7, H-8, H-2/prime,H - 5/prime), 7.9 (s, 1H, H-4).13CR M N( C D C l 3):\u03b420.8, 112.0,\n116.4, 118.8, 122.2, 125.6, 127.8, 129.3, 132.9, 134.3, 134.5, 142.6, 151.8, 160.2. MS (EI):m/z(%)=320 (100) [M\n+], 242 (18), 241 (10), 184 (18) 152 (8), 138 (11), 115 (10), 92\n(12), 63 (11), 58 (14).\nAnal. Calcd for C 14H9BrO 2S: C, 52.35; H, 2.82. Found: C, 52.32; H, 2.79.\nGeneral Procedure for the Preparation of 3-(Aminoaryl)coumarins 4a\u2013e. To a dry\n20 ml two-neck round-bottom \ufb02ask, a catalytic amount of CuI (8 mg, 5 mol%), K 2CO 3\n(0.276 g, 2.0 mmol), and molecular sieves (4 AMS, 0.500 g) were added. The two-neckround-bottom \ufb02ask was evacuated and back \ufb01lled with argon. Then, the bromo coumarin(0.263 g, 1.0 mmol), 2,2,2-tri\ufb02uoroacetamide (0.170 g, 1.5 mmol), DMEDA (0.012 ml,10 mol%), and dioxane (2 ml) were added and the mixture was stirred for 24 h, at 75\n\u25e6C. The\nmixture was then cooled to room temperature and a mixture of methanol/H 2O( 3 : 3m l )w a s\nadded. The suspension was stirred for 5 h and then extracted with EtOAc (3 \u00d720 ml). TheDownloaded by [University of Santiago de Compostela], [Dr Maria Jo\u00e3o Matos] at 07:48 05 November 2012 \n100Synthesis of 3-(Aminoaryl)coumarins 525\nresidue obtained after evaporation of the solvent was puri\ufb01ed by column chromatography\n(hexane/EtOAc, 9:1) to give the desired aminocoumarins.\n3-(4-Aminophenyl)-6-methylcoumarin (4a). Colorless solid; yield 92%; mp.\n191\u25e6C\u2013192\u25e6C.1HN M R( C D C l 3):\u03b42.43 (s, 3H, CH 3), 3.70 (s, 2H, NH 2), 7.24\u20137.36\n(m, 3H, H-3/prime,H - 5/prime, H-6), 7.54\u20137.65 (m, 4H, H-2/prime,H - 6/prime, H-5, H-7), 7.76 (s, 1H, H-4).13C\nNMR (CDCl 3):\u03b421.8, 114.4, 115.2, 117.0, 122.3, 124.6, 124.9, 127.4, 129.6, 130.2, 132.0,\n135.3, 139.9, 142.0, 157.8, 160.0. MS (EI): m/z252 (21), 251 (100) [M+], 236 (20), 152\n(21), 134 (45), 129 (23), 112 (31).\nAnal. Calcd for C 16H13NO 2: C, 76.48; H, 5.21. Found: C, 76.41; H, 5.19.\n3-(2-Aminophenyl)-6-methylcoumarin (4b). Colorless solid, 90% yield, mp.\n139\u25e6C\u2013140\u25e6C.1HN M R( C D C l 3):\u03b42.43 (s, 3H, CH 3), 3.99 (s, 2H, NH 2), 7.09\u20137.12\n(m, 1H, H-3/prime), 7.28\u20137.33 (m, 2H, H-4/prime,H - 5/prime), 7.37\u20137.43 (m, 2H, H-7, H-8), 7.57\u20137.60 (m,\n1H, H-6/prime), 7.67 (d, J=1.9, 1H, H-5), 7.80 (s, 1H, H-4).13CN M R( C D C l 3):\u03b425.1, 113.4,\n116.4, 119.4, 124.5, 127.4, 127.9, 130.1, 131.4, 131.6, 132.9, 133.1, 134.1, 140.0, 142.6,\n155.9. MS (EI): m/z(%)=252 (20), 251 (89) [M+], 236 (29), 235 (12), 178 (23), 152 (33),\n76 (13).\nAnal . Calcd for C 16H13NO 2: C, 76.48; H, 5.21. Found: C, 76.44; 5.19.\n6-Amino-8-methoxy-3-phenylcoumarin (4d). Pale yellow solid, 88% yield, mp.\n172\u25e6C\u2013173\u25e6C.1HN M R( C D C l 3):\u03b43.85 (s, 3H, -CH 3), 3.97 (s, 2H, -NH 2), 6.97 (s,\n2H, H-7), 7.13 (s, 1H, H-5), 7.24\u20137.26 (m, 3H, H-2/prime,H - 4/prime,H - 6/prime), 7.63\u20137.69 (m, 2H, H-3/prime,\nH-5/prime) 7.81 (s, 1H, H-4).13CN M R( C D C l 3):\u03b456.4, 113.87, 115.9, 116.5, 121.2, 121.4,\n126.4, 129.1, 129.8, 136.9, 147.5, 159.4, 160.3. MS (EI): m/z(%)=268 (23), 267 (100)\n[M+], 248 (9), 182 (13), 167 (16), 139 (17).\nAna. Calcd for C 16H13O3: C, 71.90; H, 4.90. Found: C, 71.91; H, 4.92.\n3-(5-Aminothien-3-yl)-6-methylcoumarin (4e). Colorless solid, 94% yield, mp.\n170\u25e6C\u2013171\u25e6C.1HN M R( C D C l 3):\u03b42.46 (s, 3H, CH 3), 7.27 (s, 1H, H-5/prime), 7.29 (s, 2H,\nNH 2), 7.36 (s, 1H, H-2/prime), 7.40 (dd, J=7.2, 2.0 Hz, 2H, H-7, H-8,), 7.56 (d, J=1.9 Hz,\n1H, H-5), 7.93 (s, 1H, H-4).13CR M N( C D C l 3):\u03b422.0, 116.7, 119.8, 122.0, 124.8, 125.6,\n126.6, 127.2, 132.3, 135.2, 138.9, 147.2, 150.61, 160.3. MS (EI): m/z(%)=258 (15), 257\n(100) [M+], 242 (18), 152 (10).\nAnal. Calcd for C 14H11NO 2S: C, 65.35; H, 4.31. Found: C, 65.32; H, 4.29.\nAcknowledgment\nThe authors thank the Spanish Ministry (PS09/00501) and Xunta da Galicia(PGIDIT09CSA030203PR and INCITE09E2R203035ES) for partial \ufb01nancial support.Maria Jo \u02dcao Matos (SFRH/BD/61262/2009) and Alexandra Gaspar (SFRH/BD/43531/2008)\nthank Fundac \u00b8\u02dcao de Ci \u02c6encia e Tecnologia for the scholarships.\nReferences\n1. F. Borges, F. Roleira, N. Milhazes, E. Uriarte and L. Santana, Front. Med. Chem., 4, 23 (2009).\n2. C. Kontogiorgis and D. Hadjipavlou-Litina, J. Enzyme Inhib. Med. Chem. ,18, 63 (2003).\n3. C. Spino, M. Dodier and S. Sotheeswaran, Bioorg. Med. Chem: Lett. ,8, 3475 (1998).\n4. I. Kempen, D. Papapostolou, N. Thierry, L. Pochet, S. Counerotte, B. Masereel, J. M. Foidart,\nM. J. Reboud-Ravaux, A. Noel and B. Pirotte, Br. J. Cancer, 88, 1111 (2003).Downloaded by [University of Santiago de Compostela], [Dr Maria Jo\u00e3o Matos] at 07:48 05 November 2012 \n101526 Matos et al.\n5. S. Vilar, E. Quezada, L. Santana, E. Uriarte, M. Yanez, N. Fraiz, C. Alcaide, E. Cano and F.\nOrallo, Bioorg. Med. Chem. Lett. ,16, 257 (2006).\n6. E. Quezada, G. Delogu, C. Picciau, L. Santana, G. Podda, F. Borges, V . Garcia-Moraes, D. Vina\nand F. Orallo, Molecules, 15, 270 (2010).\n7. L. Santana, H. Gonz \u00b4alez-D \u00b4\u0131az, E. Quezada, E. Uriarte, M. Y \u00b4a\u02dcnez, D. Vi \u02dcn aa n dF .O r a l l o , J. Med.\nChem., 51, 6740 (2008).\n8. M. J. Matos, D. Vi \u02dcna, E. Quezada, C. Picciau, G. Delogu, F. Orallo, L. Santana and E. Uriarte,\nBioorg. Med. Chem. Lett. ,19, 3268 (2009).\n9. M. J. Matos, D. Vi \u02dcna, C. Picciau, F. Orallo, L. Santana and E. Uriarte, Bioorg. Med. Chem. Lett. ,\n19, 5053 (2009).\n10. M. J. Matos, D. Vi \u02dcna, P. Janeiro, F. Borges, L. Santana and E. Uriarte, Bioorg. Med. Chem. Lett. ,\n20, 5157 (2010).\n11. A. Fais, M. Corda, B. Era, M. B. Fadda, M. J. Matos, E. Quezada, L. Santana, C. Picciau, G.\nPodda and G. Delogu, Molecules, 14, 2514 (2009).\n12. M. J. Matos, L. Santana, E. Uriarte, G. Delogu, M. Corda, M. B. Fadda, B. Era and A. Fais,\nBioorg. Med. Chem. Lett. ,21, 3342 (2011).\n13. M. J. Matos, G. Delogu, G. Podda, L. Santana and E. Uriarte, Synthesis, 2763 (2010).\n14. M. J. Matos, S. Vazquez-Rodriguez, F. Borges, L. Santana and E. Uriarte, Tetrahedron Lett., 52,\n1225 (2011).\n15. R. S. Mali and P. P. Joshi, Synth Commun., 31, 2753 (2001).\n16. Y . Ming and D. W. Boykin, Heterocycles, 26, 3229 (1987).\n17. C. Khiri, F. Ladhar, R. El Gharbi and Y . Le Bigot, Synth. Commun., 29, 1451 (1999).\n18. S. Mohanty, J. K. Makrandi and S. K. Grove, Indian J. Chem., Sect B ,28B, 766 (1989).\n19. M. E. Langmuir, J. R. Yang, A. M. Moussa, R. Laura and K. A. Lecompte, Tetrahedroon Lett.,\n36, 3990 (1995).\n20. W. H. Perkin, J. Chem. Soc.,5 3( 1868).\n21. L. M. Kabeya, A. A. de Marchi, A. Kanashiro, N. P. Lopes and C. H. da Silva, Bioor g. Med.\nChem., 15, 1516 (2007).\n22. D. Bogdal, J. Chem. Res., Synop. ,8, 468 (1998).\n23. R. S. Mali and S. G. Tilve, Synth. Commun., 20, 1781 (1990).\n24. D. V . Rao, A. A. R. Sayigh and H. Ulrich, US 3644413 A 19720222, 1972; Chem. Abst., 77, 7318\n(1972).\n25. P. T. Prendergast, PCT Int. Appl. WO 2001003681 A2 20010118, 2001; Chem. Abst., 134, 110442\n(2001).\n26. C.-Z. Tao, J. Li, Y . Fu, L. Liu and Q.-X. Guo, Tetrahedron Lett., 49, 70 (2008).\n27. D. Wang, Q. Cai and K. Ding, Adv. Synth. Catal., 351, 1722 (2009).\n2 8 . H .Z h a i ,H .L i n ,X .L ua n dX . - H .X i a ,Chem. Lett., 35, 1358 (2006).\n29. Z. Wu, Z. Jiang, D. Wu, H. Xiang and X. Zhou, Eur. J. Org. Chem. , 1854 (2010).\n30. H. Xu and C. Wolf, Chem. Med. Commun., 3035 (2009).\n31. D. Wang, Q. Cai and K. Ding, Adv. Synth. Catal., 351, 1722 (2009).Downloaded by [University of Santiago de Compostela], [Dr Maria Jo\u00e3o Matos] at 07:48 05 November 2012 \n102electronic reprint\nActa Crystallographica Section E\nStructure Reports\nOnline\nISSN 1600-5368\nEditors: W.T. A. Harrison, H. Stoeckli-Evans,\nE. R.T. Tiekink and M. Weil\n3-Phenylcoumarin\nMaria J. Matos, Lourdes Santana and Eugenio Uriarte\nActa Cryst. (2012). E 68, o2645\nThis open-access article is distributed under the terms of the Creative Commons Attribution Licence\nhttp://creativecommons.org/licenses/by/2.0/uk/legalcode , which permits unrestricted use, distribution, and\nreproduction in any medium, provided the original authors and source are cited.\nActa Crysta llographica Section E: Structure Re ports Online is the IUCr\u2019s highly popu-\nlar open-access structural j ournal. It provides a simple and easily accessi ble publication\nmechanism for the growing number of inorganic, metal-organic and organic crystal struc-\nture determinations. The electronic submission, validation, refereeing and publicationfacilities of the journal ensure very rapid and high-quality publication, whilst key indica-\ntors and validation reports provide measures of structural reliability . The journal publishes\nover 4000 structures per year. The average publication time is less than one month.\nCrystallography Journals Online is available from journals.iucr.org\nActa Cryst. (2012). E 68, o2645 Matos et al. \u00b7C15H10O2\n1033-Phenylcoumarin\nMaria J. Matos,* Lourdes Santana and Eugenio Uriarte\nDepartment of Organic Chemistry, University of Santiago de Compostela, Santiago\nde Compostela, SpainCorrespondence e-mail: mariacmatos@gmail.com\nReceived 20 July 2012; accepted 1 August 2012\nKey indicators: single-crystal X-ray study; T= 100 K; mean /C27(C\u2013C) = 0.002 A \u02da;\nRfactor = 0.040; wRfactor = 0.104; data-to-parameter ratio = 12.5.\nIn the title compound, C 15H10O2, a 3-phenyl derivative of the\ncoumarin (also known as 2 H-chromen-2-one or 2 H-1-\nbenzopyran-2-one) scaffold, the C p\u2014C p\u2014C c\u2014C ctorsion\nangle between the coumarin (c) ring system and the phenyl\n(p) ring is /C047.6 (2)/C14.\nRelated literature\nFor the synthesis of the title compound, see: Matos, Santana et\nal.. et al. (2011); Matos, Tera \u00b4net al.. et al. (2011). For examples\nof biological activity of coumarin derivatives, see: Borges et al.\n(2009); Matos et al. (2009, 2010); Matos, Santana et al.. et al.\n(2011); Matos, Tera \u00b4net al.. et al. (2011); Vin \u02dca, Matos, Ferino et\nal.(2012); Vin \u02dca, Matos Ya \u00b4n\u02dcezet al. (2012).\nExperimental\nCrystal data\nC15H10O2\nMr= 222.23\nMonoclinic, C2=c\na= 18.469 (4) A \u02da\nb= 5.9596 (12) A \u02dac= 19.274 (4) A \u02da\n/C12= 99.079 (3)/C14\nV= 2094.9 (7) A \u02da3\nZ=8\nMoK/C11radiation/C22= 0.09 mm/C01\nT= 100 K0.27/C20.22/C20.09 mm\nData collection\nBruker SMART CCD 1000\ndiffractometer\nAbsorption correction: multi-scan\n(SADABS ; Bruker, 2002)\nTmin= 0.876, Tmax=19021 measured re\ufb02ections\n1924 independent re\ufb02ections\n1492 re\ufb02ections with I>2/C27(I)\nRint= 0.042\nRe\ufb01nement\nR[F2>2/C27(F2)] = 0.040\nwR(F2) = 0.104\nS= 1.03\n1924 re\ufb02ections154 parametersH-atom parameters constrained\n/C1/C26\nmax= 0.21 e A \u02da/C03\n/C1/C26min=/C00.26 e A \u02da/C03\nData collection: SMART (Bruker, 2002); cell re\ufb01nement: SAINT\n(Bruker, 2002); data reduction: SAINT ; program(s) used to solve\nstructure: SIR97 (Altomare et al. , 1999); program(s) used to re\ufb01ne\nstructure: SHELXL97 (Sheldrick, 2008); molecular graphics:\nORTEP-3 for Windows (Farrugia, 1997); software used to prepare\nmaterial for publication: WinGX (Farrugia, 1999).\nThis work was supported by funds from the Xunta da\nGalicia (09CSA030203PR), the Ministerio de Sanidad y\nConsumo (PS09/00501) and the Fundac \u00b8a\u02dco para a Cie \u02c6ncia e\nTecnologia (SFRH/BD/61262/2009).\nSupplementary data and \ufb01gures for this paper are available from the\nIUCr electronic archives (Reference: ZJ2091).\nReferences\nAltomare, A., Burla, M. C., Camalli, M., Cascarano, G. L., Giacovazzo, C.,\nGuagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). J.\nAppl. Cryst. 32, 115\u2013119.\nBorges, F., Roleira, F., Milhazes, N., Uriarte, E. & Santana, L. (2009). Front.\nMed. Chem. 4, 23\u201385.\nBruker (2002). SMART ,SAINT andSADABS . Bruker AXS Inc., Madison,\nWisconsin, USA.\nFarrugia, L. J. (1997). J. Appl. Cryst. 30, 565.\nFarrugia, L. J. (1999). J. Appl. Cryst. 32, 837\u2013838.\nMatos, M. J., Santana, L., Uriarte, E., Delogu, G., Corda, M., Fadda, M. B., Era,\nB. & Fais, A. (2011). Bioorg. Med. Chem. Lett. 21, 3342\u20133345.\nMatos, M. J., Tera \u00b4n, C., Pe \u00b4rez-Castillo, Y., Uriarte, E., Santana, L. & Vin \u02dca, D.\n(2011). J. Med. Chem. 54, 7127\u20137137.\nMatos, M. J., Vin \u02dca, D., Janeiro, P ., Borges, F., Santana, L. & Uriarte, E. (2010).\nBioorg. Med. Chem. Lett. 20, 5157\u20135160.\nMatos, M. J., Vin \u02dca, D., Quezada, E., Picciau, C., Delogu, G., Orallo, F., Santana,\nL. & Uriarte, E. (2009). Bioorg. Med. Chem. Lett. 19, 3268\u20133270.\nSheldrick, G. M. (2008). Acta Cryst. A64, 112\u2013122.\nVin\u02dca, D., Matos, M. J., Ferino, G., Cadoni, E., Laguna, R., Borges, F., Uriarte,\nE. & Santana, L. (2012). Chem. Med. Chem. 7, 464\u2013470.\nVin\u02dca, D., Matos, M. J., Ya \u00b4n\u02dcez, M., Santana, L. & Uriarte, E. (2012). Med. Chem.\nCommun. 3, 213\u2013218.organic compounds\nActa Cryst. (2012). E 68, o2645 doi:10.1107/S1600536812034277 Matos et al. o2645Acta Crystallographica Section E\nStructure Reports\nOnline\nISSN 1600-5368\n104supplementary materials\nsup-1  supplementary materials1\n3-Phenylcoumarin2\nMaria J. Matos, Lourdes Santana and Eugenio Uriarte3\nComment 4\nCoumarin derivatives are very interesting molecu les due to the biologic al properties that they may display (B orges  et al.  5\n2009 and Matos  et al.  2009, 2010, 2011,  2012 ). The title structure is a 3-p henyl c oumarin derivative that posses one 6\naromatic ring linked at that position. Therefore, the X- ray analysis of this c ompou nd (figure 1) aims  to contribu te to the 7\nelucidation  of struct ural requirements  needed to understand  the partial  planarity  of the compou nd (coumarin  nucleus) and 8\nthe torsion  of the 3-p henyl ring. From the single-c rystal diffra ction measu rements one can conclude that the experimental 9\nbond  lengt hs are within normal values with the average the molecu le bond  lengt hs. The planarity  of the coumarin moiety  10\nis also evident  by the torsion  angles values between their carbons . Also,  the angle C5\u2014C6\u2014C7 \u2014C8  is from  -47.6\u00b0, 11\ntypical of the torsion  permitted  by the rotation  of the 3-p henyl ring. Pack ing diagram of the structure allows  the 12\ninterpretation  of the spatial orientation  of the molecu les (figure 2). 13\nExperimental 14\n3-Phenylc oumarin was prepared according to the protoc ol described by Matos et al.  (2011 ). Perkin reaction gave the 15\ndesired  coumarin derivative . A solution of 2-hydroxybenz aldehyde (0.9 g, 7.37 mmol ) and the phenylac etic acid (1.25 g, 16\n9.21 mmol ) in dimet hyl sulfoxide (15 ml) was prepared . Dicyclohexylc arbodiimide  (DCC,  2.37 g, 11.50 mmol ) was 17\nadded,  and the mixture was heated  at 110 \u00b0C for 24 h. Ic e (100 ml) and acetic acid (10 ml) were added  to the reaction 18\nmixture. After k eeping it at room  temperat ure for 2 h, the mixture was extra cted with ether (3 x 25 ml). The organi c layer 19\nwas extracted with sodium bicarbonate  solution (50 ml, 5%) and then water (20  ml). Th e solvent  was evaporated under 20\nvacuu m, and the dry resid ue was purified  by flash ch romatograp hy (hexane/ethyl acetate  9:1). A white solid  was obtained  21\nin a yield  of 67% (1.1 g). Suitable  crystals for X-ray studies were grown  from  slow evaporation  from  acetone /ethanol:  22\nMp. 131\u201313 2 \u00b0C; 1H NMR (300 MHz, CDCl 3): \u03b4 7.34\u20137.54 (5H, m, 6-H , 8-H, 9-H , 11-H, 13-H), 7.56\u20137.66 (2 H, m, 10-H, 23\n12-H), 7.72\u20137.80 ( 2H, m, 5-H, 7-H), 7.90 ( 1H, s, 4-H); 13C NMR (75.47 MHz, CDCl 3): \u03b4 116.5, 119.7, 124.5, 127.9, 24\n128.4, 128.5, 128.5, 128.9, 131.4, 134.7, 139.9, 153.5, 160.6; DEPT: 116.5, 124.5, 127.9, 128.4, 128.5, 128.5, 131.4, 25\n139.9; MS m/z 223 ([ M + 1]+, 16), 222 ( M+, 100). Anal. Calcd for C15H10O2: C, 81.07; H , 4.54. Fo und: C, 81.02; H, 4.52. 26\nRefinement 27\nRefinement  of F2 against  ALL reflec tions . The weighted  R-factor wR and goodness of fit S are based on F2, conventional 28\nR-factors R are based on F, with F set to zero for negative F2. The threshold expression  of F2 > 2\u03c3(F2) is used only for 29\ncalculating R- factors(gt) etc. and is not relevant  to the choice of reflections  for refinement . R-factors based on F2 are 30\nstatistic ally abou t twice as large  as those based on F, and R- factors based  on ALL data will be even larger . 31\nComputing details 32\nData  collec tion: BRUKER Smart ; cell refinement:  BRUKER Smart; data reduction:  BRU KER Saint ; program( s) used to 33\nsolve struct ure: SIR97  (Giacovazzo et al. , 1997); program (s) used to refine structure: SHELXL97  (Sheldrick , 2008); 34\nmolecu lar graphics: ORTEP- 3 for Windows (F arrugia, 1997); software u sed to prepare material for publication: WinGX  35\n105supplementary materials\nsup-2  publication routines  (Farrugia, 1999). 36\nfig1.tif\nFigure 1 37\nThe molecular struct ure of the title compou nd with the atom- numbering scheme. Displa cement ellipsoids are drawn at 38\nthe 50% probability  level. 39\nfig2.tif\nFigure 2 40\nA packing diagram of the title structure viewed  along the b axis. 41\n106supplementary materials\nsup-3  (I) 42\nCrystal data  43\nC15H10O2 44\nMr = 222. 23 45\nMono clinic, C2/c 46\nHall symbol: - C 2yc 47\na = 18.469 (4 ) \u00c5 48\nb = 5.9596 (12 ) \u00c5 49\nc = 1 9.274 (4) \u00c5 50\n\u03b2 = 99. 079 (3)\u00b0 51\nV = 2094.9 (7) \u00c5352\nZ = 8 53F(000) = 928\nF(000) = 928\nDx = 1.409 Mg m\u22123\nMo K\u03b1 radiation,  \u03bb = 0.7107 \u00c5\nCell parameters from  1813 reflec tions\n\u03b8 = 2.8\u201326.2\u00b0\n\u00b5 = 0.09 mm\u22121\nT = 100 K\nPrism, colou rless\n0.27 \u00d7 0.22 \u00d7 0.09 mm\nData collection 54\nSmart -CCD -1000 BR UKER 55\ndiffrac tometer\nRadiation  source: fine-focus sealed tube 56\nGrap hite mono chromator 57\n\u03c9 scans 58\nAbsorption  correc tion: multi-scan 59\nBRUKER SADABS\nTmin = 0.876, Tmax = 1 609021 measu red reflec tions\n1924 independent  reflections\n1492 reflections  with I > 2\u03c3(I)\nRint = 0.042\n\u03b8max = 25. 4\u00b0, \u03b8min = 2.1\u00b0\nh = \u221222\u2192 21\nk = 0\u21927\nl = 0\u219223\nRefinement 61\nRefinement  on F262\nLeast -squares matri x: full 63\nR[F2 > 2\u03c3(F2)] = 0.040 64\nwR(F2) = 0 .104 65\nS = 1.03 66\n1924 reflec tions 67\n154 parameters 68\n0 restraints 69\nPrimary atom  site location: structure-invariant  70\ndirec t meth odsSecondary  atom site location:  differen ce Fourier \nmap\nHydrogen site location: inferred  from  \nneigh bouring sites\nH-atom parameters constrained\nw = 1/[\u03c32(Fo2) + (0.0528 P)2 + 1.3579P] \nwhere P = (Fo2 + 2Fc2)/3\n(\u0394/\u03c3)max = 0.001\n\u0394\u03c1max = 0.21 e \u00c5\u22123\n\u0394\u03c1min = \u22120.26 e \u00c5\u22123\nSpecial details  71\n72 Geometry . All s.u.'s (except the s.u. in the dihedral angle between  two l.s. planes) are estimated u sing the full covarianc e \nmatri x. The  cell s.u.'s are taken into account individ ually in the estimation  of s.u.'s in distanc es, angles and torsion  angles ; \ncorrelations  between s.u.'s in cell parameters  are only u sed when they are defined  by crystal symmetry . An appro ximate  \n(isotropi c)\n treatment  of cell s.u.'s is used for estimating s.u.'s involving l.s. planes.\n73 Refinement . Refinement  of F2 against  ALL reflec tions . The weighted  R-factor wR and goodness of fit S are based on F2, \nconventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression  of F2 > 2\u03c3(F2) is \nused only for calculating R-factors(gt) etc. and is not relevant  to the choice of reflections  for refinement . R-factors based \non F2 are statistic ally abou t twice as large  as those based on F, and R- factors based  on ALL data will be even larger .\nFractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (\u00c52) 74\n75 xy zU iso*/Ueq\n76C1 0.21370 (8) 0.2410  (3) 0.36971 ( 8) 0.0168 ( 4)\n77 H10 .219 0.3712 0.39 85 0. 02*\n78C2 0.15672 (9) 0.2280  (3) 0.31395 (8) 0.0184  (4)\n79 H20 .1223 0.3472 0 .3054 0 .022*\n107supplementary materials\nsup-4  80C3 0.14979 (9) 0.0409 (3) 0.27041  (8) 0.0192  (4)\n81 H3 0.1115 0 .03370 .2313 0.023*\n82C4 0.19876 (9) \u22120.13 48 (3) 0.28427  (8) 0.0188 ( 4)\n83 H40 .1939 \u2212 0.263 0.2546 0.023*\n84C5 0.2549 2 (9) \u2212 0.1254 (3) 0.34124 (8 ) 0.0166 (4 )\n85 H50 .2876\u2212 0.2485 0 .3511 0.02*\n86C6 0.26348 (8) 0.0646 (3) 0.38409 (8) 0.0145  (4)\n87C7 0.32522 (8 ) 0.0774 (3) 0.44333 (8 ) 0.0146 (3)\n88C8 0.34288  (8)\u2212 0.0903 (3) 0.49004  (8) 0.0145  (3)\n89 H80 .3139 \u22120.2228 0.4858 0.017*\n90C9 0.40398 (8)\u2212 0.0744  (3) 0.54588  (8) 0.0145  (4)\n91C10 0 .42315 (8)\u2212 0.2408 (3) 0.59681 ( 8) 0.0168 (4)\n92 H10 0.39 49\u2212 0.3744 0 .5955 0 .02*\n93C11 0 .4828 6 (9) \u22120.211 6 (3) 0.64877 ( 8) 0.0201 ( 4)\n94 H11 0 .4954 \u22120.3246 0.68340 .024*\n95C12 0 .52497 (9) \u2212 0.0168 (3) 0.65072  (8) 0.0206 (4)\n96 H12 0. 56640 .001 0.6863 0.025*\n97C13 0.50708 (9) 0.1506 (3) 0.6013 7 (8) 0.0190 (4)\n98 H13 0.5357 0.28350 .6026 0.023*\n99C14 0 .44646 (8) 0.1196 (3) 0.5501 6 (8) 0.0152  (4)\n100 C15 0 .37106 (8) 0.2799 (3) 0.44882  (8) 0.0161 ( 4)\n101 O10 .42953 (6) 0.29055 ( 18) 0.50224 ( 5) 0.0177 (3)\n102 O20 .36238 (6) 0.43926 (18) 0.40948 (6) 0.0220  (3)\nAtomic displacement parameters (\u00c52) 103\n104 U11U22U33U12U13U23\n105 C1 0 .0191 (8) 0.0165 (8) 0.0160 (8) 0.0006 (7 ) 0.0062 (7)\u2212 0.0010 ( 7)\n106 C2 0 .0167 (8) 0.0186 (9) 0.0206 (8) 0.0025  (7) 0.0050  (7) 0.0052  (7)\n107 C3 0.0166 (8 ) 0.0250  (9) 0.0156 (8)\u2212 0.0040  (7) 0.0013 (6) 0.0034 (7)\n108 C4 0 .0215  (9) 0.0188 (9) 0.0167 (8)\u2212 0.0050  (7) 0.0051  (7)\u2212 0.0029 (7)\n109 C5 0 .0188 ( 8) 0.0134 (8) 0.0182  (8) 0.0012  (7) 0.0050  (7) 0.0020  (6)\n110 C6 0.0144  (8) 0.0156 (8) 0.0144  (8)\u2212 0.0023 (6) 0.0054  (6) 0.0004  (6)\n111 C7 0 .0149 (8) 0.0147  (8) 0.0152  (8) 0.0012  (6) 0.0055  (6) \u2212 0.0020  (6)\n112 C8 0 .0154  (8) 0.0132 (8) 0.0160 (8) 0.0001 (6) 0.0058  (6) \u2212 0.0028  (6)\n113 C9 0.0138 (8) 0.0167 (8) 0.0140  (8) 0.0030 (6) 0.0056 (6) \u2212 0.0019 (6)\n114 C10 0 .0174  (8) 0.0166 (8 ) 0.0177 ( 8) 0.0012  (7) 0.0066 (7 ) 0.0003 ( 7)\n115 C11 0 .0216 (9) 0.0225 (9) 0.0163 (8) 0.0063 (7) 0.0037 ( 7) 0.0017 ( 7)\n116 C12 0 .0158  (8) 0.0283 (10) 0.0171 ( 8) 0.0035 (7) 0.0010 (6) \u2212 0.0041  (7)\n117 C13 0.0174  (8) 0.0201 (9) 0.0199 (9) \u2212 0.0013 ( 7) 0.0046 (7)\u2212 0.0057  (7)\n118 C14 0 .0168 (8) 0.0162 (8) 0.0136 ( 8) 0.0038 (7) 0.0057  (6) \u2212 0.0005  (6)\n119 C15 0 .0154  (8) 0.0161 (8) 0.0171 ( 8) 0.0020  (7) 0.0038 (6) \u2212 0.0025  (7)\n120 O10 .0202  (6) 0.0138 (6) 0.0185  (6) \u2212 0.0026 (5) 0.0011 ( 5) 0.0000 ( 5)\n121 O20 .0239 (6) 0.0148  (6) 0.0265 (6) \u2212 0.0003 ( 5) 0.0017 ( 5) 0.0053 (5)\nGeometric parameters (\u00c5, \u00ba)  122\n123 C1\u2014C2 1.382 (2) C8\u2014H80 .95\n124 C1\u2014 C6 1.395 (2) C9\u2014C14 1.392 (2)\n125 C1\u2014H10 .95C 9\u2014C10 1.401 ( 2)\n108supplementary materials\nsup-5  126 C2\u2014C3 1.390 (2) C10\u2014C11 1.379 (2 )\n127 C2\u2014H20 .95C 10\u2014H10 0.95\n128 C3\u2014C4 1.382 (2 ) C11\u2014C12 1.395  (2)\n129 C3\u2014H3 0.95C 11\u2014H11 0.95\n130 C4\u2014C5 1.387 (2) C12\u2014C1 3 1.382 (2)\n131 C4\u2014H40 .95C 12\u2014H12 0.95\n132 C5\u2014C6 1.396 (2 ) C13\u2014C14 1 .383 (2)\n133 C5\u2014H50 .95C 13\u2014H 13 0.95\n134 C6\u2014C7 1 .483 (2) C14\u2014O11 .3776 (18)\n135 C7\u2014 C8 1 .350 ( 2) C15\u2014O21 .2102 ( 19)\n136 C7\u2014C15 1.468 (2) C15\u2014O11 .3709 (19)\n137 C8\u2014C9 1.434 (2)\n138\n139 C2\u2014C1 \u2014C6 120.61 (15) C9\u2014C8\u2014H81 19\n140 C2\u2014C1 \u2014H11 19.7C 14\u2014C9\u2014C10 117.94 (14)\n141 C6\u2014C1\u2014H11 19.7C 14\u2014C9\u2014C8 117.93 (14)\n142 C1\u2014C2 \u2014C3 120.03 (15) C10\u2014C9\u2014C8 124 .13 (15)\n143 C1\u2014C2 \u2014H21 20 C 11\u2014C10 \u2014C9 120.29 (15)\n144 C3\u2014C2\u2014H21 2 0 C 1 1 \u2014C10\u2014H10 119.9\n145 C4\u2014C3\u2014C2 11 9.76 (15 ) C9\u2014C10\u2014H10 119.9\n146 C4\u2014C3\u2014H3 120.1C 10\u2014C11 \u2014C12 120.22 (15)\n147 C2\u2014C3\u2014H3 120.1C 1 0 \u2014C11\u2014H11 119.9\n148 C3\u2014C4\u2014C5 120 .48 (15) C12\u2014C11\u2014H11 119.9\n149 C3\u2014C4\u2014H41 1 9.8C 13\u2014C12\u2014C11 120.71 (15)\n150 C5\u2014C4\u2014H41 1 9.8C 13\u2014C12\u2014H12 119.6\n151 C4\u2014C5 \u2014C6 120.11 (15) C11\u2014C12 \u2014H12 119.6\n152 C4\u2014C5 \u2014H51 1 9.9 C12\u2014C1 3\u2014C14 118.25 (15)\n153 C6\u2014C5\u2014H51 1 9.9 C12\u2014C13\u2014H 13 120.9\n154 C1\u2014C6\u2014C5 118.96 (14 ) C14\u2014C13\u2014H 13 120.9\n155 C1\u2014C6\u2014C7 121.09 (14 )O 1\u2014C14\u2014C13 116.88 ( 14)\n156 C5\u2014C6\u2014C7 119.94 (14)O 1\u2014C14 \u2014C9 120.55 (14)\n157 C8\u2014C7\u2014C15 118 .97 (14) C13\u2014C14\u2014 C9 122.57 (14)\n158 C8\u2014C7\u2014C6 123.41 (14)O 2\u2014C15\u2014O 11 1 6.41 (14)\n159 C15\u2014 C7\u2014C6 117.56 (14)O 2\u2014C15\u2014 C7 125.59 (15)\n160 C7\u2014C8 \u2014C9 122.02 (15)O 1\u2014C15 \u2014C7 117 .99 (14 )\n161 C7\u2014C8 \u2014H81 19 C15\u2014O1\u2014C14 122.53 (12)\n162163\nC6\u2014C1\u2014C2\u2014C3\u2212 1.8 (2) C9\u2014C10 \u2014C11\u2014C12 \u22120.5 (2)\n164 C1\u2014C2\u2014 C3\u2014C4 1.9 (2) C10\u2014C11\u2014C12\u2014 C13 0.8 (2)\n165 C2\u2014C3\u2014C4\u2014C5 \u22120.2 (2) C11\u2014C12\u2014C13\u2014C14 0 .0 (2)\n166 C3\u2014C4\u2014C5\u2014C6\u2212 1.6 (2 ) C12\u2014C1 3\u2014C14\u2014O11 79.25 ( 13)\n167 C2\u2014 C1\u2014 C6\u2014C5 0.0 (2) C12\u2014C13\u2014C14\u2014 C9\u2212 1.2 (2)\n168 C2\u2014C1 \u2014C6\u2014C7 17 9.41 (14) C10\u2014C9\u2014C14\u2014O1 \u2212178.93 ( 13)\n169 C4\u2014 C5\u2014 C6\u2014C1 1.6 (2) C8\u2014C9\u2014C14\u2014O10 .4 (2)\n170 C4\u2014C5 \u2014C6\u2014C7 \u2212177.73 ( 14) C10\u2014C9\u2014C14\u2014C1 3 1.5 (2)\n171 C1\u2014C6\u2014C7 \u2014C8 133.05 (16) C8\u2014C9\u2014C14 \u2014C13\u2212 179.15  (13)\n172 C5\u2014C6\u2014C7 \u2014C8 \u221247.6 (2) C8\u2014C7 \u2014C15 \u2014O2 178.09 (15 )\n173 C1\u2014C6\u2014C7 \u2014C15 \u221249.86 (19) C6\u2014C7\u2014C15 \u2014O20 .9 (2)\n174 C5\u2014C6\u2014C7 \u2014C15 129.50 (15) C8\u2014C7 \u2014C15 \u2014O1 \u22120.9 (2 )\n109supplementary materials\nsup-6  175 C15\u2014C7\u2014C8 \u2014C9 1.5 (2) C6\u2014C7 \u2014C15 \u2014O1 \u2212178.17 ( 12)\n176 C6\u2014C7\u2014C8 \u2014C9 178.5 9 (14)O 2\u2014C15 \u2014O1\u2014C14 \u2212179.01 ( 13)\n177 C7\u2014 C8\u2014 C9\u2014C14 \u22121.3 (2) C7\u2014C15\u2014O1\u2014C14 0 .1 (2)\n178 C7\u2014C8 \u2014C9\u2014C10 178.02  (14) C13\u2014C14\u2014O1\u2014C15 179.72 (13)\n179 C14\u2014C9\u2014C10\u2014C11 \u22120.6 (2 ) C9\u2014C14 \u2014O1\u2014C15 0.1 (2)\n180 C8\u2014C9\u2014C10 \u2014C11 \u2212179.96 (14 )\n110electronic reprint\nActa Crystallographica Section E\nStructure Reports\nOnline\nISSN 1600-5368\nEditors: W.T. A. Harrison, H. Stoeckli-Evans,\nE. R.T. Tiekink and M. Weil\nN-(2-Oxo-2 H-chromen-3-yl)cyclohexanecarboxamide\nMaria J. Matos, Lourdes Santana and Eugenio Uriarte\nActa Cryst. (2012). E 68, o3447\u2013o3448\nThis open-access article is distributed under the terms of the Creative Commons Attribution Licence\nhttp://creativecommons.org/licenses/by/2.0/uk/legalcode , which permits unrestricted use, distribution, and\nreproduction in any medium, provided the original authors and source are cited.\nActa Crysta llographica Section E: Structure Re ports Online is the IUCr\u2019s highly popu-\nlar open-access structural j ournal. It provides a simple and easily accessi ble publication\nmechanism for the growing number of inorganic, metal-organic and organic crystal struc-\nture determinations. The electronic submission, validation, refereeing and publicationfacilities of the journal ensure very rapid and high-quality publication, whilst key indica-\ntors and validation reports provide measures of structural reliability . The journal publishes\nover 4000 structures per year. The average publication time is less than one month.\nCrystallography Journals Online is available from journals.iucr.org\nActa Cryst. (2012). E 68, o3447\u2013o3448 Matos et al. \u00b7C16H17NO 3\n111N-(2-Oxo-2 H-chromen-3-yl)cyclo-\nhexanecarboxamide\nMaria J. Matos,* Lourdes Santana and Eugenio Uriarte\nDepartment of Organic Chemistry, University of Santiago de Compostela, Santiago\nde Compostela, Spain\nCorrespondence e-mail: mariacmatos@gmail.com\nReceived 15 November 2012; accepted 21 November 2012Key indicators: single-crystal X-ray study; T= 100 K; mean /C27(C\u2013C) = 0.002 A \u02da;\nRfactor = 0.045; wRfactor = 0.113; data-to-parameter ratio = 13.4.\nIn the title compound, C 16H17NO 3, the coumarin moiety is\nessentially planar [maximum deviation from the mean plane\nformed by the C and O atoms of the coumarin =\n0.0183 (12) A \u02da] and that the cyclohexane ring adopts the usual\nchair conformation. The dihedral angle between the mean\nplane of the coumarin residue and the plane of the amide\nresidue (de\ufb01ned as the N, C and O atoms) is 18.9 (2)/C14. There\nare two intramolecular hydrogen bonds involving the amide\ngroup. In one, the N atom acts as donor to the ketonic O atomand in the other, the amide O atom acts as acceptor of a C\u2014H\ngroup of the coumarin. In the crystal, molecules are linked\ninto inversion dimers by pairs of N\u2014H /C1/C1/C1O contacts and these\ndimers are linked into pairs by weak C\u2014H /C1/C1/C1O hydrogen\nbonds. The combination of these interactions creates a chainof rings which runs parallel to [2\n10]. C\u2014H /C1/C1/C1/C25and /C25\u2013/C25\n[centroid\u2013centroid distance = 3.8654 (10) A \u02da] interactions are\nalso observed.\nRelated literature\nFor the synthesis of the title compound, see: Vin \u02dca, Matos,\nFerino et al. (2012); Vin \u02dca, Matos, Ya \u00b4n\u02dcezet al. (2012). For the\nbiological activity of coumarin derivatives, see: Borges et al.\n(2009); Matos et al. (2009, 2010); Matos, Santana et al. (2011);\nMatos, Tera \u00b4net al. (2011). For graph-set analysis of hydrogen\nbonds, see: Bernstein et al. , (1995)\nExperimental\nCrystal data\nC16H17NO 3\nMr= 271.31\nTriclinic, P1\na= 6.4486 (6) A \u02da\nb= 9.6324 (11) A \u02da\nc= 11.0837 (11) A \u02da\n/C11= 83.061 (6)/C14\n/C12= 89.134 (5)/C14/C13= 73.987 (5)/C14\nV= 656.79 (12) A \u02da3\nZ=2\nMoK/C11radiation\n/C22= 0.10 mm/C01\nT= 100 K\n0.48/C20.45/C20.09 mm\nData collection\nBruker X8 APEXII KappaCCD\ndiffractometer\nAbsorption correction: multi-scan\n(SADABS ; Bruker, 2012)\nTmin= 0.910, Tmax= 1.0009698 measured re\ufb02ections\n2487 independent re\ufb02ections1834 re\ufb02ections with I>2/C27(I)\nR\nint= 0.044\nRe\ufb01nement\nR[F2>2/C27(F2)] = 0.045\nwR(F2) = 0.113\nS= 1.06\n2487 re\ufb02ections\n185 parametersH atoms treated by a mixture of\nindependent and constrained\nre\ufb01nement\n/C1/C26max= 0.20 e A \u02da/C03\n/C1/C26min=/C00.25 e A \u02da/C03\nTable 1\nHydrogen-bond geometry (A \u02da,/C14).\nCg1 and Cg2 are the centroids of the O1/C2\u2013C5/C10 and C5\u2013C10 rings,\nrespectively.\nD\u2014H/C1/C1/C1AD \u2014H H /C1/C1/C1AD /C1/C1/C1AD \u2014H/C1/C1/C1A\nN12\u2014H12 /C1/C1/C1O11 0.87 (2) 2.346 (19) 2.6990 (18) 104.7 (14)\nN12\u2014H12 /C1/C1/C1O11i0.87 (2) 2.098 (18) 2.9303 (16) 160.8 (17)\nC4\u2014H4 /C1/C1/C1O14 0.95 2.37 2.9094 (19) 115\nC7\u2014H7 /C1/C1/C1O14ii0.95 2.57 3.473 (2) 158\nC16\u2014H16 B/C1/C1/C1Cg1iii0.99 2.81 3.5732 (17) 134\nC17\u2014H17 B/C1/C1/C1Cg2iii0.99 2.70 3.5876 (19) 149\nSymmetry codes: (i) /C0x\u00fe1;/C0y;/C0z; (ii)/C0x/C01;/C0y\u00fe1;/C0z; (iii) /C0x;/C0y;/C0z.\nData collection: APEX2 (Bruker, 2012); cell re\ufb01nement: SAINT\n(Bruker, 2012); data reduction: SAINT ; program(s) used to solve\nstructure: SIR97 (Altomare et al. , 1999); program(s) used to re\ufb01ne\nstructure: SHELXL97 (Sheldrick, 2008); molecular graphics:\nPLATON (Spek, 2009); software used to prepare material for\npublication: WinGX (Farrugia, 2012).\nThis work was supported by funds of Xunta da Galicia\n(09CSA030203PR), Ministerio de Sanidad y Consumo (PS09/\n00501) and Fundac \u00b8a\u02dcop a r aaC i e \u02c6ncia e Tecnologia (SFRH/BD/\n61262/2009).organic compounds\nActa Cryst. (2012). E 68, o3447\u2013o3448 doi:10.1107/S1600536812047903 Matos et al. o3447Acta Crystallographica Section E\nStructure Reports\nOnline\nISSN 1600-5368\n112Supplementary data and \ufb01gures for this paper are available from the\nIUCr electronic archives (Reference: GO2076).\nReferences\nAltomare, A., Burla, M. C., Camalli, M., Cascarano, G. L., Giacovazzo, C.,\nGuagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). J.\nAppl. Cryst. 32, 115\u2013119.\nBernstein, J., Davis, R. E., Shimoni, L. & Chang, N.-L. (1995). Angew. Chem.\nInt. Ed. Engl. 34, 1555\u20131573.\nBorges, F., Roleira, F., Milhazes, N., Uriarte, E. & Santana, L. (2009). Front.\nMed. Chem. 4, 23\u201385.\nBruker (2012). APEX2 ,SAINT andSADABS . Bruker AXS Inc., Madison,\nWisconsin, USA.Farrugia, L. J. (2012). J. Appl. Cryst. 45, 849\u2013854.\nMatos, M. J., Santana, L., Uriarte, E., Delogu, G., Corda, M., Fadda, M. B., Era,\nB. & Fais, A. (2011). Bioorg. Med. Chem. Lett. 21, 3342\u20133345.\nMatos, M. J., Tera \u00b4n, C., Pe \u00b4rez-Castillo, Y., Uriarte, E., Santana, L. & Vin \u02dca, D.\n(2011). J. Med. Chem. 54, 7127\u20137137.\nMatos, M. J., Vin \u02dca, D., Janeiro, P ., Borges, F., Santana, L. & Uriarte, E. (2010).\nBioorg. Med. Chem. Lett. 20, 5157\u20135160.\nMatos, M. J., Vin \u02dca, D., Quezada, E., Picciau, C., Delogu, G., Orallo, F., Santana,\nL. & Uriarte, E. (2009). Bioorg. Med. Chem. Lett. 19, 3268\u20133270.\nSheldrick, G. M. (2008). Acta Cryst. A64, 112\u2013122.\nSpek, A. L. (2009). Acta Cryst. D65, 148\u2013155.\nVin\u02dca, D., Matos, M. J., Ferino, G., Cadoni, E., Laguna, R., Borges, F., Uriarte,\nE. & Santana, L. (2012). Chem. Med. Chem. 7, 464\u2013470.\nVin\u02dca, D., Matos, M. J., Ya \u00b4n\u02dcez, M., Santana, L. & Uriarte, E. (2012).\nMedChemComm ,3, 213\u2013218.organic compounds\no3448 Matos et al./C15C16H17NO 3 Acta Cryst. (2012). E 68, o3447\u2013o3448\n113supplementary materials\nsup-1 Acta Cryst.  (2012). E 68, o3447\u2013o3448    supplementary materials\nActa Cryst.  (2012). E 68, o3447\u2013 o3448    [doi:10. 1107/S1600536812047903]\nN-(2-Oxo-2H -chromen-3-yl)cyclohexanecarboxamide\nMaria J. Matos, Lourdes Santana and Eugenio Uriarte\nComment\nCoumarin derivatives are very interesting molecu les due to the biologic al properties  that they may display (B orges et al.  \n2009; Matos  et al.  2009 , 2010; Matos, Santana et al. , 2011 ); Matos, T er\u00e1n et al. , 2011 ). The  title struct ure is a 3-\nsubstitu ted c oumarin derivative that posses one c yclohexane ring linked by an amidic bridge at that position. Therefore, \nthe X-ray analysis of this compou nd (figure 1) aims to contribu te to the elucidation of struct ural requirements needed to \nunderstand the partial planarity of the compou nd (co umarin nucleus) and the torsion of the 3-substitu ent. Also, the X-ray \nanalysis allows u nderstanding the chair conformation of the cyclohexane. From the single-c rystal diffra ction \nmeasu rements it can be concluded that the experimental bond lengths are within normal values with the average the \nmolecu le bond length s. The  planarity of the c oumarin moiety is also evident by the torsion angles values between their \ncarbons and oxygen atoms. The  torsion angles C4\u2014 C3\u2014N12\u2014 C13 (-21.3\u00b0),  C3\u2014N12\u2014 C13\u2014C15 (-173.68 \u00b0) and N12\n\u2014C13\u2014C15\u2014 C16 (-1 62.13\u00b0) are typic al of the torsion permitted by the rotation  of the amidic group at position 3. Also, \nthe torsion angle C15\u2014C16\u2014C17 \u2014C18 (56.43\u00b0) is typic al of a chair conformation of a cyclohexane ring.\nThere are intramolecular short contac ts N12-H12\u00b7\u00b7\u00b7011 and C4\u2013H4 \u00b7\u00b7\u00b7O14.\nThe molecu les are linked to form c entrosymmetric R22(10) dimers, (B ernstein et al. , 1995), by the N12-H12\u00b7\u00b7\u00b7O11 (-\nx+1,-y, -z) hydrogen bond. The molecu les are also link into R22 pairs, (B ernstein et al. , 1995), by the weak C7\u00b7\u00b7\u00b7H7\u00b7\u00b7\u00b7O14 \n(-x-1,-y+1,-z) hydrogen bond.\nCombination of these pair of interac tions c reates a chain of rings which runs parallel to [210]\nThere are C\u2013H\u00b7\u00b7\u00b7 \u03c0 interac tions between C16 and C17 and the c entroids of the rings c ontaining O 11 and C9 respec tively \nat (-x, -y,-z).\nIn addition there is \u03c0\u2013\u03c0 stack ing between the rings c ontaing O 1 at (x,y,z) and (-x ,-y+1,-z) in which the c entroid to \ncentroid distanc e is 3.8 654 (10)\u00c5,  the perpendicular distanc e between the rings is 3.4428  (6)\u00c5 and the offset is 1.757\u00c5.\nExperimental \nN-(coumarin-3-yl)cy clohexanecarbox amide was prepared according to the protoc ol described by (V i\u00f1a, Matos, Ferino et \nal. 2012; V i\u00f1a, Matos, Y\u00e1\u00f1e z et al.  2012). T o a solution of 3- amino coumarin ( 1 mmol) and pyridine ( 1.1 mmol) in di-\nchlorometane (9 ml) , the corresponding acid chloride ( 1.1 mmol) was added dropwise and the reaction was stirred, at \nroom temperatu re, for 3 h. Th e solvent was evaporated  under vacuum  and the dry residu e was purified  by FC  \n(hexane/ethyl acetate 9 :1). A pale yellow solid was obtained in a yield of 72%. Suitable c rystals for X- ray studies were \ngrown from slow evaporation from  acetone/ethanol: Mp 180\u2013181 \u00b0 C.\nRefinement\nRefinement of F2 against ALL reflec tions. The weighted R-factor wR and goodness of fit S are based on F2, conventional \nR-factors R are based on F, with F set to zero for negative F2. The  threshold expression of F2 > 2\u03c3(F2) is used only for \n114supplementary materials\nsup-2 Acta Cryst.  (2012). E 68, o3447\u2013o3448    calculating R- factors(gt) etc. and is not relevant to the choic e of reflections for refinement . R-factors based on F2 are \nstatistic ally abou t twice as large as those based on F, and R- factors based on ALL data will be even larger .\nComputing details \nData  collec tion: APEX2  (Bruker, 2012); c ell refinement: SAINT  (Bruker, 2012); data reduction: SAINT  (Bruker, 2012); \nprogram( s) used to solve struct ure: SIR97  (Altomare et al. , 1999); program( s) used to refine struct ure: SHELXL97  \n(Sheldrick , 2008); molecu lar graph ics: PLATON  (Spek , 2009); software u sed to prepare material for publication: WinGX  \n(Farru gia, 2012).\nFigure 1\nThe molecular struct ure of the title c ompou nd with the atom- numbering scheme. Displac ement ellipsoids are drawn at \nthe 3 0%probability level. The dashed lines indic ate intramolecu lar close c ontac ts. \n115supplementary materials\nsup-3 Acta Cryst.  (2012). E 68, o3447\u2013o3448    \nFigure 2\nPart of the crystal struc ture of (2) showing the chain formed by molecu les linked by R22(10) and R22(18) rings which runs \nparallel to the the {210]. Atoms labelled with an asterisk (*),  hash (#) or dollar ($) , are at(-x+1,- y,-z), (-x-1,-y+1,-z) and \nx+2,y-1,z respec tively . Hydrogen atoms not involved in the hydrogen bonding h ave been omitted. \nN-(2-Oxo-2 H-chromen-3-yl)cyclohexanecarboxamide \nCrystal data \nC16H17NO3\nMr = 271.31\nTriclinic, P1\nHall symbol: -P 1\na = 6.4486 (6) \u00c5\nb = 9.63 24 (11) \u00c5\nc = 11 .0837 (11) \u00c5\u03b1 = 83.061 (6)\u00b0\n\u03b2 = 8 9.134 (5)\u00b0\n\u03b3 = 73.987 ( 5)\u00b0\nV = 656.79 (12) \u00c53\nZ = 2\nF(000) = 288\nF(000) = 288\n116supplementary materials\nsup-4 Acta Cryst.  (2012). E 68, o3447\u2013o3448    Dx = 1.372 Mg m\u22123\nMelting point: 100 K\nMo K\u03b1 radiation, \u03bb = 0.71073 \u00c5\nCell parameters from 1680 reflec tions\n\u03b8 = 2.7\u201326.3\u00b0\u00b5 = 0.10 mm\u22121\nT = 100 K\nPlate, colou rless\n0.48 \u00d7 0.45 \u00d7 0.09 mm\nData collection \nBruker X 8 APEXII K appaCCD \ndiffrac tometer\nRadiation source: fine-focus sealed tube\nGraphite monoch romator\n\u03c9 and phi scans\nAbsorption c orrec tion: multi-scan \n(SADABS ; Bruker, 2012)\nTmin = 0.910, Tmax = 1.0009698 measured reflec tions\n2487 independent reflec tions\n1834 reflec tions with I > 2\u03c3(I)\nRint = 0.044\n\u03b8max = 25. 7\u00b0, \u03b8min = 1.9\u00b0\nh = \u22127\u21927\nk = \u2212 11\u219211\nl = 0\u219213\nRefinement Refinement on F\n2\nLeast-squares matrix : full\nR[F2 > 2\u03c3(F2)] = 0.045\nwR(F2) = 0 .113\nS = 1.06\n2487  reflec tions\n185 parameters\n0 restraints\nPrimary atom site location: struc ture-invariant \ndirec t meth odsSecondary atom site location:  differen ce Fourier \nmap\nHydrogen site location: inferred from \nneigh bouring sites\nH atoms treated by a mixture of independent \nand c onstrained refinement\nw = 1/[\u03c32(Fo2) + (0.0577 P)2] \nwhere P = (F o2 + 2Fc2)/3\n(\u0394/\u03c3)max < 0.001\n\u0394\u03c1max = 0.20 e \u00c5\u22123\n\u0394\u03c1min = \u22120 .25 e \u00c5\u22123\nSpecial details  \nExperimental . 1H NMR (300 MHz, CDCl 3): \u03b4 1.27\u20131.95 (10H, m, 2H-2, 2H-3, 2H-4, 2H-5, 2H-6),  2.33\u20132 .40 (1H, m \nH-1), 7.25\u20137.29 (2H, m, H-6 , H-8), 7.33 (1 H, dd, H- 7, J=8.5, J=1.5), 7.46 (1H, dd, H-5, J=8.5, J=1.6), 8.12 (1H, s, H- 4), \n8.70 ( 1H, s, \u2013NH); 13C NMR (75 .47?MHz, CDCl 3): \u03b4 25.6,  25.7, 29.7, 43.0, 116.6, 120.2, 123.4, 124.3,  125.4, 128.0, \n129.8, 150.1, 159.2, 175.9; DEPT: 25.6,  25.7, 29.7, 43.0, 116.6, 120.2, 124.3,  125.4, 128.0; MS m/z 272 ( [M + 1]+ , 16), \n271 ( M+, 100). Anal. Calcd for C16H17NO3:  C, 70.83; H,  6.32. Found: C, 70.85; H,  6.35.\nGeometry . All s.u.'s (except the s.u. in the dihedral angle between  two l.s. planes) are estimated u sing the full covarianc e \nmatrix. The c ell s.u.'s are taken into account individually in the estimation of s.u.'s in distanc es, angles and torsion angles ; \ncorrelations between s.u.'s in cell parameters are only u sed when they are defined by crystal symmetry . An approx imate \n(isotropic) treatment of cell s.u.'s is used for estimating s.u.'s involving l.s. planes.\nRefinement . Refinement of F2 against ALL reflec tions. The weighted R-factor wR and goodness of fit S are based on F2, \nconventional R-factors R are based on F, with F set to zero for negative F2. The  threshold expression of F2 > 2\u03c3(F2) is \nused only for calculating R-factors(gt) etc. and is not relevant to the choic e of reflections for refinement . R-factors based \non F2 are statistic ally abou t twice as large as those based on F, and R- factors based on ALL data will be even larger .\nFractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (\u00c52) \nxyzU iso*/Ueq\nO10 .24398  (15) 0.35744 ( 12)\u2212 0.13872 (9) 0.0151 (3)\nC2 0.2812  (2) 0.23542 ( 18)\u2212 0.05704  (14) 0.0135 (4)\nC3 0.0969 (2 ) 0.20233 (18) 0.00628 (14) 0.0124 ( 4)\nC4 \u22120.1049 (2) 0.28990 ( 18)\u2212 0.01851 ( 13) 0.0136 (4)\nH4 \u22120.2245 0.26680 .0216 0.016*\nC5 \u22120.1385 (2) 0.41752 ( 18)\u2212 0.1053 1 (13) 0.0128 ( 4)\nC6\u2212 0.3423 (2 ) 0.51517 ( 19) \u22120 .13683 (14) 0.0157 ( 4)\n117supplementary materials\nsup-5 Acta Cryst.  (2012). E 68, o3447\u2013o3448    H6 \u22120.4679 0.4963 \u22120.1007 0.019*\nC7 \u22120.3625 (3) 0.63721 ( 19) \u22120 .21886 (14) 0.0177 ( 4)\nH7 \u22120.5009 0.7028 \u22120.2381 0.021*\nC8 \u22120.1796 (3) 0.66474 ( 19) \u22120.27 396 (14) 0.0185 ( 4)\nH8 \u22120.19380 .7492 \u22120.3307 0.022*\nC9 0.0224 (3) 0.56983 (18)\u2212 0.24641 (14) 0.0165 (4)\nH9 0.1473 0.5875 \u22120.2843 0.02*\nC10 0 .0385 (2) 0.44942 (18)\u2212 0.16300 (14) 0.0135 (4)\nO11 0 .46651 ( 16) 0.16189 (12)\u2212 0.04220  (10) 0.0183 (3)\nN12 0.1571 ( 2) 0.07624 ( 16) 0.08823 (12) 0.0147 (3)\nH12 0.285 (3) 0.019 (2 ) 0.0806 (15) 0.028 ( 5)*\nC13 0.0426 (2 ) 0.03698  (18) 0.18526 (14) 0.0139 (4 )\nO14 \u22120.13975 ( 16) 0.10822 ( 13) 0.20623 (10) 0.0219 (3)\nC15 0 .1649 (2)\u2212 0.09965 ( 18) 0.26441 ( 14) 0.0131 (4)\nH15 0.24 \u22120.1722 0.20950 .016*\nC16 0.0122 ( 2)\u2212 0.16661  (18) 0.34364 (14) 0.0160 (4)\nH16A \u22120 .0669 \u22120.0959 0.3977 0.019*\nH16B \u22120 .0948 \u22120.1882 0.2911 0.019*\nC17 0 .1367 (2)\u2212 0.30629 (19) 0.42045 ( 15) 0.0188 ( 4)\nH17A 0.0353\u2212 0.3448 0.47350 .023*\nH17B 0.2042 \u22120.3802 0.36640 .023*\nC18 0 .3111  (3) \u22120.27969 ( 19) 0.49876 (15) 0.0201 ( 4)\nH18A 0.2425 \u22120.2148 0.55950 .024*\nH18B 0.3954 \u22120.37320 .54310 .024*\nC19 0.4615 (3) \u22120.21078 ( 19) 0.42127 ( 15) 0.0212 ( 4)\nH19A 0.5427 \u22120.2807 0.3672 0.025*\nH19B 0.567 \u22120.1889 0.4748 0.025*\nC20 0.3377 ( 2)\u2212 0.07084 ( 19) 0.34427 ( 14) 0.0174 ( 4)\nH20A 0.4394 \u22120.0317 0.2920 .021*\nH20B 0.2681 0.0028 0.3981 0.021*\nAtomic displacement parameters (\u00c52) \nU11U22U33U12U13U23\nO10 .0132 (6) 0.0145 ( 7) 0.0169 (6) \u22120.0041 ( 5) 0.0012 ( 5) 0.0019 (5)\nC2 0 .0175 ( 8) 0.0115 ( 10) 0.0127 (9) \u2212 0.0048 ( 7) 0.0005 ( 7)\u2212 0.0039 (7)\nC3 0.0168 ( 8) 0.0117 ( 10) 0.0096 (8)\u2212 0.0053 (7) 0.0014 (6) \u2212 0.0015 ( 7)\nC4 0 .0145 ( 8) 0.0160 ( 10) 0.0117 (9) \u2212 0.0058 ( 7) 0.0013 (7)\u2212 0.0037 ( 8)\nC5 0 .0170 ( 8) 0.0126 (10) 0.0098 (9) \u2212 0.0048 ( 7) 0.0007 ( 7)\u2212 0.0039 (7 )\nC6 0.0153 (8) 0.0196 (11 ) 0.0125 (9) \u2212 0.0044  (7) 0.0004 ( 7)\u2212 0.0043 (8)\nC7 0 .0199 (9) 0.0175 ( 10) 0.0133 (9) 0.0000 ( 7)\u2212 0.0041 ( 7)\u2212 0.0037 ( 8)\nC8 0 .0290 (9) 0.0128 ( 10) 0.0137 (9) \u2212 0.0060 (8)\u2212 0.0040 ( 7)\u2212 0.0007 ( 8)\nC9 0.0207 (9) 0.0178 ( 10) 0.0138 (9) \u2212 0.0099 (7) 0.0015 ( 7)\u2212 0.0022 ( 8)\nC10 0 .0150 ( 8) 0.0136 (10) 0.0117 (9) \u2212 0.0029 (7 )\u2212 0.0016 (6) \u22120 .0031 (7)\nO11 0 .0129 (6) 0.0174 ( 7) 0.0229 (7 )\u2212 0.0024 ( 5) 0.0014 ( 5)\u2212 0.0005 ( 5)\nN12 0.0126 (7) 0.0145 ( 8) 0.0149 (8)\u2212 0.0011 (6) 0.0024 (6) 0.0005 (6)\nC13 0.0157 ( 8) 0.0161 ( 10) 0.0123 (9) \u22120.0079 (7) 0.0021 ( 7)\u2212 0.0036 (7)\nO14 0.0162 (6) 0.0218 ( 8) 0.0230 ( 7)\u2212 0.0005 ( 5) 0.0046 (5 ) 0.0035 (6)\nC15 0 .0161 (8) 0.0118 ( 10) 0.0112 ( 8)\u2212 0.0036 (7 ) 0.0008 (6) \u2212 0.0014 ( 7)\nC16 0.0182 ( 8) 0.0169 (10) 0.0148 (9) \u2212 0.0080 ( 7) 0.0019 (7 )\u2212 0.0019 (8 )\n118supplementary materials\nsup-6 Acta Cryst.  (2012). E 68, o3447\u2013o3448    C17 0 .0241 (9) 0.0178 ( 11) 0.0156 (9) \u22120.0083 (7) 0.0029 (7)\u2212 0.0011 ( 8)\nC18 0 .0248 (9) 0.0174 ( 11) 0.0165 (9) \u2212 0.0041 ( 8)\u2212 0.0006 (7) 0.0003 (8)\nC19 0.0213 (9) 0.0221 ( 11) 0.0194  (10)\u2212 0.0067 ( 8)\u2212 0.0049 (7) 0.0029 (8)\nC20 0 .0192 ( 8) 0.0172 ( 10) 0.0165 (9) \u2212 0.0075 ( 7)\u2212 0.0011 ( 7) 0.0013 (8)\nGeometric parameters (\u00c5, \u00ba)  \nO1\u2014C2 1.3610 ( 19) C13\u2014O14 1.2220 ( 17)\nO1\u2014C10 1.3852 ( 17) C13\u2014C15 1.514 ( 2)\nC2\u2014O11 1.2115  (17) C15\u2014 C16 1.531 (2)\nC2\u2014 C3 1.462 (2) C15\u2014 C20 1.537 (2)\nC3\u2014C4 1.3523 (1 9) C15\u2014H 15 1\nC3\u2014N12 1.391  (2) C16\u2014C17 1.526 ( 2)\nC4\u2014 C5 1.434 (2) C16\u2014H1 6A 0.99\nC4\u2014H40 .95C 16\u2014H1 6B 0.99\nC5\u2014 C10 1.389 (2) C17\u2014C18 1.525 ( 2)\nC5\u2014C6 1.410 ( 2) C17\u2014H17A 0.99\nC6\u2014C7 1.373 (2) C17\u2014H17B 0.99\nC6\u2014H6 0.95 C18\u2014 C19 1.521 ( 2)\nC7\u2014 C8 1.395 (2) C18\u2014H18A 0.99\nC7\u2014H70 .95C 18\u2014H18B 0.99\nC8\u2014 C9 1.383 (2) C19\u2014C20 1.527 (2 )\nC8\u2014H80 .95C 19\u2014H1 9A 0.99\nC9\u2014C10 1.374 ( 2) C19\u2014H19B 0.99\nC9\u2014H9 0.95 C20\u2014H20A 0.99\nN12\u2014C1 3 1.370 ( 2) C20\u2014H20B 0.99\nN12\u2014H12 0.867 (17)\nC2\u2014O 1\u2014C10 121.98 (12) C13\u2014C15\u2014 C20 111.68 (14)\nO11\u2014C2\u2014O11 17.05 (14) C16\u2014C15 \u2014C20 110.15 (13)\nO11\u2014C2\u2014C3 124.73 (15) C13\u2014C15 \u2014H15 107.8\nO1\u2014C2 \u2014C3 118.23 (13) C16\u2014C15 \u2014H15 107.8\nC4\u2014C3\u2014N12 127.29 (15 ) C20\u2014C15 \u2014H15 107.8\nC4\u2014C3\u2014C2 120.24 (15) C17\u2014C16\u2014C15 111.00 (12)\nN12\u2014C 3\u2014C2 112.46 (13) C17\u2014C1 6\u2014H16A 109.4\nC3\u2014C4\u2014C5 120.11 (15) C15\u2014C1 6\u2014H16A 109.4\nC3\u2014C4\u2014H41 19.9 C17\u2014C16\u2014H1 6B 109.4\nC5\u2014C4 \u2014H41 19.9 C15\u2014C1 6\u2014H16B 109.4\nC10\u2014C5\u2014C6 116.77 ( 15)H 16A\u2014C1 6\u2014H1 6B 108\nC10\u2014C5 \u2014C4 119.08 ( 14) C18\u2014C17 \u2014C1 6 111.32 (14)\nC6\u2014C5\u2014C4 124.15 (15) C18\u2014C17 \u2014H17A 109.4\nC7\u2014C6\u2014C5 121.11 (15) C16\u2014C17 \u2014H17A 109.4\nC7\u2014C6\u2014H6 119.4C 18\u2014C17\u2014H17B 109.4\nC5\u2014C6\u2014H6 119.4C 16\u2014C17 \u2014H17B 109.4\nC6\u2014C7\u2014C8 119.91 (15)H 17A\u2014C17 \u2014H17B 108\nC6\u2014C7\u2014H7 120 C19\u2014C18 \u2014C17 111.01 (14)\nC8\u2014C7\u2014H7 120 C19\u2014C18 \u2014H18A 109.4\nC9\u2014C8\u2014C7 120.39 (16) C17\u2014C18 \u2014H18A 109.4\nC9\u2014C8\u2014H81 19.8C 19\u2014C18 \u2014H18B 109.4\nC7\u2014C8\u2014H81 19.8C 17\u2014C18\u2014H18B 109.4\n119supplementary materials\nsup-7 Acta Cryst.  (2012). E 68, o3447\u2013o3448    C10\u2014C9\u2014C8 118.56 (15)H 18A\u2014C18 \u2014H18B 108\nC10\u2014C9\u2014H9 120.7C 18\u2014C1 9\u2014C20 111.67 (14)\nC8\u2014C9\u2014H9 120.7C 18\u2014C19\u2014H1 9A 109.3\nC9\u2014C10\u2014O11 16.42 ( 14) C20\u2014C1 9\u2014H19A 109.3\nC9\u2014C10\u2014C5 123.25 ( 14) C18\u2014C1 9\u2014H19B 109.3\nO1\u2014C10 \u2014C5 120.33 (15) C20\u2014C1 9\u2014H19B 109.3\nC13\u2014N12\u2014C 3 127.25 (13) H19A\u2014C1 9\u2014H19B 107.9\nC13\u2014N12\u2014H12 115.9 (12) C19\u2014C20 \u2014C15 110.64 ( 14)\nC3\u2014N12\u2014H12 116.6 (12) C19\u2014C20 \u2014H20A 109.5\nO14\u2014 C13\u2014N12 122.46 (15) C15\u2014C20 \u2014H20A 109.5\nO14\u2014C1 3\u2014C15 123.73 ( 14) C19\u2014C20 \u2014H20B 109.5\nN12\u2014C1 3\u2014C15 113.80 (13) C15\u2014C20 \u2014H20B 109.5\nC13\u2014C15 \u2014C16 111.49 (12)H 20A\u2014C20 \u2014H20B 108.1\nC10\u2014O1 \u2014C2\u2014O11 179.93 (1 3) C4\u2014C5\u2014C10\u2014C9\u2212 179.32  (15)\nC10\u2014O1\u2014C2 \u2014C3\u2212 0.1 (2) C6\u2014C5 \u2014C10 \u2014O1 \u2212178.81 ( 13)\nO11\u2014C2\u2014 C3\u2014C4 \u2212178.64  (15) C4\u2014C5\u2014 C10\u2014O11 .3 (2)\nO1\u2014C2\u2014 C3\u2014C4 1.4 (2) C4\u2014C3\u2014N12\u2014 C13\u2212 21.3 (3)\nO11\u2014C2\u2014C3\u2014N12 0.8 (2) C2\u2014C3\u2014N12\u2014C1 3 159.30 ( 15)\nO1\u2014C2\u2014C3\u2014N12 \u2212179.14 ( 13) C3\u2014N12\u2014 C13\u2014O14 5.0 (3)\nN12\u2014 C3\u2014C4 \u2014C5 179.33 (14) C3\u2014N12\u2014 C13\u2014C15 \u2212173.68  (14)\nC2\u2014 C3\u2014C4\u2014 C5 \u22121.3 (2)O 14\u2014 C13\u2014C15\u2014 C16 20.2 (2)\nC3\u2014C4\u2014 C5\u2014 C10 0.0 (2) N12\u2014C13\u2014C15\u2014 C16\u2212 161.13 (14)\nC3\u2014C4\u2014C5 \u2014C6\u2212 179.90 ( 14)O 14\u2014C13\u2014C15 \u2014C20 \u2212103.50 ( 18)\nC10\u2014 C5\u2014 C6\u2014C7 \u22121.3 (2) N12\u2014C13\u2014C15\u2014 C20 75. 17 (17)\nC4\u2014 C5\u2014 C6\u2014C7 178.56 (15) C13\u2014C15\u2014 C16\u2014C17 178 .50 (13)\nC5\u2014 C6\u2014C7\u2014 C8 1.1 (2) C20\u2014 C15\u2014 C16\u2014C17 \u221256.93 (18)\nC6\u2014C7\u2014 C8\u2014 C9 0.0 (2) C15\u2014C16\u2014C17\u2014 C18 56.4 3 (18)\nC7\u2014 C8\u2014 C9\u2014C10 \u22120.7 (2) C16\u2014C17\u2014 C18\u2014 C19\u2212 55.19 (18)\nC8\u2014C9\u2014C10 \u2014O11 79.81 ( 13) C17\u2014C18 \u2014C1 9\u2014C20 55 .31 (19)\nC8\u2014 C9\u2014C10\u2014 C5 0.4 (2) C18\u2014C19\u2014C20\u2014 C15 \u221256.28 ( 18)\nC2\u2014O1\u2014C10 \u2014C9 179.36 (13) C13\u2014C15 \u2014C20 \u2014C1 9\u2212 178.89 (13)\nC2\u2014O1 \u2014C10\u2014 C5 \u22121.2 (2) C16\u2014C15 \u2014C20\u2014 C19 56.65 (17)\nC6\u2014C5\u2014 C10\u2014 C9 0.6 (2)\nHydrogen-bond geometry (\u00c5, \u00ba)  \nCg1 and Cg2 are the centroids of the O1/C2\u2013C5/C10 and C5\u2013C10 rings, respec tively .\nD\u2014H\u00b7\u00b7\u00b7AD \u2014H H\u00b7\u00b7\u00b7 AD \u00b7\u00b7\u00b7AD \u2014H\u00b7\u00b7\u00b7A\nN12\u2014H12\u00b7\u00b7\u00b7O11 0.87 (2) 2.346 (19) 2.6990 ( 18) 104.7 ( 14)\nN12\u2014H12\u00b7\u00b7\u00b7O11i0.87 ( 2) 2.098 ( 18) 2.9303 (16) 160.8 ( 17)\nC4\u2014H4 \u00b7\u00b7\u00b7O14 0.952 .372 .9094 (19) 115\nC7\u2014H7\u00b7\u00b7\u00b7O14ii0.952 .57 3.473 (2) 158\nC16\u2014H1 6B\u00b7\u00b7\u00b7Cg 1iii0.99 2.81 3.5732 (17) 134\nC17\u2014H17B \u00b7\u00b7\u00b7Cg 2iii0.99 2.70 3.5876 (19) 149\nSymmetry  codes: ( i) \u2212x+1, \u2212y, \u2212z; (ii) \u2212 x\u22121, \u2212y+1, \u2212z; (iii) \u2212 x, \u2212y, \u2212z.\n120Synthesis, NMR characterization, X-ray structural analysis and theoretical\ncalculations of amide and ester derivatives of the coumarin scaffold\nMaria J. Matos\u21d1, Eugenio Uriarte, Lourdes Santana, Santiago Vilar\nDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain\nhighlights\n/C15Compound 1 (4-Methyl-N-\n(coumarin-3-yl)benzamide) was\nsynthesized.\n/C15Compound 2 (coumarin-3-yl)-4-\nmethylbenzoate was synthesized.\n/C151H and13C NMR and X-ray\ndiffractometry determined themolecular structures.\n/C15Semiempirical calculations presented\nan alternative to determine the 3D\nstructures.\n/C15AM1 and PM3 yielded resultsreproducing the whole 3D structure\nof both molecules.graphical abstract\narticle info\nArticle history:\nReceived 5 February 2013\nReceived in revised form 6 March 2013\nAccepted 6 March 2013\nAvailable online 19 March 2013\nKeywords:\nCoumarin derivatives\nSynthesis\nX-ray structural analysis\nNMR analysis\nConformational analysisSemiempirical calculationsabstract\nCompounds 1 (4-methyl-N-(coumarin-3-yl)benzamide) and 2 ((coumarin-3-yl)-4-methylbenzoate) were\nsynthesized by linking the coumarin system (3-aminocoumarin or 3-hydroxycoumarin, respectively) to a\np-toluoylchloride.1H and13C NMR and X-ray diffractometry determined the molecular structures of both\nderivatives. The X-ray results were compared to those obtained by conformational analysis followed by\nsemiempirical methodologies (AM1 and PM3). The theoretical calculations yielded results reproducing\nthe whole three-dimensional (3D) structure of both molecules in a good agreement with X-ray structural\nanalysis. The global structures of the two compounds are very similar in the two studied environments,\nmeaning that the structural determination in the gas phase can be extrapolated. A comparative study\nbetween compounds 1 and 2, based on the structural results, was carried out.\n/C2112013 Elsevier B.V. All rights reserved.\n1. Introduction\nThe complex etiology and the actual prevalence of neurodegen-\nerative diseases have led to an intensive search for compounds that\ninteract with some speci\ufb01c receptors. In particular, in our research\ngroup we have paid special attention to compounds that can inhi-\nbit monoamine oxidase B (MAO-B isoform) and acetylcholinester-\nase (AChE) enzymes. In the last years we are synthesizing and\nstudying an important family of compounds, the coumarin deriva-tives, focusing on those targets. Coumarin (2H-1-benzopyran-2-one) is a natural compound that can be found in several plants like\ntonka bean, vanilla grass and sweet woodruff [1\u20133] . Derivatives of\nthis benzopyrone are of pharmaceutical interest because they have\nbeen showing different important biological activities [1\u20133] . Cou-\nmarins have been described as anticancer, anti-in\ufb02ammatory, anti-microbial, cardioprotective, vasorelaxant and antioxidant agents\n[4\u201313] . Furthermore, several coumarins showing a signi\ufb01cant\nMAO inhibitory activity, in some cases accompanied by AChE\ninhibitory activity, have been reported by our research group,\nand some of them are suggested as potential drugs with applica-\ntion on neurodegenerative diseases [14\u201320] . Due to the biological\nimportance of these derivatives, the synthesis and characterization\n0022-2860/$ - see front matter /C2112013 Elsevier B.V. All rights reserved.\nhttp://dx.doi.org/10.1016/j.molstruc.2013.03.014\u21d1Corresponding author. Tel.: +34 881 814 936.\nE-mail addresses: mariacmatos@gmail.com (M.J. Matos), eugenio.uriarte@usc.es\n(E. Uriarte), lourdes.santana@usc.es (L. Santana), qosanti@yahoo.es (S. Vilar).Journal of Molecular Structure 1041 (2013) 144\u2013150\nContents lists available at SciVerse ScienceDirect\nJournal of Molecular Structure\njournal homepage: www.elsevier.com/locate/molstruc\n121of coumarins is a topic of interest. The interaction between a spe-\nci\ufb01c molecule, a drug candidate, and a receptor occurs through rec-\nognition between the different compounds involved. An important\nstep in the study of molecular interaction processes is the determi-\nnation of the structure of the potential drugs. This means carrying\nout an analysis of the spatial arrangement of the different atomic\ngroups and their chemical properties. In this way, the \ufb01rst step\nmust be to obtain information about the intramolecular features\nresponsible for the 3D structure of the molecule under study. The\nX-ray structure is an important tool to better understand the inter-\naction of the compound with the active site of the enzyme.\nAccording to the latest \ufb01ndings related to the conformational\npreferences of these molecules, it is interesting to investigate the\n3-D structure of novel 3-substituted coumarins by using both exper-\nimental and theoretical approaches. Computational approaches can\noffer an alternative solution to determine the three-dimensional\nmolecular structure of the compounds under study. Depending on\nthe molecular complexity and the precision required for the study,\ndifferent types of calculations can be carried out. Molecular mechan-\nics methods [21] could be appropriate for the calculation of the 3-D\nstructure of large molecules while more accurate quantum mechan-\nical methods, such as ab initio calculations [22], would require long\nperiods of time making the complexity of the calculations a limitingfactor to be applicable in large systems. An intermediate level of\naccuracy is provided by the so-called semiempirical quantum chem-\nical calculations that use some parameters from empirical data [23].Among these methods, the rapid, inexpensive and user-friendly\nAM1 and PM3 are probably two of the most popular methodologies\n[24,25] . The analysis of semiempirical methods results is an interest-\ning tool for reproducing the experimental geometry of speci\ufb01c mol-\necules for further studies directed to the molecular modeling and\ndesign of active molecules.\nIn the current work described here, experimental and theoreti-\ncal structural analysis of two synthesized 3-substituted coumarin\nderivatives, presenting at that position an amide (compound 1)\nor an ester (compound 2), were undertaken. Their structures were\ncharacterized by experimental methods such as NMR spectrometry\nand were \ufb01nally determined by X-ray diffractometry and theoret-ical calculations combining conformational analysis with AM1 and\nPM3 methods. The comparison between the theoretical and the\ncrystal structure for both compounds showed a high level of simi-\nlarity. This fact manifested the capability of the theoretical meth-\nods to reproduce the experimental molecular geometry being an\nalternative methodology to obtain three-dimensional information\nwhen the crystal structure is not available.\n2. Experimental section\n2.1. Material and measurements\nMelting points were determined using a Reichert Ko\ufb02er ther-\nmopan or in capillary tubes on a B\u00fcchi 510 apparatus and areScheme 1. Synthesis of compounds 1 and 2. Reagents and conditions: Pyridine, dicloromethane, 0 /C176C to r.t., 4 h.\nTable 1\nCrystal data and structure re\ufb01nement parameters for compounds 1 and 2.\nCompound 1 Compound 2\nEmpirical formula C17H13NO3 C17H12O4\nFormula weight 279.28 280.27\nTemperature 100(2) K 100(2) K\nWavelength 0.71073 \u00c5 0.71073 \u00c5\nCrystal system Triclinic Triclinic\nSpace group P-1 P-1\nUnit cell dimensions a = 7.9932(4) \u00c5, a= 113.893(3) /C176 a = 6.7771(7) \u00c5, a= 91.563(8) /C176\nb = 9.2074(6) \u00c5, b= 97.003(3) /C176 b = 7.0925(9) \u00c5, b= 91.436(7)/C176\nc = 10.3711(7) \u00c5, c= 101.145(3)/C176 c = 13.9318(18) \u00c5, c= 101.984(7)/C176\nVolume 667.43(7) \u00c53 654.49(14) \u00c53Z2 2\nDensity (calculated) 1.390 Mg/m3 1.422 Mg/m3\nAbsorption coef\ufb01cient 0.096 mm /C01 0.102 mm /C01\nF(0 0 0) 292 292\nCrystal size 0.38/C20.30/C20.25 mm3 0.47/C20.37/C20.14 mm3\nTheta range for data collection 2.20\u201326.37 /C176 2.93\u201326.02 /C176\nIndex ranges /C096h69,/C0116k610, 06l612 /C086h68,/C086k68, 06l617\nRe\ufb02ections collected 9965 14,492\nIndependent re\ufb02ections 2715 [R(int) = 0.0326] 2573 [R(int) = 0.0479]\nCompleteness to theta = 26.37/C176 99.6% 99.8%\nAbsorption correction Semi-empirical from equivalents Semi-empirical from equivalents\nMax. and min. transmission 0.9773 and 0.8884 1.0000 and 0.9573\nRe\ufb01nement method Full-matrix least-squares on F2 Full-matrix least-squares on F2\nData/restraints/parameters 2715/0/196 2573/0/191\nGoodness-of-\ufb01t on F2 1.078 1.084\nFinal R indices [I > 2sigma(I)] R1 = 0.0445, wR2 = 0.1049 R1 = 0.0438, wR2 = 0.1045\nR indices (all data) R1 = 0.0622, wR2 = 0.1132 R1 = 0.0610, wR2 = 0.1127\nLargest diff. peak and hole 0.218 and /C00.271 e \u00c5 /C03 0.237 and /C00.259 e \u00c5 /C03M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144\u2013150 145\n122uncorrected.1H and13C NMR spectra were recorded on a Bruker\nAMX spectrometer at 300 and 75.47 MHz, respectively, using TMS\nas internal standard (chemical shifts in dvalues, J in Hz) and\nDMSO-d6 as solvent. Mass spectra were obtained using a Hewlett\nPackard 5972-MSD spectrometer. Elemental analyses were per-\nformed using a Perkin\u2013Elmer 240B microanalyser and were with-in \u00b10.4% of calculated values in all cases. Silica gel (Merck 60,\n230\u201300 mesh) was used for \ufb02ash chromatography (FC). Analytical\nthin layer chromatography (TLC) was performed on plates pre-\ncoated with silica gel (Merck 60 F254, 0.25 mm). The purity of\ncompounds was assessed by HPLC and was found to be higher\nthan 95%.\nFig. 1. Molecular structures of compounds 1 and 2 with the atom-numbering scheme. Displacement ellipsoids are drawn at the 30% probability level.146 M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144\u2013150\n1232.2. Synthesis of compounds 1 and 2\nCompounds 1 and 2 ( Scheme 1 ) were prepared according to the\nprotocol described by us [16]. Detailed protocol is described in\nSupplementary data .\n4-Methyl-N-(coumarin-3-yl)benzamide (1). Pale yellow crys-\ntals. Mp 187\u2013188 /C176C.1H NMR: 2.49 (s, 3H, CH3); 7.33 (s, 1H, H-\n4); 7.38 (d, 2H, J = 7.6 Hz, H-6, H-8); 7.50 (d, 2H, J = 8.5 Hz, H-30,\nH-50); 7.76 (d, 1H, J = 7.6 Hz, H-7); 7.83\u20137.88 (m, 3H, H-20, H-5,\nH-60); 8.62 (s, 1H, NH).13C NMR: 21.32 (CH3); 116.35 (C-8);\n119.75 (C-4a); 124.57 (C-8a); 125.49 (C-4); 126.62 (C-5); 126.81\n(C-6); 127.94 (C-20,C-60); 128.45 (C-7); 129.64 (C-30, C-50); 130.59\n(C-10); 130.98 (C-3); 130.92 (C-40); 143.04 (C-2); 1450.53\n(NHAC@O). DEPT: 21.32 (CH3); 116.35 (C-8); 125.49 (C-4);\n126.62 (C-5); 126.81 (C-6); 127.94 (C-20, C-60); 128.45 (C-7);\n129.64 (C-30, C-50). EI MS m/z (%): 280 (9), 279 (M+, 50), 239\n(20), 134 (23), 112 (20), 98 (42) Elem. Anal. Calc. forC17H13NO3: C, 73.11; H, 4.69. Found: C, 73.09; H, 4.65.\n(Coumarin-3-yl)-4-methylbenzoate (2). Pale yellow crystals.\nMp 168\u2013169 /C176C.\n1H NMR: 2.43 (s, 3H, CH3); 7.44 (d, 2H,\nJ = 7.5 Hz, H-6, H-8); 7.51 (d, 2H, J = 8.1 Hz, H-30, H-50); 7.64 (d,\n1H, J = 7.4 Hz, H-7); 7.75 (d, 1H, J = 7.6 Hz, H-5); 8.0 (d, 2H,\nJ = 8.2 Hz, H-20, H-60); 8.20 (s, 1H, H-4).13C NMR: 21.30 (CH3);124.98 (C-8); 125.39 (C-4a); 128.71 (C-4); 129.45 (C-10); 129.93\n(C-6); 130.23 (C-5); 131.47 (C-7); 132.30 (C-30, C-50); 134.27 (C-\n20, C-60); 135.71 (C-3); 137.65 (C-40); 145.51 (C-8a); 159.21 (C-2);\n163.77 (O AC@O). EI MS m/z (%): 280 (M+, 8), 119 (100), 91 (29),\n77 (8), 65 (12). Elem. Anal. Calc. for C17H12O4: C, 70.58; H, 4.10.\nFound: C, 70.60; H, 4.13.\n2.3. X-ray data collection and reduction\nPale yellow prismatic crystals of compounds 1 (C17H13NO3)\nand 2 (C17H12O4) were mounted on a glass \ufb01ber for data collec-\ntion. Cell constants and orientation matrix were obtained by\nleast-squares re\ufb01nement of the diffraction data for 9965 and\n14,492 re\ufb02ections in the range of 2.20\u201326.37 /C176and 2.93\u201326.02 /C176,\nrespectively, measured on a Bruker APEX2 [26]. Data were col-\nlected by the xscan technique at 100 K using radiation\n(k= 0.71073 \u00c5), and were corrected for Lorentz and polarization ef-\nfects. The crystal data and structure re\ufb01nement were detailed inTable 1 (compounds 1 and 2, respectively). A semiempirical\nabsorption correction was also performed.\n2.4. Structure solution and re\ufb01nement\nThe structures were solved by direct methods [27], which re-\nvealed the positions of all non-hydrogen atoms, and were re\ufb01ned\non F2 by a full-matrix least-squares procedure using anisotropic\ndisplacement parameters. The program used to re\ufb01ne the struc-\ntures was SHELXL97 [28]. All hydrogen atoms were located from\ndifference Fourier maps and were re\ufb01ned isotropically. Atomicscattering factors were taken from International Tables for X-ray\nCrystallography [29]. Molecular graphics were generated with Pla-\nton[30]. Finally, the software used to prepare material for publica-\ntion was WinGX publication routines [31]. A summary of the\ncrystals data, experimental details, and re\ufb01nements results is given\ninTable 1 .\n2.5. Theoretical calculations\nA stochastic conformational search was carried out with the\nhelp of MOE software [32]. Partial charges were calculated using\nMMFF94 force \ufb01eld. The RMS gradient was 0.005 with an interac-\ntion limit of 500. The conformations with the lowest energy were\nrepresentative of the calculation and were optimized with MOPA-\nFig. 2. Superposition of the crystal structure (grey carbons) and the theoretical conformations (green carbons) obtained through AM1 (panels a and c) and PM3 (panels b and\nd) for compounds 1 and 2. (For interpretation of the references to color in this \ufb01gure legend, the reader is referred to the web version of this article.)\nTable 4\nRMSD between the conformations obtained through theoretical methods and the X-\nray structures for compounds 1 and 2. RMSD values are shown for distances [\u00c5], bond\nangles [ /C176], dihedral angles [/C176 ] and the heavy atoms coordinates (hydrogens were not\ntaken into account).\nCompound 1 Compound 2\nRMSD AM1 PM3 AM1 PM3\nDistance 0.014 0.015 0.015 0.011\nAngles 1.79 2.56 2.010 2.521\nDihedral angles 9.02 15.41 3.584 4.507\nHeavy atoms coordinates 0.254 0.369 0.178 0.246\nTable 5\nHydrogen bonds for compound 1 [\u00c5 and /C176].\nDAH/C1/C1/C1A d(D AH) d(H /C1/C1/C1A) d(D /C1/C1/C1A) <(DHA)\nN(12)\u2013H(12) /C1/C1/C1O(11)#1 0.835(17) 2.498(18) 3.2711(17) 154.4(15)\nSymmetry transformations used to generate equivalent atoms: #1 /C0x+1 , /C0y,\n/C0z+1 .M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144\u2013150 147\n124C in the Schr\u00f6dinger package [33,34] using AM1 and PM3 semiem-\npirical methods. The calculations were carried out in gas phase.\n3. Results and discussion\nCompound 1 was prepared in 71% yield, by amidation reaction\nof the 3-aminocoumarin with the corresponding benzoyl chloride\n(Scheme 1 )[16]. Compound 2 was prepared in 69% yield, by an\nesteri\ufb01cation reaction of the 3-hydroxycoumarin with the corre-sponding benzoyl chloride ( Scheme 1 ). Examination of the infor-\nmation obtained from the NMR spectra enabled us to assign thechemical shifts of the different protons and carbons for both com-\npounds. Also, the molecular structures of both compounds were re-\nsolved by X-ray diffractometry and are shown in Fig. 1 , together\nwith the atomic numbering scheme used.\nAs it can be observed in Fig. 1 , both molecules adopted some\nsimilar aspects in the conformation of the crystal. Both coumarin\nnucleuses and aromatic rings attached to the amidic or the esterORIGca\nFig. 3. Packing diagram of both structures viewed along the b axis.148 M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144\u2013150\n125bridges in both molecules are planar, as expected. The main differ-\nence between the molecular structures of compounds 1 and 2 is\nthat in the \ufb01rst case the substitution at position 3 of the coumarin\nscaffold is almost aligned with the substituent, and in the second\ncase it is almost perpendicular to it. The torsion angles between\nthe mean planes of compound 1 C4\u2013C3\u2013N12\u2013C13 (/C0 5.7/C176), C3\u2013\nN12\u2013C13\u2013C15 ( /C0179.68 /C176) and N12\u2013C13\u2013C15\u2013C20 ( /C0171.17 /C176) are\ntypical of the torsion permitted by the rotation of the amidic group\nat position 3. The torsion angles between the mean planes of com-\npound 2 C4\u2013C3\u2013O12\u2013C13 (/C0 72.52/C176), C3\u2013O12\u2013C13\u2013C15 (171.82 /C176)\nand O12\u2013C13\u2013C15\u2013C16 ( /C04.95/C176) are typical of the torsion permit-\nted by the rotation of the ester group at position 3. The greatest\nconformational freedom of the molecules resides, therefore, in\nthe amidic bridge of compound 1 and in the ester bridge of com-\npound 2, composed by C3\u2013N12\u2013C13\u2013C15 and C3\u2013O12\u2013C13\u2013C15,\nrespectively.\nIn addition, many interesting intramolecular contacts are pres-\nent in both compounds. In particular, looking to Fig. 1 compound 1\nshows interesting C4H /C1/C1/C1O14, C20H /C1/C1/C1O14 contacts while com-\npound 2 shows a C16H /C1/C1/C1O12 contact. Moreover in compound 1\na short contact between two hydrogens (that bonded to C16, morenegatively charged and that bonded to N12 more positively\ncharged) is present. Some references about these contacts, referred\nas non-conventional H-bond (H /C1/C1/C1H and CH /C1/C1/C1O/N contacts), have\nbeen already suggested and described [35,36] .\nCompound 1 is structurally similar to the compound described\nby Jotani et al. [37]. The phenyl ring of that molecule (N-(2-oxo-\n2H-chromen-3-yl)benzamide) forms a dihedral angle of 7.69 /C176with\nthe fused ring system. In compound 1, as in that molecule, a dihe-dral angel of 5.84/C176 is formed between the phenyl ring and the fused\nring system. The observed conformation is also stabilized by thedescribed intramolecular N AH/C1/C1/C1O and C AH/C1/C1/C1O interactions. Dong\net al. also described amidic compounds structurally related withthese derivatives [38]. As described in that manuscript, the com-\nplexity of the molecules (voluminous substituents \u2013 a benzyl group\nat position 3 and a phenylamine at position 4) changed the related\nposition of the coumarin nucleus and the benzylamide at position\n3.\nTables 2 and 3 (presented in Supplementary data) list the bond\nlengths, bond angles and dihedral angles obtained for both com-\npounds 1 and 2, respectively, according to the X-ray analysis. The\nresults for the theoretical calculations (conformational analysis\nwith the re\ufb01nement of the minimum energy structures through\nAM1 and PM3 methods), for both compounds, are also included\nin the tables.\nThe \ufb01nal structures obtained through semiempirical methods\nare highly coincident with the data extracted through X-ray. For\nthe compound 1, two possible conformational states are obtained\ndiffering in the orientation of the 4-methylphenyl system regard-\ning\nthe plane of the coumarin ring. The dihedral angle value for\nO(14)\u2013C(13)\u2013C(15)\u2013C(20) calculated through AM1 method can be\n36.2 or /C037.1 \u00c5 for the conformers. A conformational equilibrium\nresulting in two different conformations was also obtained for\nthe compound 2 through the theoretical calculations. Both possible\nconformational states differ in the orientation of the carbonyl\ngroup regarding to the plane of the coumarin ring. The dihedral an-\ngle value in C(3)\u2013O(12)\u2013C(13)\u2013O(14) could be /C07.7 or 7.2 \u00c5 for the\nconformers (AM1 method). Fig. 2 shows the superposition of the\ncrystal structure and the conformations obtained through AM1\nand PM3 for both compounds (conformers with a O(14)\u2013C(13)\u2013\nC(15)\u2013C(20) dihedral angle value of 36.2 for the compound 1 and\nC(3)\u2013O(12)\u2013C(13)\u2013O(14) dihedral value of /C07.7 for the compound\n2, using AM1 method). The comparison between the theoretical\nand the crystal structure showed a high level of similarity. The\nRMSD (root mean square deviation) values between the heavy\natoms coordinates are shown in Table 4 . AM1 and PM3 yieldedsimilar reproduction of the bond lengths whereas AM1 calculationafforded more coincident results with the crystal for angles and\ndihedral angles (see Table 4 ). However, the results described in this\narticle do not justify the selection of one of the methods. Similarresults comparing the X-ray and theoretical conformations in\npiperazine and coumarin derivatives were previously reported by\nour research group [24,25] .\nAnother important structural feature, which distinguishes the\nstudied molecules, is the capacity of formation of N(12)\u2013\nH(12) /C1/C1/C1O(11) intermolecular hydrogen bonds of compound 1, de-\ntailed in Table 5 . The presence of these hydrogen bonds and the\nconformation of the substituent at position 3 of the coumarin nu-\ncleus, distinguish the packing diagram of both molecules. Packing\ndiagram of the structures allows the interpretation of the spatial\norientation of the molecules and are shown in Fig. 3 .\n4. Conclusion\nIn summary, we have determined and analyzed the entire struc-\ntural parameters in the crystalline state of two coumarin deriva-\ntives (with amide or ester functions at position 3), and proved\nthat the results are well reproduced by conformational analysis\nand semiempirical AM1 and PM3 methods. Theoretical approaches\ncan be an alternative methodology to determine the 3D conforma-\ntion for this type of derivatives when the crystal structure is not\navailable. We can also conclude that it is possible to modulate\nthe relative position of the coumarin scaffold and the aromatic ring\nat position 3 by modifying the chemical substituent between both\nmoieties.\nAcknowledgements\nPartial \ufb01nancial support from Ministerio de Sanidad y Consumo\n(PS09/00501) and Xunta de Galicia (PGIDIT09CSA030203PR) are\ngratefully acknowledged. M.J.M. thanks Funda\u00e7\u00e3o para a Ci\u00eancia\ne Tecnologia (SFRH/BD/61262/2009) Grant. S.V. thanks the Angeles\nAlvari\u00f1o program from Xunta de Galicia (Spain).\nAppendix A. Supplementary material\nSupplementary data associated with this article can be found, in\nthe online version, at http://dx.doi.org/10.1016/\nj.molstruc.2013.03.014 .\nReferences\n[1] F. Borges, F. Roleira, N. Milhazes, L. Santana, E. Uriarte, Curr. Med. Chem. 12\n(2005) 887.\n[2] F. Borges, F. Roleira, N. Milhazes, E. Uriarte, L. Santana, Med. Chem. 4 (2009) 23.\n[3] M.E. Riveiro, N. De Kimpe, A. Moglioni, R. Vazquez, F. Monczor, C. Shayo, C.\nDavio, Curr. Med. Chem. 17 (2010) 1325.\n[4] H. Zhao, A.C. Donnelly, B.R. Kusuma, G.E.L. Brandt, D. Brown, R.A. Rajewski, G.\nVielhauer, J. Holzbeierlein, M.S. Cohen, B.S.J. Blagg, J. Med. Chem. 54 (2011)\n3839.\n[5] S. Vilar, E. Quezada, L. Santana, E. Uriarte, M. Yanez, N. Fraiz, C. Alcaide, E. Cano,\nF. Orallo, Bioorg. Med. Chem. Lett. 16 (2006) 257.\n[6] I. Kostova, S. Bhatia, P. Grigorov, S. Balkansky, V.S. Parmar, A.K. Prasad, L. Saso,\nCurr. Med. Chem. 18 (2011) 3929.\n[7] J.R. Hwu, S.-Y. Lin, S.-C. Tsay, E. De Clercq, P. Leyssen, J. Neyts, J. Med. Chem. 54\n(2011) 2114.\n[8] I. Kostova, Curr. HIV Res. 4 (2006) 347.\n[9] A. Chilin, R. Battistutta, A. Bortolato, G. Cozza, S. Zanatta, G. Poletto, M.\nMazzorana, G. Zagotto, E. Uriarte, A. Guiotto, F. Meggio, S. Moro, J. Med. Chem.\n51 (2008) 752.\n[10] J.M. Timonen, R.M. Nieminen, O. Sareila, P. Vainiotalo, E. Moilanen, P.H.\nAulaskari, Eur. J. Med. Chem. 46 (2011) 3845.\n[11] M.J. Matos, S. Vazquez-Rodriguez, L. Santana, E. Uriarte, C. Fuentes-Edfuf, Y.\nSantos, A. Mu\u00f1oz-Crego, Med. Chem. 8 (2012) 1140.\n[12] M.J. Matos, L. Santana, E. Uriarte, S. Serra, M. Corda, M.B. Fadda, B. Era, A. Fais, J.\nPharm. Pharmacol. 64 (2012) 742.\n[13] P. Anand, B. Singh, N. Singh, Bioorg. Med. Chem. 20 (2012) 1175.M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144\u2013150 149\n126[14] M.J. Matos, D. Vi\u00f1a, C. Picciau, F. Orallo, L. Santana, E. Uriarte, Bioorg. Med.\nChem. Lett. 19 (2009) 5053.\n[15] M.J. Matos, D. Vi\u00f1a, E. Quezada, C. Picciau, G. Delogu, F. Orallo, L. Santana, E.\nUriarte, Bioorg. Med. Chem. Lett. 19 (2009) 3268.\n[16] D. Vi\u00f1a, M.J. Matos, M. Y\u00e1\u00f1ez, L. Santana, E. Uriarte, MedChemComm 3 (2012) 213.\n[17] M.J. Matos, C. Ter\u00e1n, Y. P\u00e9rez-Castillo, E. Uriarte, L. Santana, D. Vi\u00f1a, J. Med.\nChem. 54 (2011) 7127.\n[18] M.J. Matos, S. V\u00e1zquez-Rodriguez, E. Uriarte, L. Santana, D. Vi\u00f1a, Bioorg. Med.\nChem. Lett. 21 (2011) 4224.\n[19] E. Molina, E. Sobarzo-S\u00e1nchez, A. Speck-Planche, M.J. Matos, E. Uriarte, L.\nSantana, M. Y\u00e1\u00f1ez, F. Orallo, Med. Chem. 12 (2012) 947.\n[20] D. Vi\u00f1a, M.J. Matos, G. Ferino, E. Cadoni, R. Laguna, F. Borges, E. Uriarte, L.\nSantana, Chem. Med. Chem. 7 (2012) 464.\n[21] J.C.A. Boeyens, P. Comba, Coord. Chem. Rev. 212 (2001) 3.\n[22] T. Helgaker, S. Coriani, P. Jorgensen, K. Kristensen, J. Olsen, K. Ruud, Chem. Rev.\n112 (2012) 543.\n[23] C.B. Barnett, K.J. Neidoo, J. Phys. Chem. B 114 (2010) 17142.\n[24] E. Estrada, J. Gonzalez, L. Santana, E. Uriarte, A. Casti\u00f1eiras, Struct. Chem. 11\n(2000) 249.\n[25] E. Quezada, S. Vilar, L. Valencia, L. Santana, R.A. Mosquera, E. Uriarte, Struct.\nChem. 17 (2006) 459.[26] Bruker, APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA,\n2012.\n[27] G.M. Sheldrick, SHELXL97. Program for the Re\ufb01nement of Crystal Structures,\nUniversity of G\u00f6ttingen, Germany, 1997.\n[28] G.M. Sheldrick, Acta Cryst. A 64 (2008) 112.[29] A.J.C. Wilson, International Tables for X-ray Crystallography, vol. C, Kluwer\nAcademic Publishers, Dordrecht, The Netherlands, 1992.\n[30] A.L. Spek, Acta Cryst. D 65 (2009) 148.[31] L.J. Farrugia, J. Appl. Cryst. 45 (2012) 849.\n[32] MOE software, version 2011.10; Chemical Computing Group, Inc., 2011.\n<www.chemcomp.com/ >.\n[33] MOPAC, James J.P. Stewart, Stewart Computational Chemistry, Colorado\nSprings, CO, USA, < http://OpenMOPAC.net > (accessed 10.12).\n[34] Maestro, version 9.2, Schr\u00f6dinger, LLC, New York, NY, 2011.[35] S. Aime, E. Diana, R. Gobetto, M. Milanesio, E. Valls, D. Viterbo, Organometallics\n21 (2002) 50.\n[36] A.V. Afonin, I.A. Ushakov, A.V. Vashchenko, D.E. Simonenko, A.V. Ivanov, A.M.\nVasil\u2019tsov, A.I. Mikhaleva, B.A. Tro\ufb01mov, Magn. Reson. Chem. 47 (2009) 105.\n[37] M.M. Jotani, B.B. Baldaniya, E.R.T. Tiekink, Acta Cryst. E 66 (2010) 778.\n[38] S. Dong, X. Liu, Y. Zhang, L. Lin, X. Feng, Org. Lett. 13 (2011) 5060.150 M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144\u2013150\n127A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors\nMaria Joao Matosa,b,*, Dolores Vi\u00f1aa,c, Elias Quezadaa,b, Carmen Picciaub, Giovanna Delogub,\nFrancisco Oralloc, Lourdes Santanaa, Eugenio Uriartea\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, 15782 Santiago de Compostela, Spain\nbDipartimento Farmaco Chimico Tecnologico, Facolt\u00e0 di Farmacia, 09124 Cagliari, Italy\ncDepartamento de Farmacolog\u00eda, Facultad de Farmacia, 15782 Santiago de Compostela, Spain\narticle info\nArticle history:\nReceived 24 March 2009Revised 17 April 2009Accepted 20 April 2009\nAvailable online 24 April 2009\nKeywords:\nCoumarin\nResveratrol\nMonoamino oxidase inhibitorsPerkin reaction3-Phenylcoumarinsabstract\n6-Methyl-3-phenylcoumarins 3\u20136 were designed, synthesized and evaluated as monoamine oxidase A\nand B (MAO-A and MAO-B) inhibitors. The synthesis of these new compounds (resveratrol\u2013coumarin\nhybrids) was carried out with good yield by a Perkin reaction, from the 5-methylsalicylaldehyde and\nthe corresponding phenylacetic acid. They show high selectivity to the MAO-B isoenzyme, with IC 50val-\nues in the nanomolar range. Compound 5is the most active compound and is several times more potent\nand selective than the reference compound, R-(/C0)-deprenyl.\n/C2112009 Elsevier Ltd. All rights reserved.\nCoumarins (or benzopyrones) are a large family of compounds,\nof natural and synthetic origin, that show numerous biological\nactivities.1Recent studies pay special attention to their antioxida-\ntive, anticarcinogenic and enzymatic inhibition properties.2\u20136In re-\ngard to the monoamine oxidase (MAO) inhibition, the recent\n\ufb01ndings revealed that MAO-A and MAO-B af\ufb01nity and selectivity\ncan be ef\ufb01ciently modulated by appropriate substitutions in the\ncoumarin ring, in particular in the 3:4 and 6:7 positions.7\u201311\nThe resveratrol (3,40,5-trihydroxystilbene) is a phytoalexin of\nnatural origin present in spermatophytes species such as vines,\nin response to damage. Resveratrol was already studied as antiox-\nidant, anti-in\ufb02ammatory, cardioprotective (vasodilatory and plate-\nlet antiaggregatory activities), anticancer, enzymatic inhibitor,\nproving to be very ef\ufb01cient in a large group of in vitro, ex vivo\nand/or in vivo experiments.12\u201315The resveratrol\u2019s cis and trans iso-\nmers are inhibitors of the MAO activity. cis-Resveratrol is less effec-\ntive than trans-resveratrol as inhibitor of MAO-A and MAO-B\nactivities.16\nDue to these coincident properties, it seems to be interesting to\ndesign and synthesize hybrids that incorporate the skeleton ofthose two kinds of molecules.\n17,18In the present compounds the\nresveratrol nucleus is blocked by the coumarin ring and can onlyassume the trans isomeric form. A series of these molecules, with\ndifferent number and position of methoxy groups in the 3-phenyl\nring (compounds 3\u20136), was synthesized and evaluated as MAOinhibitors (iMAO). These modi\ufb01cations were studied to \ufb01nd out\nhow these changes can contribute to the biological activity of thesemolecules, helping to understand a structure\u2013activity relationship\n(SAR).\nMAO is a FAD-containing enzyme with two known isoforms\n(MAO-A and MAO-B) and is present in the mitochondrial outer\nmembrane of glial, neuronal and other cells.\n19MAO enzymes inter-\nvene in the monoamines degradation and carry out an important\nphysiologic function in the adrenaline, noradrenaline and seroto-\nnin deamination (preferentially MAO-A) and in the b-phenylethyl-\namine and benzylamine deamination (preferentially MAO-B).20\nThis enzymatic function increases the synaptic concentration of\nthese neurotransmitters and conditions to a great extent the neu-\nrone\u2019s excitement of those possessing receptors for these\nmediators.21\nThe iMAO are a class of compounds that act by blocking the\nMAO enzymatic action, being used by several years in the treat-\nment of the depression and anxiety diseases (iMAO-A) or in Parkin-\nson\u2019s disease (iMAO-B).22Nowadays is being studied also in the\nAlzheimer\u2019s disease.23\nThe active sites of these two isoenzymes (MAO-A and MAO-B)\nare not completely known and for this reason there is a lack ofinformation in respect of how the inhibitors act selectively in\none of the two of them.\n10Recent X-ray crystal structures of\nMAO-B24,25and MAO-A,21,26completed with irreversible and\nreversible inhibitors, can be used in the future as a tool to the\nstructural basis to help understanding the selective enzyme\u2013ligand\nrecognition and drug development of iMAOs.21\n0960-894X/$ - see front matter /C2112009 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.bmcl.2009.04.085*Corresponding author. Tel.: +34 981 563100.\nE-mail address: mariacmatos@gmail.com (M.J. Matos).Bioorganic & Medicinal Chemistry Letters 19 (2009) 3268\u20133270\nContents lists available at ScienceDirect\nBioorganic & Medicinal Chemistry Letters\njournal homepage: www.el sevier.com/locate/bmcl\n129With the aim of \ufb01nding out new structural features for the MAO\ninhibitory activity and selectivity, we decided in this work to ex-\nplore the importance of the number and position of different meth-\noxy groups under the benzenic ring in 3-position (compounds\n427,28\u20136), to establish a relation between them and with the non\nsubstituted analogue (compound 327\u201329).\nThe preparation of these 6-methyl-3-phenylcoumarins was per-\nformed via the classical Perkin reaction.29This reaction was carried\nout by condensation of the 5-methylsalicylaldehyde 1and the con-\nveniently substituted phenylacetic acids 2, with N,N0-dicyclohexyl-\ncarbodiimide (DCC) as dehydrating agent, under DMSO re\ufb02ux,\nduring 24 h (Scheme 1 ). The reaction to obtain 3\u20136 is very clean\nand the yields are between 60% and 70%.30\u201333The obtained prod-\nucts are easy to purify by \ufb02ash chromatography, using a mixture\nof hexane/ethyl acetate in a proportion 9:1 as eluent.\nThe inhibitory MAO activity of compounds 3\u20136 was evaluated\nin vitro by the measurement of the enzymatic activity of human re-combinant MAO isoforms in BTI insect cells infected with baculo-\nvirus.\n8,34Then, the IC 50values and MAO-B selectivity ratios [IC 50\n(MAO-A)]/[IC 50(MAO-B)] for inhibitory effects of both, new com-\npounds and reference inhibitors, were calculated (Table 1).35\nThe prepared series of compounds proved to be selective as\ninhibitor of the MAO-B isoenzyme. Compound 3, none substituted\nin the phenyl ring, is by itself very active and selective againstMAO-B isoenzyme. Compound 4(with a p-methoxy group) has a\nMAO-B IC\n50similar to the R-(/C0)-deprenyl (reference MAO-B inhib-\nitor) and is more selective than this one. The most potent molecule\nof this family is compound 5, bearing two methoxy groups in 30-\nand 50-positions (IC 50= 8.98 \u00b1 1.42 nM). This one is two times more\nactive and several times more iMAO-B selective than the R-(/C0)-\ndeprenyl. Compound 6, with 3 methoxy groups, is more active than\n3(none substituted) but it loses activity in respect to the mono and\ndimethoxy derivatives (compounds 4and5, respectively). None of\nthe described compounds showed a MAO-A inhibitory activity for\nthe highest concentration tested (100 lM). This iMAO-B selectivityis an important factor to discriminate the potential therapeuticapplication of this kind of molecules.\nComparing the iMAO-B activities of 3and4, the introduction of\nap-methoxy group increases the inhibitory activity. Substitution\nwith two methoxy groups in the 3\n0- and 50-positions on the phenyl\nring, compound 5, improves the iMAO-B activity. Increasing the\nnumber of methoxy substituent to three, compound 6, decreases\nthe enzymatic inhibitory activity. However, compound 6is even\nbetter than none substituted coumarin 3. The presence of methoxy\nsubstituent in the 3-phenyl ring seems to be important to modu-\nlate and improve the inhibitory enzymatic activity of the 6-\nmethyl-3-phenylcoumarins.\nThese hybrid compounds with resveratrol\u2013coumarin skeleton\nshow high selectivity against MAO-B isoenzyme, being active in\nthe nanomolar range. Introduction of methoxy groups in the phe-nyl ring improves the activity, giving more active and selective\ncompounds than the reference ones. These modi\ufb01cations, which\nwe studying more deeply, can improve the pharmacologic pro\ufb01le\nof the synthesized coumarins in the Parkinson\u2019s disease.\nAcknowledgements\nThanks the Spanish Ministerio de Sanidad y Consumo\n(PI061457 and PI061537) and to Xunta da Galicia (PXIB20304PR,\nINCITE08PXIB203022PR and 08CSA019203PR) and Fondazione\nBanco Sardegna (Italy) for \ufb01nancial support. M.J.M. also thanks to\nMIUR the Ph.D. Grant.\nReferences and notes\n1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem.\n2005 ,12, 887.\n2. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 ,27, 713.\n3. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Enzyme Inhib. Med. Chem. 2003 ,18, 63.\n4. Kabeya, L.; Marchi, A.; Kanashiro, A.; Lopes, N.; Silva, C.; Pupo, M.; Lucisano-\nValim, Y. Bioorg. Med. Chem. 2007 ,15, 1516.\n5. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.;\nJenner, P.; Testa, B. Chem. Biod. 2006 ,3, 134.\n6. Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.; Poletto, G.;\nMazzorana, M.; Zagotto, G.; Uriarte, E.; Guiotto, A.; Pinna, L.; Meggio, F.; Moro,\nS.J. Med. Chem. 2008 ,51, 752.\n7. Santana, L.; Uriarte, E.; Gonz\u00e1lez-D\u00edaz, H.; Zagotto, G.; Soto-Otero, R.; M\u00e9ndez-\n\u00c1lvarez, E. J. Med. Chem. 2006 ,49, 1118.\n8. Santana, L.; Gonz\u00e1lez-d\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, M.; Vi\u00f1a, D.;\nOrallo, F. J. Med. Chem. 2008 ,51, 6740.\n9. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.; Soto-Otero, R.;\nM\u00e9ndez-\u00c1lvarez, E.; Carotti, A. J. Med. Chem. 2006 ,49, 4912.\n10. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.; Altomare, C.; Carotti,\nA.; Testa, B. J. Med. Chem. 2000 ,43, 4747.\n11. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini,\nP.; Alacaro, S.; Ortuso, F. Bioorg. Med. Chem. Lett. 2004 ,14, 3697.\n12. Fr\u00e9mont, L. Life Sci. 2000 ,66, 663.\n13. Orallo, F. In Resveratrol in Health and Disease ; Aggarwal, B. B., Shishodia, S., Eds.;\nCRC Press: USA, 2005; p 577.\n14. Leiro, J.; \u00c1lvarez, E.; Arranz, J.; Laguna, R.; Uriarte, E.; Orallo, F. J. Leukocyte Biol.\n2004 ,75, 1156.\n15. Orallo, F. Curr. Med. Chem. 2008 ,15, 1887.\n16. Y\u00e1nez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Commun. 2006 ,\n344, 688.\n17. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Y\u00e1nez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257.\n18. Vilar, S.; Quezada, E.; Alcaide, C.; Orallo, F.; Santana, L.; Uriarte, E. Qsar Comb.\nSci.2007 ,26, 317.\n19. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2005 ,102, 12684.\n20. Grimsby, J.; Lan, N. C.; Neve, R.; Chen, K.; Shih, J. C. J. Neurochem. 1990 ,55,\n1166.\n21. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Curr. Med. Chem.\n2004 ,11, 1983.\n22. Harfenist, H.; Heuseur, D. J.; Joyner, C. T.; Batchelor, J. F.; White, H. L. J. Med.\nChem. 1996 ,39, 1857.\n23. Wouters, J. Curr. Med. Chem. 1998 ,5, 137.\n24. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Nat.\nStruct. Biol. 2002 ,9, 22.\n25. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2003 ,100, 9750.O O OHCHO Me MeO HO\n12 3-6aR1\nR3R2\nR1\nR2\nR3\n3: R1= R2 = R3= H\n4: R1= R3= H , R2= OMe\n5: R1= R3= OMe , R2= H\n6: R1 = R2 = R3= OMe\nScheme 1. Reagents and conditions: (a) DCC, DMSO, 110 /C176C, 24 h.\nTable 1\nMAO-A and MAO-B inhibitory activity results for compounds 3\u20136 and reference\ncompounds\nCompd MAO-A IC 50 MAO-B IC 50 Ratio\n3*283.75 \u00b1 0.98 nM >352b\n4*13.05 \u00b1 0.90 nM >7663b\n5*8.98 \u00b1 1.42 nM >11,136b\n6*160.64 \u00b1 1.01 nM >623b\nR-(/C0)-Deprenyl 67.25 \u00b1 1.02 lMa19.60 \u00b1 0.86 nM 3431\nIproniazide 6.56 \u00b1 0.76 lM 7.54 \u00b1 0.36 lM 0.87\n*Inactive at 100 lM (highest concentration tested). At higher concentrations\ncompounds precipitate.\naP<0.01 versus the corresponding IC 50values obtained against MAO-B, as\ndetermined by ANOVA/Dunnett\u2019s.\nbValues obtained under the assumption that the corresponding IC 50against\nMAO-A is the highest concentration tested (100 lM).M. J. Matos et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3268\u20133270 3269\n13026. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. J. Mol.\nBiol. 2004 ,338, 103.\n27. Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. Indian J. Chem., Sect. B 1996 ,35,\n1159.\n28. Mohanty, S.; Makrandi, J. K.; Grover, S. K. Indian J. Chem., Sect. B 1989 ,28, 766.\n29. Kamat, S. P.; D \u00b4Souza, A. M.; Paknikar, S. K.; Beaucahmp, P. S. J. Chem. Res. (S)\n2002 , 242.\n30. 6-Methyl-3-phenylcumarin (3). It was obtained with a yield of 68%. Mp 148\u2013\n149/C176C (biblio. 145\u2013147 /C176C, 149\u2013150 /C176C).1H NMR (CDCl 3)d(ppm), J(Hz): 2.42\n(s, 3H, \u2013CH 3), 7.27 (m, 1H, H-7), 7.34 (m, 2H, H-40and H-8), 7.43 (m, 3H, H-\n20,H-40and H-5), 7.70 (dd, 2H, H-10and H-50,J= 7.7 and 1.8), 7.77 (s, 1H, H-4).\n13C NMR (CDCl 3)d(ppm): 21.29, 116.67, 119.57, 128.17, 128.70, 128.95,\n129.02, 129.26, 132.95, 134.65, 135.35, 140.39, 152.16, 161.31. DEPT (CDCl 3)d\n(ppm): 21.29, 100.60, 116.67, 128.17, 128.95, 129.02, 129.26, 132.95, 140.39.\nMSm/z(%): 236 (M+, 100), 208 (50), 178 (8), 165 (8) 76 (6), 51 (69). Anal. Calcd\nfor C 16H12O2: C, 81.34; H, 5.12; O, 13.54. Found: C, 81.44; H, 4.84.\n31. 3-(40-Methoxy)phenyl-6-methylcumarin (4). It was obtained with a yield of\n61%. Mp 144\u2013145oC (biblio. 143 /C176C).1H NMR (CDCl 3)d(ppm), J(Hz): 2.40 (s,\n3H, \u2013CH 3), 3.84 (s, 3H, \u2013OCH 3), 6.96 (dd, 2H, H-30and H-50,J= 6.8 and 2.1), 7.26\n(m, 3H, H-4, H-7 and H-8), 7.66 (m, 3H, H-3, H-20and H-60).13C NMR (CDCl 3)d\n(ppm): 20.75, 55.32, 113.85, 116.04, 119.54, 127.19, 127.46, 127.66, 129.77,132.02, 134.03, 138.47, 151.41, 160.05, 160.96. DEPT (CDCl\n3)d(ppm): 20.76,\n55.32, 113.85, 116.04, 127.46, 129.78, 132.01, 138.48. MS m/z(%): 266 (M+,\n100), 223 (60), 195 (24), 165 (16), 152 (13), 115 (5), 89 (5), 63 (7), 50 (6). Anal.Calcd for C\n17H14O3: C, 76.68; H, 5.30; O, 18.02. Found: C, 76.88; H, 5.32.\n32. 3-(30,50-Dimethoxy)phenyl-6-methylcumarin (5). It was obtained with a yield\nof 60%. Mp 110\u2013111oC.1H NMR (CDCl 3)d(ppm), J(Hz): 2.40 (s, 3H, \u2013CH 3), 3.82\n(s, 6H, \u2013(OCH 3)2), 6.50 (t, 1H, H-40,J= 2.1), 6.83 (d, 2H, H-20and H-60,J= 2.1),\n7.22\u20137,33 (m, 3H, H-5, H-7 and H-8), 7.74 (s, 1H, H-4).13C NMR (CDCl 3)d\n(ppm): 20.72, 55.41, 100.89, 106.72, 116.06, 119.22, 127.69, 127.93, 132.49,\n134.10, 136.68, 140.02, 151.60, 160.48, 160.61. DEPT (CDCl 3)d(ppm): 20.72,\n55.40, 100.89, 106,71, 116.06, 127.69, 132.49, 140.02. MS m/z (%): 296 (M+,\n100), 295 (17), 267 (16), 210 (8), 181 (22), 152 (13), 139 (6), 105 (8), 76 (9).\nAnal. Calcd for C 18H16O4: C, 72.96; H, 5.44; O, 21.60. Found: C, 73.23; H, 4.90.\n33. 6-Methyl-3-(30,40,50-trimethoxy)phenylcumarin (6). It was obtained with a\nyield of 70%. Mp 165\u2013166oC.1H NMR (CDCl 3)d(ppm), J(Hz): 2.43 (s, 3H, \u2013\nCH3), 3.90 (s, 3H, \u2013OCH 3), 3,92 (s, 6H, \u2013(OCH 3)2), 6.93 (d, 2H, H-20and H-60,\nJ= 2.1), 7.24\u20137.35 (m, 3H, H-5, H-7 and H-8), 7.76 (s, 1H, H-4).13C NMR (CDCl 3)\nd(ppm): 20.70, 56.19, 60.72, 105.94, 116.03, 119.24, 127.48, 127.58, 130.04,130.44, 132.38, 134.12, 139.48, 151.45, 153.02, 160.66. DEPT (CDCl 3)d(ppm):\n20.76, 56.23, 60.77, 105.97, 116.08, 127.63, 132.43, 139.54. MS m/z(%): 326\n(M+, 100), 311 (89), 283 (43), 253 (12), 225 (30), 197 (10), 169 (10), 148 (5),\n115 (8). Anal. Calcd for C 19H18O5: C, 69.93; H, 5.56; O, 24.51. Found: C, 70.14;\nH, 5.58.\n34. Determination of human monoamine oxidase (hMAO) isoform activity : The effects\nof the test compounds on hMAO isoform enzymatic activity were evaluated bya \ufb02uorimetric method following the experimental protocol previously\ndescribed by us. Brie\ufb02y, 0.1 mL of sodium phosphate buffer (0.05 M, pH 7.4)\ncontaining the test drugs in various concentrations and adequate amounts of\nrecombinant hMAO-A or hMAO-B required and adjusted to obtain in our\nexperimental conditions the same reaction velocity [165 pmol of p-tyramine/\nmin (hMAO-A: 1.1\nlg protein; speci\ufb01c activity: 150 nmol of p-tyramine\noxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-B: 7.5 lg\nprotein; speci\ufb01c activity: 22 nmol of p-tyramine transformed/min/mg\nprotein)] were placed in the dark \ufb02uorimeter chamber and incubated for\n15 min at 37 /C176C. The reaction was started by adding (\ufb01nal concentrations)\n200lM Amplex/C210Red reagent, 1 U/mL horseradish peroxidase and 1 mM p-\ntyramine. The production of H 2O2and, consequently, of resoru\ufb01n was\nquanti\ufb01ed at 37 /C176C in a multidetection microplate \ufb02uorescence reader\n(FLX800TM, Bio-Tek/C210Instruments, Inc., Winooski, VT, USA) based on the\n\ufb02uorescence generated (excitation, 545 nm, emission, 590 nm) over a 15 min\nperiod, in which the \ufb02uorescence increased linearly.Control experiments were\ncarried out simultaneously by replacing the test drugs with appropriate\ndilutions of the vehicles. In addition, the possible capacity of the above test\ndrugs to modify the \ufb02uorescence generated in the reaction mixture due to non-\nenzymatic inhibition (e.g., for directly reacting with Amplex/C210Red reagent) was\ndetermined by adding these drugs to solutions containing only the Amplex/C210\nRed reagent in a sodium phosphate buffer.The speci\ufb01c \ufb02uorescence emission(used to obtain the \ufb01nal results) was calculated after subtraction of the\nbackground activity, which was determined from vials containing all\ncomponents except the hMAO isoforms, which were replaced by a sodium\nphosphate buffer solution.\nOn the other hand, in our experiments and under our experimental conditions,\nthe control activity of hMAO-A and hMAO-B (using p-tyramine as a common\nsubstrate for both isoforms) was 165 \u00b1 2 pmol of p-tyramine oxidized to p-\nhydroxyphenylacetaldehyde/min ( n= 20).\n35. All IC\n50values shown in the table are expressed as means \u00b1 SEM from \ufb01ve\nexperiments.3270 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 19 (2009) 3268\u20133270\n131Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent\nand selective MAO-B inhibitors\nMaria Joao Matosa,b,*, Dolores Vi\u00f1aa,c, Carmen Picciaua,b, Francisco Oralloc,\nLourdes Santanaa, Eugenio Uriartea\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbDipartimento Farmaco Chimico Tecnologico, Facolt\u00e0 di Farmacia, Universit\u00e0 di Cagliari, 09124 Cagliari, Italy\ncDepartamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\narticle info\nArticle history:\nReceived 12 June 2009\nRevised 4 July 2009Accepted 7 July 2009\nAvailable online 10 July 2009\nKeywords:\nPhenylcoumarins\nMAOIsMonoamino oxidasePerkin reaction\nCoumarin\u2013resveratrol hybridsabstract\nA series of 6-methyl-3-phenylcoumarins 3-6were synthesized and evaluated as monoamine oxidase A\nand B (MAO-A and MAO-B) inhibitors. A comparative study between the three possible mono methoxy\n3-phenyl derivatives and the p-hydroxy analogue is reported. The synthesis of these new resveratrol-cou-\nmarin hybrids was carried out by a Perkin reaction between the 5-methylsalicylaldehyde and the corre-\nsponding phenylacetic acids. The p-methoxy substituted compound 3was hydrolyzed to 6by a\ntraditional reaction with hydriodic acid. The prepared compounds show high selectivity to the MAO-Bisoenzyme, some of them with IC\n50values in the low nanomolar range. Compound 4, with the methoxy\ngroup in meta position, is the most active of this series, with an IC 50against MAO-B of 0.80 nM, and is\nseveral times more potent and MAO-B selective than the R-(/C0)-deprenyl (reference compound).\n/C2112009 Elsevier Ltd. All rights reserved.\nCoumarins are present in remarkable amounts in the nature.\nThey have attracted considerable interest due to their numerous\nbiological activities depending on their substitution pattern.1\nThese compounds have been shown to possess antioxidative andanticarcinogenic properties and to inhibit several enzymes.\n2\u20136\nSome coumarin derivatives of natural and synthetic origin havebeen characterized as monoamine oxidase inhibitors (MAOIs).\n7\u201312\nMonoamine oxidase (MAO) is an FAD-containing enzyme\nbound to the mitochondrial outer membrane of neuronal, glial,\nand other cells.10,13This enzyme regulates levels of biogenic\namines (including neurotransmitters) in the brain and the periph-\neral tissues by catalyzing their deamination.11MAO exists as two\ndistinct enzymatic isoforms, MAO-A and MAO-B, based on their\nsubstrate and inhibitor speci\ufb01cities.14,15\nMAO-A preferentially deaminates serotonin, adrenaline and\nnoradrenaline. That isoenzyme is irreversibly inhibited by low con-\ncentrations of clorgyline. MAO-B preferentially deaminates b-\nphenylethylamine and benzylamine and is irreversibly inhibitedbyR-(/C0)-deprenyl.\n16The MAOIs have been used for several years\nin the treatment of depression and anxiety diseases (MAO-A inhib-itors) and in Parkinson\u2019s disease (MAO-B inhibitors).\n17\nResveratrol, structurally 3,40,5-trihydroxystilbene, is a natural\nphenolic component of Vitis vinifera L. and other spermatophytespecies, produced in response to an exterior or interior damage.18\nResveratrol shows a large number of pharmacological activities,including antiin\ufb02ammatory, antioxidant, anticancer, and cardio-\nprotective properties and enzyme inhibition.\n19\u201323cisand trans-res-\nveratrol proved to be MAO activity inhibitors, the trans isomerbeing more effective than the cis.\n24\nBecause of their similar characteristics, it was interesting to de-\nsign and synthesize hybrids that incorporate the nucleus of the\ncoumarins and resveratrol molecules.19,25In previous work, our re-\nsearch group had reported a comparative study of the importanceto the MAOI activity of the different number of methoxy groups on\nthe phenyl ring in the 3 position of coumarin. This study contrib-\nuted to establish a relationship between them and with the non-\nsubstituted analogue.\n8Based on this, and with the aim of helping\nto better understand a structure/activity relationship for the\nMAO inhibitory activity and selectivity, in this paper we report\nthe synthesis and evaluation of a new series. Maintaining the 6-\nmethyl-3-phenylcoumarin structure, the three possible different\npositions of one methoxy group in 3-phenyl ring were explored.\nWe also explored the importance of the hydrolysis of this methoxy\ngroup.\nThe synthesis of the 6-methyl-3-phenylcoumarins was carried\nout via the classical Perkin reaction.26This reaction is performed\nby condensation of the 5-methylsalicylaldehyde 1and the appro-\npriately substituted phenylacetic acids 2, with N,N0-dicyclohexyl-\ncarbodiimide (DCC) as dehydrating agent, in DMSO, at 110 /C176C, for\n0960-894X/$ - see front matter /C2112009 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.bmcl.2009.07.039*Corresponding author. Tel.: +34 1918523676.\nE-mail address: mariacmatos@gmail.com (M.J. Matos).Bioorganic & Medicinal Chemistry Letters 19 (2009) 5053\u20135055\nContents lists available at ScienceDirect\nBioorganic & Medicinal Chemistry Letters\njournal homepage: www.elsevier.com/locate/bmcl\n13324 h ( Scheme 1 ). Compounds 3,8427and 528were obtained in\nyields of 61%, 53%, and 59%, respectively. The reaction mixture\nwas puri\ufb01ed by \ufb02ash chromatography, using hexane/ethyl acetate,\nin a proportion of 9:1, as eluent.\nThe p-methoxy derivative 3was hydrolyzed with hydriodic\nacid, in the presence of acetic acid and acetic anhydride, at\n110/C176C, for 5 h (Scheme 1 ). The residue was puri\ufb01ed by crystalliza-\ntion of acetonitrile, and the phenol derivative 629was obtained\nwith a yield of 63%.\nMAO inhibiting activity of compounds 3-6 was evaluated\nin vitro by the measurement of the enzymatic activity of human re-\ncombinant MAO isoforms in BTI insect cells infected with baculo-\nvirus.8Then, the IC 50values and MAO-B selectivity ratio [IC 50\n(MAO-A)]/[IC 50(MAO-B)] for inhibitory effects of both new com-\npounds and reference inhibitors were calculated (Table 1).30\nThe resveratrol\u2013coumarin hybrid compounds 3,4,and 6\nshowed high selectivity for the MAO-B isoenzyme and inhibitory\nactivity in the nano to picomolar range. Compound 4was the most\nactive compound of this series, making the meta methoxy position\nthe most interesting position at which to improve the MAO-B-\ninhibiting activity. Compound 5has no MAOI activity up to the\nhighest tested concentration, proving that the methoxy group in\ntheortho position is not favorable to the measured enzymatic inhi-\nbition. Changes on the methoxy substituent position on the phenyl\nring in coumarin\u2019s 3 position can modulate the pharmacologic po-\ntential of the synthesized coumarins.\nComparing compound 3with its hydroxyl derivative 6, it was\nshown that the hydrolysis of methoxy groups is not, in this case,\na strategy to improve the MAOI activity. The IC 50of compound 6\nfor inhibition of MAO-B activity is approximately 10 times bigger\nthan compound 3. However, this value is also in the nanomolar\nrange, and the molecule is also a potent MAOI, selective for the\nMAO-B isoenzyme.\nIn conclusion, the synthesized resveratrol\u2013coumarin hybrid\ncompounds show high selectivity for the MAO-B isoenzyme. Mostof them present activity in the low nanomolar range. The introduc-tion of one meta methoxy group in the 3-phenyl ring improves sev-\neral times the MAO-B inhibitory activity in respect to ortho and\npara positions. Compound 4is about 24 times more active that\nR-(/C0)-deprenyl, and several times more selective than this drug.\nThe hydrolysis of methoxy groups is not a strategy to get better\nMAOI activity. These studied modi\ufb01cations can interestingly im-\nprove the pharmacologic potential of the 3-phenylcoumarins in\nthe treatment of Parkinson\u2019s disease.\nAcknowledgments\nThanks to the Spanish Ministerio de Sanidad y Consumo\n(PI061457 and PI061537) and to Xunta da Galicia (BTF20303PR,\nPXIB203022PR, and CSA019203PR) and Fondazione Banco Sarde-gna (Italy) for \ufb01nancial support. M.J.M. also thanks MIUR for a\nPhD grant.\nReferences and notes\n1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem.\n2005 ,12, 887.\n2. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 ,27, 713.\n3. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Enzyme Inhib. Med. Chem. 2003 ,18, 63.\n4. Kabeya, L.; Marchi, A.; Kanashiro, A.; Lopes, N.; Silva, C.; Pupo, M.; Lucisano-\nValim, Y. Bioorg. Med. Chem. 2007 ,15, 1516.\n5. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.;\nJenner, P.; Testa, B. Chem. Biod. 2006 ,3, 134.\n6. Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.; Poletto, G.;\nMazzorana, M.; Zagotto, G.; Uriarte, E.; Guiotto, A.; Pinna, L.; Meggio, F.; Moro,\nS.J. Med. Chem. 2008 ,51, 752.\n7. Santana, L.; Uriarte, E.; Gonz\u00e1lez-D\u00edaz, H.; Zagotto, G.; Soto-Otero, R.; M\u00e9ndez-\n\u00c1lvarez, E. J. Med. Chem. 2006 ,49, 1118.\n8. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;\nUriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268.\n9. Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, M.; Vi\u00f1a, D.;\nOrallo, F. J. Med. Chem. 2008 ,51, 6740.\n10. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.; Altomare, C.; Carotti,\nA.; Testa, B. J. Med. Chem. 2000 ,43, 4747.\n11. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.; Soto-Otero, R.;\nM\u00e9ndez-\u00c1lvarez, E.; Carotti, A. J. Med. Chem. 2006 ,49, 4912.\n12. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.;\nCarradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. J. Med. Chem. 2009 ,52,\n1935.\n13. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini,\nP.; Alacaro, S.; Ortuso, F. Bioorg. Med. Chem. Lett. 2004 ,14, 3697.\n14. Geha, R. M.; Rebrin, I.; Chen, K.; Shih, J. C. J. Biol. Chem. 2001 ,276, 9877.\n15. Johnston, J. P. Biochem. Pharmacol. 1968 ,17, 1285.\n16. Grimsby, J.;\nLan, N. C.; Neve, R.; Chen, K.; Shih, J. C. J. Neurochem. 1990 ,55,\n1166.\n17. Harfenist, H.; Heuseur, D. J.; Joyner, C. T.; Batchelor, J. F.; White, H. L. J. Med.\nChem. 1996 ,39, 1857.\n18. Fr\u00e9mont, L. Life Sci. 2000 ,66, 663.\n19. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Y\u00e1nez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257.\n20. Orallo, F. In Resveratrol in Health and Disease ; Aggarwal, B. B., Shishodia, S., Eds.;\nCRC Press: USA, 2005; p 577.\n21. Leiro, J.; \u00c1lvarez, E.; Arranz, J.; Laguna, R.; Uriarte, E.; Orallo, F. J. Leukocyte Biol.\n2004 ,75, 1156.\n22. Orallo, F. Curr. Med. Chem. 2008 ,15, 1887.\n23. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2005 ,102, 12684.\n24. Y\u00e1nez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Commun. 2006 ,\n344, 688.\n25. Vilar, S.; Quezada, E.; Alcaide, C.; Orallo, F.; Santana, L.; Uriarte, E. Qsar Comb.\nSci.2007 ,26, 317.\n26. Kamat, S. P.; D \u00b4Souza, A. M.; Paknikar, S. K.; Beaucahmp, P. S. J. Chem. Res. (S)\n2002 , 242.\n27. 3-(30-Methoxy)phenyl-6-methylcumarin (4): It was obtained with a yield of 53%.\nMp 84\u201385 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 2.44 (s, 3H, \u2013CH 3), 3.88 (s, 1H, \u2013\nOCH 3), 6.97 (m, 1H, H-40), 7.26\u20137.42 (m, 6H, H-5, H-7, H-8, H-20, H-50and H-60)\n7.78 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm): 20.77, 55.37, 114.15, 114.38,\n116.10, 119.28, 120.86, 127.70, 129.43, 132.48, 134.12, 136.12, 139.91, 140.10,\n151.60, 159.45 160.66. MS m/z(%): 267 (48), 266 (M+, 100), 239 (16), 238 (70),\n237 (20), 195 (48), 194 (16), 166 (10), 165 (29), 152 (23). Anal. Calcd for\nC17H14O3: C, 76.68; H, 5.30. Found: C, 76.76; H, 5.21.\n28. 3-(20-Methoxy)phenyl-6-methylcumarin (5): It was obtained with a yield of 59%.\nMp 177\u2013178 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 2.41 (s, 3H, \u2013CH 3), 3.82 (s, 1H,\n\u2013OCH 3), 7.02 (m, 2H, H-30, H-40), 7.24\u20137.41 (m, 5H, H-5, H-7, H-8, H-50and H-\n60) 7.69 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm): 20.80, 55.81, 111.31, 116.21,O O OHCHO Me MeOHO\n12 3:R=p-OMe\n4:R=m-OMe\n5:R=o-OMe\n6:R=p-OHaR\nOMe\nb\nScheme 1. Reagents and conditions: (a) DCC, DMSO, 110 /C176C, 24 h; (b) HI, AcOH,\nAc2O, 110 /C176C, 5 h.\nTable 1\nMAO-A and MAO-B inhibition by the prepared compounds 3\u20136and for the reference\ncompounds\nCompounds MAO-A IC 50 MAO-B IC 50 Ratio\n3*13.05 \u00b1 0.90 nM >7663b\n4*802.60 \u00b1 53.75 pM >124,595b\n5**\n6*155.59 \u00b1 17.09 nM >643b\nR-(/C0)-Deprenyl 67.25 \u00b1 1.02 lMa19.60 \u00b1 0.86 nM 3431\nIproniazid 6.56 \u00b1 0.76 lM 7.54 \u00b1 0.36 lM 0.87\n*Inactive at 100 lM (highest concentration tested). At higher concentrations the\ncompounds precipitate.\naP<0.01 versus the corresponding IC 50values obtained against MAO-B, as\ndetermined by ANOVA/Dunnett\u2019s.\nbValues obtained under the assumption that the corresponding IC 50against\nMAO-A is the highest concentration tested (100 lM).5054 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 19 (2009) 5053\u20135055\n134119.24, 120.57, 124.20, 126.36, 127.58, 130.14, 130.80, 132.21, 133.89, 141.84,\n151.82, 157.22 160.55. MS m/z(%): 267 (22), 266 (M+, 100), 265 (10), 249 (29),\n237 (22), 235 (14), 223 (22), 220 (12), 195 (29), 173 (26), 165 (25), 152 (17),145 (19), 118 (19). Anal. Calcd for C\n17H14O3: C, 76.68; H, 5.30. Found: C, 76.76;\nH, 5.22.\n29. 3-(40-Hydroxy)phenyl-6-methylcumarin (6): It was obtained with a yield of 63%.\nMp 217\u2013218 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 2.37 (s, 3H, \u2013CH 3), 6.84 (d, 2H,\nH-30and H-50,J= 8.8), 7.31 (d, 1H, H-8, J= 8.4), 7.40 (dd, 1H, H-7, J= 1.9 and8.4), 7.56 (m, 3H, H-20, H-60and H-5), 8.06 (s, 1H, H-4).13C NMR (CDCl 3)d\n(ppm): 20.31, 115.04, 115.52, 119.45, 125.29, 126.66, 127.92, 129.83, 132.00,\n133.67, 138.46, 150.79, 157.95, 160.04. MS m/z(%): 253 (13), 252 (M+, 75), 224\n(58), 223 (26), 165 (12) 152 (15), 143 (23), 99 (37), 98 (25), 83 (12), 70 (20), 56(100), 55 (27). Anal. Calcd for C\n16H12O3: C, 76.18; H, 4.79. Found: C, 75.99; H,\n4.69.\n30. All IC 50values shown in the table are expressed as means \u00b1 SEM from \ufb01ve\nexperiments.M. J. Matos et al. / Bioorg. Med. Chem. Lett. 19 (2009) 5053\u20135055 5055\n135New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors\nMaria Jo\u00e3o Matosa,b,*, Dolores Vi\u00f1ac, Patricia Janeiroa,d, Fernanda Borgesb, Lourdes Santanaa,\nEugenio Uriartea\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbCIQUP/Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, 4169-007 Porto, Portugal\ncDepartamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\ndDepartamento de Qu\u00edmica, Faculdade de Ci\u00eancias e Tecnologia, Universidade de Coimbra, 3004-535 Coimbra, Portugal\narticle info\nArticle history:\nReceived 24 June 2010\nRevised 2 July 2010\nAccepted 3 July 2010Available online 8 July 2010\nKeywords:\nPhenylcoumarins\nMAOIs\nHalogenation\nPerkin reaction\nBromo coumarin derivativesabstract\nWith the aim to \ufb01nd out the structural features for the MAO inhibitory activity and selectivity, in the\npresent communication we report the synthesis and pharmacological evaluation of a new series of\nbromo-6-methyl-3-phenylcoumarin derivatives (with bromo atom in both different benzene rings of\nthe skeleton) with and without different number of methoxy substituent at the 3-phenyl ring. The meth-\noxy substituents were introduced, in this new scaffold, in the meta and/or para positions of the 3-phenyl\nring. The synthesized compounds 3\u20137 were evaluated as MAO-A and B inhibitors using R-(/C0)-deprenyl\n(selegiline) and iproniazide as reference inhibitors, showing, most of them, MAO-B inhibitory activitiesin the low nanomolar range. Compounds 4(IC\n50= 11.05 nM), 5(IC50= 3.23 nM) and 6(IC50= 7.12 nM)\nshow higher activity than selegiline (IC 50= 19.60 nM) and higher MAO-B selectivity, with more than\n9050-fold, 30,960-fold and 14,045-fold inhibition levels, with respect to the MAO-A isoform.\n/C2112010 Elsevier Ltd. All rights reserved.\nCoumarins are a large family of compounds, of natural and syn-\nthetic origin, that presents different pharmacological activities.1\nDue to their structural variability, they occupy an important place\nin the realm of natural products and synthetic organic chemistry.\nRepresentatives of these groups of compounds are found to occur\nin the vegetable kingdom, either in the free or in the combined\nstate.2Recent studies pay special attention to their antioxidative,\nanticancer, and enzymatic inhibition properties.3\u20136Some couma-\nrins proved to be monoamine oxidase (MAO) inhibitors (MAOI).7\nRecent \ufb01ndings revealed that MAO-A and MAO-B af\ufb01nity and\nselectivity can be ef\ufb01ciently modulated by appropriate substitu-\ntions in the coumarin moiety. The 3/4 and 6/7 positions are partic-\nularly suitable to these modi\ufb01cations.8\u201314\nResveratrol, 3,40,5-trihydroxystilbene, is a natural polyphenolic\ncompound present in grapes and red wine.15In in vitro, ex vivo,\nand in vivo experiments resveratrol has shown important biologi-cal activities including antiin\ufb02ammatory, antioxidant, anticancer,\nand cardioprotective properties, besides inhibitory activity to-\nwards several enzymes.\n15\u201320\nTherefore this compound has been attracting a huge interest\nsince the last decade. Recently, it has been demonstrated that res-\nveratrol also has MAO inhibitory activity.16,21To date, most phar-\nmacological studies have considered the trans isomer to be more\neffective than the cis.22MAOs are \ufb02avoenzymes (FAD-containing enzyme) bound to the\nouter mitochondrial membrane of neuronal, glial, and other\ncells.23,24These enzymes are responsible for the oxidative deami-\nnation of neurotransmitters and dietary amines.25,26Two isoforms,\nnamely MAO-A and MAO-B, have been identi\ufb01ed basis on their\namino acid sequences, three-dimensional structure, substrate pref-\nerence and inhibitor selectivity.20,27MAO-A has a higher af\ufb01nity\nfor serotonin and noradrenaline, while MAO-B preferentially dea-\nminates phenylethylamine and benzylamine.28These properties\ndetermine the clinical interest of MAOIs. Selective MAO-A inhibi-\ntors, such as clorgyline (irreversible) and moclobemide (revers-\nible), are used for the treatment of neurological disorders, like\ndepression and anxiety,29,30whilst selective and irreversible\nMAO-B inhibitors, such as selegiline and rasagiline, are useful forthe treatment of Parkinson\u2019s\n31,32and Alzheimer\u2019s diseases.33,34As\nthe ideal drug candidate has not been attained, an intensive searchfor new and innovative MAOIs is still needed. This effort has con-\nsiderably increased in recent years.\n11\nIn this context, and in an attempt to develop novel MAO-B\nselective inhibitors, we had previously synthesized 3-arylcoumarin\nderivatives in which both the coumarin and the resveratrol tem-\nplates were present. These compounds proved to be potent and\nselective MAO-B inhibitors.8,9In this Letter, a subsequent project\nwas developed based on a 6-methyl-3-phenylcoumarin scaffold,\nwith a bromo pattern in both benzenic rings of the skeleton, and\nwith several methoxyl substituents located in the 3-phenyl ring\n(Scheme 1 ).\n0960-894X/$ - see front matter /C2112010 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.bmcl.2010.07.013*Corresponding author. Tel.: +34 981 528070.\nE-mail address: mariacmatos@gmail.com (M.J. Matos).Bioorganic & Medicinal Chemistry Letters 20 (2010) 5157\u20135160\nContents lists available at ScienceDirect\nBioorganic & Medicinal Chemistry Letters\njournal homepage: www.elsevier.com/locate/bmcl\n137The coumarin derivatives 3\u20137 were ef\ufb01ciently synthesized\naccording to the synthetic protocol outlined in Scheme 1 . The\nexperimental details are given in Ref. 35. The treatment of the pre-\ncursor 1with N-bromosuccinimide (NBS) in carbon tetrachloride\n(CCl 4) under re\ufb02ux, using 2,20-azo-bis-iso-butyronitrile (AIBN) as\ncatalyst, afforded the bromo derivative 236in a yield of 44%. The\npreparation of the 8-bromo-6-methyl-3-phenylcoumarins (4 \u20137)\nwas performed via the classical Perkin reaction.8,9,37\u201339This reac-\ntion occurs by condensation of the 3-bromo-5-methylsalicylalde-\nhyde ( 2) and the conveniently substituted phenylacetic acids,\nwith N,N0-dicyclohexylcarbodiimide (DCC) as dehydrating agent,\nin dimethyl sulfoxide (DMSO), at 110 /C176C and during 24 h ( Scheme\n1).8,9The reaction is ef\ufb01cient and the compounds 4\u20137 were ob-\ntained with yields between 45% and 50%. Compound 3was pre-\npared in the same conditions described for compounds 4\u20137, but\nstarting from the 5-methylsalicylaldehyde 1and the o-bromo-\nphenylacetic acid.\nThe inhibitory MAO activity of compounds 3\u20137 was evaluated\nin vitro by the measurement of the enzymatic activity of human\nrecombinant MAO isoforms in BTI insect cells infected with bacu-\nlovirus.8,9,40Then, the IC 50values and MAO-B selectivity ratios [IC 50\n(MAO-A)]/[IC 50(MAO-B)] for inhibitory effects of both new com-\npounds and reference inhibitors were calculated (Table 1 ).40\u201342\nIn the present communication, the effect of the introduction of a\nhalogen substituent into the 3-phenylcoumarin was studied. In\nfact a superior MAOI activity, regarding the non-halogenated\ncompounds, was observed.7,8It was shown that the introduction\nof a bromo substituent enhance the MAO-B inhibitory properties\n(potency and selectivity) of the recently described 6-methyl-3-\nphenylcoumarin (IC 50= 284 nM).7\nAs it is shown in the Table 1 , compound 3, with the halogen\natom in the 3-phenyl ring, has an IC 50in the micromolar range(IC50= 4.3 lM). When compared with the 6-methyl-3-phenyl-\ncoumarin, compound 3lost at least 15 times the MAO-B inhibitory\nactivity. The structural change obtained with compound 4, with\nthe halogen atom in the coumarin nucleus, leads to a signi\ufb01cant in-crease of the MAO-B activity (IC\n50= 11.0 nM). In fact it was greater\nthan the IC 50found for 6-methyl-3-phenylcoumarin and com-\npound 3. So, as consequence, the MAO-B selectivity had increased\ntoo (see Table 1 ). A change of the bromo atom position in the 3-\nphenylcoumarin nucleus, from 20to 8, was the other strategy per-\nformed to improve the activity (compounds 5\u20137). Compound 5,\nwith a p-methoxy substituent in the 3-phenyl ring, was the most\npotent and selective molecule, against MAO-B isoenzyme, of this\nseries, with an IC 50in the low nanomolar range (IC 50= 3.2 nM).\nThis compound is six times more active and to a great extent more\nselective than the R-(/C0)-deprenyl (IC 50= 19.6 nM, reference MAO-\nB inhibitor). Compound 6, with two methoxyl groups in the 30and\n50positions, reveal also to be a potent MAOI-B. Its activity\n(IC50= 7.1 nM) is still better than the non-phenylsubstituted com-\npound 4. Compound 7, with three methoxyl groups, present a loss\nof activity (activity in the micromolar range) and selectivity in re-\ngard to the mono and dimethoxyl derivatives (compounds 5and6,\nrespectively). Compounds 3\u20136do not exhibit MAO-A inhibitory\nactivity for the highest tested concentration (100 lM). The MAO\nselectivity is an important factor to discriminate the potentialtherapeutic application of this kind of molecules. In summary\none can say that the presence of a bromo atom in 8-position and\na restricted number of methoxyl substituents (one or two) in the\n3-phenyl ring seems to be important chemical features to\nmodulate and improve the inhibitory enzymatic activity of the\n6-methyl-3-phenylcoumarins.\nIn conclusion, in the present study it was shown that the\nsynthesized resveratrol\u2013coumarin hybrid compounds have highCHO\nOHMe CHO\nOHMe\nBrMe\nO O\nBr(b) (a)\n1 4:R=H\n5:R=4 ' - O M e\n6:R=3 ' , 5 ' - O M e\n7:R=3 ' , 4 ' , 5 ' - O M e2R\n(b)\nMe\nO O\n3Br\nScheme 1. Reagents and conditions: (a) NBS, AIBN, CCl 4, re\ufb02ux, 18 h; (b) phenylacetic acids, DCC, DMSO, 110 /C176C, 24 h.\nTable 1\nMAO-A and MAO-B inhibitory activity results for compounds 3\u20137and reference compounds\nCompounds MAO-A IC 50(nM) MAO-B IC 50(nM) Ratio\n3*4.3/C2103\u00b1 0.29 /C2103>23b\n4*11.05 \u00b1 0.81 >9050b\n5*3.23 \u00b1 0.49 >30,960b\n6*7.12 \u00b1 0.01 >14,045b\n7 31.20 /C2103\u00b1 2.09 /C21034.89/C2103\u00b1 0.22 /C21036.4\nR-(/C0)-Deprenyl 67.25 /C2103\u00b1 1.02 /C2103a19.60 \u00b1 0.86 3431\nIproniazide 6.56/C2103\u00b1 0.76 /C21037.54/C2103\u00b1 0.36 /C21030.87\n*Inactive at 100 lM (highest concentration tested). At higher concentrations the compounds precipitate.\naP<0.01 versus the corresponding IC 50values obtained against MAO-B, as determined by ANOVA/Dunnett\u2019s.\nbValues obtained under the assumption that the corresponding IC 50against MAO-A is the highest concentration tested (100 lM).5158 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 20 (2010) 5157\u20135160\n138selectivity for the MAO-B isoenzyme. Most of them present MAO-B\ninhibitory activity is in the low nanomolar range. The presence of a\nbromo atom in position 8 of the coumarin improves the activity re-\nspect to the presence of a bromo atom linked to the 3-phenyl ring.\nThe introduction of one para-methoxy group in the 3-phenyl ring\nof the 8-bromo-6-methyl-3-phenylcoumarin improve to a great\nextent the MAO-B inhibitory activity respect to the other prepared\nderivatives. In fact, the introduction of a bromo atom improves the\npharmacologic potential of the 6-methyl-3-phenylcoumarins con-\n\ufb01rming that this lead could be effectively optimized in a candidate\nfor the treatment of neurodegenerative diseases. These \ufb01nds have\nencouraged us to continue the efforts towards the optimization of\nthe pharmacologic pro\ufb01le of 6-methyl-3-phenylcoumarin.\nAcknowledgments\nThanks to the Spanish Ministry(PS0900501), to Xunta da Galicia\n(PGIDIT09CSA030203PR and INCITE09E2R203035ES) and to FCT\n(PTDC/QUI/70359/2006) for \ufb01nancial support. M.J.M. also thanks\nFCT for a Ph.D. Grant (SFRH/BD/61262/2009).\nReferences and notes\n1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem.\n2005 ,12, 887.\n2. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 ,27, 713.\n3. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Enzyme Inhib. Med. Chem. 2003 ,18, 63.\n4. Kabeya, L.; Marchi, A.; Kanashiro, A.; Lopes, N.; Silva, C.; Pupo, M.; Lucisano-\nValim, Y. Bioorg. Med. Chem. 2007 ,15, 1516.\n5. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose, S.;\nJenner, P.; Testa, B. Chem. Biodivers. 2006 ,3, 134.\n6. Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.; Poletto, G.;\nMazzorana, M.; Zagotto, G.; Uriarte, E.; Guiotto, A.; Pinna, L.; Meggio, F.; Moro,\nS.J. Med. Chem. 2008 ,51, 752.\n7. Rendenbach-M\u00fcller, B.; Traut, M.; Weifenbach, H. Bioorg. Med. Chem. Lett. 1994 ,\n4, 1195.\n8. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;\nUriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268.\n9. Matos, M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053.\n10. Santana, L.; Uriarte, E.; Gonz\u00e1lez-D\u00edaz, H.; Zagotto, G.; Soto-Otero, R.; M\u00e9ndez-\n\u00c1lvarez, E. J. Med. Chem. 2006 ,49, 1118.\n11. Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, M.; Vi\u00f1a, D.;\nOrallo, F. J. Med. Chem. 2008 ,51, 6740.\n12. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.; Soto-Otero, R.;\nM\u00e9ndez-\u00c1lvarez, E.; Carotti, A. J. Med. Chem. 2006 ,49, 4912.\n13. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.; Altomare, C.; Carotti,\nA.; Testa, B. J. Med. Chem. 2000 ,43, 4747.\n14. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini,\nP.; Alacaro, S.; Ortuso, F. Bioorg. Med. Chem. Lett. 2004 ,14, 3697.\n15. Fr\u00e9mont, L. Life Sci. 2000 ,66, 663.\n16. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Y\u00e1nez, M.; Fraiz, N.; Alcaide, C.;\nCano,\nE.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257.\n17. Orallo, F. In Resveratrol in Health and Disease ; Aggarwal, B. B., Shishodia, S., Eds.;\nCRC Press: USA, 2005; p 577.\n18. Leiro, J.; \u00c1lvarez, E.; Arranz, J.; Laguna, R.; Uriarte, E.; Orallo, F. J. Leukocyte Biol.\n2004 ,75, 1156.\n19. Orallo, F. Curr. Med. Chem. 2008 ,15, 1887.\n20. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2005 ,102, 12684.\n21. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2003 ,100, 9750.\n22. Y\u00e1nez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Commun. 2006 ,\n344, 688.\n23. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.\nE.; Mattevi, A. J. Med. Chem. 2007 ,50, 5848.\n24. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.;\nCarrupt, P.; Reist, M. J. Med. Chem. 2006 ,49, 6264.\n25. Dostert, P.; Strolin Benedetti, M.; Jafre, M. In Monoamine Oxidase: Basic and\nClinical Frontiers ; Kamijo, K., Usdin, E., Nagausu, T., Eds.; Excerpta Medica:\nAmsterdam, 1982; p 197.\n26. Singer, T. P., Muller, F., Eds.; CRC Press: London, 1991; p 437.27. Binda, C.; Li, M.; Hub\u00e1lek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2003 ,100, 9750.\n28. Yamada, M.; Yasuhara, H. Neurotoxicology 2004 ,25, 11.\n29. Rudorfer, M. V.; Potter, V. Z. Drugs 1989 ,37, 713.\n30. Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-Ikola, O.; Palm, R.\nNeurology 2006 ,66, 1200.\n31. Guay, D. R. Am. J. Geriatr. Pharmacother. 2006 ,4, 330.32. Riederer, P.; Danielczyk, W.; Grunblatt, E. Neurotoxicology 2004 ,25, 271.\n33. Youdim, M. B. H.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004 ,111,\n 1455.\n34. Cesura, A. M.; Pletscher, A. Prog. Drug Res. 1992 ,38, 171.\n35. 3-(2-Bromophenyl)-6-methylcoumarin (3): A solution of 2-hydroxy-6-\nmethylbenzaldehyde ( 1, 1.0 g, 7.34 mmol) and 2-bromophenylacetic acid\n(1.98 g, 9.18 mmol) in DMSO and DCC (2.36 g, 11.46 mmol) was heated in anoil-bath at 110 /C176C for 24 h. Triturate ice (100 mL) and acetic acid (10.0 mL)\nwere added to the reaction mixture. After keeping it at room temperature for\n2 h, the mixture was extracted with ether (3 /C225 mL). The organic layer was\nextracted with sodium bicarbonate solution (50 mL, 5%) and then water\n(20 mL). The solvent was evaporated under vacuum and the dry residue waspuri\ufb01ed by FC (hexane/ethyl acetate 9:1) to give 3(1.36 g, 59%) as a white\nsolid. Mp 141\u2013142 /C176C.\n1H NMR (CDCl 3)d(ppm): 2.45 (s, 3H, \u2013CH 3), 7.28 (m, 1H,\nH-40); 7.35 (m, 2H, H-7, H-8); 7.40 (m, 3H, H-5, H-50, H-60); 7.69 (d, 1H, H-30);\n7.71 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm): 20.8, 116.4, 118.7, 123.6, 127.4,\n127.9, 128.6, 130.1, 131.3, 132.9, 133.0, 134.3, 135.9, 142.6, 152.0, 160.0. MS m/\nz(%): 316 (5), 315 (38), 314 (M+, 100), 236 (32), 235 (80), 178 (22), 117 (7), 89\n(7), 76 (9). Anal. Calcd for C 16H11BrO 2: C, 60.98; H, 3.52. Found: C, 60.92; H,\n3.47.\nGeneral procedure for the preparation of 8-bromo-6-methyl-3-phenylcoumarins\n(4\u20137): A solution of 3-bromo-2-hydroxy-6-methylbenzaldehyde ( 2,\n0.56 mmol) and the correspondent phenylacetic acid (0.70 mmol) in DMSOand DCC (0.87 mmol) was heated in an oil-bath at 110 /C176C for 24 h. Triturate ice\n(20 mL) and acetic acid (3.0 mL) were added to the reaction mixture. After\nkeeping it at room temperature for 2 h, the mixture was extracted with ether\n(3/C225 mL). The organic layer was extracted with sodium bicarbonate solution\n(50 mL, 5%) and then water (20 mL). The solvent was evaporated under\nvacuum and the dry residue was puri\ufb01ed by FC (hexane/ethyl acetate 9:1) togive a white solid.\n8-Bromo-6-methyl-3-phenylcoumarin (4): It was obtained with a yield of 45%.\nMp 158\u2013159 /C176C.\n1H NMR (CDCl 3)d(ppm), J(Hz): 2.41 (s, 3H, \u2013CH 3), 7.28 (d, 1H,\nH-7, J= 2.3), 7.45 (m, 3H, H-30, H-40, H-50), 7.58 (m, 1H, H-5), 7.70 (m, 3H, H-4,\nH-20, H-60).13C NMR (CDCl 3)d(ppm): 20.5, 109.4, 120.5, 127.1, 128.5, 129.0,\n129.1, 134.3, 135.2, 135.6, 139.3, 148.3, 159.7. MS m/z(%): 316 (17), 315 (42),\n314 (M+, 100), 313 (99), 288 (36), 286 (15), 285 (36), 207 (30), 178 (26), 89\n(10), 76 (10). Anal. Calcd for C 16H11BrO 2: C, 60.98; H, 3.52. Found: C, 61.01; H,\n3.56.\n8-Bromo-6-methyl-3-(40-methoxyphenyl)coumarin (5): It was obtained with a\nyield of 47%. Mp 144\u2013145 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 2.40 (s, 3H, \u2013\nCH3), 3.87 (s, 3H, \u2013OCH 3), 6.98 (d, 2H, H-30, H-50,J= 7.1), 7.26 (s, 1H, H-7), 7.56\n(s, 1H, H-5), 7.67 (dd, 3H, H-4, H-20, H-60,J= 6.9 and J= 1.1).13C NMR (CDCl 3)d\n(ppm): 20.5, 55.4, 109.3, 114.0, 120.7, 126.7, 126.9, 128.5, 129.9, 135.2, 137.8,\n148.1, 159.9, 160.3. MS m/z(%): 346 (99), 345 (15), 344 (M+, 100), 303 (53), 301\n(54), 275 (15), 207 (15), 166 (17), 165 (72), 138 (17), 89 (13), 76 (14), 58 (41).\nAnal. Calcd for C 17H13BrO 3: C, 59.15; H, 3.80. Found: C, 59.17; H, 3.86.\n8-Bromo-6-methyl-3-(30,50-dimethoxyphenyl) coumarin (6): It was obtained\nwith a yield of 46%. Mp 165\u2013166 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 2.40 (s,\n3H, \u2013CH 3), 3.83 (s, 6H, (\u2013OCH 3)2), 6.51 (t, 1H, H-40J= 2.3), 6.83 (d, 2H, H-20,H -\n60,J= 2.3), 7.26 (s, 1H, H-7), 7.57 (s, 1H, H-5), 7.70 (s, 1H, H-4).13C NMR (CDCl 3)\nd(ppm): 21.0, 56.0, 101.6, 107.2, 109.9, 120.8, 127.6, 129.2, 135.7, 136.1, 136.6,\n140.0, 148.7, 160.0, 161.2. MS m/z(%): 376 (99), 375 (26), 374 (M+, 100), 238\n(37), 209 (14), 181 (36), 165 (30), 153 (18), 152 (41), 151 (17), 126 (15), 76\n(22). Anal. Calcd for C 18H15BrO 4: C, 57.62; H, 4.03. Found: C, 57.63; H, 3.98.\n8-Bromo-6-methyl-3-(30,40,50-trimethoxyphenyl) coumarin (7): It was obtained\nwith a yield of 50%. Mp 167\u2013168 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 2.41 (s,\n3H, \u2013CH 3), 3.91 (d, 9H, (\u2013OCH 3)3,J= 5.8), 6.92 (s, 2H, H-20, H-60), 7.28 (d, 1H, H-\n7,J= 6.5), 7.59 (d, 1H, H-5, J= 1.3), 7.70 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm):\n20.5, 56.1, 56.3, 60.9, 106.0, 106.2, 109.4, 120.4, 127.0, 128.7, 129.7, 135.3,\n135.6, 138.9, 148.1, 153.1, 159.7. MS m/z(%): 407 (21), 406 (99), 405 (21), 404\n(M+, 100), 391 (56), 389 (56), 363 (19), 361 (19), 303 (21), 247 (13), 187 (15),\n186 (15), 139 (19). Anal. Calcd for C 19H17BrO 5: C, 56.31; H, 4.23. Found: C,\n56.28; H, 4.19.\n36. Li, W.; Huanwang, J.; Xiuli, B.; Tao, C.; Lili, J.; Yongmin, L. Catal. Commun. 2007 ,\n8, 80.\n37. Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. Indian J. Chem., Sect B 1996 ,35B,\n1159.\n38. Mohanty, S.; Makrandi, J. K.; Grover, S. K. Indian J. Chem., Sect B 1989 ,28B, 766.\n39. Kamat, S. P.; D \u00b4Souza, A. M.; Paknikar, S. K.; Beaucahmp, P. S. J. Chem. Res., Synop.\n2002 , 242.\n40. Determination of human monoamine oxidase (hMAO) isoform activity : The effects\nof the test compounds on hMAO isoform enzymatic activity were evaluated bya \ufb02uorimetric method. Brie\ufb02y, 0.1 mL of sodium phosphate buffer (0.05 M, pH\n7.4) containing the test drugs in various concentrations and adequate amounts\nof recombinant hMAO-A or hMAO-B required and adjusted to obtain in our\nexperimental conditions the same reaction velocity [165 pmol of p-tyramine/\nmin (hMAO-A: 1.1\nlg protein; speci\ufb01c activity: 150 nmol of p-tyramine\noxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-B: 7.5 lg\nprotein; speci\ufb01c activity: 22 nmol of p-tyramine transformed/min/mg\nprotein)] were placed in the dark \ufb02uorimeter chamber and incubated for\n15 min at 37 /C176C. The reaction was started by adding (\ufb01nal concentrations)\n200lM Amplex/C210Red reagent, 1 U/mL horseradish peroxidase and 1 mM p-\ntyramine. The production of H 2O2and, consequently, of resoru\ufb01n was\nquanti\ufb01ed at 37 /C176C in a multidetection microplate \ufb02uorescence reader\n(FLX800\u2122, Bio-Tek/C210Instruments, Inc., Winooski, VT, USA) based on the\n\ufb02uorescence generated (excitation, 545 nm, emission, 590 nm) over a 15 min\nperiod, in which the \ufb02uorescence increased linearly. Control experiments wereM. J. Matos et al. / Bioorg. Med. Chem. Lett. 20 (2010) 5157\u20135160 5159\n139carried out simultaneously by replacing the test drugs with appropriate\ndilutions of the vehicles. In addition, the possible capacity of the above test\ndrugs to modify the \ufb02uorescence generated in the reaction mixture due to non-\nenzymatic inhibition (e.g., for directly reacting with Amplex/C210Red reagent) was\ndetermined by adding these drugs to solutions containing only the Amplex/C210\nRed reagent in a sodium phosphate buffer. The speci\ufb01c \ufb02uorescence emission(used to obtain the \ufb01nal results) was calculated after subtraction of the\nbackground activity, which was determined from vials containing all\ncomponents except the hMAO isoforms, which were replaced by a sodiumphosphate buffer solution. On the other hand, in our experiments and under\nour experimental conditions, the control activity of hMAO-A and hMAO-B\n(using p-tyramine as a common substrate for both isoforms) was 165 \u00b1 2 pmol\nofp-tyramine oxidized to p-hydroxyphenylacetaldehyde/min ( n= 20).\n41. All IC\n50values shown in the table are expressed as means \u00b1 SEM from \ufb01ve\nexperiments.\n42. Y\u00e1\u00f1ez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Commun. 2006 ,\n344, 688.5160 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 20 (2010) 5157\u20135160\n140MAO inhibitory activity modulation: 3-Phenylcoumarins versus\n3-benzoylcoumarins\nMaria Jo\u00e3o Matosa, Saleta Vazquez-Rodrigueza, Eugenio Uriartea, Lourdes Santanaa, Dolores Vi\u00f1ab,\u21d1\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbDepartamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\narticle info\nArticle history:\nReceived 5 April 2011\nRevised 18 May 2011Accepted 20 May 2011\nAvailable online 30 May 2011\nKeywords:\nPerkin reaction\nKnoevenagel reaction\n3-Phenylcoumarins\n3-Benzoylcoumarins\nMAOI activityComparative studyabstract\nWith the aim of \ufb01nding the structural features for the human MAO inhibitory activity and selectivity, in\nthe present communication we report the synthesis, pharmacological evaluation and a comparative\nstudy of a new series of 3-phenylcoumarins (compounds 1\u20134) and 3-benzoylcoumarins (compounds\n5\u20138). A bromo atom and a methoxy/hydroxy substituent were introduced in these scaffolds, at six and\neight positions of the coumarin moiety, respectively. The synthesized compounds 1\u20138 were evaluated\nas MAO-A and B inhibitors using R-( /C0)-deprenyl and iproniazide as reference compounds. The presence\nor absence of a carbonyl group between the coumarin and the phenyl substituent in 3 position remarks,\nrespectively, the MAO-A or MAO-B inhibitory activity. Some of the new compounds showed MAO-B\ninhibitory activities in the low nanomolar range. Compound 2(IC50= 1.35 nM) showed higher inhibitory\nactivity than the R-( /C0)-deprenyl (IC 50= 19.60 nM) and higher MAO-B selectivity, with more than 74,074-\nfold inhibition level, respecting to the MAO-A isoform.\n/C2112011 Elsevier Ltd. All rights reserved.\nCoumarins, chalcone and their natural and/or synthetic deriva-\ntives are biologically interesting compounds because of their struc-\ntural diversity. Due to this variability, these heterocyclic\ncompounds occupy an important role not only in the Organic\nChemistry but also in the Medicinal Chemistry realm.1\u20136They are\ndescribed as anticancer, anti-in\ufb02ammatory, antimicrobial, andantioxidant agents.\n7\u201316A number of studies pay special attention\nto coumarin derivatives as monoamine oxidase (MAO)17\u201323inhibi-\ntors. Recently, chalcone structure has also been identi\ufb01ed as a valid\nscaffold for monoamine oxidase inhibitors (MAOI).24Therefore, re-\ncent \ufb01ndings reveal that MAO-A and MAO-B af\ufb01nity and selectivitycan be ef\ufb01ciently modulated by appropriate substitutions in differ-\nent positions of the coumarin and chalcone moiety (Fig. 1 ).\n19,25\u201327\nMAO is a FAD-containing enzyme (\ufb02avoenzyme) bound to the\nouter mitochondrial membrane in neuronal, glial and many other\ncells.28,29Two isoforms namely as MAO-A and MAO-B have been\nidenti\ufb01ed based on their amino acid sequences, three-dimensionalstructure, substrate preference and inhibitor selectivity.\n30,31These\nisoenzymes are responsible for the oxidative deamination of neu-\nrotransmitters and dietary amines. Therefore, they are responsible\nfor the regulation of intracellular levels of biogenic amines in the\nbrain and the peripheral tissues.32,33MAO-B preferentially deami-\nnates phenylethylamine and benzylamine, while MAO-A has a\nhigher af\ufb01nity for noradrenaline and serotonin.34,35Despite ofthese differences, dopamine and tyramine are common substrates\nfor both isoforms. These properties determine the pharmacological\ninterest of MAOIs. Selective and irreversible MAO-B inhibitors,\nsuch as selegiline (R-( /C0)-deprenyl) and rasagiline are useful com-\npounds for the treatment of Parkinson36,37and Alzheimer\u2019s\ndiseases.38,39Selective MAO-A inhibitors, such as clorgyline\n(irreversible) and moclobemide (reversible), are useful for thetreatment of neurological disorders, such as depression and anxi-\nety.\n40,41All these \ufb01ndings have led us to an intensive search for\nnovel, selective and ef\ufb01cient MAO inhibitors.\nWith the aim of \ufb01nding novel and selective MAO-B inhibitors,\nwe have previously synthesized 3-arylcoumarin derivatives inwhich both the coumarin nucleus and a 3-phenyl ring were differ-\nently substituted. The experimental data show that those com-\npounds are potent and selective MAO-B inhibitors.\n20\u201323In\nparticular, the 6,8-disubstituted coumarins proved to be very inter-\nesting derivatives.22Based on the previous 3-phenylcoumarins\nexperimental results, in this paper we describe a new project with\na comparative study between 3-phenylcoumarins (compounds\n1\u20134) and 3-benzoylcoumarins (compounds 5\u20138), which are\nOO\nO\nFigure 1. Chemical structures of coumarin and trans -chalcone.\n0960-894X/$ - see front matter /C2112011 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.bmcl.2011.05.074\u21d1Corresponding author.\nE-mail address: mdolores.vina@usc.es (D. Vi\u00f1a).Bioorganic & Medicinal Chemistry Letters 21 (2011) 4224\u20134227\nContents lists available at ScienceDirect\nBioorganic & Medicinal Chemistry Letters\njournal homepage: www.elsevier.com/locate/bmcl\n141interesting semi-rigid chalcones with the a,b-unsaturated double\nbond included in the coumarin skeleton (Scheme 1 ).\nThe 6-bromo-8-methoxycoumarins42were ef\ufb01ciently synthe-\nsized by Perkin43\u201345(1and2) and Knoevenagel46,47(5and6) reac-\ntions. The hydroxy derivatives (3 ,4,7and8)42were obtained by\ntwo different hydrolysis reactions,48\u201350according to the synthetic\nprotocol outlined in Scheme 1 . Treatment of the corresponding sal-\nicylaldehyde and the conveniently substituted phenylacetic acid\nwith N,N\u2019-dicyclohexylcarbodiimide (DCC) as dehydrating agent,\nin dimethyl sulfoxide (DMSO) at 110 /C176C during 24 h, afforded the\n3-phenylcoumarins 1and 2. The consequent hydrolysis of 1and\n2in acetic acid and acetic anhydride, with hydriodic acid 57%, for\n4 h, yielded the hydroxy derivatives 3and 4.42The synthesis of\nthe 3-benzoylcoumarins 5and6was performed via condensation\nof the conveniently substituted salicylaldehyde with the corre-\nsponding b-ketoester, in ethanol at re\ufb02ux temperature for 5 or\n2 h respectively, using piperidine as basic catalyst. The resulting\nmethoxy derivatives were treated with boron tribromide at 80 /C176C\nfor 48 h, to give the corresponding hydroxy derivatives 7and 8.Starting from the same salicylaldehyde, we can afford two series,\ndiffering just in the presence (compounds 5\u20138) or absence (com-\npounds 1\u20134) of a carbonyl group between the phenyl substituent\nat the 3 position and the coumarin scaffold.\nThe inhibitory MAO activity of compounds 1\u20138 was evaluated\nin vitro by the measurement of the enzymatic activity of human re-\ncombinant MAO isoforms expressed in BTI insect cells infectedwith baculovirus.\n51Subsequently, the IC 50values and MAO-B\nselectivity indexes [IC 50(MAO-A)]/[IC 50(MAO-B)] for inhibitory ef-\nfects of both new types of compounds and reference inhibitors\nwere calculated ( Table 1 ).51\u201353\nIn the present communication, the effect of the presence or the\nabsence of a carbonyl group between the coumarin and the 3-phe-\nnyl ring is studied. Substituents and their positions in the 3-phe-\nnylcoumarin nucleus have been selected based on previousresults which showed very high MAOI activity for some deriva-\ntives. It was shown that introduction of both bromo and methoxy\nsubstituents at 6 and 8 positions respectively (compounds 1and2)\nenhances the MAO-B inhibitory properties (potency and selectiv-ity) of the described 3-phenylcoumarins, comparing to some of\nthe other previously described compounds.\n20\u201322In addition, the\nintroduction of a substituent in the para position of the 3-phenyl\nring might help to improve the activity. Consequently, when this\nsubstituent is a methoxy group (compound 2), the MAO-B inhibi-\ntory activity and selectivity improve in a great extent respectingto the other derivatives. However, replacement of the methoxy\ngroups for hydroxyl groups at the indicated positions decreases\nthe activity (compounds 3and4) validating the previous informa-\ntion we already had\n21and it can even decrease selectivity. On the\nother hand, when we analyze the second series where a 3-benzoyl\ngroup has replaced the 3-phenyl substituent, the introduced car-\nbonyl group decreases the MAOI activity against B isoform. The\n6-bromo-8-hydroxy derivatives 7and8are more active than the\ncorresponding 6-bromo-8-methoxy ones (compounds 5and 6),\nbeing the structure activity relationship just the opposite of the\n3-phenylcoumarins. Compounds 5and6do not present any MAO\ninhibitory activity at the higher tested concentration (100 lM).\nHowever, compounds 7and8increase the af\ufb01nity for the MAO-A\nreceptor, losing the MAO-B selectivity of the \ufb01rst series. A small\nchange in the structure causes a big change in the af\ufb01nity of the\nmolecules for the receptor. These preliminary results allow us to\nunderstand slightly better interactions between molecule and\nreceptor and the molecular fragments that are essential to main-\ntain and improve the MAO activity and selectivity.\nAs conclusion, it was veri\ufb01ed an important lost of the MAO-B\ninhibitory activity and selectivity when the 3-phenyl skeleton is\nsubstituted for the 3-benzoyl one. However, in some of the 3-ben-\nzoyl derivatives it was shown not only inactivity against MAO-B\nTable 1\nMAO-A and MAO-B inhibitory activity results for the synthesized compounds 1\u20138 and reference inhibitors\nCompounds MAO-A IC 50(lM) MAO-B IC 50(lM) Selectivity Index\n1*83.48x10/C03\u00b1 5.60x10/C03>1,197b\n2*1.35x10/C03\u00b1 0.09x10/C03>74,074b\n3*30.91 \u00b1 2.09 >3.2b\n4 20.74 \u00b1 1.40 16.87 \u00b1 1.14 1.2\n5** \u2014\n6** \u2014\n7 46.81 \u00b1 3.18a73.92 \u00b1 4.99 0.63\n8 19.17 \u00b1 1.29**0.19c\nR-(/C0)-Deprenyl 67.25 \u00b1 1.02a19.60x10/C03\u00b1 0.86x10/C033,431\nIproniazide 6.56 \u00b1 0.76 7.54 \u00b1 0.36 0.87\n*Inactive at 100 lM (highest concentration tested). At higher concentrations compound precipitate.\n**100lM inhibits enzymatic activity around (by approximately) 45\u201350%. At higher concentrations compound precipitate.\naP< 0.05 versus the corresponding IC 50values obtained against MAO-B, as determined by ANOVA/Dunnett\u2019s.\nbValues obtained under the assumption that the corresponding IC 50against MAO-A is the highest concentration tested (100 lM).\ncValue obtained under the assumption that the corresponding IC 50against MAO-B is the highest tested concentration (100 lM).CHO\nOHR1R1\nO O\nR2(a)\n1: R1 = Br, R2 = OMe, R3 = H\n2: R1 = Br, R2 = R3 = OMe\nR2R3\nCOOHR3\nO\nOEtO\nR3\n(c)R1\nO O\nR2\n5: R1 = Br, R2 = OMe, R3 = H\n6: R1 = Br, R2 = R3 = OMeR3O(b)\n3: R1 = Br, R2 = OH, R3 = H\n4: R1 = Br, R2 = R3 = OH\n7: R1 = Br, R2 = OH, R3 = H\n8: R1 = Br, R2 = R3 = OH(d)\nScheme 1. Reagents and conditions: (a) DCC, DMSO, 110 /C176C, 24 h; (b) HI, AcOH,\nAc2O, 0/C176C to re\ufb02ux, 4 h; (c) ethanol, piperidine, re\ufb02ux, 2\u20135 h; (d) BBr 3, DCM, 80 /C176C,\n48 h.M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 4224\u20134227 4225\n142isoenzyme, but showed MAO-A inhibitory activity and selectivity.\nTherefore, selectivity seems to depend on the nature of the couma-\nrins\u2019 substituent. In the present study it was shown that 6-bromo-\n8-methoxy-3-phenylcoumarins are an interesting scaffold for\nMAO-B inhibitory studies, whereas the 6-bromo-8-hydroxy-3-\nbenzoylcoumarins are an interesting moiety for MAO-A inhibitory\nones. Compound 2, with a p-methoxy substituent in the 3-phenyl\nring was the most potent and selective molecule of the \ufb01rst seriesagainst MAO-B isoenzyme, with an IC\n50in the low nanomolar\nrange (IC 50= 1.35 nM). This compound is \ufb01fteen times more active\nand several times more selective than the R-( /C0)-deprenyl\n(IC50= 19.6 nM, reference MAO-B inhibitor). The MAO selectivity\nis an important factor to discriminate the different potential ther-\napeutic applications of these molecules. These \ufb01ndings encourage\nus to continue the efforts towards the optimization of the pharma-cological pro\ufb01le of these structural types as important scaffolds in\nthe neurodegenerative diseases realm.\nAcknowledgments\nThanks to the Spanish Ministry (PS09/00501) and to Xunta de\nGalicia (PGIDIT09CSA030203PR and 10PXIB203303PR). M.J.M.\nthanks FCT for a PhD grant (SFRH/BD/61262/2009). S.V.R. thanks\nto Ministerio de Educaci\u00f3n y Ciencia for a PhD grant (AP2008-\n04263).\nReferences and notes\n1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem.\n2005 ,12, 887.\n2. Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. Front Med. Chem.\n2009 ,4, 23.\n3. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 ,27, 713.\n4. Murray, R. D. H. Prog. Chem. Org. Nat. Prod. 2002 ,83,1 .\n5. Go, M. L.; Wu, X.; Liu, X. L. Curr. Med. Chem. 2005 ,12, 483.\n6. Nowakowska, Z. Eur. J. Med. Chem. 2007 ,42, 125.\n7. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Enzyme Inhib. Med. Chem. 2003 ,18, 63.\n8. Kabeya, L.; Marchi, A.; Kanashiro, A.; Lopes, N.; Silva, C.; Pupo, M.; Lucisano-\nValim, Y. Bioorg. Med. Chem. 2007 ,15, 1516.\n9. Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.; Zunino, F. Bioorg.\nMed. Chem. 2010 ,18, 3543.\n10. Roussaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D. J.; Hamilakis, S. Bioorg.\nMed. Chem. Lett. 2010 ,20, 3889.\n11. Ostrov, D. A.; Hern\u00e1ndez Prada, J. A.; Corsino, P. E.; Finton, K. A.; Le, N.; Rowe, T.\nC.Antimicrob. Agents Chemother. 2007 ,51, 3688.\n12. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.;\nHong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. J. Med. Chem. 2009 ,52, 1486.\n13. Kostova, I. Curr. HIV Res. 2006 ,4, 347.\n14. Rao, Y. K.; Fang, S.; Tzeng, Y. Bioorg. Med. Chem. 2004 ,12, 2679.\n15. Ni, L.; Meng, C. Q.; Sikorski, J. A. Expert Opin. Ther. Pat. 2004 ,14, 1669.\n16. Nielsen, S. F.; Boesen, T.; Larsen, M.; Schonning, K.; Kromann, H. Bioorg. Med.\nChem. 2004 ,12, 3047.\n17.\nChimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.;\nCarradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. J. Med. Chem. 2009 ,52,\n1935.\n18. Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, M.;\nCaccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti,\nA.J. Med. Chem. 2009 ,52, 6685.\n19. Gnerre, C.; Catto, M.; Francesco, L.; Weber, P.; Carrupt, P.-A.; Altomare, C.;\nCarotti, A.; Testa, B. J. Med. Chem. 2000 ,43, 4747.\n20. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;\nUriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268.\n21. Matos, M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053.\n22. Matos, M. J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2010 ,20, 5157.\n23. Delogu, G.; Picciau, C.; Ferino, G.; Quezada, E.; Podda, G.; Uriarte, E.; Vi\u00f1a, D.\nEur. J. Med. Chem. 2011 ,49, 1147.\n24. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yanez,\nM.; Orallo, F.; Ortuso, F.; Alcaro, S. J. Med. Chem. 2009 ,52, 2818.\n25. Santana, L.; Uriarte, E.; Gonz\u00e1lez-D\u00edaz, H.; Zagotto, G.; Soto-Otero, R.; M\u00e9ndez-\n\u00c1lvarez, E. J. Med. Chem. 2006 ,49, 1118.\n26. Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, M.; Vi\u00f1a, D.;\nOrallo, F. J. Med. Chem. 2008 ,51, 6740.\n27. Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.; Soto-Otero, R.;\nM\u00e9ndez-\u00c1lvarez, E.; Carotti, A. J. Med. Chem. 2006 ,49, 4912.\n28. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.\nE.; Mattevi, A. J. Med. Chem. 2007 ,50, 5848.29. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Leonetti, F.; Catto, M.;\nCarrupt, P.; Reist, M. J. Med. Chem. 2006 ,49, 6264.\n30. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U.S.A. 2005 ,102, 12684.\n31. Binda, C.; Li, M.; Hub\u00e1lek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Proc.\nNatl. Acad. Sci. U. S. A. 2003 ,100, 9750.\n32. Dostert, P.; Strolin Benedetti, M.; Jafre, M. In Monoamine Oxidase Basic and\nClinical Frontiers ; Kamijo, K., Usdin, E., Nagausu, T., Eds.; Excerpta Medica:\nAmsterdam, 1982; p 197.\n33. Singer, T. P. F. Muller (Ed.) ; CRC Press: London, 1991. p. 437.\n34. Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. J. Mol.\nBiol. 2004 ,338, 103.\n35. Weyler, W.; Hsu, Y. P.; Breake\ufb01eld, X. O. Pharmacol. Ther. 1990 ,47, 391.\n36. Guay, D. R. Am. J. Geriatr. Pharmacother. 2006 ,4, 330.\n37. Riederer, P.; Danielczyk, W.; Grunblatt, E. Neurotoxicology 2004 ,25, 271.\n38. Youdim, M. B. H.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004 ,111, 1455.\n39. Cesura, A. M.; Pletscher, A. Prog. Drug Res. 1992 ,38, 171.\n40. Rudorfer, M. V.; Potter, V. Z. Drugs 1989 ,37, 713.\n41. Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-Ikola, O.; Palm, R.\nNeurology 2006 ,66, 1200.\n42. General procedure for the preparation of 3-phenylcoumarins ( 1and 2):a\nsolution of the conveniently substituted salicylaldehyde (0.56 mmol) and thecorrespondent phenylacetic acid (0.70 mmol) in DMSO and DCC (0.87 mmol)\nwas heated in an oil-bath at 110 /C176C for 24 h. Triturate ice (20 mL) and acetic\nacid (3.0 mL) were added to the reaction mixture. After keeping it at room\ntemperature for 2 h, the mixture was extracted with ether (3 x 25 mL). The\norganic layer was extracted with sodium bicarbonate solution (50 mL, 5%)\nand then with water (20 mL). The solvent was evaporated under vacuum\nand the dry residue was puri\ufb01ed by FC (hexane/ethyl acetate 9:1) to give\nthe desired compound.\n6-Bromo-8-methoxy-3-phenylcoumarin ( 1): it was obtained with a yield of\n50%. Mp 153\u2013154 /C176C.1H NMR (CDCl 3)d(ppm), J (Hz): 3.97 (s, 3H, \u2013OCH 3),\n7.16 (d, 1H, H-7, J= 2.0), 7.26 (d, 1H, H-5, J= 2.0), 7.43\u20137.48 (m, 3H, H-3\u2019, H-\n4\u2019, H-5\u2019), 7.68\u20137.73 (m, 3H, H-2\u2019, H-6\u2019, H-4).13C NMR (CDCl 3)d(ppm): 57.2,\n117.0, 117.3, 121.9, 122.1, 129.2, 129.8, 130.3, 134.8, 139.1, 142.8, 148.3,160.0. MS m/z(%): 332 (99), 331 (30), 330 (M+, 100), 304 (40), 302 (40), 261\n(25), 259 (26), 194 (16), 165 (12), 153 (14), 152 (88), 151 (23), 102 (19), 76(34). Anal. Calcd for C\n16H11BrO 3: C, 58.03; H, 3.35. Found: C, 58.01; H, 3.30.\n6-Bromo-8-methoxy-3-(4\u2019-methoxyphenyl)coumarin ( 2): it was obtained with\na yield of 53%. Mp 184\u2013185 /C176C.1H NMR (CDCl 3)d(ppm), J (Hz): 3.85 (s, 3H,\n\u2013OCH 3), 3.96 (s, 3H, \u2013OCH 3), 6.93\u20136.96 (m, 2H, H-3\u2019, H-5\u2019), 7.12 (d, 1H, H-7,\nJ= 1.8), 7.23 (d, 1H, H-5, J= 2.0), 7.63\u20137.67 (m, 2H, H-2\u2019, H-6\u2019), 7.69 (s, 1H,\nH-4).13C NMR (CDCl 3)d(ppm): 55.7, 56.8, 114.2, 116.2, 116.8, 121.5, 126.8,\n129.4, 130.2, 130.8, 137.3, 142.2, 147.8, 159.8, 160.6. MS m/z(%): 363 (19),\n362 (M+, 100), 361 (19), 360 (59), 334 (24), 332 (23), 319 (33), 317 (34), 291\n(11), 289 (11), 182 (18), 167 (17), 139 (21), 91 (11). Anal. Calcd forC\n17H13BrO 4: C, 56.53; H 3.63. Found: C, 56.55; H, 3.68.\nGeneral procedure for the preparation of hydroxylated 3-phenylcoumarins ( 3\nand 4). a solution of the corresponding methoxy-3-phenylcoumarin\n(0.50 mmol) in acetic acid (5.0 mL) and acetic anhydride (5.0 mL), at 0 /C176C,\nwas prepared. Hydriodic acid 57% (10.0 mL) was added dropwise. Themixture was stirred under re\ufb02ux temperature for 3 h. The solvent wasevaporated under vacuum and the dry residue was puri\ufb01ed by\nrecrystallization with CH\n3CN.\n6-Bromo-8-hydroxy-3-phenylcoumarin ( 3): it was obtained with a yield of\n61%. Mp 160\u2013161 /C176C.1H NMR (DMSO- d6)d(ppm), J (Hz): 7.19 (d, 1H, H-7,\nJ= 2.0), 7.43\u20137.49 (m, 4H, H-5, H-3\u2019, H-4\u2019, H-5\u2019), 7.70 (dd, 2H, H-2\u2019, H-6\u2019,\nJ= 7.6, J= 1.6), 8.13 (s, 1H, H-4), 10.79 (s, 1H, -OH).13C NMR (DMSO- d6)d\n(ppm): 115.5, 119.9, 120.4, 121.8, 127.9, 128.2, 128.5, 128.8, 134.4, 139.7,\n141.1, 145.6, 159.1. MS m/z(%): 319 (16), 318 (99), 317 (17), 316 (M+, 100),\n291 (12), 290 (78), 289 (13), 288 (81), 153 (22), 152 (51), 151 (12), 76 (25).\nAnal. Calcd for C 15H9BrO 3: C, 56.81; H, 2.86. Found: C, 56.78; H, 2.82.\n6-Bromo-8-hydroxy-3-(4\u2019-hydroxyphenyl)coumarin ( 4): It was obtained with a\nyield of 53%. Mp 249\u2013250 /C176C.1H NMR (DMSO- d6)d(ppm), J (Hz): 6.83 (d,\n2H, H-3\u2019, H-5\u2019, J= 8.8), 7.14 (t, 1H, H-7, J= 1.5), 7.36 (d, 1H, H-5, J= 2.0), 7.56\n(d, 2H, H-2\u2019, H-6\u2019, J= 8.5), 8.00 (s, 1H, H-4).13C NMR (DMSO- d6)d(ppm):\n115.6, 116.0, 119.9, 120.6, 122.5, 125.4, 128.2, 130.4, 138.0, 141.2, 146.0,\n158.6, 159.8. MS m/z(%): 335 (35), 334 (99), 333 (45), 332 (M+, 100), 307\n(31), 306 (99), 305 (35), 304 (99), 225 (26), 197 (29), 169 (35), 168 (46), 153\n(24), 141 (21), 140 (16), 139 (51), 118 (17), 115 (28), 98 (13), 89 (14), 84\n(18), 84 (46), 75 (11), 63 (13). Anal. Calcd for C 15H9BrO 4: C, 54.08; H, 2.72.\nFound: C, 54.00; H 2.69.\nGeneral procedure for the preparation of 3-benzoylcoumarins ( 5and6).T oa\nsolution of the appropriate b-ketoester and the corresponding\nsalicylaldehyde in ethanol was added piperidine in catalytic amount. The\nreaction mixture was re\ufb02uxed for 2\u20135 h and after completion, the reaction\nwas cooled and the precipitated was \ufb01ltered and washed with cold ethanol\nand ether to afford the desired compound. Compounds were further\nrecrystallized in methanol/CH 2Cl2.\n6-Bromo-8-methoxy-3-benzoylcoumarin ( 5): it was obtained with a yield of 49%.\nMp 207\u2013208 /C176C.1H NMR (CDCl 3)d(ppm), J (Hz): 3.82 (s, 3H, \u2013OCH 3), 7.09 (s, 1H,\nH-7), 7.14 (s, 1H, H-5), 7.24\u20137.51 (m, 3H, H-3\u2019, H-4\u2019, H-5\u2019), 7.69 (d, 2H, H-2\u2019, H-6\u2019,\nJ= 7.3), 7.78 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm): 57.2, 116.6, 118.6, 120.5,\n123.0, 128.0, 129.2, 130.0, 134.5, 136.3, 143.3, 144.6, 147.8, 157.8, 191.9. MS m/z\n(%): 360 (18), 359 (M+, 58), 358 (18), 357 (58), 105 (100), 77 (70). Anal. Calcd for\nC17H11BrO 4: C, 56.85; H, 3.09; Found: C, 56.79; H, 3.06.4226 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 4224\u20134227\n1436-Bromo-8-methoxy-3-(4 \u00b4-methoxybenzoyl)coumarin ( 6): It was obtained with\na yield of 90%. Mp 224\u2013225 /C176C.1H NMR (CDCl 3)d(ppm), J (Hz): 3.71 (s, 3H, \u2013\nOCH 3), 3.82 (s, 3H, \u2013OCH 3), 6.77 (d, 2H, H-3\u2019, H-5\u2019, J= 8.9), 7.14\u20137.16 (m, 2H, H-5,\nH-7), 7.69 (d, 2H, H-2\u2019, H-6\u2019, J= 8.9), 7.72 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm):\n55.5, 56.1, 92.8, 95.2, 103.8, 113.7, 121.2, 129.7, 132.1, 141.5, 157.9, 158.3, 159.2,\n163.8, 165.8, 190.6. MS m/z(%): 389 (87), 388 (17), 387 (M+, 90), 135 (100), 77\n(56). Anal. Calcd for C 18H13BrO 5: C, 55.55; H, 3.37. Found: C, 55.53; H, 3.34.\nGeneral procedure for the preparation of hydroxylated 3-benzoylcoumarins ( 7and\n8). To the corresponding methoxy-3-benzoylcoumarin in DCM (1 mmol), BBr 3in\nDCM (20 mmol) was added in a Schlenk tube. Tube was sealed, and the reaction\nmixture was heated at 80 /C176C for 48 h. The resulting crude was treated with MeOH\nand rotated to dryness. The obtained precipitated was recrystallized in MeOH to\nafford the desired hydroxy derivative.\n6-Bromo-8-hydroxy-3-benzoylcoumarin ( 7): it was obtained with a yield of 98%.\nMp 240\u2013242 /C176C.1H NMR (DMSO- d6)d(ppm), J (Hz): 7.29 (d, J= 2.2 Hz, 1H, H-7),\n7.61\u20137.39 (m, 3H, H-3\u2019, H-4\u2019, H-5\u2019), 7.76\u20137.67 (m, 1H, H-5), 7.93 (d, 2H, H-2\u2019, H6\u2019,\nJ= 8.0), 8.30 (s, 1H, H-4), 10.92 (s, 1H, -OH).13C NMR (DMSO- d6)d(ppm): 39.3,\n39.5, 39.7, 39.9, 40.1, 40.4, 40.6, 116.2, 120.9, 121.8, 122.0, 127.8, 129.2, 130.0,\n134.5, 136.3, 142.7, 144.8, 146.3, 157.9, 191.9. MS m/z(%): 345 (46), 343 (M+, 45),\n105 (100), 77 (58). Anal. Calcd for C 16H9BrO 4: C, 55.68; H, 2.63. Found: C, 55.63;\nH, 2.59.\n6-Bromo-8-hydroxy-3-(4 \u00b4-hydroxybenzoyl)coumarin ( 8):it was obtained with a\nyield of 40%. Mp 293\u2013295 /C176C.1H NMR (DMSO- d6)d(ppm), J (Hz): 6.86 (d, 2H, H-\n3\u2019, H-5\u2019, J= 8.7), 7.27 (d, 1H, H-7, J= 2.2), 7.46 (d, 1H, H-5 J= 2.2), 7.82 (d, 2H, H-2\u2019,\nH-6\u2019 J= 8.7), 8.18 (s, 1H, H-4), 10.62 (s, 1H, -OH), 10.89 (s, 1H, -OH).13C NMR\n(DMSO- d6)d(ppm): 115.9, 116.2, 121.0, 121.5, 121.6, 127.6, 128.5, 133.0, 142.7,\n143.5, 146.3, 157.9, 163.6, 190.0. MS m/z(%): 362 (29), 360 (M+, 30), 121 (100), 93\n(16), 65 (15). Anal. Calcd for C 16H9BrO 5: C, 53.21; H, 2.51. Found: C, 52.97; H,\n4.41.\n43. Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. Indian J. Chem., Sect B 1996 ,35B,\n1159.\n44. Mohanty, S.; Makrandi, J. K.; Grover, S. K. Indian J. Chem., Sect B 1989 ,28B, 766.\n45. Kamat, S. P.; D \u00b4Souza, A. M.; Paknikar, S. K.; Beaucahmp, P. S. J. Chem. Research\n(S)2002 , 242.\n46. Brunet, E.; Alonso, M. T.; Juanes, O.; Velasco, O.; Rodr\u00edguez-Ubis, J. C.\nTetrahedron 2001 ,57, 3105.\n47. Frederick, R.; Robert, S.; Charlier, C.; de Ruyck, J.; Wouters, J.; Pirotte, B.;\nMasereel, B.; Pochet, L. J. Med. Chem. 2005 ,48, 7592.48. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Yanez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257.\n49. Mart\u00edn-Santamar\u00eda, S.; Rodr\u00edguez, J. J.; de Pascual-Teresa, S.; Gordon, S.;\nBengtsson, M.; Garrido-Laguna, I.; Rubio-Viqueira, B.; L\u00f3pez-Casas, P. P.;\nHidalgo, M.; de Pascual-Teresa, B.; Ramos, A. Org. Bio. Chem. 2008 ,6, 3486.\n50. Albrecht, M.; Mirtschin, S.; de Groot, M.; Janser, I.; Runsink, J.; Raabe, G.; Kogej,\nM.; Schalley, C. A.; Fr\u00f6hlich, R. J. Am. Chem. Soc. 2005 ,127, 10371.\n51. Determination of human monoamine oxidase (hMAO) isoform activity. The\neffects of the tested compounds on hMAO isoform enzymatic activity wereevaluated by a \ufb02uorimetric method. Brie\ufb02y, 0.1 mL of sodium phosphate buffer\n(0.05 M, pH 7.4) containing the tested drugs in several concentrations andadequate amounts of recombinant hMAO-A or hMAO-B required and adjusted\nto obtain in our experimental conditions the same reaction velocity [165 pmol\nofp-tyramine/min (hMAO-A: 1.1 mg protein; speci\ufb01c activity: 150 nmol of p-\ntyramine oxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-\nB: 7.5 mg protein; speci\ufb01c activity: 22 nmol of p-tyramine transformed/min/\nmg protein)] were placed in the dark \ufb02uorimeter chamber and incubated for15 min at 37 /C176C. The reaction was started by adding (\ufb01nal concentrations)\n200\nlM Amplex\u00d2 Red reagent, 1 U/mL horseradish peroxidase and 1 mM p-\ntyramine. The production of H 2O2and, consequently, of resoru\ufb01n was\nquanti\ufb01ed at 37 /C176C in a multidetection microplate \ufb02uorescence reader\n(FLX800TM, Bio-Tek\u00d2 Instruments, Inc., Winooski, VT, USA) based on the\ufb02uorescence generated (excitation, 545 nm, emission, 590 nm) over a 15 min\nperiod, in which the \ufb02uorescence increased linearly. Control experiments were\ncarried out simultaneously by replacing the tested drugs with appropriate\ndilutions of the vehicles. In addition, the possible capacity of the above tested\ndrugs for modifying the \ufb02uorescence generated in the reaction mixture due to\nnon-enzymatic inhibition (e.g., for directly reacting with Amplex\u00d2 Redreagent) was determined by adding these drugs to solutions containing only\nthe Amplex\u00d2 Red reagent in a sodium phosphate buffer. The speci\ufb01c\n\ufb02uorescence emission (used to obtain the \ufb01nal results) was calculated after\nsubtraction of the background activity, which was determined from vials\ncontaining all components except the hMAO isoforms, which were replaced by\na sodium phosphate buffer solution.\n52. All IC\n50values shown in the table are expressed as means \u00b1 SEM from \ufb01ve\nexperiments.\n53. Y\u00e1\u00f1ez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Comm. 2006 ,344,\n688.M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 4224\u20134227 4227\n144Published: September 18, 2011\nr2011 American Chemical Society 7127 dx.doi.org/10.1021/jm200716y |J. Med. Chem. 2011, 54, 7127 \u20137137ARTICLE\npubs.acs.org/jmc\nSynthesis and Study of a Series of 3-Arylcoumarins as Potent and\nSelective Monoamine Oxidase B Inhibitors\nMaria J. Matos,*,\u2020Carmen Ter /C19an,\u2021Yunierkis P /C19erez-Castillo,\u2021Eugenio Uriarte,\u2020Lourdes Santana,\u2020and\nDolores Vi ~na*,\u00a7\n\u2020Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain\n\u2021Department of Organic Chemistry, Faculty of Chemistry, University of Vigo, 36310 Vigo, Spain\n\u00a7Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain\n\u2019INTRODUCTION\nCoumarins are a wide family of compounds present in\nremarkable amounts in the nature.1,2Representative compounds\noccur for instance in the vegetable kingdom, either in free or\ncombined state.1,2Because of their structural variability, these\nheterocyclic compounds occupy an important role not only in\norganic chemistry but also in medicinal chemistry.3,4Therefore,\ncoumarins have been attracting considerable interest because oftheir numerous biological activities. In the literature, coumarinderivatives have been described as anticancer,\n5antioxidant, or\nanti-in \ufb02ammatory,6vasorelaxant,7antimicrobial,8,9antiviral,10,11\nand enzymatic inhibitors.12/C014In particular, some coumarins had\nbeen previously described as monoamine oxidase inhibitors.15/C017\nMonoamine oxidases (MAOs) are FAD-depending enzymes\nfound in the outer mitochondrial membrane of neuronal, glial,\nand other mammalian cells.18These enzymes are responsible for\ncatalyzing the oxidative deamination of neurotransmitters and\ndietary amines, regulating intracellular levels of biogenic amines\nin the brain and the peripheral tissues.19,20Two enzymatic\nisoforms, named MAO-A and MAO-B, have been identi \ufb01ed on\nthe basis of their amino acid sequences,21three-dimensional\nstructure,22tissue distribution,23inhibitor selectivity,24and sub-\nstrate preferences.25The hMAO-A isoform has a higher a \ufb03nity for\nserotonin and noradrenaline, whereas hMAO-B isoform prefer-entially deaminates \u03b2-phenylethylamines and benzylamine.26,27\nOn the other hand, dopamine and tyramine are common\nsubstrates for both isoforms. These physiologic properties de-\ntermine the clinical interest of MAO inhibitors. Selective MAO-Ainhibitors, such as clorgyline (irreversible) and moclobemide(reversible), are used for the treatment of neurological disorders\nlike depression and anxiety,28while selective and irreversible\nMAO-B inhibitors, such as selegiline and rasagiline, are used inthe therapy of Parkinson \u2019s disease.29,30All of these aspects have\nled to an intensive search for novel MAO inhibitors. Additionally,the description of the crystal structure of the two MAO isoformsby Binda et al. has provided relevant information about the\nselective interactions and the pharmacophoric requirements\nneeded for the design of potent and selective inhibitors.\n31/C034\nIn recent years, interest in selective hMAO-B inhibitors has\nsigni\ufb01cantly intensi \ufb01ed due to the discovery that expression\nlevels of this isoenzyme in neuronal tissue increase 4-fold with\nage, resulting in an increment of dopamine metabolism, as well as\nof production of hydrogen peroxide, which cause oxidative stress\nand may play a relevant role in the etiology of neurodegenerative\ndiseases.35As a result, MAO-B inhibitors would be useful as\nadjuvant for the treatment of Parkinson \u2019s and Alzheimer \u2019s\ndiseases. For instance, it has been reported that selegiline\nprotects neuronal cells from the consequences of the oxidativestress in these patients.36\nIn the past few years, a broad consensus has been reached\nconcerning the necessity for the research of new, more potent,and less toxic MAO-B selective inhibitors. This research has\nresulted in a signi \ufb01cant number of compounds with di \ufb00erent\nReceived: June 6, 2011ABSTRACT: New series of 6-substituted-3-arylcoumarins dis-\nplaying several alkyl, hydroxyl, halogen, and alkoxy groups in the\ntwo benzene rings have been designed, synthesized, and eval-uated in vitro as human monoamine oxidase A and B (hMAO-A\nand hMAO-B) inhibitors. Most of the studied compounds\nshowed a high a \ufb03nity and selectivity to the hMAO-B isoen-\nzyme, with IC\n50values on nanomolar and picomolar range. Ten\nof the 22 described compounds displayed higher MAO-Binhibitory activity and selectivity than selegiline. Coumarin 7\nis the most active compound of this series, being 64 times more\nactive than selegiline and also showing the highest hMAO-B\nspeci\ufb01city. In addition, docking experiments were carried out on\nhMAO-A and h-MAO-B structures. This study provided new information about the enzyme /C0inhibitor interaction and the potential\ntherapeutic application of this 3-arylcoumarin sca \ufb00old.\n1457128 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\nstructural sca \ufb00olds.37/C042Therefore, the coumarin nucleus has\nemerged in the 1990s as a promising sca \ufb00old for MAO\ninhibitors.43Structure /C0selectivity relationship studies about\ncoumarin derivatives suggested that selectivity was mainly de-\nt e r m i n e db yt h en a t u r eo ft h el i n k a g eb e t w e e nt h ec o u m a r i na n dt h e\nlipophilic aryl groups in the position 7.44Therefore, the alkyl-\nsulfonyloxy group provided MAO-A inhibitors like esuprone,\nwhile a benzyloxy substituent led to potent and selective MAO-Binhibitors, such as 7-benzyloxy-3,4-dimethylcoumarin (Figure 1).45\nIn relation to this research, we have previously reported\ninteresting MAO inhibitory properties for several 7-substitutedcoumarins containing a benzene ring fused at 3,4 positions\n(Figure 2).46This condensation, in general, increased the\nMAO-A and MAO-B inhibitory activities, and when an addi-tional acetonyloxy group was present in the 7 position, thisresulted in compounds with very high MAO-B selectivity. These\nresults led us to analyze the importance of the aryl substituent\nunder the pyrone ring and the above-mentioned C7 substituent,\nsynthesizing a series of 3-arylcoumarin derivatives (Figure 2).\nThe substitution at C7 was removed and a smaller substituent\nwas introduced at C6 and the 3,4-condensed benzene ring hasmoved at C3, including di \ufb00erent substituent groups on it.\n47/C049\nThe high MAO-B selectivity found for this new 3-arylcoumarin\nsca\ufb00old encouraged us to synthesize and study the MAO\ninhibitory activity of new analogues, in which a variety of groups\nwith di \ufb00erent size, electronic, and lipophilic properties were\nintroduced in both aromatic rings, in order to clarify the in \ufb02uence\nof the substitution pattern in the MAO inhibitory activity andselectivity of the 3-arylcoumarin skeleton.\nFinally, on the basis of the signi \ufb01cant structural information\ncurrently available on MAOs,50/C052and to analyze the structural\nrequirements for MAO activity and selectivity, docking experi-\nments were carried out on hMAO-A and hMAO-B crystallo-\ngraphic structures.\n\u2019CHEMISTRY\nThe coumarin derivatives 1/C022were e \ufb03ciently synthesized\naccording to the protocol outlined in Scheme 1. The chemical\nstructure of the compounds is organized in Table 1. The general\nreaction conditions and the compounds characterization are\ndescribed in the Experimental Section.\nPerkin condensation of di \ufb00erent ortho -hydroxybenzaldehydes\nwith the adequate arylacetic acid, using N,N0-dicyclohexyl-\ncarbodiimide (DCC) as dehydrating agent,47,48a\ufb00ordedthe 3-arylcoumarins 1,2, and 6/C014. The treatment of the\n3-(methoxyphenyl)-6-methylcoumarins 9,4710,4812,a n d 14with\nN-bromosuccinimide (NBS), in carbon tetrachloride (CCl 4), under\nre\ufb02ux, using 2,20-azo-bis-iso-butyronitrile (AIBN) as catalyst,49\na\ufb00orded the bromomethoxy derivatives 15/C018. In addition, com-\npounds 3,19/C021were obtained by acidic hydrolysis of the respec-\ntive methoxy derivatives 2,9,10,a n d 11, using hydriodic acid\n57% in the presence of acetic acid and acetic anhydride.48\nFinally, the Williamson reaction45of the hydroxycoumarin 3\nwith chloroacetone or cyclopentyl bromide, gave the corre-\nsponding ethers 4and5, respectively. The Williamson reaction\nof the hydroxycoumarin 20with a chloroacetone gave the\ncorresponding derivative 22.\n\u2019BIOCHEMISTRY\nThe biological evaluation of the test drugs on hMAO activity\nwas investigated by measuring their e\ufb00 ects on the production of\nhydrogen peroxide (H 2O2) from p-tyramine (a common sub-\nstrate for h-MAO-A and hMAO-B), using the Amplex Red MAO\nassay kit (Molecular Probes, Inc., Eugene, Oregon, USA) and\nmicrosomal MAO isoforms prepared from insect cells (BTI-TN-\n5B1/C04) infected with recombinant baculovirus containing\ncDNA inserts for hMAO-A or hMAO-B (Sigma-Aldrich Qu\u00edmica\nSA, Alcobendas, Spain) were used as source for the two micro-\nsomal MAO isoforms.53The production of H 2O2catalyzed by\nthe two MAO isoforms can be detected using 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent), a non \ufb02uores-\ncent and highly sensitive probe that reacts with H\n2O2in the\npresence of horseradish peroxidase to produce a \ufb02uorescent\nproduct, resoru \ufb01n. New compounds and reference inhibitors\nwere unable to react directly with the Amplex Red reagent, whichindicates that these drugs do not interfere with the measure-ments. On the other hand, in our experiments and under our\nexperimental conditions, hMAO-A displayed a Michaelis con-\nstant ( K\nm) equal to 457.17 (38.62 \u03bcM and a maximum reac-\ntion velocity ( Vmax) in the control group of 185.67 (12.06\n(nmol p-tyramine/min)/mg protein, whereas hMAO-B showed\naKmof 220.33 (32.80 \u03bcMa n d Vmaxof 24.32 (1.97\n(nmol p-tyramine/min)/mg protein ( n= 5). Most tested\ncompounds, concentration-dependently inhibited this enzy-\nmatic control activity (Table 1).\n\u2019DOCKING STUDIES\nTo obtain information about enzyme /C0inhibitor interactions\nthat help us to explain the structural requirements for MAOactivity and selectivity of 3-arylcoumarin sca \ufb00old, a docking study\nwas performed. The crystallographic structure of MAO-B in\ncomplex with a coumarin inhibitor (pdb code 2V61)52and of\nMAO-A in complex with harmine (pdb code 2ZX5)51were used\nto dock the derivates under study. The docking simulations were\ncarried out using the DOCK v. 6.3 package.54\nTo validate our docking protocol, we used the 7-(3-chloro-\nbenzyloxy)-4-[(methylamino)methyl]coumarin cocrystallized\nwith the MAO-B enzyme,52as well as two other MAO inhibitors\n(3-[(4- \ufb02uorophenyl)carbamoyl]coumarin and 3-[(4-methane-\nsulfonylphenyl)carbamoyl]coumarin), all of them previouslysubjected to molecular modeling studies and having bulky\nsubstituents at the 3-position as is the case for the new coumarin\nderivates reported in our manuscript (Figure 3).15\nAlthough the proposed docking methodology is able to\nreproduce the crystallographic orientation of the MAO-B\nFigure 1. Coumarin-based MAO-A and MAO-B inhibitors.\nFigure 2. Planed modi \ufb01cations and newly synthesized coumarins.\n1467129 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\ncoumarinic inhibitor (pdb code 2V61), the successful redocking\nof the crystallographic inhibitor does not warrant a realistic\nbinding prediction of the new inhibitors proposed. To studywhether our methodology is able or not to reproduce the\npreviously described binding mode of noncrystallographic in-\nhibitors, we redocked the last two above-mentioned compounds.\nThis yielded that the obtained binding modes are in agreement\nwith the results previously reported by Chimenti et al.15\nDuring the validation of the docking protocol, we also\nincluded 3, 5, and 6 structural water molecules in the receptorstructure, yielding similar scoring and orientations for the\ncompounds as in the water depleted receptor structure. This is\nthe main reason we did not use any structural water molecule in\nthe modeling of the compounds included in the paper. Further-\nmore, the use of the water depleted receptor would allow the\nligands to explore the lower region of the binding pocket. In this\nway, the docking algorithm is able to explore orientations of the\ninhibitors with the 3-substituent oriented to the upper subpocket\nand to the FAD cofactor. Despite the fact that water molecules\nwere not considered during the ligands orientation step, thepredicted poses were rescored using the DOCK Amber-based\nscoring function, which takes into account the solvent e \ufb00ect\nusing a continuous solvent model and account for small structur-\nal rearrangements on the predicted complexes structures.55,56\nThese results support the use of our protocol for the predictionand analysis of the binding mode of the coumarin derivativesdescribed in this study.\nThe molecular docking studies were done for di \ufb00erent com-\npounds of the studied series. Although we mainly focused thepresent results on two representative compounds, the coumarin\nderivatives 9and10, with substituents in para andmeta positions\n(Figure 4). They interact with the isoenzyme in the well-known\nbinding pocket,\n32,33,50,52with the substituent at C6 pointing to\nthe FAD cofactor, Phe343, and Tyr60. The coumarin ring is\noriented toward the bottom of the substrate cavity, interacting\nwith the FAD cofactor as well as with Tyr398, Tyr435, andGln206 through van der Waals and hydrophobic interactions,\nincluding \u03c0/C0\u03c0interactions with these tyrosine residues.\nIn addition, the predicted orientation of the coumarin moiety\nallows the interaction of its oxygen atoms of the coumarin moietyScheme 1a\naReagents and conditions: (i) substituted phenylacetic acid, DCC, DMSO, 110 /C176C, 24 h; (ii) HI, AcOH, Ac 2O, re\ufb02ux, 3 h; (iii) chloroacetone, K 2CO 3,\nacetone, re \ufb02ux, 16 h; (iv) cyclopentyl bromide, K 2CO 3, acetone, re \ufb02ux, 24 h; (v) NBS, AIBN, CCl 4,r e\ufb02ux, 18 h.\n1477130 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\nwith Cys172, showing a favorable geometry for the formation\nof hydrogen bonds between the ligand and the receptor.\nMoreover, the coumarin core also interacts with Ile198,\nIle199, and Leu171. Finally, the substituted 3-phenyl ring is\noriented to an entrance cavity, an hydrophobic subpocketexisting only in the MAO-B isoform, which is de \ufb01ned by\nLeu171, Ile199, Tyr326, Phe168, Ile316, Trp119, Pro102, andPro104. This is probably one explanation to the MAO-Bselectivity of the described compounds.\n\u2019RESULTS AND DISCUSSION\nAll described coumarins in this report (compounds 1/C022)\nwere e \ufb03ciently synthesized and evaluated for their ability toTable 1. Structure and hMAO Inhibitory Activity in Vitro of the 3-Arylcoumarin Derivatives 1 /C022 and Reference Compoundsa\ncompd R R20R30R40R50IC50hMAO-A ( \u03bcM) IC 50hMAO-B SId\n1 OCH 3 HC H 3 HH b 17.05(0.88 nM >5882e\n2 OCH 3 HH C H 3 H b 1.52(0.08 nM >6789e\n3 OH H H CH 3 H 24.90(1.33 67.10(2.99 nM 372\n4 C3H5O2 HH C H 3 H b 5.52(0.29\u03bcM >18e\n5 C5H9OH H C H 3 H b 14.47(0.78\u03bcM >6.9e\n6 CH 3 HH HH b 283.75(19.90 nM >352e\n7 CH 3 HH C H 3 H b 0.31(0.02 nM >333333e\n8 CH 3 HC H 3 HH c 15.01(0.83 nM >6667e\n9 CH 3 H H OCH 3 H b 13.05(0.90 nM >7663\n10 CH 3 H OCH 3 HH b 0.80(0.05 nM >125000\n11 CH 3 OCH 3 HH H bb\n12 CH 3 H OCH 3 H OCH 3 b 8.98(1.42 nM >11136e\n13 CH 3 H OCH 3 OCH 3 H 25.14(1.68 2.73(0.12 nM 9209\n14 CH 3 H OCH 3 OCH 3 OCH 3 b 160.64(1.01 nM >623e\n15 CH 3 H Br OCH 3 H b 0.74(0.02 nM >135870e\n16 CH 3 H OCH 3 Br H b 3.25(0.17 nM >31250e\n17 CH 3 Br OCH 3 H OCH 3 b 54.03(3.91\u03bcM >1.9e\n18 CH 3 Br OCH 3 OCH 3 OCH 3 bb\n19 CH 3 H H OH H b 155.59(17.09 nM >643e\n20 CH 3 H OH H H 35.04(1.88 650.03 (34.82 nM 54\n21 CH 3 OH H H H 21.58(1.16 120.02 (6.43 nM 180\n22 CH 3 HC 3H5O2 HH c 180.04(9.65 nM >555e\nSelegiline 67.25(1.02 19.60 (0.86 nM 3431\nIproniazide 6.56(0.76 7.54 (0.36\u03bcM 0.87\naEach IC 50value is the mean (SEM from \ufb01ve experiments ( n= 5).bInactive at 100 \u03bcM (highest concentration tested), at higher concentrations the\ncompounds precipitate.c100\u03bcM inhibits the corresponding hMAO activity by approximately 40 /C045%, at higher concentrations the compounds\nprecipitate.dSelectivity index: MAO-B selectivity ratios [IC 50(MAO-A)]/[IC 50(MAO-B)] for inhibitory e \ufb00ects of both new compounds and reference\ninhibitors.eValues obtained under the assumption that the corresponding IC 50against MAO-A is the highest concentration tested (100 \u03bcM).\nFigure 3. Compounds used to validate the docking protocol.\n1487131 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\ninhibit the A and B isoforms of hMAO. The corresponding IC 50\nvalues and MAO-B selectivity ratios [IC 50(MAO-A)]/[IC 50\n(MAO-B)] are shown in Table 1. The chemical structures of the\nnewly designed compounds, as well as the biological and docking\nresults, can help us with an interesting SAR study. From the\nexperimental results, it can be observed that most of the tested\ncompounds are selective inhibitors toward MAO-B, with IC 50values in the low micro, nano, and picomolar range. Ten of the 22\ntested compounds have similar or better IC 50than the selegiline\n(IC 50= 19.60 nM, reference MAO-B inhibitor). Two of the most\nactive compounds are the coumarin derivatives 7and10, with\nIC50against hMAO-B of 0.31 and 0.80 nM, respectively. Both\ncompounds 7and10arepara ormeta substituted in the 3-phenyl\nring with a methyl or a methoxy group, respectively. With the aim\nFigure 4. Molecular docking studies of coumarin derivatives 9and10. Most stable binding poses of compound 10(a) and 9(b) into MAO-B binding\nsite, and compound 10(c) into MAO-A binding site. Compounds are colored by atom type, and predicted H-bonds are represented as green\npseudobonds. Superposition of binding poses of compound 10(d) to both isoenzymes, MAO-A (ligand and Phe208 in magenta), and MAO-B.\n1497132 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\nof introducing a group with di \ufb00erent physicochemical properties\nunder the 3-phenyl ring of the coumarin moiety, we have\nbrominated the di \ufb00erent 3-methoxyphenyl derivatives. There-\nfore, compound 15has the para andmeta positions substituted\nwith a methoxy and a bromo groups, respectively. This com-pound proved to be one of the three most active compounds,\nwith IC\n50against hMAO-B of 0.74 nM. This new substitution\nmakes this compound a better MAO-B inhibitor than the\ncorresponding derivative without the bromo atom, compound\n9, with an IC 50of 13.05 nM. On the other hand, compound 16,\nwith the para andmeta positions substituted with a bromo and a\nmethoxy groups, respectively, seems to lose MAO-B inhibitory\nactivity. So, we can infer that the presence of an electron donor\nat the para position is an important modi \ufb01cation to improve\nthe activity. From the biological data, the coumarin 7, with a\np-methyl substituent in the 3-phenyl ring and a 6-methyl sub-\nstituent in the coumarin aromatic ring, was the most potent and\nselective one against MAO-B isoenzyme. This compound was 63\ntimes more active than the selegiline, resulting also much more\nselective than it (selectivity MAO-B index >333333).\nThe activity data of new reported compounds point out that\nalmost all the substitutions at ortho position of the 3-phenyl ring\nseem to be unfavorable for the activity. Compounds 11and18,\nwith a methoxy or a bromo substituent, respectively, at the ortho\nposition are inactive at 100 \u03bcM (highest concentration tested).\nThe corresponding compound 14, compared with compound 18\nbut without the ortho -bromo atom, has an activity in the\nnanomolar range. Compound 17, also with a bromo atom at\northo position, has an MAO-B inhibitory activity in the high\nmicromolar range, while their correspondent nonbrominated\ncompound 12, with a \u201cfree\u201dortho position, has an activity against\nMAO-B in the low nanomolar range. It seems clear that the\npresence of di \ufb00erent substituents in the ortho position annulated\nor strongly decreased the inhibitory MAO-B activity. An excep-\ntion occurs when the ortho position is substituted with a hydroxyl\ngroup (compound 21). In this case, the methoxy derivative\n(compound 11) has no activity against MAO-B and the hydroxyl\none has an IC 50in the nanomolar range. This is going to be\nexplained later in the discussion of the Docking Studies. More-\nover, inhibitory MAO-B activity increases when the smalllipophilic groups (methoxy or methyl) are included at meta or\npara positions. Nevertheless, the dimethoxy-substituted com-\npound 13is less active than the meta-monosubstituted one\n(compound 10). In addition, a hydroxyl group incorporated in\npara-o rmeta-positions of the phenyl ring of the moiety seems to\nbe less favorable for the MAO-B inhibition than a methoxy ormethyl group at the same position, as it can be seen by comparing\nthe IC\n50values of compounds 7/C010with those of compounds\n19and20, respectively. Finally, a methyl group in the 6 position\nof the coumarin moiety (compound 7) provides better MAO-B\ninhibitory activity than a methoxy group (compound 2)o ra\nhydroxyl group (compound 3). Also, bulkier alkoxy substituents\nat C6, such as an 2-oxopropoxy group (compound 4)o ra\ncyclopentyloxy group (compound 5), signi \ufb01cantly reduced the\nactivity, being better tolerated in the 3-phenyl ring, in particular\nin the meta position (compound 22). Almost all the studied\ncompounds with substituents in the 3-phenyl ring proved to bemost active against the MAO-B than the nonsubstituted 6-methyl-\n3-phenylcoumarin 6(IC\n50= 283 nM). Compounds substituted in\ntheortho position (excepting compound 21, already mentioned),\ncompound 20and compounds bulky substituted (compounds 4\nand5) in position 6 were the only exception.On the basis of the docking results, the proposed binding\nmode for this series of compounds in the pocket of hMAO-B isconsistent with the observation that only small substituents are\ntolerated at position 6, as can be seen analyzing the results of thecompounds 4and5. The increase in the size of substituents at C6\nresults in a disruption of the proposed binding mode because partof the space occupied by the coumarin ring will be used by thisbulky substituent, resulting in the loss of the key interactions to\nstabilize the ligand /C0enzyme complex.\nAdditionally, the poses predicted by the docking simulations\nshow a small angle between the planes de \ufb01ned by the coumarin\nand the 3-phenyl ring. These conformations, which are stericallyprohibited when a methoxy group is included at 2\n0position of the\n3-phenyl ring, are however permitted for a hydroxyl group at the\nsame position. These conformational changes can explain why\ntheortho position substitutions of the 3-phenyl ring considerably\ndecreased or abolished the activity and why the compound 21\nhas activity against MAO-B, whereas the corresponding methoxyderivative 11is inactive at the highest tested concentration\nagainst the same enzyme (Table 1). Moreover, the docking\nresults indicate that a substituent at para-o rmeta-position of the\n3-phenyl ring makes the compound occupy the above-men-\ntioned hydrophobic subpocket (Figure 4a and 4b).\nFinally, the comparison between the predicted binding mode\nof compound 10to MAO-A (Figure 4c) with its binding mode to\nMAO-B (Figure 4d) corroborates that entrance cavity only exits\nin MAO-B because in MAO-A its formation is prevented by thepresence of the Phe208 residue instead of the Ile199 present in\nthe same position of MAO-B.\nOn the basis of the docking studies information, the high\nMAO-B selectivity of these series of compounds could beexplained by taking into account two factors: the ability of the\ncompounds to recognize and exploit the entrance cavity in\nMAO-B and the fact that, according to predicted binding mode,in MAO-A these compounds should occupy a more distant\nposition into the binding pocket to \ufb01t in the cavity and interact\nwith the binding points (ligand in magenta ball and sticks,\nFigure 4d). This movement to a deeper region in the cavity\nresults in the displacement of some water molecules conserved in\nthe X-ray structures of the MAOs, which is not necessary for thebinding to MAO-B, according to the proposed models. This\ndisplacement of the water molecules is an energetically expensive\nprocess that negatively in \ufb02uences the formation of stable com-\nplexes between the inhibitors and MAO-A.\n\u2019CONCLUSION\nIn this paper, we have used the Perkin reaction as a key step of\na good methodology for the e \ufb03cient and general synthesis of a\nselected series of 3-arylcoumarins. Most of the studied com-pounds show a high a \ufb03nity and selectivity for the MAO-B\nisoenzyme. Several compounds of these series proved to have\nmuch higher MAO-B inhibitory activity and selectivity than the\nselegiline. The docking studies performed on these compoundsshow that their interactions with the MAO-B binding pocket are\nmore intense than those with the MAO-A one. The docking\nresults are in accord with the biological data and allowed us to\nsupport an interesting SAR study. Additionally, all the resultsshow that a small substitution at C6 (methyl or methoxy groups)\nof the coumarin core seems to be important when a phenyl group\nis located at C3. A bulkier group at C6 (compounds 4and5)\ndrastically decreases the MAO-B inhibitory activity. With a small\n1507133 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\nsubstituent at C6, both kind and position of substituents included\nin the 3-aryl group play a crucial role in activity and selectivity.\nMeta andpara substituents were the most favorable positions for\nthe desired activity. Currently, further research is going to be\nconducted on the 3-arylcoumarin sca \ufb00old as potential agents for\nthe treatment of Parkinson \u2019s disease.\n\u2019EXPERIMENTAL SECTION\nChemistry. Melting points were determined using a Reichert Kofler\nthermopan or in capillary tubes on a B \u20acuchi 510 apparatus and are\nuncorrected. IR spectra were recorded on a Perkin-Elmer 1640FT\nspectrophotometer.1H and13C NMR spectra were recorded on a\nBruker AMX spectrometer at 300 and 75.47 MHz, respectively, usingTMS as internal standard (chemical shifts in \u03b4values, Jin Hz). Mass\nspectra were obtained using a Hewlett-Packard 5988A spectrometer.Elemental analyses were performed using a Perkin-Elmer 240B micro-analyser and were within (0.4% of calculated values in all cases. Silica gel\n(Merck 60, 230 /C000 mesh) was used for flash chromatography (FC).\nAnalytical thin layer chromatography (TLC) was performed on platesprecoated with silica gel (Merck 60 F254, 0.25 mm). The purity of\ncompounds 1/C022was assessed by HPLC and was found to be higher\nthan 95%.\nGeneral Procedure for the Preparation of 3-Phenylcou-\nmarins (1, 2, 6 /C014). A solution of 2-hydroxy-6-methylbenzaldehyde/\n2-hydroxy-6-methoxybenzaldehyde (7.34 mmol) and the corresponding\nphenylacetic acid (9.18 mmol) in dimethyl sulfoxide (15 mL) wasprepared. N,N\n0-Dicyclohexylcarbodiimide (11.46 mmol) was added,\nand the mixture was heated in an oil bath at 110 /C176C for 24 h. Ice\n(100 mL) and acetic acid (10 mL) were added to the reaction mixture.After keeping it at room temperature for 2 h, the mixture was extractedwith ether (3 /C225 mL). The organic layer was extracted with sodium\nbicarbonate solution (50 mL, 5%) and then water (20 mL). The solventwas evaporated under vacuum, and the dry residue was purified by FC(hexane/ethyl acetate 9:1).\n6-Methoxy-3-(3-methylphenyl)coumarin ( 1).Yield 79%; mp 98/C0\n99/C176C.\n1H NMR (CDCl 3) 2.46 (s, 3H, /C0CH 3), 3.90 (s, 3H, /C0OCH 3),\n7.01 (d, 1H, H-5, J= 2.8), 7.14 (dd, 1H, H-7, J= 9.0, J= 2.9), 7.25 /C07.41\n(m, 3H, H-50, H-40, H-8), 7.50 /C07.54 (m, 2H, H-20, H-60), 7.79 (s, 1H,\nH-4).13C NMR (CDCl 3) 21.5, 55.8, 109.9, 117.4, 119.0, 120.0, 125.7,\n128.3, 128.8, 129.2, 129.6, 134.7, 138.0, 139.6, 147.9, 156.1, 160.7. MSm/z267 ([M + 1]\n+, 30), 266 (M+, 100), 238 (38), 195 (25), 167 (14),\n165 (17), 152 (24). Anal. Calcd for C 17H14O3: C, 76.68; H, 5.30. Found:\nC, 76.72; H, 5.38.\n6-Methoxy-3-(4-methylphenyl)coumarin ( 2).Yield 76%; mp 130 /C0\n131 /C176C.1H NMR (CDCl 3) 2.40 (s, 3H, /C0CH 3), 3.86 (s, 3H, /C0OCH 3),\n7.01 (d, 1H, H-7, J= 3.9), 7.13 /C07.17 (m, 2H, H-5, H-8), 7.30 /C07.35 (m,\n2H, H-30, H-50), 7.65 (d, 2H, H-20, H-60,J= 8.1), 7.78 (s, 1H, H-4).13C\nNMR (CDCl 3) 21.3, 55.8, 109.8, 117.4, 118.9, 120.1, 128.4, 128.6,\n129.2, 131.9, 138.9, 139.0, 147.9, 156.1, 160.8. MS m/z267 ([M + 1]+,\n20), 266 (M+, 100), 238 (25), 195 (18), 165 (9), 152 (16). Anal. Calcd\nfor C 17H14O3: C, 76.68; H, 5.30. Found: C, 76.67; H, 5.23.\n6-Methyl-3-(4-methylphenyl)coumarin ( 7).Yield 72%; mp: 139 /C0\n140 /C176C.1H NMR (CDCl 3) 2.40 (s, 6H, ( /C0CH 3)2), 7.21 /C07.30 (m, 5H,\nH-5, H-7, H-8, H-30, H-50), 7.60 (d, 2H, H-20, H-60,J= 8.2), 7.72 (s, 1H,\nH-4).13C NMR (CDCl 3) 21.1, 21.6, 116.4, 119.7, 127.9, 128.4, 128.7,\n129.4, 132.2, 132.5, 134.3, 139.0, 139.4, 139.5, 151.8, 161.2. MS m/z251\n([M + 1]+, 32), 250 (M+, 100), 222 (56), 221 (24), 178 (27), 150 (12),\n136 (12), 124 (19). Anal. Calcd for C 17H14O2: C, 81.58; H, 5.64. Found:\nC, 81.52; H, 5.60.\n6-Methyl-3-(3-methylphenyl)coumarin ( 8).Yield 75%; mp 84/C0\n85/C176C.1H NMR (CDCl 3) 2.39 (s, 6H, /C0(CH 3)2), 6.98 /C07.02 (m,\n3H, H-40, H-7, H-8), 7.13 /C07.24 (m, 4H, H-20, H-5, H-50, H-60), 7.72 (s,\n1H, H-4).13C NMR (CDCl 3) 20.8, 21.5, 116.1, 119.4, 125.6, 127.6,128.3, 129.2, 129.5, 132.3, 134.1, 134.8, 138.0, 139.5, 139.8, 151.6, 160.8.MSm/z251 ([M + 1]\n+, 27), 250 (M+, 100), 222 (72), 221 (39), 178\n(32), 150 (10), 136 (10), 124 (10). Anal. Calcd for C 17H14O2: C, 81.58;\nH, 5.64. Found: C, 81.56; H, 5.62.\nGeneral Procedure for the Preparation of 3-(Bromometh-\noxyphenyl)coumarins (15 /C018). A solution of 3-(methoxyphenyl)-\ncoumarins (3.76 mmol), NBS (4.51 mmol), and AIBN (cat.) in CCl 4\n(5 mL) was stirred under reflux for 18 h. The resulting solution was filtered\nto remove the succinimide. The solvent was evaporated under vacuumand purified by flash chromatography (hexane/ethyl acetate 95:5).\n3-(3-Bromo-4-methoxy phenyl)-6-methylcoumarin ( 15).Yield: 41%;\nmp 206/C0 207 /C176C.\n1H NMR (CDCl 3) 2.42 (s, 3H, /C0CH 3), 3.94 (s, 3H,\n/C0OCH 3), 6.97 (d, 1H, H-50J= 8.7), 7.23 /C07.35 (m, 3H, H-20, H-60,\nH-5), 7.69 /C07.74 (m, 2H, H-7, H-8), 7.89 (s, 1H, H-4).13C NMR\n(CDCl 3) 20.8, 56.3, 111.5, 111.6, 116.1, 119.3, 126.3, 127.6, 128.5,\n129.0, 132.5, 133.1, 134.2, 139.1, 151.5, 156.2, 160.6. MS m/z(%) 347\n(18), 346 (98), 345 ([M + 1]+, 19), 344 (M+, 100), 303 (45), 301 (45),\n275 (11), 250 (17), 222 (13), 194 (11), 178 (13), 165 (58), 163 (11),\n139 (15), 132 (42), 82 (18), 76 (14), 63 (19), 50 (14). Anal. Calcd for\nC17H13BrO 3: C, 59.15; H, 3.80. Found: C, 59.10; H, 3.72.\n3-(4-Bromo-3-methoxy phenyl)-6-methylcoumarin ( 16).Yield: 51%;\nmp 139/C0 140 /C176C.1H NMR (CDCl 3) 2.49 (s, 3H, /C0CH 3), 3.89 (s, 3H,\n/C0OCH 3), 6.49 (dd, 1H, H-7, J= 7.4, J= 1.3), 7.08 /C07.12 (m, 3H, H-20,\nH-60, H-8), 7.32 /C07.42 (m, 2H, H-5, H-50), 7.74 (s, 1H, H-4).13C NMR\n(CDCl 3) 33.1, 55.4, 114.2, 114.7, 117.1, 119.7, 120.9, 126.8, 128.2,\n128.7, 129.6, 132.2, 134.3, 135.7, 139.4, 153.2, 159.5. MS m/z(%) 346\n(45), 345 ([M + 1]+, 10), 344 (M+, 100), 266 (49), 265 (45), 238 (24),\n237 (67), 194 (42), 165 (29), 133 (28). Anal. Calcd for C 17H14O2:C ,\n59.15; H, 3.80. Found: C, 59.17; H, 3.83.\n3-(2-Bromo-3,5-dimethoxyphenyl)-6-methylcoumarin ( 17).Yield:\n46%; mp 178 /C0179 /C176C.1H NMR (CDCl 3) 2.40 (s, 3H, /C0CH 3), 3.79 (s,\n3H,/C0OCH 3), 3.87 (s, 3H, /C0OCH 3), 6.51 (s, 2H, H-40, H-60),\n7.26/C07.33 (m, 3H, H-5, H-7, H-8), 7.60 (s, 1H, H-4).13C NMR\n(CDCl 3) 20.8, 55.6, 56.4, 100.1, 104.3, 107.4, 116.4, 118.7, 127.9, 129.0,\n132.8, 134.2, 137.6, 142.3, 152.1, 157.0, 159.7. MS m/z(%) 377 (42),\n376 ([M + 1]+, 18), 375 (M+, 100), 282 (59), 279 (14), 239 (11) 208\n(9), 152 (10), 118 (9), 58 (12). Anal. Calcd for C 18H15BrO 4: C, 57.62;\nH, 4.03. Found: C, 57.61; H, 4.08.\n3-(2-Bromo-3,4,5-trimethoxyphenyl)-6-methylcoumarin ( 18).Yield:\n50%; mp 167 /C0168 /C176C.1H NMR (CDCl 3) 2.40 (s, 3H, /C0CH 3), 3.83 (s,\n3H,/C0OCH 3), 3.90 (s, 6H, /C0(OCH 3)2), 6.72 (s, 1H, H-60), 7.25 (d, 1H,\nH-8, J= 8.4), 7.29 (d, 1H, H-5, J= 1.9), 7.34 (dd, 1H, H-7, J= 8.4, J=\n2.0), 7.63 (s, 1H, H-4).13C NMR (CDCl 3) 20.8, 55.6, 61.1, 61.1, 110.1,\n110.4, 116.4, 118.7, 127.8, 128.4, 131.2, 132.9, 134.3, 142.7, 143.4, 151.2,\n152.0, 152.7, 160.1. MS m/z(%) 408 (32), 407 ([M + 1]+, 12), 406 (M+,\n68), 404 (5) 326 (22), 325 (59), 282 (15), 264 (15) 169 (9), 139 (10).Anal. Calcd for C\n19H17BrO 5: C, 56.31; H, 4.23. Found: C, 56.38;\nH, 4.28.\nGeneral Procedure for the Preparation of Hydroxy-3-\nphenylcoumarins (3, 20 /C021). A solution of substituted 6-meth-\noxy-3-phenylcoumarin (0.50 mmol) in acetic acid (5 mL) and aceticanhydride (5 mL), at 0 /C176C, was prepared. Hydriodic acid 57% (10 mL)\nwas added dropwise. The mixture was stirred, under reflux temperature,\nfor 3 h. The solvent was evaporated under vacuum, and the dry residue\nwas purified by CH\n3CN crystallization.\n6-Hydroxy-3-(4-methylphenyl)coumarin ( 3).Yield 61%; mp 214/C0\n215 /C176C.1H NMR (DMSO- d6) 2.32 (s, 3H, /C0CH 3), 7.01 (d, 1H, H-7, J=\n8.8,J= 2.9), 7.07 (d, 1H, H-5, J= 2.8), 7.21 /C07.26 (m, 3H, H-30, H-50,\nH-8), 7.59 (d, 2H, H-20, H-60,J= 8.1), 8.08 (s, 1H, H-4), 9.77 (s, 1H,\n/C0OH).13C NMR (DMSO- d6) 21.3, 113.0, 117.1, 120.0, 120.5, 127.2,\n128.8, 129.2, 132.3, 138.5, 140.4, 146.7, 154.2, 160.5. MS m/z(%) 253\n([M + 1]+, 51), 252 (M+, 100), 225 (35), 224 (96), 223 (62) 195 (13),\n181 (17), 165 (19), 152 (31), 139 (10), 125 (15), 115 (15). Anal. Calcd\nfor C 16H12O3: C, 76.18; H, 4.79. Found: C, 76.11; H, 4.77.\n1517134 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\n3-(3-Hydroxyphenyl)-6-methylcoumarin ( 20).Yield 53%; mp 160 /C0\n161 /C176C.1H NMR (DMSO- d6) 2.32 (s, 3H, /C0CH 3), 6.77 (dd, 1H, H-40,\nJ= 7.1, J= 2.4), 7.05 /C07.07 (m, 2H, H-5, H-8), 7.21 /C07.25 (m, 2H, H-50,\nH-60), 7.38 (dd, 1H, H-7, J= 8.5, J= 1.8), 7.50 (s, 1H, H-20), 8.08 (s, 1H,\nH-4), 9.52 (s, 1H, /C0OH).13C NMR (DMSO- d6) 20.8, 115.9, 116.1,\n119.6, 127.3, 128.7, 129.7, 133.0, 134.2, 136.4, 140.8, 151.5, 157.5, 160.2.\nMSm/z254 (12), 253 ([M + 1]+, 63), 252 (M+, 73), 251 (15), 225 (46),\n223 (53), 195 (33), 194 (18), 181 (29), 178 (17), 166 (12), 165 (42),\n152 (43), 139 (13), 126 (24), 111 (19), 63 (16), 51 (16). Anal. Calcd for\nC16H12O3: C, 76.18; H, 4.79. Found: C, 76.20; H, 4.83.\n3-(2-Hydroxyphenyl)-6-methylcoumarin ( 21).Yield 56%; mp 167 /C0\n168 /C176C.1H NMR (DMSO- d6) 2.38 (s, 3H, /C0CH 3), 6.30 /C06.35 (m, 2H,\nH-30, H-50), 7.22 /C07.24 (d, 1H, H-5, J= 1.5), 7.29 /C07.31 (m, 2H, H-40,\nH-60), 7.34 (d, 1H, H-8, J= 8.4), 7.44 (dd, 1H, H-7, J= 8.4, J= 1.5), 7.97\n(s, 1H, H-4), 9.60 (s, 1H, /C0OH).13C NMR (DMSO- d6) 20.3, 115.6,\n118.7, 119.0, 122.3, 125.9, 128.0, 129.6, 130.8, 132.3, 133.6, 141.8, 151.2,\n155.0, 159.5. MS m/z253 ([M + 1]+, 18), 252 (M+, 100), 251 (10), 234\n(12), 223 (58), 195 (35), 194 (5), 181 (18), 165 (17), 152 (18), 126 (5),\n63 (6), 51 (6). Anal. Calcd for C 16H12O3: C, 76.18; H, 4.79. Found: C,\n76.20; H, 4.81.\nGeneral Procedure for the Preparation of 2-Oxopropoxy-\n6-phenylcoumarin (4, 22). Under a suspension of anhydrous\nK2CO 3(0.25 mmol) and the corresponding hydroxycoumarin (0.13\nmmol), in anhydrous acetone (3 mL), the chloroketone (0.25 mmol)\nwas added. The suspension was stirred, at reflux temperature, for 16 h.\nThe mixture was cooled, and the precipitate was recovered by filtration\nand washed with anhydrous acetone (3 /C240 mL). The solvent was\nevaporated under vacuum, and the dry residue was purified by FC(hexane/ethyl acetate 85:15).\n3-(4-Methylphenyl)-6-(2-oxopropoxy)coumarin ( 4).Yield 74%; mp\n128/C0129 /C176C.\n1H NMR (CDCl 3) 2.33 (s, 3H, /C0CH 3), 2.42 (s, 3H,\n/C0CH 3), 4.64 (s, 2H, /C0CH 2), 6.96 (d, 1H, H-5, J= 2.9), 7.14 (dd, 1H,\nH-7, J= 9.0, J= 2.9), 7.28 /C07.33 (m, 3H, H-30, H-50, H-8), 7.60 /C07.65\n(m, 2H, H-20, H-60), 7.74 (s, 1H, H-4).13C NMR (CDCl 3) 21.3, 26.6,\n73.5, 111.0, 117.7, 119.2, 120.2, 128.4, 129.0, 129.2, 131.7, 138.6, 139.1,\n148.4, 154.2, 160.6, 204.7. MS m/z309 ([M + 1]+, 31), 308 (M+, 100),\n266 (12), 265 (50), 236 (15), 235 (26), 207 (31) 195 (12), 179 (16),178 (16), 165 (11), 153 (12), 129 (20). Anal. Calcd for C\n19H16O4:C ,\n74.01; H, 5.23. Found: C, 73.90; H, 5.18.\n6-Methyl-3-[3-(2-oxopropoxy)phenyl]coumarin ( 22).Yield 71%;\nmp 107/C0 108 /C176C.1H NMR (CDCl 3) 2.31 (s, 3H, /C0CH 3), 2.43 (s,\n3H,/C0CH 3), 4.61 (s, 2H, /C0CH 2), 6.94 (d, 1H, H-5, J= 1.2), 7.24 /C07.42\n(m, 6H, H-7, H-8, H-20, H-40, H-50, H-60), 7.77 (s, 1H, H-4).13C NMR\n(CDCl 3) 20.8, 26.6, 73.1, 114.8, 115.0, 116.1, 119.2, 121.9, 127.7, 129.7,\n132.6, 134.2, 136.4, 140.2, 151.6, 157.6, 160.6, 205.3. MS m/z309 ([M +\n1]+, 14), 308 (M+, 70), 266 (55), 265 (50), 237 (29), 236 (21), 235\n(20), 178 (24), 165 (10). Anal. Calcd for C 19H16O4: C, 74.01; H, 5.23.\nFound: C, 74.08; H, 5.30.\nPreparation of 6-(2-Cyclopentyloxy)-3-(4-methylphenyl)-\ncoumarin (5). Under a suspension of anhydrous K 2CO 3(0.25 mmol)\nand the 6-hydroxycoumarin 3(0.13 mmol), in anhydrous acetone\n(3.0 mL), the cyclopentyl bromide (0.25 mmol) was added. The\nsuspension was stirred, at reflux temperature, for 24 h. The mixture\nwas cooled, and the precipitate was recovered by filtration and washed\nwith anhydrous acetone (3 /C240.0 mL). The solvent was evaporated\nunder vacuum, and the dry residue was purified by FC (hexane/ethyl\nacetate 9:1). Yield 58%; mp 147/C0 148 /C176C.1H NMR (CDCl 3) 1.37/C01.99\n(m, 8H, ( /C0CH 2)4), 2.52 (s, 3H, /C0CH 3), 4.89 (s, 1H, H-100), 7.05 (d,\n1H, H-5, J= 2.7), 7.17 (dd, 1H, H-7, J= 9.0, J= 2.7), 7.36 /C07.40 (m, 3H,\nH-30, H-50, H-8), 7.72 (d, 2H, H-20, H-60,J= 8.1), 7.84 (s, 1H, H-4).13C\nNMR (CDCl 3) 21.3, 24.0, 32.8, 80.0, 111.8, 117.3, 120.1, 120.3, 128.4,\n128.4, 129.1, 132.0, 138.8, 139.2, 147.6, 154.6, 160.9. MS m/z321 ([M + 1]+,\n7), 320 (M+, 28), 253 (19), 252 (100), 224 (38), 223 (13), 152 (11).\nAnal. Calcd for C 21H20O3: C, 78.75; H, 6.29. Found: C, 78.69; H, 6.24.Determination of hMAO Isoform Activity. Briefly, 0.1 mL of\nsodium phosphate buffer (0.05 M, pH 7.4) containing different con-\ncentrations of the test drugs (new compounds or reference inhibitors) invarious concentrations and adequate amounts of recombinant hMAO-A\nor hMAO-B required and adjusted to obtain in our experimental\nconditions the same reaction velocity, i.e., to oxidize (in the control\ngroup) the same concentration of substrate: 165 pmol of p-tyramine/\nmin (hMAO-A, 1.1 \u03bcg protein; specific activity, 150 nmol of p-tyramine\noxidized to p-hydroxyphenylacetaldehyde/min/mg protein; hMAO-B,\n7.5\u03bcg protein; specific activity, 22 nmol of p-tyramine transformed/\nmin/mg protein) were incubated for 15 min at 37 /C176C in a flat-black-\nbottom 96-well microtest plate and placed in the dark fluorimeterchamber. After this incubation period, the reaction was started by adding(final concentrations) 200 \u03bcM Amplex Red reagent, 1 U/mL horse-\nradish peroxidase, and 1 mM p-tyramine. The production of H\n2O2and,\nconsequently, of resorufin was quantified at 37 /C176C in a multidetection\nmicroplate fluorescence reader (FLX800, Bio-Tek Instruments, Inc.,Winooski, VT, USA) based on the fluorescence generated (excitation,\n545 nm, emission, 590 nm) over a 15 min period, in which the\nfluorescence increased linearly.\nControl experiments were carried out simultaneously by replacing\nthe test drugs (new compounds and reference inhibitors) with appro-\npriate dilutions of the vehicles. In addition, the possible capacity of the\nabove test drugs to modify the \ufb02uorescence generated in the reaction\nmixture due to nonenzymatic inhibition (e.g., for directly reacting with\nAmplex Red reagent) was determined by adding these drugs to solutions\ncontaining only the Amplex Red reagent in a sodium phosphate bu \ufb00er.\nTo determine the kinetic parameters of hMAO-A and hMAO-B ( K\nmand\nVmax), the corresponding enzymatic activity of both isoforms was\nevaluated (under the experimental conditions described above) in thepresence of a number (a wide range) of p-tyramine concentrations.\nThe speci \ufb01c\ufb02uorescence emission (used to obtain the \ufb01nal results)\nwas calculated after subtraction of the background activity, which was\ndetermined from vials containing all components except the hMAO\nisoforms, which were replaced by a sodium phosphate bu \ufb00er solution. In\nour experimental conditions, this background activity was practically\nnegligible.\nMolecular Docking Simulations. The crystallographic structure\nof MAO-B in complex with a coumarin inhibitor (pdb code 2V61)52and\nthe MAO-A in complex with harmine (pdb code 2ZX5)51were used to\ndock the coumarins under study. For both isoenzymes, hydrogen atomsand charges were added to the receptor structure using the UCSFChimera,\n57and the atomic charges of the FAD cofactor were calculated\nusing GAMESS.58\nThree-dimensional conformers for the compounds were generated\nusing the OMEGA software.59A maximum of 50000 conformations per\nmolecule were generated using an energy window of 10 kcal. Allrotatable bonds were considered during the torsion search, using theMerck Molecular Force Field (MMFF), and duplicate conformers werediscarded based on a root-mean-square (rms) value of 0.5 \u00c5. A\nmaximum number of 300 conformers were saved for each compound.\nAfterward, AM1-BCC charges were added to each conformer using theMOLCHARGE program, which is part of the QUACPAC package.\n60\nRigid docking was carried out for each ligand conformer using the\nDOCK 6.3 package.54A maximum of 5000 orientations per ligand was\nassayed. The energy grid-based scoring function was selected for posesquality evaluation. The \ufb01ve lowest scored poses for each ligand\nconformer were saved, allowing for a maximum of 1500 saved poses\nfor each compound. Afterward, the \ufb01ve lowest scored conformers of\neach ligand were rescored, using the DOCK Amber-based scored\nfunction, considering only the \ufb02exibility of the ligand. Finally, the pose\nwith the lowest Amber-based scoring value for each compound wasrescored, with the same scoring function, considering both the ligandand the binding. We chose the Amber-based scoring function to take\n1527135 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\ninto account small structural rearrangements on both ligand and\nreceptor as well as the e \ufb00ect of the solvent through a GB/SA continuum\nmodel for the solvation free energy.55,56Molecular graphics images were\nproduced using the UCSF Chimera package from the Resource for\nBiocomputing, Visualization, and Informatics at the University ofCalifornia, San Francisco (supported by NIH P41 RR001081).\n\u2019AUTHOR INFORMATION\nCorresponding Author\n*Phone: +34 981 563100. Fax: +34 981 544912. E-mail:\nmariajoao.correiapinto@rai.usc.es (M.J.M.) and mdolores.vina@usc.es (D.V.).\n\u2019ACKNOWLEDGMENT\nWe are grateful to the Xunta de Galicia (09CSA030203PR,\nPGIDIT07PXIB, 10PXIB203303PR) and Ministerio de Sanidad\ny Consumo (FIS PI09/00501) for \ufb01nancial support. M. Jo ~ao\nMatos thanks Fundac -~ao de Ci ^encia e Tecnologia for the fellow-\nship. Y. P /C19erez-Castillo thanks OpenEye Scienti \ufb01c Software for\nproviding an Academic License for using their software at the\nLaboratory for Medicinal Chemistry of the Rega Institute for\nMedical Research at the Katholieke Universiteit Leuven.\n\u2019DEDICATION\nThis article is dedicated to the memory of Prof. Francisco Orallo\n\u2019ABBREVIATIONS USED\nhMAO, human monoamine oxidase; FAD, \ufb02avin adenine dinu-\ncleotide; IC 50, half maximal inhibitory concentration; cDNA,\ncDNA; SAR, structure /C0activity relationship; PDB, Protein\nData Bank; HPLC, high-performance liquid chromatography\n\u2019REFERENCES\n(1) Murray, R. D. H.; Mendez, J.; Brown, S. A. The natural\ncoumarins occurrence. In Chemistry and Biochemistry ; John Wiley and\nSons: Chichester, UK, 1982.\n(2) Murray, R. D. H. Naturally occurring plant coumarins. Prog.\nChem. Org. Nat. Prod. 2002 ,83,1\u2013673.\n(3) (a) Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E.\nSimple coumarins and analogues in medicinal chemistry: occurrence,\nsynthesis and biological activity. Curr. Med. Chem. 2005 ,12, 887\u2013 916.\n(b) Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. SimpleCoumarins: Privileged Sca \ufb00olds in Medicinal Chemistry. Front. Med.\nChem. 2009 ,4,2 3\u201385.\n(4)/C19OKennedy, R. Coumarins. Biology, Applications and Mode of\nAction; Thornes, R. D., Ed.; John Wiley and Sons: New York, 1997.\n(5) (a) Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.;\nZunino, F. Design, synthesis and anticancer activities of stilbe-\nne/C0coumarin hybrid compounds: identi \ufb01cation of novel proapoptotic\nagents. Bioorg. Med. Chem. 2010 ,18, 3543 \u20133550. (b) Riveiro, M. E.;\nMoglioni, A.; Vazquez, R.; Gomez, N.; Facorro, G.; Piehl, L.; de Celis,E. R.; Shayo, C.; Davio, C. Structural insights into hydroxycoumarin-\ninduced apoptosis in U-937 cells. Bioorg. Med. Chem. 2008 ,\n16, 2665\u2013 2675.\n(6) (a) Fylaktakidou, K. C.; Hadjipavlou-Litina, D. J.; Litinas, K. E.;\nNicolaides, D. N. Natural and synthetic coumarin derivatives with anti-\nin\ufb02ammatory/antioxidant activities. Curr. Pharm. Des. 2004 ,\n10, 3813\u2013 3833. (b) Roussaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina,\nD. J.; Hamilakis, S. A novel synthesis of 3-aryl coumarins and evaluation\nof their antioxidant and lipoxygenase inhibitory activity. Bioorg. Med.\nChem. Lett. 2010 ,20, 3889 \u20133892.(7) Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Yanez, M.; Fraiz,\nN.; Alcaide, C.; Cano, E.; Orallo, F. Design, synthesis, and vasorelaxantand platelet antiaggregatory activities of coumarin /C0resveratrol hybrids.\nBioorg. Med. Chem. Lett. 2006 ,16, 257\u2013261.\n(8) Ostrov, D. A.; Hern /C19andez Prada, J. A.; Corsino, P. E.; Finton,\nK.\nA.; Le, N.; Rowe, T. C. Discovery of novel DNA gyrase inhibitors by\nhigh-throughput virtual screening. Antimicrob. Agents Chemother. 2007 ,\n51, 3688 \u20133698.\n(9) Chimenti, F.; Bizzarri, B.; Bolasco, A.; Secci, D.; Chimenti, P.;\nGranese, A.; Carradori, S.; Rivanera, D.; Zicari, A.; Scaltrito, M. M.; Sisto,\nF. Synthesis, selective anti- Helicobacter pylori activity, and cytotoxicity of\nnovel N-substituted-2-oxo-2 H-1-benzopyran-3-carboxamides. Bioorg.\nMed. Chem. Lett. 2010 ,20, 4922\u2013 4926.\n(10) Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. H.; Das, A. R.;\nChakraborty, S. K.; Hong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R.\nStructure-activity relationship of new anti-hepatitis C virus agents:\nheterobicycle /C0coumarin conjugates. J. Med. Chem. 2009 ,52, 1486\u2013 1490.\n(11) Kostova, I. Coumarins as inhibitors of HIV reverse transcrip-\ntase. Curr. HIV Res. 2006 ,4, 347\u2013 363.\n(12) Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.;\nPoletto, G.; Mazzorana, M.; Zagotto, G.; Uriarte, E.; Guiotto, A.;\nMeggio, F.; Moro, S. Coumarin as attractive casein kinase 2 (CK2)\ninhibitor sca \ufb00old: an integrate approach to elucidate the putative binding\nmotif and explain structure /C0activity relationships. J. Med. Chem. 2008 ,\n51, 752\u2013 759.\n(13) Zhou, X.; Wang, X. B.; Wang, T.; Kong, L. Yi. Design, synthesis,\nand acetylcholinesterase inhibitory activity of novel coumarin analogues.Bioorg. Med. Chem. 2008 ,16, 8011 \u20138021.\n(14) Garino, C.; Tomita, T.; Pietrancosta, N.; Laras, Y.; Rosas, R.\nNaphthyl and coumarinyl biarylpiperazine derivatives as highly potent\nhuman \u03b2-secretase inhibitors. Design, synthesis, and enzymatic BACE-1\nand cell assays. J. Med. Chem. 2006 ,49, 4275 \u20134285.\n(15) Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.;\nGranese, A.; Carradori, S.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S.\nSynthesis, molecular modeling, and selective inhibitory activity against\nhuman monoamine oxidases of 3-carboxamido-7-substituted coumarins.\nJ. Med. Chem. 2009 ,52, 1935 \u20131942.\n(16) Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.;\nLeonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-\nAlvarez, E.; Passeleu, C.; Carotti, A. Discovery of a novel class of potent\ncoumarin monoamine oxidase B inhibitors: development and biophar-\nmacological pro \ufb01ling\nof 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)-\nmethyl]-2 H-chromen-2-one methanesulfonate (NW-1772) as a highly\npotent, selective, reversible, and orally active monoamine oxidase B\ninhibitor. J. Med. Chem. 2009 ,52, 6685\u2013 6706.\n(17) Gnerre, C.; Catto, M.; Francesco, L.; Weber, P.; Carrupt, P.-A.;\nAltomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxidase by\nfunctionalized coumarin derivatives: biological activities, QSAR, and\n3D-QSARs. J. Med. Chem. 2000 ,43, 4747 \u20134758.\n(18) Tipton, K. F. Enzymology of monoamine oxidase. Cell. Bio-\nchem. Funct. 1986 ,4,7 9 \u201387.\n(19) Dostert, P.; Strolin, B. M.; Jafre, M. Monoamine oxidase: basic and\nclinical frontiers. In Excerpta Medica; Elsevier: Amsterdam, 1982; pp 197.\n(20) Singer, T. P. In Chemistry and Biochemistry of Flavoenzymes ;\nMuller, F., Ed.; CRC Press: Boca Raton FL, 1991; Vol. 2, pp 437.\n(21) Bach, A. W. J.; Lan, N. C.; Johnson, D. L.; Abell, C. W.;\nBembenek, M. E.; Kwan, S. W.; Seeburg, P. H.; Shih, J. C. cDNA cloning\nof human liver monoamine oxidase A and B: molecular basis of\ndi\ufb00erences in enzymatic properties. Proc. Natl. Acad. Sci. U.S.A. 1988 ,\n85, 4934 \u20134938.\n(22) Wouters, J. Structural aspects of monoamine oxidase and its\nreversible inhibition. Curr. Med. Chem. 1998 ,5, 137 \u2013162.\n(23) Grimsby, J.; Lan, N. C.; Neve, R.; Chen, K.; Shih, J. C. Tissue\ndistribution of human monoamine oxidase A and B mRNA. J. Neuro-\nchem. 1990 ,55, 1166\u2013 1169.\n(24) Kalgutkar, A. S.; Castagnoli, N., Jr.; Testa, B. Selective inhibitors\nof monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic\nsite and mechanism. Med. Res. Rev. 1995 ,15, 325 \u2013388.\n1537136 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\n(25) Geha, R. M.; Rebrin, I.; Chen, K.; Shih, J. C. Substrate and\ninhibitor speci\ufb01 cities for human monoamine oxidase A and B are\nin\ufb02uenced by a single amino acid. J. Biol. Chem. 2001 ,276, 9877 \u20139882.\n(26) Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.;\nTsukihara, T. Structure of rat monoamine oxidase A and its speci \ufb01c\nrecognitions for substrates and inhibitors. J. Mol. Biol. 2004 ,\n338, 103\u2013 115.\n(27) Weyler, W.; Hsu, Y. P. P.; Breake \ufb01eld, X. O. Biochemistry and\ngenetics of monoamine oxidase. Pharmacol. Ther. 1990 ,47, 391\u2013 417.\n(28) Rudorfer, M. V.; Potter, V. Z. Antidepressants. A comparative\nreview of the clinical pharmacology and therapeutic use of the \u201cnewer \u201d\nversus the \u201colder \u201ddrugs. Drugs 1989 ,37, 713\u2013 738.\n(29) (a) Gerlach, M.; Double, K.; Reichmann, H.; Riederer, P.\nArguments for the use of dopamine receptor agonists in clinical and\npreclinical Parkinso /C19ns diseases. J. Neural Transm. Suppl. 2003 , 167\u2013 193.\n(b) Fernandez, H. H.; Chen, J. J. Monamine oxidase inhibitors: current\nand emerging agents for Parkinson disease. Clin. Neuropharmacol. 2007 ,\n30, 150\u2013 168.\n(30) Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxi-\ndase-B inhibition in Alzheimer \u2019s disease. Neurotoxicology 2004 ,\n25, 271\u2013 277.\n(31) Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.;\nMattevi, A. Structure of human monoamine oxidase B, a drug target forthe treatment of neurological disorders. Nature Struct. Mol. Biol. 2002 ,\n9,2 2 \u201326.\n(32) (a) Binda, C.; Li, M.; Hub /C19alek, F.; Restelli, N.; Edmondson,\nD. E.; Mattevi, A. Insights into the mode of inhibition of human\nmitochondrial monoamine oxidase B from high-resolution crystal\nstructures. Proc. Natl. Acad. Sci. U.S.A. 2003 ,100,\n9750 \u20139755. (b) De\nColibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A.\nThree-dimensional structure of human monoamine oxidase A (MAO-A):relation to the structures of rat MAO-A and human MAO B. Proc. Natl.\nAcad. Sci. U.S.A. 2005 ,102, 12684 \u201312689.\n(33) Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson,\nD. E.; Mattevi, A. Crystal structures of monoamine oxidase B in complexwith four inhibitors of the N-propargylaminoindane class. J. Med. Chem.\n2004, 47, 1767\u2013 1774.\n(34) Milczek, E. M.; Bonivento, D.; Binda, C.; Mattevi, A.; McDonald,\nI. A.; Edmondson, D. E. Structural and mechanistic studies of mofegiline\ninhibition of recombinant human monoamine oxidase B. J. Med. Chem.\n2008 ,51,8 0 1 9 \u20138026.\n(35) Sayre, L. M.; Perry, G.; Smith, M. A. Oxidative stress and\nneurotoxicity. Chem. Res. Toxicol. 2008 ,21, 172 \u2013188.\n(36) Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO\ninhibitors: safety and future. Neurotoxicology 2004 ,25,1 1\u201320.\n(37) Filip, V.; Kolibas, E. Selegiline in the treatment of Alzheimer \u2019s\ndisease: a long-term randomized placebo-controlled trial. Czech and\nSlovak senile dementia of Alzheimer type study group. J. Psychiatr.\nNeurosci. 1999 ,24, 234 \u2013243.\n(38) (a) Annan, N.; Silverman, R. B. New analogs of N-(2-\naminoethyl)-4-chlorobenzamide (Ro 16 /C06491). Some of the most\npotent monoamine oxidase-B inactivators. J. Med. Chem. 1993 ,\n36, 3968 \u20133970. (b) Harfenist, M.; Joyner, C.; Mize, P.; White, H.\nSelective inhibitors of monoamine oxidase. 2. Arylamide SAR. J. Med.\nChem. 1994 ,37, 2085 \u20132089.\n(39) Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.;\nCarradori, S.; Yanez, M.; Orallo, F.; Sanna, M. L.; Gallinella, B.; Cirilli, R.Synthesis, stereochemical separation, and biological evaluation of selec-\ntive inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcy-\nclohexylidene)hydrazines. J. Med. Chem. 2010 ,53, 6516 \u20136520.\n(40)\nChimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.;\nGranese, A.; Carradori, S.; Alcaro, S.; Ortuso, F.; Yanez, M.; Orallo, F.;Cirilli, R.; Ferretti, R.; La Torre, F. Synthesis, stereochemical identi \ufb01ca-\ntion, and selective inhibitory activity against human monoamine oxidase-\nB of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. J. Med.\nChem. 2008 ,51, 4874 \u20134880.\n(41) (a) Frederick, R.; Dumont, W.; Ooms, F.; Aschenbach, L.; Van der\nSchyf, C. J.; Castagnoli, N.; Wouters, J.; Krief, A. Synthesis, structuralreassignment, and biological activity of type B MAO inhibitors based on\nthe 5H -indeno[1,2- c]pyridazin-5-one core. J. Med. Chem. 2006 ,\n49, 3743 \u20133747. (b) Carotti, A.; Catto, M.; Leonetti, F.; Campagna, F.;\nSoto-Otero, R.; Mendez-Alvarez, E.; Thull, U.; Testa, B.; Altomare, C.\nSynthesis and monoamine oxidase inhibitory activity of new pyridazine-,pyrimidine-, and 1,2,4-triazine-containing tricyclic derivatives. J. Med.\nChem. 2007 ,50, 5364 \u20135371.\n(42) Leonetti, F.; Capaldi, C.; Pisani, L.; Nicolotti, O.; Muncipinto,\nG.; Stefanachi, A.; Cellamare, S.; Caccia, C.; Carotti, A. Solid-phasesynthesis and insights into structure /C0activity relationships of sa \ufb01namide\nanalogues as potent and selective inhibitors of type B monoamineoxidase. J. Med. Chem. 2007 ,50, 4909\u2013 4916.\n(43) Rendenbach, B.; Weifenbach, H.; Teschendorf, H. J. Prepara-\ntion of 7-(arylalkoxy)coumarins as central nervous system agents.\n(BASF AG). Patent DE 3834861 A1, 1990, .\n(44) Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De\nMarco, A.; Rose, S.; Jenner, P.; Testa, B. Lipophilicity plays a major rolein modulating the inhibition of monoamine oxidase B by 7-substituted\ncoumarins. Chem. Biodiversity 2006 ,3, 134\u2013 149.\n(45) Santana, L.; Uriarte, E.; Gonz /C19alez-D\u00edaz, H.; Zagotto, G.; Soto-\nOtero, R.; E. M /C19endez- /C19Alvarez, E. A QSAR model for in silico screening\nof MAO-A inhibitors. Prediction, synthesis, and biological assay of novelcoumarins. J. Med. Chem. 2006 ,49, 1149 \u20131156.\n(46) Santana, L.; Gonz /C19alez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y /C19a~nez,\nM.; Vi ~na, D.; Orallo, F. Quantitative structure/C0 activity relationship and\ncomplex network approach to monoamine oxidase A and B inhibitors. J.\nMed. Chem. 2008 ,51,\n6740 \u20136751.\n(47) Matos, M. J.; Vi ~na, D.; Quezada, E.; Picciau, C.; Delogu, G.;\nOrallo, F.; Santana, L.; Uriarte, E . A new series of 3-phenylcoumarins as\npotent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett. 2009 ,\n19, 3268 \u20133270.\n(48) Matos, M. J.; Vi ~na, D.; Picciau, C.; Orallo, F.; Santana, L.;\nUriarte, E. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as\npotent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett. 2009 ,\n19, 5053 \u20135055.\n(49) Matos, M. J.; Vi ~na, D.; Janeiro, P.; Borges, F.; Santana, L.;\nUriarte, E. New halogenated 3-phenylcoumarins as potent and selective\nMAO-B inhibitors. Bioorg. Med. Chem. Lett. 2010 ,20, 5157 \u20135160.\n(50) Hub /C19alek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castaganoli,\nN.; Edmondson, D. E. Demonstration of isoleucine 199 as a struc-\ntural determinant for the selective inhibition of human monoamine\noxidase B by speci \ufb01c reversible inhibitors. J. Biol. Chem. 2005, 280,\n16761 \u201315766.\n(51) Son, S.-Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.;\nTsukihara, T. Stucture of human monoamine oxidase A at 2.2 \u00c5resolution: the control of opening the entry for substrates/inhibitors.Proc. Natl. Acad. Sci. U.S.A. 2008 ,105, 5739\u2013 5744.\n(52) Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.;\nEdmondson, D. E.; Mattevi, A. Structures of human monoamine oxidase\nB complexes with selective noncovalent inhibitors: sa \ufb01namide and\ncoumarin analogs. J. Med. Chem. 2007 ,50, 5848 \u20135852.\n(53) Y /C19a~nez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory e \ufb00ects of cis\nandtrans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake\nand on monoamine oxidase activity. Biochem. Biophys. Res. Commun.\n2006 ,344, 688 \u2013695.\n(54) Lang, P. T.; Brozell, S. R.; Mukherjee, S.; Pettersen, E. F.; Meng,\nE. C.; Thomas, V.; Rizzo, R. C.; Case, D. A.; James, T. L.; Kuntz, I. D.\nDOCK 6: combining techniques to model RNA /C0small molecule\ncomplexes. RNA 2009 ,15,\n 1219\u2013 30.\n(55) Onufriev, A.; Bashford, D.; Case, D. A. Exploring protein native\nstates and large-scale conformational changes with a modi \ufb01ed general-\nized Born model. Proteins 2004 ,55, 383 \u2013394.\n(56) Graves, A. P.; Shivakumar, D. M.; Boyce, S. E.; Jacobson, M. P.;\nCase, D. A.; Shoichet, B. K. Rescoring Docking Hit Lists for Model\nCavity Sites: Predictions and Experimental Testing. J. Mol. Biol. 2008 ,\n377, 914 \u2013934.\n(57) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.;\nGreenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera \u2014a\n1547137 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, 54, 7127\u20137137Journal of Medicinal ChemistryARTICLE\nvisualization system for exploratory research and analysis. J. Comput.\nChem. 2004 ,25, 1605 \u20131612.\n(58) Schmidt, M. W.; Baldridge, K. K.; Boatz, J. A.; Elbert, S. T.;\nGordon, M. S.; Jensen, J. H.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.;\nSu, S.; Windus, T. L.; Dupuis, M.; Montgomery, J. A. General atomic and\nmolecular electronic structure system. J. Comput. Chem. 1993 ,\n14, 1347\u2013 1363.\n(59) OMEGA 2.3.2; OpenEye Scienti \ufb01c Software, Inc.: Santa Fe,\nNM, 2008; www.eyesopen.com.\n(60) QUACPAC, version 1.3.1 ; OpenEye Scienti \ufb01c Software, Inc.:\nSanta Fe, NM, 2008; www.eyesopen.com.\n155Reprint\n\u00a9 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim\n157/C23 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimTable of Contents\nD. Vi\u00c7a, M. J. Matos,* G. Ferino,*\nE. Cadoni, R. Laguna, F . Borges, E. Uriarte,\nL. Santana\n464 \u2013 4708-Substituted 3-Arylcoumarins as\nPotent and Selective MAO-B\nInhibitors: Synthesis, Pharmacological\nEvaluation, and Docking Studies\nB-selective! With the aim of finding\nnew selective MAO-B inhibitors, herein\nwe report the synthesis, in vitro evalua-\ntion, and a docking simulation of a new\nseries of 3-arylcoumarins variously sub-\nstituted at the 8-position as potential in-\nhibitors of hMAO-A and B. Most of the\nstudied compounds have high affinity\nand selectivity for hMAO-B, with IC50\nvalues in the low micro- to nanomolar\nrange.\n158DOI: 10.1002/cmdc.201100538\n8-Substituted 3-Arylcoumarins as Potent and Selective\nMAO-B Inhibitors: Synthesis, Pharmacological Evaluation,\nand Docking Studies\nDolores Vi\u00c7a,[d]Maria J. Matos,*[a, c]Giulio Ferino,*[b]Enzo Cadoni,[b]Reyes Laguna,[d]\nFernanda Borges,[a]Eugenio Uriarte,[c]and Lourdes Santana[c]\nIntroduction\nWith the increase in the aging population in modern society,\nneurodegenerative diseases (NDs) are becoming increasingly\nprevalent pathologies. Maintaining the quality of life for the\nworld \u2019s aging population is among the most important chal-\nlenges in medicine today. Alzheimer\u2019s disease (AD) is the most\nprevalent of the NDs, followed by Parkinson\u2019s disease (PD). The\ndevelopment of effective neuroprotective therapies that either\nslow or halt disease progression in the earliest stages, or palli-\nate the appearance of symptoms, is one of the main goals for\nresearchers in this area.\nIncreased activity in monoamine oxidase A and B (MAO-A\nand MAO-B) is associated with decreased quantities of endoge-nous and exogenous monoamines. The two isoforms of MAO\nare responsible for catalyzing the oxidative deamination of\nneurotransmitters and dietary amines, thus regulating the in-\ntracellular levels of biogenic amines in the brain and peripheral\ntissues.\n[1, 2]MAOs are FAD-dependent enzymes found in the\nouter mitochondrial membrane of various cell types such as\nneuronal, glial, and other mammalian cells.[3]MAO-A and B\nhave been identified and differentiated through their primary\nsequences,[4]three-dimensional structures,[5]tissue distribu-\ntion,[6]inhibitor selectivity,[7]and substrate preferences.[8]Due\nto their affinity for different substrates, these enzymes are in-\nvolved in different pathologies such as anxiety and depression\n(MAO-A), and PD and AD (MAO-B). The MAO-A isoform hashigher affinity for serotonin and noradrenalin, whereas the\nMAO-B isoform preferentially deaminates b-phenylethylamines\nand benzylamine.\n[9, 10]Dopamine and tyramine are common\nsubstrates for both isoforms. These physiological properties\ntherefore determine the clinical interest of MAO inhibitors. Se-\nlective MAO-A inhibitors such as clorgyline (irreversible) andmoclobemide (reversible) are used for the treatment of neuro-\nlogical disorders,[11]whereas selective and irreversible MAO-B\ninhibitors such as selegiline and rasagiline are used for thetreatment of NDs.\n[12\u201314]\nInterest in selective MAO inhibitors, especially those for\nMAO-B, has increased significantly in recent years. This is relat-ed to the recent discovery that the increase in MAO-B activity\nis associated with gliosis, which can result in high levels of hy-\ndrogen peroxide and oxidative free radicals. It was reported\nthat the expression levels of this isoform in neuronal tissue in-\ncrease fourfold with age. The increment of dopamine metabo-lism, as well as the described oxidative stress, may play a role\nin the etiology of ND.\n[15,16]Rasagiline is a good MAO-B inhibitor\ndue to its capacity to protect neuronal cells from the conse-\nquences of oxidative stress in patients.[16,17]\n[a]Dr. M. J. Matos, Prof. F . Borges\nCIQUP/Departamento de Qu/C237mica e Bioqu/C237micaFaculdade de Ci\u00dencias, Universidade do Porto, 4169-007 Porto (Portugal)\nE-mail: mariacmatos@gmail.com\n[b]Dr. G. Ferino, Prof. E. Cadoni\nDipartimento di Scienze Chimiche, Universit/C224 degli studi di Cagliari\nComplesso Universitario di Monserrato\nS.S. 554, 09042, Monserrato Cagliari (Italy)\nE-mail: giulioferino@unica.it\n[c]Dr. M. J. Matos, Prof. E. Uriarte, Prof. L. Santana\nDepartamento de Qu/C237mica Org/C181nica, Facultad de Farmacia\nUniversidad de Santiago de Compostela\n15782 Santiago de Compostela (Spain)\n[d]Dr. D. Vi\u00c7a, Dr. R. LagunaDepartamento de Farmacolog/C237a, Facultad de Farmacia\nUniversidad de Santiago de Compostela\n15782 Santiago de Compostela (Spain)Neurodegenerative disorders are becoming more prevalent\ngiven the increase in the aging population. This has inspired\nactive research in the development of new drugs that couldmark an important advance in the treatment of complex dis-\neases such as Alzheimer \u2019s and Parkinson \u2019s. With the aim of\nfinding new MAO-B-selective inhibitors, we report the synthe-\nsis, in vitro evaluation, and docking simulation of a new series\nof 3-arylcoumarins variously substituted at the 8-position. Most\nof the studied compounds show high affinity and selectivity\nfor the hMAO-B isoform, with IC\n50values in the low micro- tonanomolar range. Some of them have greater hMAO-B inhibi-\ntory activity and selectivity than the reference compound, sele-\ngiline. Compounds 7and 8are the most active of this series,\nwith compound 8being fivefold more potent against MAO-B\nand severalfold more selective than selegiline. Docking experi-\nments were carried out with hMAO-B crystal structures, provid-\ning new information about the enzyme\u2013inhibitor interaction\nand the potential therapeutic application of the new 8-substi-\ntuted 3-arylcoumarins.\n464\n /C23 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim ChemMedChem 2012, 7, 464 \u2013 470MED\n159Osthole (7-methoxy-8-isopentenoxycoumarin), an active con-\nstituent of Cnidium monnieri (L.)Cusson was reported in 1996\nto have various pharmacological activities.[18]It has shown pro-\ntective effects in animal models of central nervous system\n(CNS) diseases owing to its anti-oxidative and anti-apoptotic\nactivity.[19]\nSeveral natural and synthetic coumarins[20\u201324]have been\ncited since the 1990s as having a promising scaffold for MAO\ninhibition.[25\u201328]Structure\u2013selectivity relationship studies sug-\ngested that selectivity is modulated by the nature and position\nof the linkage between the coumarin moiety and the lipophilic\naryl groups.[29]Substitution patterns at the 3- and 7-positions\nhave been thoroughly studied. Some 3-arylcoumarins with var-ious substituents in either the 3-aryl or coumarin rings were\nalso reported as potent and selective MAO-B inhibitors.\n[30\u201334]In\nthose studies, small substituents (especially methyl groups) at\nposition 6 of the coumarin moiety and the introduction of an\naryl ring at position 3 of the scaffold proved to be important\nfor potent MAO-B inhibitory activity and selectivity.[35,36]\nAlternatively, it was reported that alkylsulfonyloxy groups at\nposition 7 of the coumarin moiety produce MAO-A inhibitors\nsuch as esuprone, while a benzyloxy substituent at the same\nposition leads to potent and selective MAO-B inhibi-\ntors.[25\u201327, 29,37, 38]The presence of an acetonyloxy group at posi-\ntion 7 with a benzene ring fused at positions 3 or 4 led tocompounds with very high MAO-B selectivity.\n[39]Therefore, it is\nclear that substitutions on the coumarin moiety can modulateMAO-A and B activity and selectivity. Furthermore, work related\nto the chromone ring, an isomer of the coumarin scaffold, has\nalso been carried out. Those with substituents at position 3 of\ntheg-pyrone nucleus act preferentially as MAO-B inhibitors,\nwith IC\n50values in the nanomolar to micromolar range.[40]\nTaking into account previous studies, and particularly the\nvery high MAO-B selectivity observed for 6-substituted 3-aryl-coumarins,\n[30\u201332, 35]we continued our exploration of substitu-\ntions on the coumarin ring system. We were motivated to syn-\nthesize and study the MAO inhibitory activity of new ana-\nlogues in which a range of groups of various size and lipophi-\nlicity were introduced at position 8 of the coumarin aromatic\nring and at position 4 of the 3-aryl ring. Both aromatic rings\nwere substituted in order to clarify the influence of the posi-\ntion and substitution pattern on MAO inhibitory activity and\nselectivity by the 3-arylcoumarins. Given that there are no\nother published studies regarding 8-substituted coumarins,this is an interesting scaffold to explore.\nCrystal structures of the two MAO isoforms have provided\nrelevant information about the selective interactions and phar-\nmacophore requirements for the design of potent and selec-\ntive inhibitors.\n[41\u201346]Based on the significant structural informa-\ntion that is currently available,[47,48]and to analyze the structur-\nal requirements for MAO activity and selectivity, docking ex-\nperiments were carried out on crystallographic structures of\nthe human MAO-B isoform, hMAO-B. These studies are very\nhelpful for corroborating and clarifying the experimental data\nobtained in order to develop a rational drug design project.Results\nChemistry\nCoumarin derivatives 1\u20139were efficiently synthesized accord-\ning to the protocol outlined in Scheme 1.[31\u201333, 49]The structures\nof the described compounds were confirmed by1H NMR,\n13C NMR, mass spectrometry, elemental analyses, and melting\npoints. The general reaction conditions and compound charac-\nterization data are described below in the Experimental Sec-\ntion.\nPerkin condensation of various ortho -hydroxybenzaldehydes\nwith the appropriate arylacetic acid, using N,N\u2019-dicyclohexylcar-\nbodiimide (DCC) as dehydrating agent, was the key step toafford the desired 3-arylcoumarins. This is a very easy and ver-\nsatile reaction that affords different families of substituted cou-marins with a wide range of substituent patterns.\nPharmacology: inhibition of MAO\nEvaluation of the test compounds on hMAO activity was per-\nformed by measuring their effects on the production of hydro-\ngen peroxide from para -tyramine (a common substrate for\nhMAO-A and hMAO-B) using the Amplex Red MAO assay kit(Molecular Probes Inc., Eugene, OR, USA) and microsomal MAO\nisoforms prepared from insect cells (BTI-TN-5B1-4) infected\nwith recombinant baculovirus containing cDNA inserts for\nhMAO-A or hMAO-B (Sigma\u2013Aldrich Qu/C237mica S.A., Alcobendas,\nSpain).\n[50]\nThe production of hydrogen peroxide catalyzed by the two\nMAO isoforms can be detected using 10-acetyl-3,7-dihydroxy-\nphenoxazine (Amplex Red reagent), a non-fluorescent and\nhighly sensitive probe that reacts with H2O2in the presence of\nhorseradish peroxidase to produce a fluorescent product, re-\nsorufin. New compounds and reference inhibitors were unable\nto react directly with the Amplex Red reagent, indicating that\nthese drugs do not interfere with the assay measurements. In\nour experiments and under specific conditions, hMAO-A dis-\nplayed a Michaelis constant (KM) of 457.17 /C638.62 mmand a\nmaximum reaction velocity (Vmax) in the control group of\n185.67 /C612.06 (nmol p-tyramine) min/C01(mg protein)/C01, whereas\nhMAO-B showed a KMof 220.33 /C632.80 mmand a Vmaxof\n24.32 /C61.97 (nmol p-tyramine) min/C01(mg protein)/C01(n=5).\nScheme 1. Reagents and conditions: a) DCC, DMSO, 110 8C, 24 h.\nChemMedChem 2012 , 7, 464 \u2013 470 /C23 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.chemmedchem.org 465\n8-Substituted 3-Arylcoumarins as MAO-B Inhibitors\n160Most tested compounds inhibited this enzymatic control activi-\nty in a concentration-dependent manner (Table 1).\nTable 2 lists the results of the reversibility and irreversibility\ntests for compound 8and reference inhibitors. hMAO-B inhibi-\ntion is irreversible in the presence of 8as shown by the lack of\nrestored enzyme activity after repeated washing. Similar results\nwere obtained for selegiline. In contrast, significant recovery of\nhMAO-B activity was observed after repeated washing of\nisatin, indicating that this drug is a reversible inhibitor of\nhMAO-B.\nMolecular docking studies\nDocking studies were performed to better understand the\nmanner in which 8-substituted 3-arylcoumarins interact with\nthe hMAO-B binding pocket. The X-ray crystal structure of\nhMAO-B in complex with 4-carboxaldehyde-7-(3-chlorobenzy-\nloxy)coumarin (c17) was used as the model for docking calcu-\nlations (PDB code: 2V60).[48]Water molecules close to the bind-ing site were considered for the experiments because theyform an extensive hydrogen bond network amongst each\nother and with the enzyme; moreover, some of these water\nmolecules proximal to the FAD cofactor appear to be highly\nconserved in hMAO-B isoforms.\n[51]\nQM-polarized ligand docking (QPLD)[52]followed by post-\ndocking processing operated with Prime MM-GBSA[53]was\nused as protocol for this study. Briefly, in the QPLD step, theligand was first docked into the enzyme using Glide;\n[54]quan-\ntum mechanical calculations were then made to take into ac-\ncount the polarization of the charges in the ligand by the\nenzyme. Finally, ligands with improved charges were re-docked\ninto the enzyme (see the Experimental Section below for de-\ntails). The best pose of each compound derived from QPLD\nwas subjected to an energy calculation and minimization with\nPrime MM-GBSA. Prime was used in this study with the sole\naim of minimizing the input poses derived from QPLD, taking\ninto account a flexible enzyme region defined by a distance of\n5 /C138 from the ligand. We validated our docking protocol by re-\ndocking the co-crystallized coumarin c17 inside the binding\ncleft. The best docking pose shows an RMSD of 0.47 /C138 for\nheavy atoms.\nThe first simulation was made with the aim of visualizing\nthe binding mode of the most active compounds (Figure 1 a).\nThe best docking poses were retrieved for compounds 7,8,\nand 9, which manifest the same pattern. The coumarin ring oc-\ncupies the substrate cleft facing the FAD cofactor, leaving the\n3-arylcoumarin moiety directed toward the entry cavity. All\nthree poses are stabilized by a hydrogen bond between the\ncarbonyl oxygen atom of the coumarin and Cys172. Tyr326 is\ninvolved in a p\u2013pstacking interaction with 3-arylcoumarin\nrings. Conversely, good van der Waals and electrostatic interac-tions with Phe168, Leu171, Ile198, Ile199, Ile316, Phe343,\nTyr398, and Thy435 were observed.\nIn the second docking calculation we investigated the best-\npose solutions adopted from 8-ethoxy-3-arylcoumarins (Fig-\nure 1 b). The patterns adopted from compounds 1,2,a n d 3\ncould be considered generally the same, while small differen-\nces can be observed between the most active compounds 2\nand 3with respect to compound 1. The hydrogen bond with\nCys172 was maintained for all the three coumarins. The me-\nthoxy oxygen atom of compound 2acts as a hydrogen bond\nacceptor with a water molecule, forming a hydrogen bond at adistance of 1.91 /C138. For compound 3, Tyr326 contributes to\nligand stabilization by forming a p\u2013pstacking interaction with\nthe 3-aryl ring of the coumarin. Furthermore, the ethoxy groupat position 8 is positioned in a different manner for compound\n1than its positioning for coumarins 2and 3. Coumarin 1\ntherefore shows good hydrophobic pattern recognition onlywith Trp119 and Phe103, whereas compounds 2and 3interact\nwith Trp119, Leu164, Leu167, Phe168, and Ile316 (Figure 1 b).\nRegarding the presence of a bulkier (relative to methoxy or\nmethyl) hydrophobic group at position 8, the para -3-aryl sub-\nstituent seems to modulate the inhibitory activity of coumarinderivatives.\nFinally, with the aim of analyzing the differences between\nsubstitutions at positions 8 and 6 of the coumarin nucleus, weTable 1. Structure and in vitro hMAO inhibitory activity of 3-arylcoumarin\nderivatives 1\u20139and reference compounds.\nCompd IC50[nm][a]SI[b]\nhMAO-A hMAO-B\n1 * 1.06/C148 103/C60.71 /C148 103>94[c]\n2 * 208.82 /C613.98 >479[c]\n3 * 148.53 /C69.96 >673[c]\n4 ** 150.02 /C610.04 >667[c]\n5 * 3.31/C148 103/C60.22 /C148 103>30[c]\n6 6.26 /C148 103/C60.23 /C14810378.28 /C65.25 79\n7 21.60 /C148 103/C60.97 /C1481033.43/C60.23 6.297\n8 ** 4.51 /C60.24 >22.173[c]\n9 * 19.90 /C61.33 >5.025[c]\nselegiline 67.25 /C148 103/C61.02 /C14810319.60 /C60.86 3.431\niproniazide 6.56 /C148 103/C60.76 /C1481037.54/C148 103/C60.36 /C148 1030.87\nrasagiline 16.44 /C148 103/C60.85 /C14810368.96 /C63.63 238\n[a] Values represent the mean /C6SEM of five experiments (n =5).*: Inac-\ntive at 100 mm(highest concentration tested); at higher concentrations\nthe compounds precipitate. **: 100 mminhibits the corresponding hMAO\nactivity by ~40\u201345 %; at higher concentrations the compounds precipi-\ntate. [b] Selectivity index: MAO-B selectivity ratios [IC50 (MAO-A) ]/[IC50 (MAO-B) ]\nfor inhibitory effects of both new compounds and reference inhibitors.\n[c] Values obtained under the assumption that the corresponding IC50\nvalue against MAO-A is the highest concentration tested (100 mm).\nTable 2. Reversibility and irreversibility of hMAO-B inhibition by deriva-\ntive8and reference inhibitors.\nCompd hMAO-B inhibition [%][a]\nBefore washing After repeated washing\n8(10 nm) 53.05 /C63.58 57.15 /C63.86\nselegiline (20 n m) 56.34 /C65.37 58.67 /C66.60\nisatin (33 mm) 63.45 /C64.28 23.10 /C60.52[b]\n[a] Values represent the mean /C6SEM of five experiments (n =5). [b] Level\nof statistical significance: p<0.01 versus the corresponding percent\nhMAO-B inhibition before washing, as determined by ANOVA/Dunnett\u2019s\ntest.\n466 www.chemmedchem.org /C23 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim ChemMedChem 2012, 7, 464 \u2013 470MED M. J. Matos, G. Ferino, et al.\n161analyzed the most stable pose retrieved for compound 6and\ncompared it with the results obtained for the analogue 6-\nmethyl-3-phenylcoumarin, previously reported by us[28](Fig-\nure 1 c). Interestingly, both structures share the phenyl ring\nfacing the FAD cofactor, directed toward the aromatic cage\nformed by Tyr398 and Tyr435, and leave the methyl group oc-\ncupying the same position in the binding pocket. In both\nstructures the methyl group is involved in hydrophobic inter-actions with the residues Trp119, Leu164, Leu167, and Phe168,\nwhich form part of highly hydrophobic region of the entrance\ncavity in the enzyme. For compound 6the carbonyl fragment\nis situated toward Cys172, establishing a hydrogen bond with\na distance of 1.99 /C138. Strong hydrophobic interactions were\nalso observed with Tyr326. Regarding 6-methyl-3-phenylcou-\nmarin, the first relevant contribution to complex energy stabili-\nzation is related to the hydrogen bond formed with a water\nmolecule situated 2.08 /C138 from the oxygen atom of the carbon-\nyl group. Indeed, the carbonyl group is placed in a different\nmanner relative to 6. The 3-phenyl moiety of 6-methyl-3-phe-\nnylcoumarin is also involved in favorable hydrophobic interac-\ntions with Leu171, Ile198, and Tyr398. This could partially ex-\nplain why compound 6shows better MAO-B inhibitory activity\nthan the previously described 6-methyl-substituted ana-\nlogue.[30]\nDiscussion\nAll the described coumarins (compounds 1\u20139) were efficiently\nsynthesized by an easy and versatile methodology (Scheme 1).\nThey were also evaluated for their ability to inhibit the A and B\nisoforms of hMAO. The corresponding IC50values and MAO-B\nselectivity ratios [IC50 (MAO-A) ]/[IC50 (MAO-B) ] are listed in Table 1.\nPosition 8 of the 3-arylcoumarin moiety has never been de-\nscribed as a potential location for modulating the inhibitory ac-tivities of MAO-A and MAO-B. Analysis of the experimental\ndata revealed that seven of the nine tested compounds are se-\nlective inhibitors of MAO-B, with IC\n50values in the low micro-\nand nanomolar ranges. Three compounds of this series have\nsimilar or better IC50values than selegiline (IC50=19.60 n m),\nthe most potent MAO-B inhibitor used as reference. The mostactive compounds of this series are the coumarin derivatives 7\n(IC\n50=3.43 nm)a n d 8(IC50=4.51 nm), which are about sixfold\nmore active than the reference compound. Compound 8is\nFigure 1. a) Comparison of the most stable binding modes of compounds 7,\n8, and 9into hMAO-B (PDB code: 2V60). The binding pocket surface is col-\nored according to residue property: green for hydrophobic residues and tur-\nquoise for polar uncharged residues. Ligands are represented in tube\nformat; carbon atoms are yellow for 7, green for 8, and purple for 9. The\nFAD cofactor and water molecules are depicted in ball-and-stick format;\ncarbon atoms are grey. Interacting residues are represented in wire, with\ncarbon atoms in grey. The hydrogen bond is displayed as a yellow dotted\nline, and nonpolar hydrogen atoms are omitted. b) Superimpositions of thebest-pose solutions for compounds 1,2, and 3(shown in tube format)\ndocked into hMAO-B (PDB code: 2V60). Coumarins and the interacting resi-\ndues with their ethoxy groups are colored by the same scheme: green for 1,\npurple for 2, and turquoise for 3. Tyr326 and Cys172 are also shown. All resi-\ndues are displayed in wire format. The water molecule involved in hydrogen\nbonding (yellow dotted line) and FAD are represented in ball-and-stick\nformat with carbon atoms in grey. c) Best poses of compound 6and 6-\nmethyl-3-phenylcoumarin into hMAO-B (PDB code: 2V60). The ligands are\ndisplayed in tube format and are colored in accordance with the residueswith which they interact (green for 6and purple for 6-methyl-3-phenylcou-\nmarin). Residues colored in yellow interact with both ligands (see text fordiscussion). Cys172 (carbon atom in green) and a water molecule (ball andstick) are also shown. The hydrogen bond is displayed as a yellow dottedline. FAD is shown in ball-and-stick format with carbon atoms in grey. Only\nhydrogen atoms involved in hydrogen bonding are displayed.\nChemMedChem 2012 , 7, 464 \u2013 470 /C23 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.chemmedchem.org 467\n8-Substituted 3-Arylcoumarins as MAO-B Inhibitors\n162also severalfold more selective than selegiline. The steric bulk\nof the substituent at position 8 seems to be important for\nmodulating MAO-B inhibitory activity. All the described methyl\nderivatives showed better inhibition results than the corre-\nsponding methoxy or ethoxy derivatives. As shown in Fig-\nure 1 a, those compounds exhibit a unique binding pattern,\nmanifesting good interactions with key residues in the binding\npocket. These results are in accordance with experimental\ndata.\nIn comparing the 8-methyl derivatives 6\u20139, it can be ob-\nserved that the introduction of various substituents at the para\nposition of the 3-phenyl ring is a good strategy for improving\nthe desired MAO-B inhibitory activity. Moreover, with a me-\nthoxy, methyl, or bromo substituent at that position, the com-\npounds are very selective for the MAO-B isoform (compounds\n7,8, and 9, respectively). Compounds 6and 7are better MAO-\nB inhibitors than the previously reported analogues 6-methyl-\n3-phenylcoumarin (IC50=283 nm) and 3-(4 \u2019-methoxyphenyl)-6-\nmethylcoumarin (IC50=13 nm), respectively.[28]These data indi-\ncate that substitution of the 3-phenylcoumarin at position 8\ncould be a good strategy for searching out better MAO-B in-\nhibitors than those previously described.\nThe chemical structures of the newly designed compounds,\nalong with the results of biological and docking studies, can\nhelp with a SAR study. The activity data for these compounds\nindicate that the varied nature of the substitutions at posi-\ntion 8 of the aromatic ring of the coumarin moiety would be\nmore favorable for modulating the activity. Moreover, MAO-B\ninhibitory activity also increases if small lipophilic and electron-\ndonating groups (methoxy or methyl) are included at posi-\ntion 4 of the 3-phenyl ring.\nConclusions\nWe used the Perkin reaction as a suitable method for the effi-cient and general synthesis of a series of 8-substituted 3-aryl-\ncoumarins. Most of the compounds studied show high affinity\nand selectivity for the MAO-B isoform. Docking studies per-\nformed for these compounds allowed us to establish and cor-\nroborate the nature of the interactions between the com-\npounds and the MAO-B enzyme. Both the type and position of\nthe substituents on the 3-aryl group and at position 8 of the\ncoumarin moiety play a crucial role in both activity and selec-\ntivity. Further research into this interesting scaffold is currently\nongoing.\nExperimental Section\nGeneral methods\nStarting materials and reagents were obtained from commercial\nsuppliers and were used without purification (Sigma\u2013Aldrich). Melt-\ning points (mp) are uncorrected and were determined with a\nReichert Kofler thermopan or in capillary tubes in a B/C252chi 510 ap-\nparatus.1H NMR (300 MHz) and13C NMR (75.4 MHz) spectra were\nrecorded with a Bruker AMX spectrometer using [D6]DMSO or\nCDCl3as solvent. Chemical shifts ( d) are expressed in ppm using\nTMS as an internal standard. Coupling constants ( J) are expressedin Hz. Spin multiplicities are given as s (singlet), d (doublet), dd(doublet of doublets), and m (multiplet). Mass spectrometry was\ncarried out with a Kratos MS-50 or a Varian MAT-711 spectrometer.\nElemental analyses were performed with a PerkinElmer 240B micro-\nanalyzer and are within /C60.4 % of calculated values in all cases.\nThe analytical results show /C2195% purity for all compounds. Flash\nchromatography (FC) was performed on silica gel (Merck 60, 230\u2013\n400 mesh); analytical TLC was performed on pre-coated silica gel\nplates (Merck 60 F\n254). Organic solutions were dried over anhydrous\nNa2SO4. Concentration and evaporation of the solvent after reac-\ntion or extraction was carried out on a rotary evaporator (B/C252chi Ro-\ntavapor) operating at reduced pressure.\nSynthesis\nGeneral synthetic methodology for 3-phenylcoumarins 1\u20139: A\nsolution of 3-ethoxy-2-hydroxybenzaldehyde/2-hydroxy-3-methoxy-\nbenzaldehyde/2-hydroxy-3-methylbenzaldehyde (7.4 mmol) andthe corresponding phenylacetic acid (9.2 mmol) in DMSO (15 mL)was prepared. N,N\u2019-Dicyclohexylcarbodiimide (11.5 mmol) was\nadded, and the mixture was heated in an oil bath at 110 8Cf o r\n24 h. Triturate ice (100 mL) and acetic acid (10 mL) were added tothe reaction mixture. After keeping it at room temperature for 2 h,\nthe mixture was extracted with Et\n2O (3 /C148 25 mL). The precipitated\ndicyclohexylurea was filtered off. The organic layer was washed\nwith a solution of sodium bicarbonate (50.0 mL, 5%). The organic\nphase was stirred for 1 h with 5% aqueous sodium metabisulfiteto remove the unreacted hydroxybenzaldehyde, then washed with\nH\n2O (20 mL) and dried (Na2SO4). The solvent was evaporated under\nvacuum, and the dry residue was purified by FC (hexane/EtOAc\n9:1).\n8-Ethoxy-3-phenylcoumarin (1) : Pale-yellow solid (700 mg, 55%):\nRf=0.33 (hexane/EtOAc, 8:2); mp: 117\u2013118 8C;1H NMR (300 MHz,\nCDCl3):d=1.50 (t, J=7.0 Hz, 3 H, CH3), 4.21 (dd, J=14.0, 7.0 Hz,\n2H , C H2), 7.09 (t, J=6.9 Hz, 2 H, H-6, H-7), 7.21 (t, J=7.8 Hz, 1H, H-\n5), 7.42\u20137.48 (m, 3 H, H-3 \u2019, H-4\u2019 , H-5\u2019 ), 7.72 (dd, J=7.7, 1.4 Hz, 2 H,\nH-2\u2019, H-6\u2019 ), 7.79 ppm (s, 1H, H-4);13C NMR (75 MHz, CDCl3):d=\n14.8, 65.0, 114.5, 119.3, 120.4, 124.3, 128.3, 128.4, 128.5, 128.8,\n134.8, 140.1, 143.4, 146.3, 160.2 ppm; IR (KBr): n\u02dc=2850, 1718, 1699,\n1468 cm/C01; MS (EI, 70 eV): m/z(%): 267 (22) [ M+H]+, 266 (100) [ M+\n]; HRMS-FAB: m/z[M+H]+calcd for C17H14O3: 267.1021, found:\n267.1017; Anal. calcd for C17H14O3: C 76.68, H 5.30, found: C 76.66,\nH 5.28.\n8-Ethoxy-3-(4 \u2019-methoxyphenyl)coumarin (2) : White solid (870 mg,\n61%): Rf=0.21 (hexane/EtOAc, 8:2); mp: 99\u2013100 8C;1H NMR\n(300 MHz, CDCl3):d=1.50 (t, J=7.0 Hz, 3H, CH3), 3.84 (s, 3 H,\nOCH3), 4.19 (dd, J=14.0, 7.0 Hz, 2H, CH2), 6.84\u20137.26 (m, 5 H, H-3 \u2019,\nH-5\u2019, H-5, H-6, H-7), 7.69 (t, J=7.7 Hz, 2 H, H-2 \u2019, H-6\u2019 ), 7.73 ppm (s,\n1 H, H-4);13C NMR (75 MHz, CDCl3):d=14.8, 55.4, 64.8, 113.8, 114.0,\n119.1, 120.49, 124.2, 127.1, 127.8, 129.7, 129.8, 138.6, 138.7, 146.2,\n160.0 ppm; IR (KBr): n\u02dc=2927, 2841, 1716, 1460 cm/C01; MS (EI,\n70 eV): m/z(%): 297 (18) [ M+H]+, 296 (100) [ M+]; HRMS-FAB: m/z\n[M+H]+calcd for C18H16O4: 297.1127, found: 297.1117; Anal. calcd\nfor C18H16O4: C 72.96, H 5.44, found: C 72.91, H 5.39.\n8-Ethoxy-3-(4 \u2019-methylphenyl)coumarin (3) : White solid (650 mg,\n48%): Rf=0.30 (hexane/EtOAc, 8:2); mp: 109\u2013110 8C;1H NMR\n(300 MHz, CDCl3):d=1.51 (td, J=7.0, 1.8 Hz, 3 H, CH3), 2.39 (s, 3 H,\nCH3), 4.20 (dd, J=7.0, 1.8 Hz, 2H, CH2), 706\u20137.10 (m, 2H, H-5, H-6),\n7.18 (dd, J=8.0, 1.9 Hz, 1 H, H-7), 7.26 (d, J=1.6 Hz, 2 H, H-3\u2019 , H-5\u2019 ),\n7.61 (dd, J=8.1, 1.8 Hz, 2 H, H-2\u2019 , H-6\u2019 ), 7.74 ppm (s, 1H, H-4);\n13C NMR (75 MHz, CDCl3):d=14.8, 21.3, 65.0, 114.4, 119.2, 120.5,\n124.3, 128.3, 128.4, 129.2, 131.9, 138.8, 139.4, 143.3, 146.3,\n468 www.chemmedchem.org /C23 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim ChemMedChem 2012, 7, 464 \u2013 470MED M. J. Matos, G. Ferino, et al.\n163160.3 ppm; IR (KBr): n\u02dc=2857, 1707, 1663, 1470 cm/C01; MS (EI,\n70 eV): m/z(%): 281 (27) [ M+H]+, 280 (100) [ M+]; HRMS-FAB: m/z\n[M+H]+calcd for C18H16O3: 281.1178, found: 281.1167; Anal. calcd\nfor C18H16O3: C 77.12, H 5.75, found: C 77.07, H 5.80.\n3-(4\u2019-Bromophenyl)-8-methoxycoumarin (5) : Pale-yellow solid\n(880 mg, 62%): Rf=0.24 (hexane/EtOAc, 8:2); mp: 169\u2013170 8C;\n1H NMR (300 MHz, CDCl3):d=3.92 (s, 3 H, -OCH3), 7.07\u20137.12 (m, 3 H,\nH-5, H-6, H-7), 7.15 (dd, J=7.8, 1.5 Hz, 2 H, H-2 \u2019,H - 6 \u2019), 7.58 (dd, J=\n7.8, 1.5 Hz, 2 H, H-3\u2019 ,H - 5 \u2019), 7.80 ppm (s, 1 H, H-4);13C NMR (75 MHz,\nCDCl3):d=56.0, 113.4, 119.3, 120.1, 123.2, 124.5, 127.4, 130.1,\n131.6, 133.5, 140.0, 141.8, 147.3, 161.7 ppm; IR (KBr): n\u02dc=2850,\n1701, 1660, 1068 cm/C01; MS (EI, 70 eV): m/z(%): 331 (22) [ M+H]+,\n330 (100) [ M+]; HRMS-FAB: m/z[M+H]+calcd for C16H11BrO3:\n330.9970, found: 330.9969; Anal. calcd for C16H11BrO3: C 55.04, H\n3.75, found: C 55.05, H 3.77.\n3-(4\u2019-Methoxyphenyl)-8-methylcoumarin (7) : Pale-yellow solid\n(610 mg, 66%): Rf=0.33 (hexane/EtOAc, 8:2); mp: 100\u2013101 8C;\n1H NMR (300 MHz, CDCl3):d=2.50 (s, 3H, CH3), 3.86 (s, 3 H, OCH3),\n6.98 (dd, J=8.9, 1.2 Hz, 2 H, H-3\u2019 , H-5\u2019 ), 7.18\u20137.20 (m, 1H, H-7), 7.37\n(d,J=7.7 Hz, 2 H, H-5, H-6), 7.66\u20137.76 ppm (m, 3 H, H-2\u2019 , H-6\u2019 , H-4);\n13C NMR (75 MHz, CDCl3):d=15.5, 55.4, 113.9, 119.5, 124.0, 125.4,\n125.8, 127.2, 127.4, 129.8, 132.3, 139.0, 151.6, 160.0, 160.9 ppm; IR\n(KBr): n\u02dc=2837, 1708, 1462 cm/C01; MS (EI, 70 eV): m/z(%): 267 (31)\n[M+H]+, 266 (100) [ M+]; HRMS-FAB: m/z[M+H]+calcd for\nC17H14O3: 267.1021, found: 267.1013; Anal. calcd for C17H14O3:C\n76.68, H 5.30, found: C 76.58, H 5.40.\n3-(4\u2019-Methylphenyl)-8-methylcoumarin (8) : White solid (580 mg,\n67%): Rf=0.42 (hexane/EtOAc, 8:2); mp: 111\u2013112 8C;1H NMR\n(300 MHz, CDCl3):d=2.40 (s, 3 H, CH3), 2.50 (s, 3H, CH3), 7.16 (d, J=\n7.5 Hz, 1 H, H-7), 7.23\u20137.26 (m, 2H, H-5, H-6), 7.37 (d, J=7.5 Hz, 2 H,\nH-3\u2019, H-5\u2019 ), 7.62 (d, J=8.1 Hz, 2H, H-2\u2019 , H-6\u2019 ), 7.77 ppm (s, 1H, H-4);\n13C NMR (75 MHz, CDCl3):d=15.4, 21.2, 119.4, 124.0, 125.5, 125.8,\n128.4, 129.1, 131.9, 132.5, 138.8, 139.5, 139.7, 151.8, 160.8 ppm; IR\n(KBr): n\u02dc=1697, 1460 cm/C01; MS (EI, 70 eV): m/z(%): 251 (27) [ M+\nH]+, 250 (98) [ M+]; HRMS-FAB: m/z[M+H]+calcd for C17H14O2:\n251.1072, found: 251.1062; Anal. calcd for C17H14O2: C 81.58, H\n5.64, found: C 81.61, H 5.72.\n3-(4\u2019-Bromophenyl)-8-methylcoumarin (9) : White solid (1.2 g,\n65%): Rf=0.42 (hexane/EtOAc, 8:2); mp: 193\u2013194 8C;1H NMR\n(300 MHz, CDCl3):d=2.51 (s, 3 H, CH3), 7.22 (t, J=7.7 Hz, 1H, H-7),\n7.38\u20137.42 (m, 2H, H-5, H-6), 7.57\u20137.60 (m, 4H, H-2\u2019 , H-3\u2019 , H-5\u2019 , H-6 \u2019),\n7.82 ppm (s, 1 H, H-4);13C NMR (75 MHz, CDCl3):d=15.4, 119.2,\n123.0, 124.2, 125.7, 126.0, 126.7, 130.1, 131.6, 133.0, 133.7, 140.4,\n151.9, 160.4 ppm; IR (KBr): n\u02dc=1706, 1462, 1065 cm/C01; MS (EI,\n70 eV): m/z(%): 315 (25) [ M+H]+, 314 (95) [ M+]. HRMS-FAB: m/z\n[M+H]+calcd for C16H11BrO2: 315.0021, found: 315.0024; Anal.\ncalcd for C16H11BrO2: C 60.98, H 3.52, found: C 60.90, H 3.43.\nDetermination of MAO isoform activity\nThe effects of the new synthesized compounds on hMAO isoform\nactivity were evaluated with a fluorimetric method previously de-scribed by us.\n[38]Briefly, sodium phosphate buffer (0.1 mL, 0.05 m,\npH 7.4) containing the test drugs (new compounds or reference in-\nhibitors) at various concentrations and adequate amounts of re-\ncombinant hMAO-A or hMAO-B required and adjusted to obtain\nthe same reaction velocity under our experimental conditions\n[hMAO-A: 1.1 mg protein, specific activity: 150 (nmol p-tyramine\noxidized to p-hydroxyphenylacetaldehyde) min/C01(mg protein)/C01;\nhMAO-B: 7.5 mg protein, specific activity: 22 (nmol p-tyramine\ntransformed) min/C01mg protein)/C01] were incubated for 15 min at37 8C in a flat- and black-bottomed 96-well microplate, placed in\nthe dark fluorimeter chamber. After this incubation period, the re-\naction was started by adding (final concentrations) 200 mmAmplex\nRed reagent, 1 U mL/C01horseradish peroxidase and 1 m mp-tyra-\nmine. The production of H2O2and, consequently, of resorufin was\nquantified at 37 8C in a multidetection microplate fluorescence\nreader (FLX800, Bio-Tek Instruments Inc., Winooski, VT, USA) based\non the fluorescence generated ( lexcitation : 545 nm, lemission : 590 nm)\nover a 15 min period, in which the fluorescence increased linearly.\nControl experiments were carried out simultaneously by replacing\nthe test drugs (new compounds and reference inhibitors) with ap-\npropriate dilutions of the vehicles. In addition, the potential capaci-ty of the above test drugs to modify the fluorescence generated in\nthe reaction mixture through non-enzymatic inhibition (e.g., react-\ning directly with the Amplex Red reagent) was determined by\nadding these drugs to solutions containing only the Amplex Red\nreagent in a sodium phosphate buffer. The specific fluorescence\nemission (used to obtain the final results) was calculated after sub-\ntraction of the background activity, which was determined fromvials containing all components except the hMAO isoforms, which\nwere replaced by a sodium phosphate buffer solution.\nReversibility and irreversibility experiments\nTo evaluate whether compound 8and reference inhibitors are re-\nversible or irreversible hMAO-B inhibitors, an effective centrifuga-tion\u2013ultrafiltration method (so-called repeated washing) was\nused.\n[55]\nMolecular docking\nThe Schr\u00e7dinger 2011 package was employed for all computer cal-\nculations in this work.\nProtein and ligand preparation\nThe Protein Preparation Wizard[56]workflow was used to prepare\nthe hMAO-B crystal structure (PDB code: 2V60) as the target in\ndocking simulations. Water molecules beyond 5 /C138 from the ligand\nwere deleted, and hydrogen atoms were added and subsequently\nminimized using the OPLS_2005 force field. The refinement stage\nof the protein reorients the hydroxy groups, amide groups of as-\nparagine and glutamine residues, and optimizes the protonation\nstate of histidines. Furthermore the orientation of water moleculeswas varied in order to optimize hydrogen bonding.\nCoumarin derivatives were prepared according to the LigPrep tool\nof Maestro 9.1.\n[57]Different ionization states at pH 7.0 /C62.0 and tau-\ntomers were generated. The MMFFs force field was used for the\nminimization of structures.\nQM-polarized ligand docking procedure\nThe grid box was centered in the co-crystallized ligand c17 with alength of 20 /C138 and a receptor van der Waals scaling of 1.0. The ini-tial docking was performed with Glide at Standard Precision (SP)\nlevel, generating the initial charges on the ligands with semiempiri-\ncal method; eight poses per ligand were retained. Ab initio density\nfunctional theory (DFT) was used for the full quantum mechanical\n(QM) treatment of the ligand. Ligand charges were calculated byJaguar\n[58]using the 6-31G*/LACVP* basis set, B3LYP density func-\ntional, and Ultrafine SCF accuracy level. Finally, Glide with extra\nChemMedChem 2012 , 7, 464 \u2013 470 /C23 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.chemmedchem.org 469\n8-Substituted 3-Arylcoumarins as MAO-B Inhibitors\n164precision (XP) mode was used to re-dock the ligands with im-\nproved QM charges, returning the best four poses for each ligand.\nAcknowledgements\nWe are grateful to the Xunta de Galicia (09CSA030203PR, PGI-\nDIT07PXIB, 10PXIB203303PR), the Spanish Ministerio de Sanidad y\nConsumo (FIS PS09/00501), MIUR, Cagliari University (National\nProject \u201cStereoselezione in Sintesi Organica metodologie ed Appli-\ncazioni\u201d), CINMPIS, and FIRB for partial financial support. M.J.M.\nthanks Funda\u00c5\u00bco de Ci\u00dencia e Tecnologia for the fellowship\n(SFRH/BD/61262/2009).\nKeywords: coumarins \u00b7heterocycles \u00b7molecular modeling \u00b7\nmonoamine oxidase \u00b7perkin reaction\n[1] P . Dostert, B. M. Strolin, M. Jalfre, Monoamine Oxidase: Basic and Clinical\nFrontiers in Excerpta Medica , Elsevier, Amsterdam, 1982, pp. 197 \u2013 208.\n[2] T. P. Singer in Chemistry and Biochemistry of Flavoenzymes, Vol. 2 (Ed.: F.\nMuller), CRC Press, Boca Raton, 1991 , pp. 437 \u2013470.\n[3] K. F. Tipton, Cell. Biochem. Funct. 1986 ,4, 79 \u2013 87.\n[4] A. W. J. Bach, N. C. Lan, D. L. Johnson, C. W. Abell, M. E. Bembenek, S. W.\nKwan, P . H. Seeburg, J. C. Shih, Proc. Natl. Acad. Sci. USA 1988, 85,\n4934 \u20134938.\n[5] J. Wouters, Curr. Med. Chem. 1998 ,5, 137 \u2013 162.\n[6] J. Grimsby, N. C. Lan, R. Neve, K. Chen, J. C. Shih, J. Neurochem. 1990,\n55, 1166 \u2013 1169.\n[7] A. S. Kalgutkar, N. Castagnoli, Jr., B. Testa, Med. Res. Rev. 1995 ,15, 325 \u2013\n388.\n[8] R. M. Geha, I. Rebrin, K. Chen, J. C. Shih, J. Biol. Chem. 2001, 276, 9877 \u2013\n9882.\n[9] J. Ma, M. Yoshimura, E. Yamashita, A. Nakagawa, A. Ito, T. Tsukihara, J.\nMol. Biol. 2004 ,338, 103 \u2013115.\n[10] W. Weyler, Y.-P. P . Hsu, X. O. Breakefield, Pharmacol. Ther. 1990 ,47, 391 \u2013\n417.\n[11] M. V. Rudorfer, V. Z. Potter, Drugs 1989 ,37, 713 \u2013 738.\n[12] M. Gerlach, K. Double, H. Reichmann, P. Riederer, J. Neural Transm.\nSuppl. 2003 , 167 \u2013 193.\n[13] H. H. Fernandez, J. J. Chen, Clin. Neuropharmacol. 2007 ,30, 150 \u2013 168.\n[14] P . Riederer, W. Danielczyk, E. Grunblatt, Neurotoxicology 2004, 25, 271 \u2013\n277.\n[15] L. M. Sayre, G. Perry, M. A. Smith, Chem. Res. Toxicol. 2008 ,21, 172 \u2013188.\n[16] M. Yamada, H. Yasuhara, Neurotoxicology 2004, 25, 11 \u201320.\n[17]\nH. Zheng, M. Fridkin, M. B. H. Youdim, Neurochem. Res. 2010 ,35,2 1 1 7 \u2013\n2123.\n[18] J. R. Hoult, M. Paya, Gen. Pharmacol. 1996 ,27, 713 \u2013722.\n[19] W. B. Liu, J. Zhou, Y. Qu, X. Li, C. T. Lu, K. L. Xie, X. L. Xun, Z. Fei, Neuro-\nchem. Int. 2010 ,57, 206 \u2013215.\n[20] R. D. H. Murray, J. Mendez, S. A. Brown, The Natural Coumarins: Occur-\nrence in Chemistry and Biochemistry , Wiley, Chichester, 1982 .\n[21] R. D. H. Murray, Prog. Chem. Org. Nat. Prod. 2002 ,83, 1 \u2013673.\n[22] F. Borges, F. Roleira, N. Milhazes, L. Santana, E. Uriarte, Curr. Med. Chem.\n2005 ,12, 887 \u2013 916.\n[23] F. Borges, F. Roleira, N. Milhazes, L. Santana, E. Uriarte, Front. Med. Chem.\n2009 ,4, 23 \u2013 85.\n[24] Coumarins: Biology, Applications, and Mode of Action (Eds.: R. O\u2019Ken-\nnedy, R. D. Thornes), Wiley, New York, 1997 , pp. 348.\n[25] F. Chimenti, D. Secci, A. Bolasco, P. Chimenti, B. Bizzarri, A. Granese, S.\nCarradori, M. Yanez, F. Orallo, F. Ortuso, S. Alcaro, J. Med. Chem. 2009 ,\n52, 1935 \u20131942.\n[26] L. Pisani, G. Muncipinto, T. F. Miscioscia, O. Nicolotti, F. Leonetti, M.\nCatto, C. Caccia, P. Salvati, R. Soto-Otero, E. Mendez-Alvarez, C. Passeleu,\nA. Carotti, J. Med. Chem. 2009 ,52, 6685 \u20136706.[27] C. Gnerre, M. Catto, L. Francesco, P. Weber, P.-A. Carrupt, C. Altomare, A.\nCarotti, B. Testa, J. Med. Chem. 2000 ,43, 4747 \u20134758.\n[28] B. Rendenbach, H. Weifenbach, H. J. Teschendorf (BASF AG), Patent\nDE 3834861 A1, 1990 .\n[29] A. Carotti, C. Altomare, M. Catto, C. Gnerre, L. Summo, A. De Marco, S.\nRose, P. Jenner, B. Testa, Chem. Biodiversity 2006 ,3, 134 \u2013149.\n[30] M. J. Matos, D Vi\u00c7a, E. Quezada, C. Picciau, G. Delogu, F. Orallo, L. Santa-\nna, E. Uriarte, Bioorg. Med. Chem. Lett. 2009 ,19, 3268 \u20133270.\n[31] M. J. Matos, D. Vi\u00c7a, C. Picciau, F. Orallo, L. Santana, E. Uriarte, Bioorg.\nMed. Chem. Lett. 2009 ,19, 5053 \u20135055.\n[32] M. J. Matos, D. Vi\u00c7a, P. Janeiro, F. Borges, L. Santana, E. Uriarte, Bioorg.\nMed. Chem. Lett. 2010 ,20, 5157 \u20135160.\n[33] G. Delogu, C. Picciau, G. Ferino, E. Quezada, G. Podda, E. Uriarte, D.\nVi\u00c7a, Eur. J. Med. Chem. 2011 ,46, 1147 \u2013 1152.\n[34] M. J. Matos, S. V/C181zquez-Rodriguez, E. Uriarte, L. Santana, D. Vi\u00c7a, Bioorg.\nMed. Chem. Lett. 2011 ,21, 4224 \u20134227.\n[35] M. J. Matos, C. Ter/C181n, Y. P/C216rez-Castillo, E. Uriarte, L. Santana, D. Vi\u00c7a, J.\nMed. Chem. 2011 ,54, 7127 \u20137137.\n[36] D. Vi\u00c7a, M. J. Matos, M. Y/C181\u00c7ez, L. Santana, E. Uriarte, MedChemComm\n2011 , DOI: 10.1039/C1MD00221J.\n[37] L. Santana, E. Uriarte, H. Gonz/C181lez-D/C237az, G. Zagotto, R. Soto-Otero, E.\nM/C216ndez-/C141lvarez, J. Med. Chem. 2006, 49, 1149 \u20131156.\n[38] L. Santana, H. Gonz/C181lez-D/C237az, E. Quezada, E. Uriarte, M. Y/C181\u00c7ez, D. Vi\u00c7a, F.\nOrallo, J. Med. Chem. 2008 ,51, 6740 \u20136751.\n[39] M. Catto, O. Nicolotti, F. Leonetti, A. Carotti, A. Favia, R. Soto-Otero, E.\nM/C216ndez-/C141lvarez, A. Carotti, J. Med. Chem. 2006 ,49, 4912 \u2013 4925.\n[40] A. Gaspar, T. Silva, M. Y/C181\u00c7ez, D. Vi\u00c7a, F. Orallo, T. Ortuso, E. Uriarte, S.\nAlcaro, F. Borges, J. Med. Chem. 2011 ,54, 5165 \u20135173.\n[41] C. Binda, P. Newton-Vinson, F. Hubalek, D. E. Edmondson, A. Mattevi,\nNat. Struct. Mol. Biol. 2002 ,9, 22 \u201326.\n[42] C. Binda, M. Li, F. Hub/C181lek, N. Restelli, D. E. Edmondson, A. Mattevi, Proc.\nNatl. Acad. Sci. USA 2003 ,100, 9750 \u2013 9755.\n[43] L. De Colibus, M. Li, C. Binda, A. Lustig, D. E. Edmondson, A. Mattevi,\nProc. Natl. Acad. Sci. USA 2005 ,102, 12684 \u201312689.\n[44] C. Binda, F. Hubalek, M. Li, Y. Herzig, J. Sterling, D. E. Edmondson, A.\nMattevi, J. Med. Chem. 2004 ,47, 1767 \u2013 1774.\n[45] E. M. Milczek, D. Bonivento, C. Binda, A. Mattevi, I. A. McDonald, D. E.\nEdmondson, J. Med. Chem. 2008 ,51, 8019 \u2013 8026.\n[46] F. Hub/C181lek, C. Binda, A. Khalil, M. Li, A. Mattevi, N. Castaganoli, D. E. Ed-\nmondson, J. Biol. Chem. 2005 ,280, 15 761 \u201315 766.\n[47] S-Y . Son, J. Ma, Y. Kondou, M. Yoshimura, E. Yamashita, T. Tsukihara, Proc.\nNatl. Acad. Sci. USA 2008 ,105, 5739 \u2013 5744.\n[48] C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D. E. Edmond-\nson, A. Mattevi, J. Med. Chem. 2007 ,50, 5848 \u20135852.\n[49] M. J. Matos, G. Delogu, G. Podda, L. Santana, E. Uriarte, Synthesis 2010 ,\n16, 2763 \u20132766.\n[50] M. Y/C181\u00c7ez, N. Fraiz, E. Cano, F. Orallo, Biochem. Biophys. Res. Commun.\n2006 ,344, 688 \u2013695.\n[51] D. E. Edmondson, C. Binda, J. Wang, A. K. Upadhyay, A. Mattevi, Bio-\nchemistry 2009 ,48, 4220 \u2013 4230.\n[52] Schr\u00e7dinger Suite 2011: QM-Polarized Ligand Docking Protocol, Glide\nversion 5.7, Jaguar version 7.8, QSite version 5.7, Schr\u00e7dinger LLC, New\nYork, NY (USA), 2011 .\n[53] Prime version 3.0, Schr\u00e7dinger LLC, New York, NY (USA), 2011 .\n[54] Glide version 5.7, Schr\u00e7dinger LLC, New York, NY (USA), 2011 .\n[55] F. Chimenti, R. Fioravanti, A. Bolasco, P . Chimenti, D. Secci, F. Rossi, M.\nYanez, F. Orallo, F. Ortuso, S. Alcaro, J. Med. Chem. 2009, 52, 2818 \u2013 2824.\n[56] Schr\u00e7dinger Suite 2011: Protein Preparation Wizard, Epik version 2.2,\nImpact version 5.7, Prime version 3.0, Schr\u00e7dinger LLC, New York, NY\n(USA), 2011 .\n[57] LigPrep version 2.5, Schr\u00e7dinger LLC, New York, NY (USA), 2011 .\n[58] Jaguar version 7.8, Schr\u00e7dinger LLC, New York, NY (USA), 2011 .\nReceived: November 18, 2011\nRevised: January 13, 2012\nPublished online on January 27, 2012\n470 www.chemmedchem.org /C23 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim ChemMedChem 2012, 7, 464 \u2013 470MED M. J. Matos, G. Ferino, et al.\n165Send Orders of Reprints at bspsaif@emirates.net.ae  \n2210  Current Topics in Medicinal Chemistry, 2012 , 12, 2210 -2239  \n  1568-02 66/12 $5 8.00+.00 \u00a9 2012 B entham Science Publishers  Focusing on New Monoamine  Oxidase Inhibitors: Differently  Substit uted \nCoumarins As An  Intere sting Scaffol d \nMaria Jo\u00e3o Matos1, Dolores Vi\u00f1a2, Saleta V azquez-Rodrigu ez1, Eugenio Uriarte1 and  \nLourdes Santana1,* \n1Departamento de Qu\u00edmica  Org\u00e1nica,  Facultad  de Farmacia,  Universidad de Santiago de Compostela,  Spain; \n2Departamento  de Farmacolog\u00eda, Facultad  de Farmacia,  Universidad de Santiago de Compostela,  Spain  \nAbstract: It is commonly a ccepted t hat monoamine ox idase (MAO) may play a critical role in th e reg ulation of t he cen-\ntral nervo us system a ctivity and contrib ute to t he pat hogenesis of human ne urodegenerative and depressive disorders . This \nhas en couraged an ac tive resear ch in th e development of new dr ugs, M AO in hibitors, sin ce they may represent an impor-\ntant advanc e in t he treatment of comple x diseases s uch as A lzheimer and Parkinson, w hich are be coming prevalent pa -\nthol\nogies du e to t he increase of aging popu lation of developed c ountries so cieties . Different resear ch grou ps are inten -\nsively wor king in t his area wit h the aim of finding new M AO sele ctive in hibitors . Differently su bstituted coumarins have \nbeen synt hesized and eval uated as M AO-A and M AO-B  inhibitors . The p urpose of t his review is to s ummari ze the find -\nings reported in t his area, parti cularly fo cuses on t he coumarin s caffold . \nKeywords: Coumarins, Alzheimer disease, par kinson disease, monoamine ox idase, M AO in hibitors . \n1. INT RODUCTION \n Monoamine ox idase (MAO) is a FA D-depending enz yme \nfound in t he outer mito chondrial membrane of ne uronal, \nglial and ot her mammalian c ells [1] . This en zyme is respon -\nsible for c ataly zing t he oxidative deamination of ne uro-\ntransmitters and dietary amines, reg ulating intra cellular lev -\nels of biogenic  amines in t he brain and t he periph eral tiss ues \n[2, 3]. It is well -known t hat M AO p lays a c ritical role in t he \nregulation of c entral nervou s system a ctivity and contribu tes \nto th e pat hogenesis of human ne urodegenerative and depres -\nsive disorders [4] . Fifty years ago t he first generation of \nMAO in hibitors (MAOIs ) was developed and applied in \ntherapy as anti -depressive compo unds. However, for many \nyears M AOIs were c onsidered useless in t herapy d ue to t he \nserio us side effe cts ind uced by t hese dr ugs [5].  Later, two \nenzymati c isoforms, named M AO-A and M AO-B , hav e been \nidentified on t he basis of t heir amino a cid se quen ces [6], \nthree-dimensional struc ture [7], tiss ue distrib ution [8], in -\nhibitor sele ctivity [ 9] and s ubstrate preferen ces [10].  The \nMAO-A isoform has higher affinity for serotonin and \nnoradrenaline, w hereas th e MAO-B  isoform, preferentially \ndeaminates /g1-phenylet hylamines and benz ylamine [11, 12].  \nOn the other hand, dopamine and tyramine are c ommon s ub-\nstrates for bot h isoforms . As a res ult of t hese p hysiologic al \nproperties, M AOIs becam e again th e center of s cientific  and \npharmac ologic al interest, providing new dru gs for t he ther-\napy of P arkinson\u00b4s diseases (P D), Alzheimer\u00b4s disease (AD ) \nand vario us types of depression [13 ]. Additionally, th e  \n \n*Address correspondenc e to t his author at t he Departamento de Q u\u00edmica \nOrg\u00e1nica, Facultad de F arma cia, Universidad de Santiago de Compostela, \nSpain ; Tel: 00 34 88181100014 936; E-mail: lo urdes.santana@ usc.es \n \nThis manuscript  is dedicated  to Prof Francisco Orallo  in memoriam,  who \nhad introduced and incentivated  us in the study of the MAOIs.  description of t he crystal str ucture of t he two M AO isoforms \nby C . Binda et al. has provided relevant information abou t \nthe sele ctive intera ctions and t he pharma cophoric require-\nments needed for t he design of potent and sele ctive in hibi-\ntors [14- 18].  \n M AO-A plays an important role in ne uropsych iatric and \nbehavioural disorders . The importanc e of t his isoform is \nsuggested by t he aggressive ph enotype seen in male mi ce \ndeficient in M AO-A  and in males in a Du tch ki ndred bearing \na spontaneou s mutation (resulting in a premat ure stop)  in th e \nmao-A gene [19 ]. Similarly, maltreated ch ildren, w hose \ngenotype confers low levels of M AO-A  expression, more \noften develop conduc t disorder, antisoc ial personality and \nadult violent crime t han children wit h a high-activity M AO-\nA genotype do [20].  Relatively modest ch anges in M AO-A  \nactivity /function can have important ne uropsych iatric conse-\nquen ces as demonstrated by t he fac t that [11C]-harmine -\nlabeled is elevated by only 3 4% throughout the brain of u n-\ntreated depressed patients c ompared to c ontrols, yet it ap -\npears to be t he major c ontribu tor to th e monoamine metabo -\nlism in th ese same patients [21].  Depression not only may \npromote cognitive impairment, bu t also may be a ris k factor \nfor AD [22].  Not s urprisingly, M AO-A w hich is often a tar -\nget for t he treatment of depression, is also a potential ris k \nfactor for late -onset AD [2 3-26]. In contrast to irreversible \nMAOI-A  as c lorgyline, reversible in hibitors are better toler -\nated and h ave been parti cularly effi cacious  in treating de -\npression [27] and c ognitive disorders [28] in t he elderly . In \naddition, inh ibition of M AO-A  activity prote ct against stri -\natal damage produc ed by t he mito chondrial poison malonate \nand appears to rely on attenu ation of dopamine -derived rea c-\ntive o xygen spe cies (ROS) [29], wh ile apoptosis following \nserum starvation is reduc ed in M AO-A  defi cient cortical \nbrain cells [ 30]. \n167Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2211  \n On the other hand, it h as been demonstrated t hat sele ctive \nand irreversible M AOIs -B, such as selegiline and rasagiline, \nare important mole cules in th e therapy of PD as well as in \npatients wit h mild A D-type dementia [3 1-33]. Both MAO-B  \npositive astro cytes [ 34] and RO S [35] have been fo und in t he \nvicinity of /g1-amyloid (A/g1) plaques. Selegiline and rasagiline \ncan also e xert ne uroprote ction at lower c oncentrations t han \nthose re quired for in hibition of t he enzym e [ 36]. It has been \nassociated wit h activation of Bc l-2 family members, intera c-\ntion wit h the mito chondrial pore c omple x and modu lation of \namyloid pre cursor protein cleavage [ 37].  \n The importanc e of t he discovery of dru gs asso ciated with  \nneurodegenerative diseases ( ND) has emerged wit h the sig -\nnificant in crease of life e xpectancy. \n Co umarins are a wide family of c ompo unds present in \nremark able amo unts in t he nat ure  [3 8, 39]. Representative \ncompou nds occu r for instan ce in th e vegetable k ingdom, \neither in free or c ombined state [40, 41] . The versatile and \nefficient synt hetic accessibility and t he substitution capabil -\nity ma ke them privileged s caffolds not only in organic  chem-\nistry b ut also in t he medi cinal chemistry field [42] . In the \nliteratu re, coumarin derivatives h ave been des cribed as anti -\ncancer [4 3, 44], antiox idant or anti -inflammatory [45, 46 ], \nvasorela xant [47], antimi crobial [48, 49 ], antiviral [50, 51], \nand en zymati c inhibitors [52 -54].  \n In 19 81, it was fou nd for t he first time an interesting \nMAOI activity of th e coumarin moiety, w hen an organo -\nphosph ate gro up was atta ched to t he umbelliferone ring [55] . \nBut it was only in th e 1990\u00b4s wh en the coumarin n ucleus \ne\nmerged as a promising s caffold for M AOIs [5 6]. In parti cu-\nlar, some c oumarins isolated from Psoralea  corylifolia  L., \nPeucedanum j aponicum  L. or Monascus  anka K. have been \ndescribed as M AOIs [57- 59]. Although natural coumarins \ngenerally s how low M AO in hibitory poten cy, properly modi -\nfied nat ural coumarins have been characterized as potent and \nselective M AOIs . For example, t he desmet hyl congener of \ngeiparvarin, a nat ural 7- substitued coumarin from t he leaves \nof Geijera parviflora  L., exhibites potent and sele ctive \nMAO-B  inhibition Fig. (1) [60]. \nFig. (1).  Umbelliferone and geiparvarin derivatives . \n \n Several resear ch grou ps have been ex ploring t he impor -\ntance of t he number and position of different s ubstituents on \nthe coumarin n ucleus, taking into a ccount vol ume, lipoph il-\nicity, steri c impediment, ele ctron wit hdrawing and ele ctron \ndonating characteristic s. Different s ubstituents were atta ched \nto th e coumarin s keleton wit h the aim of improving both  \nactivity and sele ctivity Fig. (2). Although pos itions 3  and 7 \nof the coumarin ring were t he most st udied, all t he substitu-\ntion possibilities were ta ken into a ccount and a big nu mber \nof coumarin derivatives h ave been synt hesized and eval uated as M AOIs, being most of t hem ac tive and sele ctive against \nMAO-B  isoen zyme [6 1-81]. \n It is important to mention t hat the IC50 values given in t he \nfollowing tables res ulted from different e xperimental set -\ntings .  \n2. COUMAR IN DERIVATIV ES AND MAO ACTIVITY \n The first str ucture-activity relations hip stu dies (SAR) \nabout coumarin derivatives s uggested t hat selec tivity was \nmainly determined by t he natu re of t he linkage between t he \ncoumarin and t he substituent grou p at position 7.  A series of \n7-hydrox ycoumarin derivatives I bearing at position 7 et her, \nester or c arbamate f unctions of varying si ze and lipoph ilicity \nhave been investigated for t heir in vitro  MAO-A  and -B  in-\nhib\nitory a ctivities . Most of t hese compo unds res ulted to be \npreferentially M AOIs-B. SAR studies also sh owed t hat lipo -\nphilicity is an important property to mod ulate t he MAO-B  \ninhibition potenc y of t he above mentioned c oumarins [ 61-\n68]. A 7-benz yloxy grou p proved to be t he favou ring s ub-\nstituent for t he binding of coumarins to M AO-B , whereas a \n/g1-electron- poor ph enyl ring at position 7 seems to improve \nboth MAO-A a nd M AO-B  inhibitiory a ctivities, leading to \nmore a ctive b ut slig htly less sele ctive in hibitors [ 62]. A. Ca-\nrotti et al. described a large family of c ompo unds related to \nthese str uctures. On the other hand, it h as been proved t hat \nan al kylsulfonylox y grou p at position 7 provided M AOIs -A \nlike esuprone . This effe ct is even more pronou nced in t he \nphenyl s ulfonates in w hich the subs tit ution wit h elec tron \nwithdrawing grou ps lead to more potent and h ighly sele ctive \nMAOIs-A.  Also, B. Rendenba ch-Mueller et al. synthesized \nand st udied t he potential of et her derivatives and s ulfonic  \nacid esters F ig. (3), checking t hat introd uction of a s ulfonic \nester lin kage, instead of t he ether bridge, dramati cally \nchanged t he activity profile of t he new c ompou nds [63] . \n S ubs\ntitutions at position 3  and/or 4 of t he coumarin n u-\ncleus also contribu te to mod ulate M AO-B  inhibitory a ctivity \nand A/B sele ctivity of t he previou sly desc ribed derivatives . \nIt can be inferred t hat the MAO-B  binding site s hould accept \nlipoph ilic substituents of limited si ze at positions 3 and/or 4 \nof the coumarin n ucleus, whereas hydroph ilic or larger hy-\ndroph obic grou ps  are not well tolerated [6 2]. However, de -\nrivatives of 7- benz yloxycoumarins bearing properly sele cted \npolar s ubstituents at position 4 led to new M AOIs-B with an \nimproved ph arma cokinetic profile and a h igher dr uggability \n[64].  \n B. Rendenba ch-M\u00fcller et al. also ex plored t he impor -\ntance of t he presen ce of a h eteroarylal koxy grou p at position \n7 of t he coumarin s caffold to modu late t he activity against \nMAO i\nsoforms [56 ]. In this stu dy, small al kyl, ph enyl or \nhalogen grou ps were introduc ed at positions 3  and 4 of t he \nskeleton . The same au thors eval uated and des cribed het-\neroarylal koxycoumarins as potent and sele ctive M AOIs -B \n[63, 65, 68]. Only small s ubstituents, as met hyl grou ps, were \nintrod uced at positions 3  and 4 of t his coumarin n ucleus.  \n Based on previo usly des cri bed S AR studies, introduc tion \nof cycloalip hatic or benz ene rings f used at 3 ,4-positions was \nperformed on 7-hydrox ycoumarin derivatives . A. Carotti et \nal. and B. Rendenba ch-Mueller et al. described series of \nthese derivatives wit h interesting M AO-B  properties [6 2, 65,\n1682212    Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n \nFig. (2). Chemical str uctures of known coumarins as M AOIs. \n \n \nFig. (3).  7-Alkyloxy and s ulfonylox y coumarin derivatives . \n \n66]. L. Santana et al. have reported t hat annelation wit h 5- \nand 6-membered rings on t he coumarin n ucleus, in addition \nto 7 -acetonylox y-substitutents, s howed higher a ctivity \nagainst bot h MAO isoforms t han the 7-hydrox y pre cursors \n[66]. These derivatives presented different M AO-A/ MAO-B \nselectivity profiles, as s hown in t he (Table 2). \n In order to c omplete t he study of 7- substitu ted coumarin \nderivatives, A. Carotti et al. synt hesized and eval uated t he in \nvitro  biologic al M AO a ctivity of novel series of c oumarins \nbearing different s ubstituents at position 7.  Such s ubstituents \nconsisted of a ph enyl ring link ed to a coumarin core by \nbridges of different si ze, lengt h and lipoph ilic and ele ctronic  \nnature. In general, isosteri c variations of t he oxymet hylene \nlinker  lead to in hibitors wit h lower MAO-B  affinity and B/A \nselectivity [ 62, 67]. \n The reported res ults for 7- substituted coumarins contain-\ning a benz ene ring fu sed at 3 ,4 positions en couraged M . J. \nMatos et al. to analy ze the importanc e of t he aryl s ubstituent \non the pyrone ring, synt hesizing a series of 3-aryl coumarin \nderivatives IV. The substitution at C7 was removed and small s ubstituents were introd uced eith er at C6  [69 -74] \nor/and C8 [75, 76 ] positions . The high MAO-B  sele ctivity \nfound for t his new 3-aryl coumarin s caffold en couraged t he \nauthors to synt hesize and st udy the MAO in hibitory a ctivity \nof new analogu es. A variety of grou ps wit h different si ze, \nelectronic and lipoph ilic properties were introduc ed in both  \naromati c rings, in order to clarify t he infl uence of t he substi-\ntuti\non pattern in t he MAO in hibitory a ctivity and sele ctivity \nof the 3-aryl coumarin s keleton [69-7 6]. Most a ctive com-\npounds present para  or meta  substitutions in t he 3-phenyl \nring. /g1The best c ompou nd of t he des cribed series is t he 6-\nmethyl-3-(4\u2019- methylphenyl)coumarin (compou nd 245), wit h \nan IC50 of 0.3 1 nM . This compo und proved to be not only 6 4 \ntimes more a ctive in vitro  than selegiline ( the referen ce com-\npound) but also several times more sele ctive t han it (com-\npound 245 is > 97 fold more sele ctive t han selegiline ) [72] ./g1\n Additionally, a hydrox yl grou p at position 4 of t he cou-\nmarin s keleton was introduc ed. This modifi cation allowed to \nconsider th e similarity of th e core str ucture of t he 4-\nhydrox ycouma\nrin comparing wit h the 2-hydrox yisoflavone . \nTaking into a ccount the obtained res ults, it c ould be estab -\n169Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2213  \nTable 1. Ch emical Structures and MAO I nhibition  Data of 7-hydroxycoumarin  Derivatives I (Compou nds 1-192) \nO O ROR4\nR3 R6\nR8R5\n \n \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g46M) MAO-B \nIC50 (/g46M) Ref. \n1 H H C H3 H H OCH 3 80.3 0 > 100 66 \n2 H H C H3 H H C H3 > 100 71.3 2 66 \n3 H H C H3 H H H > 100 80. 41 66 \n4 H N H2 H H H OCH 3 > 100 > 100 66 \n5 \nOCH3 H3C\n CH 3 C H3 H H H 11. 0 0. 004 61 \n6 H3CO\nO  CH 3 C H3 H H H 9.20 0.9 4 61 \n7 \nOO\nH3C  CH 3 C H3 H H H 5 .90 0. 11 61 \n8 O\nOCH3 H3C\n CH 3 C H3 H H H 7 .70 0. 014 61 \n9 O\nOCH3 H3CCH3\n CH 3 C H3 H H H 4 .10 0. 004 61 \n10 O\nO CH 3 C H3 H H H 20 (15%)  0 .028 61 \n11 O\nO CH 3 C H3 H H H 10 (0%) 10 (27%)  61 \n12 N\nO CH 3 C H3 H H H 34.0 0. 89 61 \n13 N\nHO\nH3C CH 3 C H3 H H H 0 .70 0. 84 61 \n14 NHCH3\nH3CO\n CH 3 C H3 H H H 1 .13 0 .14 61 \n15 H3CO\n H H H H H > 100 0. 044 66 \n16 O\n H C H3 H H H 0 .041 0. 006 66 \n17 O\n H C H3 H H OCH 3 2 .66 0 .86 66 \n18 O\n H C H3 H H C H3 0 .007 0. 011 66 \n19 O\n H C H3 H H H 4 3.0 > 100 66 \n20 O\n H C H3 H H OCH 3 15. 45 > 100 66 \n21 O\n H C H3 H H C H3 0 .40 0. 004 66 \n22 CH 3 C H3 C H3 H H H 0 .071 0. 0005 63 \n1702214    Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 1) contd\u2026. \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g38M) MAO-B \nIC50 (/g38M) Ref. \n23  CH 3 C H3 H H H 31.60 3.24 67 \n24 \nCH3H3C\n Cl CH 3 H H H > 10 0. 004 56  \n25  H H H H H 6.76 0 .055 62 \n26  CH 3 H H H H 5 .50 0. 007 67 \n27  H C H3 H H H 1 .95 0. 018 62 \n28  CH 3 C H3 H H H 0 .69 0 .004 62 \n29  H OH H H H 15 (26%) 1 .58 62 \n30  H C F3 H H H > 5 1 .38 62 \n31   CH 3 H H H 3 (4%) 3 (8%) 62 \n32  H \n H H H > 4 > 4 62 \n33  CH 3 C H3 H H C H3 0 .56 3.31 62 \n34  CH 3 C H3 H \nO H > 0.4 > 0.4 62 \n35  CH 3 C H3 H OH H 112. 20 3.09 62 \n36 CH3\n CH 3 C H3 H H H 3.55 0.3 2 62 \n37 CH3\n CH 3 C H3 H H H > 0.54 0. 001 56  \n38 H3C\n CH 3 C H3 H H H 0 .39 0 .001 56  \n39 H3C CH 3 C H3 H H H 0 .56 0 .001 56  \n40 CH3\nH3C  CH 3 C H3 H H H > 10 0. 004 56  \n41 \nH3CH3C\n H H H H H > 10 0. 002 56  \n42 \nH3CH3C\n H C H3 H H H > 10 0. 005 56  \n43 \nH3CH3C\n CH 3 H H H H > 10 0. 003 5 6 \n44 \nH3CH3C\n CH 3 C H3 H H H > 10 0. 007 56  \n45 \nH3CH3C\n CH 3 C H3 H Cl H > 10 0. 031 56  \n46 \nH3CH3C\n CH 3 C H3 H H C H3 > 100 > 100 63 \n47 H3C\nH3CCH3\n CH 3 C H3 H H H > 10 10. 0 63 \n48 \nH3CH3C\nH3C CH 3 C H3 H H H > 10 0. 032 56  \n49 F F\nF\n CH 3 C H3 H H H 0 .30 0. 001 56  \n50 F\nF\nF  CH 3 C H3 H H H > 10 0. 002 56  \n171Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2215  \n(Table 1) contd\u2026. \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g37M) MAO-B \nIC50 (/g37M) Ref. \n51 H3CO\n CH 3 C H3 H H H 1 .51 0. 004 62 \n52 H3CO CH 3 C H3 H H H 2 .10 0. 0006  5 6 \n53 OF\nF\nF\n CH 3 C H3 H H H 5 .89 0 .011 62 \n54 F\n CH 3 C H3 H H H 0 .58 0. 003 62 \n55 F CH 3 C H3 H H H 0 .12 0. 003 62 \n56 F\nF CH 3 C H3 H H H 0 .12 0. 001 62 \n57 F\nF  CH 3 C H3 H H H 0 .68 0. 003 62 \n58 HO\nF CH 3 C H3 H H H 0 .11 0. 007 62 \n59 F F\nF\nF F CH 3 C H3 H H H 0 .69 0 .006 62 \n60 Cl\n CH 3 H H H H 12. 59 0 .005 67 \n61 Cl\n CH 3 C H3 H H H 1 .12 0. 003 62 \n62 Cl CH 3 C H3 H H H 0 .12 0. 003 62 \n63 O2N\n H C H3 H H H 0 .13 0 .013 62 \n64 O2N\n CH 3 C H3 H H H 0 .076 0 .003 62 \n65 O2N CH 3 C H3 H H H 0 .83 0 .009 62 \n66 O2N\nO2N  CH 3 C H3 H H H 0 .18 0. 006 62 \n67 H2N\n CH 3 C H3 H H H 1 .0 0. 035 62 \n68 H\nN\nOH3C\n CH 3 C H3 H H H 7 .08 0. 25 62 \n69 HO\n CH 3 C H3 H H H 0 .42 0. 010 62 \n70 CN\n CH 3 C H3 H H H 0 .42 0. 023 62 \n71 NC\n CH 3 C H3 H H H 0 .22 0. 011 62 \n72 NC CH 3 C H3 H H H 0 .10 0. 004 62 \n73 (CH2)2 CH 3 C H3 H H H 1 .0 0. 006 62 \n74 (CH2)2 CH 3 C H3 H C H2CH 3 H > 10 0. 010 56  \n75 \nOH CH 3 C H3 H H H 10. 0 0. 071 67 \n1722216     Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 1) contd\u2026. \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g38M) MAO-B \nIC50 (/g38M) Ref. \n76 \nO CH 3 C H3 H H H 9.77 0. 018 67 \n77 (CH 2)3 H H H H H 1 .50 0. 004 56  \n78 (CH 2)3 CH 3 C H3 H H H 1 .20 0. 004 56  \n79 (CH2)2\nO CH 3 C H3 H H H 10. 23 0 .027 67 \n80 H\nH CH 3 C H3 H H H 31.62 0. 11 67 \n81 H\nH H H H H H 100. 0 0. 058 67 \n82 N\n CH 3 C H3 H H H 1 .80 0. 009 63 \n83 N\n CH 3 C H3 H Cl H > 10 0. 0007 65 \n84  CH 3 C H3 H H H > 10 0. 011 65 \n85 O\nO  CH 3 C H3 H H H 10. 0 0. 008 65 \n86 O\n CH 3 C H3 H H H > 10 0. 002 65 \n87 SO2\nH3C  CH 3 C H3 H H H 110. 0 > 100 63 \n88 SO2 H3C CH 3 C H3 H H H 0 .008 5. 0 63 \n89 S\nO2(CH2)4\nH3C CH 3 C H3 H H H 0 .016 2 .20 63 \n90 SO2(CH 2)7\nH3C CH 3 C H3 H H H 0 .034 > 10 63 \n91 SO2 H H H H H 0 .45 54.9 5 67 \n92 SO2 CH 3 C H3 H H H 0 .024 1. 10 63 \n93 SO2 H3C CH 3 C H3 H H H 0 .047 15 (17%)  62 \n94 SO2 H3CO CH 3 C H3 H H H 0 .071 16.98 62 \n95 SO2 Cl CH 3 C H3 H H H 0 .005 0. 004 63 \n96 SO2 NC\n CH 3 C H3 H H H 0 .008 > 100 63 \n97 SO2 Br CH 3 C H3 H H H 0 .006 > 100 63 \n98 SO2 O2N CH 3 C H3 H H H 0 .013 2 (20%)  62 \n99 SO2 CH 3 C H3 H H H 2 .0 100. 0 67 \n100 \nSO2 CH 3 C H3 H H H 2 .82 0. 87 67 \n101 O Cl\n CH 3 C H3 H H H > 10 0. 017 65 \n102 SH3C\n CH 3 C H3 H H H 0 .35 0. 0005 65 \n103 S\nCH3 CH 3 C H3 H H H 0 .23 0 .0005 65 \n104 SH3C\nH3CH3C\n CH 3 C H3 H H H > 10 0. 001 65 \n173Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2217  \n(Table 1) contd\u2026. \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g37M) MAO-B \nIC50 (/g37M) Ref. \n105 S\nNH3C\n CH 3 C H3 H H H 10. 0 0. 003 65 \n106 S\nN CH 3 C H3 H H H 3.20 0. 006 65 \n107 NN\nOH3C  CH 3 C H3 H H H 10. 0 0. 001 68 \n108 S\nNH3C\nCH3  CH 3 C H3 H H H > 10 0. 003 65 \n109 S\nNH3C\nH3C Cl CH 3 H Cl H > 10 0. 002 65 \n110 S\nN\n CH 3 C H3 H H H 10. 0 0. 001 65 \n111 S\nN\n Cl CH 3 H Cl H > 10 0. 002 65 \n112 \nN\nOH3C\n CH 3 C H3 H H H 1 .50 0. 002 65 \n113 NOH3C\n CH 3 C H3 H H H 10. 0 0. 002 65 \n114 NOOH3C\n CH 3 C H3 H H H 10. 0 0. 005 65 \n115 \nNOH3CCH3\n CH 3 C H3 H H H 6.0 0. 0007 65 \n116 \nNOH3COCH3\n CH 3 C H3 H H H 2 .90 0. 001 65 \n117 NOH3C\nCH3  CH 3 C H3 H H H 10. 0 0. 002 65 \n118 \nNOCH3\nH3C\nH3C\n CH 3 C H3 H H H > 10 0. 001 65 \n119 \nN\nO  CH 3 C H3 H H H > 10 0. 001 65 \n120 \nO\nN  CH 3 C H3 H H H 7 .0 0. 001 65 \n121 \nN\nO  CH 3 C H3 H H H > 10 0. 001 65 \n122 \nNO  CH 3 C H3 H H H > 10 0. 001 65 \n123 NO\n CH 3 C H3 H H H > 10 0. 014 65 \n124 \nN\nOCH3\n CH 3 C H3 H H H 20. 0 0. 0006  65 \n125 \nNOO CH 3 C H3 H H H 5 .0 0. 004 65 \n126 \nNNH3CCH3\nCH3 CH 3 C H3 H H H 10. 0 0. 005 65 \n127 \nN\nNH3CCH3\nH3C  CH 3 C H3 H H H > 10 0. 002 65 \n1742218     Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 1) contd\u2026. \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g38M) MAO-B \nIC50 (/g38M) Ref. \n128 \nNNCH3\nH3C\nH3C  Cl CH 3 H H H > 10 0. 002 65 \n129 \nNNCH3\nH3C\nH3C  CH 3 C H3 H C H2CH 3 H > 10 0. 009 65 \n130 NNH3C\nH3C  CH 3 C H3 H H H > 10 0. 010 65 \n131 N\nN\nOH3C  CH 3 C H3 H H H 5 .60 0. 015 65 \n132 N\nN\nO\n CH 3 C H3 H H H 10. 0 0. 001 65 \n133 NN\nO O H3C  CH 3 C H3 H H H > 10 0. 008 65 \n134 N\nNOH3C\n CH 3 C H3 H H H 4 .0 0. 004 65 \n135 N\nN\nOCH3\nH3C\n CH 3 C H3 H H H > 10 0. 001 65 \n136 N\nN\nO  CH 3 C H3 H H H 7 .0 0. 001 65 \n137 N\nNN\nH3CCH3 CH 3 C H3 H H H > 10 0. 013 65 \n138 NN\nSH3C\nCH3  CH 3 C H3 H H H > 10 0. 001 68 \n139 NN\nSH3C\nCH3  CH 3 C H3 H Cl H > 10 0. 003 68 \n140 NN\nSH3C  CH 3 C H3 H H H 3.60 0. 003 65 \n141 NN\nSH3C  CH 3 C H3 H C H2CH 3 H > 10 0. 007 65 \n142 NN\nSH3C  CH 3 H H H H > 10 0. 015 65 \n143 NN\nSH3C  Cl CH 3 H H H > 10 0. 006 65 \n144 NN\nSH3C  CH 3 C H3 H Br H > 10 0. 001 65 \n145 NN\nSCH3\n CH 3 C H3 H H H > 10 0. 002 68 \n146  H NHNH2O\n H H H 1 .44 0. 040 64 \n147 Cl\n H NHNH2O\n H H H 2 .50 0. 090 64 \n148 Cl\n H NHO\nNH2 H H H > 100 > 10 64 \n175Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2219  \n(Table 1) contd\u2026. \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g37M) MAO-B \nIC50 (/g37M) Ref. \n149  H NH2O\n H H H 8 .0 0. 20 64 \n150 Cl\n H NH2O\n H H H 2 6.0 0. 030 64 \n151 F\n H NH2O\n H H H 70. 0 0. 050 64 \n152 HO\n H NH2O\n H H H 4 .27 1. 0 64 \n153  H NH2CH3O\n H H H 2 .80 0. 015 64 \n154 Cl\n H NH2CH3O\n H H H 0 .50 0. 024 64 \n155 Cl\n H NHO\nCH3 H H H > 100 > 10 64 \n156 Cl\n H NHO\n H H H > 100 5. 0 64 \n157  H NO\nCH3CH3\n H H H 2 3.10 0. 40 64 \n158 Cl\n H NO\nCH3CH3\n H H H > 100 0. 040 64 \n159 Cl\n H NO\nCH3\nCH3 H H H > 100 > 10 64 \n160 \nN  H NH2O\n H H H 21. 0 1.3 0 64 \n161 N\n H NH2O\n H H H 2 6.50 2. 0 64 \n162  H NH2O\nH3C\n H H H 6.26 0 .10 64 \n163 F\n H NH2O\nH3C\n H H H 2 .0 0. 10 64 \n164  H H\nN\nCH3\n H H H 15. 40 0. 028 64 \n165 Cl\n H H\nN\nCH3\n H H H 5 .94 0. 013 64 \n166 F\n H HN\nCH3\n H H H 1 3.50 0. 018 64 \n1762220    Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 1) contd\u2026. \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g38M) MAO-B \nIC50 (/g38M) Ref. \n167 O\nO\n H H\nN\nCH3\n H H H 5 .40 0. 020 64 \n168 F\n H H\nN CH3\n H H H 22.6 0 0. 10 64 \n169 F\n H H\nN CH3\nCH3 H H H 91.0 3.80 64 \n170 Cl\n H HN\n H H H > 100 3.60 64 \n171  H N\nCH3CH3\n H H H 100. 0 1. 80 64 \n172 Cl\n H N\nCH3CH3\n H H H 50. 80 1. 12 64 \n173 F\n H N\nCH3CH3\n H H H > 100 0. 51 64 \n174 Cl\n H NH3C\n H H H > 100 8. 0 64 \n175  H NH2\n H H H 4 .40 0. 021 64 \n176 Cl\n H NH2\n H H H 2 .0 0. 015 64 \n177  H CN\n H H H 0 .20 0. 23 64 \n178 Cl\n H CN\n H H H 0 .47 0. 016 64 \n179  H HNNH2\nO  H H H 100. 0 0.6 8 64 \n180 Cl\n H HNNH2\nO H H H 10 (35%) 0 .21 64 \n181  H NNH2\nO H H H 99.80 16. 10 64 \n182 Cl\n H NNH2\nO H H H 10 (5%) 9.60 64 \n183 Cl\n H HNNH2\nOCH2OH\n H H H > 100 2. 40 64 \n184  H H\nNO\nNH2 H H H 22. 70 1. 80 64 \n185  H NO\nNH2\n H H H 35.0 0.3 8 64 \n186 F\n H NO\nNH2\n H H H > 100 0. 85 64 \n177Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2221  \n(Table 1) contd\u2026. \nCpds R R3 R4 R5 R6 R8 MAO-A \nIC50 (/g49M) MAO-B \nIC50 (/g49M) Ref. \n187 Cl\n H NH2\n H H H 31.80 0. 25 64 \n188 Cl\n H NH\nCH3 H H H 74. 0 0.3 0 64 \n189  H N\nCH3CH3\n H H H 25.9 0 0. 46 64 \n190 H H H H \nO H 2 3.44 2. 04 62 \n191 H C H3 C H3 H \nO H 112. 20 3.09 62 \n192 H C H3 C H3 \nO H H 30 (35%) 30 (18%)  62 \n \nTable 2. Chemi cal Structures and MAO I nhibition  Data of Substituted Co umarin s with 3,4-fused Cycloalip hatic or Benzene Rings \nII (Compou nds 193-211) \nO O RO\nR8  \nCpds R R3 R4 R8 MAO-A \nIC50 (/g49M) MAO-B \nIC50 (/g49M) Ref. \n193   H 1 .58 0. 003 62 \n194   H 1 .58 0. 003 62 \n195   H 1 (7%) 0 .050 62 \n196 \nNNSH3C\n  H > 10 0. 007 65 \n197 NNH3C\nH3CH3C\n  H > 10 0. 10 65 \n198 H  H 48. 20 > 100 66 \n199 H  OCH3 63.53 > 100 66 \n200 H  CH 3 > 100 > 100 66 \n201 H \n OCH3 > 100 50. 20 66 \n202 H \n CH 3 60.11 > 100 66 \n203 H3C O\n  OCH3 0 .12 12.9 8 66 \n1782222    Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 2) contd\u2026. \nCpds R R3 R4 R8 MAO-A \nIC50 (/g48M) MAO-B \nIC50 (/g48M) Ref. \n204 H3C O\n  CH 3 0 .24 0. 17 66 \n205 H3C O\n  OCH3 0 .37 12. 12 66 \n206 H3C O\n  CH 3 0 .004 17.3 0 66 \n207 H3C O\n  OCH3 11.93  9.36 66 \n208 H3C O\n  CH 3 2 .56 28. 13 66 \n209 Br\nO\n  CH 3 0 .13 1 .18 66 \n210 Br\nO\n  CH 3 0 .70 0. 24 66 \n211 Br\nO\n  CH 3 2 .38 0. 001 66 \n \nTable 3. Ch emical Structures and MAO I nhibition  Data of Coumarin s Bearin g a Carbo, Thio or Aza Spacer at Position  7 III (212-\n225) \nO O R7R4\nR3\n \n \nCpds R7 R3 R4 MAO-A \nIC50 (/g48M) MAO-B \nIC50 (/g48M) Ref. \n212 H\nH  CH 3 C H3 0 .41 0. 028 62 \n213 \nS CH 3 C H3 10. 0 0. 040 67 \n214 S\nO\nO CH 3 C H3 18.6 2 2. 75 67 \n215 SO2\nNH3C\nH3C CH 3 C H3 4 .57 31.62 67 \n216 SO2\nHNH3C\n CH 3 C H3 67.61 40 (29%) 62 \n217 \nHNO\n CH 3 C H3 1 .38 0. 19 62 \n218 \nHN CH 3 C H3 1 .58 0. 16 62 \n219  CH 3 C H3 7 .08 0. 46 67 \n179Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2223  \n(Table 3) contd\u2026. \nCpds R7 R3 R4 MAO-A \nIC50 (/g47M) MAO-B \nIC50 (/g47M) Ref. \n220 O\n H H 0 .39 0 .085 62 \n221 NH\n H H 41.69  2 .14 62 \n222 S\n H H 3.80 1. 29 67 \n223 SO\n H H 6.17 0. 58 67 \n224 SO\nO  H H 21. 88 25. 70 67 \n225 \nOO\n H H 9.55 2. 40 67 \n \nTable 4. Ch emical Structures and MAO I nhibition  Data of Differently  Substituted 3-arylcoumarin s IV (C ompou nds 226 -286) \nO OR3'\nR4'\nR6R4R2'\nR5'\nR7\nR8  \n \nCpds R2\u2019 R3\u2019 R4\u2019 R5\u2019 R4 R6 R7 R8 MAO-A \nIC50 (/g47M) MAO-B \nIC50 (/g1M) Ref \n226 H H H H H H H H > 100 11. 81 74 \n227 OH H H H H Cl H  H > 100 0. 44 69 \n228 H OH H H H Cl H  H > 100 0. 21 69 \n229 H H OH H H Cl H  H > 100 0. 13 69 \n230 OCH 3 H H H H Cl H  H > 100 > 100 69 \n231 H OCH 3 H H H Cl H  H > 100 0. 001 69 \n232 H H OCH 3 H H H H H > 100 0. 004 69 \n233 OH H H H H Br H H > 100 0. 48 69 \n234 H OH H H H Br H H > 100 0. 29 69 \n235 H H OH H H Br H H > 100 0.6 4 69 \n236 OCH 3 H H H H Br H H > 100 > 100 69 \n237 H OCH 3 H H H Br H H > 100 0. 002 69 \n238 H H OCH 3 H H Br H H > 100 0. 006 69 \n239 H H H H H Br H OCH 3 > 100 0. 083 7 3 \n240 H H H H H Br H OH > 100 30.91 73  \n241 H H OCH 3 H H Br H OCH 3 > 100 1.3 5 73  \n \n1802224    Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 4) contd\u2026. \nCpds R2\u2019 R3\u2019 R4\u2019 R5\u2019 R4 R6 R7 R8 MAO-A \nIC50 (/g39M) MAO-B \nIC50 (/g1M) Ref \n242 H H OH H H Br H OH 20. 74 16. 87 73  \n243 H H H H H C H2Br H H > 100 0. 043 69 \n244 H H H H H C H3 H H > 100 0. 28 72 \n245 H H C H3 H H C H3 H H > 100 0.3 1x 10-3 72 \n246 H C H3 H H H C H3 H H > 100 0. 015 72 \n247 H OCH 3 H H H C H3 H H > 100 0. 80x 10-3 72 \n248 H OH H H H C H3 H H 35.04 0.6 5 72 \n249 H H OCH 3 H H C H3 H H > 100 0. 013 72 \n250 H H OH H H C H3 H H > 100 0. 16 72 \n251 H OCH 3 OCH 3 H H C H3 H H 25. 14 0. 003 72 \n252 H OCH 3 H OCH 3 H C H3 H H > 100 0. 009 72 \n253 H OCH 3 OCH 3 OCH 3 H C H3 H H > 100 0. 16 72 \n254 H Br OCH 3 H H C H3 H H > 100 0. 74x 10-3 72 \n255 H OCH 3 Br H H C H3 H H > 100 0. 003 72 \n256 H O\nH3CO\n H H H C H3 H H > 100 0. 18 72 \n257 OCH 3 H H H H C H3 H H > 100 > 100 72 \n258 OH H H H H C H3 H H 21. 58 0. 12 72 \n259 Br H H H H C H3 H H > 100 4.3 4 75 \n260 Br OCH 3 H OCH 3 H C H3 H H > 100 54. 03 72 \n261 Br OCH 3 OCH 3 OCH 3 H C H3 H H > 100 > 100 72 \n262 H H H H H C H3 H Br > 100 0. 011 75 \n263 H H OCH 3 H H C H3 H Br > 100 0. 003 75 \n264 H OCH 3 H OCH 3 H C H3 H Br > 100 0. 007 75 \n265 H OCH 3 OCH 3 OCH 3 H C H3 H Br 31.20 4. 89 75 \n266 H C H3 H H H OCH 3 H H > 100 0. 018 72 \n267 H H C H3 H H OCH 3 H H > 100 0. 002 72 \n268 H H C H3 H H OH H H 24.9 0 0. 067 72 \n269 H H C H3 H H O\nH3CO\n H H > 100 5. 52 72 \n270 H H C H3 H H O\n H H > 100 14. 47 72 \n271 H H H H H H H C H3 6.26 0 .078 76  \n272 H H OCH 3 H H H H C H3 21.6 0 0. 003 7 6 \n273 H H C H3 H H H H C H3 > 100 0. 005 76  \n274 H H Br H H H H C H3 > 100 0. 020 76  \n275 H H H H H H H OCH 3 > 100 0. 15 76  \n276 H H Br H H H H OCH 3 > 100 0. 003 7 6 \n277 H H H H H H H OCH2CH3 > 100 1. 06 76 \n181Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2225  \n(Table 4) contd\u2026. \nCpds R2\u2019 R3\u2019 R4\u2019 R5\u2019 R4 R6 R7 R8 MAO-A \nIC50 (/g47M) MAO-B \nIC50 (/g1M) Ref \n278 H H OCH 3 H H H H OCH2CH3 > 100 0. 21 76  \n279 H H C H3 H H H H OCH2CH3 > 100 0. 15 76  \n280 H H H H OH H H H > 100 > 100 77 \n281 H H OCH 3 H OH H H H > 100 69.59 77 \n282 H H OCH 3 H OH C H3 H H > 100 32.04 77 \n283 H H OCH 3 H OH Cl H H > 100 > 100 77 \n284 H Cl OCH3 H OH H H H > 100 9.26 77 \n285 H Cl OCH3 H OH C H3 H H > 100 42.6 8 77 \n286 H Cl OCH3 H OH Cl H H > 100 2. 79 77 \n \nTable 5. Chemi cal Structures and MAO I nhibition  Data of Differently  Substituted 3-heteroaryl coumarin s V (Compou nds 287-298 ) \nO OHeterocycleR5\nR6\nR7  \n \nCpds R3 R5 R6 R7 MAO-A \nIC50 (/g47M) MAO-B \nIC50 (/g47M) Ref \n287 S\n H H H > 100 6.37 79  \n288 S\n H OCH 3 H > 100 0.63  7 9 \n289 S\n H H OCH 3 > 100 0. 26 7 9 \n290 S\n OCH3 H OCH 3 > 100 > 100 79 \n291 S\n H H H > 100 13.30 79 \n292 S\n H OCH 3 H > 100 0. 23 7 9 \n293 S\n H H OCH 3 4 .16 0 .056 7 9 \n294 S\n OCH3 H OCH 3 > 100 > 100 79  \n295 H\nN\n H H H > 100 1.9 2 79 \n1822226     Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 5) contd\u2026. \nCpds R3 R5 R6 R7 MAO-A \nIC50 (/g48M) MAO-B \nIC50 (/g48M) Ref \n296 H\nN\n H OCH 3 H > 100 > 100 79  \n297 H\nN\n H H OCH 3 9.67 0. 046 7 9 \n298 HN\n OCH3 H OCH 3 > 100 > 100 79  \n \nTable 6. Ch emical Structures and MAO I nhibition  Data of 3-carbonyl coumarin  Derivatives VI (Compou nds 299-316 ) \nO ORO\nR6\nR7\nR8  \n \nCpds R R6 R7 R8 MAO-A \nIC50 (/g48M) MAO-B \nIC50 (/g48M) Ref \n299 CH 3 H H H  > 100 14. 45 78 \n300 CH 3 H H OH 39.36 42. 13 78 \n301 CH 3 H OH H  > 100 > 100 78 \n302 CH 3 OH H H 100 (45%)  64.17 78 \n303 CH 3 H OCH 3 H 100 (45%)  15. 40 78 \n304 CH 3 H N (CH2CH 3)2 H > 100 18. 07 78 \n305 CH 3 C H3 H H  > 100 100 (45%)  78 \n306 CH 3 Cl H H > 100 17. 72 78 \n307 CH 3 Br H H 51.63  100 (45%)  78 \n308 CH 3 \n H 100 (45%)  2 .01 78 \n309 CH 3 Cl H Br 55 .16 0 .14 78 \n310 CH 3 Br H Br > 100 0.20 78 \n311 CH 3 I H I  > 100 >100 78 \n312 Cl H H H 0 .060 0. 12 80 \n313 Cl CH 3 H H 0 .029 0 .10 80 \n314 Cl Br H H 0 .020 0. 11 80 \n315 Cl Cl H H 0 .030 0. 010 80 \n316 Cl NO 2 H H 0 .029 0 .10 80 \n183Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2227  \nTable 7. Ch emical Structures and MAO I nhibition  Data of 3-benzoylcoumarin  Derivatives VII (C ompou nds 317-332) \nO O R4'R6\nR7\nR8O\n \n \nCpds R4\u2019 R6 R7 R8 MAO-A \nIC50 (/g49M) MAO-B \nIC50 (/g49M) Ref \n317 H H H H > 100 > 100 78 \n318 H Br H H > 100 > 100 78 \n319 H Br H OCH 3 > 100 > 100 73  \n320 H Br H OH 4 6.81 73.92 73  \n321 OH Br H OH 1 9.17 > 100 73 \n322 OCH3 Br H OCH3 > 100 > 100 73  \n323 H H H OH 40. 47 27. 11 78 \n324 H OH H H 51.66  17.9 7 78 \n325 H H OH H > 100 > 100 78 \n326 H H OCH 3 H > 100 100 (45%)  78 \n327 H H N (CH 2CH 3)2 H > 100 23. 84 78 \n328 H C H3 H H > 100 100 (45%)  78 \n329 H Cl H H > 100 > 100 78 \n330 H Cl H Br > 100 100 (45%)  78 \n331 H Br H Br > 100 100 (45%)  78 \n332 H I H I > 100 > 100 78 \n \nTable 8. Ch emical Structures and MAO I nhibition  Data of 3-carboxycoumarin  Derivatives VIII (C ompo unds 333-368) \nO OORR6\nR7\nR8O\n \n \nCpds R R6 R7 R8 MAO-A \nIC50 (/g49M) MAO-B \nIC50 (/g49M) Ref \n333 CH 2CH 3 H H H 0 .23 5 .01 80 \n334 CH 2CH 3 H H OH 40. 55 14. 81 78 \n335 CH 2CH 3 H OH H > 100 > 100 78 \n336 CH 2CH 3 OH H H 4 9.07 10. 06 78 \n337 CH 2CH 3 H OCH 3 H  100 (45%)  2 3.46 78 \n1842228     Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 8) contd\u2026. \nCpds R R6 R7 R8 MAO-A \nIC50 (/g38M) MAO-B \nIC50 (/g38M) Ref \n338 CH 2CH 3 OCH3 H H > 100 21.63  78 \n339 CH 2CH 3 H N (CH2CH 3)2 H > 100 45. 52 78 \n340 CH 2CH 3 Cl H Br > 100 17. 51 78 \n341 CH 2CH 3 Br H Br  > 100 100 (45%)  78 \n342 CH 2CH 3 I H I > 100 > 100 78 \n343 CH 2CH 3 H \nO H 4 6.35 0. 021 78 \n344 CH 2CH 3 C H3 H H 0 .19 1 .0 80 \n345 CH 2CH 3 Br H H 0 .21 1. 0 80 \n346 CH 2CH 3 Cl H H 0 .50 1. 0 80 \n347 CH 2CH 3 N O2 H H 0 .26 1 .0 80 \n348 CH 2CH 3 H O\n H > 100 0. 007 78 \n349 CH 2CH 3 H OCl\n H > 100 0. 061 78 \n350 CH 2CH 3 H O H3C\nH3C\nH3C\n H > 100 3.75 78 \n351 CH 2CH 3 H OCl\nCl\n H > 100 0. 009 78 \n352 H H H H 15. 14 0. 017 80 \n353 H C H3 H H 12. 02 0. 019 80 \n354 H Br H H 1 .0 0. 033 80 \n355 H Cl H H 0 .50 0. 023 80 \n356 H N O2 H H 0 .068 0. 019 80 \n357 H H H OH 5 9.61 100 (45%)  78 \n358 H OH H H 40. 20 100 (45%)  78 \n359 H H OCH 3 H > 100 100 (45%)  78 \n360 H OCH 3 H H > 100 > 100 78 \n361 H H N (CH 2CH 3)2 H > 100 > 100 78 \n362 H Cl H Br > 100 > 100 78 \n363 H Br H Br > 100 > 100 78 \n364 H I H I > 100 17. 78 78 \n365 H H \nO H > 100 8.6 2 78 \n366 H H OCl\n H > 100 1. 80 78 \n/g1\n185Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2229  \n(Table 8) contd\u2026. \nCpds R R6 R7 R8 MAO-A \nIC50 (/g50M) MAO-B \nIC50 (/g50M) Ref \n367 H H O H3C\nH3C\nH3C\n H > 100 > 100 78 \n368 H H OCl\nCl\n H > 100 0. 41 78 \n \nTable 9. Ch emical Structures and MAO I nhibition  Data of 3-carboxyhydrazide and 3-c arboxami de Coumarin  Derivatives IX \n(Compou nds 36 9-432) \nO OO\nN\nR7R''\nR'\n \n \nCpds R\u2019 R\u2019\u2019 R7 MAO-A \nIC50 (/g50M) MAO-B \nIC50 (/g50M) Ref \n369 NH2 H H > 100 0. 003 78 \n370 HN\n H H 41. 40 4. 52 78 \n371 \nHNO2N\n H H 39.56 > 100 78 \n372 HN CH3\n H H 58. 43 > 100 78 \n373 HN Cl\n H H 48. 02 1. 19 78 \n374 \nHN NO2O2N\n H H 60.49 5 6.12 78 \n375  H H > 100 0. 50 81 \n376 \nCH3CH3\n H H > 100 25.36  81 \n377 \nCH3CH3\n H H > 100 3.27 81 \n378  H H > 100 > 100 81 \n379 NH2 H H > 100 7.6 8 81 \n380  H H 1 3.12 0. 76 81 \n381 \n H H > 100 0.9 1 81 \n1862230    Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 9) contd\u2026. \nCpds R\u2019 R\u2019\u2019 R7 MAO-A \nIC50 (/g39M) MAO-B \nIC50 (/g39M) Ref \n382 CH3\n H H 14. 50 0.6 0 81 \n383 OCH3\n H H > 100 0.6 4 81 \n384 F\n H H > 100 0. 25 81 \n385 CF3\n H H > 100 0. 25 81 \n386 CH3\n H H 1 9.45 0. 71 81 \n387 \nCH3 H H 15.6 7 0. 89 81 \n388 \nCH3CH3\n H H 15. 14 0.6 5 81 \n389 \nOOCH2CH3\n H H 15.9 8 > 100 81 \n390 OCH3\n H H > 100 0. 82 81 \n391 SCH3\n H H 14. 76 2 .84 81 \n392 F\n H H 1 3.06 0 .067 81 \n393 CO2H\n H H 9.97 1. 14 81 \n394 COCl\n H H 9.67 > 100 81 \n395 SO2CH3\n H H 9.33 0 .001 81 \n396 OH\n H H > 100 0. 80 81 \n397 Cl\nH3C  H H > 100 19. 07 81 \n398 \nH3CCH3\n H H 15.9 5 22. 45 81 \n399 \nH3CCH3\n H H 12.3 2 13. 74 81 \n400 \nH3C CH3 H H 20.63  18. 27 81 \n401 \nH3CH3C\n H H 9.79 1 .29 81 \n/g1\n \n187Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2231  \n(Table 9) contd\u2026. \nCpds R\u2019 R\u2019\u2019 R7 MAO-A \nIC50 (/g38M) MAO-B \nIC50 (/g38M) Ref \n402 \nFF\n H H 12. 76 9.23 81 \n403 \nCH3CH3\n H H 18. 77 0.3 8 81 \n404 \nOCH3OCH3\n H H 9.45 0. 86 81 \n405 \nCH3CH3\n H H 17. 56 0 .70 81 \n406 \nOCH3OCH 3\n H H 61.46 4 .18 81 \n407 \nFF F\nF\nF  H H > 100 0. 46 81 \n408 \nFF F\nCN\nF  H H 1 6.04 0. 86 81 \n409 N\nFF F\nF  H H 11. 43 0 .58 81 \n410 \n H H > 100 1.96  81 \n411 \n H H > 100 > 100 81 \n412  CH 3 H > 100 8. 89 81 \n413 \n CH 3 H > 100 > 100 81 \n414   H > 100 > 100 81 \n415  H O > 100 64.45 81 \n416 \nCH3CH3\n H O 63.52 > 100 81 \n417 \nCH3CH3\n H O 58.64 9.59 81 \n418 CH3\nCH3 H O 60.93 3.69 81 \n419 \nFF F\nCN\nF  H O 61.38 16. 54 81 \n1882232    Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n(Table 9) contd\u2026. \nCpds R\u2019 R\u2019\u2019 R7 MAO-A \nIC50 (/g40M) MAO-B \nIC50 (/g40M) Ref \n420 \n H O 51.89 63.52 81 \n421 \nH3CCl\n H O 49.75 61.49 81 \n422 \nOCH3OCH3\n H O > 100 4.39  81 \n423 \nOCH3OCH 3\n H O 52.89 3.36 81 \n424 \n H O > 100 0.99  81 \n425 HN\n H O 41.40 4. 52 81 \n426 \nFF F\nCN\nF  H \nOF\n 58.49 3.45 81 \n427 \n H \nOF\n 55.83 > 100 81 \n428 \nH3CCl\n H \nOF\n 59.56 41.6 4 81 \n429 \nOCH3OCH3\n H \nOF\n 49.20 2. 87 81 \n430 \nOCH3OCH 3\n H \nOF\n 52.62 21. 56 81 \n431 CH3\nCH3 H \nOF\n > 100 > 100 81 \n432 \nOCH3OCH3\n CH 3 O > 100 2.3 7 81 \n \nlished a potential th erapeu tic appli cation of t hese flavon -\noids/coumarins analog ues as a new interesting s caffold with  \ninterest against age -related ne urodegenerative diseases s uch \nas PD or A D [77].  \n G. Delogu  et al. synt hesized new c oumarin derivatives V \nin w hich the 3-aryl ring is ch anged for a h eteroaryl gro up \nand e xplored t he importan ce of t he number and position of \nmethoxy grou ps on ( 1H)-ben zopyran str ucture [79 ]. In ge n-\neral, t hese derivatives were fo und to be sele ctive for t he \nMAO-B  isoform, wit h 7-methoxy-3-heteroarylc oumarins \nexhibiting inh ibition poten cies in t he low nanoMolar range \n[79].  S ubstitution of t he coumarin n ucleus at position 3  has \nbeen widely c arried o ut with phenyl and met hyl grou ps, bu t \nless data h ave been reported wit h polar grou ps like ketone \nalkylic (Table 6), ke tone aryli c (Table 7) and carboxylic acid \nor ethyl esth er (Table 8). D. Secci et al. have dedi cated par -\nticular attention to t he study of t he infl uence of t hese grou ps \non M AO in hibitory a ctivity and on A/B selectivity . For these \nderivatives, t he steri c hindran ce of t he substituent at position \n6 is parti culary important, in w hich only small s ubstituen ts \nare tolerated [78, 80].  3-Carbonyl chloride coumarins \nshowed a h igh potenc y against bot h isoforms [80].   \n189Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2233  \n By analyz ing the data reported in t he previou s (Table 6), \nit can be seen t hat 3-met hylketone coumarin derivatives \nshowed better inh ibitory a ctivity and sele ctivity against \nMAO-B  than their corresponding aryl ketones VII (Table 7). \nLikewise, an important lost of t he MAO-B  inhibitory a ctivity \nwas verified wh en the 3-phenyl s keleton was s ubstituted for \nthe 3-ben zoyl one [73 ]. Therefore, t he simple introd uction of \na ca\nrbonyl bridge between t he coumarin and t he 3-phenyl \nring changes dramati cally t he activity profiles . \n Compo unds bearing a C O2Et moiety at C 3 position, im -\nproved t he inhibitory ac tivity and sele ctivity towards MAO-\nB. However, t he hydrolysis of et hyl esters to t he correspond-\ning carboxylic acids de creased t he sele ctivity and t he inhibi-\ntory a ctivity towards M AO-B  [78, 80].  Results of M AO a c-\ntivity are s howed in (Table 8). \n D . Secci et al. also des cribed a series of 3-c arbox y hy-\ndrazide coumarin derivatives [78] as well as a series of 3-\ncarboxamide coum arin derivatives (T able 9) [81].  It can be \nseen t hat the majority of t he compou nds s how a sele ctive \ninhibitory a ctivity toward th e MAO-B  isoenz yme. Substitu-\ntion at position 7 on t he coumarin ring by a benz yloxy grou p \nleads to a dec rease in t he activity against bot h MAO iso -\nforms . Inhibitory a ctivity in creased w hen th e nitrogen is s ub-\nstituted by a ph enyl grou p. \n Takin g into a ccount the activity of th e above mentionated \namido coumaris, M . J. Matos et al. synt hetized analogs X \nand st udied t he possibility of link ing the amidi c grou p to t he \ncoumarin by t he nitrogen atom [74] . These compou nds could \nbe considered inverse amidi c derivatives wit h respe ct to th e \nlast des cribed mole cules IX. In spite of th ese considerations, \nthe new c ompo unds res ulted to be poor M AOIs . Howe ver, \nsome of t hem s howed AChE inhibitory a ctivity, being c on-\nsidered t herefore as d ual M AO/A ChE inhibitors [74].  Com -\npounds wit h such d ual in hibitory a ctivities are e xpected to \nhave potential for t he treatment of AD be cause they mig ht \ndecrease /g1-amyloid deposition [82] . \n3. SYNTH ETIC M ETHODOLOG IES \n D ue to t he interest of coumarins in ind ustry as additives \nin food, agroch emicals, cosmeti cs and ph ar ma ceuticals, syn -\nthesis of th e coumarin template is a topi c of cu rrent interest \nin organi c chemistry . Different met hodologies can be u sed to \nobtain t he des cribed compou nds, depending on t he starting \nmaterials and on t he desired final s ubstituents. Classi cally, \nthe most important synt hetic methodologies to obtain simple \ncoumarins are t he Pechmann, Perkin, Knoevenagel and Wit-\ntig rea ctions . \n The Pechmann rea ction allows to obtain t he couma rin \nscaffold by c ondensation of ph enols wit h /g1-ketoesters, in t he \npresen ce of a cid catalysts (usually s ulphuric  acid) (Scheme \n1). Although this is th e most c lassical synt hetic route to ob-\ntain th e coumarin n ucleus wit h alkyl, aryl, halogen, haloge-\nnomet hyl or h ydrox y substitu ents, some slig ht modifi cat ions \nto th e traditional P echmann rea ction were performed, de -\npending on t he stability and rea ctivity of t he used p henols \nand /g1-dicarbonyls [6 2, 64, 66, 8 3-85].  Several efforts are still \nbeing devoted to improve its performan ce by t he use of spe -\ncific catalysts and /or mi crowave radiation in ioni c liquids \nmedia or solvent -free conditions [86-8 9]. The use of perch lo-ric acid as t he condensing agent allows, for e xample, t he \nsynthesis of differently s ubstituted 7-hydro xycouma rin de -\nrivatives [9 0]. \n The Perkin rea ction is an aldoli c condensation of an or-\ntho-hydrox ybenz aldehyde and t he conveniently s ubstituted \nacid an hydrides, in t he presen ce of an al kali salt of th e acid \n(Scheme 2). This meth odology is perh aps the most dire ct and \nsimple met hod known for t he preparation of 3-aryl cou mar -\nins. However, t he overall yields of t he final produc ts in th ese \nre\nactions are invariably low and t he variety of s ubstrates is, \nin most cases, limited [47].  Thus, a lig htly modified version \nof this meth odology is c ommonly used for t he synt hesis of \nthe 3-aryl or 3-heteroaryl s ubstituted coumarins [ 69-73, 75, \n76, 91]. In this rea ction, t he coumarin n ucleus is obtained \nstarting from th e ortho-hydrox ybenz aldehyde and t he con-\nveniently s ubstituted aryla cetic acid, in th e presen ce o f N,N\u2019 -\ndicyclohexylcarbodiimide (DCC ), the deh ydrating agent, \nunder DMS O reflux.  \n The Knoevenagel rea ction is a c ondensation rea ction t hat \naffords t he coumarin derivatives starting from ortho -\nhydrox ybenz aldehydes and a ctive met hylene compou nds, in \npresen ce of ammonia or amines ( Scheme 2). The reac tion is \nusually catalysed by wea k bases or by s uitable combinations \nof amines (usually piperidine ) and c a rbox ylic or Lewis ac ids \nunder homogeneou s conditions [78, 81].  The use of Mel-\ndrum\u00b4s a cid in presen ce ionic  liquids, res ults a simple and \nalternative met hod to obtain 3-c arboxycoumarins [ 92]. A \nlarge list of coumarins has been synt hesised using t he \nKnoevenagel condensation . Benzoyl coumarins [7 3], as well \nas amino [ 93], amides [9 4], and 3-al kylamino s ubstituted \ncoumarins are some ex am ples of th e potential of th is met h-\nodology [56 , 68]. \n In order to afford m ultigram s cale synt hesis and easy \npurification, F. Chimenti et al. described t he preparation of \nthe 3-carboxycoumarin s caffold by t he hetero cyclization \nreaction of 2-hydrox ybenz aldoximes and c arbon s uboxide \n(Scheme 3) [80].  The basi c hydrolysis of t he carbox amide \nin\ntermediate and t he subsequent f unctionali zation of t he car-\nboxylic acid intermediate, affords c arbox ycoumarin deriva -\ntives wit h high MAO inhibitory ac tivity . \n Wittig rea ction is also an effic ient and easy met hod for \nthe synt hesis of coumarins (Scheme 4). This meth od consists \nin th e reac tion of ortho -hydrox ycarbonyl aromatic  com-\npounds wit h phos ph onium ylides and t he subsequent in -\ntramole cular cyclization [9 5]. This type of rea ction is a use-\nful meth od to obtain prenylated coumarins [ 96, 97]. Also, \naryl-, alkoxy-, or carboxycoumarin derivatives can be ob -\ntained via Wittig rea ction, under classical conditions or im -\nproved protoc ols [70, 9 8, 99]. A variety of nitro/ amine cou-\nmarins was prepared using mi cr owave irradiation in solvent \nfree conditions [96] and large combinatorial libraries of 3-\nhalogenoc oumarins were obtained by one-pot  three compo -\nnent bromination/ Wittig /cyclization pro cess [100].  \n The palladiu m catalysed chemistry is an alternative \nmethodology for t he preparation of 4 -substituted coumarin \nderivatives . 4-Aryl/ alkylcoumarins can be obtained from t he \ncorresponding ph enols by palladi um-catalysis reac tion with  \nthe appropriated propiolates or a crylates [101 -103]. \n1902234    Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n \nScheme 1. Pechmann reac tion. \n \nScheme 2. Perkin and Knoevenagel rea ctions . \n \n \nScheme 3. Hetero cyclization reac tion of 2 -hydrox ybenz aldoximes and c arbon s uboxide. \n \n \nScheme 4. Wittig rea ction. \n \n Spe cial mention m ust be made regarding t he aryl cou-\nmarin derivatives . Additionally to t he above mentioned c y-\nclo-condensation rea ctions, 3- and or 4- arylcoumarins can be \nobtained, starting from h alogen or hydrox ycoumarins by \ndirect cross-coupling palladi um arylation . The most c ommon \nhalogenc oumarin used as starting material is t he 3-bromo \nderivative . Therefore, libraries of 3-arylcoumarins were pre -\npared starting from t he 3-bromoc oumarin by P d-cataly zed  \ncoupling wit h boroni c esters, ac etylenes, or vinyl c ompou nds \n[104].  However, very re cently o ur resear ch grou p has used \nfor the first time th e 3-chlorocoumarin as starting material \nand has prepared different 3-aryl coumarins by a P d-\ncataly zed cross-coupling rea ction using a c atalyti c comple x \nPd-salen [105] . \n Other starting materials for t he arylation of t he coumarin \nring are t he 4-hydrox ycoum arin derivatives . Due to t he spe -\ncial rea ctivity of th e 4-hydrox ycoumarin ring, t he coupling \narylation can ta ke pla ce in eit her 3 or 4 positions, depending \non the rea ction conditions . The general palladi um protoc ol or \nthe Suzuk i-Miya ura couplings are an effi cient met hod for \ncoupling 4-hydrox ycoumarins . Through the intermediated \ntriflate and tosylate derivatives, 4 -ar yl coumarins can be pre -\npared in h igh yields [9 8, 106 , 107].  However, t he coupling arylation can ta ke pla ce also at position 3.  Reaction of 4-\nhydrox ycoumarins wit h iodobenz ene diac etate gives t he 3-\nphenyliodoni um zwitterion intermediates w hich couple with  \nsubstituted arylboroni c acids in th e palladiu m-cataly zed Su-\nzuki-type rea ctions  [77]. The exc e llent yields ma ke this \nmethod a val uable tool for generating diversified 4-hydrox y-\n3-aryl coumarin derivatives . According to t hese met hodolo -\ngies, wh en t he starting c ompou nds are 4 -hydrox y-3-\nbromoc oumarins, it is possible to design an effi cient proto col \nfor t he synt hesis of 3- and /or 4- arylcoumarin derivatives \n[108].  \n The SAR studies performed wit h coumarin derivatives \nsuggested t hat ac tivity and sele ctivity were mainly deter -\nmined by t he char ac teristi cs of t he substituents in th e cou-\nmarin moiety [6 1, 64]. For this reason, du ring t he last years \nnew synt hetic strategies h ave been des cribed using as start -\ning materials t he previo usly synt hesized coumarin ring . Most \nof the coumarin derivatives were prepared by n ucleophilic \nsubstitution of simple h ydrox y, amine or halogen coumarins \nunder refl ux of a cetone, xylene, eth anol, or ot her solvents in \nthe  presen ce of potassi um carbonate (Scheme 5). Therefore, \ncoumarins wit h benz yloxy [64, 84] and some al kylsulfony-\nloxy [67] grou ps were e xtensively synt hesized as a ctive and\n191Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2235  \nTable 10. Ch emical Structures and MAO I nhibition  Data of 3-carboxami docoumarin  Derivatives X (C ompo unds 433-445) \nOH\nN\nOR6 O\nR\n \n \nCpds R6 R MAO-A \nIC50 (/g46M) MAO-B \nIC50 (/g46M) Ref \n433 H  > 100 0. 76 74 \n434 CH 3 CH3\n 45.97 0. 17 74 \n435 H CH3 > 100 7.96  74  \n436 H OCH3\n > 100 30.50 74  \n437 H Cl > 100 1.9 5 74  \n438 H NO2\n > 100 > 100 74  \n439 H OCH3\nOCH 3 > 100 58.3 8 74  \n440 H OCH3\nOCH3OCH 3\n > 100 72. 58 74  \n441 H Cl\nCl > 100 5.95 74  \n442 H  > 100 49.96 74  \n443 H C H3 38.93 > 100 74  \n444 H C H2Br > 100 > 100 74  \n445 H C H2Cl > 100 > 100 74  \n \n \nScheme 5. Synthetic strategies u sing as starting materials t he previo usly synt hesized coumarin ring . \n1922236     Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \n \nScheme 6. Functionali zation of coumarins to afford t he corresponding amino, carboxamido or amidoc oumarin derivatives . \n \nselective M AO in hibitors . The etherification of h ydrox y-\ncoumarins and amino coumarins were commonly performed \nby Williamson- type rea ctions [74].  So, different s ubstituted \nbromides were fu rnished target c oumarins in t he presen ce of \npotassi um carbonate and et hanol, under refl ux [64, 66, 67, \n84]. The same et herification rea ction occu rs adding s uitable \nbromides and potassi um carbonate in dry a cetone, using \nN,N\u2019 -dicyclohexyl-18-crown-6-et her  as chelating agent [81].  \nThis type of rea ction was also possible starting from t he \nformation of t he bromomet hylcoumarin and t he subsequent \nnucleophilic displa cement of bromide by h ydrox y or amine \nsubstituted mole cules (for e xample p henol or aniline)  [62]. \nIn general, t hese et herifications were t he most c ommon s ub-\nstitutions under t he coumarin n ucleus  to afford t he desired \nMAO activity.  The synt hesis of al kylsulfonylox y derivatives \nwas carried o ut starting from t he corresponding hydrox y-\ncoumarins wit h a conveniently s ubstituted s ulfonyl chloride \nin pyridine [ 67]. The thioeth er derivatives were prepared by \nrefluxing bromides and t hiols in MeCN in t he presen ce of \npotassi um carbonate . Sulfoxide and s ulfone derivatives were \nobtained by ox idation of t hioeth ers wit h sodi um periodate or \npotassi um permanganate, respe ctively [ 61]. So me f unction-\nalizations can also be performed by mi crowave irradiation \n[84].  \n Halogeno, carboxy or nitroc oumarins can also be used as \nstarting synt hons for t he subsequent f unctionali zation afford-\ning an array of t he corresponding amino, c arboxamido or \namido coumarins, compou nds wit h inhibitory M AO a ctivity \n(Scheme 6). \n Finally it m ust be mentioned t hat 3-aryl and 3-\nbenz oylcoumarins can be f urther  s ubstituted in different po-\nsitions of bot h aromati c rings u sing t he same aforementioned \nmethodologies [69-7 3, 75, 76 ]. Bromination of t he deriva -\ntives was performed wit h N-bromos uccinimide (NBS), in \ncarbon tetra chloride (CCl 4) under refl ux, using 2,2\u2019- azo-bis-\niso-butyronitrile (AIB N) as c atalyst [ 69, 70].  The met hoxy/ \nethoxy derivatives c an be h ydrolyz ed eit her wit h hydriodic  \nacid, in t he presen ce of a cetic acid and a cetic anhydride or \nBBr3 in DCM [69, 72, 73 , 75].  The Williamson rea ction of \nthe hydrox yl substituted aryl coumarins, as des cribed for \nsimple coumarins, was performed wit h differently s ubsti-tuted chlorides or bromide to give t he corresponding et hers \n[72].  \n3. CONCLUSION \n Sin ce the pioneering work  of H.  A. Kadir et al. [55], and \nthe disc overy of t he potential of th e coumarin s caffold \nagainst bot h MAO isoforms, new generations of differently \nsubstituted mole cules have been synt hesized  and eval uated \nin vitro  in p harma cologic al assays . Some of t he des cribed \nderivatives are very a ctive and sele ctive compou nds, with  \nIC50 in th e low nanomolar range . These findings pave t he \nway for new promise for effi cient and safe t herapeu tic solu-\ntions of an inc reasing and important problem of t he devel-\noped countries: t he neu rodegenerative diseases . Furthermore, \nbased on t hese important st udies, t here are several ongoing \nproje cts for t he rational str ucture-based dru g design of new \nmole cules.  \nCONFLICT OF INT ERE ST \n The author(s) confirm t hat this arti cle content has no c on-\nflicts of interest . \nACKNOWL EDGEMENT S \n De clared none . \nREFERENC ES \n[1] Tipton, K. F. Enzymology of monoamine o xidase . Cell. Biochem. \nFunct. , 1986 , 4, 79-87. \n[2] Dostert, P.; Strolin, B.  M.; Jafre, M . Monoamine ox idase: basi c and \nclinical frontiers.  In Excerpta  Medica ; Elsevier: Amsterdan, 1 982, \npp. 197. \n[3] Singer, T. P. In Chemistry  and Biochemistry  of Flavoenzymes ; \nMuller, F., Ed.; CRC Pre ss: Boca Raton FL, 1991; Vol. 2, pp.  437. \n[4] Youdim, M . B.; Bakhle, Y. S. Monoamine ox idase: isoforms and \ninhibitors in P arkinson\u00b4s disease and depressive illness . Br. J. \nPharm. , 2006 , 147, S287-S2 96. \n[5] Youdim, M . B.; Finberg, J . P. M.; Tipton, K. F. Monoamine o xi-\ndase. In:  Advances  in Experimental  Pharmacology.  Catecholamine.  \nII. ed. Trendelenb urg, U . & Weiner, U ., Berlin: Springer-V erlag, \n1988, pp.  119-192. \n[6] Bach, A. W. J.; Lan, N . C.; Johnson, D . L.; Abell, C . W.; Bem-\nbene k, M. E.; Kwan, S . W.; Seeb urg, P. H.; Shih, J. C. cDNA  clon-\ni\nng of human liver monoamine o xidase A and B: molecular basis of \n193Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2237  \ndifferen ces in en zymati c properties . Proc. Natl. Acad.  Sci. U S A, \n1988 , 85, 4 934-4938.  \n[7] Wouters, J . Structural aspec ts of monoamine ox idase and its re -\nversible in hibition . Curr.  Med.  Chem. , 1998 , 5, 137-162. \n[8] Grimsby, J .; Lan, N . C.; Neve, R.; C hen, K.; Shih, J. C. Tis sue \ndistrib ution of hu man monoamine o xidase A and B m RNA. J. Neu-\nrochem. , 1990, 55, 11 66-1169.  \n[9] Kalgutkar, A. S.; Castagnoli, N . Jr.; Testa, B. Sele ctive in hibitors \nof monoamine o xidase (MAO-A  and M AO-B)  as probes of its cata-\nlytic site and me chanism . Med.  Res. Rev., 1995 , 15, 3 25-388. \n[\n10] Geha, R. M .; Rebrin, I.; Chen, K.; Shih, J. C. Substrate and in hibi-\ntor spe cificities for human monoamine o xidase A and B  are infl u-\nenced by a single amino a cid. J. Biol. Chem. , 2001 , 276, 9877-\n9882. \n[11] Ma, J .; Yoshimura, M .; Yamas hita, E.; Nakagawa, A.; Ito, A.; \nTsukihar a, T. Structure of rat monoamine ox idase A and its spec ific \nrecognitions for s ubstrates and in hibitors . J. Mol. Biol. , 2004 , 338, \n103- 115. \n[12] Weyler, W.;  Hsu, Yun P. P.; Breakefield, X. O. Biochemistry and \ngeneti cs of monoamine o xidase . Pharmacol.  Ther. , 1990 , 47, 391-\n417.  \n[13] Smith, R. G. The agi ng pro cess: wh ere are t he drug opport unities ? \nCurr.  Opin.  Chem. Biol. , 2000, 4, 371-3 76. \n[14] Binda, C .; Newton -Vinson, P.; Hubalek, F.; Edmondson, D . E.; \nMattevi, A. Structure of human monoamine o xidase B, a dr ug tar-\nget for t he treatment of neu rologi cal disorders . Nat. Struct.  Mol.  \nBiol. , 2002 , 9, 22-26. \n[15] Bi nda, C .; Li, M.; Hub\u00e1lek, F.; Restelli, N .; Edmondson, D . E.; \nMattevi, A. Insig hts into th e mode of inh ibition of human mito -\nchondrial monoamine o xidase B from h igh-resol ution crystal str uc-\ntures. Proc.  Natl.  Acad.  Sci. U S A, 2003 , 100, 9750-9 755. \n[16] De Colib us, L.; Li, M.; Binda, C .; Lust ig, A.; Edmondson, D . E.; \nMattevi, A. Three-dimensional str ucture of human monoamine \noxidase A (MAO-A) : Relation to t he structures of rat M AO-A  and \nhuman M AO B. Proc. Natl. Acad.  Sci. U S A, 2005 , 102, 12684-\n12689. \n[17] Binda, C .; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J .; Edmon d-\nson, D . E.; Mattevi, A. Crystal struc tures of monoamine ox idase B \nin comple x with four inhibitors of t he N-propargylaminoindane \nclass. J. Med.  Chem. , 2004 , 47, 1767-1774.  \n[18] Milczek, E. M.; Bonivento, D .; Binda C .; Mattevi, A.; McDonald, \nI. A.; Edmondson, D . E. Structural and mechanisti c studies of \nmofegiline in hibition of re com binant human monoamine o xidase \nB. J. Med.  Chem. , 2008 , 51, 8019- 8026.  \n[19] Brunner, H. G.; Nelen, M .; Brea kefield, X. O.; Ropers H. H.; van \nOost B. A. Abnormal be haviour asso ciated with  a point mu tation in \nthe structural gene for monoamine ox idase A. Science , 1993, 262, \n578-580 . \n[20] Caspi, A.; McCla y, J .; Moffitt, T. E.; Mill, J .; Martin, J .; Craig, I.  \nW.; Taylor, A.; Poulton, R. Role of genotype in t he cycle of vio-\nlence in maltreated children.  Science , 2002 , 297, 851-854.  \n[21] Meyer, J . H.; Ginovart, N .; Boovariwala, A.; Sagrati, S .; Hussey, \nD.; Garc\u00eda, A.; Young, T.; Praschak-Rieder, N .; Wilson, A. A.; \nHoule , S . Elevated monoamine o xidase a levels in t he brain: an e x-\nplanation for t he monoamine imbalanc e of major depression . Arch. \nGen.  Psych. , 2006 , 63, 1209- 1216. \n[22] Thorpe, L.; Groulx, B. Depressive syndromes in dementia . Can . J. \nNeurol. Sci., 2001 , 28, 83-95 . \n[23] Nish imura, A. L.; Guindalini, C.;  Oliveira, J . R.; Nitrini, R.; Bahia, \nV. S.; de Brito -Mar ques, P. R.; Otto, P. A.; Zatz , M. Monoamine \noxidase a polymorp hism in B razilian patients: ris k factor for late -\nonset Alzheimer\u00b4s disease?  J. Mol. Neurosci. , 2005 , 27, 21 3-217. \n[\n24] Wu, C. K.; Mes ulam, M . M.; Geula, C . Age-related loss of c al-\nbindin from hu man basal forebrain cholinergi c neurons. Neurore-\nport., 1997 , 8, 2209- 2213. \n[25] Emilsson, L.; Saetre, P.;  Balciuniene, J .; Castensson, A.;  Cairns, \nN.; Jazin, E. E. Increased monoamine ox idase messenger RNA ex-\npression levels in frontal cortex  of Alzheimer\u00b4s disease patients . \nNe\nurosci. Lett., 2002 , 326, 56-60. \n[26] Takehashi, M.; Tanaka, S.; Maslia h, E.; Ueda, K.  Association of \nmonoamine ox idase A gene polymorph ism with  Alzheimer\u00b4s dis -\nease patients . Neurosci.  Lett., 2002 , 327, 7 9-82. \n[27] Amrein, R.; Martin, J . R.; Cameron A. M. Moclobemida in patients \nwith dementia and depression.  Adv. Neurol. , 1999 , 80, 5 0 9-519. [28] Gareri, P.; Falconi, U .; De F azio, P.; De Sarro, G. Conventional \nand new antidepressant dr ugs in t he eldery . Prog. Neurobiol. , 2000 , \n61, 3 53-396.  \n[29] Maragos, W . F.; Young, K. L.; Altman C . S.; Pocernich, C . B.; \nDrake, J.; Butterfield, D . A.; Seif, I.; Holschneider, D . P.; Chen, K. ;  \nShih J. C. Strial damage ans o xidative stress ind uced by t he mito -\nchondrial to xin malonate are red uced in c lorgyline -treated rats and \nMAO-A  deficient mi ce. Neurochem.  Res., 2004 , 29, 741-74 6. \n[30] Ou, X. M.; Chen K.; Shih J. C. Monoamine ox idase A and re -\npressor RI are envolved in apoptoti c signaling pat hway. Proc. Natl . \nAcad. Sci. U S A , 2006 , 1 0 3, 10923-10928. \n[31] Gerlach, M .; Double, K.; Reichmann, H.; Riederer, P. Arguments \nfor the use of dopamine re ceptor agonists in clinical and pre clinical \nParkinson\u00b4s diseases . J. Neural  Transm.  Suppl ., 2003 , 167-193. \n[32] Fernande z, H. H.; Chen, J. J. Monamine ox idase in hib itors: current \nand emerging agents for P arkinson disease.  Clin.  Neuropharmacol. , \n2007 , 30, 150 -168.  \n[33] Riederer, P.; Daniel czyk, W.; Grunblatt, E. Monoamine ox idase -B \ninhibition in A lzheimer\u00b4s disease.  Neurotoxicology , 2004 , 25, 271-\n277. \n[34] Saura, J.; Luque J . M.; Cesura, A. M.; Da Prada, M .; Chan-Palay, \nV.; Huber , G.; Loffler, J .; Richards, J .G. Increased monoamine \noxidase B activity in pla que-asso ciated astro cytes of Alzheimer \nbrains revealed by qu antitative en zyme radioa utograp hy. Neurosci-\nence , 1994 , 62, 15-30. \n[35] McLellan, M . E.; Kajdas z, S. T.; Hyman, B. T.; Bacskai, B. J. In \nvivo imaging of reac tive o xyge n spec ies spe cifically asso ciated \nwith thioflavine S -positive amyloid pla ques by m ultiphoton mi -\ncroscopy. J. Neurosci ., 2003 , 23, 2212-2217 . \n[36] Magyar, K.; Szende, B. Deprenyl, a selec tive M AO-B  inhibitor, \nwith apoptoti c and anti -apoptoti c properties . Neurotoxicology , \n2004 , 25, 233-242. \n[37] Youdim, M . B.; Edmondson, D .; Tipton, K. F. The ther apeu tic \npotential of monoamine ox idase in hibitors . Nat. Rev. Neurosci. , \n2006 , 7, 295-309. \n[38] Murray, R. D. H.; Mendez , J.; Brown, S . A. The nat ural coumarins \noccurren ce. In Chemistry  and Biochemistry ; John Wiley and Sons: \nChichester, 1 982. \n[39] Murray, R. D. H. Na turally o ccurring plant c oumarins . Prog.  \nChem.  Org.  Nat. Prod. , 2002 , 83, 1-673. \n[40] Borges, F.; Roleira, F.; Milhazes, N .; Santana, L.; Uriarte, E. Sim -\nple coumarins and analogu es in medi cinal chemistry: occu rrence, \nsynthesis and biologi cal ac tivity . Curr.  Med.  Chem. , 2005 , 12, 887-\n916. \n[41] Borges, F.; Ro leira, F.; Milhazes, N.; Uriarte, E.; Santana, L.  \nSimple Co umarins: Privileged S caffolds in Medi cinal C hemistry . \nFront.  Med.  Chem. , 2009 , 4, 23-85. \n[42] O\u00b4Kennedy, R. Coumarins . Biology, appli cations and mode of \naction, Thornes R.D. (Ed), John Wiley and Sons: New Y ork, 1997. \n[43] Belluti, F.; Fontana, G.; Bo, L.; Carenini, N .; Giommarelli, C.;  \nZunino, F. D esign, synt hesis and anti cancer ac tivities of stilbene - \ncoumarin hybrid compou nds: identifi cation of novel proapoptoti c \nagents . Bioorg.  Med.  Chem. , 2010 , 18, 3 543-3550.  \n[44] Riveiro, M . E.; Moglioni, A.;  Vazquez, R.; Gomez, N.; Facorro, \nG.; Piehl, L.; de Celis, E. R.; S hayo, C .; Davio, C . Structural in -\nsights into h ydrox ycoumar in-ind uced apoptosis in U -937 cells. \nBioorg.  Med.  Chem. , 2008 , 16, 2 665-2675. \n[45] Fylaktakidou, K. C.; Hadjipavlo u-Litina, D . J.; Litinas, K. E.; Nico-\nlaides, D . N. Natural and synt hetic coumarin derivatives wit h anti-\ninflammatory /antio xidant a ctivities . Curr.  Pharm.  Des., 2004 , 10, \n3813-\n3833. \n[46] Roussaki, M.; Kontogiorgis, C .; Hadjipavlo u-Litina, D . J.; Hami-\nlakis, S. A novel synt hesis of 3-aryl coumarins and eval uation of \ntheir antio xidant and lipo xygenase in hibitory a ctivity . Bioorg.  Med.  \nChem.  Lett., 2010 , 20, 3889-38 92.  \n[47] Vilar, S .; Quezada, E.; Santana, L.;  Uriarte, E.; Yanez , M.; Fra iz, \nN.; Alcaide, C .; Cano, E.;  Orallo, F. Design, synt hesis, and vasore -\nlaxant and platelet antiaggregatory a ctivities of c oumarin -\nresveratrol hybrids . Bioorg.  Med.  Chem.  Lett., 2006 , 16, 257-2 61. \n[48] Ostrov, D.  A.; Hern\u00e1ndez Prada, J . A.; Corsino, P. E.; Finton, K. \nA.; Le, N.; Rowe, T. C. Di scovery of novel DN A gyrase in hibitors \nby high-throughput virt ual screening.  Antimicrob.  Agents  Che-\nmother. , 2007 , 51, 3688 -3698. \n[49] Chimenti, F.; Bizzarri, B.; Bolasco, A.; Secci, D .; Chimenti, P.; \nGranese, A.; Carradori, S .; Rivanera, D .; Zicari, A.; Scaltrito, M . \nM.; Sisto, F.  Synt hesis, sele ctiv e anti -Helicobacter pylori a ctivity, \n1942238     Current  Topics  in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. \nand cytotox icity of novel N -substitu ted-2-oxo-2H-1-benz opyran-3-\ncarbox amides . Bioorg.  Med.  Chem.  Lett., 2010 , 20, 4922-4926. \n[50] Neyts, J.;  De Cler cq, E.; Sing ha, R.; Chang, Y. H.; Das, A.  R.; \nChakr aborty, S . K.; Hong, S.  C.; Tsay, S.- C.; Hsu, M.-H.; Hwu, J. \nR. Str ucture-activity relations hip of new anti -Hepatitis C viru s \nagents: heterobi cycle-coumarin conjugates . J. Med.  Chem. , 2009 , \n52, 1486- 1490. \n[51] Kostova, I. Coumarins as inh ibitors of HIV reverse trans criptase.  \nCurr.  HIV Re s ., 2006 , 4, 347-363.  \n[52] Chilin, A.; Battistu tta, R.; Bortolato, A.; Cozza, G.; Zanatta, S .; \nPoletto, G.; Mazzorana, M .; Zagotto, G.;  Uriarte, E.;  Guiotto, A.; \nMeggio, F.; Moro, S . Coumarin as attrac tive casein kinase 2 (CK 2) \ninhibitor s caffold: an integrate approa ch to el ucidate t he putative \nbinding motif and ex plain str ucture-activity relations hips. J. Me d.  \nChem. , 2008 , 51, 752-75 9. \n[53] Zhou, X.; Wang, X.  B.; Wang, T.; Kong, L. Yi. Design, synt hesis, \nand ac etylcholinesterase in hibitory a ctivity of novel c oumarin ana-\nlogues. Bioorg.  Med.  Chem.,  2008 , 16, 8011- 8021.  \n[54] Garino, C .; Tomita, T.; Pietran costa, N .; Laras, Y.; Rosas, R.; \nHe\nrbette, G.; Maigret, B.; Qu\u00e9l\u00e9ver, G.; Iwatsu bo, T.; Kraus, J. L. \nNaphthyl and c oumarinyl biarylpipera zine derivatives as highly po -\ntent human /g1-secretase in hibitors . Design, synt hesis, and en zymati c \nBACE-1 and cell assays . J. Med.  Chem. , 2006 , 49, 4275-4285.  \n[55] Kadir, H. A.; Knowles, C . O. Inhibition of rat brain monoamine \noxi dase by inse cticides, a caricides and related c ompou nds Gen.  \nPharmacol. , 1981, 12, 239-247. \n[56] Rendenba ch, B.; Weifenbach, H.; Teschendorf, H. J. Preparation of \n7-(arylal koxy)coumarins as c entral nervo us system agents . Ger. Of-\nfen. (1990), DE 3834861 A1 199 00419.   \n[57] Kong,  L. D.; Tan, R. X.; Woo, A.  Y.; Cheng, C . H. Inhibition of rat \nbrain monoamine o xidase a ctivities by psoralen and isopsoralen: \nimplic ations for t he treatment of affec tive disorders . Pharmacol.  \nToxicol. , 2001 , 88, 75 -80. \n[58] Huong, D . T.; Choi, H. C.; Rho, T. C.; Lee, H. S.; Lee, M . K., Kim, \nY. H. Inhibitory a ctivity of monoamine o xidase by c oumar ins from \nPeucedan um japoni cum. Arch. Pharm.  Res., 1999 , 22, 3 24-3 26. \n[59] Hossain, C . F.; Okuyama, E.; Yamazaki, M. A new series of c ou-\nmarin derivatives h aving monoamine o xidase inh ibitory a ctivity \nfrom Monas cus anka. Chem. Pharm.  Bull. , 1996 , 44, 15 35-1539.  \n[60] Carotti, A.; Carrieri, A.; Chimich i, S.; Bocca lini, M .; Cosimelli, B.;  \nGnerre, C.; Carotti, A.;  Carru pt, P.-A.; Testa, B. Nat ural and syn -\nthetic Geiparavins are strong and sele ctive M AO-B in hibitors . Syn-\nthesis and S AR studies. Bioorg.  Med.  Chem.  Lett., 2002 , 12, 3551-\n3555. \n[61] Carotti, A.; Altomare, C .; Catto, M .; Gnerre, C.; S ummo, L.; De \nMarco, A.; Rose, S .; J enner, P.;  Testa, B. Lipoph ilicity plays a ma -\njor role in mod ulating th e inh ibition of monoamine ox idase B by 7 -\nsubstitu ted coumarins . Chem.  Biodivers. , 2006 , 3, 134-149.  \n[62] Gnerre, C.; Catto, M .; Francesco, L.; Weber, P.;  Carru pt, P-A.;  \nAltomare, C.; Carotti, A.;  Testa, B. Inhibition of monoamine o xi-\ndase by f unctionaliz ed coumar in derivatives: biologi cal ac tivities, \nQSAR, and 3 D-QSARs. J. Med.  Chem ., 2000 , 43, 4747-4758.  \n[63] Rendenba ch-M\u00fcller, B; Schlecker, R.; Traut, M.; Weifenba ch, H. \nSynthesis of c oumarins as s ubtype -sele ctive in hibitors of mono -\namine o xidase in hibitors . Bioorg.  Med.  Chem.  Lett., 1994 , 4, 1195-\n1198. \n[64] Pis\nani, L.; M uncipinto, G.; Mis cioscia, T. F.; Nicolotti, O.; Leon-\netti, F.; Catto, M .; Caccia, C .; Salvati, P.;  Soto-O tero, R.; Mendez-\nAlvarez , E.; Passele u, C.; Carotti, A. Disc overy of a novel class of \npotent coumarin monoamine ox idase B in hibitors: development \nand biop harma cologi cal profiling of 7-[(3-ch loroben zyl)oxy]-4-\n[(met hyl amino)met hyl]-2H-ch romen -2-one met hanesulfonate \n(NW -1772) as a h ighly potent, selec tive, reversible, and orally a c-\ntive monoamine o xidase B inhibitor.  J. Med.  Chem. , 2009 , 52, \n6685-6 706. \n[65] Frickel, F.-F.;  Kuekenhoehner, T.; Rendenbach- M\u00fcller, B.; \nWeifenbach, H.; Teschendforf, H.-J. Preparation of 7-\n(heteroc ycly lmet hoxy)coumarins as monoamine ox idase in hibitors . \nGer. Offen. (1990), DE 3834860 A1 199 00419.  \n[66] Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, \nM.; Vi\u00f1a, D.; Orallo, F. Quantitative struc ture-activity relations hip  \nand comple x networ k approach to monoamine o xidase A and B in -\nhibitors . J. Med.  Chem. , 2008 , 51, 6 740-6 751. \n[67] Catto, M .; Nicolotti, O.; Leonetti, F.; Carotti, A.;  Favia, A. D.; \nSoto-Otero, R.; M\u00e9nde z-\u00c1lvare z, E.; Carotti, A.  Structural Insigh ts \ninto Monoamine Ox idase Inhibitory Potency and Selec tivity of 7-Substitu ted Co umarins from Ligand - and T arget -Based Ap-\nproach es. J. Med.Chem. , 2006 , 49, 4912-4925. \n[68] Rendenba ch-M\u00fcller, B.; Bulrich, K.; Weifenba ch, H. \n[(Aryl)alkyloxy]thiocoumarins, pro cess for t heir preparation and \ntherapeu tical agents c ontaining th em. Eur. Pat. Appl. (1994), EP \n594036 A1 199 40 427.  \n[69] Santana, L.; Orallo, F.; Vi\u00f1a, D.; Matos, M .J.; Quezada, E.; Ya\u00f1ez, \nM.; Vilar, S .; Uriarte, E. Use of 6-substitu ted 3-phenylcoumarins as \nselective monoamine ox idase B inhibitors for treating ne urodegen -\nerative diseases and obesity and preparation of new derivatives . \nSpan . (2010), E S 2343347 A1 20100728.   \n[70] Matos, M.  J.; Vi\u00f1a,  D .; Quezada, E.; Picciau, C.; Delog u, G.; \nOrallo, F.; Santana, L.; Uriarte, E.  A new series of 3-p henyl cou-\nmarins as potent and sele ctive M AO-B in hibitors . Bioorg.  Med.  \nChem.  Lett., 2009 , 19, 3268-3270. \n[71] Matos, M . J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.;  Uriarte, \nE. Synt hes is and eval uation of 6-methyl-3-phenylcoumarins as po -\ntent and sele ctive M AO-B in hibitors . Bioorg.  Med.  Chem.  Lett., \n2009 , 19, 505 3-5055.  \n[72] Matos, M.  J.; Ter\u00e1n, C.; P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; \nVi\u00f1a, D. Synt hesis and St udy of a Series of 3-A rylcoumarins as P o-\ntent and Sele ctive Monoamine Ox idase B Inhibitors.  J. Med.  \nCh\nem., 2011 , 54, 7127\u20137137. \n[73] Matos, M.  J.; V\u00e1zquez-Rodrig uez, S.; Uriarte, E.; Santana, L.; \nVi\u00f1a, D. MAO inhibitory a ctivity mod ulation: 3-phenylcoumarins \nversus 3-benz oylcoumarins . Bioorg.  Med.  Chem.  Lett., 2011, 21, \n4224\u20134227.  \n[74] Vi\u00f1a, D.; Matos, M.  J.; Y\u00e1\u00f1ez, M.; Sa ntana, L.; Uriarte, E.  3-\nSubstitu ted coumarins as d ual inhibitors of A ChE and M AO for th e \ntreatment of A lzheimer\u00b4s disease.  Med.  Chem.  Commun. , 2012 , 3, \n213- 218. \n[75] Matos, M.  J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, \nE. New h alogenated 3-phenylcoumarins as potent and sele ctive \nMAO-B  inhibitors . Bioorg.  Me d.  Chem.  Lett., 2010, 20, 5157-\n5160. \n[76] Vi\u00f1a, D.; Matos, M . J.; Ferino, G.; Cadoni, E.;  Laguna, R.; Borges, \nF.; Uriarte, E.; Santana, L. 8-Substitu ted-3-aryl coumarins as P otent \nand Sele ctive M AO-B Inhibitors: Synt hesis, Pharmac ologi cal \nEvaluation and Do cking St udies. ChemMedChem , 2012 , 7, 464-\n470. \n[77] Serra, S .; Ferino, G.; Matos, M . J.; V\u00e1zque z-Rodr \u00edguez, S.; Delog u, \nG.; Vi\u00f1a, D.; Cadoni, E.;  Santana, L.; Uriarte, E. Hydrox ycoumar-\nins as sele ctive M AO-B in hibitors . Bioorg.  Med.  Chem.  Lett., 2012 , \n22, 258-2 61. \n[78] Secci, D .; Carradori, S .; Bolas co, A.; Chimenti, P.; Yanez, M.; \nOrtuso, F.; Alcaro, S . Synt hesis and selec tiv e human monoamine \noxidase in hibition of 3-c arbonyl, 3-acyl, and 3-carbox yhydrazido \ncoumarin derivatives . Eur. J. Med.  Chem. , 2011 , 46, 4846- 4852.  \n[79] Delog u, G.; Picciau, C.; Ferino, G.; Quezada, E.; Podda, G.; Uri-\narte, E.; Vi\u00f1a, D. Synt hesis, human monoamine o xidase in hibitory \nactivity and molecular do cking st udi es of 3-h eteroaryl coumarin de-\nrivatives . Eur. J. Med.  Chem. , 2011 , 49, 1147-1152.  \n[80] Chimenti, F.; Secci, D .; Bolas co, A.; Chimenti, P.; Granese, A.; \nBefani, O.; Turini, P.; Alcaro, S .; Ortuso, F. Inhibition of mono -\namine o xidases by coumarin -3-acyl derivatives: biologic al ac tivity \nand compu tational st udy. B ioorg.  Med.  Chem.  Lett., 2004, 14, \n3697 -3703. \n[81] Chimenti, F.; Secci, D .; Bolas co, A.; Chimenti, P.; Bizarri, B.; \nGranese, A.; Carradori, S .; Y\u00e1\u00f1ez, M.; Orallo, F.; Ortuso, F.; Al-\ncaro, S . Synt hesis, mole cular modeling, and sele ctive in hibitory a c-\ntivity against human monoamine o xidases of 3-c arboxamido -7-\nsubstitu te d coumarins . J. Med.  Chem. , 2009 , 52, 1935-1942.  \n[82] Br\u00fchlmann, C .; Ooms F.; Carru pt, P-A.;  Testa, B.; Catto, M .; Le-\nonetti, F.; Altomare, C .; Carotti, A.  Coumarins derivatives as d ual \ninhibitors of a cethylcolinesterase and monoamine ox idase . J. Med.  \nChem. , 2001 , 44, 3 195-3198. \n[83] S\nantana, L.; Uriarte, E.;  Gonz\u00e1lez-D\u00edaz, H.; Zagotto, G.; Soto -\nOtero, R.; M\u00e9ndez- \u00c1lvarez , E. A QSAR model for in silico  screen-\ning of M AO-A  inhibitors . Prediction, synt hesis, and biologi cal as-\nsay of novel c oumarins . J. Med.  Chem. , 2006 , 49, 1149- 1156. \n[84] Binda, C .; Wang, J .; Pisani, L.; Caccia, C .; Carotti, A.; S alvati, P.; \nEdmondson, D .E.; Mattevi, A. Structures of human monoamine \noxidase B comple xes wit h sele ctive nonc ovalent inh ibitors: safi -\nnamide and c oumarin analogs . J. Med.  Chem. , 2007 , 50, 5848-\n5852.  \n195Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20    2239  \n[85] Campos -Toimil, M .; Orallo, F.; Santana, L.; Uriarte, E.  Synt hesis \nand vasorela xant ac tivity of new coumarin and f urocoumarin de-\nrivatives . Bioorg.  Med.  Chem.  Lett. 2002 , 12, 783-786. \n[86] Gao, S hu-T.; Li, C; Wang, Y; Ma, Jing -J; Wang, C ; Zhang, Jing -\nW. NbCl5 -catalyz ed, solvent -free, one-pot synt hesis of coumarins . \nSynth.  C ommun.  2011 , 41, 1486- 1491. \n[87] Suresh Kuarm, B.; Venu Mad hav, J.; Vijaya Laxmi, S .; Rajitha, B.; \nThirupathi Reddy, Y.; Narsim ha Reddy, P.;  A.  Croo ks, P. A. \nExpeditio us Pechmann condensation by u sing biodegradable \ncellulose s ulfuric acid as a solid a cid catalyst . Synth.  C ommun. , \n2010 , 40, 33 58-336 4. \n[88] Kumar, V.; Tomar, S .; Patel, R.; Yousaf, A.; Parmar, V. S.; Mal -\nhotra, S . V. FeCl3-catalyz ed Pechmann synt hesis of c oumarins in \nionic liquids . Synth.  Commun. , 2008 , 38, 2646-2654. \n[89] Reddy, Y. T.; Sonar, V.  N.; Croo ks,  P. A.; Dasari, P. K.; Reddy, P. \nN.; Rajit ha, B. Ceri c ammoni um nitrate (CA N): An effi cient cata-\nlyst for t he coumarin synt hesis via Pechmann condensation using \nconventional heating and mi crowave irradiation.  Synth.  Commun. , \n2008 , 38, 2082-2088.  \n[90] Timonen, J . M.; Nieminen, R. M .; Sareila, O.;  Vainiotalo, P.; \nMoilanen, E.; Aula s kari, P. H. Synt hesis and anti -inflammatory \neffects of a series of novel 7 -hydroxycoumarin derivatives . Eur. J. \nMed.  Chem. , 2011 , 46, 3845-3 850. \n[91] Bakhchinian, R.; Terrier, F.; Kirkiacharian, S .; Resche-Rigon, M .; \nBoucho ux, F.; C\u00e9r\u00e8de, E.  Synt hesis and relative binding affinity to \nhuman steroid re ceptors of s ubstitu ted 3-arylo xycouma rins . Il Far-\nmaco , 2003 , 58, 1201-1207.  \n[92] Darvat kar, N . B.; Deor ukhkar, A. R.; Bhilare, S . V.; Raut, D. G.; \nSalunkhe, M . M. Ionic liquid -mediated synt hesis of c oumarin-3-\ncarbox ylic acids via K noevenagel condensation of Meldr um's acid \nwith ortho-hydroxyaryl alde hydes. Synt h.  Commun. , 2008 , 38, \n3508-3 513. \n[93] Frere, S .; Thiery, V.; Besson, T. Microwave acceleration of t he \nPechmann rea ction on grap hite/montmorillonite K10: appli cation to \nthe preparation of 4-s ubstitu ted 7 -amino coumarins . Tetrahedron  \nLett., 2001 , 42, 2791-2794.  \n[94] Lal D har, Y.; S.; Sing h, S.; Rai , V. K. A one-pot [ Bmim] OH-\nmediated synt hesis of 3- benz amidoc oumarins . Tetrahedron Lett., \n2009 , 50, 2208-2212.  \n[95] Mali, R. S.; Josh i, P. P. Usefu l synt heses of prenylated - and \npyrano-3- arylcoumarins . Synth Commun. , 2001 , 31, 275 3-2760. \n[96] Valizadeh, H.; Shockravi, A.; Heravi, M . M.; Ghadim, H. A. Mi-\ncrowave -induced in sit u Wittig rea ction of sali cylaldeh ydes wit h \nethyl chloroa cetate and triph enylph osph ine in solventless system . J. \nChem.  Res. Synop. , 2003 , 11, 718-720 . [97] M\nali, R. S.; Josh i, P. P. Usef ul synt heses of prenylated c oumarins \nand pyrano-3- arylcoumarins . Synth.  Commun. , 2001 , 31, 275 3-\n2760.  \n[98] Upad hyay, P. K.; Kumar, P. A novel synt hesis of coumarins em -\nploying triph enyl(/g1-carbox ymethylene)phosph orane imidaz olide as \na C-2 synthon. Tetrahedron  Lett., 2009 , 50, 236-238. \n[99] Har\nayama, T.; Katsuno, K.; Nish ioka, H.; Fujii, M.; Nishita, Y.; \nIshii, H.; Kaneko, Y. A convenient synt hesis of a simple c oumarin \nfrom salic yclaldehyde and Wittig reagent.  I. A synthesis of \nmethoxy- and hydroxycoumarins. Heterocycles , 1994 , 392, 613-\n622.  \n[\n100] Audisio, D.; Messaoudi, S.; Brion, J.-D.; Alami, M. A simple syn-\nthesis of functionalized 3-bromoc oumarins by a one -pot three-\ncomponent reac tion. Eur. J. Org.  Chem. , 2010 , (6), 1046- 1051, \nS1046/ 1-S1046/18. \n[101]  Kotani, M.; Yamamoto, K.; Oyamada, J.; Fujiwara, Y.; Kitamura, \nT. A convenient synthesis  of c oumarins by palladi um(II)-catalyzed \nreaction of ph enols with propiolic acids. Synthesis , 2004 , 9, 1466-\n1470.  \n[102]  Li, K.; Zeng, Y.; Neuenswander, B.; Tunge, J. A. Sequential Pd \n(II)- Pd (0) catalysis for th e rapid synthesis of coumarins. J. Org.  \nChem. , 2005 , 70, 6515-6 518. \n[103] Fernandes, T. A.; Carvalho, R. C. C.; Gonc al ves, T. M. D.; Costa, \nP.R. R. A tandem palladi um-catalyz ed Heck-lactonization through \nthe reac tion of ortho-iodophenols with /g2-substitu ted acrylates: syn-\nthesis of 4,6-substitu ted coumarins. Tetrahedron  Lett., 2008 , 49, \n3322-33 25. \n[104]  Schiedel, M-S.; Briehn, C. A.; Bauerle, P. Single-compou nd librar-\nies of organic materials: parallel synth esis and screening of fluores-\ncent dyes. Angew.  Chem.  Int. Edit. , 2001 , 40, 4677-4680. \n[105]  Matos, M. J.; Vazquez-Rodrigu ez, S.; Borges, F.; Santana, L.;  \nUriarte, E. Synthesis of 3- arylcoumarins via Suzuk i-cross-coup ling \nreactions of 3-ch lorocoumarin. Tetrahedron  Lett., 2011 , 52, 1225-\n1227.  \n[106] Rao, M. L. N.; Venkatesh, V.; Jadhav, D. N. Palladiu m-catalyz ed \nsynthesis of 4-arylcoumarins using triarylbism uth compounds as \natom-efficient multicoupling organometalli c nucleophiles. Eur. J. \nOrg\n. Chem. , 2010 , 20, 3945-39 55. \n[107]  Wu, J.; Zhang, L.; Xia, H-G.  Palladium-catalyzed Suzuk i-Miyaura \ncouplings of potassi um aryl trifl uoroborates wit h 4-\ntosyloxycoumarins or 4-tosylo xyquinolin-2(1H)-one. Tetrahedron  \nLett., 2006 , 47, 1525-1528.   \n[108]  Zhang, Liang; M. T.; Fan,  R. A.; Wu, J. General and effi cient route \nfor th e synthesis of 3 ,4-disubstitu ted coumarins via Pd-catalyzed \nsite-selective cross-coupling reac tions. J.Org.  Chem. , 2007 , 72, \n7279- 7286. \n \n \nReceived: March 20, 2012 Revised: June  15, 2012 Accepted: June  18, 2012 \n \n196Original article\nNovel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: Synthesis,\nin vitro and in vivo assays, theoretical evaluation of ADME properties and docking\nstudy\nMaria J. Matosa,*, Santiago Vilara,b, Rosa M a Gonzalez-Francoc, Eugenio Uriartea, Lourdes Santanaa,\nCarol Friedmanb, Nicholas P. Tatonettib, Dolores Vi\u00f1ad, Jose A. Fontenlac\naDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbDepartment of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032, USA\ncDepartment of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain\ndDepartment of Pharmacology, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain\narticle info\nArticle history:\nReceived 11 December 2012\nReceived in revised form\n4 February 2013\nAccepted 8 February 2013Available online 16 February 2013\nKeywords:\n(Coumarin-3-yl)carbamate scaffold\nMonoamine oxidase (MAO)\nIn vitro assays\nIn vivo assays\nADME propertiesDocking studiesabstract\nA series of (coumarin-3-yl)carbamates was synthesized and evaluated in vitro as monoamine oxidase\n(MAO-A and MAO-B) inhibitors. Most of the new compounds selectively inhibited MAO-B isoenzyme\nwith IC50values in the micro or nanoMolar ranges. Since these compounds must achieve the brain\ncells, theoretical evaluation of ADME properties were also carried out. Compound 8(benzyl(coumarin-3-\nyl)carbamate), which presented the most interesting in vitro MAO-B inhibitory pro \ufb01le (IC50against MAO-\nB\u00bc45 nM), was subjected to further studies. This in vitro MAO-B inhibitory activity is comparable with\nthat of the selegiline, the reference compound (IC 50against MAO-B \u00bc20 nM). Taking into account the\nin vitro results of compound 8,in vivo assays and docking calculations were also carried out for this\nderivative.\n/C2112013 Elsevier Masson SAS. All rights reserved.\n1. Introduction\nQuality of life of the aging population in the today\u2019 s society is, to a\ngreat extent, determined by the normal aging process of neurons in\nthe central nervous system (CNS) and especially in diseases charac-\nterized by accelerated neuronal loss, which are traditionally desig-\nnated as neurodegenerative diseases (ND). These diseases are major\ncontributors to disability and morbidity around the world. Alz-\nheimer \u2019s disease (AD) is the most prevalent ND followed by Parkin-\nson \u2019s disease (PD). AD is the most common cause of senile dementia,\naffecting approximately 3% of the population between the ages of\n65e74 and nearly 50% of those 85 years and older [1e4]. PD, thesecond most important ND, is characterized by loss of dopaminergic\nneurons in the nigrostriatal pathway. These neurons extend from the\nzona compacta of the substantia nigra (SNC) to the striatum. Thesymptoms of PD, resting tremor, rigidity and bradykinesia, appear\nwhen about 80% of dopaminergic neurons have been destroyed [5].\nThe etiology is not completely known, but several risk factors havebeen identi \ufb01ed, including environmental factors, genetics, and age.\nSeveral research hypotheses exist regarding the pathogenesis,\nincluding different mechanisms that may be involved in the devel-\nopment of disease, such as oxidative stress, in \ufb02ammation, excito-\ntoxicity, mitochondrial dysfunction and proteolytic stress [6e8].I n\nthe 50 \u2019s, dopamine (DA) was described as a neurotransmitter, which\nshowed low levels in the basal ganglia in animal models of parkin-\nsonism. After the success of a placebo-controlled trial, levo-dopa (LD)\nbecame an essential drug for the treatment of PD [9]. Even today the\nstandard treatment of PD is the combination of LD with inhibitors ofperipheral dopa decarboxylase (DDC), to avoid the formation of DA in\nthe periphery. LD is also associated to inhibitors of the enzyme\ncatechol-O-methyltransferase (COMT) and prevents the formation of\n3-O-methyldopa (3-OMD) [10]. Among other drugs that can be used*Corresponding author. Tel.: \u00fe34 981 563100; fax: \u00fe34 981 544912.\nE-mail addresses: mariacmatos@gmail.com ,mariajoao.correiapinto@rai.usc.es\n(M.J. Matos), qosanti@yahoo.es (S. Vilar), rosamaria.gonzalez.franco@rai.usc.es\n(R.M. Gonzalez-Franco), eugenio.uriarte@usc.es (E. Uriarte), lourdes.santana@\nusc.es (L. Santana), friedman@dbmi.columbia.edu (C. Friedman), npt@\ndbmi.columbia.edu (N.P. Tatonetti), mdolores.vina@usc.es (D. Vi\u00f1a),\njoseangel.fontenla@usc.es (J.A. Fontenla).\nContents lists available at SciVerse ScienceDirect\nEuropean Journal of Medicinal Chemistry\njournal homepage: http://www.elsevier.com/locate/ejmech\n0223-5234/$ esee front matter /C2112013 Elsevier Masson SAS. All rights reserved.\nhttp://dx.doi.org/10.1016/j.ejmech.2013.02.009European Journal of Medicinal Chemistry 63 (2013) 151 e161\n197to treat PD, selective inhibitors of monoamine oxidase B (MAO-B)\nplay an important role [11e13].\nInterest in selective monoamine oxidase inhibitors (MAOIs),\nespecially those for MAO-B, has increased signi \ufb01cantly in recent\nyears. This is related to the recent discovery an increase in MAO-B\nactivity is associated with gliosis, which can result in high levels of\nhydrogen peroxide and oxidative free radicals. Evidence exists that\nas aging progresses activity of MAO-B in the brain increases, but not\nso for MAO-A. The largest increases are in the basal ganglia and\nthalamus, followed by the frontal cortex and, to a lesser extent,\ncerebellum and parietal and temporal cortices [14].\nIncreased activity of MAO-A and MAO-B is associated with loss\nof endogenous and exogenous monoamine amounts. The two iso-\nforms of the MAO enzyme are responsible for catalyzing the\noxidative deamination of neurotransmitters and dietary amines,\nregulating intracellular levels of biogenic amines in the brain and\nthe peripheral tissues [15,16] . MAOs are FAD-depending enzymes\nfound in the outer mitochondrial membrane of different cells, suchas neuronal, glial and other mammalian cells [17]. MAO-A and\nMAO-B have been characterized and compared according to theiramino acid sequences [18], three-dimensional structure [19], tissue\ndistribution [20], inhibitor selectivity [21] and substrate prefer-\nences [22]. The similarities of the genes encoding the two isoforms\nof MAO suggest that both derived from a common ancestral gene.\nOverall MAO-A and MAO-B share 70% amino acid sequence, how-\never similarity is higher in some regions, including the pentapep-\ntide (Ser-Gly-Gly-Cys-Tyr) that allows the covalent attachment of\nFAD through cysteine. DA and tyramine are common substrates for\nboth the MAO-A and MAO-B isoforms. However, the MAO-A iso-\nform has a higher af \ufb01nity for serotonin and noradrenaline, while\nthe MAO-B isoform preferentially deaminates\nb-phenylethylamines\nand benzylamine [23].Due to their general af \ufb01nity for different\nsubstrates, these enzymes are involved in different pathologiessuch as anxiety and depression (MAO-A), and PD and AD (MAO-B).\nSelective MAO-A inhibitors, such as clorgyline (irreversible) and\nmoclobemide (reversible), are used for the treatment of neuro-\nlogical disorders [24], whereas selective and irreversible MAO-B\ninhibitors, such as selegiline and rasagiline, are used in the treat-ment of ND [25]. Several studies point to the neuroprotective role of\nMAO-B inhibitors (MAOI-B) in PD and their modifying effect by\ndelaying the progression of the disease. Rasagiline, a selective\nMAOI-B, has been reported to retard further deterioration of\ncognitive functions, displaying an important neuroprotective ac-\ntivity against the consequences of oxidative stress in patients\n[26,27] .\nCoumarins are a large family of compounds from both natural\nand synthetic origin and display a variety of pharmacological\nproperties. Due to their structural variability and versatile synthetic\nmethodologies they occupy an important place in the realm of\nnatural products and synthetic organic chemistry. Recent studies\npay special attention to their antioxidative and enzymatic inhibi-\ntion properties, regarding their potential against ND [28].\nNumerous functionalized coumarins have been displaying potentMAO and/or AChE inhibitory activities and some of them have been\nproposed for treating AD [29e 31]. Substitution in position 3 of the\ncoumarin nucleus modulates MAO-B as well as AChE inhibitory\nactivity. Our research group has reported, in several studies, the\nimportance to the MAO inhibitory activity of different substituents\non the phenyl ring (directly linked to the coumarin or spaced with a\ncarbonyl or amide group) at position 3 of the coumarin moiety ( Fig\n1)[32e 37]. Also, we have veri \ufb01ed an important loss of the MAO-B\ninhibitory activity and selectivity when the 3-phenyl group was\nsubstituted for the 3-benzoyl one. Therefore, the presence or\nabsence of a carbonyl group between the coumarin and the phenyl\nsubstituent at position 3 modulated, respectively, the MAO-A orMAO-B inhibitory activity ( Fig. 1 )[38]. Introduction of an amidic\ngroup between the 3-substituted phenyl ring and the coumarinafforded compounds that showed a selective inhibitory activity\ntoward hMAO-B [30,39] , some of them also described as dual in-\nhibitors of MAO and AChE in the microMolar range [30].\nTaking into account previous studies [32e 38], our current work\nis focused on modifying the molecular structure of our very potent\nMAO-B inhibitors by introducing new functional groups at position\n3 to improve their activities and potential for treating PD. In addi-\ntion, preliminary studies established that carbamates (showing\nalkyl or aryl groups) were moderate MAO-B substrates [40] and\nseries of coumarins, incorporating this type of substituents at po-sition 7, differing for size and hydrophobicity have been also re-\nported [41].\nGuided by the wealth of information on structure-af\ufb01 nity and\nstructure selectivity relationships (SAFIRs and SSRs, respectively)\nwe have been encouraged to synthesized and study the in vitro\nMAO-A and MAO-B inhibitory activity of new (coumarin-3-yl)carbamate derivatives, in which a variety of groups with different\nsize, electronic properties and lipophilicity were introduced. This\nlimited, albeit crucial, structural modi \ufb01cation, if tolerated, would\nha\nve enabled us to identify new MAO-B inhibitors with an\nimproved pharmacokinetic pro \ufb01le and a higher druggability.\nThe best MAO-B inhibitor analogue in vitro (compound 8) was\nstudied in silico and in vivo , in order to gain a better understanding\nof its activity and to assess its potential for PD. In addition, com-\npound 8exhibited appropriate pharmacologic features that are\npresented and discussed in this paper, along with new SAFIRs, SSRs,and docking studies that provided a consistent picture of the main\nbinding interactions modulating the MAO inhibitory potency and\nMAO-B isoform selectivity of this new class of coumarins. Thesestudies help to corroborate and clarify the previously obtained\nin vitro experimental data and promote rational drug design.\n2. Results and discussion\n2.1. Chemistry\nAll the described (coumarin-3-yl)carbamates (compounds 1e8)\nwere ef \ufb01ciently synthesized by a versatile methodology and eval-\nuated for their ability to inhibit the A and B isoforms of hMAO. The\nchemical structure and general synthetic procedure of coumarin\nderivatives 1e8, with general structure I, were outlined in Scheme\n1. A direct acylation reaction of the commercially available 3-\naminocoumarin with the conveniently substituted acid chloride,\nusing pyridine in dichloromethane, at room temperature, for 3 h,\nafforded the differently substituted (coumarin-3-yl)carbamates.\nReaction conditions and compound characterization are described\nin the Experimental section .\nFig. 1. 3-Substituted coumarins with MAO activity which have been previously re-\nported by our research group.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 152\n1982.2. Pharmacology\n2.2.1. In vitro inhibition of MAO\nAll the described (coumarin-3-yl)carbamates (compounds 1e8)\nwere evaluated for their ability to inhibit the A and B isoforms of\nhMAO. The corresponding IC50values and hMAO-B selectivity ratios\n[IC50(hMAO-A)]/[ IC50(hMAO-B)] are shown in Table 1 .\nThe biological evaluation of the test drugs on hMAO activity was\ninvestigated by measuring their effects on the production of\nhydrogen peroxide (H 2O2)f r o m p-tyramine (a common substrate\nforhMAO-A and hMAO-B), using the Amplex/C210Red MAO assay kit\n(Molecular Probes, Inc., Eugene, Oregon, USA) and microsomal\nMAO isoforms prepared from insect cells (BTI-TN-5B1-4) infected\nwith recombinant baculovirus containing cDNA inserts for hMAO-A\norhMAO-B (Sigma eAldrich Qu\u00edmica S.A., Alcobendas, Spain) [42].\nThe production of H 2O2catalyzed by the two MAO isoforms can be\ndetected using 10-acetyl-3,7-dihydroxyphenoxazine (Amplex/C210Red\nreagent), a non- \ufb02uorescent and highly sensitive probe that reacts\nwith H 2O2in the presence of horseradish peroxidase to produce a\n\ufb02uorescent product, resoru \ufb01n. New compounds and reference in-\nhibitors were unable to react directly with the Amplex/C210Red re-\nagent, which indicates that these drugs do not interfere with the\nmeasurements. On the other hand, in our experiments and underspeci \ufb01c conditions, hMAO-A displayed a Michaelis constant ( Km)\nequal to 457.17 /C638.62 mM and a maximum reaction velocity ( Vmax)\nin the control group of 185.67 /C612.06 (nmol p-tyramine/min)/mg\nprotein, whereas hMAO-B showed a Kmof 220.33 /C632.80 mM and\nVmaxof 24.32 /C61.97 (nmol p-tyramine/min)/mg protein ( n\u00bc5).\nMost of the tested compounds concentration-dependently inhibi-\nted this enzymatic control activity ( Table 1 ).\nAs reported in Table 1 , none of the studied (coumarin-3-yl)car-\nbamates showed activity against MAO-A isoform at the highest\ntested concentration (100 mM). Activity against MAO-B isoform\ndepended on the substituents linked to the carbamate group.\nTherefore, the steric bulkiness of the carbamate \u2019s alkyl substituent\ndeterminates the activity of these derivatives. Ethyl (coumarin-3-yl)carbamate (compound 2) resulted more active against MAO-B than\nthe methyl (coumarin-3-yl)carbamate (compound 1), which is\ninactive. Isopropyl (coumarin-3-yl)carbamate (compound 3)p r o v e d\nto be more active than the ethyl derivative (compound 2). In the same\nway, isobutyl (coumarin-3-yl)carbamate (compound 4)p r o v e dt ob e\napproximately 36 times more potent than the isopropyl (coumarin-\n3-yl)carbamate (compound 3). One possible explanation for the\nactivity \u2019s modulation is the importance of the volume that these\nadditional atoms occupy in the MAO-B binding pocket. The results ofthe docking calculations corroborated this statement.\nThe introduction of a chlorine atom on the methyl group of\ncompound 1(compound 5) does not seem to improve the activity.\nCompound 5is inactive at the maximum tested concentration\n(100\nmM). However, the introduction of a bromine atom on the ethyl\nof compound 2(compound 6) improved activity over six times.\nCompounds 3and6, with an isopropyl or a bromoethyl attached\nto the carbamate, presented a similar pro \ufb01le against MAO-B, with\nIC50values of 6.63 and 5.08 mM, respectively.\nThe last strategy for the MAO-B activity modulation was the\nintroduction of an aromatic ring to the carbamate linker. Com-\npounds 7and8, presenting an aromatic ring directly connected to\nthe carbamate or linked by a methylene bridge, respectively, were\nprepared. Compound 8proved to be 540 times more active than\ncompound 7. Compounds 2and 7, presenting an ethyl group or a\nbenzene ring attached, respectively, to the carbamate, showed IC50\nvalues against MAO-B in the same range (33.38 and 24.30 mM,\nrespectively). Compound 8(IC50hMAO-B \u00bc45 nM) presented an\nactivity in the same range of selegiline ( IC50hMAO-B \u00bc20 nM) and\nrasagiline ( IC50hMAO-B \u00bc69 nM), presenting a high selectivity\ncomparing to the reference compounds. These data encourage us todeeply study compound 8as an interesting candidate for in vivo\nassays.\nIn general, the presented derivatives are not better MAO-B in-\nhibitors than some of the previously described 3-arylcoumarins[36]. However, some of these new compounds proved to be bet-\nter MAO-B inhibitors than the previously described amide de-\nrivatives [35]. These data are an important observation to follow up\na rational design of more potent and selective 3-substitutedcoumarin derivatives.\n2.2.2. In vivo assays\n2.2.2.1. - Unpretreated mice. In vivo activity of derivative 8, which\nresulted the most active compound of the series in the in vitro as-\nsays, was evaluated on unpretreated mice. This test was performed\nto observe the results of the administration of selegiline and\ncompound 8in normal mice. Doses of 10 mg/kg of compound 8did\nnot present signi \ufb01cant effect on the motor activity, velocity, time\nmoving and straightening of the animals respecting to the control\ngroup. However, selegiline caused a signi \ufb01cant decrease of these\nparameters when the same dose (10 mg/kg) was used ( Fig. 2 ).\nSelegiline, which was used as MAOI-B drug reference, is\nmetabolized to amphetamine derivatives. Therefore, it could beTable 1\nIn vitro h MAO-A and hMAO-B inhibitory Activities of (Coumarin-3-yl)carbamates 1e\n8and reference compounds.a\nCompounds IC50hMAO-A ( mM) IC50hMAO-B ( mM) S. I.b\n1 ** * e\n2 * 33.38 /C62.25 >3.0c\n3 * 6.63 /C60.45 >15c\n4 * 0.185 /C60.012 >541c\n5 ** e\n6 * 5.08 /C60.34 >19c\n7 * 24.30 /C61.64 >4.1c\n8 * 0.045 /C60.003 >2,222c\nSelegiline 67.25 /C61.02 0.020 /C60.009 3431\nIproniazide 6.56 /C60.76 7.54 /C60.36 0.87\nRasagiline 16.44 /C60.85 0.069 /C60.004 238\n*Inactive at 100 mM (highest concentration tested); at higher concentrations the\ncompounds precipitate.**100\nmM inhibits the corresponding hMAO activity by approximately 40 e45%, at\nhigher concentrations the compounds precipitate.\naEach IC50value is the mean /C6S.E.M. from \ufb01ve experiments ( n\u00bc5).\nbSelectivity index: hMAO-B selectivity ratios [ IC50(hMAO-A)]/[ IC50(hMAO-B)] for\ninhibitory effects of both new compounds and reference inhibitors.\ncValues obtained under the assumption that the corresponding IC50against\nhMAO-A is the highest concentration tested (100 mM).\nScheme 1. Reagents and conditions: a) substituted acid chloride, pyridine, DCM, r. t.,\n3h .M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 153\n199expected an increase in motor activity. However, in our experi-\nments, acutely administered and at the used dosage, signi \ufb01cantly\nreduced motor activity. In the literature mixed results were found\nregarding its effects on motor activity [11e13].\n2.2.2.2. - Potentiation effect of L-dopa/carbidopa (LD/CD) in micepretreated with reserpine. This model aims to highlight the possible\npotentiation of the effect of LD in mice treated with reserpine. If thenew molecule acted as a MAO-B inhibitor in vivo at the tested dose,\nby inhibiting the metabolism of DA, an increase in the residence\ntime of the DA in nigrostriatal synaptic cleft would be observed.\nReserpine blocks the VMAT (vesicular monoamine transporter),\npreventing proper storage of synthesized DA, causing depletion of\ndopaminergic nerve terminals and including the nigrostriatal\npathway, leading to hypokinesia in experimental animals. It is\nimportant to notice that reserpine is not very selective and also\naffects the vesicular storage of NA and 5-HT.\nFollowing this model, selegiline (10 mg/kg) signi \ufb01cantly\nincreased motor activity regarding the control group as well as the\nothers analyzed parameters. Increasing the average speed of ani-\nmals, the percentage of time moving and the number of straight-\nening, were although quite variable. Compound 8(10 mg/kg)\nshowed a slight tendency to increase the motor activity as well asthe percentage of time moving ( Fig. 3 ).\nIn order to check the tendency of the compound 8, the assays\nwere repeated at a higher dose (100 mg/kg) ( Fig. 4 ).\nIncreasing the dose it can be appreciated an increase in motor\nactivity of animals treated with the compound 8, although no sta-\ntistically signi \ufb01cant differences were obtained. The rest of the\nanalyzed parameters: velocity, percentage of time and straightening\nmovement behavior of the mice treated with compound 8, followed\nthe same pattern as in the case of motor activity.\nBy analyzing how motor activity, velocity and movement have\nevolved over time, it was possible to notice that the start of activityin mice treated with selegiline was much faster than in mice treatedwith compound 8. Nevertheless, in the last minute, all the pa-\nrameters evaluated for animals treated with compound 8were\ncomparable with those registered for mice treated with selegiline.\nAlso, statistically signi \ufb01cant differences were obtained compared to\nvehicle treated animals ( Fig. 5 ).\nDuring the performance of all assays, mortality in experimental\nanimals was monitored for 24 h and 48 h, after the execution\nthereof. In mice treated with reserpine, the mortality was drasti-\ncally reduced by administration of compound 8at the dose of\n100 mg/kg. Therefore, increasing the dosage not only improvedlocomotor activity, but also reduced mortality.\nThe observation that the compound 8showed in vivo activity,\neven at high concentrations, con \ufb01rmed the interest of its in vitro\nactivity. Analyzing these data, it was possible to prove that com-\npound 8not only achieved the proposed target, but also it was\ncapable to mimic the effects of the reference drug.\n2.3. Molecular docking studies\nMolecular docking simulations were performed for the most\nactive coumarin 8, in order to understand the enzyme-inhibitor key\ninteractions that contribute to the most stable complex confor-\nmation. A similar docking protocol was recently used by our group\n[35] where the crystal structure of the hMAO-B in complex with 7-\n(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin c1\n 7(PDB: 2V60\neFig. 6 )[43,44] was taken into account. The water molecule that\nestablishes a hydrogen bond with the co-crystallized coumarin c17\nin the hMAO-B was retained and QM-polarized ligand docking\ncombined with Prime MM-GBSA was performed with the help of\nMaestro software [45e 47].\nThe validation of the docking protocol was carried out through\nthe calculation of the RMSD (root mean square deviation) of the\nheavy atoms coordinates between the theoretical and experimental\nFig. 2. Results obtained in unpretreated mice. A) Motor activity; B) Velocity; C) Movement; D) Straightening. **p<0.01.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 154\n200Fig. 3. Results obtained in mice pretreated with reserpine, LD/CD and selegiline or compound 8(10 mg/kg). A) Motor activity; B) Velocity; C) Movement; D) Straightening.\n**p<0.01.\nFig. 4. Results obtained in mice pretreated with reserpine, LD/CD and selegiline (10 mg/kg) or compound 8(100 mg/kg). A) Motor activity; B) Velocity; C) Movement; D)\nStraightening. *p<0.05.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 155\n201conformations of the ligands from different crystal structures (PDB:\n2V60, 2XFN, 1OJ9, 1OJD, 2V61, 2V5Z, 2BK3, 1OJA, 4A79, 3PO7)\n[47].The docking was able to successfully reproduce the crystallo-\ngraphic orientation of the different hMAO-B inhibitors showing a\nRMSD value of 0.44 for the coumarin derivative c17in the 2V60\nstructure (RMSD values in Table 2 ).\nThe validated docking protocol was applied to the coumarin 8\nand the most favourable docking conformation was retrieved from\nthe calculation. The coumarin ring is slightly placed towards the\nbottom comparing to the crystallized ligand c17(Fig. 7 ). The phenyl\nring in the benzopyrone system is oriented towards the FADcofactor whereas the benzyl group is directed towards the hydro-\nphobic pocket in the entrance cavity establishing hydrophobic in-\nteractions with residues Phe103, Pro104, Trp119, Leu164, Leu167,\nPhe168, Ile199 and Ile316. Different residues interact with the\nligand through van der Waals interactions ( Fig. 7 b), mainly de \ufb01ned\nby Ile199, Leu171, Gln206, Tyr326, Ile198, Tyr398 and Phe168. Theanalysis of the binding mode also showed arene-H interactions\nbetween the residue Tyr326 and the benzopyrone ring as well asbetween Ile316 and the phenyl ring placed in the hydrophobic area.\nThe results extracted from docking simulations for the compound 8\nare in agreement with the binding modes described for coumarinsin previous publications [35,36] .\nDocking studies for the hMAO-A have been recently published\n[36,39] . In this article, to study the selectivity of compound 8to-\nwards the hMAO-B we also docked the compound to the hMAO-A.\nAccording to docking calculations, the hMAO-A cavity with water\nmolecules did not have enough space to appropriately accommo-date compound 8. However, we also carried out molecular docking\nwith no water molecules. The RMSD between the calculated and thecrystal coordinates for the ligand harmine was 0.54/C23A. Molecular\ndocking results without water molecules in the hMAO-A showed a\nconformation for compound 8placed deeply in the cavity (see\nFig. 7 c). This theoretical conformation would have to displace three\nwater molecules preserved in the hMAO-A crystal structure that can\nplay an important energetic role in the complex stabilization. Thisnecessary water displacement for the compound 8to bind the\nhMAO-A could be an energetically unfavourable process that limits\nligand binding potential, explaining the lack of activity shown bycompound 8in the experimental assays. The results are in agree-\nment with a previous publication in which the coumarin ring wasshifted towards a deeper region in the case of hMAO-A [36].\nOn the other hand, both isoenzymes present some different\nresidues in the pocket, such as the Phe208 residue in the hMAO-A\ninstead of the Ile199 in the hMAO-B that affect the shape and nature\nof the cavity. This fact plays an important role and in \ufb02uences\nthe\nstabilization of a particular ligand inside the protein pocket.\nThrough molecular docking simulations we analyzed the\npossible binding mode for the compound 8and proposed, as said\nbefore, that the coumarin ring is directed towards the FAD cofactor\nin the hMAO-B and the benzyl group is positioned inside the hy-\ndrophobic entrance cavity in a similar way to the co-crystallized\ncoumarin c17in the 2V60 structure. However, the length of the\ncompound 8causes the coumarin ring \u2019s position to shift towards\nthe FAD compared to the coumarin c17in 2V60. On the other hand,\nhydrophobic substituents in the carbamate group are well accom-\nmodated in the hydrophobic entrance cavity. The usefulness of the\ndescribed docking protocol is supported by the fact that docking\nsimulations previously published showed similar binding modes\nfor this type of compounds [35,36] .On the other hand, the selec-\ntivity of some coumarins towards hMAO-B has been recently\nstudied [36]. Interactions with a deeper region were found with the\nMAO-A, which can exert different in \ufb02uence in the stabilization of\nthe ligand-protein complexes.\n2.4. Theoretical evaluation of ADME properties\nIn order to better understand the overall properties of the\ndescribed compounds, the lipophilicity (expressed as the octanol/\nwater partition coef \ufb01cient and herein called log P), was calculated\nusing the Molinspiration property calculation program [48]. The\nFig. 5. Evolution of motor activity, velocity and movement of mice treated with reserpine, LD/CD and further treated with compound 8(100 mg/kg) or selegiline (10 mg/kg).\n*p<0.05.\nFig. 6. Chemical structure of c17 (7-(3-chlorobenzyloxy)-4-carboxaldehyde-\ncoumarin).Table 2\nRMSD values between different co-crystallized ligands with hMAO-B and the\ncalculated conformations through molecular docking (/C23A).\nPDB code RMSD (root mean\nsquare deviation)\n2V60 0.442XFN 0.56\n1OJ9 0.59\n1OJD 1.17\n2V61 1.30\n2V5Z 1.462BK3 1.61\n1OJA 1.87\n4A79 2.20\n3PO7 2.62M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 156\n202Fig. 7. a) Comparison of the co-crystallized ligand c17(purple color) and the calculated pose for the compound 8(colored by element, green carbons) by the docking simulation in\nthehMAO-B . b) Analysis of the binding mode proposed for the compound 8in the hMAO-B. FAD cofactor and residues in purple establish van der Waals interactions with the ligand.\nResidues in yellow establish both van der Waals and hydrophobic forces. Arene-H interactions with Tyr326 and Ile316 are represented in white. The FAD cofactor and the water\nmolecule are represented in CPK. c) Comparison of the conformation of compound 8in the hMAO-B (green carbons; grey ribbons) and hMAO-A (pink carbons; blue ribbons). The\ncompound is placed in a deeper region in the hMAO-A. However, for this buried conformation to happen the compound would have to displace three water molecules preserved in\nthehMAO-A crystal structure that establish an H-bond network with the protein. The water displacement could negatively in \ufb02uence the ligand eprotein complex formation\nexplaining the lack of activity shown in in vitro assays. According to docking results, this process is not necessary for the binding to hMAO-B. (For interpretation of the references to\ncolour in this \ufb01gure legend, the reader is referred to the web version of this article.)M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 157\n203theoretical prediction of ADME properties (molecular weight, log P,\nnumber of hydrogen donors and acceptors) of all the studied\ncompounds ( 1e8) was carried out and is presented in Table 3\n[49,50] .\nFrom the data presented in Table 3 , it was remarkable that all the\ndescribed coumarin derivatives possess log Pvalues compatible\nwith those required to cross membranes. TPSA, described to be a\npredictive indicator of membrane penetration, was also found to be\npositive. In addition, it can be observed that no violations of Lip-\ninski\u2019 s rule (molecular weight, log P, number of hydrogen donors\nand acceptors) were found. As MAOIs have to pass different\nmembranes and reach the CNS, this supports the potential of these\nderivatives as drug candidates.\n3. Conclusion\nIn this study, a general and ef \ufb01cient synthesis of a new series of\n(coumarin-3-yl)carbamates was developed. Most of the synthe-\nsized derivatives were selective inhibitors of MAO-B isoform in\nthe micro or nanoMolar range. In addition, it can be observed that\nno violations of Lipinski \u2019s rule were observed for all the studied\nderivatives. Therefore, the described compounds may presentdesirable ADME properties. Benzyl(coumarin-3-yl)carbamate\n(compound 8), the most active compound in vitro against MAO-B,\nwas evaluated in vivo . In mice pretreated with reserpine, the\nadministration of compound 8 (100 mg/kg) resulted in an increase\nof the motor activity, velocity and movement comparable with\nselegiline, in the last minute of the experiment. Molecular docking\nsimulations were also performed to study the binding mode of the\ncompound 8inside the hMAO-B, further analyzing isoenzyme\nselectivity and rationalizing the drug-design of this type of\nderivatives.\n4. Experimental protocols\n4.1. General\nStarting materials and reagents were obtained from commercial\nsuppliers and were used without further puri \ufb01cation (Sigma e\nAldrich). Melting points (mp) are uncorrected and were deter-\nmined with a Reichert Ko \ufb02erthermopan or in capillary tubes in a\nB\u00fcchi 510 apparatus.\n1H NMR (300 MHz) and13C NMR (75.4 MHz)\nspectra were recorded with a Bruker AMX spectrometer usingDMSO- d\n6or CDCl 3as solvent. Chemical shifts ( d) are expressed in\nppm using TMS as an internal standard. Coupling constants ( J)a r e\nexpressed in Hz. Spin multiplicities are given as s (singlet),\nd (doublet), dd (doublet of doublets), and m (multiplet). Mass\nspectrometry was carried out with a Hewlette Packard-5972-MSD\nspectrometer. Elemental analyses were performed with a Perki-nElmer 240B microanalyzer and are within 0.4% of calculatedvalues in all cases. Flash chromatography (FC) was performed on\nsilica gel (Merck 60, 230 e400 mesh); analytical TLC was performed\non pre-coated silica gel plates (Merck 60 F254). Organic solutionswere dried over anhydrous Na\n2SO4. Concentration and evaporation\nof the solvent after reaction or extraction was carried out on a ro-\ntary evaporator (B\u00fcchi Rotavapor) operating at reduced pressure.\nThe analytical results showed >95% purity for all compounds.\n4.2. General methodology to prepare (coumarin-3-yl)carbamates\n1e8\n3-Aminocoumarin (1 mmol) was dissolved in dichloromethane\n(9 mL) and pyridine (1.1 mmol) was added. The mixture was cooled\nto 0/C14C. The corresponding acid chloride (1.1 mmol) was added\ndropwise at this temperature, and the mixture was stirred, at room\ntemperature, for 3 h. The solvent was evaporated under vacuum\nand the dry residue was puri \ufb01ed by FC (hexane/ethyl acetate 9:1) to\ngive the desired (coumarin-3-yl)carbamates 1e8[51,52] .\n4.2.1. Methyl (coumarin-3-yl)carbamate ( 1)\nOrange needles. Yield 64%. mp 130 e131/C14C.1H NMR (300 MHz;\nDMSO- d6)d(ppm): 3.68 (s, 3H, OCH 3), 7.42 (m, 1H, H-6), 8.05 (t, 1H,\nJ\u00bc7.5 Hz, H-8), 8.23 (s,1H, H-4), 8.55 (td,1H, J\u00bc7.7,J\u00bc1.4 Hz, H-7),\n8.90 (dd, 1H, J\u00bc7.5, J\u00bc1.3 Hz, H-5), 9.18 (s, 1H, NH).13C NMR\n(75 MHz; DMSO-d 6)d: 62.1, 90.7, 115.6, 116.0, 122.7, 127.2, 127.3,\n142.4, 145.9, 146.0, 159.2. EI-MS m/z 220 (15), 219 (M\u00fe, 100), 188\n(22), 187 (96), 147 (22), 132 (82), 104 (25), 77 (28), 59 (11). Anal.\nCalcd. for C 11H9NO4: C, 63.16; H, 4.24. Found: C, 63.14; H, 4.21.\n4.2.2. Ethyl (coumarin-3-yl)carbamate ( 2)\nPale yellow needles. Yield 74%. mp 113 e114/C14C.1H NMR\n(300 MHz; CDCl 3)d(ppm): 1.31 (t, 3H, J\u00bc7.2 Hz, CH 3), 4.24 (dd, 2H,\nJ\u00bc14.2, J\u00bc7.1 Hz, CH 2), 7.24e7.30 (m, 2H, H-6, H-8), 7.39 (td, 1H,\nJ\u00bc7.3,J\u00bc1.0 Hz, H-7), 7.46 (dd, 1H, J\u00bc7.7,J\u00bc1.5 Hz, H-5), 7.49 (s,\n1H, NH), 8.27 (s, 1H, H-4).13C NMR (75 MHz; CDCl 3)d: 14.4, 61.9,\n116.3, 119.3, 120.8, 124.3, 125.0, 127.4, 129.2, 149.6, 153.3, 158.5. EI-\nMSm/z 234 (38), 233 (M\u00fe, 100), 161 (12), 134 (27), 98 (50), 84\n(30), 69 (41), 56 (66). Anal. Calcd. for C 12H11NO4: C, 61.80; H, 4.75.\nFound: C, 61.83; H, 4.78.\n4.2.3. Isopropyl (coumarin-3-yl)carbamate ( 3)\nOrange needles. Yield 65%. mp 94 e95/C14C.1H NMR (300 MHz;\nDMSO- d6)d(ppm): 1.24 (dd, 6H, J\u00bc6.2,J\u00bc1.5 Hz, OCH 3), 4.90 (td,\n1H, J\u00bc6.2, J\u00bc1.5 Hz, CH), 7.29 e7.37 (m, 1H, H-6), 7.40 (d, 1H,\nJ\u00bc6.0 Hz, H-8), 7.45-7.52 (m, 1H, H-7), 7.68 (d, 1H, J\u00bc6.0 Hz, H-5),\n8.22 (s, 1H, H-4), 8.90 (s, 1H, NH).13C NMR (75 MHz; DMSO- d6)d:\n21.3, 62.1, 100.7, 115.6, 116.0, 122.7, 127.2, 127.3, 142.4, 145.9, 146.0,\n159.2. EI-MS m/z248 (9), 247 (M\u00fe, 20), 220 (15), 219 (100), 188 (22),\n187 (96),147 (22),132 (82),104 (25), 77 (28), 59 (11). Anal. Calcd. for\nC13H13NO4: C, 63.15; H, 5.30. Found: C, 63.14; H, 5.28.\n4.2.4. Chloromethyl (coumarin-3-yl)carbamate ( 5)\nYellow needles. Yield 75%. mp 129 e130/C14C.1H NMR (300 MHz;\nDMSO- d6)d(ppm): 5.97 (s, 2H, CH 2Cl), 7.31 e7.41 (m, 2H, H-6, H-8),\n7.52 (dd, 1H, J\u00bc7.7,J\u00bc1.2 Hz, H-7), 7.73 (dd, 1H, J\u00bc7.7,J\u00bc1.2 Hz,\nH-5), 8.27 (s. 1H, H-4), 9.87 (s, 1H, NH).13C NMR (75 MHz; DMSO-\nd6)d: 71.2, 99.8, 116.0, 119.3, 124.0, 125.1, 128.2, 130.3, 150.3, 151.7,\n157.3. EI-MS m/z255 (33), 254 (12), 253 (M\u00fe, 71),188 (52),187 (100),\n174 (58),160 (22),132 (88), 104 (35), 77 (35), 51 (30). Anal. Calcd. for\nC11H8ClNO 4: C, 52.09; H, 3.18. Found: C, 53.00; H, 3.21.\n4.2.5. 2-Bromoethyl (coumarin-3-yl)carbamate ( 6)\nPale yellow needles. Yield 71%. mp 129 e130/C14C.1H NMR\n(300 MHz; DMSO-d 6)d(ppm): 3.73 (t, 2H, J\u00bc5.6 Hz, CH 2Br), 4.45 (t,\n2H,J\u00bc5.6 Hz, CH 2), 7.30-7.41 (m, 2H, H-6, H-8), 7.50 (dd, 1H, J\u00bc7.7,Table 3\nStructural properties of the (coumarin-3-yl)carbamates derivatives 1e8.a\nComp. log P MolecularweightTPSA H-bond\nacceptorsH-bonddonorsVolume\n1 1.65 219.20 68.54 5 1 185.52\n2 2.25 233.22 68.54 5 1 202.32\n3 2.39 247.25 68.54 5 1 218.91\n4 3.00 261.28 68.54 5 1 235.71\n5 2.24 253.64 68.54 5 1 199.30\n6 2.61 312.12 68.54 5 1 220.45\n7 3.02 281.27 68.54 5 1 240.37\n8 3.24 295.29 68.54 5 1 257.17\nalogPeoctanol/water partition coef \ufb01cient; TPSA etopological polar surface\narea. The data was determined with Molinspiration calculation software [48].M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 158\n204J\u00bc1.5 Hz, H-7), 7.70 (dd, 1H, J\u00bc7.7,J\u00bc1.4 Hz, H-5), 8.22 (s, 1H, H-\n4), 9.25 (s,1H, NH).13C NMR (75 MHz; DMSO- d6)d: 22.4, 64.9,116.0,\n118.7, 124.5, 125.1, 128.0, 129.9, 134.3, 149.9, 153.3, 157.5. EI-MS m/\nz314 (8), 313 (M\u00fe, 29), 312 (4), 311 (28), 187 (24), 174 (27), 161 (23),\n132 (100), 109 (38), 107 (40), 103 (20), 77 (60), 51 (48). Anal. Calcd.\nfor C 12H10BrNO 4: C, 46.18; H, 3.23. Found: C, 46.20; 3.25.\n4.2.6. Benzyl (coumarin-3-yl)carbamate ( 8)\nPale yellow needles. Yield 80%. mp 107 e108/C14C.1H NMR\n(300 MHz; CDCl 3)d(ppm): 5.21 (s, 3H, CH 2), 7.27e7.36 (m, 3H, H-6,\nH-7, H-8), 7.38-7.41 (m, 5H, H-20, H-30, H-40, H-50,H 60), 7.47 (dd, 1H,\nJ\u00bc7.7,J\u00bc1.5 Hz, H-5), 7.60 (s, 1H, H-4) 8.30 (s, 1H, NH).13C NMR\n(75 MHz; CDCl 3)d: 67.5, 116.3, 119.8, 121.0, 124.1, 125.1, 127.4, 128.2,\n128.5,128.7, 129.2, 135.5, 149.6,153.0, 158.3. EI-MS m/z296 (25), 295\n(M\u00fe, 100), 251 (12), 91 (58). Anal. Calcd. for C 17H13NO4: C, 68.42; H,\n4.42. Found: C, 68.45; H, 4.46.\n4.3. Determination of MAO isoforms activity4.3.1. In vitro assays\nThe effects of the new synthesized compounds on hMAO iso-\nform enzymatic activity were evaluated by a \ufb02uorimetric method\nfollowing the experimental protocol previously described by us\n[42]. Brie \ufb02y, 0.1 mL of sodium phosphate buffer (0.05 M, pH 7.4)\ncontaining the test drugs (new compounds or reference inhibitors)in various concentrations and adequate amounts of recombinant\nhMAO-A or hMAO-B required and adjusted to obtain in our\nexperimental conditions the same reaction velocity, ( hMAO-A:\n1.1 mg protein; speci \ufb01c activity: 150 nmol of p-tyramine oxidized to\np-hydroxyphenylacetaldehyde/min/mg protein; hMAO-B: 7.5 mg\nprotein; speci \ufb01c activity: 22 nmol of p-tyramine transformed/min/\nmg protein) were incubated for 15 min at 37\n/C14Ci na \ufb02at-\nblackbottom 96-well microtest /C212plate, placed in the dark \ufb02uo-\nrimeter chamber. After this incubation period, the reaction was\nstarted by adding ( \ufb01nal concentrations) 200 mM Amplex/C210Red re-\nagent, 1 U/mL horseradish peroxidase and 1 mM p-tyramine. The\nproduction of H 2O2and, consequently, of resoru \ufb01n was quanti \ufb01ed\nat 37/C14C in a multidetection microplate \ufb02uorescence reader\n(FLX800 /C212, Bio-Tek/C210Instruments, Inc., Winooski, VT, USA) based on\nthe\ufb02uorescence generated (excitation, 545 nm, emission, 590 nm)\nover a 15 min period, in which the \ufb02uorescence increased linearly.\nControl experiments were carried out simultaneously by replacingthe test drugs (new compounds and reference inhibitors) with\nappropriate dilutions of the vehicles. In addition, the possible ca-\npacity of the above test drugs to modify the \ufb02uorescence generated\nin the reaction mixture due to non-enzymatic inhibition (e.g., fordirectly reacting with Amplex\n/C210Red reagent) was determined by\nadding these drugs to solutions containing only the Amplex/C210Red\nreagent in a sodium phosphate buffer. The speci \ufb01c\ufb02uorescence\nemission (used to obtain the \ufb01nal results) was calculated after\nsubtraction of the background activity, which was determined from\nvials containing all components except the hMAO isoforms, which\nwere replaced by a sodium phosphate buffer solution.\n4.3.2. In vivo assays\n4.3.2.1. Animals. Charles River \u201cCD1 \u201dmice weighing 30 /C65 g were\nhoused in groups of 4 or 8 animals under regulated conditions(light/dark cycle between 8.00 and 20.00 h at 21 /C62\n/C14C) in standard\nMakrolon cages (215 /C2465/C2145 mm3). The animals received\nstandard laboratory chow and tap water ad libitum until the\nbeginning of the experiments.\n4.3.2.2. Drugs and chemicals. Reserpine, LD (200 mg/kg) and sele-\ngiline (10 mg/kg) were supplied by Sigma eAldrich (St. Louis, MO,\nUSA) and CD (50 mg/kg) was kindly provided by DupontPharma.Sodium carboxymethyl cellulose (CMCNa) was supplied by Merck\n(Madrid, Spain). All the used chemicals were of analytical grade. In\nbehavioral experiments all compounds were administered in0.01\nmL/g intraperitoneal (ip) injections. A suspension of 1% CMCNa was\nused as control whileselegiline was used as MAO-B drug baseline.\nCompound 8was tested at doses of 10 and 100 mg/kg, in a sus-\npension of 1% CMCNa.\n4.3.2.3. Locomotor activity. The locomotor activity of animals in\nsquare arenas (50 /C250/C230 cm3) under a video camera sus-\npended from the ceiling was recorded over a 1 h period between\n10.00 and 14.00 h and analyzed using a computerized animal\nobservation system (EthovisionV. 3.1.16, Noldus Information\nTechnology, Wageningen, The Netherlands), located in a separated\nroom. The variables considered were distance traveled (in cm),\nvelocity (cm/s), % time moving during the test run and\nstraightening.\n4.3.2.4. Protocol. Animal models for study were twofold:\n- Unpretreated mice: Compound 8was tested by ip adminis-\ntration at doses of 10 mg/kg or 100 mg/kg in untreated mice,\ncomparing with the vehicle (1% CMCNa) and selegiline (10 mg/\nkg). The pharmacological effect was evaluated during 1 h\nimmediately after administration.\n- Potentiation effect of LD/CD in mice pretreated with reserpine:\nThis model involves the administration of reserpine (2.5 mg/kg,\nip) to the animals 22 h before the completion of each trial. After\nthis time, the vehicle (1% CMCNa) or new molecules under test\nwere administered. LD/CD (200:50 mg/kg) were administered\n30 min later. Locomotor activity was evaluated 1 h after the last\nadministration during a period of 1 h.\n4.3.2.5. Expression of results, plotting and statistical analysis.\nResults are expressed as mean /C6standard error of the mean\n(x/C6SEM). The minimum number of animals used in each assay was\n8(n\u00bc8). The graphical representation and statistical analysis were\nperformed using GraphPad Prism (V 4.3) (San Diego, USA). Statis-\ntically signi \ufb01cant differences were determined by one-way ANOVA\n(treatment) followed by the Dunnet test or by two-way ANOVA(treatment-time) followed by Boferroni test.\n4.4. Molecular docking\nMaestro software available in Schr\u00f6dinger 2011 package [45]\nwas used to carry out all the molecular docking simulations.4.4.1. Protein and ligand preparation\nProtein Preparation Work \ufb02ow in Maestro software [45] was used\nto pre-process the crystal structure of the hMAO-B in complex with\nthe coumarin c17(PDB code: 2V60) and the crystal structure of the\nhMAO-A with the ligand harmine (PDB code: 2Z5X). Only the water\nmolecule that establishes a hydrogen bond with the co-crystallized\ncoumarin was retained in the calculations for the hMAO-B. Two\ndifferent protocols were followed in the hMAO-A: 1) no water\nmolecules were retained in the cavity protein and 2) only waters\nwithin 5/C23A from the ligand were retained. Hydrogen were added and\nenergy minimized with the OPLS_2005 force \ufb01eld. Optimizations of\nthe hydrogen bonding network and the protonation states of some\nresidues were also carried out through this procedure.\nThe dataset of different ligands belonging to hMAO-B and hMAO-\nA as well as the coumarin derivative 8were prepared with the Lig-\nPrep module [53]. Protonation states at pH 7.0 /C62.0 and tautomers\nwere generated and optimized using OPLS_2005 force \ufb01eld.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 159\n2054.4.2. Ligand docking procedure\nA receptor grid was calculated and centred in the co-crystallized\nligand c17in the hMAO-B and in the harmine in the hMAO-A with\nan outer box length of 20/C23A. The receptor van der Waals scaling\nfactor was 1.0 with a partial charge cut-off of 0.25. The docking\nprotocol included QM-polarized ligand docking [46]. The ligands\nwere docked to the protein structure using Standard Precision (SP)level and three poses per ligand were retained. New partial charges\nof the ligands inside the protein pocket were calculated with the\nhelp of Jaguar module [54]. The ligands with the improved charges\nwere redocked using Extra Precision (XP) mode and three poses perligand were retained. Finally, the best pose according to the energy\nscore E\nmodel was optimized using MM-GBSA in Prime module [53]\ntaking into account a \ufb02exible protein region de \ufb01ned by 5/C23A from\nthe ligand.\nAverage MMGBSA free energy of binding calculated from the\nthree complexes extracted from QM-polarized docking was cali-\nbrated with the experimental af \ufb01nity (p Ki) for different known li-\ngands (data shown in Table 4 ).\nAcknowledgments\nWe are grateful to the Xunta de Galicia (09CSA030203PR, PGI-\nDIT07PXIB, 10PXIB203303PR) and Spanish Ministerio de Sanidad y\nConsumo (FIS PS09/00501). MJM thanks Funda\u00e7\u00e3o de Ci\u00eancia e\nTecnologia for the fellowship (SFRH/BD/61262/2009). SV thanks the\nAngeles Alvari\u00f1o program from Xunta de Galicia (Spain).\nReferences\n[1] Y. Zhu, K. Xiao, L. Ma, B. Xiong, Y. Fu, H. Yu, W. Wang, X. Wang, D. Hu, H. Peng,\nJ. Li, Q. Gong, Q. Chai, X. Tang, H. Zang, J. Li, J. Shen, Bioorg. Med. Chem. 17\n(2009) 1600 e1613.\n[2] E. Scarpini, P. Scheltens, H. Feldman, Lancet Neurol. 2 (2003) 539 e547.\n[3] H.W. Querfurth, F.M. LaFerla, N. Engl. J. Med. 362 (2010) 329 e344.\n[4] J. Saura, J.M. Luque, A.M. Cesure, M. Da Prada, V. Chan-Palay, G. Huber,\nJ. Lof\ufb02er, J.G. Richard, Neuroscience 62 (1994) 15 e30.\n[5] M.B.H. Youdim, Exp. Neurobiol. 19 (2010) 1 e14.\n[6] W. Dauer, S. Przedborski, Neuron 39 (2003) 889 e909.\n[7] G.E. Meredith, S. Totterdell, M. Beales, C.K. Meshul, Exp. Neurol. 219 (2009)\n334e340.\n[8] C.W. Olanow, K.S.P. McNaught, Mov. Disord. 21 (2006) 1806 e1823.\n[9] M.D. Yahr, R.C. Duvoisin, M.J. Schear, R.E. Barrett, M.M. Hoehn, Arch. Neurol.\n21 (1969) 343 e354.\n[10] A. Carlsson, J. Neural Transm. 109 (2002) 777 e787.\n[11] E. Abel, Physiol. Behav. 57 (1995) 611 e613.[12] G. Engberg, T. Elebring, H. Nissbrandt, J. Pharmacol. Exp. Ther. 259 (1991)\n841e847.\n[13] D.K. Ingram, H.L. Wiener, M.E. Chachich, J.M. Long, J. Hengemihle, M. Gupta,\nNeurobiol. Aging 14 (1993) 431 e440.\n[14] T. Nagatsu, Neurotoxicology 25 (2004) 11 e20.\n[15] P. Dostert, B.M. Strolin, M. Jalfre, Monoamine oxidase: basic and clinical\nfrontiers, in: Exerpta Medica, Elsevier, Amsterdam, 1982, pp. 197 e208.\n[16] T.P. Singer, in: F. Muller (Ed.), Chemistry and Biochemistry of Flavoenzymes,\nvol. 2, CRC Press, Boca Raton, 1991, pp. 437 e470.\n[17] K.F. Tipton, Cell Biochem. Funct. 4 (1986) 79 e87.\n[18] A.W.J. Bach, N.C. Lan, D.L. Johnson, C.W. Abell, M.E. Bembenek,\nS.W. Kwan, P.H. Seeburg, J.C. Shih, Proc. Natl. Acad. Sci. U. S. A. 85 (1988)\n4934e4938.\n[19] J. Wouters, Curr. Med. Chem. 5 (1998) 137 e162.\n[20] J. Grimsby, N.C. Lan, R. Neve, K. Chen, J.C. Shih, J. Neurochem. 55 (1990) 1166 e\n1169.\n[21] A.S. Kalgutkar, N. Castagnoli Jr., Med. Res. Rev. 15 (1995) 325 e388.\n[22] R.M. Geha, I. Rebrin, K. Chen, J.C. Shih, J. Biol.Chem. 276 (2001) 9877 e9882.\n[23] J. Ma, M. Yoshimura, E. Yamashita, A. Nakagawa, A. Ito, T. Tsukihara, J. Mol.\nBiol. 338 (2004) 103 e114.\n[24] M.V. Rudorfer, V.Z. Potter, Drugs 37 (1989) 713 e738.\n[25] H.H. Fernandez, J.J. Chen, Clin. Neuropharmacol. 30 (2007) 150 e168.\n[26] H. Zheng, M. Fridkin, M.B.H. Youdim, Neurochem. Res. 35 (2010) 2117 e\n2123.\n[27] M.B. Youdim, A.O. Bar, M. Yogev-Falach, O. Weinreb, W. Maruyama, M. Naoi,\nT. Amit, J. Neurosci. Res. 79 (2005) 172 e179.\n[28] F. Borges, F. Roleira, N. Milhazes, E. Uriarte, L. Santana, Front. Med. Chem. 4\n(2009) 23 e85.\n[29] R. Hoerr, M. Noeldner, CNS Drug Rev. 8 (2002) 143 e158.\n[30]\nD. Vi\u00f1a, M.J. Matos, M. Y\u00e1\u00f1ez, L. Santana, E. Uriarte, MedChemComm 3 (2011)\n213e218.\n[31] C. Br\u00fchlmann, F. Ooms, P.A. Carrupt, B. Testa, M. Catto, F. Leonetti, C. Altomare,\nA. Carotti, J. Med. Chem. 44 (2001) 3195 e3198.\n[32] M.J. Matos, D. Vi\u00f1a, E. Quezada, C. Picciau, G. Delogu, F. Orallo, L. Santana,\nE. Uriarte, Bioorg. Med. Chem. Lett. 19 (2009) 3268 e3270.\n[33] M.J. Matos, D. Vi\u00f1a, C. Picciau, F. Orallo, L. Santana, E. Uriarte, Bioorg. Med.\nChem. Lett. 19 (2009) 5053 e5055.\n[34] M.J. Matos, D. Vi\u00f1a, P. Janeiro, F. Borges, L. Santana, E. Uriarte, Bioorg. Med.\nChem. Lett. 20 (2010) 5157 e5160.\n[35] D. Vi\u00f1a, M.J. Matos, G. Ferino, E. Cadoni, R. Laguna, F. Borges, E. Uriarte,\nL. Santana, Chem. Med. Chem. 7 (2012) 464 e470.\n[36] M.J. Matos, C. Ter\u00e1n, Y. P\u00e9rez-Castillo, E. Uriarte, L. Santana, D. Vi\u00f1a, J. Med.\nChem. 54 (2011) 7127 e7137.\n[37] S. Serra, G. Ferino, M.J. Matos, S. V\u00e1zquez-Rodr\u00edguez, G. Delogu, D. Vi\u00f1a,\nE. Cadoni, L. Santana, E. Uriarte, Bioorg. Med. Chem. Lett. 22 (2012) 258 e261.\n[38] M.J. Matos, S. V\u00e1zquez-Rodr\u00edguez, E. Uriarte, L. Santana, D. Vi\u00f1a, Bioorg. Med.\nChem. Lett. 21 (2011) 4224 e4227.\n[39] F. Chimenti, D. Secci, A. Bolasco, P. Chimenti, B. Bizzarri, A. Granese,\nS. Carradori, M. Y\u00e1\u00f1ez, F. Orallo, F. Ostusi, S. Alcaro, J. Med. Chem. 52 (2009)\n1935e1942.\n[40] P. Flaherty, K. Castagnoli, Y.-X. Wang, N. Castagnoli, J. Med. Chem. 39 (1996)\n4756e4761.\n[41] A. Carotti, C. Altomare, M. Catto, C. Gnerre, L. Summo, A. De Marco, S. Rose,\nP. Jenner, B. Testa, Chem. Biodiversity 3 (2006) 134 e149.\n[42] M. Y\u00e1\u00f1ez, N. Fraiz, E. Cano, F. Orallo, Biochem. Biophys. Res. Commun. 344\n(2006) 688 e695.Table 4\nExperimental and calculated af \ufb01nities (p Ki) for different known ligands.\nCompoundsahMAO-B Compounds hMAO-A\nExperimental p KibCalculated p Ki Experimental p Ki Calculated p Kic\n2V60 6.40 7.65 2Z5X 8.30 7.60\n2V61 7.00 7.89 CHEMBL1813518 5.81 7.26\n2V5Z 6.35 7.12 CHEMBL466872 7.21 7.28\n2BK3 6.10 6.92 CHEMBL1645551 6.30 7.55\n1OJA 5.52 5.89 CHEMBL602466 7.29 6.53\n3PO7 5.51 6.38 CHEMBL1645547 8.44 7.81\nCHEMBL1813523 8.52 7.41 CHEMBL1645545 8.41 7.73\nCHEMBL1642678 9.55 7.09\nCHEMBL466872 8.40 7.00\nhMAO-B hMAO-A\nExperimental IC50 Calculated p KidExperimental IC50 Calculated p Ki\nCompound 8 0.045 mM 7.01 Inactive at 100 mM 6.69\naPDB and CHEMBL codes.\nbpKi values extracted from Binding DB.\ncCalculated values using the hMAO-A docking with no water in the pocket (for the crystallized harmine in 2Z5X, both hMAO-A docking protocols were taken into account).\ndCalculated p Ki for compound 8is provided through the equations with r\u00bc0.42 and r\u00bc0.41 for the hMAO-B and hMAO-A respectively.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 160\n206[43] C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D.E. Edmondson,\nA. Mattevi, J. Med. Chem. 50 (2007) 5848 e5852.\n[44] RCSB Protein Data Bank: http://www.rcsb.org/ (accessed Jun 2012).\n[45] Maestro, Version 9.2, Schr\u00f6dinger, LLC, New York, NY, 2011.\n[46] QM-polarized Ligand Docking Protocol; Glide Version 5.7, Jaguar Version 7.8,\nQSite Version 5.7, Schr\u00f6dinger, LLC, New York, NY, 2011.\n[47] Prime, Version 3.0, Schr\u00f6dinger, LLC, New York, NY, 2011.\n[48] M Cheminformatics, Bratislava, SlovakRepublic, http://www.molinspiration.\ncom/services/properties.html (accessed Jun 2012).[49] C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Adv. Drug Deliv. Rev. 23\n(1997) 3 e26.\n[50] P. Ertl, B. Rohde, P. Selzer, J. Med. Chem. 43 (2000) 3714 e3717.\n[51] M.J. Matos, A. Gaspar, S. Kachler, K.-N. Klotz, F. Borges, L. Santana, E. Uriarte,\nJ. Pharm. Pharmacol. 65 (2013) 30 e34.\n[52] H. Takahashi, H. Takechi, K. Kubo, T. Matsumoto, Heterocycles 72 (2007)\n123e126.\n[53] LigPrep, Version 2.5, Schr\u00f6dinger, LLC, New York, NY, 2011.\n[54] Jaguar, Version 7.8, Schr\u00f6dinger, LLC, New York, NY, 2011.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 161\n2073-Substituted coumarins as dual inhibitors of AChE and MAO for the\ntreatment of Alzheimer\u2019s disease\nDolores Vi ~na,aMaria Joa \u02dco Matos, *bMatilde Y /C19a~nez,aLourdes Santanaband Eugenio Uriarteb\nReceived 30th August 2011, Accepted 3rd October 2011\nDOI: 10.1039/c1md00221j\nThe complex etiology of Alzheimer\u2019s disease (AD) has encouraged active research in the development\nof multi-target drugs with two or more complementary biological activities, since they may represent animportant advance in the treatment of this disease. A series of 3-substituted coumarins were synthesizedand evaluated as monoamino oxidases (MAO) and acetylcholinesterase (AChE) inhibitors. Most of the3-benzamide coumarin derivatives inhibited both MAO-B and AChE with values in the micromolarrange. It might be a promising direction for developing novel drugs as potential agents for the treatmentof AD patients.\n1. Introduction\nThe frequency, morbidity and complexity of neurodegenerative\ndiseases make them the greatest therapeutic challenge tomedicine today. Among them, Alzheimer\u2019s disease (AD) is themost common cause of senile dementia, affecting approxi-mately 3% of the population between the ages of 65\u201374 and\nnearly 50% of those 85 years and older.\n1This disease is char-\nacterized by a decreased number of cholinergic neurons in the\nhippocampus and amygdala, which is clinically re\ufb02ected in the\nappearance of speci\ufb01c symptoms: progressive impairment inmemory and intellectual ability to perform basic activities ofdaily living.\n2Although the etiology of AD is not completely\nknown, deposits of aberrant proteins, namely b-amyloid (A b)\nand s-protein, oxidative stress, dyshomeostasis of biometals\nand low levels of acetylcholine (ACh) seem to play signi\ufb01cantroles.\n3Monoamine oxidase B (MAO-B) activity is also\nincreased in association with gliosis, which can result in higher\nlevels of H 2O2and oxidative free radicals which are a possible\nsource of oxidative stress for vulnerable neurons affected by\nAD.4Anti-acetylcholinesterase (anti-AChE) agents such as\ntacrine, galantamine, and donepezil have shown a modest\nimprovement in memory and cognitive function but do not\nappear to prevent or slow the progressive neurodegeneration.5\nOn the other hand, rasagiline, a selective MAO-B inhibitor, has\nbeen reported to retard the further deterioration of cognitivefunctions, displaying neuroprotective activity.\n6Because of thecomplexity of this disease, drugs hitting a single target may beinadequate for the treatment of AD. It has encouraged activeresearch in the development of multifunctional drugs with twoor more complementary biological activities, since they may\nrepresent an important advance in the treatment of the\ndisease.\n7,8Recently, a new bifunctional drug, ladostigil, was\ndeveloped by combining the neuroprotective effects of rasagi-line with the cholinesterase inhibitory activity in a single\nmolecule. Ladostigil inhibits both cholinesterase (acetylcholin-\nesterase and butyrylcholinesterase) and brain monoamineoxidases (MAO-A and MAO-B).\n9\nCoumarins are a large family of compounds, of natural and\nsynthetic origin, that display a variety of pharmacologicalproperties. Due to their structural variability they occupy animportant place in the realm of natural products and synthetic\norganic chemistry. Recent studies pay special attention to their\nantioxidative and enzymatic inhibition properties.\n10Numerous\nfunctionalized coumarins have been presented as potent MAOand/or AChE inhibitors and some of them have been proposedfor treating AD.\n11,12Substitution in position 3 of the coumarin\nnucleus modulated AChE as well as MAO-B inhibitoryactivity.\n123-(Piperazine-1-carbonyl)coumarins showed signi\ufb01-\ncant anti-AChE activities.13Phenyl, methyl, carboxylic acids,\nethyl ester or acyl chloride groups in that position resulted in\npotent MAO inhibitors.14Our research group has reported, in\nseveral studies, the importance of the MAO inhibitory activity of\ndifferent substituents on the phenyl ring in position 3 of the\ncoumarin (Fig. 1\u2014 I).15\u201318Our work is now focused on modifying\nthe molecular structure of these potent MAO-B inhibitors,\nintroducing either an arylamide group (amidic group between the\ncoumarin and the 3-phenyl ring) (Fig. 1\u2014 II) or an alkylamide\ngroup in that position (Fig. 1\u2014 III) in order to provide them with\nadditional biological properties, such as AChE inhibition,\nbecoming useful for treating AD.aDepartamento de Farmacolog /C19\u0131a, Facultad de Farmacia, Universidad de\nSantiago de Compostela, 15782 Santiago de Compostela, Spain. E-mail:\nmdoloresvina@usc.es; Fax: +34 98159 4595; Tel: +34 9815 63100\nbDepartamento de Qu /C19\u0131mica Org /C19anica, Facultad de Farmacia, Universidad\nde Santiago de Compostela, 15782 Santiago de Compostela, Spain.E-mail: mariajoao.correiapinto@rai.usc.es; Fax: +34 981 544912; Tel:\n+34 981 563100\nThis journal is \u00aaThe Royal Society of Chemistry 2012 Med. Chem. Commun. , 2012, 3, 213\u2013218 | 213Dynamic Article Links C< MedChemComm\nCite this: Med. Chem. Commun. , 2012, 3, 213\nwww.rsc.org/medchemcomm CONCISE ARTICLE\n2092. Chemistry\nCoumarin derivatives 1\u20133, with general structures I, were\nsynthesized according to the protocol outlined in Scheme 1,\nunder Perkin condensation conditions, starting from the corre-sponding ortho -hydroxybenzaldehyde and the substituted aryl-\nacetic acid.\n15\u201320Compounds 4\u201316, with general structures IIand\nIII, were also ef\ufb01ciently synthesized according to the protocol\noutlined in Scheme 1.21\u201328Coumarins 4\u201316 were prepared start-\ning from a condensation of a commercially available salicy-laldehyde and the ethyl nitroacetate. The reaction was performedin a dry Schlenk tube, with acetic anhydride as solvent, in the\npresence of sodium hydride, at room temperature, for three\nhours. The 3-aminocoumarins were prepared from previously\nsynthesized 3-nitrocoumarins, in ethanol, with Pd/C as catalystunder H\n2atmosphere. An acylation reaction of the 3-amino-\ncoumarin with the conveniently substituted acid chloride, usingpyridine and dichloromethane, at room temperature, forthree hours, afforded the differently substituted 3-amidocou-marins 4\u201316.\nThe chemical structure of the synthesized compounds\n1\u201316 is detailed in Table 1. Reaction conditions and\ncompound characterization are described in the Experimentalsection.\nFig. 1 General structures of the coumarin derivatives.\nScheme 1 Reagents and conditions : (i) DCC, DMSO, 110/C14C, 24 h; (ii)\nNaH, Ac 2O, r. t., 3 h; (iii) H 2, EtOH, Pd/C, r. t., 3 h; (iv) substituted acid\nchloride, pyridine, DCM, r. t., 3 h.Table 1 Structures of the studied compounds 1\u201316\nCompounds\n RR 1\n1 H\n2 CH 3\n3 CH 3\n4 CH 3\n5 H\n6 H\n7 H\n8 H\n9 H\n10 H\n11 H\n12 H\n13 H\n214 | Med. Chem. Commun. , 2012, 3, 213\u2013218 This journal is \u00aaThe Royal Society of Chemistry 2012\n2103. Pharmacology\n3.1. Inhibition of MAO\nThe potential effects of the newly synthesized compounds on\nhMAO activity were investigated by measuring their effects onthe production of hydrogen peroxide (H\n2O2) from p-tyramine,\nusing the Amplex Red MAO assay kit (Molecular Probes, Inc.,\nEugene, Oregon, USA) and MAO isoforms in microsomes\nprepared from insect cells (BTI-TN-5B1-4) infected withrecombinant baculovirus containing cDNA inserts for hMAO-Aor hMAO-B (Sigma-Aldrich Qu /C19\u0131mica S.A., Alcobendas, Spain).\nThe inhibition of hMAO activity was evaluated using the above\nmethod following the general procedure described previously by\nus.\n29The test compounds did not show any interference with the\nreagents used for a biochemical assay. The control activity ofhMAO-A and hMAO-B using p-tyramine as the common\nsubstrate was 165 /C62 pmol of p-tyramine oxidized to\np-hydroxyphenylacetaldehyde per min ( n\u00bc20).\nThe results of the hMAO-A and hMAO-B inhibition studies\nwith our compounds are reported in Table 2 together with theMAO-B selectivity index. Enzymatic assays revealed that most of\nthe test compounds were moderate to potent hMAO inhibitors at\neither low micromolar to nanomolar concentrations, showingselectivity toward hMAO-B.\n3.2. Inhibition of AChE\nThe method of Ellman\n30was used to determine the in vitro\ncholinesterase activity. The activity was measured by the increase\nin absorbance at 412 nm due to the yellow color of 5-mercapto-2-nitrobenzoic acid produced by the reaction of thiocholine withdithiobisnitrobenzoate. Thiocholine was generated from ace-\ntylthiocholine using human recombinant AChE expressed in\nHEK 293 cells (Sigma-Aldrich Qu /C19\u0131mica S.A., Alcobendas,\nSpain). The control activity from hAChE using acetylthiocholineas substrate was 0.66 /C60.13 mM of acetylthiocholine to oxidized\nthiocholine per min ( n\u00bc20).\nAssays were performed with a blank containing all compo-\nnents except AChE, in order to account for nonenzymatic reac-\ntion. The reaction rates were compared and the percent\ninhibition due to the presence of test compounds was calculatedand the IC\n50values are reported in Table 3. These data show thatsome of the compounds exhibited moderate inhibitory activityagainst the AChE.\n4. Results and discussion\nCompounds 1\u201316 were prepared and tested for their in vitro\ninhibitory activity against MAO-A and -B isoforms, inTable 1 (Contd. )\nCompounds\n RR 1\n14 H\n15 H\n16 H\nTable 2 IC50values and hMAO-B selectivity index for the new\ncompounds and reference inhibitors on the enzymatic activity of human\nrecombinant MAO isoforms expressed in baculovirus-infected BTI insectcellsa\nCompounds MAO-A (IC 50) MAO-B (IC 50) SI MAO-Be\n1c11.81 /C60.80mM >8.5f\n2c283.75 /C625.50 nM >352f\n3c308.52 /C620.69 pM >324,128f\n4 45.97 /C63.11mMa0.17/C60.01mM 270\n5c7.96/C60.53mM >12.6f\n6c0.76/C60.05mM >131f\n7c30.50 /C62.06mM >3.3f\n8c1.95/C60.13mM >52f\n9cc\n10c58.38 /C63.91mM >1.7f\n11c72.58 /C64.90mM >1.4f\n12c5.95/C60.40mM >16.8f\n13c49.96 /C63.35mM >2.0f\n14 38.93 /C62.63mMd<0.40f\n15cc\n16cc\nR-(/C0)-Deprenyl 67.25 /C61.02mMb14.80 /C60.99 nM 4,544\nIproniazide 6.56 /C60.76mM 7.54 /C60.36mM 0.87\naEach IC 50value is the mean /C6SEM from \ufb01ve experiments ( n\u00bc5).\nbLevel of statistical signi\ufb01cance: P< 0.01 versus the corresponding\nIC50values obtained against MAO-B, as determined by ANOVA/\nDunnett\u2019s.cInactive at 100 mM (highest concentration tested). At\nhigher concentrations the compounds precipitate.d100mM inhibits\nenzymatic activity by approximately 40\u201345%.eSI MAO-B \u00bc\n[IC50(MAO-A)]/[IC 50(MAO-B)].fValues obtained under the\nassumption that the corresponding IC 50against either MAO-A or\nMAO-B is the highest concentration tested (100 mM).\nTable 3 IC50values index for the new compounds and reference\ninhibitors on the enzymatic activity of human recombinant AChE\nexpressed in HEK 293 cellsa\nCompounds IC50AChE/ mM\n1b\n2b\n3b\n4 41.37 /C62.80\n5 18.38 /C61.23\n6b\n7 69.47 /C64.65\n8 18.71 /C60.84\n9 12.89 /C60.70\n10b\n11b\n12 15.01 /C60.68\n13b\n14b\n15b\n16b\nTacrine 0.15/C60.01\nEserine 0.16/C60.01\naEach IC 50value is the mean /C6SEM from \ufb01ve experiments ( n\u00bc5).\nbInactive at 100 mM (highest concentration tested). At higher\nconcentrations the compounds precipitate.\nThis journal is \u00aaThe Royal Society of Chemistry 2012 Med. Chem. Commun. , 2012, 3, 213\u2013218 | 215\n211microsomes prepared from insect cells (BTI-TN-5B1-4) infected\nwith recombinant baculovirus containing cDNA inserts forMAO-A or -B as well as against AChE recombinant, expressed\nin HEK 293 cells.\nAryl substitutions in position 3 of the coumarin moiety proved\nto be important for the MAO-B activity and selectivity.\n15\u201318Also,\nthe presence of an amidic group in the same position was an\nimportant structural change to improve the AChE inhibitory\nactivity.13Therefore, the introduction of both structural frag-\nments in that position was thought as a possible strategy todevelop dual MAO-B/AChE inhibitors.\nAccording to our previous results, 3-arylcoumarins 1\u20133\nshowed activity against MAO-B isoform in the micro, nano andpicomolar range. The introduction of a methyl group in the six\nposition of the coumarin moiety improved the MAO-B activity\nand selectivity approximately 50-fold (comparing compounds 2\nand1). Additionally, the introduction of another methyl group in\nposition para of the 3-aryl ring of the same scaffold increased the\nMAO-B inhibitory activity and the selectivity almost 1000-fold\n(comparing compounds 3and2). None of the above-mentioned\ncompounds showed inhibitory activity against AChE.\nTaking into account that compound 3was the most potent\nMAO-B inhibitor, an amidic group was introduced between thecoumarin moiety and the 3-aryl ring. This new derivative(compound 4) presented inhibitory activity against AChE and\nboth MAO isoforms, in the micromolar range. Despite these\nresults, the presence of both methyl groups in the six position and\nthe amidic group between the coumarin and 3-aryl ring leads toan unwanted loss of MAO selectivity.\nConsidering the 3-benzamidecoumarins as a new scaffold with\nthe desirable dual MAO-/AChE inhibitory activities, modi\ufb01ca-tions under this skeleton were done in order to improve the\nMAO-B selectivity and the AChE inhibitory activity. The elim-\nination of the methyl group in the six position (compound 5)\nleads to a selective MAO-B inhibitor, with an increase in AChEinhibitory activity. Based on these experimental data, the\nimportance of the substitutions under the aryl ring of the\n3-benzamidecoumarins was studied. Unsubstituted 3-benzamide\ncoumarin (compound 6) improved the MAO-B activity\napproximately 10-fold compared with compound 5. However,\nthis compound proved to be inactive against AChE, showing\nthat the substituents under the aryl ring are important tomodulate the AChE inhibitory activity. Therefore, different\nsubstituents were introduced in several positions of this ring. A\nmethoxy group incorporated in the para position of the ring\n(compound 7) seems to be less favorable for the AChE and\nMAO-B inhibition than a methyl group (compound 5). A chloro\ngroup in the same position allows a new compound ( 8) with\nsimilar AChE inhibitory activity to compound 5and a slight\nincrease of the inhibitory MAO-B activity. Introduction of\na nitro group at the same position (compound 9) leads to\na slightly more active compound against AChE, but inactive\nagainst MAO-B.\nAnother strategy to modulate the dual AChE/MAO-B activi-\nties was the introduction of more than one substituent under the\naryl ring. Introduction of additional methoxy groups in this ring\nleads to inactive AChE inhibitory compounds ( 10,11), also with\na decrease in the MAO-B inhibitory activity. However, intro-\nduction of a second chloro atom in the meta position of the arylring resulted in a compound ( 12) with similar AChE and MAO-B\ninhibitory activities to the mono-substituted derivative\n(compound 8). From the experimental results it can be observed\nthat the nature, number and position of the substituents in thearyl ring are important to modulate the AChE and MAO-Binhibitory activities.\nFinally, in order to determine the importance of the aryl ring,\nit was replaced with an alkyl or haloalkyl group (compounds 13\u2013\n16). None of these compounds presented inhibitory activity\nagainst AChE. Compound 13, with a cycloalkyl linked to the\namidic group, instead of an aromatic ring, also presentedinhibitory activity against MAO-B. However, this activity isapproximately 66-fold less than that presented by compound 6.\nSubstitution by a less bulky group leads to a compound ( 14)\nwhich\npresents inhibitory activity against MAO-A, in the\nmicromolar range. Introduction of a haloalkyl group in the same\nposition leads to inactive compounds against both MAO iso-\nforms and AChE (compounds 15and16).\n5. Experimental\n5.1. General methods\nStarting materials and reagents were obtained from commercial\nsuppliers and were used without puri\ufb01cation. Melting points(mp) are uncorrected and were determined with a ReichertKo\ufb02er thermopan or in capillary tubes in a Buchi 510 apparatus.\n1H NMR (300 MHz) and13C NMR (75.4 MHz) spectra were\nrecorded with a Bruker AMX spectrometer using DMSO-d 6or\nCDCl 3as solvent. Chemical shifts ( d) are expressed in parts per\nmillion (ppm) using TMS as an internal standard. Coupling\nconstants Jare expressed in hertz (Hz). Spin multiplicities are\ngiven as s (singlet), d (doublet), dd (doublet of doublets) and m\n(multiplet). Mass spectrometry was carried out with a Kratos\nMS-50 or a Varian MAT-711 spectrometer. Elemental analyses\nwere performed by a Perkin-Elmer 240B microanalyzer and werewithin /C60.4% of calculated values in all cases. The analytical\nresults were $95% purity for all compounds. Flash Chroma-\ntography (FC) was performed on silica gel (Merck 60, 230\u2013400 mesh); analytical TLC was performed on precoated silica gelplates (Merck 60 F254). Organic solutions were dried overanhydrous sodium sulfate. Concentration and evaporation of the\nsolvent after reaction or extraction were carried out on a rotary\nevaporator (B \u20acuchi Rotavapor) operating at reduced pressure.\n5.2. Synthesis\n5.2.1. General synthetic methodology for the 3-amidocou-\nmarin moiety (4\u201316). General methodology to prepare 3-nitro-\ncoumarins: In a 20-mL dry Schlenk tube, to a solution of theconveniently substituted salicylaldehyde (2.5 mmol) and ethylnitroacetate (2.5 mmol), in acetic anhydride, NaH (2.5 mmol)was added in small portions, and the reaction mixture was stirredfor 3 hours, at room temperature. The obtained crude was\n\ufb01ltered and washed with diethyl ether. The solid was then puri-\n\ufb01ed by \ufb02ash chromatography (hexane/ethyl acetate 9 : 1) to givethe desired coumarins.\nGeneral methodology to prepare 3-aminocoumarins: the\npreviously prepared 3-nitrocoumarin (2.5 mmol) was dissolvedin ethanol and a catalytic amount of Pd/C was added to the\n216 | Med. Chem. Commun. , 2012, 3, 213\u2013218 This journal is \u00aaThe Royal Society of Chemistry 2012\n212mixture. The solution was stirred, at room temperature, under\nH2atmosphere, for 5 hours. After the completion of the reaction,\nthe mixture was \ufb01ltered to eliminate the catalyst. The obtained\ncrude was then puri\ufb01ed by \ufb02ash chromatography (hexane/ethyl\nacetate 9 : 1) to give the desired coumarins.\nGeneral methodology to prepare 3-amidocoumarins: To\na solution of 3-aminocoumarin (1 mmol) and pyridine\n(1.1 mmol) in dichloromethane (9 mL), the corresponding acid\nchloride (1.1 mmol) was added dropwise and the reaction wasstirred, at room temperature, for 3 hours. The solvent wasevaporated under vacuum and the dry residue was puri\ufb01ed by FC(hexane/ethyl acetate 9 : 1).\n3-(4\n0-Methoxybenzamide)-6-methylcoumarin (4). (0.61 g,\n72%); cream solid; mp 125\u2013126/C14C;1H NMR (300 MHz, DMSO-\nd6) 2.27 (s, 3H, C H3), 2.39 (s, 3H, C H3), 6.86 (s, 1H, H-4), 7.06\u2013\n7.32 (m, 5H, H-5, H-7, H-8, H-30,H-50), 7.93 (d, J\u00bc8.4 Hz, 1H,\nH-20), 8.04 (d, J\u00bc8.2 Hz, 1H, H-60), 8.08 (s, 1H, NH);13C NMR\n(75.4 MHz, DMSO- d6) 21.4, 21.8, 117.1, 119.9, 121.8, 122.3,\n126.4, 127.5, 128.9, 132.3, 135.2, 137.4, 141.3, 150.6, 160.1, 165.4;EI-MS ( m/z): 294 [M + 1]\n+, 293 [M+]; Anal. calcd for C 18H15NO 3:\nC 73.71, H 5.15. Found: C 73.70, H 5.13%.\n3-(30,40-Dimethoxybenzamide)coumarin (10 ).(0.72 g, 81%);\nwhite solid; mp 187\u2013188/C14C;1H NMR (300 MHz, DMSO- d6)\n3.83 (s, 6H, (OCH 3)2), 7.09 (d, J\u00bc8.5 Hz, 1H, H-50), 7.33\u20137.44\n(m, 2H, H-6, H-60), 7.51\u20137.61 (m, 3H, H-20,H-7,H-8) 7.74 (d,\nJ\u00bc7.7 Hz, 1H, H-5), 8.55 (s, 1H, H-4), 9.51 (s, 1H, NH);13C\nNMR (75.4 MHz, DMSO- d6) 55.8, 55.9, 98.2, 101.4, 110.9,\n111.2, 111.3, 116.1, 121.3, 124.4, 125.2, 127.1, 128.2, 130.3, 148.6,150.2, 153.0, 165.8; EI-MS ( m/z): 326 [M + 1]\n+, 325 [M+]; Anal.\ncalcd for C 18H15NO 5: C 66.46, H 4.65. Found: C 66.49, H 4.68%.\n3-(30,40,50-Trimethoxybenzamide)coumarin (11 ).(0,55, 65%);\nwhite solid; mp 145\u2013146/C14C;1H NMR (300 MHz, DMSO- d6)\n3.73 (s, 3H, OC H3), 3.86 (s, 6H, (OCH 3)2), 7.37\u20137.45 (m, 4H, H-\n20,H-60,H-6, H-8), 7.54 (d, J\u00bc7.1 Hz, 1H, H-5), 7.75 (dd, J\u00bc\n7.2; 1.4 Hz, 1H, H-7), 8.52 (s, 1H, H-4), 9.7 (s, 1H, NH);13C\nNMR (75.4 MHz, DMSO- d6) 57.8, 60.8, 106.0, 116.7, 119.9,\n124.8, 125.7, 128.8, 128.9, 129.4, 131.1, 141.5, 151.1, 153.4, 158.5,166.1; EI-MS ( m/z): 356 [M + 1]\n+, 355 [M+]; Anal. calcd for\nC19H17NO 6: C 64.22, H 4.82. Found: C 64.25, H 4.85%.\n3-(30,40-Dichlorobenzamide)coumarin ( 12).(0.76 g, 89%);\nlight yellow solid; mp 262\u2013263/C14C;1H NMR (300 MHz, DMSO-\nd6) 7.37\u20137.45 (m, 2H, H-6, H-8), 7.55 (d, J\u00bc8.5 Hz, 1H, H-50),\n7.76\u20137.83 (m, 1H, H-5), 7.90 (d, J\u00bc8.4 Hz, 1H, H-60), 7.75 (dd,\nJ\u00bc7.7; 1.4 Hz, 1H, H-7), 8.19 (s, 1H, H-4), 8.58 (s, 1, H-20), 10.0\n(s, 1H, NH);13C NMR (75.4 MHz, DMSO- d6) 116.5, 116.7,\n120.0, 121.8, 125.7, 126.0, 127.9, 128.3, 128.8, 129.9, 133.2, 133.8,136.3, 136.9, 158.4, 166.1; EI-MS ( m/z): 334 [M + 1]\n+, 333 [M+]:\nAnal. calcd for C 16H9Cl2NO 3: C 57.51, H 2.71. Found: C 57.53,\nH 2.73%.\n2-Bromo- N-(coumarin-3-yl)acetamide (15 ).(0.70 g, 76%);\nwhite solid; mp 199\u2013200/C14C;1H NMR (300 MHz, DMSO- d6)\n4.28 (s, 2H, C H2), 7.30\u20137.40 (m, 2H, H-6, H-8), 7.52 (dd, J\u00bc7.3;\n1.6 Hz, 1H, H-7), 7.72 (dd, J\u00bc7.8; 1.4 Hz, 1H, H-5), 8.63 (s, 1H,\nH-4), 10.22 (s, 1H, NH);13C NMR (75.4 MHz, DMSO- d6) 62.2,116.7, 120.2, 122.9, 124.2, 125.8, 128.7, 130.5, 150.3, 158.5, 172.4;EI-MS ( m/z): 282 [M + 1]\n+, 281 [M+]; Anal. calcd for\nC11H8BrNO 3: C 46.84, H 2.86. Found: C 46.87, H 2.90%.\n5.3. Determination of MAO isoforms activity\nThe effects of the new synthesized compounds on hMAO iso-\nform enzymatic activity were evaluated by a \ufb02uorimetric method\nfollowing the experimental protocol previously described by us.19\nBrie\ufb02y, 0.1 mL of sodium phosphate buffer (0.05 M, pH 7.4)\ncontaining the test drugs (new compounds or reference inhibi-\ntors) in various concentrations and adequate amounts ofrecombinant hMAO-A or hMAO-B, required and adjusted to\nobtain in our experimental conditions the same reaction velocity\n(hMAO-A: 1.1 mg protein; speci\ufb01c activity: 150 nmol ofp-tyramine oxidized to p-hydroxyphenylacetaldehyde/min/mg\nprotein; hMAO-B: 7.5 mg protein; speci\ufb01c activity: 22 nmol of\np-tyramine transformed/min/mg protein), were incubated for\n15 min at 37\n/C14C in a \ufb02at-black bottom 96-well microtest plate,\nplaced in the dark \ufb02uorimeter chamber. After this incubation\nperiod, the reaction was started by adding (\ufb01nal concentrations)200 mM Amplex Red reagent, 1 U mL\n/C01horseradish peroxidase\nand 1 mM p-tyramine. The production of H 2O2and, conse-\nquently, of resoru\ufb01n was quanti\ufb01ed at 37/C14C in a multidetection\nmicroplate \ufb02uorescence reader (FLX800, BioTek Instruments,Inc., Winooski, VT, USA) based on the \ufb02uorescence generated(excitation, 545 nm, emission, 590 nm) over a 15 min period, inwhich the \ufb02uorescence increased linearly.\nControl experiments were carried out simultaneously by\nreplacing the test drugs (new compounds and reference inhibi-tors) with appropriate dilutions of the vehicles. In addition, the\npossible capacity of the above test drugs to modify the \ufb02uores-\ncence generated in the reaction mixture due to non-enzymaticinhibition ( e.g., for directly reacting with Amplex Red reagent)\nwas determined by adding these drugs to solutions containingonly the Amplex Red reagent in a sodium phosphate buffer.\nThe speci\ufb01c \ufb02uorescence emission (used to obtain the \ufb01nal\nresults) was calculated after subtraction of the backgroundactivity, which was determined from vials containing allcomponents except the hMAO isoforms, which were replaced by\na sodium phosphate buffer solution.\n5.4. Determination of AChE activity\nThe AChE activity was evaluated by studying the hydrolysis of\nacetylthiocholine following the method of Ellman.\n30The assay\nsolution consisted of a 50 mM phosphate buffer pH \u00bc7.4, with\nthe addition of 0.25 mM 5,50-dithio-bis(2-nitrobenzoic acid),\n0.165 unit per mL recombinant acetylcholinesterase expressed in\nHEK 293 (Sigma-Aldrich Qu /C19\u0131mica S.A., Alcobendas, Spain),\nand 5 mM of substrate (acetylthiocholine iodide). Testcompounds were added to the buffer and preincubated at 37\n/C14C\nwith the enzyme for 5 min followed by the addition of cromogeneand substrate. The activity was determined by measuring theincrease in absorbance at 412 nm at 1 min intervals for 10 min\nat 37\n/C14C.\nControl experiments were carried out simultaneously by\nreplacing the test drugs (new compounds and reference inhibi-tors) with appropriate dilutions of the vehicles. The speci\ufb01c\nThis journal is \u00aaThe Royal Society of Chemistry 2012 Med. Chem. Commun. , 2012, 3, 213\u2013218 | 217\n213absorbance (used to obtain the \ufb01nal results) was calculated after\nsubtraction of the background activity, which was determinedfrom vials containing all components except the AChE, which\nwas replaced by a sodium phosphate buffer solution.\nConclusions\nIn the current study, a series of 3-substituted coumarin deriva-\ntives were synthesized and evaluated as inhibitors of MAO and\nAChE. In general, and in accordance with previous results, an\naryl ring in that position, additionally to the substitution in thesix position of the coumarin, led to interesting MAO inhibitors\nwhich lack the activity on AChE. Introduction of an amidic\ngroup between the 3-substituted aryl rings and the coumarin\nafforded compounds which can behave as dual inhibitors of\nMAO (mainly MAO-B) and AChE in the micromolar range.Replacement of the aryl ring for an alkylamidic group affordedinactive compounds against MAO and AChE. According to ourresults, 3-benzamidecoumarins proved to be interesting dual\ninhibitors, suggesting a therapeutic opportunity worth exploring.\nAcknowledgements\nThanks to the Spanish Ministry (PS09/00501) and to Xunta da\nGalicia (PGIDIT09CSA030203PR and 10PXIB203303PR). M.J.\nM. thanks FCT for a PhD grant (SFRH/BD/61262/2009).\nNotes and references\n1 Y. Zhu, K. Xiao, L. Ma, B. Xiong, Y. Fu, H. Yu, W. Wang, X. Wang,\nD. Hu, H. Peng, J. Li, Q. Gong, Q. Chai, X. Tang, H. Zang, J. Li and\nJ. Shen, Bioorg. Med. Chem. , 2009, 17, 1600.\n2 E. Scarpini, P. Scheltens and H. Feldman, Lancet Neurol. , 2003, 2,\n539.\n3 H. W. Querfurth and F. M. LaFerla, N. Engl. J. Med. , 2010, 362, 329.\n4 J. Saura, J. M. Luque, A. M. Cesure, M. Da Prada, V. Chan-Palay,\nG. Huber, J. Lof\ufb02er and J. G. Richard, Neuroscience , 1994, 62, 15.\n5 M. Weinstock, CNS Drugs , 1999, 12, 307.\n6 M. B. Youdim, T. Amit, M. Falach-Yogev, O. Bar-Am,\nW. Maruyama, M. Naoi and T. Amit, J. Neurosci. Res. , 2005, 79, 172.7 A. Cavalli, M. L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti,\nM. Recanatini and C. Melchiorre, J. Med. Chem. , 2008, 51,\n347.\n8 M. I. Fern /C19andez-Bachiller, C. P /C19erez, G. C. Gonz /C19alez-Mu ~noz,\nS. Conde, M. G. L /C19opez, M. Villarroya, A. G. Garc /C19\u0131a and\nM. I. Rodr /C19\u0131guez-Franco, J. Med. Chem. , 2010, 53, 4927.\n9 M. Yogev-Falach, O. Bar-Am, T. Amit, O. Weinreb and\nM. B. Youdim, FASEB J. , 2006, 20, 2177.\n10 F. Borges, F. Roleira, N. Milhazes, E. Uriarte and L. Santana, Front.\nMed. Chem. Online , 2009, 4, 23.\n11 R. Hoerr and M. Noeldner, CNS Drug Rev. , 2002, 8, 143.\n12 C. Br \u20acuhlmann, F. Ooms, P.-A. Carrupt, B. Testa, M. Catto,\nF. Leonetti, C. Altomare and A. Carotti, J. Med. Chem. , 2001, 44,\n3195.\n13 X. Zhou, X.-B. Wang, T. Wang and L.-Y. Kong, Bioorg. Med. Chem. ,\n2008, 16, 8011.\n14 F. Chimenti, D. Secci, A. Bolasco, P. Chimenti, A. Granese,\nO. Befani, P. Turini, S. Alcaro and F. Ortuso, Bioorg. Med. Chem.\nLett., 2004, 14, 3697.\n15\nJ. F. Archer and J. Grimshaw, J. Chem. Soc. B , 1969, 3, 266.\n16 M. Natarajan, T. Manimaran and V. T. Ramakrishnan, Indian J.\nChem., Sect. B: Org. Chem. Incl. Med. Chem. , 1984, 23, 529.\n17 M. J. Matos, D. Vi ~na, E. Quezada, C. Picciau, G. Delogu, F. Orallo,\nL. Santana and E. Uriarte, Bioorg. Med. Chem. Lett. , 2009, 19,\n3268.\n18 M. J. Matos, D. Vi ~na, C. Picciau, F. Orallo, L. Santana and\nE. Uriarte, Bioorg. Med. Chem. Lett. , 2009, 19, 5053.\n19 M. J. Matos, D. Vi ~na, P. Janeiro, F. Borges, L. Santana and\nE. Uriarte, Bioorg. Med. Chem. Lett. , 2010, 20, 5157.\n20 M. J. Matos, S. V /C19azquez-Rodr /C19\u0131guez, E. Uriarte, L. Santana and\nD. Vi ~na,Bioorg. Med. Chem. Lett. , 2011, 21, 4224.\n21 C. S. Barnes, M. I. Strong and J. L. Occolowitz, Tetrahedron , 1963,\n19, 839.\n22 D. S. Goldfarb, US Pat. Appl. Publ. , US 20090163545 A1 20090625,\n2009.\n23 J. R. Merchant and G. Martyres, Curr. Sci. , 1981, 50, 410.\n24 J. B. Lambooy, J. Am. Chem. Soc. , 1956, 78, 771.\n25 G. Rodighiero and C. Antonello, Boll. Chim. Farm. , 1958, 97, 592.\n26 A. Jain and A. K. Mukerjee, J. Prakt. Chem. , 1989, 331, 493.\n27 V. Maddi, S. N. Mamledesai, D. Satyanarayana and S. Swamy,\nIndian J. Pharm. Sci. , 2007, 69, 847.\n28 M. Lacova, J. Chovancova and V. Konecny, Chem. Pap. , 1986, 40,\n121.\n29 L. Santana, H. Gonz /C19alez-D /C19\u0131az, E. Quezada, E. Uriarte, M. Y /C19a~nez,\nD. Vi ~na and F. Orallo, J. Med. Chem. , 2008, 51, 6740.\n30 G. L. Ellman, K. D. Counrtney, V. Andres and\nR. M. A. Featherstone, Biochem. Pharmacol. , 1961, 7, 88.\n218 | Med. Chem. Commun. , 2012, 3, 213\u2013218 This journal is \u00aaThe Royal Society of Chemistry 2012\n214New halogenated phenylcoumarins as tyrosinase inhibitors\nMaria Jo\u00e3o Matosa,\u21d1, Lourdes Santanaa, Eugenio Uriartea, Giovanna Delogub, Marcella Cordac,\nMaria Benedetta Faddac, Benedetta Erac, Antonella Faisc\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbDipartimento Farmaco Chimico Tecnologico, Facolt\u00e0 di Farmacia, Universit\u00e0 degli Studi di Cagliari, 09124 Cagliari, Italy\ncDipartimento di Scienze della Vita e dell\u2019Ambiente, Universit\u00e0 degli Studi di Cagliari 09042 Monserrato, Cagliari, Italy\narticle info\nArticle history:\nReceived 25 February 2011\nRevised 30 March 2011\nAccepted 3 April 2011Available online 9 April 2011\nKeywords:\nCoumarinsTyrosinase inhibitors\nPerkin reaction\nHydrolysis reactionabstract\nWith the aim to \ufb01nd out structural features for the tyrosinase inhibitory activity, in the present commu-\nnication we report the synthesis and pharmacological evaluation of a new series of phenylcoumarin\nderivatives with different number of hydroxyl or ether groups and bromo substituent in the scaffold.\nThe synthesized compounds 5\u201312 were evaluated as mushroom tyrosinase inhibitors showing, two of\nthem, lower IC 50than the umbelliferone. Compound 12(IC50= 215 lM) is the best tyrosinase inhibitor\nof this series.\n/C2112011 Elsevier Ltd. All rights reserved.\nTyrosinase (EC 1.14.18.1) is a multifunctional dinuclear copper\ncentre enzyme widely distributed in nature and mainly involved\nin the formation of pigments such as melanins and other polyphe-\nnolic compounds.1Tyrosinase oxidizes phenols and diphenols\nusing a catalytic mechanism that depends on the presence of cop-per at its active site.\n1In fungi and vertebrates, tyrosinase catalyzes\nthe two initial steps for the formation of the melanin pigments(melanogenesis), starting from the tyrosine.\n2This enzyme cataly-\nses the conversion of tyrosine to DOPA and the oxidation of theresultant DOPA.\n2So, this enzyme is responsible for the pigmenta-\ntion of the skin, eyes and hair.3In fact, tyrosinase inhibitors have\nbeen used as depigmenting agents for the treatment or preventionof hyperpigmentation disorders.\n4Also, tyrosinase is involved in the\nprocess to maintain the appearance, \ufb02avour, texture and nutri-tional value of many fresh-cut products.\n5The enzyme extracted\nfrom the mushroom A. bisporus has high homology with the mam-\nmalian one. So, it is suited as a model for melanogenesis and tyros-\ninase bio-pathways studies.\nCoumarins are a large family of compounds, of natural and syn-\nthetic origin, which presents different pharmacological activities.6\nStructurally they are lactones of the cinnamic acid. Due to their\nstructural variability, they occupy an important place in the realm\nof natural products and synthetic organic chemistry.7Recent stud-\nies pay special attention to their antioxidative, antiin\ufb02amatory,anticancer and enzymatic inhibition properties.\n8\u201314Resveratrol \u20133,40,5-trihydroxystilbene\u2014is a natural polypheno-\nlic compound present in grapes and red wine.15It is a phytoalexin\nproduced by some species in response to an external or internal\ndamage (such as a fungal infection).15,16In in vitro, ex vivo and\nin vivo experiments, resveratrol has shown important pharmaco-logical activities including antiin\ufb02ammatory, antioxidant, antican-\ncer and cardioprotective properties, besides inhibitory activity\ntowards several enzymes.\n15\u201319Therefore, this compound has been\nattracting a huge pharmacological interest since the last decade.\nIn recent studies, some coumarins proved to be mushroom\ntyrosinase inhibitors.20,21In these studies, esculetin and umbellif-\nerone exhibited some of the strongest inhibitory activities of thetested series. Masamoto et al. investigated the structure\u2013activity\nrelationship of 18 coumarins for their inhibitory activity against\nmushroom tyrosinase. They found that esculetin exhibited the\nstrongest inhibitory activity of those series.\n20Recently, and in con-\ntrast with the Masamoto\u2019s \ufb01ndings, Sollai et al. have shown thatesculetin is considered to be a tyrosinase substrate rather than\nan inhibitor, whereas umbelliferone seems to be an inhibitor of\nthe mentioned oxidase.\n22These recent \ufb01ndings revealed that\ntyrosinase af\ufb01nity can be ef\ufb01ciently modulated by appropriate\nsubstitutions in the coumarin moiety. The introduction of hydroxyl\ngroups in different positions is particularly suitable to these\nmodi\ufb01cations.20,21Recently, it has been demonstrated that also\nresveratrol and other stilbenes23have inhibitory effects against\nmushroom tyrosinase activity.24Resveratrol showed stronger\nDOPA oxidase inhibitory activity than kojic acid (reference inhibi-\ntor).25In fact, until the last years, polyphenols are the largest\nscaffold in tyrosinase inhibition.23,26Their activity depends on\n0960-894X/$ - see front matter /C2112011 Elsevier Ltd. All rights reserved.\ndoi:10.1016/j.bmcl.2011.04.012\u21d1Corresponding author.\nE-mail address: mariacmatos@gmail.com (M.J. Matos).Bioorganic & Medicinal Chemistry Letters 21 (2011) 3342\u20133345\nContents lists available at ScienceDirect\nBioorganic & Medicinal Chemistry Letters\njournal homepage: www.elsevier.com/locate/bmcl\n215the presence and position of additional substituents whether a pol-\nyphenol may act as an inhibitor.26So, it was proved that both stil-\nbene and coumarin derivatives show interesting inhibitory effectsagainst tyrosinase.\nTyrosinase inhibitors could have broad applications. As the\nideal drug candidate has not been attained, an intensive search\nfor new and innovative tyrosinase inhibitors is still needed. This ef-\nfort has considerably increased in recent years. In this context, and\nin an attempt to develop novel tyrosinase inhibitors, we had previ-\nously synthesized and described 3-arylcoumarin derivatives in\nwhich both the coumarin and the resveratrol templates were\npresent.\n21\nResveratrol ( Fig. 1 , A) and umbelliferone (B) are very good\ntyrosinase inhibitors.2,20Umbelliferone-resveratrol hybrid (C) and\n3-phenylumbelliferone (D) are less active than the mentioned\ncompounds (IC 503.68 mM and >10, respectively). Although, the pre-\nviously derivative described by us 6,8,30,40,50-pentahydroxy proved\nto be the most active compound of the evaluated 3-arylcoumarin\nseries, with an IC 50of 0.27 mM.21This molecule have two hydroxyl\ngroups under the coumarin ring, being like the coumarin-resveratrol\nhybrid (E).\nBased on these results,21in the present work we proposed to\ncontinue the 3-phenylcoumarin scaffold study, with different sub-\nstitutions like methoxyl, ethoxyl, hydroxyl and/or bromo under the\n6, 8 and 40positions ( Scheme 1 ). We decided to explore the impor-\ntance of the number and position of ether and hydroxyl groups lo-cated in the 3-phenyl ring or in the aromatic ring of the coumarin\nand, at the same time, the bromination of the coumarin moiety.\nThe coumarin derivatives 5\u201312\n27were ef\ufb01ciently synthesized\naccording to the synthetic protocol outlined in Scheme 1 . The 3-\nphenylcoumarins 5\u20138 were prepared starting from the conve-\nniently substituted phenylacetic acid 1or2and the appropriate\nsalicylaldehyde 3or4, using dicyclohexylcarbodiimide (DCC) as\ndehydrating agent, by Perkin reaction,28\u201331in dimethylsulfoxide\n(DMSO). These reactions gave 55%, 59%, 61% and 60% yield, respec-\ntively. Hydrolysis of the methoxyl/ethoxyl groups, by treatment\nwith hydriodic acid 57% in acetic acid/acetic anhydride (1:1),32\ngave the hydroxyl derivatives 9,10,11and 12in 64%, 60%, 61%\nand 53% yield, respectively. The obtained products were easy topurify by \ufb02ash chromatography, using a mixture of hexane/ethyl\nacetate, in a proportion 9:1, as eluent.\nThe tyrosinase inhibitory activity of compounds 5\u201312 was eval-\nuated in vitro by the measurement of the enzymatic activity ofmushroom tyrosinase enzyme extracted from the mushroom spe-\ncieA. bisporus .\n33Then, the IC 50values for inhibitory effects of the\nnew compounds were calculated (Table 1 ).\nIn the present communication, the effect of the introduction of a\nhalogen substituent into different hydroxy-3-phenylcoumarins\nwas proposed. In fact, a higher tyrosinase inhibitory activity,\nregarding the non-halogenated compounds, was observed. The\nstructural change obtained from compound 9to compound 10\nand from 11to12, with the bromo atom in the coumarin nucleus,\nleads to a signi\ufb01cant increase of the tyrosinase activity (from mil-\nimolar to micromolar range).\nAs it is shown in the Table 1 , compound 12is the most active\ncompound of this series. This compound, with a bromo atom and\ntwo hydroxyl groups in the 3-phenylcoumarin moiety, has an\nIC50in the micromolar range (IC 50= 215 lM). As expected, the\nmore hydroxyl groups in the coumarin moiety, the better activity\nthe compounds have. When compared with compound 10, the\nintroduction of one hydroxyl group more in compound 12in-\ncreases at least 1.5 times the tyrosinase inhibitory activity. Com-\npound 12shows, in fact, a lightly higher inhibitory activity than\nthe 6,8-dihydroxy-3-(30,40,50-trihydroxyphenyl)coumarin (IC 50=\n270lM), previously described by us.21The presence in 6 and 40OO\ntrans-Resveratrol (A) Umbelliferone (B)HO\nOO\nUmbelliferone-resveratrol\nhybrid (C)HOOH\nOH\nOO\nCoumarin-resveratrol\nhybrid (E)HO\nOHOHHOOH\nOH\nOO\n3-Phenylumbelliferone (D)HO\nFigure 1. Tyrosinase inhibitors with coumarin/resveratrol derivative structures.OOH\nOHO\nRO\nOH\nR1R2\naR2\nR1R\n1R=H\n2R = OMe3R1= OEt; R2=H\n4R1= OMe; R2=B r5R=H ;R1= OEt; R2=H\n6R=H ;R1=O M e ;R2=B r\n7R=O M e ;R1= OEt; R2=H\n8R = OMe; R1=O M e ;R2=B r\nb\nOOR2\nR1R\n9R=H ;R1=O H ;R2=H\n10 R=H ;R1=O H ;R2=B r\n11 R=O H ;R1=O H ;R2=H\n12 R=O H ;R1=O H ;R2=B r\nScheme 1. Reagents and conditions: (a) DCC, DMSO, 110 /C176C, 12 h; (b) HI/AcOH/\nAc2O, 0/C176C\u2013rt, 3 h.\nTable 1\nInhibitory effect of compounds 5\u201312and umbelliferone on mushroom\ntyrosinase activity\nCompounds IC50(mM) ( L-DOPA 0.5 mM)\n5 2.07 \u00b1 0.07\n6 >5.0\n7 >5.0\n8 1.36 \u00b1 0.12\n9 >5.0\n10 0.302 \u00b1 0.002\n11 1.30 \u00b1 0.08\n12 0.215 \u00b1 0.085\nUmbelliferone 0.42a\naObtained from data in Ref.21M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 3342\u20133345 3343\n216positions, at the same time, of a bromo and a hydroxyl substituent,\nrespectively, contributed to an increase of the inhibitory activity.\nThe experimental results show that the methoxyl and ethoxyl\nderivatives (compounds 5\u20138) do not present any signi\ufb01cant activ-\nity against the tested enzyme. These results suggest that the bro-\nmination of the hydroxycoumarins, in spite of the bromination of\nmethoxycoumarins, could be an important step in the synthesis\nof novel tyrosinase inhibitors.\nThe inhibitory mechanism of the compound 12was determined\nusing a Lineweaver\u2013Burk double reciprocal plot (Figure ure2). The\ndata, displayed as a plot of 1/V versus 1/[S], gave three straight lines\nwith different slopes and a horizontal line that intersected at the\nsame point. With an increase in compound concentration, the Vmax\nvalue decreased, whereas the Kmvalue was unchanged, suggesting\nthat this compound is a non-competitive tyrosinase inhibitor. The\ninhibition constant of this compound (K I= 0.189 mM) was deter-\nmined by plotting the intercept values versus the concentration ofthe corresponding compound, as shown in Figure 2 .\nIn conclusion, in the present study it was shown that the syn-\nthesized coumarin-resveratrol hybrid compounds have inhibitory\nactivity against mushroom tyrosinase. Some of them present tyros-\ninase inhibitory activity in the micromolar range. The presence of a\nbromo atom in position 6 of the hydroxycoumarins improves the\ninhibitory activity respect to the other synthesized derivatives.\nSo, the introduction of a bromo atom improves the pharmacologi-\ncal potential of these 3-phenylcoumarins, con\ufb01rming that this lead\ncould be effectively optimized in a candidate for the treatment of\nsome hyperpigmentation skin diseases. These \ufb01nds have encour-\naged us to continue the efforts towards the optimization of the\npharmacological pro\ufb01le of these 3-phenylcoumarins.\nAcknowledgement\nThanks to the Spanish Ministry (PS0900501) and to Xunta da\nGalicia (INCITE09E2R203035ES and PGIDIT09CSA030203PR) for\n\ufb01nancial support. We are also grateful to the RAS\u2013LR7/2007\n(CRP2_133). This work was also supported by funds of Cagliari Uni-\nversity (for the biological assays). M.J.M. also thanks the FCT for a\nPhD grant (SFRH/BD/61262/2009). The authors are grateful to\nProfessor Gianni Podda, of Cagliari University, for insightful\nsuggestions.\nReferences and notes\n1. Lerch, K. Life Chem. Rep. 1987 ,5, 221.\n2. Kim, Y. M.; Yun, J.; Lee, C.; Lee, H.; Min, K. R.; Kim, Y. J. Biol. Chem. 2002 ,277,\n16340.3. Solano, F.; Briganti, S.; Picardo, M.; Ghanem, G. Pigm. Cell Res. 2006 ,19, 550.\n4. He, Q.; Luo, Y.; Chen, P. Food Chem. 2008 ,110, 847.\n5. Qiu, L.; Chen, Q. H.; Zhuang, J. X.; Zhong, X.; Zhou, J. J.; Guo, Y. J.; Chen, Q. X.\nFood Chem. 2009 ,112, 609.\n6. Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. Front. Med. Chem.\n2009 ,4, 23.\n7. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 ,27, 713.\n8. Kontogiorgios, C. A.; Savvoglou, K.; Hadjipavlou-Litina, D. J. J. Enzyme Inhib.\nMed. Chem. 2006 ,21, 21.\n9. Roussaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D. J.; Hamilakis, S. Bioorg.\nMed. Chem. Lett. 2010 ,20, 3889.\n10. Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.; Zunino, F. Bioorg.\nMed. Chem. 2010 ,18, 3543.\n11. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. J. Enzyme Inhib. Med. Chem. 2003 ,18,\n63.\n12. Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1\u00f1ez, M.; Vi\u00f1a, D.;\nOrallo, F. J. Med. Chem. 2008 ,51, 6740.\n13. Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; Rose,\nS.; Jenner, P.; Testa, B. Chem. Biod. 2006 ,3, 134.\n14. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;\nUriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268.\n15. Fr\u00e9mont, L. Life Sci. 2000 ,66, 663.\n16. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Y\u00e1nez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257.\n17. Orallo, F., Jr. In Resveratrol in Health and Disease ; Aggarwal, B. B., Shishodia, S.,\nEds.; CRC Press: USA, 2005; p pp 577.\n18. Leiro, J.; \u00c1lvarez, E.; Arranz, J.; Laguna, R.; Uriarte, E.; Orallo, F. J. Leukocyte Biol.\n2004 ,75, 1156.\n19. Orallo, F. Curr. Med. Chem. 2008 ,15, 1887.\n20. Masamoto, Y.; Murata, Y.; Baba, K.; Shimoishi, Y.; Tada, M.; Takahata, K. Biol.\nPharm. Bull. 2004 ,27, 422.\n21. Fais, A.; Corda, M.; Era, B.; Fadda, M. B.; Matos, M. J.; Quezada, E.; Santana, L.;\nPicciau, C.; Podda, G.; Delogu, G. Molecules 2009 ,14, 2514.\n22. Sollai, F.; Zucca, P.; Sanjust, E.; Steri, D.; Rescigno, A. Biol. Pharm. Bull. 2008 ,31,\n2187.\n23. Song, S.; Lee, H.; Jin, Y.; Ha, Y.; Bae, S.; Chung, H.; Suha, H. Bioorg. Med. Chem.\nLett. 2007 ,17, 461.\n24. Likhitwitayawuid, K. Curr. Sci. 2008 ,94, 44.\n25. Likhitwitayawuid, K.; Sritularak, B.; De-Eknamkul, W. Planta Med. 2000 ,66,\n275.\n26. Chang, Te.-S. Int. J. Mol. Sci. 2009 ,10, 2440.\n27. 8-Ethoxy-3-phenylcoumarin (5). It was obtained with a yield of 55% mp 117\u2013\n118/C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 1.50 (t, 3H, \u2013CH 3,J= 7.0), 4.21 (dd, 2H,\n\u2013CH 2,J= 14.0 and J= 7.0), 7.09 (t, 2H, H-6, H-7, J= 6.9), 7.21 (t, 1H, H-5, J= 7.8),\n7.42\u20137.48 (m, 3H, H-30, H-40, H-50), 7.72 (dd, 2H, H-20, H-60,J= 7.7 and J= 1.4),\n7.79 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm): 14.8, 65.0, 114.5, 119.3, 120.4,\n124.3, 128.3, 128.4, 128.5, 128.8, 134.8, 140.1, 143.4, 146.3, 160.2. MS m/z(%):\n267 (16), 266 (M+, 83), 239 (16), 238 (20), 212 (14) 211 (20), 181 (15), 153 (25).\nAnal. Calcd for C 17H14O3: C, 76.68; H 5.30. Found: C, 76.66; H, 5.35.\n6-Bromo-8-methoxy-3-phenylcoumarin (6). It was obtained with a yield of 59%\nmp 153\u2013154 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 3.97 (s, 3H, \u2013OCH 3), 7.16 (d,\n1H, H-7, J= 2.0), 7.26 (d, 1H, H-5, J= 2.0), 7.42\u20137.47 (m, 3H, H-30, H-40, H-50),\n7.68\u20137.78 (m, 3H, H-20, H-60, H-4).13C NMR (CDCl 3)d(ppm): 57.2, 117.0, 117.3,\n121.9, 122.1, 129.2, 129.8, 130.3, 134.9, 139.1, 142.9, 148.3, 160.0. MS m/z(%):\n332 (99), 331 (30), 330 (M+, 100), 304 (40), 302 (40), 261 (25), 259 (26), 194\n(16), 165 (12), 153 (14), 151 (23), 102 (19), 76 (34). Anal. Calcd for C 16H11BrO 3:\nC, 58.03; H, 3.35. Found: C, 58.01; H, 3.30.\n8-Ethoxy-3-(40-methoxyphenyl)coumarin (7). It was obtained with a yield of 61%\nmp 99\u2013100 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 1.50 (t, 3H, \u2013CH 3,J= 7.0), 3.84\n(s, 3H, \u2013OCH 3), 4.19 (dd, 2H, \u2013CH 2,J= 14.0, J= 7.0), 6.84\u20137.26 (m, 5H, H-30, H-50,\nH-5, H-6, H-7), 7.69 (t, 2H, H-20, H-60,J= 7.7), 7.73 (s, 1H, H-4).13C NMR (CDCl 3)\nd(ppm): 14.8, 55.4, 64.8, 113.8, 114.0, 119.1, 120.49, 124.2, 127.1, 127.8, 129.7,\n129.8, 138.6, 138.7, 146.2, 160.0. MS m/z(%): 297 (35), 296 (M+, 100), 268 (54),\n240 (47) 225 (45), 197 (13), 152 (11), 139 (15). Anal. Calcd for C 18H16O4:C ,\n72.96; H, 5.44. Found: C, 72.91; H, 5.39.\n6-Bromo-8-methoxy-3-(40-methoxyphenyl)coumarin (8). It was obtained with a\nyield of 60% mp 183\u2013184 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 3.85 (s, 3H, \u2013\nOCH 3), 3.96 (s, 3H, \u2013OCH 3), 6.94\u20136.98 (m, 2H, H-30, H-50), 7.12 (d, 1H, H-7,\nJ= 1.8), 7.23 (dd, 1H, H-5, J= 2.1 and J= 0.9), 7.63\u20137.69 (m, 3H, H-4, H-20, H-60).\n13C NMR (CDCl 3)d(ppm): 55.7, 56.8, 114.2, 116.2, 116.8, 121.5, 126.8, 129.4,\n130.2, 130.8, 137.3, 142.2, 147.8, 159.8, 160.6. MS m/z(%): 363 (19), 362 (M+,\n100), 361 (19), 334 (24), 332 (23), 319 (33), 317 (34), 291 (11), 289 (11), 182\n(18), 167 (17), 139 (21), 91 (11). Anal. Calcd for C 17H13BrO 4: C, 56.53; H 3.63.\nFound: C, 56.55; H, 3.68.\n8-Hydroxy-3-phenylcoumarin (9). It was obtained with a yield of 64% mp 199\u2013\n200/C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 7.14\u20137.19 (m, 3H, H-5, H-6, H-7), 7.40\u2013\n7.49 (m, 3H, H-30, H-40, H-50), 7.70\u20137.78 (m, 2H, H-20, H-60), 8.19 (s, 1H, H-4),\n10.25 (s, 1H, \u2013OH).13C NMR (CDCl 3)d(ppm): 118.0, 118.6, 120.4, 124.6, 126.7,\n128.2, 128.5, 134.7, 141.0, 141.7, 144.3, 159.6. MS m/z(%): 239 (16), 238 (M+,\n100), 210 (80), 181 (13), 153 (22) 152 (20), 105 (9), 76 (15), 51 (6). Anal. Calcd\nfor C 15H10O3: C, 75.62; H, 4.23. Found: C, 75.57; H, 4.28.\n6-Bromo-8-hydroxy-3-phenylcoumarin (10). It was obtained with a yield of 60%\nmp 163\u2013164 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 7.19 (d, 1H, H-7, J= 2.0), 7.42\u2013\n7.51 (m, 4H, H-5, H-30, H-40, H-50), 7.70 (dd, 2H, H-20, H-60,J= 7.6 and J= 1.6), 8.13\n(s, 1H, H-4), 10.79 (s, 1H, \u2013OH).13C NMR (CDCl 3)d(ppm): 115.5, 119.9, 120.4,\n121.8, 127.9, 128.3, 128.5, 128.8, 134.4, 139.7, 141.1, 145.6, 159.1. MS m/z(%):-10123456789\n-7 -2 3\n1/[S] (mM-1) 1/V (OD/min)-100.511.522.533.5\n0 50 100 150 200 250\n[I]1/V\nFigure 2. Lineweaver\u2013Burk plots for inhibition of compound 12on mushroom\ntyrosinase for catalysis of L-DOPA. Inhibitor concentrations were 0 ( /C7), 0.050 mM\n(j), 0.100 mM ( N), 0.200 mM ( d). The inset represents the secondary plot of 1/ Vmax\nversus concentration of compound 12, to determine the inhibition constant ( Ki).3344 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 3342\u20133345\n217318 (99), 317 (17), 316 (M+, 100), 291 (12), 289 (13), 153 (22), 152 (51), 151 (12),\n76 (25). Anal. Calcd for C 15H9BrO 3: C, 56.81; H, 2.86. Found: C, 56.77; H, 2.81.\n8-hydroxy-3-(40-hydroxy)phenylcoumarin (11). It was obtained with a yield of\n61% mp 237\u2013238 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 6.81-6.85 (m, 2H, H-30,H -\n50), 7.03-7.12 (m, 3H, H-5, H-6, H-7), 7.55\u20137.59 (m, 2H, H-20, H-60), 8.05 (s, 1H, H-\n4), 9.80 (s, 1H, \u2013OH), 10.15 (s, 1H, \u2013OH).13C NMR (CDCl 3)d(ppm): 115.3, 117.8,\n118.6, 120.9, 124.7, 125.6, 126.8, 130.1, 139.2, 141.6, 144.5, 158.2, 160.1. MS m/z\n(%): 255 (18), 254 (M+, 100), 227 (16), 226 (98), 197 (15), 169 (12), 115 (12). Anal.\nCalcd for C 15H10O4: C, 70.83; H, 3.87. Found: C, 70.80; H, 3.83.\n6-Bromo-8-hydroxy-3-(40-hydroxyphenyl)coumarin (12). It was obtained with a\nyield of 53% mp 249\u2013250 /C176C.1H NMR (CDCl 3)d(ppm), J(Hz): 6.83 (d, 2H, H-30,H -\n50,J= 8.8), 7.14 (t, 1H, H-7, J= 1.5), 7.36 (d, 1H, H-5, J= 2.0), 7.56 (d, 2H, H-20, H-60,\nJ= 8.5), 8.00 (s, 1H, H-4).13C NMR (CDCl 3)d(ppm): 115.6, 116.0, 119.9, 120.6,\n122.5, 125.4, 128.2, 130.4, 138.0, 141.2, 146.0, 158.6, 159.8. MS m/z(%): 334 (99),\n333 (45), 332 (M+, 100), 307 (31), 305 (35), 225 (26), 197 (29), 169 (35), 168 (46),\n153 (24), 141 (21), 140 (16), 118 (17), 115 (28), 98 (13), 89 (14), 84 (18), 75 (11),\n63 (13). Anal. Calcd for C 15H9BrO 4: C, 54.08; H 2.72. Found: C 54.01, H 2.69.\n28. Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. Indian J. Chem. 1996 ,35B, 1159.\n29. Perkin, W. H. J. Chem. Soc. 1868 ,21, 53.30. Matos, M. J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2010 ,20, 5157.\n31. Matos, M. J.; Delogu, G.; Podda, G.; Santana, L.; Uriarte, E. Synthesis 2010 ,16,\n2763.\n32. Matos, M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053.\n33. Pre-incubation with the enzyme: 1/15 M phosphoric acid buffer solution (pH 6.8,\n1.8 mL), an aqueous solution of mushroom tyrosinase (1000 U/mL, Sigma\nChemical Co., 0.1 mL) and DMSO (0.1 mL) with or without the sample. The\nmixture was incubated at 25 /C176C for 10 min. Then, a 1.05 mM of L-3,4-\ndihydroxyphenylalanine (DOPA) solution (1 mL) was added and the reaction\nwas monitored at 475 nm, for 5 min. The percent of tyrosinase activity inhibition\nwas calculated as: inhibition (%) = (A /C0B)/A/C2100, where A represents the\ndifference in the absorbance of control sample between 0.5 and 1.0 min, and B\nrepresents the difference in absorbance of the test sample between 0.5 and\n1.0 min. The IC 50value, a concentration giving 50% inhibition of tyrosinase\nactivity, was determinate by interpolation of dose\u2013response curves. Themushroom tyrosinase activity was determinate by spectrophotometric assays(Varian Cary 50). Umbelliferone was used as a reference tyrosinase inhibitor.M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 3342\u20133345 3345\n218Tyrosine-like condensed derivatives as tyrosinase inhibitors\nMaria Jo\u00e3o Matosa, Lourdes Santanaa, Eugenio Uriartea, Silvia Serraa,b, Marcella Cordac,\nMaria Benedetta Faddac, Benedetta Eracand Antonella Faisc\naDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, Spain and\nbDipartimento Farmaco Chimico T ecnologico, Facolt\u00e0 di Farmacia andcDipartimento di Scienze della Vita e dell\u2019Ambiente, Universit\u00e0 degli Studi di\nCagliari, Cagliari, Italy\nKeywords\ndepigmenting agents; mixed-type inhibitor;\ntyrosinase inhibition; tyrosine-like compounds\nCorrespondence\nMaria Jo\u00e3o Matos, Department of OrganicChemistry , University of Santiago de\nCompostela, Fac Farmacia, Campus Vida,\nSantiago de Compostela, 15782, Spain.\nE-mail: mariajoao.correiapinto@rai.usc.es\nReceived October 11, 2011\nAccepted January 5, 2012\ndoi: 10.1111/j.2042-7158.2012.01467.xAbstract\nObjectives W e report the pharmacological evaluation of a new series of\n3-aminocoumarins differently substituted with hydroxyl groups, which have been\nsynthesized because they include in their structures the tyrosine fragment (tyrosine-\nlike compounds), with the aim of discovering structural features necessary fortyrosinase inhibitory activity.Methods The synthesized compounds 4and 7\u20139 were evaluated in vitro as mush-\nroom tyrosinase inhibitors.Key \ufb01ndings T wo of the described compounds showed lower IC50 (concentration\ngiving 50% inhibition of tyrosinase activity) than umbelliferone, used as a referencecompound.Conclusions Compound 7(IC50 =53mm) was the best tyrosinase inhibitor of this\nsmall series, having an IC50 value 10-fold lower than umbelliferone. Compound 7\n(3-amino-7-hydroxycoumarin) had amino and hydroxyl groups precisely mimick-ing the same positions that both groups occupy on the tyrosine molecule.\nIntroduction\nT yrosinase (EC 1.14.18.1) is a multifunctional dinuclearcopper centre metalloenzyme widely distributed in nature.\n[1]\nThis enzyme catalyses two distinct reactions of conversionof the tyrosine: 3 \u2032-hydroxylation of l-tyrosine into l-3,4-\ndihydroxyphenylalanine (L-DOPA) and oxidation of theresultant L-DOPA into DOPA quinone, which further poly-merizes spontaneously into melanin.\n[2]Most melanin-\nbiosynthesis inhibitors are phenol or catechol analogues,which are structurally similar to tyrosinase substrates:tyrosine or L-DOPA.\n[3]Therefore, tyrosine-like molecules\ncould be an interesting scaffold to the tyrosinase inhibitionprocess. T yrosinase is mainly involved in the formation ofpigments such as melanins and other polyphenolic com-\npounds.\n[1]T yrosinase oxidizes phenols and diphenols using a\ncatalytic mechanism dependent on the presence of copper at\nits active site.[1,2]This enzyme is responsible for unwanted\nbrowning of fruits and vegetables.[4]Therefore, it is involved\nin the process of maintaining the appearance, \ufb02avour, textureand nutritional value of many fresh-cut products.\n[4]T yrosi-\nnase is also responsible for the colouring of skin, hair and eyesin animals, including humans.\n[5]In fact, tyrosinase inhibitors\nhave been used as depigmenting agents for the treatment or\nprevention of hyperpigmentation disorders.[6]In recent years,many tyrosinase inhibitors have been reported, includingvitamin C (ascorbic acid), kojic acid, umbelliferone, resvera-\ntrol, hydroquinone and oxyresveratrol.\n[7\u201312]Because of the\nstructural similarity, umbelliferone was used as a reference\ninhibitor (Figure 1).\nCoumarins are a large family of compounds, of natural and\nsynthetic origin, which present different pharmacological\nactions.[13]Chemically they are lactones of cinnamic acid.\nTheir structural variety is responsible for the importantplace that they occupy in the natural product and syntheticorganic chemistry realm.\n[14]Some important studies pay\nspecial attention to their antioxidative, anti-cancer anti-in\ufb02ammatory, cardioprotective and enzymatic inhibitoryproperties.\n[15\u201321]In recent studies, some coumarins proved\nto be mushroom tyrosinase inhibitors.[22,23]In those studies,\nesculetin (6,7-dihydroxycoumarin) and umbelliferone (7-hydroxycoumarin) exhibited some of the strongest inhibi-tory activity of the tested series, with esculetin proving tobe the strongest inhibitor of the series.\n[22]Recently, and\nin contrast to the initial \ufb01ndings, Sollai et al . showed that\nesculetin is a tyrosinase substrate rather than an inhibitor,whereas umbelliferone seems to be an inhibitor of\ntyrosinase.\n[24]These studies revealed that tyrosinase af\ufb01nitybs_bs_banner\nAnd PharmacologyJournal of PharmacyResearch Paper\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2012 Journal of Pharmacy and Pharmacology, 64, pp. 742\u2013746\n219can be ef\ufb01ciently modulated by appropriate substitutions in\nthe coumarin moiety. The introduction of different numbersof hydroxyl groups in different positions of the coumarin isone of the most important modi\ufb01cations.\n[22,23]Also, until\nrecently, polyphenols were the largest scaffold in tyrosinaseinhibition.\n[25,26]\nT yrosinase inhibitors could have broad applications. As the\nideal drug candidate has not been attained, an intensivesearch for new tyrosinase inhibitors is still needed. This effort\nhas considerably increased in the recent years. In this context,\nand in an attempt to develop novel tyrosinase inhibitors, wehad previously synthesized and described 3-arylcoumarinderivatives in which both the coumarin and the resveratroltemplates were present.\n[23,27]Based on this work, and with the\naim of \ufb01nding new structure\u2013activity features, we proposethe study of a series of tyrosine-like condensed molecules(Figure 1). The similarity of these compounds to the tyrosi-nase substrate is the novelty of this study. The proposed com-\npounds are structurally related to the amino acid tyrosine, the\nnatural substrate of this enzyme. T yrosinase inhibitors basedon the aminocoumarin scaffold have not been previouslystudied.\nMaterials and Methods\nW e synthesized (Figure 2) and evaluated a small series of3-aminocoumarins. W e decided to explore the importance ofthe position of a hydroxyl group under the 3-aminocoumarinmoiety, based on the idea of mimicking the molecular struc-\nture of the tyrosinase substrate.\nThe coumarin derivatives 4and 7\u20139\n[28\u201330]were ef\ufb01ciently\nsynthesized according to the protocol outlined in Figure 2.\nStarting from different substituted commercially available\nsalicylaldehydes and ethyl nitroacetate, we afforded3-nitrocoumarins 1\u20133 in good yields (75\u201395%). They were\nsynthesized in a dry Schlenk tube, with acetic anhydride\nas solvent, in the presence of sodium hydride, at room tem-\nperature, for 3 h. The reaction mixture was puri\ufb01ed by\n\ufb02ash chromatography, using hexane/AcOEt (9 : 1) as eluent.The 3-aminocoumarins 4\u20136 were prepared from previously\nsynthesized 3-nitrocoumarins, in EtOH, with Pd/C as cata-lyst, under H\n2atmosphere. The obtained products were\npuri\ufb01ed by crystallization in AcOEt to give the desired\n3-aminocoumarins, in a yield of 95%. The hydroxy deriva-\ntives 7and 8were obtained from the methoxy derivatives\n(compounds 5and 6, respectively) by a hydrolysis reaction\nwith hydriodic acid, in the presence of acetic acid and aceticanhydride, at 110\u00b0C, for 5 h. The residue was puri\ufb01ed by\ncrystallization of acetonitrile, and the hydroxy derivatives\nwere obtained in a yield of 60%. Compound 9\n[31]was\nobtained via reduction reaction, under the same conditionsas described above, of the commercially available 4-hydroxy-3-nitrocoumarin, in a yield of 93%.\nThe biological assays were carried out using the following\nprotocol. Pre-incubation with the enzyme was carried out:\n1/15mphosphoric acid buffer solution (pH 6.8, 1.8 ml),\nan aqueous solution of mushroom tyrosinase (1000 U/ml;\nSigma Chemical Co., Milan, Italy, 0.1 ml) and dimethylsulfoxide (DMSO) (0.1 ml) with or without the sample.The mixture was incubated at 25\u00b0C for 10 min. Then, 1.5 m m\nL-DOPA solution (1 ml) was added and the reaction wasmonitored at 475 nm for 5 min. The percent of tyrosinaseactivity inhibition was calculated as: inhibition (%) =\n(A-B)/A \u00a5100, where A represents the difference in the\nabsorbance of control sample between 0.5 and 1.0 min, andB represents the difference in absorbance of the test samplebetween 0.5 and 1.0 min. The mushroom tyrosinase acti-vity was determined by spectrophotometric assays (V arian\nCary 50). Umbelliferone was used as a reference tyrosinaseinhibitor.\nStatistical methods\nAll experiments were carried out three times. Continuousvariables were expressed as mean /H11006SD. The IC50 value (con-\ncentration giving 50% inhibition of tyrosinase activity) was\ndetermined by interpolation of dose\u2013response curves and alldata were statistically evaluated using Student\u2019s t-test or\nMann\u2013Whitney test (Statistica 6; Statsoft T ulsa, T ulsa, OK,USA). T o assess the slopes of curves in Figure 3 the Kruskal\u2013W allis test followed by Dunn\u2019s post-hoc test (Statistica 6;Statsoft T ulsa) was used. The criterion for statistical signi\ufb01-\ncance was generally taken as P<0.05.\nResults\nThe tyrosinase inhibitory activity of compounds 4and 7\u20139\nwas evaluated in vitro by measuring the enzymatic activity ofHO HO\nHONH2\nNH2O\nO OO OOH\nTyrosine Umbelliferone\nTyrosine-like compounds\nFigure 1 Chemical structures of tyrosine (tyrosinase substrate),\ntyrosine-like condensed molecules and umbelliferone (tyrosinase\ninhibitor).MariaJo\u00e3o Matos et al. Tyrosine-like tyrosinase inhibitors\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2012 Journal of Pharmacy and Pharmacology, 64, pp. 742\u2013746\n220mushroom tyrosinase enzyme extracted from the mushroom\nAgaricus bisporus . Then, the IC50 values for the inhibitory\neffects of the new compounds were calculated (T able 1).\nIn the presence of compound 7, kinetic studies on mush-\nroom tyrosinase, using a Lineweaver\u2013Burk double reciprocal\nplot (Figure 3), showed that compound 7was a mixed-type\ninhibitor. Increasing the concentration of 7resulted in a\nfamily of lines with different slope and intercept, which inter-sected in the second quadrant. This behaviour showed thatcompound 7can bind not only with free enzyme but also\nwith the enzyme\u2013substrate complex, with different equilib-rium constants. The inhibition constants for the inhibitorbinding with free enzyme, K\nI(2.14 mm), and with enzyme\u2013\nsubstrate complex, K IS(0.78 mm), were obtained from the\nlinear secondary plots of 1/V maxand K m/V maxversus the con-\ncentration of compound 7, respectively.\nDiscussion\nIn this communication, the possible tyrosinase inhibitoryeffect of coumarins that incorporate a portion of tyrosine ontheir skeletons was described. The introduction of a hydroxyl\nsubstituent into different positions of the 3-aminocoumarinmoiety was studied. In this way a small series of compounds\nthat are both tyrosine (tyrosinase substrate) and umbellifer-one (tyrosinase inhibitor) analogues was obtained.\nIt is known that umbelliferone (7-hydroxycumarin) has a\ntyrosinase inhibitor effect (IC50 =0.42 mm), despite having\nno amino group in its position 3. The 3-aminocoumarin(compound 4) was synthesized and evaluated and did not\nshow tyrosinase inhibitory activity. Then, other coumarinswere prepared, maintaining the amino group in the3-position, also incorporating a hydroxyl group in different\npositions of the coumarin skeleton.\nDifferent synthetic methodologies were carried out to\nobtain compounds 7and 8, which have the hydroxyl group in\npositions 7 and 8, respectively, of the coumarin nucleus(benzene ring) and compound 9, with the hydroxyl group in\nposition 4 of the coumarin (pyrone ring). As shown in\nT able 1, compound 7was the most active compound of this\nseries, with an IC50 value in the micromolar range (53 mm).\nThis compound was more than 10 times more active than\numbelliferone, the reference compound. Compound 7had\nthe amino and hydroxyl groups that precisely mimicked the\nsame positions that both groups occupy on the tyrosine mol-ecule. Compound 8was inactive against tyrosinase whereasO\nH\nR1 R1\nR2NO 2\nR2\nR2\nNO 2 NH2R2NH2 NH2\nR1 R1O2N\nOHO\nO\nO\nOO OOH OH\nOO O OO Oa\n1 R1 = R2 = H\n2 R1 = OMe, R 2 = H\n3 R1 = H, R 2 = OMe\n7 R1 = OH, R 2 = H\n8 R1 = H, R 2 = OH4 R1 = R2 = H\n5 R1 = OMe, R 2 = H\n6 R1 = H, R 2 = OMeb\nc\nb\n9\nFigure 2 Protocols for synthesis of coumarin derivatives. Reagents and conditions: (a) acetic anhydride, NaH, r .t., 3 h; (b) H 2, EtOH, Pd/C, r .t., 5 h; (c) HI,\nAcOH, Ac 2O, 110\u00b0C, 5 h.Tyrosine-like tyrosinase inhibitors MariaJo\u00e3o Matos et al.\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2012 Journal of Pharmacy and Pharmacology, 64, pp. 742\u2013746\n221compound 9was active against this enzyme (IC50 =\n0.26 mm). Compound 9presented only slightly higher tyrosi-\nnase inhibitory activity than umbelliferone.\nTherefore, it can be inferred that the tyrosinase inhibitory\nactivity depends on the position of the hydroxyl group in the\ncoumarin moiety. Also, the presence of the hydroxyl group at\nthe same position that of tyrosine and umbelliferone isimportant to the inhibitory activity.\nConclusions\nThis study showed that some of the synthesized tyrosine-likecondensed derivatives have inhibitory activity against mush-room tyrosinase. The two active compounds present tyrosi-\nnase inhibitory activity in the micromolar range. Thepresence of a hydroxyl group in the seven position of the3-aminocoumarin, the same position as in tyrosine and\numbelliferone, improves the inhibitory activity with respectto the other synthesized derivatives and the reference com-pound. So, the introduction of hydroxyl groups improves thepharmacological potential of these 3-aminocoumarins, con-\ufb01rming that this lead could be effectively optimized in a can-didate for the treatment of some hyperpigmentation skindiseases. These \ufb01ndings have encouraged us to continue theeffort towards the optimization of the pharmacological\npro\ufb01le of these coumarins.\nDeclarations\nCon\ufb02ict of interest\nThe Author(s) declare(s) that they have no con\ufb02icts of inter-\nest to disclose.\nFunding\nThis work was partially supported by the Ministerio deSanidad y Consumo [grant number FIS PS09/00501], Xuntada Galicia [grant number INCITE09E2R203035ES and\nPGIDIT09CSA030203PR], RAS\u2013LR7/2007 [grant number\nCRP2_133] and Universit\u00e0 degli Studi di Cagliari. This workwas also partially supported by Funda\u00e7\u00e3o de Ci\u00eancia e T ecno-logia [grant number SFRH/BD/61262/2009].05101520253035\n1/[S] m M\u201310.00\n0 0.02 0.04 0.06 0.081.002.003.004.00\n0.001.002.003.00\n\u20134 \u20132 024 6 8 1 0 1 21/V (ODnm)[I] (m M)\n0 0.02 0.04 0.06 0.08\n[I] (m M)1/Vmax Km/Vmax\nFigure 3 Lineweaver\u2013Burk plots for inhibition of compound 7on mushroom tyrosinase for catalysis of L-DOPA. Inhibitor concentrations were 0 ( /H17004),\n0.010 m M(/H17033), 0.025 m M(x), 0.050 m M(/H17009), 0.070 m M(). The insets are the secondary plots of 1/V maxand K m/V maxversus concentration of compound\n7, respectively .\nT able 1 Inhibitory effect of compounds 4and 7\u20139 and umbelliferone\non mushroom tyrosinase activity\nCompounds IC50 (m M) (L-DOPA 0.5 m M)\n4 >5.0\n7 0.05/H110060.01\n8 >5.0\n9 0.25/H110060.003\nUmbelliferone 0.42a\naObtained from Fais et al.[23]. These results are average results of three\nexperiments.MariaJo\u00e3o Matos et al. Tyrosine-like tyrosinase inhibitors\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2012 Journal of Pharmacy and Pharmacology, 64, pp. 742\u2013746\n222References\n1. Lerch K. Molecular and active site\nstructure of tyrosinase. Life Chem Rep\n1987; 5: 221\u2013234.\n2. Kim YM et al . Oxyresveratrol and\nhydroxystilbene compounds. Inhibi-\ntory effect on tyrosinase and mecha-\nnism of action. J Biol Chem 2002; 277:\n16340\u201316344.\n3. Passi S, Nazzaro-Porro M. Molecular\nbasis of substrate and inhibitoryspeci\ufb01city of tyrosinase: phenolic com-\npounds. Br J Dermatol 1981; 104: 659\u2013\n665.\n4. Qiu L et al . Inhibitory effects of\na-cyano-4-hydroxycinnamic acid onthe activity of mushroom tyrosinase.\nFood Chem 2009; 112: 609\u2013613.\n5. Solano F et al . Hypopigmenting agents:\nan update review on biological, chemi-\ncal and clinical aspects. Pigment Cell\nRes 2006; 19: 550\u2013571.\n6. He Q et al . Elucidation of the mecha-\nnism of enzymatic browning inhibitionby sodium chlorite. Food Chem 2008;\n110: 847\u2013851.\n7. Shin NH et al . Oxyresveratrol as the\npotent inhibitor on dopa oxidase activ-ity of mushroom tyrosinase. Biochem\nBiophys Res Commun 1998; 243: 801\u2013\n803.\n8. Palumbo A et al . Mechanism of\ninhibition of melanogenesis by hydro-quinone. Biochem Biophys Acta 1991;\n1073: 85\u201390.\n9. Smit N et al . The combined effects of\nextracts containing carotenoids andvitamins e and c on the growth and pig-\nmentation of cultured human melano-\ncytes. Skin Pharmacol Physiol 2004; 17:\n238\u2013245.\n10. Lim JT. T reatment of melasma\nusing kojic acid in a gel containinghydro- quinone and glycolic acid. Der-\nmatol Surg 1999; 25: 282\u2013284.\n11. Maeda K, Fukuda M. Arbutin: mecha-\nnism of its depigmenting action in\nhuman melanocyte culture. J Pharma-\ncol Exp Ther 1996; 276: 765\u2013769.\n12. Ohguchi K et al .G n e t o la sap o t e n t\ntyrosinase inhibitor from genus\nGnetum .Biosci Biotechnol Biochem\n2003; 67: 1587\u20131589.\n13. Borges F et al . Simple coumarins: privi-\nleged scaffolds in medicinal chemistry.\nFront Med Chem 2009; 4: 23\u201385.\n14. Hoult JRS, Pay\u00e1 M. Pharmacological\nand biochemical actions of simple cou-\nmarins: natural products with thera-\npeutic potential. Gen Pharmacol 1996;\n27: 713\u2013722.\n15. Vi\u00f1a D et al . 3-Substituted coumarins\nas dual inhibitors of AChE and MAOfor the treatment of Alzheimer\u2019s\ndisease. MedChemComm 2012; 3: 213.\n16. Roussaki M et al . A novel synthesis of\n3-aryl coumarins and evaluation of\ntheir antioxidant and lipoxygenaseinhibitory activity. Bioorg Med Chem\nLett 2010; 20: 3889\u20133892.\n17. Belluti F et al . Design, synthesis\nand anticancer activities of stilbene-coumarin hybrid compounds: identi\ufb01-\ncation of novel proapoptotic agents.\nBioorg Med Chem 2010; 18: 3543\u2013\n3550.\n18. Kontogiorgis C, Hadjipavlou-Litina\nDJ. Biological evaluation of severalcoumarin derivatives designed as pos-\nsible anti-in\ufb02ammatory/antioxidant\nagents. J Enzyme Inhib Med Chem 2003;\n18: 63\u201369.\n19. Santana L et al . Quantitative structure-\nactivity relationship and complexnetwork approach to monoamine\noxidase A and B inhibitors. J Med Chem\n2008; 51: 6740\u20136751.20. Matos MJ et al . Synthesis and study\nof a series of 3-arylcoumarins as potent\nand selective monoamine oxidase B\ninhibitors. J Med Chem 2011; 54: 7127\u2013\n7137.\n21. Matos MJ et al . A new series of\n3-phenylcoumarins as potent andselective MAO-B inhibitors. Bioorg\nMed Chem Lett 2009; 19: 3268\u20133270.\n22. Masamoto Y et al . Inhibitory effects of\nesculetin on melanin biosynthesis. Biol\nPharm Bull 2004; 27: 422\u2013425.\n23. Fais A et al . T yrosinase inhibitor activ-\nity of coumarin-resveratrol hybrids.\nMolecules 2009; 14: 2514\u20132520.\n24. Sollai F et al . Umbelliferone and\nesculetin: inhibitors or substrates for\npolyphenol oxidase? Biol Pharm Bull\n2008; 31: 2187\u20132193.\n25. Song S et al . Syntheses of hydroxy\nsubstituted 2-phenyl-naphthalenes asinhibitors of tyrosinase. Bioorg Med\nChem Lett 2007; 17: 461\u2013464.\n26. Chang TS. An updated review of tyrosi-\nnase inhibitors. I n tJM o lS c i2009; 10:\n2440\u20132475.\n27. Matos MJ et al . New halogenated phe-\nnylcoumarins as tyrosinase inhibitors.\nBioorg Med Chem Lett 2011; 21: 3342\u2013\n3345.\n28. Mahajani PB, Ray JN. Synthesis of\nsome amino acids and related pro-ducts. J Ind Chem Soc 1956; 33: 455\u2013\n458.\n29. Antonello C et al . 3-Amino- and 3-oxy-\nderivatives of psoralen: preparationand interactions with DNA. Farmaco\n1981; 36: 565\u2013584.\n30. Boschetti E et al . Hydroxy derivatives\nof coumarin. ZA 6801304 19680801.1968.\n31. Reppel L et al . Preparation of ami-\nnocoumarins. Arch Pharm 1963; 296:\n365\u2013399.Tyrosine-like tyrosinase inhibitors MariaJo\u00e3o Matos et al.\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2012 Journal of Pharmacy and Pharmacology, 64, pp. 742\u2013746\n223Targeting adenosine receptors with coumarins: synthesis and\nbinding activities of amide and carbamate derivatives\nMaria Jo\u00e3o Matosa,b, Alexandra Gaspara, Sonja Kachlerc, Karl-Norbert Klotzc, Fernanda Borgesa,\nLourdes Santanaband Eugenio Uriarteb\naCIQUP/Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, Porto, Portugal,bDepartamento de Qu\u00edmica Org\u00e1nica,\nFacultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, Spain andcInstitut f\u00fcr Pharmakologie und T oxikologie,\nUniversit\u00e4t W\u00fcrzburg, W\u00fcrzburg, Germany\nKeywords\nadenosine receptor ligands; amide derivatives;binding af\ufb01nity; carbamate derivatives;\ncoumarins\nCorrespondence\nMaria Jo\u00e3o Matos, Departamento de Qu\u00edmicaOrg\u00e1nica, Facultad de Farmacia, Universidad de\nSantiago de Compostela, Spain.\nE-mail: mariajoao.correiapinto@rai.usc.es\nReceived April 19, 2012\nAccepted June 29, 2012\ndoi: 10.1111/j.2042-7158.2012.01571.xAbstract\nObjectives With the aim of \ufb01nding the structural features governing binding activ-\nity and selectivity against adenosine receptors (ARs), several 3-subtituted coumarins\nwith amide (compounds 3\u20136) and carbamate (7\u20139) functions were synthesized.\nT o study its possible in\ufb02uence on the binding activity and selectivity, a hydroxylsubstituent was also introduced at position 4 of the coumarin moiety.Methods A new series of coumarins ( 3\u20139) were synthesized and evaluated by\nradioligand binding studies towards ARs.Key \ufb01ndings None of the 4-hydroxy derivatives ( 4, 8and 9) showed binding\naf\ufb01nity for any of the ARs. None of the compounds interacted with the hA\n2BAR\n(K i>100 000 nm). Compounds 3,5,6and 7had different activity pro\ufb01les with\ndissimilar binding af\ufb01nity and selectivity towards human A 1,A 2Aand A 3ARs.\nConclusions The most remarkable derivative is compound 7, which presents the\nbest af\ufb01nity and selectivity for the A 3adenosine receptor (K i=5500 nm).\nIntroduction\nCoumarins and their natural and synthetic derivatives arepharmacologically interesting compounds due to their struc-tural diversity.\n[1,2]Due to the synthetic accessibility and sub-\nstitution variability these heterocyclic compounds play animportant role not only in organic chemistry but also in the\ufb01eld of medicinal chemistry.\n[3\u201310]In fact, coumarins have\nbeen previously described as anti-cancer, antiviral, anti-in\ufb02ammatory, antimicrobial, enzyme-inhibitory and anti-oxidant agents.\n[3\u201318]\nAdenosine displays a wide number of physiological actions\nthrough activation of four different receptors: A 1,A 2A,A 2B\nand A 3,[19]These four subtypes are cell membrane-bound\nG-protein-coupled receptors that regulate diverse physiolo-gical functions.\n[20,21]Adenosine receptors (ARs) have been\nrecognized as important pharmacological targets since theyare involved in diverse pathological processes such as sepsis,in\ufb02ammation, myocardial infarction, asthma, diabetes,\nobesity and neurodegenerative diseases.\n[22,23]\nIn recent years, the search for innovative ligands showing\nselectivity and potency towards individual subtypes of AR has\nbeen intensi\ufb01ed as the role of these receptors in many areas is\ncontinuously expanding.[24,25]In particular, A 3AR has beenthe subject of intensive research during the last decade as it is\nrecognized as being a potential therapeutic target due to its\ncontribution to important pathological processes.[26]Evi-\ndence has been acquired supporting the signi\ufb01cant role of this\nAR subtype in in\ufb02ammation, cell growth and immunosup-pression.\n[27]Therefore, A 3AR agonists represent a new thera-\npeutic window for cancer, cerebral ischaemia and myocardialischaemia,\n[28]while A 3AR antagonists can be effective as anti-\nin\ufb02ammatory, anti-asthma and anti-glaucoma treatment.[29]\nSince AR ligands have broad applications, and an ideal\ndrug candidate has not yet been attained, intensive research inthis area is still needed. This effort has considerably increased\nin recent years. In this context, and with the aim of \ufb01nding\nnew structure\u2013activity features, this work based on coumarinderivatives was carried out. T o our knowledge, no infor-mation has been published so far concerning the coumarin\nscaffold as a putative ligand of the ARs. Therefore, this is an\ninnovative study, performed for the \ufb01rst time, on this interest-ing and versatile moiety. Our groups have recently proposedchromone derivatives, which are isomers of coumarins, to bea valid scaffold for the design of novel AR ligands.\n[30,31]These\nrecent \ufb01ndings, and the lack of data on the coumarin scaffold,bs_bs_banner\nAnd PharmacologyJournal of PharmacyResearch Paper\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 30\u201334\n225encouraged us to explore the ARs\u2019 binding activity of a\nselected series of coumarin derivatives.\nMaterials and Methods\nChemistry\nThe coumarin derivatives were ef\ufb01ciently synthesized accord-ing to the protocol outlined in Figure 1. Coumarins 3\u20139\nwere prepared starting from the commercially available\n3-aminocoumarin (compound 1) or from 3-amino-4-\nhydroxycoumarin (compound 2), which was previously\nsynthesized.\n[32\u201335]The 3-amino-4-hydroxycoumarin 2was\nprepared under a reduction reaction of the commerciallyavailable 3-nitro-4-hydroxycoumarin, in ethanol, with Pd/Cas catalyst, under H\n2atmosphere, with a yield of 90%. An acy-\nlation reaction of the 3-aminocoumarins 1or2with the con-\nveniently substituted acid chloride or chloroformate, usingpyridine in dichloromethane from 0\u00b0C to room tempera-ture, stirring overnight, afforded the differently substituted\n3-amidocoumarins ( 3\u20136) or 3-carbamatecoumarins ( 7\u20139),\nin yields between 77 and 85%. The reaction conditions and\nchemical characterization of the new compounds are detailedin the experimental section.\n[32\u201335]Synthetic methodologies\nMelting points were determined using a Reichert Ko\ufb02er ther-mopan or in capillary tubes on a B\u00fcchi 510 apparatus (Flawil,Switzerland) and are uncorrected. IR spectra were recorded\non a Perkin-Elmer 1640FT spectrophotometer (W altham,\nMA, USA).\n1H and13CN M Rs p e c t r aw e r er e c o r d e do naB r u k e r\nAMX spectrometer at 300 and 75.47 MHz, respectively, usingtetramethylsilane (TMS) as internal standard (chemical shiftsind-values, J in Hz). Mass spectra were obtained using a\nHewlett-Packard 5988A spectrometer. Elemental analyseswere performed using a Perkin-Elmer 240B microanalyserand were within /H110060.4% of calculated values in all cases. Silica\ngel (Merck 60, 230\u201300 mesh) was used for \ufb02ash chromatogra-phy (FC). Analytical thin-layer chromatography (TLC) was\nperformed on plates pre-coated with silica gel (Merck 60 F254,\n0.25 mm). The purity of compounds was assessed by high-performance liquid chromatography (HPLC) coupled witha diode array detector (DAD) on a Thermo Quest Spectra-system (Thermo Fisher Scienti\ufb01c, W altham, MA, USA)equipped with a P4000 pump, an UV6000 UV-Vis diodearray detector and an SN4000 interface operated via a personalcomputer. Instrument software ChromQuest 5.0 (ThermoFisher Scienti\ufb01c, W altham, MA, USA) was used for data\nacquisition. Different analytical columns and mobile phases\n(all solvents were HPLC grade) were tested. The mobile phasewas H\n2O:C H 3CN (70 : 30) and an Eclipse xdb C18 column\n(5mm particle size, 0.46 mm i.d., 25 cm length; Agilent\nT echnologies, Santa Clara, CA, USA) was used. The purity\nof the compounds was found to be higher than 95%.\nPreparation of 3-amino-4-hydroxycoumarin (2)\nThe commercially available 4-hydroxy-3-nitrocoumarin\n(Sigma-Aldrich, St. Louis, MO, USA) (2.5 mmol) was dis-solved in ethanol and a catalytic amount of Pd/C was added\nto the mixture (Sigma-Aldrich). The solution was stirred, at\nroom temperature, under H\n2atmosphere, for 5 h. After the\ncompletion of the reaction, the mixture was \ufb01ltered to elimi-nate the catalyst. The obtained crude product was then puri-\n\ufb01ed by FC (hexane\u2013ethyl acetate, 9 : 1) to give the desired\ncoumarin 2, in a yield of 90%.\n[32]\nGeneral procedure for the preparation of3-substituted coumarins (3\u20139)\nThe 3-aminocoumarin (Sigma-Aldrich) ( 1) or 3-amino-4-\nhydroxycoumarin (2) (1 mmol) was dissolved in dichlo-romethane (9 ml), then pyridine (Sigma-Aldrich) (1.1 mmol)\nwas added and the mixture was cooled to 0\u00b0C. Differently sub-stituted acid chloride or chloroformate (Sigma-Aldrich)\n(1.1 mmol) was added drop-wise at this temperature, and the\nmixture was stirred overnight at room temperature. The batchwas evaporated and puri\ufb01ed by column chromatography(hexane\u2013ethyl acetate, 9 : 1) to give the desired compound.OH\nNO 2NH2\n1: R = H\n2: R = OH\n3: R = H ; R1 = COCH 3\n4: R = OH ; R1 = COCH 3\n5: R = H ; R1 = COCH 2Br\n6: R = H ; R1 = COCH 2Cl\n7: R = H ; R1 = COOCH 2CH(CH 3)2\n8: R = OH ; R1 = COOCH 2CH(CH 3)2\n9: R = OH ; R1 = COOCH 2CH3O O(a)\n(b)O O\nO OR\nR\nNHR1\nFigure 1 Protocol for synthesis of coumarin derivatives. Reagents\nand conditions: (a) H 2, EtOH, Pd/C, r .t., 5 h; (b) R1Cl, pyridine, dichlo-\nromethane, 0\u00b0C to r .t, overnight.Maria Jo\u00e3o Matos et al. Targeting AR with coumarins\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 30\u201334\n226Biological assays\nThe af\ufb01nity of compounds 3\u20139 for the human AR subtypes\nhA 1,hA 2A,hA 3, was determined with radioligand competi-\ntion experiments in Chinese hamster ovary (CHO) cells\nthat were stably transfected with the individual receptorsubtypes.\n[36,37]The radioligands used were 1 n m (2R,\n3R,4S,5R)-2-(2-Chloro-6-cyclopentylamino-purin-9-yl)-5-hydroxymethyl-tetrahydro-3,4-diol ([\n3H]CCPA) for hA 1,\n10 nm (1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl- b-D-\nribofuronamide) ([3H]NECA) for hA 2A, and 1 nm 2-(1-\nhexynyl)-N6-methyladenosine [3H] ([3H]HEMADO) for\nhA 3receptors. The results were expressed as K is (dissociation\nconstants), which were calculated with the program SCT-FIT .\n[38]Due to the lack of a suitable radioligand for hA 2Brecep-\ntors, the potency of antagonists at the hA 2Breceptor (expressed\non CHO cells) was determined by inhibition of NECA-stimulated adenylyl cyclase activity.\n[36]\nStatistical analysis\nKivalues (T able 1) are reported as geometric means of three\nindependent experiments with each tested concentration ofcompound measured in duplicate. As an interval estimate forthe dissociation constants, 95% con\ufb01dence intervals are given\nin parentheses.\nResults\nStructural identi\ufb01cation\n3-(Isobutylcarbamate)coumarin ( 7): Yield 78%. Mp\n92\u201393\u00b0C.1H NMR dppm (CDCl 3-300 MHz): 1.39 (6H, d,\nJ=6.8 Hz, 2xCH 3), 2.38 (1H, s, CH), 4.39 (2H, d, J =6.7 Hz,\nCH 2), 7.69 (1H, s, H-4), 7.70\u20137.74 (2H, m, H-6, H-8), 7.80\n(1H, dd, J =7.3, 1.8 Hz, H-7), 7.88 (1H, dd, J =7.6, 1.8 Hz,\nH-5), 8.7 (1H, s, NH).13C NMR dppm (CDCl 3-75 MHz):\n19.6, 28.5, 72.6, 116.9, 120.5, 121.4, 125.0, 125.7, 128.1, 129.8,150.2, 154.1, 159.1. MS (ESI): 262 (7), 261 (M\n+, 42), 188 (23),\n161 (70), 133 (28), 57 (41). Anal. Calcd for C 14H 15NO 4:C ,\n64.36; H, 5.79. Found: C, 64.39; H, 5.83.4-Hydroxy-3-(isobutylcarbamate)coumarin ( 8): Yield\n77%. Mp 103\u2013104\u00b0C.1H NMR dppm (CDCl 3-300 MHz):\n0.96 (6H, d, J =6.6 Hz, 2xCH 3), 2.00 (1H, s, CH), 4.00 (2H,\nd, J=7.0 Hz, CH 2), 7.28\u20137.37 (2H, m, H-6, H-8), 7.52\u20137.62\n(1H, m, H-7), 7.93 (1H, dd, J =7.9, 2.0 Hz, H-5), 7.48 (1H, s,\nNH), 12.38 (1H, s, OH).13C NMR dppm (CDCl 3-75 MHz):\n18.9, 27.9, 73.6, 104.0, 116.2, 117.1, 123.8, 124.6, 131.2,\n150.1, 150.3, 157.1, 160.6. MS (ESI): 278 (7), 277 (M+, 40),\n203 (27), 177 (100), 148 (15), 121 (65), 88 (18), 57 (50).Anal. Calcd for C\n14H 15NO 5: C, 60.64; H, 5.45. Found: C,\n60.60; H, 5.41.\n3-(Ethylcarbamate)-4-hydroxycoumarin ( 9): Yield 85%.\nMp 152\u2013153\u00b0C.1H NMR dppm (CDCl 3-300 MHz): 1.35\n(3H, s, CH 3), 4.28 (2H, s, CH 2), 7.24\u20137.35 (4H, m, H-5, H-6,\nH-7, H-8), 7.93 (1H, s, NH), 12.35 (1H, s, OH).13C NMR\ndppm (CDCl 3-75 MHz): 14.4, 63.7, 104.1, 116.2, 117.1,\n123.8, 124.6, 131.2, 150.1, 150.3, 157.0, 160.6. MS (ESI): 250(10), 249 (M\n+, 43), 203 (59), 177 (30), 148 (41), 121 (61), 65\n(13). Anal. Calcd for C 12H 11NO 5: C, 57.83; H, 4.45. Found:\nC, 57.85; H, 4.47.\nBiological results\nThe data from radioligand binding experiments forcompounds 3\u20139 are summarized in T able 1. Details for\npharmacological experiments are described in Materials andMethods and in previous work.\n[36\u201338]\nDiscussion\nA novel coumarin series possessing a common planarN-C =O framework, represented by an amidic or a carbam-\nate group at position 3, were studied for their ability to bind toARs. In addition, the presence or the absence of a hydroxylgroup at position 4 was also explored in these preliminarystudies.\nThe experimental results (T able 1) reveal that none of the\n4-hydroxy derivatives (compounds 4,8and 9) have binding\naf\ufb01nity for any AR subtype. The presence of a hydroxyl func-tion at position 4 of the coumarin scaffold is not tolerated,T able 1 Af\ufb01nity (K i), for binding to human A 1,A 2Aand A 3adenosine receptors expressed in CHO cells, of coumarins 3\u20139, in radioligand binding assays\nCompoundKi(nM) Selectivity\nhA 1 hA 2A hA 3 hA 1/hA 3 hA 2A/hA 3\n3 53 900 (35 900\u201381 100) >30 000 7 160 (5 700\u20139 000) 7.5 >4.2\n4 >100 000 >100 000 >100 000 \u2013 \u2013\n5 25 000 (21 600\u201329 000) >30 000 27 800 (22 600\u201334 300) >0.9 >1.1\n6 7 760 (4 070\u201314 800) 36 600 (20 500\u201365 500) 13 700 (12 000\u201315 600) 0.57 2.7\n7 >100 000 >100 000 5 500 (3 490\u20138 670) >18.2 >18.2\n8 >100 000 >100 000 >100 000 \u2013 \u2013\n9 >100 000 >30 000 >100 000 \u2013 \u2013\nThese results are the average of three experiments.Targeting AR with coumarins Maria Jo\u00e3o Matos et al.\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 30\u201334\n227notwithstanding the presence of acetamide (compound\n4), isobutylcarbamate (compound 8) or ethylcarbamate\n(compound 9) at position 3. On the other hand, for com-\npounds 3,5,6and 7different activity pro\ufb01les with diverse\nbinding af\ufb01nity and selectivity towards human hA 1,hA 2A\nand hA 3ARs were observed. Compound 3, with an aceta-\nmide group at position 3 of the coumarin moiety, has a\nhigher af\ufb01nity to hA 3AR (K i=7160 nm) than to hA 1\n(K i=53 900 nm) and no af\ufb01nity for hA 2Aand hA 2B. Replacing\nthe acetamide substituent with bromoacetamide (compound5) decreased the binding af\ufb01nity and selectivity for hA\n3AR\n(hA 1Ki=25 000 nm and hA 3Ki=27 800 nm). Nevertheless it\nis interesting to note that the af\ufb01nity for hA 1AR is enhanced\nby this substitution. The substitution of a bromine for a chlo-rine atom leads to compound 6, which is almost twice as\nselective for hA\n1than hA 3AR and about \ufb01ve times more selec-\ntive for hA 1than hA 2AAR. The substitution of the acetamide\ngroup (compound 3) for an isobutylcarbamate function\n(compound 7) allows one to obtain a very active and selective\ncompound for hA 3ARs (K i=5500 nm; Selectivity index (SI)\nhA 1/hA 3and hA 2A/hA 3>18.2). The change of the amide to an\namide-like functional group (carbamate) in the coumarinnucleus brings about a noticeable af\ufb01nity and selectivity forhA\n3ARs. The additional oxygen of the carbamate functional-\nity, which exerts a unique steric and electronic environmen-tal, seems to have an important role for the ligand\u2013receptorinteraction. The interesting result found for compound 7\nprovides a stimulus for the design and synthesis of newcoumarin-based hA\n3AR selective ligands.Conclusions\nEvidence was acquired demonstrating that coumarin isa potential scaffold for the design of novel AR ligands. A\ndetailed analysis of the experimental results obtained so far\nallow us to conclude that the af\ufb01nity and/or selectivity of thecoumarins towards ARs may be greatly in\ufb02uenced by thenature of their substituents. Compound 7exhibits the best\nperformance and can be considered as the starting point forthe design and synthesis of new coumarins as hA\n3AR selective\nligands. The easy synthetic routes and the decoration capabil-ity of coumarins make them a privileged structure for drugdiscovery concerning ARs.\nDeclarations\nCon\ufb02ict of interest\nThe Author(s) declare(s) that they have no con\ufb02icts ofinterest to disclose.\nFunding\nPartial \ufb01nancial support from Ministerio de Sanidady Consumo (PS09/00501), Xunta de Galicia\n(PGIDIT09CSA030203PR) and Funda\u00e7\u00e3o para a Ci\u00eancia e\nT ecnologia (projects PTDC/QUI/70359/2006 and PTDC/QUI-QUI/113687/2009) are acknowledged. M. J. Matos andA. Gaspar thank FCT grants (SFRH/BD/61262/2009; SFRH/BD/43531/2008).\nReferences\n1. Borges F et al . Simple coumarins and\nanalogues in medicinal chemistry:\noccurrence, synthesis and biological\nactivity. Curr Med Chem 2005; 12: 887\u2013\n916.\n2. Borges F et al . Simple coumarins: privi-\nleged scaffolds in medicinal chemistry.Front Med Chem 2009; 4: 23\u201385.\n3. Kabeya L et al . Inhibition of horserad-\nish peroxidase catalytic activity by new3-phenylcoumarin derivatives: syn-\nthesis and structure-activity relation-\nships. Bioorg Med Chem 2007; 15:\n1516\u20131524.\n4. Belluti F et al . Design, synthesis\nand anticancer activities of stilbene-coumarin hybrid compounds: identi\ufb01-\ncation of novel proapoptotic agents.\nBioorg Med Chem 2010; 18: 3543\u20133550.\n5. Roussaki M et al . A novel synthesisof 3-aryl coumarins and evaluation of\ntheir antioxidant and lipoxygenase\ninhibitory activity. Bioorg Med Chem\nLett 2010; 20: 3889\u20133892.\n6. Ostrov DA et al .D i s c o v e r yo fn o v e l\nDNA gyrase inhibitors by high-throughput virtual screening. Anti-\nmicrob Agents Chemother 2007; 51:\n3688\u20133698.\n7. Neyts J et al . Structure-activity rela-\ntionship of new anti-hepatitis C virusagents: heterobicycle-coumarin conju-\ngates. J Med Chem 2009; 52: 1486\u20131490.\n8. Kostova I. Coumarins as inhibitors of\nHIV reverse transcriptase. Curr HIV\nRes 2006; 4: 347\u2013363.\n9. Nielsen SF et al . Antibacterial chal-\ncones \u2013 bioisosteric replacement of the4\u2032-hydroxy group. Bioorg Med Chem\n2004; 12: 3047\u20133054.\n10. Pisani L et al . Discovery of a novel\nclass of potent coumarin monoamineoxidase B inhibitors: development and\nbiopharmacological pro\ufb01ling of 7-[(3-\nchlorobenzyl)oxy]-4-[(methylamino)-\nmethyl]-2H-chromen-2-onemethanesulfonate (NW-1772) as a\nhighly potent, selective, reversible,\nand orally active monoamine oxidase\nB inhibitor. J Med Chem 2009; 52:\n6685\u20136706.\n11. Matos MJ et al . A new series of\n3-phenylcoumarins as potent andselective MAO-B inhibitors. Bioorg\nMed Chem Lett 2009; 19: 3268\u20133270.\n12. Matos MJ et al . Synthesis and evalua-\ntion of 6-methyl-3-phenylcoumarinsas potent and selective MAO-B inhibi-\ntors. Bioorg Med Chem Lett 2009; 19:\n5053\u20135055.\n13. Matos MJ et al . Halogenated\n3-phenylcoumarins as potent andselective MAO-B inhibitors. Bioorg\nMed Chem Lett 2010; 20: 5157\u20135160.Maria Jo\u00e3o Matos et al. Targeting AR with coumarins\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 30\u201334\n22814. Matos MJ et al . Synthesis and study of a\nseries of 3-arylcoumarins as potent and\nselective monoamine oxidase B inhibi-tors. J Med Chem 2011; 54: 7127\u20137137.\n15. Matos MJ et al . New halogenated\nphenylcoumarins as tyrosinase inhibi-\ntors. Bioorg Med Chem Lett 2011; 21:\n3342\u20133345.\n16. Vi\u00f1a D et al . 3-Substituted coumarins\nas dual inhibitors of AChE and MAO\nfor the treatment of Alzheimer\u2019s\ndisease. MedChemComm 2011; 3: 213\u2013\n218.\n17. Serra S et al . Hydroxycoumarins\nas selective MAO-B inhibitors. Bioorg\nMed Chem Lett 2012; 22: 258\u2013261.\n18. Chimenti F et al . Synthesis, molecular\nmodeling, and selective inhibitory\nactivity against human monoamine\noxidases of 3-carboxamido-7-\nsubstituted coumarins. J Med Chem\n2009; 52: 1935\u20131942.\n19. Fredholm BB et al . International Union\nof Pharmacology. XXV . Nomenclature\nand classi\ufb01cation of adenosine recep-\ntors. Pharm Rev 2001; 53: 527\u2013552.\n20. Klotz KN. Adenosine receptors and\ntheir ligands. Naunyn Schmiedebergs\nArch Pharmacol 2000; 362: 382\u2013391.\n21. Baraldi PG et al . A(3) adenosine recep-\ntor ligands: history and perspectives.Med Res Rev 2000; 20: 103\u2013128.\n22. Wilson CN. Adenosine receptors and\nasthma in humans. Br J Pharmacol\n2008; 155: 475\u2013486.\n23. Baraldi PG et al . Adenosine receptor\nantagonists: translating medicinalchemistry and pharmacology into\nclinical utility. Chem Rev 2008; 108:\n238\u2013263.\n24. Kim Y et al . Novel 2- and 4-substituted\n1H-imidazo[4,5-c]quinolin-4-aminederivatives as allosteric modulators of\nthe A3 adenosine receptor. J Med Chem\n2009; 52: 2098\u20132108.\n25. Bansal R et al . Synthesis of a new\nseries of 1H-imidazol-1-yl substituted8-phenylxanthines as adenosine recep-\ntor ligands. Chem Biol 2011; 8: 1290\u2013\n1300.\n26. Luan F et al . Af\ufb01nity prediction on A3\nadenosine receptor antagonists: thechemometric approach. Bioorg Med\nChem 2011; 19: 6853\u20136859.\n27. Gessi S et al . The A3 adenosine recep-\ntor: an enigmatic player in cell biology.Pharmacol Ther 2008; 117: 123\u2013140.\n28. Lee EJ et al . A novel adenosine analog,\nthio-Cl-IB-MECA, induces G\n0/G 1cell\ncycle arrest and apoptosis in human\npromyelocytic leukemia HL-60 cells.\nBiochem Pharmacol 2005; 70: 918\u2013\n924.\n29. Meade CJ et al .I nv i v or o l eo ft h e\nadenosine A3 receptor: N6-2-(4-aminophenyl)ethyladenosine induces\nbronchospasm in BDE rats by a neu-\nrally mediated mechanism involving\ncells resembling mast cells. J Pharmacol\nExp Ther 1996; 279: 1148\u20131156.\n30. Gaspar A et al .D i s c o v e r yo fn o v e lA\n3\nadenosine receptor ligands based on\nchromone scaffold. Biochem Pharmacol\n2012; 84: 21\u201329.31. Gaspar A et al .R e c e p t o r e sA 3da adeno-\nsina: uma nova abordagem terap\u00eautica\nno c\u00e2ncer. Quim Nova 2011; 34: 1417\u2013\n1424.\n32. Fritz A et al . Cumarindiol und\nCumarin-Chromon- T automerie (Cou-\nmarindiol and coumarin-chromone\ntautomerism). Chem Ber 1951; 84: 319\u2013\n329.\n33. Barnes CS et al . 2,2-Dimethylch-\nromene dimer. 2,2-Dimethylchromene\nand related compounds. Tetrahedron\n1963; 19: 839\u2013847.\n34. Stammer CH. Reaction of two\noxazolo[4\u2032,5\u2032: 3,4]coumarins with\nalkali. J Org Chem 1960; 25: 460\u2013\n461.\n35. Merchant JR, Martyres G. Some ami-\nnocoumarin derivatives possessinglocal anesthetic activity. Curr Sci 1981;\n50: 410\u2013411.\n36. Klotz KN et al . Comparative pharma-\ncology of human adenosine receptorsubtypes \u2013 characterization of stablytransfected receptors in CHO cells.\nNaunyn Schmiedebergs Arch Pharmacol\n1997; 357: 1\u20139.\n37. Klotz KN et al . [3H]HEMADO-a novel\ntritiated agonist selective for the\nhuman adenosine A3 receptor. Eur J\nPharmacol 2007; 556: 14\u201318.\n38. De Lean A et al . V alidation and statisti-\ncal analysis of a computer modelingmethod for quantitative analysis of\nradioligand binding data for mixtures\nof pharmacological receptor subtypes.\nMol Pharmacol 1982; 21: 5\u201316.Targeting AR with coumarins Maria Jo\u00e3o Matos et al.\n\u00a9 2012 The Authors. JPP \u00a9 2012\nRoyal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 30\u201334\n229231232233234235236Molecules  2013, 18, 1394-1404; doi:10.3390/mole cules18021394 \n \nmolecules \nISSN 1420-3049 \nwww. mdpi.com/journal/molecules \nArticle  \nSynthesis and Structure-Activity Relationships of  \nNovel Amino/Nitro Substituted 3-Arylcoumarins as  Antibacterial Agents \nMaria J. Matos 1,*, Saleta V azquez-Rodrigue z 1, Lourdes S antana 1, Eugenio Uriarte 1,  \nCristina Fu entes-Edfuf 2, Ysabel Santos 2 and Angeles Mu\u00f1oz-C rego 2 \n1 Departamento de Qu \u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, \n15782 Santiago de Compostela, Spain; E- Mails: svre77@gmail.c om (S.V.-R.); \nlourdes.santana@usc.es (L.S.); eugenio.uriarte@usc.es (E.U.) \n2 Departamento de Microbiolog\u00eda y Parasitolog\u00eda, Facultad de Biolog\u00eda,  \nUniversidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain ;  \nE-Mails: cristina.fuentesedfuf@gmail .com (C.F.-E.); ysabel.santos@usc.es (Y.S.); \na.munoz.crego@usc.es  (A.M.-C.) \n* Author to whom correspondence sho uld be addressed ; E-Mail: maria cmatos@gmail.com ;  \nTel.: +34-981-528-070; Fax: +34-981-594-912.  \nReceived : 24 December 2012; in revised form: 1\n5 January 2 013 / Accepted: 17 January 2013 / \nPublished: 24 January 2013 \n \nAbstract:  A new series of amino/nitro-substituted 3-arylc oumarins were synt hesized and \ntheir antibac terial ac tivity against c linical isolates of Staphylococcus  aureus  (Gram-positive)  \nand Escherichia coli (Gram-negative) was evaluated. Some of these molecules exhibited \nantibacterial activity against S. aureus  comparable to the standards used (oxolinic acid and \nampicillin). The preliminary str ucture-activity  relationsh ip (SAR) study showed th at the \nantibacterial activity against S. aureus  depends on the position of the 3-arylcoumarin \nsubstitu tion pattern.  With the aim of finding th e structural feat ures for the antibac terial \nactivity and selec tivity, in th e present manu script different positions of nitro, met hyl, \nmethoxy, amino and bromo su bstitu ents on th e 3-arylcoumarin scaffold were reported. \nKeywords:  amino/nitro su bstitu ted 3-arylc oum arins;  Perkin reaction; antibacterial assays; \nS. aureus;  E. coli  \n OPE N ACCE SS\n237Molecules  2013, 18 1395 \n \n 1. Introduction \nDrug disc overy is c onsidered a c omplex  and slow ac tivity.  However, with  the intention of \ndiscovering new chemi cal entities in a new and more effi cient way, medic inal chemistry researchers \nhave developed new approaches and methods. Some of the new products are based on diversity \nmolecules found and extracted from natural sources . Coumarins are a large family of compou nds of \nnatural or synthetic origin, associated with remarkable pharmacologi cal activ ities [1,2]. They occur \nnaturally in plants and mi croorganisms and appro ximately 1,000 coumarin derivatives h ave been \nisolated from over 800 species [2]. The fused heterocyclic framework of coumarins has been used as a \nprototype scaffold for the synthesis of a wide variety of analog ues in order to study and improve their \nbiological properties. Its structural variety is responsible for t he important pla ce they occupy in the \nrealm of natural products and synth etic organic chemistry [2,3 ]. Some coum arins have been stu died for \ntheir antimicrobial [4\u20137], cardioprotective [8], anticancer [ 9,10], antioxidative [11] and enzymatic  \ninhibition properties [12\u201317]. Goth described the antibacterial properties of coumarins for the first time \nin 1945 when he studied the dicoumarol (Figure 1) [18]. Some ot her coumarin derivatives have proven \nto display antibacterial and antif ungal activities [1 9\u201322]. A study of c oum arin derivatives substituted \non th e pyrone ring indic ated th at 3-carboxyl derivatives show signifi cant activities [23]. Different  \n4-substitu ted coumarins, such as 4-chloroc oumarins, exhibit also an interesting antimi crobial  \nprofile [24,25]. Novobiocin (Figure 1), chlorobiocin and coumermy cin A1 are important natu ral \noccurring antibiotic s in wh ich the coumarin nucleu s is present in t heir sk eleton [26]. \nFigure 1.  Chemical structures of dicoumarol and novobiocin. \n \nThe most active of them is novobiocin, isolated from Streptomyces  niveus  and wh ich is mainly \nactive against G ram-positive bac teria.  Although they antagoniz e the B subunit of th e essential E. coli \nDNA gyrase supertwisting activity in vitro  and th e bac terial multiplic ation, th ey are not u sed in th e \nclinic due to their relatively weak  activity against Gram -negative bacteria, side effe cts and poor water \nsolubility [4,26]. On the other han d, these three examples are antibioti cs, which present activity  \nagainst meth icillin-resistant S. aureus (MRSA) [26]. The nu mber of multidru g-resistant (MDR) \nbacteria is increasing and the Gram-positive MR SA are of particular importance. The ability of  \n238Molecules  2013, 18 1396 \n \n S. aureus species to develop resistan ce to virtu ally all antibiotic s is a major c oncern and th e disc overy \nof new antimic robial agents is essential to combat this problem [27]. M RSA  are often an important \nproblem for severe infe ctions in patients, especially if they are imm unosuppressed, during long stays in \nhospitals [27].  The dramatic  worldwide inc rease of dangerou s infec tions by resistant and mu lti-resistant \nmicrobes makes, therefore, the search of new mole cules and new chemical entities an important topi c \nin medicinal chemistry [28,29] . As the ideal drug candidate has not been attain ed, an intensive sear ch \nfor new and innovative antimicrobials is still needed . Unfortunately, due to economic reasons, \npharmac eutical companies h ave considerably de creased this effort in re cent years [30]. \n2. Results an d Discussion \nBased on previous findings in the area [24,25], and in o ur experience with s ubstituted  \n3-arylcoumarins [15,31,32], in the present wor k we proposed the synthesis and antibacterial eval uation \nof a series o\nf different substitu ted amino/nitro 3-arylc oumarins (Scheme 1). With the aim of finding \nthe structural featu res for the antibac terial activity and selec tivity, we dec ided to ex plore the \nimportance of the nature and position of small gro ups (meth oxy, bromo, nitro, amino and meth yl \nsubstituents) into bot h coumarin nuc leus and 3-aryl ring (Scheme 1). \nScheme 1. Synthesis of 3-arylcou marins ( 1\u201311).  \n \nReagents and conditions : (a) NaH , acetic anhydride, r.t., 3 h; (b) H2, Pd/C, eth anol, r. t., 3 h. \nNew derivatives 2, 4\u20137 and 9\u201311, as well as the already described compounds 1, 3 and 8 [33\u201336], \nwere effic iently synthesized according to th e synthetic protocol outlined in Scheme 1 .  \n3-Arylc oumarins 1\u201310 were synt hesized in a dry Schlenk t ube, in presenc e of sodium hydride and with \nacetic anhydride as solvent, at room temperat ure for three hours. The reaction mi xture was purified  by \nflash chromatography, using hexane/ethyl acetate as eluent in a proportion of 9:1. Starting from \ndifferent commercially available s ubstitu ted salicylaldehydes and the respectively substituted \nphenylac etic acids, we obtained ten derivates in good yields (60\u201375%). The derivative 11 was obtained \n239Molecules  2013, 18 1397 \n \n from 4, in eth anol, with  palladiu m/carbon as c atalyst and under hydrogen atmosp here for three hours. \nThe reaction mi xture was purified by flash chromatography, using hexane/ethyl acetate as eluent, in a \nproportion of 9:1. We obtained the desired derivate in good yield (80%). Then, two different \nmethodologies were employed for th e antibacterial evaluation of these compounds: disk diffusion test \nand microdilution meth od. Clinic al antim icrobial drugs\u2013oxolinic a cid and ampicillin\u2013were used as \npositive controls.  The inh ibition zones for growth inhibitory effects of the new compounds and \ncontrols were measu red in millimetres (Table 1, method A). The minimum in hibitory concentrations \n(MICs) of the new c ompou nds and c ontrols were measu red in mic rogram/millilitre (Table 1, meth od B). \nTable 1.  In vitro  antibacterial activity a of amino/nitro substituted 3-arylcoumarins 1\u201311 \n(A) expressed as inhibition zones (mm ) b and ( B) expressed as MICs (\u03bcg/mL). \nCompou nds Method A (mm) M ethod B (\u03bcg/mL) \nS. aureus E. coli S. aureus E. coli \n1 19  N A 128 - \n2 25 NA  64 - \n3 22 N A 32 - \n4 22 NA  32 - \n5 25 NA  64 - \n6 32 N A 8 - \n7 14 NA  256  - \n8 NA  N A >512 - \n9 N A N A >512 - \n10 N A N A >512 - \n11 18 N A 128 - \nOxolinic  acid 26  31 2 <1 \nAmpicillin 32 23  2 8 \na These results are average res ults of three experiments; b The compounds were used at the concentration of \n100 \u03bcg/disk and the inhibition zones are stated in mm ; NA = not active; diameter of in hibition zone /g148 5 mm. \nThe obtained inhibition zones revealed th at all the 6-nitro derivatives (compounds 1\u20137) presented \nantibacterial activity against S. aureus , showing inhibition zones ranging between 14 and 32 mm . The \namino derivative 11 presented ac tivity against th e same bac terial strain.  The 3-arylc oumarins nitro \nsubstituted only in th e 3-aryl ring (compounds 8\u201310) were inactive against S. aureus in th e in vitro  \ndisk diffusion test assays, independently of th e relative position of this nitro gro up (para or  meta \npositions). From the data, it is shown that compound 6 and ampic illin presented th e same inhibition \nzone against S. aureus  (32 mm) and a higher inhibition zone th an th e oxolinic  acid (26 mm). Hence, \nthe preliminary ex perimental data revealed t hat some of the tested c ompou nds sh owed a very \ninteresting activity profile against S. aureus when compared with the standards ampicillin and ox olinic \nacid. In addition, the different nature and position of the substituent in the coum\narin scaffold seems to \ninflu ence the antibac terial ac tivity.   \nIn order to deeply stu dy th e antibac terial ac tivities and quantify the previously mentioned \ninformation, MICs of compounds 1\u201311 against S. aureus  were also determined. This second \nmethodology (method B) is used to clarify and refine t he previously resu lts obtained by method A, \nwhich could be influenced by differences in the diff usion of the compounds. This study was performed \n240Molecules  2013, 18 1398 \n \n against the same bacteria strain, by a mi crodilu tion assay with  serial dilutions (from 512 to 1 /g541g /mL) \nof the synthesized and the reference compounds. MICs of compounds 1\u201311 against E. coli were not \nevaluated, taking into account the lack of inhibition zones in the previous disk diffusion test  \n(inhibition zones /g148 5 mm). Analysing the MICs results for S. aureus , it is c lear th at the presence of a \nnitro substituent at the six position of coum\narin moiety (compou nds 1\u20137) is more benefic ial th an its \npresence only at meta  or para positions of the 3-aryl ring (compounds 8\u201310).  \nCompou nds with  nitro su bstitu ents eith er in th e coumarin moiety and in th e aryl grou p (compou nds \n1 and 4) are not better than compounds wh ere th e nitro in th e aryl ring is substituted for a m ethyl or a \nmethoxy group (compounds 2 and 3 compared to c ompou nd 1, and compounds 5 and 6 compared to \ncompound 4). However, compound 4 (MIC = 32 \u03bcg/mL), with  the nitro substitu ent in meta  position of \nthe 3-aryl ring, is better than compound 1 (MIC = 128 \u03bcg/ mL), with  the same su bstitu ent in para  \nposition. The presence of a m\nethyl grou p in th e meta  position is the best substitution when one nitro \nsubstituent is present at six position of th e coumarin moiety (compou nd 6, MIC = 8 \u03bcg/mL). In \ngeneral, meta  substitutions are more favourable than para, being th e meta-methyl su bstitu ent th e most \nactive, followed by meta-nitro and finally meta -methoxy. There is one exception to t his conclusion. \nThe introduction of a brom\no atom at th e same position was th e worst substitution of the studied  \n3-aryl-6-nitrocoumarins (compound 7, MIC = 256 \u03bcg/mL). A para- methyl su bstitu ent in th e 3-aryl \nring (compound 3, MIC = 32 \u03bcg/ mL) is the best substitution in this para  position. Therefore, th e  \npara- me\nthyl su bstitu tion is better th an th e para- nitro and para-met hoxy substitutions. Comparing the \ntwo positions in th e 3-aryl ring, th e substitu tions by methyl groups are more favourable for the desired \nactivity.  The substitu tion of nitro by amino grou ps significantly decreases th e activity of th e desc ribed \ncompou nds (comparing compou nds 4 and 11).  \nIn order to evalu ate if there was a correlation between th e activity and th e li pophilicity, and to better \nunderstand the overall properties of t he desc ribed compou nds, logP  (octanol/water partition \ncoefficient) values were calcu lated using the Molinspiration property calculation program [37]. The \nresults are presented in Table 2.  \nTable 2.  LogP (octanol/water partition coefficient)  values calculated for the amino/nitro \nsubstituted 3-arylc oum arins 1\u201311 a. \nCompou nds Lo gP \n1 3,631 \n2 3,729 \n3 4,120 \n4 3,607 \n5 3,705 \n6 4,096 \n7 4,457 \n8 3,729 \n9 3,705 \n10 4,120 \n11 1,841 \na The data was determined wit h Molinspiration calculation software [ 37]. \n241Molecules  2013, 18 1399 \n \n Analysing the obtained data, it can be concluded th at there are no linear c orrelations between th e \nlipophilicity and the activity of th e compou nds. Compou nds 5 and 6 are two of the best compounds \nagainst S. aureus , presenting intermediate, but different, logP values (3.705 and 4.096 respectively). \nThe compou nds with  the lowest (compou nd 11, 1. 841) and th e highest (com pou nd 7, 4. 457) logP  \npresented activity. Compound 9, with the same logP as compound 5, resu lted to be inac tive. Also, \ncompou nd 10, with  the same lipoph ilicity profile as c ompou nd 3 (logP = 4.12), resulted to be inactive. \nTherefore, there are no clear correlation between a ctivity and logP values. It is important to high light \nthat the calculated logP val ues for all \nthe described compounds are lower than 5. \n3. Experimental \n3.1. Chemistry \nMerck supplied th e entire chemic als used in th e synth esis. Melting points ( mp) are u ncorrec ted \nwere determined using a Reichert Kofler thermopan or in capillary tu bes on a B \u00fcchi 510 apparatu s and \nare uncorrected. 1H-NMR (300 MHz) and 13C-NMR (75.4 MHz) spectra were recorded with a Bruker \nAMX spectrometer. C hemical shifts (/g303) are expressed in parts per million ( ppm) using TMS as an \ninternal standard.  Spin mu ltiplic ities are given as s (singlet), d ( doublet), dd (doublet of doublets) and \nm (multiplet). Mass spe ctrometry was c arried ou t with a Kratos MS -50 or a Varian MAT- 711 \nspectrometer. Elem ental analyses were performed by a Perkin-Elmer 240B mi croanalyzer and were \nwithin \u00b10.4% of calculated valu es in all cases. Flash Chromatography (FC) was performed on  \nsilica gel (Merck 60, 230\u2013400 mesh); analytical TLC was performed on precoated silica gel plates \n(Merck 6 0 F254). \nGeneral Procedure for th e preparation of 3-arylcoumarins 1\u201310. In a 20 mL  dry Schlenk t ube, to a \nsolution of the conveniently su bstitu t\ned salic ylaldeh yde (2.46 mmol)  and the arylac etic acid (2.46 mmol) , \nin acetic anhydride (6 mL), NaH (2.46 mmol) was added in small portions, and the reaction mixture \nwas stirred for 3 hours, at room temperatu re. The obtained crude was filtered and washed with diethyl \nether. The solid was t hen pu rified by flash  chrom atography (hexane/ethyl ac etate 9:1) to give th e \ndesired coumarins 1\u201310.  \n3-(4/g397-Methoxyphenyl)-6-nitrocoumarin  (2). Pale yellow solid, 75% yield. Mp: 6 2\u201363 \u00b0C. 1H-NMR  \n(CDCl3) /g303 (ppm): 3.80 (s, 3H, OCH3), 7.05 (d, 2H , H-3/g397, H-5/g397, J = 9.45 Hz), 7.62\u20137.69 (m, 3H, H-2/g397, H-6/g397, \nH-8), 8.36 (s, 1H, H-4), 8.73 (d, 2H, H-5, H-7, J = 2.93 Hz). 13C-NMR  (CDCl3) /g303 (ppm): 55.9, 116.4, \n119.7, 127.9, 128.4, 128.6, 129.2, 132.2, 132.5, 134.3, 139.1, 139.4, 151.5, 155.8, 161.2. ESI-MS m/z: \n297 (M+, 100). Anal. Calcd. for C 16H11NO5: C, 64.65; H, 3.73; Found: C, 64.67; H, 3.76. \n3-(3/g397-Nitrophenyl)- 6-nitrocoumarin  (4). Pale yellow solid, 69% yield.  Mp: 87\u2013 88 \u00b0C. 1H-NMR (CDCl3) /g303 \n(ppm): 7.57\u20137.63 (m, 2H, H-8, H-6/g397), 7.71\u20137.77 (m, 1H, H-5/g397), 8.15 (s, 1H, H-4), 8.42-8.63 (m, 4H,  \nH-4/g397, H-2, H-5, H-7). 13C-NMR  (CDCl3) /g303 (ppm): 118.1, 120.2, 123.1, 123.3, 124.3. 124.5, 124.7, \n129.4, 133.6, 135.1, 141.2, 144.6, 147.9, 159.2, 160.5. ESI-MS m/z: 312 (M+, 100). Anal. Calcd. for \nC15H8N2O6: C, 50.70; H, 2.58. Found: C, 50.72; H, 2.60. \n242Molecules  2013, 18 1400 \n \n 3-(3/g397-Methoxyphenyl)-6-nitrocoumarin  (5). Pale yellow solid, 71% yield. Mp: 53\u201354 \u00b0C. 1H-NMR  \n(CDCl3) /g303 (ppm): 3.71 (s, 3H, OCH3), 6.80 (s, 1H, H-2/g397), 7.17\u20137.22 (m, 3H, H-4/g397, H-5/g397, H-6/g397), 7.57 (d, \n1H, H-8, J = 6.5 Hz), 7.77 (s, 1H, H-5), 8.19 (d, 1H, H-7, J = 6.5 Hz), 8.39 (s, 1H , H-4). 13C-NMR \n(CDCl3) /g303 (ppm): 55.4, 84.5, 112.4, 115.5, 122.0, 123.5, 125.8, 126.8, 129.5, 129.7, 136.9, 145.7, \n153.2, 159.6, 168.7, 173.0. ESI-MS m/z: 297 (M+, 100). Anal. Calcd. for C 16H11NO5: C, 6 4.65; H, \n3.73. Found: C, 64.63; H, 3.70. \n3-(3/g397-Methylphenyl)-6-nitrocoumarin  (6). Pale yellow solid, 69% yield. Mp: 55 \u201356 \u00b0C. 1H-NMR  \n(CDCl3) /g303 (ppm): 2.25 (s, 3H, CH3), 6.90\u20137.30 (m, 5H, H-2/g397, H-4/g397, H-5/g397, H-6/g397, H-8), 7.75 (s, 1H, H-4), \n8.44 (d, 1H , H-7, J = 2.8 Hz), 8.62 (d, 1H , H-5, J = 2.8 Hz). 13C-NMR  (CDCl3) /g303 (ppm): 21.5, 118.4, \n123.3, 124.5, 124.6, 124.8, 125.9, 126.6, 128.3, 128.5, 132.7, 138.4, 141.1, 144.6, 159.3, 160.9.  \nESI-MS m/z: 281 ( M+, 100). Anal. Calcd. for C 16H11NO4: C, 68.32; H, 3.94. Found: C, 68.31; H, 3.92. \n3-(3/g397-Bromophenyl)-6-nitrocoumarin  (7). Pale yellow solid, 60% yield. Mp: 240\u2013 241 \u00b0C. 1H-NMR  \n(CDCl3) /g303 (ppm): 7.12\u20137.26 (m, 2H, H-4/g397, H-5/g397), 7.46\u2013 7.71 (m, 5H, H-2/g397, H-6/g397, H-5, H-7, H-8), 7.78  \n(s, 1H , H-4). 13C-NMR  (CDCl3) /g303 (ppm): 117.9, 122. 7, 123.1, 124. 5, 124.6, 124.8, 127.9, 129.5, 129.7, \n130.8, 134.6, 140.7, 144.6, 159.1, 161.1. ESI-MS m/z: 345 (M+, 100). Anal. Calcd. for C 15H8BrNO 4: \nC, 52.05; H, 2.33. Found: C, 52.01; H, 2.30.  \n6-Methoxy-3-(3 /g397-nitrophenyl)coumarin  (9). Pale yellow solid, 73% yield. Mp: 84\u2013 85 \u00b0C. 1H-NMR \n(CDCl3) /g303 (ppm): 3.77 (s, 3H, OCH3), 7.01\u2013 7.10 (m, 2H, H-5, H-7), 7.54\u2013 7.59 (m, 2H, H-5/g397, H-6/g397), \n7.71 (d, 1H , H-8, J = 7.6 Hz), 8.06\u2013 8.09 (m, 2H, H-2/g397, H-4/g397), 8.15 (s, 1H , H-4). 13C-NMR  (CDCl3) /g303 \n(ppm): 56.7, 115.0, 116.8, 122.3, 124.9, 128.7, 130.2, 134.2, 135.5, 137.2, 138.0, 143.3, 148.3, 156.8, \n167.7, 172.7. ESI-MS m/z: 297 (M+, 100). Anal. Calc d. for C 16H11NO5: C, 64.65; H, 3.73. Found: C, \n64.63; H, 3.70. \n6-Methyl-3-(4/g397-nitrophenyl)coumarin (10). Pale yellow solid, 75% yield. Mp: 100 \u2013101 \u00b0C. 1H-NMR \n(CDCl3) /g303 (ppm): 2.36 (s, 3H, CH3), 7.21 (d, 2H , H-7, H-8, J = 8.2 Hz), 7.38 (s, 1H , H-5), 7.63\u2013 7.70  \n(m, 2H, H-2/g397, H-6/g397), 7.99\u2013 8.20 (m, 2H, H-3/g397, H-5/g397), 8.38 (s, 1H, H-4). 13C-NMR  (CDCl3) /g303 (ppm): \n20.6, 122.6, 123.9, 125.1, 127.9, 130.2, 131.4, 136.4, 136.6, 136.8, 137.2, 148.1, 149.3, 170.2, 190.6. \nESI-MS m/z: 281 ( M+, 98). Anal. Calcd. for C 16H11NO4: C, 68.32; H, 3.94. Found: C, 68.38; H, 3.99.  \nProcedure for the Preparation of 3-(3 /g397-Aminophenyl)-6-Amino coumarin (11) \nThe previously prepared 3-(3 /g397-nitrophenyl)-6-nitrocoumarin (4, 2.46 mmol) was dissolved in \nethanol (5 mL) and a c atalytic  amount of Pd/C was added to the mi xture. The solution was stirred, at \nroom\n temperature, under a H 2 atmosph ere, for 3  h. After completion of th e reac tion, th e mixture was \nfiltered to eliminate th e catalyst. The obtained crude was then pu rified by flash  chromatography \n(hexane/ethyl ac etate 9:1) to give th e desired coumarin 11 as a wh ite solid in 80 % yield.  Mp:  \n105\u2013 106 \u00b0C. 1H-NMR (CDCl3) /g303 (ppm): 4.02 (s, 2H, NH 2), 6.50\u20136.55 (m, 1H, H-4/g397) 6.56 (s, 1H, H-2/g397),  \n6.69\u20136.73 (m, 1H, H-6/g397) 6.80 (dd, 2H, H-5, H-7, J = 7.8, J = 2.4 Hz), 7.30\u20137.38 (m, 2H, H-5/g397, H-8), \n8.4 (s, 1H, H-4). 13C-NMR  (CDCl3) /g303 (ppm): 114.9, 115.7, 116.7, 120.9, 123.6, 125.4, 127.2, 128.6, \n243Molecules  2013, 18 1401 \n \n 133.7, 135.8, 136.2, 143.3, 145.5, 149.7, 161.9. ESI-MS m/z: 252 ( M+, 100). Anal. Calcd. for \nC15H12N2O2: C, 71.42; H, 4.79. Found: C, 71.45; H, 4.82.  \n3.2. Biological Assays \nDisk Diffusion Test:  The antimicrobial ac tivity of th e compounds was assayed by the disk diffusion \nmethod, following the procedures of th e Clinic al and L aboratory Standards Institute (CLSI, 2006). The \ninoculum was prepared as a saline suspension of colonies from a 24 h M ueller Hinton Agar (MHA)  \n(Cultim\ned, Barcelona, Spain)  plate cultu re of the microorganisms, containing appro ximately 1 \u00d7  108 \ncolony forming units (CFU)/mL (OD620 of 0,09). Colony counts on inocul um suspension were verified \nby th e plate dilu tion meth od using MHA plates and counting the ba cterial colonies produced.  The \nentire surface of the MHA plate was inoculated by strea king with  the swab c ontaining the inocu lum. \nAntimicrobial solution (concentration of 10000 \u03bcg/mL) was prepared using DMSO  as solvent. Sterile \ndisks of 6  mm diameter (L iofilchem, Roseto degli A bruzz i, Italy) embedded i n the drug at a final \nconcentration of 100 \u03bcg /disk were kept on agar s urface. Sterile disks embedded with DMSO were used \nas a negative c ontrol.  The plates were incubated at 37 \u00b0C for 24 h. Zones of inhibition were measured \nin millimeter.   \nDisk Minimum Inhibitory Concentrations  (MICs): The MI Cs were evaluated using the broth \nmicrodilution method, following the procedures of th e Clinical and L aboratory Standards Institute \n(CLSI, 2006). Broth  microd\nilution tests were performed with 96 sterile flat-bottom mi crotiter plates \n(Becton Dickinson Labware Europe, Madrid, Spain). Antimicrobials were serially dil uted (512 to  \n1 /g541g/mL) in Mueller-Hinton Broth (MHB) (Cultimed)  and th en one hundred mi croliters of each \ndilution were deposited into ea ch well. The inoculum was prepared by ma king a MHB s uspension of \ncolonies from a 24 h MHA (Cultimed) plate culture of th e m icroorganisms, containing approx imately  \n1 \u00d7 108 colony forming units (CFU)/mL (OD620 of 0,09). The inoculum was diluted 1:100 in MHB to \nyield 1 \u00d7  106 CFU/ mL. Ten microliters of this suspension was inocu lated into the each well.  Colony \ncounts on inoculum s uspension were verified by t he plate dilution method using MHA plates and \ncounting the bacterial colonies produced. M HB with and without inocul um was used as growth-control \nand negative c ontrol, respec tively.  The plates were in cubated at 37 \u00b0C for 24 h. The MIC was \nestablished comparing the amo unt of growth in the wells containing th e antim icrobial agents with t he \namount of growth in the growth-control wells both with t he unaided eye and by using a photometric \ndevic e (OD620). \n4. Conclusions  \nIn conclusion, in th e present study it was shown that eight out of the eleven synthesized \namino/ nitro- substitu ted 3-arylc oumarins have inhibitory activity against S. aureus. MIC determinations \nproved that the tested compounds presented different profiles against S. aureus  due to their \nsubstituents, being 3-(3 /g397-methylphenyl)-6-nitroc oumarin (6) the best on e. A nitro su bstitu ent at th e  \n6-position of th e coumarin moiety seems to be essential for th e antibacterial ac tivity of th is kind of \ncompou nds. The introduction of an amino su bstitu ent seems to decrease t he described activity.  The \npharmac ologic al potential of t hese amino/nitro- substitu ted 3-arylc oumarins confirms that this scaffold \ncan be effec tively optimiz ed into a candidate for the treatment of some ba cterial infectious diseases. \n244Molecules  2013, 18 1402 \n \n Acknowledgments \nThanks are due to the Ministerio Espa \u00f1ol (PS09/00501), Xunta da G alicia \n(PGIDIT09CSA030203PR and PGIDT08MMA011200PR)  and IN845B-2010/089 for the financial \nsupport. M.J.M. thanks to Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia for a PhD grant \n(SFRH/BD/6 1262/2009). S .V.R. thanks the Ministerio de Educaci\u00f3n  y Ciencia for a PhD grant \n(AP2008-04263). \nReferenc es \n1. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.;  Uriarte, E. Simple c oumarins and analogu es in \nmedicinal chemistry: Occurrenc e, synthesis and biological activity.  Curr. Med. Chem. 2005, 12, \n887\u2013916. \n2. Borges, F.; Roleira, F.; Milh azes, N.; Uriarte, E.; Santana, L. Simple c oumarins: Privileged \nscaffolds in medi cinal chemistry.  Front. Med. Chem. 2009, 4, 23\u201385.  \n3. Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.; Poletto, G.; Mazzorana, M.;  \nZagotto, G.; Uriarte, E.; Guiotto, A.; et al. Cou marin as A ttractive Casein Kinase 2 ( CK2) \nInhibitor scaffold: An integrate approach to elucidate the putative binding motif and explain \nstruc ture\u2013activity relationsh ips. J. Med. Chem.  2008, 51, 752\u2013759. \n4. Hooper, D.C.; Wilfson, J.S.; M cHugh, G.L.; Winters, M.B.; Swartz, M.N. In vitro  activity of \nDNA gyrase inhibitors, singly and in combination, against Mycobacterium avium  complex. \nAntimicrob. Agents Chemother.  1982, 22, 662\u2013671. \n5. Ostrov, D.A.; Hern\u00e1ndez Prada, J.A.; Corsino, P.E.; Finton, K.A.; Le, N.; Rowe, T.C. Disc overy of \nnovel DNA  gyrase inh ibitors by h igh-throughput virtu al screening.  Antimicrob. Agents  Chemother.  \n2007, 51, 3688\u20133698.  \n6. Chimenti, F.; Bizzarri, B.; Bolasc o, A.; Secci, D.; C himenti, P.; Granese, A.; Carradori, S.; \nRivanera, D.; Zicari, A.; Scaltrito, M.M.; et al. Synth esis, Selec tive anti-Helicobacter pylori  \nactivity, And cytotoxicity of novel N-substitu ted-2-oxo-2H-1-benzopyran-3-carboxamides . \nBioorg. Med. Chem. Lett. 2010, 20, 4922\u20134926.  \n7. Matos, M. J.; Vazquez-Rodrigu ez, S.; Santana, L.; Uriarte, E.; Fuentes-Edfuf, C.; Santos, Y.; \nMu\u00f1oz-Crego, A. Looking for new targets: Simple c oumarins as antiba cterial agents. Med. Chem.  \n2012, 8, 1140\u20131145. \n8. Vilar, S.; Quezada, E.; Santana, L.;  Uriarte, E.;  Yanez, M.; Fraiz, N.; Alcaide, C.; Cano, E.; Orallo, F. \nDesign, Synthesis, and Vasorelaxant and platelet antiaggregatory ac tivities of coumarin- resveratrol \nhybrids.  Bioorg. Med. Chem. Lett.  2006 , 16, 257\u2013261. \n9. Riveiro, M.E.; Moglioni, A.; Vazquez, R.; Gomez , N.; Facorro, G.; Piehl, L.; de Celis, E.R.; \nShayo, C.; Davio, C. Structural insights into hydroxycoumarin -induced apoptosis in U -937 cells. \nBioorg. Med. Chem. 2008, 16, 2665\u20132675. \n10. Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.; Z unino, F. Design, Synthesis and \nantic ancer ac tivities of stilbene -coumarin hybrid compounds: Identification of novel proapoptoti c \nagents.  Bioorg. Med. Chem. 2010, 18, 3543\u20133550. \n245Molecules  2013, 18 1403 \n \n 11. Roussaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D.J.; Hamilakis, S. A novel synthesis of  \n3-aryl coumarins and evalu ation of th eir antioxidant and lipoxygenase inhibitory activity.  \nBioorg. Med. Chem. Lett.  2010, 20, 3889\u20133892. \n12. Fais, A.; Corda, M.; Era, B.; Fadda, M.B.; Matos, M.J.; Q uezada, E.; Santana, L.; Picciau, C.; \nPodda, G.; Delogu, G. Tyrosinase inhibitor a ctivity of c oumarin-resveratrol hybrids.  Molecules  \n2009, 14, 2514\u20132520. \n13. Matos, M.J.;  Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.; Uriarte, E.  \nA New series of 3-phenylcoumarins as potent and selec tive MAO-B inhibitors. Bioorg. Med. \nChem. Lett.  2009, 19, 3268\u20133270. \n14. Matos, M.J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. New halogenated  \n3-phenylcoumarins as potent and selective MAO-B inhibitors.  Bioorg. Med. Chem. Lett. 2010,  \n20, 5157\u20135160. \n15. Matos, M. J.; Ter\u00e1n, C.; P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. Synthesis and study \nof a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.  \nJ. Med. Chem. 2011, 54, 7127\u20137137. \n16. Matos, M. J.; Vi\u00f1a, D.; Picciau , C.; Orallo, F.; Santana, L.; Uriarte, E. Synth esis and evaluation of \n6-methyl-3-phenylcoumarins as potent and sele ctive MAO-B inhibitors. Bioorg. Med. Chem. Lett. \n2009, 19, 5053\u20135055. \n17. Delogu, G.; Picciau, C.;  Ferino, G.; Quezada, E.; Podda, G.; Uriarte, E.; Vi\u00f1a, D. Synthesis, \nHuman monoamine oxidase inhibitory activity and molecular docking studies of  \n3-heteroarylcoumarin derivatives. Eur. J. Med. Chem.  2011, 49, 1147\u20131152. \n18. Goth, A. The antibac terial properties of di cumarol. Science 1945, 101, 383. \n19. Hoettecke, N.; Rotzoll, S.; Albrecht, U.; Lalk, M.; Fischer, C.; Langer, P. Synthesis  \nand antimicrobial activity of 2-alkenylchroman -4-ones, 2-alkenylthiochroman-4-ones and  \n2-alkenylquinol-4-ones. Bioorg. Med. Chem. 2008, 16, 10319\u201310325. \n20. Shi, Y.; Zhou, C. Synthesis and evaluation of a class of new coumarin triazole derivatives as \npotential antimi crobial agents.  Bioorg. Med. Chem. Lett.  2011, 21, 956\u2013960. \n21. Patil, S.A.; Unki, S.N.; Kulkarni, A.D.; Naik, V.H.;  Badami, P.S. Synth esis, Ch aracterization,  \nIn vitro  antimicrobial and DN A cleavage stu dies of Co(II), Ni(II) and Cu(II) complex es with  \nONOO donor coumarin Schiff bases. J. Mol. Struct. 2011, 9 85, 330\u2013338. \n22. Sabry, N.M.; Mohamed, H.M.; Khattab, E.S.A.E.H.; Motlaq, S.S.; El-Agrody, A.M. Synthesis of \n4H-chromene, Cou marin, 12H-chromeno[2,3- d]pyrimidine derivatives and some of their \nantimic robial and cytotoxicity ac tivities.  Eur. J. Med. Chem.  2011, 46, 765\u2013772. \n23. Kawase, M.; Varu, B.; Shah, A.; Motohashi, M.; Tani, S.; Saito, S. Antimicrobial activity of new \ncoumarin derivatives.  Arzneimittelforschung  2001, 51, 67\u201371. \n24. Patel, D.; Kumari, P.; Patel, N.  Synthesis, characterization and biologi cal evaluation of some \nthiazolidinone derivatives as antimi crobial agents.  J. Chem. Pharm. Res.  2010, 2, 84\u201391. \n25. Patel, D.; Kumari, P.; Patel, N.  Synth esis and characterization of some new thiazolidinones \ncontaining coumarin moiety and th eir antimicrobial stu dy. Arch. Appl. Sci. Res.  2010, 2, 68\u201375. \n26. Laurin, P.; Ferrou d, D.;  Klich, M.;  Dupuis-Hamelin, C.;  Mauvais, P.; Lassaigne, P.; Bonnefoy, A.; \nMusicki, B. Synth esis and in vitro  evalu ation of novel h ighly potent coumarin inhibitors of gyrase \nB. Bioorg. Med. Chem. Lett.  1999, 9 , 2079\u20132084. \n246Molecules  2013, 18 1404 \n \n 27. Nathan, C. Antibiotics at the crossroads. Nature  2004, 431, 899\u2013902. \n28. Rachakonda, S.; Cartee, L. C hallenges in antimi crobial dru g disc overy and the potential of \nnucleoside antibioti cs. Curr. Med. Chem.  2004, 11, 775\u2013793. \n29. Walsh, C. Antibiotics, Actions, Origins, Resistance ; ASM: Washington, DC, USA, 2003. \n30. Von Nussbaum, F.; Brands, M.; Hinzen, B.; Weigand, S.; H\u00e4bich, D. Antibacterial natural \nproducts in medicinal chemistry - exodus or revival?  Angew. Chem. Int. Ed. 2006, 45, 5072\u20135129. \n31. Matos, M.J.; Delogu, G.; Podda, G.; Santana, L.; Uriarte, E. Regioselec tive synth esis of  \nbromo- substitu ted 3-arylcoumarins.  Synthesis 2010, 16, 2763\u20132766. \n32. Matos, M.J.; Vazquez-Rodriguez, S .; Borges, F.; Santana, L.; Uriarte, E. Synth esis of  \n3-arylcoumarins via Suzuki-cross-coupling reactions of 3-chlorocoumarin. Tetrahedron Lett. \n2011, 72, 1225\u20131227. \n33. Krishnaswamy, N.R.; Seshadri, T.R.; Sharma, B.R. Nitro derivatives of 3-phenylcoumarins.  \nInd. J. Chem. 1969, 7, 49\u201355.  \n34. Rao, D.V.; Sayig h, A.R.; Ulrich, H. Aminoph enyl alkoxy coumarins.  US 3676436 A, 11 Ju ly 19 72. \n35. Kremky, E. Chromatograph ic method for the separation and identific ation of some coumarin \nderivatives. Organika  1979, 159\u2013163. \n36. Piazzi, L.; Cavalli, A.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.;  Andrisano, V.; \nRecanatini, M.; Rampa, A. Extensive SAR and c ompu tational stu dies of  \n3-{4-[(benzylmet hylamino)methyl]phenyl}-6,7-dimethoxy-2 H-2-chromenone (AP2238)  \nDerivatives. J. Med. Chem.  2007, 50, 4250\u20134254. \n37. M cheminformati cs, Bratislava, Slovak  Republic. Available online: \nhttp://www.molinspiration.com /servic es/properties.html (accessed on 14 December 200 9). \nSample Availability : Samples of the compounds are available from t he authors. \n\u00a9 2013 by the authors; licensee MD PI, Basel, Switzerland.  This article is an open access article  \ndistributed under the terms and conditions of the Creative Commons Attribution license \n(http://creativecommons .org/licenses/by/3.0/). \n247New hydroxylated 3-arylcoumarins, synthesis and electrochemical study\nPatricia Janeiroa,b, Maria J. Matosb, Lourdes Santanab, Eugenio Uriarteb, Ana M. Oliveira-Bretta,\u21d1\naDepartamento de Qu\u00edmica, Faculdade de Ci\u00eancias e Tecnologia, Universidade de Coimbra, 3004-535 Coimbra, Portugal\nbDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain\narticle info\nArticle history:\nReceived 12 September 2012\nReceived in revised form 17 October 2012Accepted 18 October 2012\nAvailable online 27 October 2012\nKeywords:\nCoumarins\nGlassy carbon\nCyclic voltammetryDifferential pulse voltammetry\nSquare wave voltammetryabstract\nA selected series of new different substituted 3-arylcoumarins have been designed, synthesized, and\nevaluated their electrochemical redox mechanisms. The relevant structural information about coumarinswas considered in order to better understand the structure/electrochemical relationship. The in\ufb02uence of\nbromine, methyl or other hydroxyl groups in different positions of the coumarin scaffold, by cyclic,\ndifferential pulse and square wave voltammetry at a glassy carbon electrode at different pHs was inves-\ntigated. A comparative study of differently substituted 8-hydroxy-3-arylcoumarins was performed.\n/C2112012 Elsevier B.V. All rights reserved.\n1. Introduction\nIn recent years, phytochemical compounds have achieved great\ninterest due to their presence in bioactive dairy products. Fruits,\nvegetables, oil and wine have been studied as health protectors be-\ncause of the antioxidant potential of their phenolic compounds.\nRecent studies have shown that many dietary phenolic com-\npound constituents derived from plants are more effective\nantioxidants in vitro than vitamins E or C, and thus might contrib-\nute signi\ufb01cantly to the protective effects in vivo. These compounds\nare known to be the most common secondary metabolites in the\nvegetable kingdom [1\u20133] . Studies demonstrated the antioxidant\nproperties of phenolic compound constituents of plants, and their\nhelp in the identi\ufb01cation of the active constituents in beverages,\nvegetables and fruit that may help sustain antioxidant status and\nprotect against free radical damage [1].\nPhenolic compounds are a very wide group of compounds\nimportant in hormones, vitamins, and food antioxidants. Their\nmechanism of action as antioxidants seems to involve the ability\nof phenols to scavenge radicals by an electron transfer process in\nwhich phenol is converted into a phenoxyl radical. A simple\nmethod was developed for estimating \ufb02avonoid antioxidant\nactivity involving the quantitative correlation between lipid\nperoxidation inhibition and the half-wave potential ( E1/2)[4].\nMost phenolic compounds can be electrochemically oxidized\ndue to the hydroxyl groups attached to the aromatic rings. It is\nknown that pH is one of the most signi\ufb01cant factor determiningthe antioxidant activity of phenolic compounds. The dependence\nof the phenol derivatives oxidation potential, E1/2, on solution pH\nhas been studied thoroughly for different classes of polyphenolsusing a glassy carbon electrode [5\u201311] .\nThese parameters gave information not only for evaluating\nthe antioxidant potentialities of polyphenols but also for\nunderstanding their reaction mechanisms. Cyclic voltammetry\nhas also been used for the evaluation of the antioxidant capacity\nof several polyphenols and their mixtures [12].\nThe activity of phenols towards free radical protection is impor-\ntant due to their scavenging role, related to their ability to react\nwith radicals much more rapidly than with other organic\nsubstrates. Interest in the potential health bene\ufb01ts associated with\ndietary consumption of phenolic compounds has increased\nsigni\ufb01cantly in the last decades.\nA well know and extensively studied polyphenolic natural phy-\ntoalexin is resveratrol [13]. This 3,4\n0,5-trihydroxystilbene is pro-\nduced by some spermatophytes species, such as vines, in\nresponse to damage. Resveratrol has already been studied for itsantioxidant, anti-in\ufb02ammatory, cardio-protective (vasodilator\nand platelet anti-aggregator), anticancer and enzymatic inhibitory\nproperties, proving to be very ef\ufb01cient in a large group of in vitro ,\nex vivo and/or in vivo experiments [14,15] .\nThe fusion of a pyrone with a benzene ring gives rise to a class\nof heterocyclic compounds known as benzopyrones or coumarins[16]. Coumarins are a wide group of compounds present in\nremarkable amounts in the nature [17]. Representatives of this\ngroup occur in the vegetable kingdom, either in free or combined\nstate [18]. Due to their structural variability, they are an elite\nclass of compounds which occupy an important role in synthetic\n1572-6657/$ - see front matter /C2112012 Elsevier B.V. All rights reserved.\nhttp://dx.doi.org/10.1016/j.jelechem.2012.10.020\u21d1Corresponding author. Tel.: +351 239 835295.\nE-mail address: brett@ci.uc.pt (A.M. Oliveira-Brett).Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251\nContents lists available at SciVerse ScienceDirect\nJournal of Electroanalytical Chemistry\njournal homepage: www.elsevier.com/locate/jelechem\n249organic chemistry [19]. Coumarins have been attracting consider-\nable interest due to their numerous biological activities, usually\nassociated to low toxicity, depending on their substitution pattern\n[20]. There are many possible permutations offered by substitu-\ntion and conjugation, and this readily explains why so many syn-thetic analogues featuring coumarin structural motif are\ninvestigated due to their wide range of biological properties\n[21]. In the literature, coumarins are described as anticancer\n[22,23] , antioxidant [24,25] , antimicrobial [26], antiviral [27],\nvasorelaxant [28], anti-in\ufb02ammatory [29] and enzymatic inhibi-\ntors [30\u201333] . Indeed, some coumarins are now commercially\navailable as medicines.\nNatural products have a special ability to interact with more\nthan one target [29]. In medicinal chemistry, this represents a\nsigni\ufb01cant source of inspiration for the design and synthesis of\nproperly functionalized analogues with the aim of improving the\npharmacological pro\ufb01le. Limited data are available to demonstrate\nthe antioxidant activities of coumarins [34,35] .\nIn this study an ef\ufb01cient methodology of synthesis followed by\nthe investigation of the electrochemical mechanism of oxidation of\nseveral coumarin-resveratrol hybrids was undertaken. The electro-\nchemical mechanisms were studied for a wide range of solution\nconditions, using cyclic, differential and square wave voltammetry.\nThe information on these mechanisms was obtained at different\npH and is shown to play a crucial role in understanding its\nantioxidant activity.\n2. Experimental\n2.1. Materials and methods\nThe coumarin-resveratrol hybrid derivatives 1\u201310[33,36\u201338]\nwere ef\ufb01ciently synthesized according to the protocol outlined in\nScheme 1 . The general conditions and the compounds character-\nization are described below.\nPerkin condensation of differently substituted ortho -hydroxy-\nbenzaldehydes with the corresponding arylacetic acids, using\nN,N\n0-dicyclohexylcarbodiimide (DCC) as dehydrating agent, in\nDMSO, afforded the 3-phenylcoumarins 1\u20135. Compounds 6\u201310\nwere synthesized starting from the respective methoxy/ethoxy\nderivatives 1\u20135by hydrolysis reaction, using hydriodic acid 57%.\nMelting points were determined using a Reichert Ko\ufb02er ther-\nmopan or in capillary tubes on a B\u00fcchi 510 apparatus. IR spectra\nwere recorded on a Perkin-Elmer 1640FT spectrophotometer.1H\nand13C NMR spectra were recorded on a Bruker AMX spectrometer\nat 300 and 75.47 MHz, respectively, using TMS as internal standard(chemical shifts in dvalues, Jin Hz).\nMass spectra were obtained using a Hewlett Packard 5988A\nspectrometer. Elemental analyses were performed using a Per-\nkin-Elmer 240B microanalyser and were within \u00b10.4% of calculated\nvalues in all cases. Silica gel (Merck 60, 230\u201300 mesh) was used for\n\ufb02ash chromatography (FC).\nAnalytical thin layer chromatography (TLC) was performed on\nplates precoated with silica gel (Merck 60 F254, 0.25 mm).\nAll supporting electrolyte solutions were prepared using\nanalytical grade reagents and puri\ufb01ed water from a Millipore\nMilli-Q system (conductivity 60.1\nlSc m/C01),Table 1 . Experiments\nwere carried out at room temperature (25 \u00b1 1 /C176C) and in the\npresence of dissolved oxygen.\nThe pH measurements were carried out with a Crison micropH\n2001 pH-meter with an Ingold combined glass electrode. All\nexperiments were done at room temperature (25 \u00b1 1 /C176C) and mic-\nrovolumes were measured using EP-10 and EP-100 Plus MotorizedMicroliter Pippettes (Rainin Instrument Co. Inc., Woburn, USA).2.2. General procedure for the preparation of 3-phenylcoumarins (1\u2013\n5)\nTo a solution of the (7.34 mmol) hydroxybenzaldehyde and\n(9.18 mmol) phenylacetic acid in (15 mL) dimethyl sulfoxide,\n(11.46 mmol) N,N\n0-dicyclohexylcarbodiimide was added and the\nmixture was heated in an oil-bath at 110 /C176C for 24 h. Triturate ice\n(100 mL) and acetic acid (10 mL) were added to the reaction mix-\nture. After keeping it at room temperature for 2 h, the mixture was\nextracted with ether (3 /C225 mL). The organic layer was extracted\nwith sodium bicarbonate solution (50 mL, 5%) and then water(20 mL). The solvent was dried with sodium sulfate and evaporated\nunder vacuum. The residue was puri\ufb01ed by FC (hexane/ethyl ace-\ntate 9:1).\n2.2.1. 8-Ethoxy-3-phenylcoumarin (1 )\nYield 55%; mp 117\u2013118 /C176C.\n1H NMR (CDCl 3): 1.50 (t, 3H, \u2013CH 3,\nJ= 7.0), 4.21 (dd, 2H, \u2013CH 2,J= 14.0, 7.0), 7.09 (t, 2H, H-6, H-7,\nJ= 6.9), 7.21 (t, 1H, H-5, J= 7.8), 7.42\u20137.48 (m, 3H, H-30, H-40,H -\n50), 7.72 (dd, 2H, H-20, H-60,J= 7.7, 1.4), 7.79 (s, 1H, H-4).13C\nNMR (CDCl 3): 14.8, 65.0, 114.5, 119.3, 120.4, 124.3, 128.3, 128.4,\n128.5, 128.8, 134.8, 140.1, 143.4, 146.3, 160.2. MS m/z(%): 267\n([M+1]+, 16), 266 (M+, 83), 239 (16), 238 (20), 212 (14) 211 (20),\n181 (15), 153 (25). Anal. Calcd for C 17H14O3: C, 76.68; H, 5.30.\nFound: C, 76.66; H, 5.28.\n2.2.2. 8-Ethoxy-3-(40-methoxyphenyl)coumarin ( 2)\nYield 61%; mp 99\u2013100 /C176C.1H NMR (CDCl 3): 1.50 (t, 3H, \u2013CH 3,\nJ= 7.0), 3.84 (s, 3H, \u2013OCH 3), 4.19 (dd, 2H, \u2013CH 2,J= 14.0, 7.0),\n6.84\u20137.26 (m, 5H, H-30, H-50, H-5, H-6, H-7), 7.69 (t, 2H, H-20,H -\n60,J= 7.7), 7.73 (s, 1H, H-4).13C NMR (CDCl 3): 14.8, 55.4, 64.8,\n113.8, 114.0, 119.0, 120.5, 124.2, 127.0, 127.8, 129.7, 129.8,\n138.6, 138.7, 146.2, 160.0. MS m/z(%): 297 ([M+1]+, 35), 296 (M+,\n100), 268 (54), 240 (47) 225 (45), 197 (13), 152 (11), 139 (15). Anal.Calcd for C\n18H16O4: C, 72.96; H, 5.44. Found: C, 72.91; H, 5.39.\n2.2.3. 8-Ethoxy-3-(40-methylphenyl)coumarin ( 3)\nYield 48%; mp: 109\u2013110 /C176C.1H NMR (CDCl 3): 1.51 (td, 3H, \u2013CH 3,\nJ= 7.0, J= 1.8), 2.39 (s, 3H, \u2013CH 3), 4.20 (dd, 2H, \u2013CH 2,J= 7.0, J= 1.8),\n7.06\u20137.10 (m, 2H, H-5, H-6), 7.18 (dd, 1H, H-7, J= 8.0, 1.9), 7.26 (d,\n2H, H-30, H-50,J= 1.6), 7.61 (dd, 2H, H-20, H-60,J= 8.1, 1.8), 7.74 (d,\n1H, H-4, J= 1.9).13C NMR (CDCl 3): 14.81, 21.30, 64.96, 114.37,\n119.24, 120.51, 124.26, 128.34, 128.39, 129.15, 131.88, 138.83,\n139.39, 143.31, 146.32, 160.26. MS m/z(%): 281 ([M+1]+, 16), 280\n(M+, 80), 252 (78), 225 (16), 224 (56), 223 (20), 165 (30), 142\n(45), 115 (17). Anal. Calcd for C 18H16O3: C, 77.12; H, 5.75. Found:\nC, 77.07; H, 5.80.\n2.2.4. 6-Bromo-8-methoxy-3-(40-methoxyphenyl)coumarin (4 )\nYield 53%; mp 144\u2013145 /C176C.1H NMR (CDCl 3): 3.85 (s, 3H, \u2013\nOCH 3), 3.96 (s, 3H, \u2013OCH 3), 6.93\u20136.96 (m, 2H, H-30, H-50), 7.12 (d,\n1H, H-7, J= 1.8), 7.23 (d, 1H, H-5, J= 2.0), 7.63\u20137.67 (m, 2H, H-20,\nH-60), 7.69 (s, 1H, H-4).13C NMR (CDCl 3): 55.7, 56.8, 114.2, 116.2,\n116.8, 121.5, 126.8, 129.4, 130.2, 130.8, 137.3, 142.2, 147.8,\n159.8, 160.6. MS m/z(%): 363 ([M+1]+, 19), 362 (M+, 100), 361\n(19), 360 (59), 334 (24), 332 (23), 319 (33), 317 (34), 291 (11),289 (11), 182 (18), 167 (17), 139 (21). Anal. Calcd for C\n17H13BrO 4:\nC, 56.53; H, 3.63. Found: C, 56.55; H, 3.68.\n2.2.5. 6-Bromo-8-methoxy-3-(40-methylphenyl)coumarin (5 )\nYield 56%; mp 164\u2013165 /C176C.1H NMR (CDCl 3): 2.40 (s, 3H, \u2013CH 3),\n3.98 (s, 3H, \u2013OCH 3), 7.15 (s, 1H, H-7), 7.22\u20137.28 (m, 3H, H-30, H-50,\nH-5), 7.61 (d, 2H, H-20, H-60,J= 8.2), 7.67 (s, 1H, H-4).13CN M R\n(CDCl 3): 21.3, 56.5, 116.0, 116.1, 116.6, 121.3, 128.4, 129.2, 129.6,\n131.3, 137.6, 137.8, 139.3, 147.6, 159.4. MS m/z(%): 347 (25),\n346 (98), 345 ([M+1]+, 26), 344 (M+, 100), 318 (47), 316 (46), 275244 P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251\n250(18), 273 (18), 208 (11), 166 (52), 165 (43), 115 (15), 83 (14). Anal.\nCalcd for C 17H13BrO 3: C, 59.15; H, 3.80. Found: C, 59.11; H, 3.87.\n2.3. General procedure for the preparation of hydroxy-3-phenylcoumarins (6\u201310)\nTo a solution of (0.50 mmol) substituted methoxy/ethoxy-3-\nphenylcoumarin in (5 mL) acetic acid and (5 mL) acetic anhydride\nat 0/C176C, (10 mL) hydriodic acid 57% was added dropwise. The mix-\nture was stirred, under re\ufb02ux, for 3 h. The solvent was evaporatedunder vacuum and the dry residue was puri\ufb01ed by CH\n3CN\ncrystallization.\n2.3.1. 8-Hydroxy-3-phenylcoumarin (6 )\nYield 64%; mp 199\u2013200 /C176C[33].\n2.3.2. 8-Hydroxy-3-(40-hydroxyphenyl)coumarin ( 7)\nYield 41%; mp 237\u2013238 /C176C[33].2.3.3. 8-Hydroxy-3-(40-methylphenyl)coumarin ( 8)\nYield 56%; mp 199\u2013200 /C176C.1H NMR (CDCl 3): 2.33 (s, 3H, \u2013CH 3),\n7.06 (dd, 2H, H-5, H-6, J= 6.8, 2.9), 7.10\u20137.21 (m, 3H, H-30, H-50,H -\n7), 7.25 (d, 2H, H-20, H-60,J= 8.0), 8.15 (s, 1H, H-4), 10.22 (s, 1H, \u2013\nOH).13C NMR (CDCl 3): 20.8, 117.8, 118.5, 120.4, 124.5, 126.6,\n128.3, 128.8, 131.8, 138.0, 140.3, 141.5, 144.2, 159.7. MS m/z(%):\n253 ([M+1]+, 38), 252 (M+, 100), 225 (26), 223 (23), 165 (15), 153\n(12), 152 (25), 115 (11). Anal. Calcd for C 16H12O3: C, 76.08; H,\n4.79. Found: C, 76.02; H, 4.83.\n2.3.4. 6-Bromo-8-hydroxy-3-(40-hydroxyphenyl)coumarin ( 9)\nYield 56%; mp 249\u2013259 /C176C.1H NMR (CDCl 3): 6.83 (d, 2H, H-30,\nH-50,J= 8.8), 7.14 (d, 1H, H-7, J= 1.9), 7.36 (d, 1H, H-5, J= 2.0),\n7.56 (d, 2H, H-20, H-60,J= 8.5), 8.00 (s, 1H, H-4).13C NMR (CDCl 3):\n115.6, 116.0, 119.9, 120.6, 122.5, 125.4, 128.2, 130.4, 138.0, 141.2,\n146.0, 158.6, 159.8; MS m/z(%): 335 (35), 334 (99), 333 ([M+1]+,\n45), 332 (M+, 100), 307 (31), 305 (35), 225 (26), 197 (29), 169\n(35), 168 (46), 153 (24), 141 (21), 140 (16), 139 (51), 118 (17),\n115 (28), 84 (18), 84 (46). Anal. Calcd for C 15H9BrO 4: C, 54.08; H,\n2.72. Found: C, 54.05; H, 2.69.\n2.3.5. 6-Bromo-8-hydroxy-3-(40-methylphenyl)coumarin (10 )\nYield 43%; mp 192\u2013193 /C176C.1H NMR (CDCl 3): 2.35 (s, 3H, \u2013CH 3),\n7.19 (d, 1H, H-7, J= 2.3), 7.27 (d, 2H, H-30, H-50,J= 8.0), 7.40 (d, 1H,\nH-5, J= 2.2), 7.61 (d, 2H, H-20, H-60,J= 8.1), 8.10 (s, 1H, H-4), 10.80\n(s, 1H, \u2013OH).13C NMR (CDCl 3): 20.9, 115.52, 119.8, 120.3, 121.8,\n127.8, 128.4, 128.8, 131.5, 138.4, 139.0, 141.0, 145.6, 159.2. MS\nm/z(%): 333 (17), 332 (98), 331 ([M+1]+, 18), 330 (M+, 100), 305\n(13), 304 (77), 303 (22), 302 (79), 223 (12), 166 (14), 165 (30),Scheme 1. Synthesis experimental conditions: (i) DCC, DMSO, 110 /C176C, 24 h; (ii) HI, AcOH, Ac 2O, re\ufb02ux, 3 h.\nTable 1\nSupporting electrolytes.\npH Composition\n4.5 HAcO + NaAcO\n7.0 NaH 2PO4+N a 2HPO 4\n8.5 NaH 2PO4+N a 2HPO 4P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251 245\n251152 (30), 115 (14). Anal. Calcd for C 16H11BrO 3: C, 58.03; H, 3.35.\nFound: C, 58.06; H, 3.37.\n2.4. Voltammetric measurements\nVoltammetric experiments were carried out using an Autolab\nPGstat 10 running with GPES 4.9 software, Eco-Chemie, Utrecht,\nThe Netherlands. Measurements were carried out using a three-\nelectrode system in a 0.5 mL one-compartment electrochemical\ncell (Cypress System Inc., USA). Glassy carbon electrode (GCE,\nd= 1.5 mm) was the working electrode, Pt wire the counter elec-\ntrode and the Ag/AgCl (3 M KCl) reference electrode. The experi-\nmental conditions for cyclic voltammetry were scan rate\n50 mV s/C01. For differential pulse (DP) voltammetry were: pulse\namplitude 50 mV, pulse width 70 ms and scan rate 5 mV s/C01. For\nsquare wave (SW) voltammetry were: pulse of 50 mV, frequency\nof 10 Hz and a potential increment of 2 mV, corresponding to an\neffective scan rate of 20 mV s/C01.\nThe GCE was polished using diamond particles of 3 lm (Kemet,\nUK) before each electrochemical experiment. After polishing, it\nwas rinsed thoroughly with Milli-Q water. Following this\nmechanical treatment, the GCE was placed in buffer supporting\nelectrolyte and voltammograms were recorded until a steady state\nbaseline voltammograms were obtained. This procedure ensured\nvery reproducible experimental results.\n3. Results\nRelevant aspects concerning the electrochemistry of the\nhydroxylated 3-arylcoumarins were investigated using cyclic vol-\ntammetry (CV), differential pulse (DP) voltammetry and square\nwave (SW) voltammetry.\nThe effect on the oxidation potential caused by the presence of a\nhalogen on the coumarin structure was investigated. Halogens,substituents that are more electronegative than carbon, will induc-\ntively pull the electron density out of the ring. Due to the lone elec-\ntron pairs this compounds are able to donate electronic density\nstabilizing the reaction intermediates by resonance in the ortho\nand para positions.\nThe effect of an alkyl group, in this speci\ufb01c case a methyl group,\nin the oxidation potential of a compound was also studied. The al-\nkyl groups are electron donating, activating the ring enabling faster\nreaction rates.\n3.1. Cyclic voltammetry\nThe compound 6was investigated by CV in pH 7.0, Fig. 1 ,\nshowing on the \ufb01rst scan oxidation peak P\n1,a t Ep1= +0.65 V,\ncorresponding with an irreversible reaction. The value of\n|Ep/C0Ep/2| = +50 mV indicates that one electron is involved in the\n\ufb01rst oxidation process [39]. A reduction peak P 2c, on the reverse\nscan, appears at Ep2c= +0.05 V corresponding to the reduction of\nthe oxidation products formed during the oxidation at peak P 1.\nIn the second scan at lower potentials a new oxidation peak P 2a,\natEp2a= +0.08 V, con\ufb01rmed the reversibility of peak P 2, that occurs\nwith the transfer of two electrons [40]. The same behavior was\nfound for compounds 8and10, both with only one oxidizable hy-\ndroxyl group on their structure.\nCVs of compound 8showed an identical behavior to compound\n6. That means that the presence of a weak electron donating sub-\nstituent, in a different ring where the hydroxyl group is, does not\nin\ufb02uence the oxidation potential. The strong adsorption of the oxi-\ndation products, which blocked the electrode surface, was also ob-\nserved for compounds 6,8and10, and oxidation peak P 1current\nalways decreased in the second scan.In the case of compound 10,Fig. 2 , the oxidation peak P 1ap-\npears at a slightly higher potential, at Ep1= +0.71 V. This can be\ndue to the presence of bromine, an electron withdrawing substitu-\nent which causes an acidity increment on the phenol moiety. The\noxidation process corresponding to the peak P 1is irreversible for\ncompounds 6,8and10and occurs with the transfer of one elec-\ntron. It has been proved in this work that the oxidation of the hy-\ndroxyl group at the position C8 occurs irreversibly and it is formed\nan oxidation product which is oxidized at a lower potential in a\nreversible process.\nThe compounds 6,8and10oxidation products are electroactive\nand reversibly oxidized at peak P 2a\u2013P2cwith the transfer of two\nelectrons. The compound 10peak P 1oxidation product, occurs at\nreversible peak P 2a\u2013P2c,Ep2a= +0.08 V and Ep2c= +0.05 V, and pre-\nsented a very similar behavior to compound 6,Fig. 1 , showing that\nbromine does not interfere on the redox reaction of compound 10\noxidation product, with the oxidisable hydroxyl group and the-0,2 0,0 0,2 0,4 0,6 0,8 1,0 1,20.2 \u03bcA\nP2cP2aP1\nE / V (vs. Ag/AgCl)\nFig. 1. CVs in 0.5 mM compound 6, in 0.2 M phosphate buffer pH = 7.0: (\u2014) \ufb01rst,\n(- - -) second and ( /C15/C15/C15) third scans. Scan rate 50 mV s/C01.\n-0,2 0,0 0,2 0,4 0,6 0,8 1,0 1,2P2cP2aP1\n0.2 \u03bcA\nE / V (vs. Ag/AgCl)\nFig. 2. CVs in 0.5 mM compound 10, in 0.2 M phosphate buffer pH = 7.0: (\u2014) \ufb01rst,\n(- - -) second and ( /C15/C15/C15) third scans. Scan rate 50 mV s/C01.246 P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251\n252halogen in the meta position in the same ring. It can be remarked\nthat compound 10peak P 2current was lower than compound 6\npeak P 2current, which could indicate that the different substitu-\nents do not affect the peak P 1current, but affect the peak P 2\ncurrent.\nThe presence of electron withdrawing substituents, that deacti-\nvate the ring, causes an increase in acidity of the phenol. This effect\ninvolves charge, when the substituents are situated in the ortho-\nand para- positions, in respect to the hydroxyl group, due to conju-\ngation of these positions with the group. This explains that the oxi-\ndation potential of compound 10peak P 1occurs at a slightly higher\noxidation potential than the compound 6peak P 1that presents a\nnot so acidic hydroxyl group. The CV study was done in the pH\nrange between 4.5 and 8.5. The oxidation process is complex and\npH-dependent, indicating that the oxidation of all compounds oc-curs associated with a proton transfer.\n3.2. Differential pulse voltammetry\nTo clarify the mechanism of oxidation of this series of com-\npounds DP voltammetry was used. Successive DP voltammograms\nin 0.5 mM compound 8, in pH 4.5, acetate buffer showed the occur-\nrence of one oxidation peak P\nl,a t Ep1= +0.80 V, and after the\nsecond scan peak P 2,a t Ep2= +0.20 V, which corresponds to the\noxidation of the peak P loxidation product, Fig. 3 . The peak P lwidth\nat half height was W1/2= 100 mV indicating an oxidation process\nwith one electron involved [39].\nThe peak P 1current decreased and peak P 2current increased\nwith increasing number of scans. This con\ufb01rms that a strong\nadsorption of the oxidation product of compound 8on the elec-\ntrode blocks the electrode surface.\nThe same DP voltammetric behavior found for compound 8was\nobserved for compounds 6and 10,Fig. 4 , but the compound 10\npeak P 1oxidation was for a higher potential than at compounds\n6and8, while compound 10peak P 2had the same peak potential\nas in compounds 6and8, but compound 10peak P 2current was\nlower.\nThe DP voltammogram in compound 7, that has two hydroxyl\ngroups, presented two oxidation peaks due to two oxidizable hy-\ndroxyl groups, Fig. 5 . In the \ufb01rst DP voltammogram the oxidation\npeak P lwidth at half height was W1/2/C24200 mV corresponding to\ntwo oxidation peaks overlapped, that was con\ufb01rmed after the\nbaseline was subtracted in the DP voltammogram. The peaks over-\nlap is due to the two similar hydroxyl groups in the compound 7,\nthe hydroxyl groups in positions C40and C8 of the 3-arylcoumarin,\nand the oxidation occurs at similar potentials, as they are both phe-\nnol groups.\nThe \ufb01rst scan DP voltammogram in compound 7showed also\nanother oxidation peak, peak P 2,a tEp2= +0.17 V, at a lower poten-\ntial, corresponding to the oxidation of a catechol group. Although\npeak P 2appears already on the \ufb01rst scan, peak P 2is due to the oxi-\ndation product of peak P 1. This denotes that compound 7was oxi-\ndized during its synthesis before the electrochemical experiences.\nThe peak P 2width at half height was W1/2/C2460 mV indicating that\ntwo electron are involved in the oxidation process, con\ufb01rming thatis a catechol moiety oxidation product of peak P\n1[39,40] .\nOn the second scan, the oxidation product formed after P 1oxi-\ndation, peak P 3,a tEp3= +0.05 V, occurs, as observed by CV, and is\ndue to the oxidation of the hydroxyl group at position C8 in theP\n1oxidation product. This is con\ufb01rmed by the appearance of peak\nP3only in the second scan and also at lower oxidation potential.\nThe peak P 3width at half height was W1/2/C2460 mV indicates that\ntwo electrons are involved on the oxidation of the hydroxyl group\nat position C8 oxidation product of compound 7. The strong\nadsorption of the oxidation products, which blocked the electrode0,0 0,2 0,4 0,6 0,8 1,0 1,2P2\nP1\n0.5 \u03bcA\nE / V (vs. Ag/AgCl)\nFig. 3. Successive DP voltammograms (1 ?5) in 0.5 mM compound 8, in 0.2 M\nacetate buffer pH = 4.5. Scan rate 5 mV s/C01.0,0 0,2 0,4 0,6 0,8 1,0 1,250 nAP2\nP1\nE / V (vs. Ag/AgCl)\nFig. 4. DP voltammograms in 0.5 mM compound 10, in 0.2 M acetate buffer\npH = 4.5: (\u2014) \ufb01rst, ( /C15/C15/C15) second and (- - -) third scans. Scan rate 5 mV s/C01.\n-0,2 0,0 0,2 0,4 0,6 0,8 1,0 1,2P3\nP2P1\n0.2 \u03bcA\nE / V (vs. Ag/AgCl)\nFig. 5. DP voltammograms in 0.5 mM compound 7, in 0.2 M phosphate buffer\npH = 7.0: (\u2014) \ufb01rst and ( /C15/C15/C15) second scans. Scan rate 5 mV s/C01.P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251 247\n253surface, enabled to observe more easily on the second scan the\noverlap that occurs in P 1corresponding to a transfer of one elec-\ntron in each peak.\nThe DP voltammetric study was undertaken for compounds 6,8\nand10, for a wide pH range and the potentials of peaks P 1,P2and\nP3were shifted to more negative values with increasing pH. The\ndependence of Epvs. pH was linear the whole pH range studied\nand followed the relationships presented in Table 1 . The Epvs.\npH, relationship enables the determination of the number of pro-\ntons involved in the oxidation process. In all cases the oxidation\npotential was pH-dependent following a linear relationship with\nthe slope of /C00.059 V, which corresponds to a electron transfer\nreaction involving the same number of electrons and protons.\nFrom Table 2 , the transfer of one electron and one proton occurs\nfor peak P 1, attributed to the hydroxyl group correspondent to a\nphenol group, whereas, oxidation product peaks P 2and P 3, both oc-\ncur with the transfer of two electrons and two protons.\nCompound 9shows a DP voltammogram very similar to that of\ncompound 7,Fig. 6 . The oxidation peak P 1observed is broad, indi-\ncating the presence of two hydroxyl groups that oxidize at similar\npotential. It also appears in the \ufb01rst scan a peak P 2at lower poten-\ntial. The peak P 3, a product of oxidation of P 1, appears in the second\nscan. A great decrease in peak P 1current on the second scan\nindicates a strong adsorption of oxidation products formed onthe electrode surface. The halogen group attached to the aromatic\nring, with the hydroxyl group, has an electron withdrawing effect\nthat makes the ring poorer in electron density. This causes a\ndeactivating effect and a decreasing in the reactivity of the ring.\n3.3. Square wave voltammetry\nThe advantages of SW voltammetry are greater speed of analy-\nsis, lower consumption of electro-active species in relation to DP\nvoltammetry, and reduced problems with blocking of the electrode\nsurface. A great advantage of the square-wave method is the pos-\nsibility to see during one scan if the electron transfer reaction is\nreversible or not. Since the current is sampled in both the positive\nand the negative-going pulses, peaks corresponding to the oxida-\ntion or reduction of the electroactive species at the electrode sur-\nface are obtained in the same experiment.\nThe SW voltammetry conditions chosen led to well-de\ufb01ned SW\nvoltammograms, and showed similar results to CV and DP voltam-\nmetry, i.e. the same oxidation peaks and oxidation products peaks,\na strong adsorption on the second scan and the decrease of the oxi-\ndation potential with increasing pH.\nTherefore, the irreversibility of P\n1and the reversibility of their\noxidation product P 2, in compounds 6,8and 10, was con\ufb01rmed\nby SW voltammetry, Fig. 7 . Compounds 7and9with two hydroxyl\ngroups in their structure, presented the irreversible peak P 1with\noverlapping, at Ep1= +0.85 V, and two reversible peaks, peak P 2,\natEp2= +0.39 V, due to oxidation during synthesis, and peak P 3,\natEp3= +0.21 V, Fig. 8 , con\ufb01rmed in the second scan after reversing\nthe potential scan just before peak P 1and obtaining P 3.4. Discussion\nAll described 3-arylcoumarins (compounds 1\u201310 ) were ef\ufb01-\nciently synthesized, characterized and evaluated for their antioxi-\ndant functionality. Relevant aspects concerning the\nelectrochemistry (compounds 6\u201310 ) of this selected series of syn-\nthesised coumarin-resveratrol hybrids were obtained. It was foundthat the different substituents have only a slightly effect upon\nTable 2\nDP voltammetric data for compounds 6\u201310.\nPeak P 1 Peak P 2 Peak P 3\nEpvs. pH e/C0H+Epvs. pH e/C0H+Epvs. pH e/C0H+\n6 Ep= 0.98\u20130.057 pH pH 1 1 Ep= 0.47\u20130.056 pH pH 2 2 \u2013 \u2013 \u2013\n7 Ep= 0.96\u20130.061 pH 1 1 Ep= 0.61\u20130.059 pH 2 2 Ep= 0.48\u20130.059 pH 2 2\n8 Ep= 1.02\u20130.059 pH 1 1 Ep= 0.46\u20130.060 pH 2 2 \u2013 \u2013 \u2013\n9 Ep= 1.03\u20130.060 pH 1 1 Ep= 0.62\u20130.058 pH 2 2 Ep= 0.46\u20130.059 pH 2 2\n10 Ep= 1.08\u20130.060 pH 1 1 Ep= 0.43\u20130.057 pH 2 2 \u2013 \u2013 \u20130,0 0,2 0,4 0,6 0,8 1,0 1,20.1 \u03bcAP3\nP2P1\nE / V (vs. Ag/AgCl)\nFig. 6. DP voltammograms in 0.5 mM compound 9, in 0.1 M phosphate buffer\npH = 7.0: (\u2014) \ufb01rst, (- - -) second and ( /C15/C15/C15) third scans. Scan rate 5 mV s/C01.\n-0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2P1P2\nIbIfIt\n1 \u03bcA\nE / V (vs. Ag/AgCl)\nFig. 7. Second SW voltammogram in 0.5 mM of compound 6, in pH = 8.5, third scan.\nIt\u2013 total current, If\u2013 direct current and Ib\u2013 forward current; f= 25 Hz, DE= 2 mV,\nmeff=5 0m Vs/C01.248 P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251\n254reactivity of the selected coumarins. Also differences in the electro-\nactive substituents on similar structures lead to characteristic dif-\nferences in their voltammetric behavior.\nConsidering that the electrochemical behavior of these com-\npounds depends on their structural characteristics, useful informa-\ntion on their antioxidant functionality can be drawn from the CV,\nDP and SW voltammograms for each hydroxylized compound per-\nformed at different pH values.\nAll synthetized compounds possess in common a hydroxyl\ngroup on position C8 and differ by the presence or absence of bro-\nmine, an electron withdrawing atom, in the benzene ring and the\npresence or absence of a hydroxyl strong electron donating group\nor a methyl weak electron donating group in the benzene ring\nlinked to the position C3 of the coumarin structure. Electrochemi-\ncal studies of this series of compounds allowed to investigate thein\ufb02uence on the oxidation potential of hydroxycoumarins ofdifferent substituents.\nThe results indicated that compounds 6,8and10oxidation oc-\ncurs in one step whereas compounds 7and9oxidation occurs in\ntwo consecutive steps in for 4.5 < pH < 8.5. The irreversibility of\nall these steps was established by CV and SW voltammetry. The\ninvolvement of one electron and one proton in the oxidation steps\nwas evaluated from the peak width at half height of the DP voltam-\nmograms and the slope of E\npvs. pH plot for each compound is in\nTable 1 . The oxidation products oxidation peaks of each compound\ninvolved always two electrons and two protons.\nCompounds 9and10with bromine at position C6 on the cou-\nmarin moiety have the highest oxidation potentials on the series\nstudied. This is due to the presence of an electron withdrawing\nsubstituent which causes an acidity increment on the phenol.\nTherefore, the reactivity of these compounds is different from the\nothers. An oxidation mechanism was proposed for compounds 6,\n8and10,Scheme 2 .\nCyclic voltammograms of compound 8showed an identical\nbehavior to compound 6. That means that the presence of a methyl\ngroup weak electron donating substituent, in a different ring from\nthe hydroxyl group, does not in\ufb02uence the reactivity of the com-\npounds and the oxidation potential.\nCompounds 7and9besides the hydroxyl group on the position\nC8 have another hydroxyl group in position C40, and this two oxi-\ndations potentials are very near and their peaks overlap. The oxida-tion mechanism occurs in two consecutive irreversible reactions\nwith the transfer of an electron and a proton for the overlapped\npeaks in P\n1.\nThe oxidation products formed after peak P 1,identi\ufb01ed as peak\nP3, corresponds to the oxidation of the hydroxyl group on position\nC8, present in compounds 6,8and 10. The oxidation products\nformed after peak P 1,identi\ufb01ed as peak P 2, had a reversible oxida-\ntion process with transfer of two protons and two electrons with\noxidation potential values with similar characteristics to a catechol\ngroup, corresponding to the oxidation of the hydroxyl group on po-\nsition C8, present in compounds 7and9. An oxidation mechanism\nwas proposed for compounds 7and9,Scheme 3 .0.0 0.2 0.4 0.6 0.8 1.0 1.2IbIfItP2\nP1'P1P3\n1 \u03bcA\nFig. 8. Second SW voltammogram in 0.5 mM compound 9, in 0.1 M acetate pH = 4.5\nbuffer, fourth scan. It\u2013 total current, If\u2013 forward current and Ib\u2013 backward current;\nf= 25 Hz, DE= 2 mV, meff=5 0m Vs/C01.\nScheme 2. Proposed oxidation mechanism for compounds 6,8and10.P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251 249\n2555. Conclusions\nThe synthesis of ten new 3-arylcoumarins was carried out in an\nef\ufb01cient, direct and versatile way using a Perkin reaction as key\nstep. The ether derivatives had been hydroxylated, with good\nyields, giving the corresponding hydroxyl derivatives that were\nstudied. All the new 3-arylcoumarins were electrochemically oxi-\ndized. The electrochemical data showed that all these novel cou-\nmarins can be oxidized at relatively low potentials, and the\nelectrochemical results demonstrated that using electrochemical\nmethods the electron transfer mechanisms of this new series of\n3-arylcoumarins can be clari\ufb01ed. In compounds 6,8and10, with\nonly one oxidizable hydroxyl group on their molecule, the electro-chemical behavior showed that one electron is involved in the oxi-\ndation process that occurs in one step. In compounds 7and9the\noxidation occurred in two consecutive steps. It was demonstrated\nthan it was easier to oxidize the hydroxyl group at position C8 of\nthe coumarin structure than the hydroxyl group at position C4\n0.\nAs expected, the radical phenoxyl in C40is more stable. The exper-\niments showed an irreversible reaction corresponding to the oxida-\ntion of the hydroxyl groups at positions C8 and C40. This behavior,\nwhich is related with their molecular structure, clearly showed\ntheir good antioxidant properties.\nAcknowledgements\nFinancial support from Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia\n(FCT), Ph.D. Grants SFRH/BD/28333/2006 (P. Janeiro) and SFRH/\nBD/61262/2009 (M.J. Matos), project, PTDC/QUI-QUI/098562/\n2008, POPH and POFC-QREN (co-\ufb01nanced by the European Com-\nmunity Funds FSE e FEDER/COMPETE), CEMUC-R (Research Unit\n285), Xunta de Galicia (PGIDIT09CSA030203PR) and Ministerio de\nSanidad y Consumo of Spain (FIS PS09/00501), are gratefully\nacknowledged.\nReferences\n[1] C.A. Rice-Evans, N.J. Miller, G. Paganga, Trends Plant Sci. 2 (1997) 152.\n[2] M. Naczk, F. Shahidi, J. Pharm. Biomed. Anal. 41 (2006) 1523.\n[3] D. Ryan, M. Antolovich, P. Prenzler, K. Robards, S. Lavee, Scientia Horticulturae\n92 (2002) 147.[4] S. Van Acker, D.J. Van der Berg, M.N.J.L. Tromp, D.H. Grif\ufb01oen, W.P. Van\nBennekom, W.J.F. Van der Vijgh, A. Bast, Free Radical Biol. Med. 20 (1996) 331.\n[5] P. Janeiro, A.M. Oliveira-Brett, Anal. Chim. Acta 518 (2004) 109.\n[6] P. Janeiro, A.M. Oliveira-Brett, Electroanalysis 17 (2005) 733.\n[7] P. Janeiro, A.M. Oliveira-Brett, Electroanalysis 19 (2007) 1779.\n[8] P. Janeiro, O. Corduneanu, A.M. Oliveira-Brett, Electroanalysis 17 (2005) 1059.\n[9] M.E. Ghica, A.M. Oliveira-Brett, Electroanalysis 17 (2005) 313.\n[10] P. Janeiro, I. Novak, M. Seruga, A.M. Oliveira-Brett, Anal. Lett. 17 (2007) 3309.\n[11] A.M. Oliveira-Brett, M.E. Ghica, Electroanalysis 15 (2003) 1745.\n[12] H. Hotta, H. Sakamoto, S. Nagano, T. Osakai, Y. Tsujino, Biochim. Biophys. Acta\n1526 (2001) 159.\n[13] L. Fr\u00e9mont, Life Sci. 66 (2000) 663.\n[14] F. Orallo, in: B.B. Aggarwal, S. Shishodia (Eds.), Resveratrol in Health and\nDisease, CRC Press, USA, 2005.\n[15] F. Orallo, Curr. Med. Chem. 15 (2008) 1887.\n[16] F. Borges, F. Roleira, N. Milhazes, E. Uriarte, L. Santana, Front. Med. Chem. 4\n(2009) 23.\n[17] J.R.S. Hoult, M. Pay\u00e1, Gen. Pharmacol. 27 (1996) 713.[18] C. Kontogiorgis, D.J. Hadjipavlou-Litina, Enzyme Inhib. Med. Chem. 18 (2003)\n63.\n[19] M.J. Matos, C. Ter\u00e1n, Y. P\u00e9rez-Castillo, E. Uriarte, L. Santana, D. Vi\u00f1a, J. Med.\nChem. 54 (2011) 7127.\n[20] L. Kabeya, A. Marchi, A. Kanashiro, N. Lopes, C. Silva, M. Pupo, Y. Lucisano-\nValim, Bioorg. Med. Chem. 15 (2007) 1516.\n[21] A. Chilin, R. Battistutta, A. Bortolato, G. Cozza, S. Zanatta, G. Poletto, M.\nMazzorana, G. Zagotto, E. Uriarte, A. Guiotto, L. Pinna, F. Meggio, S. Moro, J.\nMed. Chem. 51 (2008) 752.\n[22] F. Belluti, G. Fontana, L. Bo, N. Carenini, C. Giommarelli, F. Zunino, Bioorg. Med.\nChem. 18 (2010) 3543.\n[23] M.E. Riveiro, A. Moglioni, R. Vazquez, N. Gomez, G. Facorro, L. Piehl, E.R. de\nCelis, C. Shayo, C. Davio, Bioorg. Med. Chem. 16 (2008) 2665.\n[24] C.A. Kontogiorgios, K. Savvoglou, D.J. Hadjipavlou-Litina, J. Enzyme Inhib. Med.\nChem. 21 (2006) 21.\n[25] M. Roussaki, C.A. Kontogiorgis, D.J. Hadjipavlou-Litina, S. Hamilakis, Bioorg.\nMed. Chem. Lett. 20 (2010) 3889.\n[26] D.A. Ostrov, J.A. Hern\u00e1ndez Prada, P.E. Corsino, K.A. Finton, N. Le, T.C. Rowe,\nAntimicrob. Agents Chemother. 51 (2007) 3688.\n[27] I. Manolov, S. Raleva, P. Genova, A. Savov, L. Froloshka, D. Dundarova, R.\nArgirova, Bioinorg. Chem. Appl. 2006 (2006) 71938.\n[28] S. Vilar, E. Quezada, L. Santana, E. Uriarte, M. Yanez, N. Fraiz, C. Alcaide, E. Cano,\nF. Orallo, Bioorg. Med. Chem. Lett. 16 (2006) 257.\n[29] K.C. Fylaktakidou, D.J. Hadjipavlou-Litina, K.E. Litinas, D.N. Nicolaides, Curr.\nPharm. Des. 10 (2004) 3813.\n[30] M.J. Matos, D. Vi\u00f1a, E. Quezada, C. Picciau, G. Delogu, F. Orallo, L. Santana, E.\nUriarte, Bioorg. Med. Chem. Lett. 19 (2009) 3268.\n[31] D. Vi\u00f1a, M.J. Matos, G. Ferino, E. Cadoni, R. Laguna, F. Borges, E. Uriarte, L.\nSantana, Chem. Med. Chem. 7 (2012) 464.\n[32] D. Vi\u00f1a, M.J. Matos, M. Y\u00e1\u00f1ez, L. Santana, E. Uriarte, Med. Chem. Comm. 3\n(2012) 213.\n[33] M.J. Matos, L. Santana, E. Uriarte, G. Delogu, M. Corda, M.B. Fadda, B. Era, A.\nFais, Bioorg. Med. Chem. Lett. 21 (2011) 3342.\n[34] B. Fernandez-Puntero, I. Barroso, I. Iglesias, J. Benedi, A. Villar, Biol. Pharm. Bull.\n24 (2001) 777.Scheme 3. Proposed oxidation mechanism for compounds 7and9.250 P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251\n256[35] I.A. Vladimirov, E.A. Parfenov, O.M. Epanchintseva, L.D. Smirnov, Bull. Exp. Biol.\nMed. 112 (1991) 472.\n[36] M.J. Matos, D. Vi\u00f1a, P. Janeiro, F. Borges, L. Santana, E. Uriarte, Bioorg. Med.\nChem. Lett. 20 (2010) 5157.\n[37] M.J. Matos, G. Delogu, G. Podda, L. Santana, E. Uriarte, Synthesis 16 (2010)\n2763.[38] M.J. Matos, S. Vazquez-Rodriguez, F. Borges, L. Santana, E. Uriarte, Tetrahedron\nLett. 52 (2011) 1225.\n[39] C.-M.A. Brett, A.M. Oliveira-Brett, Cyclic voltammetry and linear sweep\ntechniques, in: Electrochemistry. Principles, Methods and Applications,\nOxford University Press, UK, 1993, pp. 174\u2013198.\n[40] T.A. Enache, A.M. Oliveira-Brett, J. Electroanal. Chem. 655 (2011) 9\u201316.P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243\u2013251 251\n257Remarkable antioxidant properties of a series\nof hydroxy-3-arylcoumarinsq\nMaria Jo\u00e3o Matosa,b,\u21d1, Fernanda P\u00e9rez-Cruzc, Saleta Vazquez-Rodrigueza, Eugenio Uriartea,\nLourdes Santanaa, Fernanda Borgesb, Claudio Olea-Azarc,\u21d1\naDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain\nbCIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal\ncDepartment of Inorganic and Analytical Chemistry, Laboratory of Free Radicals and Antioxidants, Faculty of Chemical and Pharmaceutical Sciences,\nUniversity of Chile, Santiago de Chile, Chile\narticle info\nArticle history:\nReceived 13 December 2012\nRevised 26 March 2013\nAccepted 3 April 2013\nAvailable online 19 April 2013\nKeywords:\n3-Arylcoumarins\nHydroxyl derivativesORAC-FL assays\nESR assays\nCV assaysAntioxidant capacityabstract\nIn the present work we synthesized a series of hydroxy-3-arylcoumarins (compounds 1\u20139), some of them\npreviously described as MAO-B selective inhibitors, with the aim of evaluating their antioxidant proper-\nties. Theoretical evaluation of ADME properties of all the derivatives was also carried out. From the\nORAC-FL, ESR and CV data it was concluded that these derivatives are very good antioxidants, with a very\ninteresting hydroxyl, DPPH and superoxide radicals scavenging pro\ufb01les. In particular compound 9is the\nmost active and effective antioxidant of the series (ORAC-FL = 13.5, capacity of scavenging hydroxyl\nradicals = 100%, capacity of scavenging DPPH radicals = 65.9% and capacity of scavenging superoxide\nradicals = 71.5%). Kinetics pro\ufb01le for protection \ufb02uorescein probe against peroxyl radicals by additionof antioxidant molecule 9was also performed. Therefore, it can operate as a potential candidate for pre-\nventing or minimizing the free radicals overproduction in oxidative-stress related diseases.\n/C2112013 The Authors. Published by Elsevier Ltd. All rights reserved.\n1. Introduction\nPhenolic compounds are bioactive substances widely distrib-\nuted in the vegetable kingdom. Generally, this group of compounds\nhas one or more aromatic rings in their structure and one or more\nhydroxyl groups. They have been described to act as natural anti-\noxidants and their presence contributes to prevent or minimize\nseveral types of oxidative processes.1Due to their antioxidant\nactivity their ingestion is correlated with interesting bene\ufb01ts to\nhealth. Therefore, the research and characterization of new bioac-\ntive phenolic substances from diet has been intensi\ufb01ed in the last\nyears, either for the development of nutraceutics or medicines.1\nDue to their antioxidant properties they can protect cells from\nthe oxidative damage of the reactive oxygen species (ROS). In fact,\nthe overproduction of free radicals have been related to cellular\nmembrane and DNA damage, and indirectly with aging and\noxidative-stress related diseases like cancer, cardiovascular andneurodegenerative pathologies.2Therefore, antioxidants are very\nimportant for protecting the organisms from oxidative disorders,in which ROS are also involved.\n3,4Antioxidants are capable of\ndecrease or prevent oxidation processes through different mecha-\nnisms, such as scavenging free radicals, inhibition of pro-oxidant\nenzymes or chelation of transition metal ions.5\nAn increasing number of reports suggested the involvement of\noxidative stress in neurodegenerative diseases (ND), where the in-\ncreased formation of ROS can contribute to neuronal damage and\ncell death.3,4\nSuggestion has been made that the etiology of Parkinson\u2019s (PD)\nand Alzheimer\u2019s (AD) diseases may be closely linked to biochemi-\ncal changes resultant from this oxidative stress.6\u20138Dopamine (DA)\nauto-oxidation naturally produces oxidative species and maycontribute to ND such as PD and ischemia/reperfusion-induced\ndamage. Monoamine oxidase (MAO) enzyme (particularly\nMAO-B) is responsible for metabolizing DA and plays an important\nrole in oxidative stress through altering the redox state of neuronal\nand glial cells, leading to neuronal death.\n9Consequences are an\nover-production of MAO and non-MAO initiated hydrogen perox-ide (H\n2O2) by proliferated reactive microglia and inability of\nneurons to dispose of H 2O2and other recative species like peroxyl\nradicals.10H2O2produces highly toxic ROS, namely hydroxyl\n0968-0896/$ - see front matter /C2112013 The Authors. Published by Elsevier Ltd. All rights reserved.\nhttp://dx.doi.org/10.1016/j.bmc.2013.04.015qThis is an open-access article distributed under the terms of the Creative\nCommons Attribution License, which permits unrestricted use, distribution, and\nreproduction in any medium, provided the original author and source are credited.\n\u21d1Corresponding authors. Tel.: +34 981594912; fax: +34 981528070.\nE-mail addresses: mariacmatos@gmail.com (M.J. Matos), colea@uchile.cl\n(C. Olea-Azar).Bioorganic & Medicinal Chemistry 21 (2013) 3900\u20133906\nContents lists available at SciVerse ScienceDirect\nBioorganic & Medicinal Chemistry\njournal homepage: www.elsevier.com/locate/bmc\n259radical, by Fenton reaction that is catalyzed by iron and neuro-\nmelanin.11Concerning the mechanism of the clinical ef\ufb01cacy of\nMAO-B inhibitors in PD, the inhibition of DA degradation (asymptomatic effect) and also the prevention of the formation of\nneurotoxic DA degradation products, that is, ROS and DA derived\naldehydes have been speculated.\n12The neuroprotective effect of\nrasagiline, a well-known MAO-B inhibitor, might be explained\nthrough multiple mechanisms, possibly due to reduction of DA\ncatabolism with a subsequent increased activity on dopaminergic\nD2receptors and suppressing the action of ROS as well.13So, the\npossible mechanism of neuroprotection of MAO-B inhibitors may\nbe related not only to MAO-B inhibition but also to induction and\nactivation of multiple factors related with oxidative stress and\napoptosis.14\nCoumarins are a family of compounds widely distributed in the\nnature.15Due to their structural features, and biological properties,\nnamely anticancer, anti-in\ufb02ammatory, antioxidant, antithrom-\nbotic, vasorelaxant, antiviral and enzymatic inhibition agents, they\nhave been ascribed as important building blocks in Organic\nChemistry and Medicinal Chemistry.16\u201323\nRecently, it was shown by our group that 3-substituted aryl\ncoumarins are potent and selective MAO-B inhibitors.24\u201330In addi-\ntion, it has been found that hydroxycoumarins are antioxidants\nscavenging ROS and/or chelating transition metals, exhibiting\ntissue-protective properties.6,31\u201333The complementarity of these\nactivities for 3-arylcoumarins was not previously studied anddescribed. The versatility of the used reactions allowed obtaining\na family of compounds with hydroxyl and/or methyl substituents\nin different positions of the molecule. The election of these deriva-\ntives has considered the previously MAO-B inhibitory pharmaco-\nlogical evaluation and the low cost of the commercial reagents to\nbegin with. Also, the in\ufb02uence of the substituents in the desired\nactivity was taken into account.\n2. Materials and methods\n2.1. Chemistry\nMelting points were determined using a Reichert Ko\ufb02er ther-\nmopan or in capillary tubes on a B\u00fcchi 510 apparatus and are\nuncorrected.\n1H and13C NMR spectra were recorded on a Bruker\nAMX spectrometer at 300 and 75.47 MHz, respectively, usingTMS as internal standard (chemical shifts in dvalues, Jin Hz). Mass\nspectra were obtained using a Hewlett\u2013Packard 5988A spectrome-\nter. Elemental analyses were performed using a Perkin\u2013Elmer 240B\nmicroanalyser and were within \u00b10.4% of calculated values in all\ncases. Silica gel (Merck 60, 230-00 mesh) was used for \ufb02ash chro-\nmatography (FC). Analytical thin layer chromatography (TLC) was\nperformed on plates precoated with silica gel (Merck 60 F254,\n0.25 mm).\n2.1.1. General procedure for the preparation of methoxy-3-\narylcoumarins\nTo a solution of the conveniently substituted ortho -hydroxy-\nbenzaldehyde (7.34 mmol) and the corresponding phenylacetic\nacid (9.18 mmol) in dimethyl sulfoxide (15 mL), N,N\n0-dicyclohexyl-\ncarbodiimide (11.46 mmol) was added. The mixture was heated at110/C176C for 24 h. Then, ice (100 mL) and acetic acid (10 mL) were\nadded to the reaction mixture. After keeping it at room tempera-\nture for 2 h, the mixture was extracted with ether (3 /C225 mL).\nThe organic layers were combined and washed with sodium bicar-bonate solution (50 mL, 5%) and water (20 mL). Subsequently, the\nsolvent was evaporated under vacuum and the dry residue was\npuri\ufb01ed by \ufb02ash chromatography (hexane/ethyl acetate 9:1), togive the desired methoxy-3-arylcoumarins.\n23,282.1.2. General procedure for the preparation of hydroxy-3-\narylcoumarins\nTo a solution of a methoxy-3-arylcoumarin (0.50 mmol) in ace-\ntic acid (5 mL) and acetic anhydride (5 mL), at 0 /C176C, hydriodic acid\n57% (10 mL) was added dropwise. The mixture was stirred under\nre\ufb02ux, for 3 h. The solvent was evaporated under vacuum and\nthe dry residue was puri\ufb01ed by crystallization (CH 3CN).23,28,34\n2.1.2.1. 3-(30,40-Dihydroxyphenyl)-6-methylcoumarin (4).\nYield: 92%; mp 199\u2013200 /C176C;1H NMR (300 MHz, DMSO- d6):d2.43\n(s, 3H, \u2013CH 3), 6.43 (s, 1H, H-20), 7.01 (d, J= 7.1 Hz, 1H, H-50), 7.14\n(d,J= 7.0 Hz, 1H, H-60), 7.28\u20137.32 (m, 2H, H-7, H-8), 7.57 (d,\nJ= 2.2 Hz, 1H, H-5), 7.83 (s, 1H, H-4), 10.40 (s, 2H, \u2013OH);13C\nNMR (75 MHz, DMSO- d6):d20.7, 100.1, 110.7, 111.6, 115.7,\n119.4, 120.1, 127.3, 127.4, 132.1, 133.7, 138.8, 146.5, 146.8,151.3, 161.6; EI MS m/z: 269 (13), 268 (M\n+, 100), 241 (31), 240\n(70), 239 (22), 165 (30), 125 (12), 111 (10); Anal. Calcd for\nC16H12O4: C, 71.64; H, 4.51. Found: C, 71.60; H, 4.49.\n2.1.2.2. 3-(30,40-Dihydroxyphenyl)-8-m ethylcoumarin (5).\nYield: 85%; mp 205\u2013206 /C176C;1H NMR (300 MHz, DMSO- d6):d\n2.50 (s, 3H, \u2013CH 3), 6.80 (d, J= 8.3 Hz, 1H, H-50), 7.05 (dd,\nJ=8 . 2 , J= 2.2 Hz, 1H, H-60), 7.22 (d, J= 2.2 Hz, 1H, H-20), 7.25\n(d,J= 7.6 Hz, 1H, H-6), 7.44 (dd, J=7 . 4 , J=1 . 0H z , 1 H , H - 7 ) ,\n7.57 (dd, J=7 . 6 , J= 1.1 Hz, 1H, H-5), 8.09 (s, 1H, H-4), 9.09\n(s, 1H, \u2013OH), 9.24 (s, 1H, \u2013OH);13C NMR (75 MHz, DMSO-\nd6):d14.9, 115.4, 116.0, 119.5, 119.9, 124.1, 124.6, 125.7,\n126.1, 126.5, 132.2, 138.7, 144.8, 146.2, 150.9, 159.9; EI MS\nm/z: 270 (12), 269 (76), 268 (M+, 82), 241 (47), 240 (100)\n239 (57), 211 (23), 166 (19), 165 (58), 152 (18), 139 (14),125 (30), 111 (28), 82 (19); Anal. Calcd for C\n16H12O4:C ,\n71.64; H, 4.51. Found: C, 71.63; H, 4.49.\n2.1.2.3. 3-(30,50-Dihydroxyphenyl)-8-m ethylcoumarin (6).\nYield: 90%; mp 180\u2013181 /C176C;1H NMR (300 MHz, DMSO- d6):d\n2.49 (s, 3H, \u2013CH 3), 6.70 (s, 3H, H-20,H - 40,H - 60), 7.26 (t,\nJ= 7.6 Hz, 1H, H-6), 7.48 (d, J= 7.8 Hz, 1H, H-7), 7.62 (d,\nJ= 7.7 Hz, 1H, H-5), 8.11 (s, 1H, H-4), 10.27 (s, 2H, OH);13C\nNMR (75 MHz, DMSO- d6):d15.3, 103.3, 107.2, 119.6, 124.5,\n125.1, 126.8, 127.2, 133.1, 136.6, 140.9, 151.6, 158.5, 160.0;\nEI MS m/z: 269 (21), 268 (M+, 100), 241 (12), 240 (63), 239\n(26); Anal. Calcd for C 16H12O4: C, 71.64; H, 4.51. Found: C,\n71.60; H, 4.50.\n2.1.2.4. 3-(30,40,50-Trihydroxyphenyl)-8-methylcoumarin (7).\nYield: 82%; mp 189\u2013190 /C176C.1H NMR (300 MHz, DMSO- d6):d2.49\n(s, 3H, \u2013CH 3), 6.95 (s, 2H, H-20,H - 60), 7.20 (t, J= 7.4 Hz, 2H, H-6,\nH-7), 7.38 (d, J= 7.4 Hz, 1H, H-5), 7.79 (s, 1H, H-4), 10.55 (s, 2H,\n\u2013OH), 10.60 (s, 1H, \u2013OH);13CN M R( 7 5 M H z ,D M S O - d6DMSO- d6):\nd15.6, 106.1, 119.4, 124.2, 125.4, 125.7, 127.7, 130.4, 132.7,\n135.6, 139.8, 146.7, 146.9, 160.6; EI MS m/z: 285 (16), 284 (M+,\n100), 283 (84), 256 (32), 181 (10) 141 (10); Anal. Calcd for\nC16H12O5: C, 67.60; H, 4.25. Found: C, 67.61; H, 4.28.\n2.2. Antioxidant assays\n2.2.1. Oxygen radical antioxidant capacity-\ufb02uorescein (ORAC-FL)\nThe ORAC analyses were carried out on a Synergy HT multi\ndetection microplate reader, from Bio-Tek Instruments, Inc.\n(Winooski, USA), using white polystyrene 96-well plates, pur-\nchased from Nunc (Denmark). Fluorescence was read from the\ntop, with an excitation wavelength of 485/20 nm and an emission\n\ufb01lter of 528/20 nm. The plate reader was controlled by Gen 5 soft-\nware. The reaction was carried out in 75 mM sodium phosphate\nbuffer (pH 7.4), and 200 lL \ufb01nal volume. FL (70 nM, \ufb01nal concen-\ntration) and hydroxy-3-arylcoumarin solutions in methanol withM. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906 3901\n260a range of concentration between 0.3 and 2 lM were placed in\neach well of 96-well plate. The mixture was pre-incubated for\n15 min at 37 /C176C, before rapidly adding the AAPH solution\n(18 mM, \ufb01nal concentration). The microplate was immediatelyplaced in the reader and automatically shaken prior to each read-\ning. The \ufb02uorescence was recorded every 1 min for 120 min. A\nblank with FL and 2,2\n0-azobis(2-methylpropionamidine)dihydro-\nchloride (AAPH) using methanol instead of the antioxidant solution\nwere used in each assay. Five calibration solutions using Trolox\n(0.5\u20132.5 lM) as antioxidant were also done. The inhibition capac-\nity was expressed as ORAC values and is quanti\ufb01ed by integrationof the area under the curve (AUC\nNET). All reaction mixtures were\nprepared in triplicate and at least three independent assays wereperformed for each sample. The area under the \ufb02uorescence decay\ncurve (AUC) was calculated integrating the decay of the \ufb02uores-cence where F\n0is the initial \ufb02uorescence read at 0 min and Fis\nthe \ufb02uorescence read at time. The net AUC corresponding to the\nsample was calculated by subtracting the AUC corresponding to\nthe blank. Data processing was performed using Origin Pro 8 SR2\n(Origin Lab Corporation, USA).\n2.2.2. Hydroxyl radical scavenging assay using electron spin\nresonance (ESR)\nReactivity of all the hydroxy-3-arylcoumarin derivatives against\nthe hydroxyl radical was investigated using the non-catalytic Fen-ton type method. ESR spectra were recorded in the X band\n(9.7 GHz) using a Bruker ECS 106 spectrometer with a rectangular\ncavity and 50 kHz \ufb01eld modulation, equipped with a high-sensitiv-\nity resonator at room temperature. Spectrometer conditions were:\nmicrowave frequency 9.81 GHz, microwave power 20 mW, modu-\nlation amplitude 0.91 G, receiver gain 59 db, time constant\n81.92 ms and conversion time 40.96 ms. The scavenging activity\nof each derivative was estimated by comparing the DMPO-OH ad-\nduct signals in the antioxidant\u2013radical reaction mixture and the\ncontrol reaction at the same reaction time, and is expressed as\nscavenging percent of hydroxyl radical.\nTo prepare the samples, 150\nlLo fN,N-dimethylformamide (DMF)\nand 50 lL of NaOH (3 mM) were mixed, followed by the addition of\n50lL of 5,5-dimethyl-1-pyrroline- N-oxide (DMPO) spin trap (30 mM\n\ufb01nal concentration) and \ufb01nally 50 lL of hydrogen peroxide 30%. The\nmixture was put in an ESR cell and the spectrum was recorded after\n\ufb01ve minutes of reaction. All the compounds were studied to 4 mM\n\ufb01nal concentration (300 lL \ufb01nal volume).\n2.2.3. DPPH radical scavenging assay using ESR\nThe 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radical scavenging\ncapacity35\u201338of the hydroxy-3-arylcoumarin derivatives was\ndetermined by an ESR spectrometry method.39\u201343Each hydroxy-\n3-arylcoumarin solution was mixed with DPPH stock solution toinitiate the antioxidant\u2013radical reaction. All the reaction mixtures\ncontained 1.0 mM of DPPH and 1.0 mM of the studied compound.\nThe control solution was prepared in absence of the studied com-\npounds. Both DPPH and compounds solutions were prepared in\nacetonitrile. ESR signals were recorded after \ufb01ve minutes of reac-\ntion. Spectrometer conditions were: microwave frequency\n9.81 GHz, microwave power 20 mW, modulation amplitude 0.95\nG, receiver gain 59 db, time constant 81.92 ms and conversion time\n40.96 ms. The scavenging activity of each compound was esti-\nmated by comparing the DPPH signals in the antioxidant\u2013radical\nreaction mixture and the control reaction at the same reaction\ntime, and was expressed as scavenging percent of DPPH.\n2.2.4. Superoxide antioxidant assay using cyclic voltammetry\n(CV)\nCyclic voltammetry (CV) measurements were performed in a\nMetrohm 693VA instrument with a 694VA stand convertor and a693VA processor, at room temperature, using a three-electrode\ncell. A glassy carbon (GC) electrode presenting an area of\n0.03 cm\n2was used as the working electrode. The electrode surface\nwas polished to a mirror \ufb01nish with alumina powder (0.3 and\n0.05lM) before use and after each measurement. Platinum wire\nwas used as auxiliary electrode and silver-silver chloride (Ag/AgCl,\n3 M KCl) of Metrohm Company with a plastic tip was used as a ref-\nerence electrode. The CV experiments were carried out in dimethyl\nsulfoxide (DMSO) of analytical grade (Sigma\u2013Aldrich) with 0.1 M of\ntetrabutylammonium perchlorate (TBAP) as supporting electrolyte.\nSuperoxide anion radical was generated in DMSO containing TBAP\n0.1 M. The scan rate was kept 30 mV/s and potential window was\n/C01.0 to /C00.0 V. The atmospheric solubility of oxygen in DMSO was\n2.1 mM.44The \ufb01nal concentration of each derivative (30 lM) was\nachieved by additions of the corresponding aliquot of stock solu-\ntion (10 mL \ufb01nal volume). Finally, the antioxidant activity was as-\nsessed from the change in the cathodic current of the\nvoltammograms in absence and present of the derivatives, using\npertinent mathematical formulations.\n2.2.5. Data statistical analysis\nStatistical analyses were conducted using GraphPad Prism 5\nsoftware (GraphPad Software, Inc., San Diego, CA). The data are ex-\npressed as means \u00b1 SD. The experimental data were analyzed by\none-way analysis of variance (ANOVA), and differences between\ngroups were assessed using Tukey\u2019s post-test. The level of signi\ufb01-\ncance was set at p<0.05, and all experiments were replicated\n3 times.\n3. Results\n3.1. Chemical synthesis\nCoumarin derivatives 1\u20139were ef\ufb01ciently synthesized accord-\ning to the protocol outlined in Scheme 1 . The general reaction con-\nditions and the characterization data of the new compounds were\ndescribed in the experimental section. Perkin condensation of dif-\nferent ortho -hydroxybenzaldehydes with the adequate arylacetic\nacid, using N,N0-dicyclohexylcarbodiimide (DCC) as dehydrating\nagent,28afforded the methoxy-3-arylcoumarins. Hydroxyl deriva-\ntives were obtained from the above-mentioned methoxy substi-\ntuted precursors by acidic hydrolysis, using hydriodic acid 57% in\nthe presence of acetic acid and acetic anhydride.28\n3.2. Antioxidant capacity assays\nThe evaluation of the antioxidant activity of the studied com-\npounds was performed towards different types of reactive oxygen\nor nitrogen species\u2014peroxyl, hydroxyl, superoxide and DPPH rad-\nicals. ORAC-FL, ESR and CV assays were the techniques used to ob-\ntain the desired results.\nThe peroxyl radical scavenging activity of the synthesized\nhydroxy-3-arylcoumarins was evaluated by the oxygen radical\nabsorbance capacity (ORAC) method45This assay use a \ufb02uores-\ncence-based technology (ORAC-FL) and allow obtaining a relativeantioxidant index by using as reference trolox, a hydrosoluble vita-\nmin E derivative. The exposition of the \ufb02uorophore, in this case\n\ufb02uorescein (FL) to the peroxyl radical lead to an oxidation process\nre\ufb02ected as a decay of \ufb02uorescence emission through time. In\nORAC assays, the loss of \ufb02uorescence of FL generally corresponds\nto an induction time and is reliant on antioxidant capacity of a\ncompound. In fact, it refers to the time in which the FL is protected\nagainst the oxidative damage of peroxyl radicals and this behavior\nis associated to a competitive reaction between the radical and the\nantioxidant.\n46,47ORAC data take into account the induction time,3902 M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906\n261initial rate and the range of total antioxidant inhibition in one\nvalue.46\nResults expressed as ORAC-FL values are presented in Table 1 .\nAll the obtained ESR results for the% scavenging of the hydroxyl\nand DPPH radicals are also illustrated in Table 1 . In addition, % of\nsuperoxide radical scavenging, performed by CV, are also repre-sented in Table 1 .\nThe ORAC-FL pro\ufb01le, intensity of \ufb02uorescence at 528 nm versus\nthe incubation time was obtained for all derivatives. Compounds 3\nand9(8.4 and 13.5, respectively) display the highest ORAC-FL in-\ndexes, comparing with the \ufb02avonoids quercetin and catechin that\nare very well known natural antioxidant compounds. Figure 1\nshows the kinetic pro\ufb01le for protection of FL probe against peroxyl\nradicals obtained in presence of increasing concentrations of com-\npound 9. It was obtained a pro\ufb01le of \ufb02uorescence measure at\n528 nm versus the incubation time at different concentration, for\nall derivatives.In order to study the antioxidant reactivity of all the synthe-\nsized hydroxy-3-arylcoumarin derivatives towards hydroxyl radi-\ncals, a non-catalytic and competitive type Fenton system in\nwhich the DMPO spin trap was performed.\n48The ESR spin-trapping\nspectrum obtained in the control assay (DMPO+ N,N-dimethylform-\namide + NaOH + H 2O2) presents four hyper\ufb01ne lines, due to the\nDMPO-OH adduct formation, as it is shown in Figure 2 (red line).\nFor each putative antioxidant coumarin compounds ESR spectra\nwere also acquired to check their capacity of scavenging hydroxyl\nradicals. The data obtained with compound 2is depicted in Figure 2\n(black line).\nThe intensity of the spectra decreases when the hydroxy-3-aryl-\ncoumarin derivatives were added into the system. For compound 9,\n100% of scavenging of hydroxyl radicals was obtained (Fig. 3 \u2014black\nline). This type of response was observed for all derivatives, re\ufb02ect-\ning different percentage of the hydroxyl radical scavenging activity\n(Table 1 ).\nThe stable free radical DPPH assay has been used for detecting\nthe antioxidant activity in several chemical analyses.35\u201338Cur-\nrently, DPPH assay is considered an easy and accurate method,\nappropriate for measuring the antioxidant capacity of fruits, vege-\ntables, juices or extracts.39This is due to the electronic properties\nshared by DPPH and peroxyl radicals (the unpaired electron isdelocalized through the pair of nitrogen or oxygen atoms, respec-CHO\nOHRCOOH\nR1\nOORR1\nOORR11:R=6 - C H 3;R1=4 ' - O H\n2:R=6 - C H 3;R1=3 ' - O H\n3:R=6 - C H 3;R1=2 ' - O H\n4:R=6 - C H 3;R1=3 ' , 4 ' - O H\n5:R=8 - C H 3;R1=3 ' , 4 ' - O H\n6:R=8 - C H 3;R1=3 ' , 5 ' - O H\n7:R=8 - C H 3;R1=3 ' , 4 ' , 5 ' - O H\n8:R=8 - O H;R 1=4 ' - C H 3\n9:R=8 - O H;R 1=4 ' - O HR or R 1=O C H 3i\nii\nScheme 1. Reagents and conditions: (i) DCC, DMSO, 110 /C176C, 24 h; (ii) HI 57%, AcOH, Ac 2O, re\ufb02ux, 3 h.\nTable 1\nORAC-FL index and hydroxyl, DPPH and superoxide radical scavenging data obtained\nfor compounds 1-9\nCompd ORAC-\nFL\nindex% Scavenging\nhydroxyl\nradicalsa% Scavenging\nDPPH radicalsa% Scavengingsuperoxide\nradicals\nb\n1 6.1 100 27.7 17.4\n2 6.7 5.2 3.4 17.5\n3 8.4 100 10.6 25\n4 5.3 6.05 28.3 28.9\n5 5.7 100 66.7 77.3\n6 5.5 75 11.2 22.6\n7 5.3 100 100 76.5\n8 6.3 16 28.6 17.4\n9 13.5 100 65.9 71.5\nTrolox 1.0 \u2014 \u2014 \u2014\nQuercetin 7.28c\u2014 20.0d\u2014\nCatechin 6.76c\u2014 44.5d\u2014\naThe scavenging activity of hydroxyl and DPPH radicals effect was calculated as\nfollows: [( A0/C0Ax)/A0]/C2100, where Axand A0are the double-integral ESR for the\n\ufb01rst line of samples in the presence and absence of test compounds, respectively.\nbThe scavenging activity of superoxide radical effect was calculated as follows:\n[(Ipc blank /C0Ipc aox)/ Ipc blank] /C2100, where Ipc blank is cathodic current in the\nabsence of the studied compounds and Ipc aox is the cathodic current in the\npresence of the studied compounds.\ncData collected from Ref. 45.\ndData collected from Ref. 49.\nFigure 1. ORAC-FL pro\ufb01le (kinetic pro\ufb01le for protection FL probe against peroxyl\nradicals) for compound 9.M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906 3903\n262tively), in such way that the reaction rate between DPPH and sev-\neral antioxidants provides a good approximation for scavenging\nactivities with lipid peroxyl radicals.40,41ESR spectra of DPPH in\nabsence and presence of compounds 4,7and 9are showed in\nFigure 4 .Superoxide anion radical was generated by one electron reduc-\ntion of the atmospheric molecular oxygen dissolved in DMSO at\nroom temperature (25 /C176C). Then, the voltammetric performance\nof the nine compounds was studied, one by one, in DMSO and TBAP0.1 M. The resultant CV responses for derivative 5,7and9, and in\nabsence of any derivative (blank) are represented in Figure 5 .\n3.3. Theoretical evaluation of ADME properties\nIn order to better understand the overall properties of the de-\nscribed compounds, the lipophilicity (expressed as the octanol/water partition coef\ufb01cient and herein called log P), was calculated\nusing the Molinspiration property calculation program.\n50The the-\noretical prediction of ADME properties (molecular weight, log P,\nnumber of hydrogen donors and acceptors) of all the compoundswas carried out and is presented in Table 2 .\n51,52\n4. Discussion\nIn previous works, 3-arylcoumarin derivatives were described\nas potent and selective MAO-B inhibitors.28This family of com-\npounds and their remarkable data on the selective inhibition of\nMAO-B isoenzyme and putative application for ND therapy were\nthe inspiration for this work. In particular, compounds 1\u20133were\npreviously described as potent and selective MAO-B inhibitors,with IC\n50values between 120 and 650 nM.28On the other hand\nthe recent medicinal chemistry paradigms in the drug design,\nnamely the rational discovery of multi-target drugs, as a promising\nstrategy to combat this type of multifactorial diseases prompted us\nto look for other properties for this type of coumarins. Based on\nthis data, a new family of derivatives sharing the same scaffold\nand type of substituents was designed and synthesized.\nThe evaluation of the antioxidant activity of the hydroxy-3-\narylcoumarin compounds was performed towards different types\nof reactive oxygen or nitrogen species\u2014peroxyl, hydroxyl, superox-\nide and DPPH radicals. ORAC-FL, ESR reactivity and CV assays were\nthe techniques used to achieve the goals. From the obtained data, it\nwas concluded that the antioxidant scavenging activity is related\nwith the type of substituents presented in the 3-arylcoumarin\nskeleton.\nCompound 9was found to be the most interesting coumarin of\nthe series. This compound has two hydroxyl groups in its structure,\none at position 8 and another at position 40of the 3-arylcoumarin\nscaffold. The other compounds have structural combinations oftwo types of substituents (methyl and one, two or three hydroxyl\ngroups). Compounds 1,3,5and7have ORAC-FL values between\nFigure 2. ESR spectra obtained for the control (adduct DMPO-OH without\nantioxidant molecule\u2014red line) and for adduct DMPO-OH in the presence of\ncompound 2(black line).\nFigure 3. ESR spectra obtained for the control (adduct DMPO-OH without\nantioxidant molecule\u2014red line) and for adduct DMPO-OH in the presence ofcompound 9(black line).\nFigure 4. ESR signal from DPPH radical in absence (blank) and presence of\ncompounds 4,7and9.\nFigure 5. Cyclic voltammograms of superoxide radical in absence (blank) and\npresence of compounds 5,7and 9in DMSO + TBAP 0.1 M, on GC (working\nelectrode) versus. Ag/AgCl, at room temperature, with scan rate of 30 mV/s.3904 M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906\n2635.3 and 8.4 and the higher scavenging activity towards hydroxyl\nradicals (100% /C0total scavenging). From these derivatives, com-\npound 7presented the best DPPH and superoxide radicals scaveng-\ning (100 and 76.5%, respectively). Compounds 1and3have on their\nstructure a methyl group at position 6 of the coumarin moiety and\na hydroxyl group in the 3-aryl ring. The ORAC-FL indexes are 6.1\nand 8.4, respectively, but the position of the hydroxyl group in\nthe exocyclic aromatic ring seems to have no in\ufb02uence on the hy-\ndroxyl radical scavenging capacity (100%, in both cases). The DPPH\nradical scavenging values of these compounds are, respectively,\n27.7% and 10.6% and superoxide radical scavenging values are,\nrespectively, 17.4% and 25%. Their pro\ufb01les are, therefore, very sim-\nilar. Compounds 5and7have a methyl group at position 8 of the\ncoumarin moiety, and two or three hydroxyl groups, respectively,in the 3-aryl ring. Both ORAC-FL values (5.7 and 5.3, respectively),\nhydroxyl radical scavenging capacity (100%) and superoxide radi-\ncal scavenging capacity (77.3% and 76.5%, respectively) are similar,\nproving that the presence of the extra hydroxyl group does not\nseem to signi\ufb01cantly affect the peroxyl, hydroxyl and superoxide\nradicals scavenging activities. One the other hand, DPPH radical\nscavenging capacity is 66.7% for compound 5and 100% for com-\npound 7. Compounds 2,4and 8, with ORAC-FL values between\n5.3 and 6.7, presented the lowest hydroxyl scavenging capacity(between 5.2% and 16%). Compound 2presented also the lowest\nDPPH radical scavenging capacity (3.4%) and compounds 1and8\nthe lowest superoxide radical scavenging capacities (17.4%). Com-\nparing the data obtained for compound 4(3\n0,40-dihydroxy substi-\ntuted) and for compound 1(40-hydroxy substituted), it can be\nconcluded that the presence of two hydroxyl groups led to the\ndecline in the ORAC-FL index (6.1\u20135.3) and the hydroxyl radical\nscavenging capacity (100%\u20136.05%). Comparing compound 4with\n2(30-hydroxy substituted), it is also noted a decrease in the\nORAC-FL index (from 6.7 to 5.3), caused by the presence of two hy-\ndroxyl groups in the molecule. However, the hydroxyl radical scav-\nenging capacity is almost the same (6.05% and 5.2%, respectively).\nSuperoxide radical scavenging capacity is also similar (28.9 and\n17.5, respectively). Compounds 4and5have the same substitution\npattern, changing only the position of the methyl group from 6 to8. This modi\ufb01cation strongly affects the hydroxyl radical scaveng-\ning capacity (from 6.05% to 100%), the DPPH radical scavenging\ncapacity (from 28.3% to 66.7%) and superoxide radical scavenging\ncapacity (from 28.9% to 77.3%). Compound 6, with a methyl group\nat position 8 of the coumarin moiety and two hydroxyl groups at\npositions 3\n0and 50of the 3-aryl ring, in spite of presenting an\nORAC-FL value of 5.5 and low DPPH and superoxide radicals scav-\nenging (11.2 and 22.6, respectively), evidence a signi\ufb01cant ten-\ndency to scavenge hydroxyl radicals (75%).\nAs said before, the highest ORAC-FL values were found for com-\npounds 3and9(8.4 and 13.5, respectively). The results are very\ninteresting comparing with the ORAC-FL values of catechin (6.76)\nand quercetin (7.28), very well known natural antioxidants. Com-paring with trolox (ORAC-FL = 1.0), the interesting ORAC-FL values\nof compounds 3and 9make them promising antioxidant mole-\ncules. It is important to notice that compound 5,7and9presented\ngood trends against all the studied radicals.\nFrom the obtained data, it is also remarkable that all the couma-\nrin derivatives possess log Pvalues compatible with those required\nto cross membranes. TPSA, described to be a predictive indicator ofmembrane penetration, is also found to be positive. In addition, it\ncan be observed that no violations of Lipinski\u2019s rule (molecular\nweight, log P, number of hydrogen donors and acceptors) were\nfound. This is important information about the promising potentialof these derivatives.\nAll the synthesized compounds, in spite of presenting different\nchemical substituents, disclose interesting ORAC-FL values, in most\ncases accompanied by a remarkable ability to scavenge hydroxyl,\nDPPH and superoxide radicals. Therefore, the data acquired so far\nare relevant allowing proposing hydroxy-3-arylcoumarins as a va-\nlid scaffold for the design of novel antioxidants.\n5. Concluding remarks\nIn conclusion, in the current work coumarins presenting very\npromising antioxidant pro\ufb01les were described. Compound 9\nproved to be the most interesting molecule of the whole series,\nwith an ORAC-FL of 13.5, 100% of scavenging of hydroxyl radicals,\n65.9% of scavenging of DPPH radicals and 71.5% of scavenging of\nsuperoxide radicals. This derivative has presented good antioxi-\ndant capacity towards different types of reactive oxygen or nitro-\ngen species\u2014peroxyl, hydroxyl, superoxide and DPPH radicals.\nCompound 3, previously describe as very good selective MAO-B\ninhibitor, presented also a very interesting antioxidative pro\ufb01le.\nIt is important to notice that compound 5and 7also presented\ngood trends against all the studied radicals. In addition, it can beobserved that no theoretical violations of Lipinski\u2019s rule were ob-\nserved for all the studied derivatives. Therefore, the described\ncompounds seem to present desirable ADME properties. Based on\nthese results, it can be concluded that especially compounds 3\nand9are potential candidates for a further optimization process\nand could be successfully employed in the prevention or minimiza-\ntion of the oxidative damage caused by overproduction of oxygen\nfree radicals.\nAcknowledgments\nThe current work was supported by Mecesup (Project\nUCH-0601), CONICYT-Chile (Project N 24110059), Funda\u00e7\u00e3o paraa Ci\u00eancia e Tecnologia (Project PTDC/QUI-QUI/113687/2009) and\npersonal funds from the researchers. M.J. Matos thanks Funda\u00e7\u00e3o\npara a Ci\u00eancia e Tecnologia (SFRH/BD/61262/2009) Ph.D. Grant, F.\nP\u00e9rez-Cruz thanks CONICYT-Chile PhD. grant, Becas-Chile andTable 2\nTheoretical structural properties of the hydroxy-3-arylcoumarins derivatives 1\u20139a\nCompd logP Molecular weight TPSA n-OH acceptors n-OHNH donors Volume\n1 3.68 252.27 50.44 3 1 224.57\n2 3.66 252.27 50.44 3 1 224.57\n3 3.89 252.27 50.44 3 1 224.57\n4 3.19 268.27 70.67 4 2 232.59\n5 3.17 268.27 70.67 4 2 232.59\n6 3.11 268.27 70.67 4 2 232.59\n7 2.88 284.27 90.90 5 3 240.61\n8 3.92 252.27 50.44 3 1 224.57\n9 2.99 254.24 70.67 4 2 216.03\nalogP\u2014octanol/water partition coef\ufb01cient; TPSA\u2013topological polar surface area; n-OH\u2014number of hydrogen acceptors; n-OHNH\u2014number of hydrogen bond donors. The\ndata was determined with Molinspiration calculation software.50M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906 3905\n264Fulbright doctoral stay fellowships and S. Vazquez-Rodriguez\nthanks Ministerio de Educaci\u00f3n y Ciencia (AP2008-04263) PhD.\nGrant.\nReferences and notes\n1.Guardado-Yordi, E.; P\u00e9rez-Molina, E.; Matos, M. J.; Uriarte, E. In Nutrition, Well-\nBeing and Health ; Bouayed, J., Bohn, T., Eds.; InTech, 2012. Chapter 2 .\n2.Tyagi, Y. K.; Kumar, A.; Raj, H. G.; Vohra, P.; Gupta, G.; Kumari, R.; Kumar, P.;\nGupta, R. K. Eur. J. Med. Chem. 2005 ,40, 413.\n3.Hamdi, N.; Puerta, C.; Valerga, P. Eur. J. Med. Chem. 2008 ,43, 2541 .\n4.Panteleon, V.; Kostakis, I. K.; Marakos, P.; Pouli, N.; Andreado, I. Bioorg. Med.\nChem. Lett. 2008 ,18, 5781 .\n5.Nordberg, J.; Arn\u00e9r, E. S. Free Radic. Biol. Med. 2001 ,31, 1287 .\n6.Jenner, P. Ann. Neurol. 2003 ,53, S26. discussion S36\u2013S38 .\n7.Berg, D.; Gerlach, M.; Youdim, M. B.; Double, K. L.; Zecca, L.; Riederer, P.; Becker,\nG.J. Neurochem. 2001 ,79, 225.\n8.Riederer, P.; So\ufb01c, E.; Rausch, W. D.; Schmidt, B.; Reynolds, G. P.; Jellinger, K.;\nYoudim, M. B. J. Neurochem. 1989 ,52, 515.\n9.Gerlach, M.; Ben-Shachar, D.; Riederer, P.; Youdim, M. B. H. J. Neurochem. 1994 ,\n63, 793.\n10. Shoham, S.; Youdim, M. B. Cell Mol. Biol. 2000 ,46, 743.\n11. Youdim, M. B.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004 ,111, 1455 .\n12. Nagatsu, T.; Sawada, M. J. Neural Transm. Suppl. 2006 ,71,5 3.\n13. Seif-El-Nasr, M.; Atia, A. S.; Abdelsalam, R. M. Arzneimittelforschung 2008 ,58,\n160.\n14. Betard,\nR.; Sherer, T. B.; Greenamyre, J. T. Bioassays 2002 ,24, 308 .\n15. Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. Front. Med. Chem.\n2009 ,4,2 3.\n16. Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.; Zunino, F. Bioorg.\nMed. Chem. 2010 ,18, 3543 .\n17. Fylaktakidou, K. C.; Hadjipavlou-Litina, D. J.; Litinas, K. E.; Nicolaides, D. N. Curr.\nPharm. Des. 2004 ,10, 3813 .\n18. Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Yanez, M.; Fraiz, N.; Alcaide, C.;\nCano, E.; Orallo, F. Bioorg. Med. Chem. Lett. 2006 ,16, 257.\n19. Kostova, I. Curr. HIV Res. 2006 ,4, 347.\n20. Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S.\nK.; Hong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. J. Med. Chem. 2009, 52,\n1486.\n21. Vi\u00f1a, D.; Matos, M. J.; Y\u00e1\u00f1ez, M.; Santana, L.; Uriarte, E. Med. Chem. Commun.\n2012 ,3, 213.\n22. Garino, C.; Tomita, T.; Pietrancosta, N.; Laras, Y.; Rosas, R. J. Med. Chem. 2006 ,\n49, 4275 .\n23. Matos, M. J.; Santana, L.; Uriarte, E.; Delogu, G.; Corda, M.; Fadda, M. B.; Era, B.;\nFais, A. Bioorg. Med. Chem. Lett. 2011 ,21, 3342 .24. Matos, M. J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.;Uriarte, E. Bioorg. Med. Chem. Lett. 2009 ,19, 3268 .\n25. Matos,\n M. J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2009 ,19, 5053 .\n26. Matos, M. J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. Bioorg. Med.\nChem. Lett. 2010 ,20, 5157 .\n27. Matos, M. J.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. Bioorg.\nMed. Chem. Lett. 2011 ,21, 4224 .\n28. Matos, M. J.; Ter\u00e1n, C.; P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. J. Med.\nChem. 2011 ,54, 7127 .\n29. Serra, S.; Ferino, G.; Matos, M. J.; Vazquez-Rodriguez, S.; Delogu, G.; Vi\u00f1a, D.;Cadoni, E.; Santana, L.; Uriarte, E. Bioorg. Med. Chem. Lett. 2012 ,22, 258.\n30. Vi\u00f1a, D.; Matos, M. J.; Ferino, G.; Cadoni, E.; Laguna, R.; Borges, F.; Uriarte, E.;Santana, L. ChemMedChem 2012 ,7, 464.\n31. Symeonidis, T.; Chamilos, M.; Hadjipavlou-Litina, D. J.; Kallitsakis, M.; Litinas,\nK. E. Bioorg. Med. Chem. Lett. 2009 ,19, 1139 .\n32. Fylaktakidou, K. C.; Hadjipavlou-Litina, D. J.; Litinas, K.; Nicolaides, D. N. Curr.\nPharm. Des. 2004 ,10, 3813 .\n33. Kostova, I. Mini-Rev. Med. Chem. 2006 ,6, 365.\n34. Buu-Hoi, N. P.; Eckert, B.; Royer, R. J. Org. Chem. 1954 ,19, 1548 .\n35. Espinoza, M.; Olea-Azar, C.; Speisky, H.; Rodr\u00edguez, J. Spectrochim. Acta Part A:\nMol. Biomol. Spectrosc. 2009 ,71, 1638 .\n36. Guo, Q.; Zhao, B.; Shen, S.; Hou, J.; Hu, J.; Xin, W. Biochime. Biophys. Acta (BBA) \u2013\nGen. Subjects 1999 ,1427,1\n 3.\n37. Jin, Z.-Q.; Chen, X. J. Pharmacol. Toxicol. Methods 1998 ,39,6 3.\n38. Suvarna, A. M.; Sunandana, C. S. Phys. C: Supercond. 1997 ,276,6 5.\n39. S\u00e1nchez-Moreno, C. Food Sci. Technol. Int. 2002 ,8, 121.\n40. Brand-Williams, W.; Cuvelier, M. E.; Berset, C. Food Sci. Technol. 1995 ,28,2 5.\n41. Valgimigli, L.; Banks, J. T.; Ingold, K. U.; Lusztyk, J. J. Am. Chem. Soc. 1995 ,117,\n9966 .\n42. Rodr\u00edguez, J.; Olea-Azar, C.; Cavieres, C.; Norambuena, E.; Delgado-Castro, T.;\nSoto-Delgado, J.; Araya-Maturana, R. Bioorg. Med. Chem. 2007 ,15, 7058 .\n43. Yu, L.; Haley, S.; Perret, J.; Harris, M.; Wilson, J.; Qian, M. J. Agric. Food Chem.\n2002 ,50, 1619 .\n44. Ahmed, S.; Shakeel, F. Pak. J. Pharm. Sci. 2012 ,25, 501 .\n45. Ou, B.; Hampsch-Woodill, M.; Prior, R. L. J. Agric. Food Chem. 2001 ,49, 4619 .\n46. Niki, E. Free Radic. Biol. Med. 2010 ,49, 503 .\n47. Bisby, R. H.; Brooke, R.; Navaratnam, S. Food Chem. 2008 ,108, 1002 .\n48. Yoshimura, Y.; Inomata, T.; Nakazawa, H.; Kubo, H.; Yamaguchi, F.; Ariga, T. J.\nAgric. Food Chem. 1999 ,47, 4653 .\n49. Jullian, C.; Moyano, L.; Ya\u00f1ez, C.; Olea-Azar, C. Spectrochim. Acta, Part A Mol.\nBiomol. Spectrosc. 2007 ,67, 230 .\n50. M cheminformatics, Bratislava, Slovak Republic, http://www.molinspiration.\ncom/services/properties.html (2012).\n51. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Delivery Rev.\n1997 ,23,3.\n52. Ertl, P.; Rohde, B.; Selzer, P. J. Med. Chem. 2000 ,43, 3714 .3906 M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900\u20133906\n265New Insights into Functional  and Struc tural Properties of 3-Arylcoumarins as an \nInteresting Scaffol d in MAO-B I nhibition  \n \nMaria J. Matos,1,* Santiago Vilar,1,2,* Ver\u00f3nica Garc \u00eda-Morales,3 Carol Friedman,2 Eugenio Uriarte,1 \nLourdes Santana1 and Dolores Vi\u00f1a3 \n \n1Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 \nSantiago de Compostela, Spain \n2Department of Biomedical Informatics, Columbia University Medi cal Center, New York, NY 10032, \nUSA  \n3Department of Pharmacology, Center for Research in Molecular Medicine and Chronic Disease, \nUniversity of Santiago de Compostela, 15782 Santiago  de Compostela, Spain \nE-MAIL: mariacmatos@gmail.com, qosanti@yahoo.es, veronica.garcia9@rai.usc.es, \nfriedma@dbmi.columbia.edu, eugenio.uriarte@usc.es, lourdes.santana@usc.es, mdolores.vina@usc.es. \n \n* Department of Biomedical Informatics, Columbia University Medi cal Center, New York, NY 10032, \nUSA. Fax: +34 981 544912; Tel: +34 981 563100; E-mail: qosanti@yahoo.es, \nmariacmatos@gmail.com \nABSTRACT: Design, synthesis, pharmacological evaluation and theoretical studies of a new series of \nhalogenated 3-arylcoumarins were performed with the aim of finding new structural and biological features. This series displays several alkyl, hydroxyl, halogen and/or alkoxy groups in both benzene \nrings of the 3-arylcoumarin scaffold. Most of the studied compounds showed a high affinity and \nselectivity to the hMAO-B isoenzyme, with IC\n50 values on the low-nanoMolar (compounds 6, 7, 10, 16, \n17, 20 and 23) and picoMolar range (compounds 5, 8, 9, 11, 12, 14 and 15). Most of the evaluated \n267compounds displayed higher MAO-B inhibitory activity and selectivity than selegiline. Coumarin 12 is \nthe most active compound, being several times more active than selegiline and showing the highest \nhMAO-B specificity. To better understand the structure-activity relationships, docking experiments \nwere carried out on hMAO structures. Finally, the prediction of passive blood-brain partitioning based \non in silico derived physicochemical descriptors was performed.  \n \nKEYWORDS: Coumarin derivatives, Perkin reaction, Williamson reaction, hydrolysis reaction, \nmonoamine oxidase inhibitors, docking studies, passive blood-brain partitioning model. \n \nIntroduction \nNeurological diseases are considered as one of the important challenges in today\u2019s medicine because \nof the complexity, frequency of occurrence and progressive development of these pathologies. Among \nthese, neurodegenerative disorders as Alzheimer\u00b4s disease (AD) and Parkinson\u00b4s disease (PD) play a \nmajor role.1,2 PD is the second most common neurodegenerative disease in the western countries and up \nto now it cannot be cured. The disease is characterized by a loss of dopaminergic neurons in the substancia nigra pars compacta and other regions and the formation of intraneuronal aggregates known \nas Lewy bodies (LBs). LBs mainly consist of \u03b1-synuclein which is misfolded and fibrillated under \npathogenic circumstances.\n1 The loss of dopamine (DA) leads to a dysregulation of the motor circuits \nwhich result symptomatically in tremor, bradykinesia, rigidity and postural instability.2 Additionally \nother neurotransmitter systems are affected, explaining the manifestation of symptoms like depression, \nsleeping abnormalities, anxiety and reduction of cognitive abilities.2 \nUnless a basal understanding of PD exists, in treatment, the missing DA is still replaced, without \ntargeting the progress of neurodegeneration of dopaminergic and nondopaminergic neurons. L-dopa as a \nDA prodrug and drugs modifying the DA levels, as well as dopaminic receptor agonists, muscarinic receptor agonists, catecol- O-methyltransferase (COMT) inhibitors and selective monoamine oxidase \n268type B inhibitors (MAOI-B) are used in therapy.1,3 Moreover, MAOI-B like selegiline show \nneuroprotective effects via a pathway unrelated to the MAO inhibition.4 Therapy combining several \ndrugs is common and is still widely used, but recently approaches have been done to combine different \npharmacophoric features addressing several molecular targets in one molecule.3 Novel strategies to treat \nPD also focus on the formation of \u03b1-synuclein fibrils and the different possibilities to maintain the \nnative protein by considering chaperone activity,5 fibril proteolysis via autophagic systems6 and \npathways of phosphorylation.7  \nMAO is an important flavin -containing enzyme w hich catalyzes the oxidative deamination of \nmonoamines8 and is located in the outer mitochondrial membrane of ne urons and other cells.9 These \nenzymes are responsible for catalyzing the oxidative deamination of neurotransmitters and dietary \namines, regulating intracellular levels of biogeni c amines in the brain and the peripheral tissues.10 In \nhumans, two subtypes of M AO, called M AO-A and MAO-B, exist. M AO-A catabolizes more \nfavourable serotonin and norepinep hrine, whereas the isoform B s hows a higher affinity to \nphenylethylamine and benzylamine.11,12 On the other hand, DA and tyramine are common substrates for \nboth isoforms. The enzymatic isoforms have been identified on the basis of their amino acid \nsequences,13 three-dimensional structure,14 tissue distribution,15 inhibitor selectivity16 and substrate \npreferences.17 Due to this, they play an important role in the inactivation of ne urotransmitters and are \ntargeted if a dysreg ulation of ne urotransmitter levels, like in neurological disorders, occurs. The \nphysiologic properties determine the clinical interest of M AO inhibitors. M AOI-A (clorgyline and \nmoclobemide) are used in the treatment of depression and an xiety,18 while M AOI-B (selegiline and \nrasagiline) have been applied to PD t herapy (Figure 1).19,20  \n269 \nFigure 1. Chemical structure of MAOI-A (clorgyline and moclobemide) and MAOI-B (selegiline and \nrasagiline). I \u2013 irreversible. R \u2013 reversible. \n \nIn recent years, interest in selective hMAO-B inhibitors has significantly intensified due to the \ndiscovery that expression levels of this isoenzyme in neuronal tissue increase 4-fold with age, resulting \nin an increment of DA metabolism, as well as of production of hydrogen peroxide (H2O2), which cause \noxidative stress, and may play a relevant role in the etiology of neurodegenerative diseases.21 This \nresearch has resulted in a significant number of compounds with different structural scaffolds.22-29 \nAdditionally, the des cription of the crystal str ucture of the two MAO isoforms by Binda et al. has \nprovided relevant information abo ut the selective interactions and t he pharmacophoric requirements \nneeded for the design of potent and sele ctive inhibitors.30-34 \nDue to the presence of MAO in the brain cells, MAOIs must be able to achieve and cross the blood-\nbrain barrier (BBB), which prevents the access of polar molecules to the brain. The distribution of the \ncompounds between blood and brain is a very important consideration for new drug candidates. The \nprediction of passive blood-brain partitioning based on in silico derived physicochemical descriptors it \nis an interesting tool.35 \nDue to the above described, in the last few years, a broad consensus has been reached concerning the \nnecessity for the research of new, more potent and less toxic MAO-B selective inhibitors. \n270Coumarin is a natural molecule which can be found in several plants like tonka bean, vanilla grass \nand sweet woodruff.36 Derivatives of this benzopyrone are of pharmaceutical interest because they have \nbeen showing different biological activities.36 Works have been done that describe the coumarins as \nanticancer, anti-inflammatory, antimicrobial, cardioprotective, vasorelaxant and antioxidant agents.36-46 \nAlso, the coumarin nucleus has emerged in the 1990\u00b4s as a promising scaffold for MAO inhibitors.47 \nStructure-selectivity relationship st udies about coumarin derivatives suggested that selectivity was \nmainly determined by the nature of the linkage between the coumarin and the lipophilic aryl groups.48 \nFurthermore, several coumarins showing a significant MAO inhibitory activity (Figure 2) have been \nreported and some of them are suggested as potential drugs against neurodegenerative diseases.49-53  \n \nFigure 2. Structures of known coumarin-based MAOIs (esuprone and LU53439).  R \u2013 reversible.  \n Our research group has been able to present 3- arylcoumarins (coumarin -stilbene derivatives - Figure \n3) that show a high selectivity and affinity to M AO-B isoenzyme.\n54-63  These results encouraged us to \nsynthesize and study the MAO inhibitory activity of new analog ues, in which a variety of gro ups wit h \ndifferent si ze, electronic and lipophilic properties were introduced in both aromatic rings, in order to \nclarify the infl uence of the substitution pattern in the MAO inhibitory activity and selectivity of t he 3-\narylcoumarin skeleton.  \n271 \nFigure 3. General chemical structure of synthesized stilbene-coumarin hybrid scaffold. \n \nBased on the significant structural information currently available on MAOs,64-67 and to analyze the \nstructural requirements for MAO a ctivity, do cking experiments were carried out on hMAO-B and \nhMAO-A crystallograp hic structures . Considering t he preliminary interesting results, our research group \nis still looking for more active and selective M AOIs. \n \nResults \nChemistry \nThe coumarin derivatives 1-23 were efficiently synthesized according to t he protocol outlined in \nScheme 1. The detailed chemical structures of t he compounds are organized in Table 1. The general \nreaction conditions and t he compounds characterization are described in the experimental section.  \nPerkin condensation of different ortho-hydroxybenzaldehydes wit h the adequate arylacetic a cid, \nusing N,N\u2019-dicyclohexylcarbodiimide (DCC) as dehydrating agent,55-57 afforded t he 3-arylcoumarins 1-\n3, 5-8 and 11-15.54,60,68 The treatment of the 4-(methoxyphenyl)-6-methylcoumarin 7 and 3-\n(methoxyphenyl)-6-methylcoumarin 8,57 with N-bromosuccinimide (NBS), in carbon tetrachloride \n(CCl 4), under refl ux, using 2,2\u2019-azobisisobutyronitrile (AIBN) as catalyst,60 afforded t he bromomethoxy \nderivatives 9 and 10,57 respectively. In addition, compounds 4, 16 and 17 were obtained by acidic \n272hydrolysis of the respective methoxy derivatives 3, 14 and 15, using hydriodic a cid 57% in the presence \nof acetic acid and acetic anhydride .56 Finally, the Williamson reaction of hydroxycoumarins 16 and 17 \nwith chloroacetone, 2-chloroacetyl chloride or cyclopentyl bromide,57 gave the corresponding et hers 18-\n20 and 21-23, respectively.  \nHO\nOHR\nO OR\nO OOR4'\nO OOR4'\nOR2'R3'\nR4'\n1 R = R 2' = R 3' = R 4' = H\n2 R = CH 3 , R2' = R 3' = R 4' = H\n3 R = OCH 3 , R2' = R 3' = R 4' = H\n5 R = CH 3 , R2' = R 3' = H , R 4' = CH 3\n6 R = CH 3 ,R2' = R 4' = H , R 3' = CH 3\n7 R = CH 3 , R2' = R 3' = H, R 4' = OCH 3\n8 R = CH 3 , R2' = R 4' = H, R 3' = OCH 3\n11 R = CH 3 , R2' = R 3' = H, R 4' = Br\n12 R = CH 3 , R2' = R 4' = H, R 3' = Br\n13 R = CH 3 , R2' = Br , R 3' = R 4' = H\n14 R = OCH 3 , R2' = R 3' = H, R 4' = Br\n15 R = OCH 3 , R2' = R 4' = H, R 3' = Bri\nCOOHR3'\nR2' R4'\niiiO OH3CR3'\nR4'\n9 R3' = Br, R 4' = OCH 3\n10 R3' = OCH 3 , R4' = Br\niiO OHOR3'\nR4'\n16 R3' = H , R 4' = Br\n17 R3' = Br  , R4' = H\nO OOClOR4'18 R3' = H , R 4' = Br\n21 R3' = Br  , R4' = H19 R3' = H , R 4' = Br\n22 R3' = Br  , R4' = H\n20 R3' = H , R 4' = Br\n23 R3' = Br  , R4' = Hiv\nR3' R3'\nR3'4 R = OH , R 2' = R 3' = R 4' = Hii\n \nScheme 1. Reagents and conditions: (i) DCC, DMSO, 110 \u00baC, 24 h; (ii) HI, AcOH, Ac2O, reflux, 3 h; \n(iii) NBS, AIBN, CCl 4, reflux, 18 h; (iv) chloroacetone or cyclopentyl bromide or 2 -chloroacetyl \n273chloride, K 2CO3, acetone, refl ux, 16-24 h. \n \nPharmacology \nThe biological evaluation of the test drugs on hMAO a ctivity was investigated  by measuring their \neffects on the production of hydrogen peroxide (H2O2) from p-tyramine (a common substrate for \nhMAO-A and hMAO-B), using the Amplex Red MAO assay kit (Molecular Probes, Inc., Eugene, \nOregon, USA) and microsomal MAO isoforms prepared from insect cells (BTI-TN-5B1-4) infected \nwith recombinant baculovirus containing cDNA inserts for hMAO-A or hMAO-B (Sigma-Aldrich \nQu\u00edmica S.A., Alcobendas, Spain).69 The production of H 2O2 catalyzed by the two MAO isoforms can \nbe detected using 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent), a non -fluorescent and \nhighly sensitive probe t hat reacts with H2O2 in the presence of horseradis h peroxidase to prod uce a \nfluorescent product, resorufin. New compounds and reference inhibitors were unable to react directly \nwith the Amplex Red reagent, w hich indicates that these drugs do not interfere with t he measurements. \nOn the other hand, in our experiments and under our experimental conditions, hMAO-A displayed a \nMichaelis constant (Km) equal to 457.17 \u00b1 38.62 \u00b5M and a maximum reaction velocity (Vmax) in the \ncontrol group of 185.67 \u00b1 12.06 (nmol p-tyramine/min)/mg protein, whereas hMAO-B s howed a K m of \n220.33 \u00b1 32.80 \u00b5M and V max of 24.32 \u00b1 1.97 (nmol p-tyramine/min)/mg protein (n = 5). Most tested \ncompounds concentration-dependently inhibited this enzymatic control activity (Table 1).  \n \nTable 1. Chemical Structure and hMAO-A and hMAO-B Inhibitory Activity In vitro  of the Synthesized \nDerivatives 1-23 and Reference Compounds (Selegiline and Iproniazide)a \n \nCompo unds R R2\u2019 R3\u2019 R4\u2019 IC 50 hMAO-A  IC50 hMAO-B  S. I.b \n2741 H H H H * 11. 81\u00b10. 80 \u03bcM > 8.5c \n2 CH3 H H H * 283. 75\u00b119.9 0 nM > 352c \n3 OCH3 H H H * 413. 25 \u00b1 6 0.50 nM > 242c \n4 OH H H H 2 9.89 \u00b1 2.02 \u00b5M 3.39 \u00b1 0 .23 \u00b5M 8 .8 \n5 CH3 H H C H3 * 310.0\u00b120. 0 pM > 333,333c \n6 CH3 H C H3 H ** 15. 01\u00b10. 83 nM > 6,667c \n7 CH3 H H OCH3 * 1 3.05\u00b10.90 nM > 7,663c \n8 CH3 H OCH3 H * 800. 0\u00b150. 0 pM > 125,000c \n9 CH3 H Br OCH3 * 740. 0\u00b120. 0 pM > 135,870c \n10 CH3 H OCH3 Br * 3.25\u00b10. 17 nM > 31,250c \n11 CH3 H H Br ** 387.04\u00b125.96  pM > 258,371c \n12 CH3 H Br H * 1 34.04\u00b18.99  pM > 746,045c \n13 CH3 Br H H * 4 .34\u00b10.29 \u03bcM > 23c \n14 OCH3 H H Br * 320.0\u00b10.17 pM > 312,500c \n15 OCH3 H Br H * 650.0\u00b10.35 pM > 153,846c \n16 OH H H Br 12 .83\u00b10.66 \u03bcM 32.0\u00b11.7 nM 387 \n17 OH H Br H * 8 .0\u00b10.43 nM > 12,500c \n18 C3H5O2 H H Br * ** - \n19 C5H9O H H Br * 7 .02\u00b10.3 8 \u03bcM > 14c \n20 C2H2O2Cl H H Br 12.66 \u00b10.84 \u03bcM 7 .01\u00b10. 47 nM 1,80 9 \n27521 C3H5O2 H Br H * 1 .48\u00b10. 079 \u03bcM > 68c \n22 C5H9O H Br H 44.29\u00b12.40 \u03bcM 1 .79\u00b10.096 \u03bcM 25 \n23 C2H2O2Cl H Br H * 2 .4\u00b10.14 nM > 37,037c \nSelegiline - - - - 67.25\u00b11. 02 \u00b5M 1 9.60\u00b10.86 nM 3,431 \nIpronia zide - - - - 6.56\u00b10.76 \u00b5M 7 .54\u00b10.36  \u00b5M 0 .87 \n \na Each IC50 value is the mean \u00b1 S.E.M. from five e xperiments (n = 5). * Inactive at 100 \u00b5M (highest \nconcentration tested), at higher concentrations t he compounds precipitate. ** 100 \u03bcM inhibits the \ncorresponding hMAO a ctivity by appro ximately 40-45%, at higher concentrations t he compounds \nprecipitate. b Selectivity index: MAO-B selectivity ratios [IC 50 (MAO-A)]/[IC 50 (MAO-B)] for \ninhibitory effe cts of bot h new compounds and reference inhibitors. c Values obtained under the \nassumption that the corresponding IC 50 against M AO-A is the highest concentration tested (100 \u03bcM). \n \nPrediction of passive blood-brain partitioning  \nCompounds designed to be effective in the central nervous system (CNS) should be able to cross the \nBBB to reach the therapeutic target. It has been shown that compounds with logBB (logarithm of the \nratio of the concentration of the compound in the brain and in the blood) <-1 are poorly distributed in \nthe brain while molecules with logBB>0.3 can cross readily the BBB.70,71 The distribution of the \ncompounds 1-23 between the blood and the brain was calculated through a discriminant equation \nextracted from a model recently published.35 The equation discriminates between compounds with \nlogBB using a cut-off of 0.3 (see the equation in the Methods section). Topological polar surface area (TPSA) and the logarithm of octanol/water partition coefficient (logP(o/w)) were calculated and their \nvalues were substituted in the equation (1). If the result in the equation is >0 the compounds are \n276predicted to have a logBB \u22650.3 which means that the compounds readily cross the BBB.70 If the result is \n<0 the compounds could still cross the BBB but with logBB<0.3. Although two different models with \ncut-off of 0.3 and -1 were recently published,35 only the equation using the threshold of 0.3 was used \nsince all the compounds were predicted to cross readily the BBB (see Table 2). In order to better \nunderstand t he overall properties of t he described compounds, the theoretical prediction of other ADME \nproperties (molecular weight, logS, number of hydrogen donors and acceptors) of all the studied \ncompounds (1-23) was carried out and is presented in Table 2.  \n \nTable 2. Molecular Descriptors (TPSA and logP(o/w)) Included in Equation (1) and logBB Prediction \nfor the Compounds Included in the Study. Other Calculated Theoretical Descriptors.  \nCompo unds logP(o/w) TPSA Value in \nequation  (1) logBB\u2265\u22650.3 Other descriptor s \na_acc a_don lip_ \ndruglike lip_ \nviolation  logS mr Weight \n1 3.881 26.3 00 0.9 27 + 1 0 1 0 -4.55 6.63 222. 24 \n2 4.216 26.300 1. 100 + 1 0 1 0 -5.02 7. 08 236. 27 \n3 3.874 35.530 0.66 8 + 2 0 1 0 -4.60 7. 27 252. 27 \n4 3.61 46. 530 0. 227 + 2 1 1 0 -4.19 6.76 238.24 \n5 4.514 26.3 00 1. 254 + 1 0 1 0 -5.50 7. 52 250.3 0 \n6 4.551 26.3 00 1. 273 + 1 0 1 0 -5.50 7. 52 250.3 0 \n7 4.172 35.530 0. 822 + 2 0 1 0 -5.07 7. 72 266.3 0 \n8 4.209 35.530 0. 841 + 2 0 1 0 -5.07 7. 72 266.3 0 \n9 5.005 35.530 1. 252 + 2 0 1 0 -6.16 8.47 345.19 \n10 5.005 35.530 1. 252 + 2 0 1 0 -6.16 8.47 345.19 \n11 5.014 26.3 00 1. 512 + 1 0 1 0 -6.11 7. 82 315.17 \n12 5.051 26.3 00 1. 531 + 1 0 1 0 -6.11 7. 82 315.17 \n277 \nlogP(o/w) = log of t he octanol/water partition coeffi cient; TPSA  = topological polar surfa ce area; a_a cc \n= number of hydrogen bond acceptor atoms; a_don = n umber of hydrogen bond donor atoms ; \nlip_druglike = 1 if lip_violation < 2; lip_violation = n umber of violations of Lipinski' s Rule; logS = log \nof the aqueous sol ubility (mol/L); mr = molecular refractivity; weight = molecular weight. \n \nDocking Studies \nMolecular docking calculations were performed to detect the most likely ligand-protein conformation \nfor the 3-arylcoumarin derivatives. Following a similar docking protocol recently published,57 the \ncrystal structure of the hMAO-B in complex with 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin \n(PDB: 2V60)67 was used to dock the compounds under study. Water molecules were deleted with the \nexception of the water molecule establishing a hydrogen bond with the crystallographic ligand. The \ndocking simulations were carried out using QM-polarized ligand docking module in Maestro software \n(see Experimental section for a detailed description). To validate the docking protocol we used the co-13 5.012 26.3 00 1. 511 + 1 0 1 0 -6.11 7. 82 315.17 \n14 4.672 35.530 1. 080 + 2 0 1 0 -5.69 8.01 331.16 \n15 4.709 35.530 1. 099 + 2 0 1 0 -5.69 8.01 331.16 \n16 4.408 46. 530 0.639 + 2 1 1 0 -5.28 7. 50 317.14 \n17 4.445 46. 530 0.6 58 + 2 1 1 0 -5.28 7. 50 317.14 \n18 4.353 52.6 00 0. 442 + 3 0 1 0 -6.03 9.02 373.20 \n19 6.209 35.530 1. 873 + 2 0 1 1 -6.65 9.67 385.26 \n20 5.077 52.6 00 0. 816 + 3 0 1 0 -6.84 9.06 393.6 2 \n21 4.39 52.6 00 0. 462 + 3 0 1 0 -6.03 9.02 373.20 \n22 6.246 35.530 1. 892 + 2 0 1 1 -6.65 9.67 385.26 \n23 5.114 52.6 00 0. 835 + 3 0 1 0 -6.84 9.06 393.6 2 \n278crystallized 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin (PDB: 2V60) as well as the crystallized \nligands from other hMAO-B structures (PDB: 1OJ9, 1OJA, 1OJD, 2BK3, 2V5Z, 2V61, 2XFN, 3PO7, \n4A79).72 The RMSD (root mean square deviation) of the heavy atoms coordinates between the \ncalculated and crystallized poses was evaluated and showed a value of 0.26 for the coumarin derivative c17 in the hMAO-B 2V60 structure (see Table 3 and Figure 4a).  \n \nTable 3. RMSD Values Between the Most Stable Poses Calculated through QM-polarized Docking and \nDifferent Co-crystallized Ligands for hMAO-B.  \nPDB c ode RMSD  (root mean s quare deviation ) \n2V60 0.26 \n2XFN 0.77 \n1OJ9 0.85 \n1OJD 1.29 \n2V61 1.38 \n2V5Z 1.45 \n2BK3 1.51 \n1OJA 1.90 \n3PO7 2.66 \n4A79 2.68 \n \nOnce the protocol was validated, molecular docking calculations were carried out also for the \ncompounds of the synthesized series in the hMAO-B, although two of the most active compounds with substitutions at 6 position of the coumarin ring and meta  or para positions in the 3-aryl ring were \n279considered representative of the study (compounds 12 and 14, see Figure 4b-4d). The most favourable \ndocking poses according to the energy score Emodel were retrieved for all the compounds.  As it was \nreported previously in this type of compounds,57,61 docking simulations in hMAO-B showed that the \ncoumarin ring is oriented toward the bottom of the binding pocket in 15 out of the 23 docked coumarin \nderivatives. This fact showed the preference of this type of compounds to adopt the described binding \nconformation (see Figure 4). The phenyl ring in the benzopyrone system interacts with the FAD \ncofactor, Tyr60, Tyr398, Tyr435 and Phe343 through van der Waals and hydrophobic interactions. The \n3-aryl fragment is directed towards the hydrophobic area in the entrance cavity, establishing for \ncompound 12 (the best compound of the presented series) hydrophobic and van der Waals interactions \nmainly with residues Trp119, Leu164, Leu167, Phe168, Ile199 and Ile316. The analysis of the binding mode for the compounds 12 and 14 also showed that the ligand conformations are stabilized by a \nhydrogen bond between the Cys172 and the oxygen in the carbonyl group of the coumarin ring. \nHowever, the hydrogen bond angle is not optimum due to the Cys172 also interacts through an \nintramolecular hydrogen bond with Phe168. In both compounds, the Leu171 and the Ile199 establish an \narene-H interaction with the coumarin ring and the 3-aryl ring respectively. The ligands also establish \nCoulomb interactions with the FAD cofactor and some residues, such as Glu84, Phe103, Leu171, \nIle198, Ile199, Tyr326 and Tyr398. This fact supports the usefulness of the described protocol to \nanalyze the binding mode of this type of coumarin derivatives. However, the most stable ligand \nconformation could be highly dependent on the nature of the substituents in the 3-aryl ring as well as the \ncoumarin nucleus. \n280 \nFigure 4. a) Comparison of the co-crystallized ligand c17 (colored by element, green carbons) in the \ncrystal hMAO-B (PDB: 2V60) and the most stable pose retrieved by the docking calculation (red color). \nThe FAD cofactor is colored in yellow and the water molecule in blue. b) Comparison of the most stable \nbinding modes for the compounds 12 and 14 (colored by element, grey carbons) against the co-\ncrystallized compound c17 in the crystal hMAO-B (colored by element, green carbons). c) Analysis of \nthe most stable pose of the compound 12 into the hMAO-B pocket. The hydrogen bond between Cys172 \nand the oxygen in the carbonyl group along with the arene-H interactions with Leu171 and Ile199 are \nrepresented in white. Gln206 and Cys172 (violet) establish van der Waals interactions with the ligand. \nLeu328 and Pro104 (red color) interact with the compound 12 through hydrophobic forces. Residues \nthat establish both hydrophobic and van der Waals interactions with the ligand are colored in orange. d) \nMost stable binding mode for the compound 14 in the hMAO-B. The hydrogen bond between Cys172 \n281and the coumarin along with the arene-H interactions are represented in white. The binding pocket is \ncolored according to the residue property: the hydrophobic residues are colored in red and the \nhydrophilic residues are colored in green. \n \nIn this article, we also st udied hMAO selectivity using in silico evidences. We used the hMAO-A \ncrystal str ucture 2Z5X to dock t he compound 11 that showed low hMAO-A a ctivity. Water molecules \nwithin 5 \u00c5  from t he co-crystallized ligand were retained in the calculation. The RMSD between the \ntheoretical and the crystallized conformation for the ligand harmine was 0.49 \u00c5. The compound 11 was \nplaced in a similar area as the co-crystallized ligand (see Figure 5a). However, unlike the harmine \nligand, t he pose for compound 11 determined by do cking did not s how any hydrogen bond contacts wit h \nany water molecules. This fa ct could explain the difference of hMAO-A a ctivity between both \ncompounds. To further st udy the hMAO-A a ctivity, compound 20 was also investigated by do cking. No \nwater molecules were retained in the cavity due to the larger size of the compound. The docking pose is \nin agreement with t he previous calculation (see Figure 5b). However, the oxyacetyl chloride chain at \nposition 6 is placed deeply in the cavity. Although t his conformation should have to displace some \nwater molecules present in the crystal str ucture that establish an important H- bond network with t he \nprotein and this process could be energetically unfavourable, limiting the ligand binding potential, t he \ncarbonyl oxygen replaced a water molecule and establis hed a H-bond with t he Tyr197 that could \nstabilize the ligand conformation (see Figure 5b). \n \n282 \nFigure 5. a) Comparison of the co-crystallized ligand harmine (colored by element, green carbons) in \nthe hMAO-A (PDB: 2Z5X) and the pose retrieved by the docking calculation for compound 11 (pink \ncarbons). The ligand harmine establishes H-bond interactions with two water molecules whereas \ncompound 11 did not yield H-bond interactions. b) Comparison of the binding modes for the \ncompounds 11 (pink carbons) and 20 (aquamarine carbons) in the hMAO-A. The carbonyl group in the \noxyacetyl chloride chain at position 6 of t he compound 20 establishes an H-bond with t he residue \nTyr197. \n \nDiscussion \nAll the des cribed coumarins in t his report (compounds 1-23) were effi ciently synthesized and evaluated \n283for their ability to inhibit the A and B isoforms of hMAO. The corresponding IC50 values and hMAO-B \nselectivity ratios [IC 50 (MAO-A)]/[IC 50 (MAO-B)] are shown in Table 1. The chemical structures of the \nnewly designed compounds, as well as the biological and docking results, can help us with an \ninteresting structure-activity relationship (SAR) study. A theoretical prediction, based on in silico \nderived physicochemical des criptors, of the BBB cross was carried out and the res ults also encouraged \nus to e xplore the potential of this chemical family as drug candidates. All the compounds 1-23 were \npredicted to readily cross the BBB a ccording to t he theoretical model. The model is very simple and \nexplains t he BBB crossing through passive diff usion without taking into account other phenomena, such \nas active transport mechanisms or the action of efflux p umps.  Different authors developing QSPR \nmodels to evaluate the blood-brain partition coeffi cient have found the logarithm of the octanol/water \npartition coefficient and polar surfa ce area as good des criptors to e xplain this property.70,73,74 In \naddition, other molecular descriptors important in ADME properties, s uch as aqueous sol ubility, have \nbeen calculated. Although many drugs in the market have a logS value greater than -4 our compounds \nstill present acceptable ranges of sol ubility with an average logS=- 5.7. In addition, it can be observed \nthat no violations of Lipinski\u2019s rule (molecular weight, logP, number of hydrogen donors and acceptors) \nwere found for almost all t he compounds (21 from 23). As MAOIs have to pass different membranes \nand reach the CNS, this supports the potential of these derivatives as dr ug candidates.  \nFrom the experimental results it can be observed t hat most of the tested compounds are selective \ninhibitors toward hMAO-B isoenzyme, with IC50 values in the low -nano and pi coMolar range . In fact, \nonly compound 18 proved to be inactive against both isoenzymes . Fourteen from the twenty-three tested \ncompounds presented similar or better IC50 against hMAO-B t han the selegiline (IC 50 = 19.60 nM, \nreference hMAO-B inhibitor), with a much better selectivity profile . Thus, compounds 5, 8, 9, 11, 12, \n14 and 15 proved to in hibit selectively the B isoform of t he hMAO enzyme, with e xtremely good \ninhibitory activities in the picoMolar range. Compound 1, the 3-arylcoumarin skeleton, presented a \nhMAO-B a ctivity (IC 50 = 11.81 \u00b5M) in the same range of ipronia zide (IC 50 = 7.54 \u00b5M), being several \n284times more selective than this reference compound. This was t he inspiration to continue with t he \nsynthesis of new derivatives presenting t his scaffold. The presence of one methyl group at position 6 \n(compound 2) increased the hMAO-B a ctivity forty times, maintaining t he excellent selectivity (IC50 \nhMAO-B = 284 nM). The presence of a methoxyl group at the same position afforded compound 3, \nwhich s howed similar M AOI-B a ctivity to compound 2 (IC 50 hMAO-B = 413 nM). The hydrolysis of \nthat methoxyl group into a hydroxyl one (compound 4) resulted in a signifi cant loss of activity against \nhMAO-B (IC 50 = 3.39 \u03bcM). Nevertheless, compound 4 was still better M AOI-B t han the non-\nsubstituted 3-phenylcoumarin (compound 1). According to t his data, derivatives s ubstituted at position 6 \nwere explored in the current work. According to previo us work,54-61 it was the very interesting profile of \ncompound 9, with a methoxy group at position 4 and a bromine atom at position 3 of the 3-aryl group, \nwhich made us have a special interest for t he bromine derivatives . Also based on previo us work,54-61 and \nin the IC50 values of t he compounds 11-13 against hMAO-B enzyme, meta  and para positions proved to \nbe the most favourable points to s ubstitute. Therefore, further experimental work was developed ta king \nthis information into a ccount.  \nFour of the most active compounds are the new coumarin derivatives 11, 12, 14 and 15, with  IC50 \nagainst hMAO-B between 134 and 650 pM. Compounds 11 and 12 present a methyl group at position 6 \nof the scaffold, changing only the position of bromine atom lin ked in the 3-aryl ring, w hereas \ncompounds 14 and 15 have the same substitution pattern. In this case position 6 is substituted wit h a \nmethoxy group, and the bromine atom is also presented respe ctively in meta  and para positions of t he 3-\naryl ring. Comparing the presence of a methyl group (compounds 5 and 6) or a methoxy group \n(compounds 7 and 8) in the 3-aryl ring, keeping the same scaffold, wit h the compound 11 and 12, \npresenting a bromine atom at t he same positions, it can be observed a general improvement of t he \nactivity. So, we can infer that the presence of an electron withdrawing atom (bromine atom) instead of \nan electron donating gro up (methyl or methoxyl) at those positions is an important modifi cation to \nimprove the activity. Based on these new results obtained for compounds 11-12 and 14-15, keeping the \n285bromine atom in meta  and para positions, we decided to deeply explore the importance of the nature of \nthe substitution at position 6. Eight new derivatives (compounds 16-23) have been synthesized wit h the \naim of introd ucing gro ups wit h different physicochemical properties at position 6 of the coumarin \nmoiety.  \nCompounds 16 and 17, obtained by hydrolysis of the 6-methoxy derivatives 14 and 15, showed only \na slight loss of a ctivity. These compounds are still good candidates, with IC50 values against hMAO-B \nof 32 and 8 nM, respectively. Having these hydroxyl derivatives as starting materials, Williamson type \nreactions were carried out to obtain compounds 18-23. The biological res ults did not significantly \nimproved, but it was fo und some interesting data. Either the 6-(2-oxopropoxy) derivatives 18 and 21, or \nthe 6-(cyclopentyloxy) derivatives 19 and 22, lost significantly the inhibitory activity and sele ctivity \nagainst hMAO-B. Compounds 20 and 23, with only one chlorine atom more, respe cting to compounds \n18 and 21, respectively, presented a very interesting a ctivity profile, wit h activities against hMAO-B \nbetween 2 and 7 nM . Nevertheless, compound 20 presenting the bromine atom in para position, lost \nboth potency and selectivity against this isoform.  \nTo better understand t he experimental results, and to s upport the structure-activity relationship st udy, \ndocking calculations were performed . Based on the docking results, we have proposed a general binding \nconformation for the coumarins under study in the hMAO-B pocket that orientates the coumarin ring \ntowards the FAD cofactor whereas the 3-aryl ring is directed to the entrance hydrophobic cavity. This \nfact is in accordance with t he observation that small s ubstituents at position 6 are better tolerated than \nbulky substituents . An increase of the size of the substituents at position 6 in the compounds 18-23 \nshowed a loss of hMAO-B a ctivity probably due to the lack of spa ce in the binding cavity with a \npossible disruption of t he proposed binding mode and possible s hift of t he coumarin n ucleus towards t he \nhydrophobic cavity. On the other hand, polar s ubstituents with ability to establish hydrogen bonds, such \nas hydroxyl groups, could cause an opposite s hift of the coumarin ring towards t he FAD cofactor with \nthe consequent disruption of some hydrophobic interactions between t he 3-aryl ring and the \n286hydrophobic entrance cavity. In fact, docking analysis of the compounds 16 and 17 with a hydroxyl \nsubstituent at position 6 s howed the possibility of establis hing a hydrogen bond with t he FAD cofactor \nfavourable for the compound binding but causing at the same time a de crease in the hydrophobic \ninteraction contribution by t he 3-aryl fragment . Similar do cking results could explain the different \npotency shown by compounds 1 and 2 against the hMAO-B (IC 50 values are 11.81 and 0.284 \u03bcM \nrespectively). The docking retrieved a pose for compound 1 slightly shifted towards the FAD that could \ndiminish t he contribution of the hidrophobic interactions to the binding with t he entran ce cavity. \nHowever, the coumarin ring for compound 2 is placed in a very similar manner as the compounds 12 \nand 14, shown in Figure 4, that allows a better fit for t he 3- aryl ring in the hidrophobic cavity .  \nThe 3-aryl ortho bromine s ubstituted derivatives have experimentally shown a decrease of activity \nsince the meta  or para bromine s ubstituted compounds showed a better accommodation in the \nhydrophobic cavity.57 In fact, the bromine atom in ortho s howed a s horter distance to the carbonyl \noxygen of the Phe168. Docking analysis suggests that polar substituents at ortho position of the 3-aryl \nring, such as hydroxyl groups, could improve the hMAO-B a ctivity compared to hydrophobic \nsubstituents . The compound 13 with bromine atom in ortho s howed an IC50 = 4.34 \u03bcM whereas a similar \ncompound with hydroxyl substituent was recently reported to have an improved activity (IC 50 = 0.12 \n\u03bcM).57 Contrarily, polar s ubstituents at meta  and para positions are not as appropriate for t he activity as \nhydrophobic s ubstitutions. This fa ct corroborates t he information that was also recently reported by o ur \nresearch group.57 \nSelectivity of t his type of compounds towards hMAO-B has also been studied showing the ability of \nthe compounds to recognize the pocket in hMAO-B w hereas a more limited binding has been fo und \nagainst the hMAO-A. On one hand, compound 11 did not s how H-bond interactions with hMAO-A. On \nthe other hand, and alt hough compound 20 showed the capability of s hifting some water mole cules \nplaced deeply in the cavity through t he establishment of an H-bond with Tyr197, this overall pro cess \ncould energetically limit the ligand-protein binding. Both isoenzymes differ in some residues in the \n287pocket that affect selectively the binding of the studied coumarins.  \n \nConclusion  \nIn this study, a general and effi cient synthesis of a new series of 3-arylcoumarins was developed \nusing the Perkin, hydrolysis and t he Williamson reactions. Determination of hMAO isoform activity \nwas carried out and the majority of the compounds exhibited selectivity for the hMAO-B isoenzyme \nwith high affinity, in the range of nano and picoMolar concentrations . Compound 12 is more than 6000 \ntimes more active and more than 200 times more sele ctive than selegiline (reference compound) against \nMAO-B isoenzyme. Molecular docking studies were performed to establis h the nature of the interaction \nbetween the studied compounds and hMAO enzymes leading to a rationalization of structure -activity \nrelationship for t he synthesized series. Additionally, predi ction of blood-brain partitioning through a \nQSPR model showed the great potential of this type of compounds to cross the BBB and acting in the \nCNS. The res ults encourage to f urther explore the potential of this chemical family as dr ug candidates \nfor the treatment of Parkinson\u2019s disease.  \nExperimental Section Chemistry. Melting points were determined using a Reichert Kofler thermopan or in capillary tubes on \na B\u00fcchi 510 apparatus and are uncorrected. \n1H and 13C NMR spectra were recorded on a Bruker AMX \nspectrometer at 300 and 75.47 MHz, respectively, using TMS as internal standard (chemical shifts in \u03b4 \nvalues, J in Hz). Mass spectra were obtained using a Hewlett Packard 5972-MSD spectrometer . Silica \ngel (Merck 60, 230\u201300 mesh) was used for flas h chromatography (FC). Analytical thin layer \nchromatography (TLC) was performed on plates precoated with silica gel (Merck 60 F254, 0.25 mm). \nThe purity of the compounds was assessed by high performance liquid chromatography (HPLC ) \ncoupled at diode array detector (DAD G1315D, Agilent Technologies ) on an Agilent Technologies 1200 \nseries equipped with a G1311A quaternary pump. Instrument software Agilent ChemStation for LC and \n288CE systems was used for data acquisition. Different analyti cal columns and mobile phases (all solvents \nwere HPLC grade) were tested. The mobile p hase was H 2O:CH 3CN=70:30 and an Eclipse xdb C18 \ncolumn (5 \u03bcm particle size, 0.46 mm i.d., 25 cm length; Agilent Technologies) was used. The purity of \nthe compounds was fo und to be \u2265 95%.  \n \nGeneral P rocedure for the Preparation  of 3-Phenylcoumarins 1-3, 5-8 and 11-15.  A solution of 2-\nhydroxy-5-methylbenzaldehyde/2-hydroxy-5-methoxybenzaldehyde (7.34 mmol) and the corresponding \nphenylacetic acid (9.18 mmol) in dimethyl sulfoxide (15 mL) was prepared. N,N\u2019-\ndicyclohexylcarbodiimide (11.46 mmol) was added and the mixture was heated in an oil-bath at 110 \u00baC \nfor 24 h. Ice (100 mL) and acetic acid (10 mL) were added to the reaction mixture. After keeping it at room temperature for 2 h, the mixture was extracted with ether (3 x 25 mL). The organic layer was \nextracted with sodium bicarbonate solution (50 mL, 5%) and then water (20 mL). The solvent was \nevaporated under vacuum and the dry residue was purified by FC (hexane/ethyl acetate 9:1). \n  \n3-(4-Bromophenyl)-6-methylcoumarin (11). Yield 62%; mp 197-198 oC. 1H NMR (CDCl 3) 2.44 (s, \n3H, CH 3), 7.24 (dd, 1H, H-7, J=7.9, J=1.6), 7.36 (dd, 2H, H-5, H-8, J=7.9, J=1.7), 7.56-7.62 (m, 4H, H-\n2\u2019, H-3\u2019, H-5\u2019, H-6\u2019), 7.78 (s, 1H, H-4). 13C NMR (CDCl 3) 20.8, 116.2, 119.2, 123.0, 127.0, 127.7, \n130.1, 131.6, 132.8, 133.7, 134.3, 139.9, 151.7, 160.5. MS m/z 317 (18), 316 (99), 315 ([M + 1]+, 19), \n314 (M+, 100), 288 (34), 287 (22), 286 (34), 285 (17), 179 (17), 178 (36), 152 (9), 118 (14), 89 (11), 76 \n(12). Anal. Calcd for C 16H11BrO 2: C, 60.98; H, 3.52. Found: C, 61.00; H, 3.56. \n3-(3-Bromophenyl)-6-methylcoumarin (12). Yield 65%; mp 159-160 oC. 1H NMR (CDCl 3) 2.45 (s, \n3H, CH 3), 7.25-7.30 (m, 2H, H-7, H-8), 7.36 (dd, 2H, H-4\u2019, H-5\u2019, J=7.9, J=2.1), 7.56 (dd, 1H, H-6\u2019, \nJ=7.8, J=2.2), 7.68 (d, 1H, H-5, J=2.0), 7.80 (s, 1H, H-4), 7.86 (t, 1H, H-2\u2019, J=1.8). 13C NMR (CDCl 3) \n20.8, 116.2, 119.1, 122.4, 127.2, 127.8, 129.9, 131.4, 131.7, 132.9, 134.3, 136.7, 140.4, 140.6, 151.7, \n160.3. MS m/z 317 (18), 316 (99), 315 ([M + 1]+, 19), 314 (M+, 100), 286 (34), 285 (17), 179 (17), 178 \n(36), 152 (9), 118 (14), 89 (11), 76 (12). Anal. Calcd for C 16H11BrO 2: C, 60.98; H, 3.52. Found: C, \n28960.94; H, 3.49. \n3-(4-Bromophenyl)-6-methoxycoumarin (14). Yield 70%; mp 174-175 \u00baC. 1H NMR (CDCl 3) 3.88 (s, \n3H, OCH 3), 6.99 (d, 1H, H-5, J=2.8), 7.13 (dd, 1H, H-7, J=9.1, J=3.0), 7.29 (d, 1H, H-8, J=9.1), 7.54-\n7.60 (m, 4H, H-2\u2019, H-3\u2019, H-5\u2019, H-6\u2019), 7.79 (s, 1H, H-4). 13C NMR (CDCl 3) 55.8, 109.9, 117.5, 119.5, \n119.8, 123.2, 127.5, 130.1, 131.6, 133.6, 139.8, 148.0, 156.2, 160.4. MS m/z 333 (17), 332 (99), 331 \n([M + 1]+, 17), 330 (M+, 100), 304 (14), 302 (14), 261 (11) 259 (11), 180 (12), 152 (55), 126 (20), 76 \n(11). Anal. Calcd for C 16H11BrO3: C, 58.03; H, 3.35. Found: C, 57.97; H, 3.30. \n3-(3-Bromophenyl)-6-methoxycoumarin (15). Yield 72%; mp 151-152 \u00baC . 1H NMR (CDCl 3) 3.91 (s, \n3H, CH 3), 7.02 (d, 1H, H-5, J=2.9), 7.17 (dd, 1H, H-7, J=8.0, J =2.9), 7.34 (dd, 2H, H-4\u2019, H-5\u2019 J=10.0, \nJ=3.9), 7.57 (dd, 1H, H-6\u2019, J=9.8, J=2.8), 7.70 (d, 1H, H-8, J=7.7), 7.82 (s, 1H, H-4), 7.78 (t, 1H, H-2\u2019, \nJ=1.8). 13C NMR (CDCl 3) 55.7, 110.0, 117.5, 119.7, 120.0, 122.5, 127.1, 127.3, 129.9, 131.4, 131.8, \n136.7, 140.3, 148.1, 156.2, 160.3. MS m/z  333 (17), 332 (99), 331 ([M + 1]+, 18), 330 (M+, 100), 304 \n(14), 302 (14), 180 (14), 152 (44), 126 (16). Anal. Calcd for C 16H11BrO3: C, 58.03; H, 3.35. Found: C, \n58.07; H, 3.40. General P rocedure for the Preparation  of 3-(Bromomethoxyphenyl)coumarins 9 and 10. A \nsolution of 3-(methoxyphenyl)coumarins (7 or 8, 3.76 mmol), NBS (4.51 mmol) and AIBN (cat.) in \nCCl\n4 (5 mL) was stirred under refl ux for 18 h. The res ulting solution was filtered to  remove the \nsuccinimide. The solvent was evaporated under vacuum and purified by flash chromatography \n(hexane/ethyl acetate 95:5)  to obtain respectively compounds 9 and 10 in yields of 41% and 51%.61 \nGeneral P rocedure for the Preparation of Hydroxy -3-phenylcoumarins 4, 16 and 17. A solution of \nsubstituted 6-methoxy-3-phenylcoumarin (3, 14 or 15, 0.50 mmol) in acetic a cid (5 mL) and acetic \nanhydride (5 mL), at 0 \u00baC, was prepared. Hydriodic a cid 57% (10 mL) was added dropwise. The \nmixture was stirred, under refl ux temperature, for 3 h. The solvent was evaporated under vacuum and \nthe dry resid ue was purified by CH 3CN crystallization to yield 4, 16 and 17, respectively .  \n3-(4-Bromophenyl)-6-hydroxy coumarin (16). Yield 85%; mp 224-225 \u00baC. 1H NMR (DMSO-d 6) 7.04-\n2907.13 (m, 2H, H-5, H-8), 7.30 (dd, 1H, H-7, J=8.7, J=2.6), 7.63-7.74 (m, 4H, H-2\u2019, H-3\u2019, H-5\u2019, H-6\u2019), \n8.24 (s, 1H, H-4), 9.82 (s, 1H, OH). 13C NMR (DMSO-d 6) 113.1, 117.3, 120.4, 120.5, 122.3, 126.1, \n131.1, 131.6, 134.5, 141.4, 146.9, 154.3, 160.2. MS m/z 319 (19), 318 (99), 317 ([M + 1]+, 19), 316 \n(M+, 100), 290 (58), 288 (60), 181 (19), 153 (12), 152 (44), 126 (15), 118 (11), 76 (14). Anal. Calcd for \nC15H9BrO3: C, 56.81; H, 2.86. Found: C, 56.77; H, 2.81. \n3-(3-Bromophenyl)-6-hydroxy coumarin (17). Yield 89%; mp 219-220 \u00baC . 1H NMR (DMSO-d 6) 7.06 \n(t, 2H, H-5, H-8, J=8.8), 7.28 (d, 1H, H-7, J=8.9), 7.42 (td, 1H, H-5\u2019, J=8.6, J=2.4), 7.61 (dd, 1H, H-4\u2019, \nJ=8.0, J=1.3), 7.73 (dd, 1H, H-6\u2019, J=7.8, J=1.4), 7.93 (d, 1H, H-2\u2019, J=1.5), 8.26 (s, 1H, H-4), 9.80 (s, \n1H, OH). 13C NMR (DMSO-d 6) 113.2, 117.3, 120.3, 120.6, 121.9, 125.7, 128.0, 130.7, 131.5, 131.6, \n137.6, 142.0, 146.9, 154.3, 160.2. MS m/z  319 (16), 318 (99), 317 ([M + 1]+, 18), 316 (M+, 100), 290 \n(55), 288 (57), 181 (27) 153 (17), 152 (50), 151 (13), 126 (16), 119 (17), 76 (14), 71 (15), 69 (12), 57 \n(24), 55 (16). Anal. Calcd for C 15H9BrO3: C, 56.81; H, 2.86. Found: C, 56.86; H, 2.90. \nGeneral P rocedure for the Preparation  of 6-(2-Oxopropoxy)-3-phenylcoumarins 18 and 21. To a \nsuspension of anhydrous K2CO3 (16 or 17, 0.25 mmol) and the corresponding hydroxycoumarin (0.13 \nmmol), in anhydrous acetone (3 mL), the chloroacetone (0.25 mmol) was added. The suspension was \nstirred, at refl ux temperature, for 16 h. The mixture was cooled and the precipitate was recovered by \nfiltration and was hed with anhydrous acetone (3 x 40 mL). The solvent was evaporated under vacuum \nand the dry resid ue was purified by FC (hexane/ethyl acetate 85:15)  to obtain 18 and 21, respectively.  \n3-(4-Bromophenyl)-6-(2-oxopropoxy )coumarin (18). Yield 81%; mp 157-158 \u00baC . 1H NMR (CDCl 3) \n2.35 (s, 3H, CH 3), 4.66 (s, 2H, CH 2), 6.98 (d, 1H, H-5, J=2.9), 7.20 (dd, 1H, H-7, J=9.1, J=2.9), 7.30 (d, \n1H, H-8, J=9.1), 7.55-7.67 (m, 4H, H-2\u2019, H-3\u2019, H-5\u2019, H-6\u2019), 7.79 (s, 1H, H-4). 13C NMR (CDCl 3) 26.6, \n73.5, 111.1, 117.9, 119.8, 119.9, 123.4, 127.9, 130.1, 131.7, 133.4, 139.4, 148.6, 154.3, 160.2, 204.6. \nMS m/z 376 (11), 375 (72), 374 (100), 373 ([M + 1]+, 73), 372 (M+, 99), 332 (28), 331 (87), 330 (30), \n329 (88), 302 (28), 301 (54), 245 (31), 164 (48), 163 (78), 152 (84), 151 (19), 126 (48). Anal. Calcd for \nC18H13BrO 4: C, 57.93; H, 3.51. Found: C, 57.87; H, 3.47. \n2913-(3-Bromophenyl)-6-(2-oxopropoxy )coumarin (21). Yield 83%; mp 167-168 \u00baC. 1H NMR (CDCl 3) \n2.30 (s, 3H, CH 3), 4.61 (s, 3H, CH 2), 6.94 (d, 1H, H-5, J=3.0), 7.15 (dd, 1H, H-7, J=9.1, J =2.0), 7.33 \n(dd, 2H, H-4\u2019, H-5\u2019, J=8.1, J =2.4), 7.53 (d, 1H, H-8, J=9.1), 7.66 (dd, 1H, H-6\u2019, J=8.2, J=2.3), 7.75 (t, \n1H, H-2\u2019, J=2.5), 7.83 (s, 1H, H-4).13C NMR (CDCl 3) 26.6, 73.5, 111.1, 117.9, 119.8, 119.9, 122.5, \n127.2, 127.5, 130.0, 131.4, 132.0, 136.5, 139.9, 148.6, 154.3, 160.1, 204.5. MS m/z 375 (20), 374 (100), \n373 ([M + 1]+, 21), 372 (M+, 100), 331 (43), 329 (43), 301 (15) 273 (10), 164 (17), 163 (31), 152 (30), \n126 (13). Anal. Calcd for C 18H13BrO 4: C, 57.93; H, 3.51. Found: C, 57.88; H, 3.47. \nPreparation  of 6-(2-Cyclopentyloxy)-3-phenylcoumarins 19 and 22. To a suspension of anhydrous \nK2CO3 (0.25 mmol) and the corresponding 6-hydroxycoumarin (16 or 17, 0.13 mmol), in anhydrous \nacetone (3.0 mL), the cyclopentyl bromide (0.25 mmol) was added. The suspension was stirred, at \nreflux temperature, for 24 h. The mixture was cooled and the precipitate was recovered by filtration and \nwashed with anhydrous acetone (3 x 40 mL). The solvent was evaporated under vacuum and the dry \nresidue was purified by FC (hexane/ethyl acetate 9:1) to obtain 19 and 22, respectively.  \n3-(4-Bromophenyl)-6-(cyclopentyloxy)coumarin (19). Yield 63%; mp 164-165 oC. 1H NMR (CDCl 3) \n1.27-1.41 (m, 4H, 2xH-3\u2019\u2019, 2xH-4\u2019\u2019), 1.49-1.72 (m, 2H, 2xH-5\u2019\u2019), 1.77-2.29 (m, 2H, 2xH-2\u2019\u2019), 4.38 (m, \n1H, H-1\u2019\u2019), 6.96 (d, 1H, H-5, J=2.7), 7.15 (dd, 2H, H-7, H-8, J=9.1, J=2.7), 7.2-7.38 (m, 2H, H-2\u2019, H-\n6\u2019) 7.44-7.67 (m, 2H, H-3\u2019, H-5\u2019), 7.76 (s, 1H, H-4). 13C NMR (CDCl 3) 24.0, 32.8, 80.1, 111.9, 117.5, \n119.8, 120.9, 123.0, 123.1, 127.3, 130.2, 131.6, 133.7, 139.9, 147.8, 154.7. MS m/z 387 (6), 386 (25), \n385 ([M + 1]+, 6), 384 (M+, 25), 319 (22), 318 (100), 317 (24), 316 (99), 290 (41) 288 (42), 181 (11), \n152 (38). Anal. Calcd for C 20H17BrO3: C, 62.35; H, 4.45. Found: C, 62.40; H, 4.49. \n3-(3-Bromophenyl)-6-(cyclopentyloxy)coumarin (22). Yield 65%; mp 228-229 oC. 1H NMR (CDCl 3) \n1.57-1.99 (m, 8H, 2xH-2\u2019\u2019, 2xH-3\u2019\u2019, 2xH-4\u2019\u2019, 2xH-5\u2019\u2019), 4.77 (m, 1H, H-1\u2019\u2019), 6.95 (d, 2H, H-5, J=3.0), \n7.05 (dd, 2H, H-7, H-8, J=8.8, J=2.7), 7.24-7.35 (m, 2H, H-4\u2019, H-5\u2019), 7.53 (m, 1H, H-6\u2019), 7.76 (s, 1H, \nH-4), 7.84 (t, 1H, H-2\u2019, J=2.0). 13C NMR (CDCl 3) 24.0, 32.7, 80.1, 111.9, 117.5, 119.7, 121.0, 122.5, \n127.0, 127.3, 129.9, 131.4, 131.7, 136.8, 140.4, 147.8, 154.7, 160.4. MS m/z 387 (11), 386 (45), 385 (M \n292+ 1]+, 12), 384 (M+, 45), 319 (19), 318 (100), 317 (22), 316 (100), 290 (27) 288 (27), 152 (11). Anal. \nCalcd for C 20H17BrO3: C, 62.35; H, 4.45. Found: C, 62.30; H, 4.39. \nPreparation  of 2-[(3-Penhylcoumarin-6-yl)oxy]acetyl chloride 20 and 23. To a suspension of \nanhydrous K2CO3 (0.25 mmol) and the corresponding 6-hydroxycoumarin (16 or 17, 0.13 mmol), in \nanhydrous acetone (3.0 mL), the 2-chloroacetyl chloride (0.25 mmol) was added. The suspension was \nstirred, at refl ux temperature, for 24 h. The mixture was cooled and t he precipitate was recovered by \nfiltration and was hed with anhydrous acetone (3 x 40 mL). The solvent was evaporated under vacuum \nand the dry residue was purified by FC (hexane/ethyl acetate 8:2) to obtain 20 and 23, respectively.  \n2-[(3-(4-Bromophenyl)coumarin-6-yl)oxy]acetyl chloride (20). Yield 63%; mp 118-119 oC. 1H NMR \n(CDCl 3) 5.52 (s, 2H, CH 2), 7.05-7.09 (d, 1H, H-5, J=2.5), 7.19 (d, 1H, H-8, J=8.3), 7.26 (dd, 1H, H-7, \nJ=8.8, J=2.4), 7.60-7.72 (m, 4H, H-2\u2019, H-3\u2019, H5\u2019, H6\u2019), 8.20 (s, 1H, H-4). 13C NMR (CDCl 3) 89.0, \n113.1, 117.2, 120.4, 122.3, 126.1, 131.0, 131.4, 131.6, 134.4, 141.3, 146.8, 154.3, 160.2, 169.0. MS m/z \n393 ([M + 1]+, 10), 392 (M+, 50), 319 (14), 318 (82), 317 (15), 316 (82), 297 (11) 295 (11), 290 (42), \n288 (43), 216 (13), 214 (13), 181 (16), 172 (48), 171 (26), 170 (50), 169 (24), 152 (30), 126 (24), 118 \n(11), 90 (20), 89 (13). Anal. Calcd for C 17H10BrClO 4: C, 51.87; H, 2.56. Found: C, 51.79; H, 2.52. \n2-[(3-(3-Bromophenyl)coumarin-6-yl)oxy]acetyl chloride (23). Yield 66%; mp 157-158 oC. 1H NMR \n(CDCl 3) 5.04 (s, 2H, CH 2), 7.05-7.08 (m, 1H, H-5, J=3.0), 7.25 (dd, 1H, H-7, J=8.0, J=3.5), 7.40 (d, \n1H, H-8, J=8.0), 7.58-7.63 (m, 2H, H-4\u2019, H-5\u2019), 7.72 (dd, 1H, H-6\u2019, J=7.6, J=1.2), 7.91 (d, 1H, H-2\u2019, \nJ=1.3), 8.24 (s, 1H, H-4). 13C NMR (CDCl 3) 65.5, 112.6, 113.2, 117.3, 120.2, 120.6, 121.9, 125.7, \n128.1, 130.8, 131.7, 137.6, 142.0, 146.9, 154.3, 160.2, 169.5. MS m/z 393 ([M + 1]+, 10), 392 (M+, 50), \n391 (17), 390 (86), 389 (17), 388 (86), 319 (16), 318 (99), 317 (29) 316 (100), 315 (13), 290 (53), 289 \n(19), 288 (54), 181 (21), 153 (17), 152 (60), 126 (23), 119 (16). Anal. Calcd for C 17H10BrClO 4: C, \n51.87; H, 2.56. Found: C, 51.82; H, 2.52. \n \nDetermination  of hMAO Isoform Ac tivity. Briefly, 0.1 mL of sodium phosphate buffer (0.05 M, pH \n2937.4) containing different concentrations of t he test drugs (new compounds or reference inhibitors) in \nvarious concentrations and adequate amounts of re combinant hMAO-A or hMAO-B required and \nadjusted to obtain in our experimental conditions t he same reaction velocity, i .e., to oxidize (in the \ncontrol group) t he same concentration of substrate: 165 pmol of p-tyramine/min (hMAO-A: 1.1 \u03bcg \nprotein; specifi c activity: 150 nmol of p-tyramine oxidized to p-hydroxyphenylacetaldehyde/min/mg \nprotein; hMAO-B: 7.5 \u03bcg protein; specifi c activity: 22 nmol of p-tyramine transformed /min/mg protein) \nwere incubated for 15 min at 37 \u00baC in a flat -black-bottom 96-well microtest plate, placed in the dark \nfluorimeter chamber. After this incubation period, the reaction was started by adding (final \nconcentrations) 200 \u03bcM Amplex Red reagent, 1 U/mL horseradis h peroxidase and 1 mM p-tyramine. \nThe production of H 2O2 and, consequently, of resorufin was quantified at 37 \u00b0C in a multidetection \nmicroplate fl uorescence reader (FLX 800, Bio-Tek Instruments, Inc., Winooski, VT, USA) based on the \nfluorescence generated (excitation, 545 nm, emission, 5 90 nm) over a 15 min period, in w hich the \nfluorescence increased linearly.  \nControl experiments were carried out simultaneously by repla cing the test drugs (new compounds \nand reference inhibitors) with appropriate dilutions of the vehicles. In addition, the possible capacity of \nthe above test drugs to modify the fl uorescence generated in the reaction mixture due to non -enzymatic \ninhibition (e.g., for directly reacting with Amplex Red reagent) was determined by adding t hese drugs to \nsolutions containing only the Amplex Red reagent in a sodium phosphate buffer. To determine the \nkinetic parameters of hMAO-A and hMAO-B (Km and V max), the corresponding enzymatic a ctivity of \nboth isoforms was evaluated (under the experimental conditions des cribed above) in the presence of a \nnumber (a wide range) of p-tyramine concentrations. \nThe specifi c fluorescence emission (used to obtain the final res ults) was calculated after subtraction \nof the background activity, which was determined from vials containing all components e xcept the \nhMAO isoforms, which were replaced by a sodium phosphate buffer solution. In our experimental \nconditions, t his background activity was pra ctically negligible.  \n294 \nPrediction of passive blood-brain partitioning and calculation of molecular descriptors.  \nThe procedure to calculate the theoretical logBB (the logarithm of the ratio of the concentration of \nthe compound in brain and in blood) was described with more detail in a previous publication.41 The \nligands were prepared with LigPrep using Maestro 9.2 software75,76 and the protonation state was \nestablished with Ionizer at pH 7. After calculating the atomic charges with the Gasteiger (PEOE) model, \nthe descriptors TPSA (Topological Polar Surface Area) and logP(o/w) (log octanol/water partition \ncoefficient) were calculated with MOE 2011.10.77 The descriptors\u00b4 values were introduced in the \nfollowing equation described by Vilar et al.:41 \n()1 0.3462-TPSA 0.0277- logP(o/w) 0.5159 log \u00d7 \u00d7 = BBclass  \nN=307  U=0.70  F(2, 304)=63.79  p<0.0001 \nwhere N is the number of compounds used in the training set of t he model developed to extract the \ndiscriminant equation, U is the Wilks\u00b4statistic, F is the Fisher ratio and p is the significance level. If the \nresult in the equation is >0 the compounds are predicted to have a logBB\u22650.3 which means that the \ncompounds readily cross the blood-brain barrier.70 If the result is <0 the compounds could still cross the \nblood-brain barrier but with logBB<0.3.  \nCalculation of other molecular descriptors, such as pharmacophore atom type descriptors, atom \ncounts and physical properties, were also carried out with MOE 2011.10.77 \n \nMolecular Docking Simulations.  \nMolecular docking simulations were carried out using Maestro software in the Schr\u00f6dinger 2011 \npackage.76 \nhMAO-B: \nLigand dataset preparation:  The dataset was composed of 23 coumarin derivatives and different ligands \nbelonging to hMAO-B crystal structures (PDB: 1OJ9, 1OJA, 1OJD, 2BK3, 2V5Z, 2V60, 2V61, 2XFN, \n2953PO7, 4A79).72 Different protonation states at pH 7.0\u00b12.0 using Epik and tautomers were generated \nwith LigPrep module.75 All the structures were optimized using OPLS_2005 force field. \nProtein structure preparation:  The crystal structure of the hMAO-B in complex with a coumarin \nderivative (PDB code: 2V60) was pre-processed using the Protein Preparation Workflow in Maestro \nsoftware.76 A water molecule establishing a hydrogen bond with the co-crystallized ligand was retained. \nHydrogens were added through this procedure and minimized with the OPLS_2005 force field while \nheavy atoms were constrained. Hydrogen bonding optimization was carried out and included the \nreorientation of hydroxyl groups, the water molecule and amide groups of Asn and Gln residues. \nProtonation states of His, Asp and Glu residues were also optimized.  \nReceptor grid generation:  A receptor grid was calculated using a van der Waals scaling factor of 1.0 \nwith a partial charge cut-off of 0.25. The grid was centered in the co-crystallized coumarin derivative c17 with an outer box length of 20 \u00c5. \nQM-polarized ligand docking procedure: In the first step of the QM-polarized docking,\n78 the ligands \nwere docked to the hMAO-B (2V60) using Standard Precision level (SP scoring function) of Glide79 and \nthree poses for each ligand were retained. Next, polarization of the ligand charges by the receptor was calculated. Quantum mechanical calculations using Jaguar with 6-31G*/LACVP* basis set, B3LYP \ndensity f unctional, and Ultrafine SC F accuracy level are carried out to determine the partial charges on \nthe ligands atoms inside t he protein pocket. In the third step, t he ligands were redo cked with t he new \ncharges using Extra Precision (XP) mode and t hree poses were retained for ea ch ligand . Ligands van der \nWaals s caling was 0.8. The selection of the final pose was made taking into account the energy score \nE\nmodel that combines the energy grid score, GlideScore and internal strain energy used in the \nconformational search. \nhMAO-A: Similar treatment was carried out for the hMAO-A crystal structure with the ligand harmine \n(PDB code: 2Z5X). \n \n296Acknow ledgment. We are gratef ul to the Xunta de Galicia (09CSA030203PR, PGIDIT07PXIB, \n10PXIB203303PR) and Ministerio de Sanidad y Cons umo (FIS PS09/00501) for financial support. \nMaria Jo\u00e3o Matos t hanks Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia for the fellowship \n(SFRH/BD/61262/2009). Santiago Vilar thanks the Angeles Alvari\u00f1o program from Xu nta de Galicia \n(Spain). \n \nREFERENCES  \n(1) Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. \nMulti-target-directed ligands to combat neurodegenerative diseases . J. Med. Chem. 2008, 51, 347-372. \n \n(2) Farnikova, K.; Krobot, A.; Kanovsky, P. Musculoskeletal problems as an initial manifestation of \nParkinson' s disease: A retrospective study. J. Neur. Sci. 2012, 319, 102-104.  \n (3) Youdim, M. B.; Buccaf usco, J. J . Multi-functional drugs for various CNS targets in the treatment of \nneurodegenerative disorders . Trends Pharmacol. Sci. 2005, 26, 27-35. \n \n(4) Nagatsu, T.; Sawada, M. Molecular mechanism of the relation of monoamine o xidase B and its \ninhibitors to Parkinson' s disease: possible impli cations of glial cells.  J. Neural. Transm. 2006, 71, 53-65. \n \n(5) Bilen, J.; Bonini, N . M. Drosophila as a model for human neurodegenerative disease.  Annu. Rev. \nGenet. 2005, 39, 153-171.  (6) Cuervo, A. M.; Stefanis, L.; Fredenburg, R.; Lansbury, P. T.; Sulzer, D. Impaired degradation of \nmutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305, 1292-1295. \n (7) Okochi, M.; Walter, J.; Koyama, A.; Nakajo, S.; Baba, M.; Iwatsubo, T.; Meijer, L.; Kahle, P. J.; \nHaass, C. Constitutive phosphorylation of t he Parkinson' s disease associated alpha-synuclein. J. Biol. \nChem. 2000, 275, 390-397. \n \n(8) Wimbis cus, M.; Kostenko, O.; Malone, D . MAO inhibitors: ris ks, benefits, and lore. Clevel. Clin. J. \nMed. 2012, 77, 859-882. \n297 \n(9) Tipton, K. F. Enzymology of monoamine o xidase. Cell. Biochem. Funct. 1986, 4, 79-87.  \n \n(10) Dostert, P.; Strolin B. M .; Jafre, M. Monoamine oxidase: basic and clinical frontiers . In Excerpta \nMedica; Elsevier: Amsterdan, 1982, pp. 1 97. (c) Singer, T. P. In Chemistry and Biochemistry of \nFlavoenzymes ; Muller, F., Ed.; CR C Press: Boca Raton FL, 1991; Vol. 2, pp. 437. \n (11) Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. Structure of rat \nmonoamine oxidase A and its specifi c recognitions for substrates and in hibitors.  J. Mol. Biol.  2004, 338, \n103-115.  \n \n(12) Weyler, W.; Hsu, Yun P. P.; Breakefield, X. O. Biochemistry and genetics of monoamine oxidase. \nPharmacol. Ther. 1990, 47, 391-417. \n (13) Bach, A. W. J.; Lan, N. C .; Johnson, D. L.; Abell, C. W .; Bembenek, M. E.; Kwan, S. W .; Seeburg, \nP. H.; Shih, J.  C. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of \ndifferences in enzymatic properties. Proc. Natl. Acad. Sci. 1988, 85, 4934-4938.  \n (14) Wouters, J. Structural aspects of monoamine o xidase and its reversible in hibition. Curr. Med. \nChem. 1998, 5, 137-162. \n (15) Grimsby, J.; Lan, N. C .; Neve, R.;  Chen, K.; Shih, J. C . Tissue distribution of human monoamine \noxidase A and B mRNA. J. Neurochem. 1990, 55, 1166-1169.  \n (16) Kalgutkar, A. S.; Castagnoli, N . Jr.; Testa, B. Selective inhibitors of monoamine o xidase (MAO-A \nand MAO-B) as probes of its catalytic site and mechanism. Med. Res. Rev. 1995, 15, 325 -388.  \n \n(17) Geha, R. M.; Rebrin, I.; Chen, K.; Shih, J. C . Substrate and inhibitor spe cificities for human \nmonoamine oxidase A and B are influenced by a single amino acid. J. Biol. Chem. 2001, 276, 9877-\n9882. \n \n(18) Rudorfer, M. V.; Potter, V. Z. Antidepressants . A comparative review of t he clinical pharmacology \nand therapeutic use of the \u201cnewer\u201d vers us the \u201colder\u201d dr ugs. Drugs 1989, 37, 713-738.  \n \n298(19) (a) Gerlach, M.; Double, K.; Reichmann, H.; Riederer, P. Arguments for the use of dopamine \nreceptor agonists in clinical and preclinical Parkinson\u00b4s diseases. J. Neural Transm. Suppl. 2003, 167-\n193. (b) Fernandez, H. H.; Chen, J. J . Monamine oxidase inhibitors: current and emerging agents for \nParkinson disease. Clin. Neuropharmacol. 2007, 30, 150-168.  \n \n(20) Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxidase -B inhibition in Alzheimer\u00b4s \ndisease. Neurotoxicology  2004, 25, 271-277. \n \n(21) Sayre, L. M.; Perry, G.; Smit h, M. A. Oxidative stress and ne urotoxicity. Chem. Res. Toxicol. 2008, \n21, 172-188.  \n(22) Filip, V.; Kolibas, E. Selegiline in the treatment of Alzheimer' s disease: a long -term randomized \nplacebo-controlled trial. C zech and slovak senile dementia of Alzheimer type study group. J. Psychiatr. \nNeurosci. 1999, 24, 234-243.  \n (23) Annan, N.; Silverman, R. B. New analogs of N-(2-aminoethyl)-4-chlorobenzamide (Ro 16-6491). \nSome of the most potent monoamine oxidase -B inac tivators. J. Med. Chem. 1993, 36, 3968-3970.  \n \n(24) Harfenist, M.; Joyner, C.; Mize, P.; White, H. Selective inhibitors of monoamine o xidase. 2 . \nArylamide SAR. J. Med. Chem. 1994, 37, 2085-2089. \n (25) Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S .; Yanez, M.; Orallo, \nF.; Sanna, M . L.; Gallinella, B.; Cirilli, R. Synt hesis, stereo chemical separation, and biological \nevaluation of sele ctive inhibitors of human MAO-B: 1-(4-Arylthiazol-2-yl)-2-(3-\nmethylcyclohexylidene)hydrazines . J. Med. Chem. 2010, 53, 6516-6520. \n \n(26) C himenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S .; \nAlcaro, S.; Ortuso, F.; Yanez, M.; Orallo, F.; Cirilli, R.; Ferretti, R.; La Torre, F. Synthesis, \nstereochemical identification, and selective inhibitory activity against human monoamine oxidase -B of \n2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones. J. Med. Chem.  2008, 51, 4874-4880.  \n \n(27) Frederick, R.; Dumont, W.; Ooms, F.; Aschenbach, L.; Van der Schyf, C. J .; Castagnoli, N .; \nWouters, J.; Krief, A. Synthesis, structural reassignment, and biologi cal activity of type B MAO \ninhibitors based on t he 5H- indeno[1,2-c]pyridazin-5-one core. J. Med. Chem. 2006, 49, 3 743-3747.  \n299 \n(28) Carotti, A.; Catto, M.; Leonetti, F.; Campagna, F.; Soto -Otero, R.; Mendez-Alvarez, E.; Thull, U.; \nTesta, B.; Altomare, C. Synt hesis and monoamine o xidase inhibitory activity of new pyrida zine -, \npyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J. Med. Chem. 2007, 50, 5364-5371.  \n \n(29) Leonetti, F.; Capaldi, C.; Pisani, L.; Nicolotti, O.; Muncipinto, G.; Stefanachi, A.; Cellamare, S.; \nCaccia, C.; Carotti, A. Solid -phase synthesis and insights into str ucture-activity relationships of \nsafinamide analog ues as potent and sele ctive inhibitors of type B monoamine oxidase. J. Med. Chem. \n2007, 50, 4909-4916.   (30) Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D. E.; Mattevi, A. Structure of human \nmonoamine oxidase B, a drug target for the treatment of neurological disorders . Nat. Struct. Mol. Biol.  \n2002, 9, 22-26. \n (31) Binda, C.; Li, M.; Hub\u00e1lek, F.; Restelli, N.; Edmondson, D. E.; Mattevi, A. Insights into the mode \nof inhibition of human mitochondrial monoamine oxidase B from high- resolution crystal str uctures. \nProc. Natl. Acad. Sci. U.  S. A. 2003, 100, 9750-9755.  \n (32) De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D. E.; Mattevi, A. Three-dimensional \nstructure of human monoamine oxidase A (MAO-A): Relation to the structures of rat MAO-A and \nhuman MAO B. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12684-12689.  \n (33) Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J .; Edmondson, D. E.; Mattevi, A. Crystal \nstructures of monoamine o xidase B in complex with fo ur inhibitors of the N -propargylaminoindane \nclass. J. Med. Chem. 2004, 47, 1767-1774.  (34) Milczek, E. M.; Bonivento, D .; Binda C.; Mattevi, A.; M cDonald, I. A.; Edmondson, D. E. \nStructural and mechanistic studies of mofegiline inhibition of re combinant human monoamine oxidase \nB. J. Med. Chem. 2008, 51, 8019-8026.  \n (35) Vilar, S.; C hakrabarti, M.; Costanzi, S. Prediction of passive blood-brain partitioning: \nstraightforward and effe ctive classifi cation models based on in silico derived physicochemical \ndescriptors . J. Mol. Graph. Model.  2010, 28, 899-903.  \n \n300(36) (a) Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Simple coumarins and analogues \nin medicinal chemistry: occurrence, synthesis and biological activity. Curr. Med. Chem. 2005, 12, 887-\n916. (b) Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L.  Simple Coumarins: Privileged \nScaffolds in Medi cinal Chemistry. Front. Med. Chem. 2009, 4, 23-85. \n \n(37) (a) Belluti, F.; Fontana, G.; Bo, L.; Carenini, N.; Giommarelli, C.; Z unino, F. Design, synthesis and \nanticancer activities of stilbene - coumarin hybrid compounds: identifi cation of novel proapoptoti c \nagents. Bioorg. Med. Chem. 2010, 18, 3543-3550. (b) Riveiro, M. E.; Moglioni, A.; Vazquez, R.; \nGomez, N.; Facorro, G.; Piehl, L.; de Celis, E. R.; Shayo, C.; Davio, C. Structural insights into \nhydroxycoumarin -induced apoptosis in U-937 cells. Bioorg. Med. Chem. 2008, 16, 2665-2675. \n \n(38) Vilar, S.; Q uezada, E.; Santana, L.; Uriarte, E.; Yanez, M.; Fraiz, N.; Alcaide, C.; Cano, E.; Orallo, \nF. Design, synthesis, and vasorela xant and platelet antiaggregatory activities of coumarin -resveratrol \nhybrids. Bioorg. Med. Chem. Lett. 2006, 16, 257-261. \n \n(39) Roussaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D. J .; Hamilakis, S. A novel synthesis of 3-\naryl coumarins and evaluation of their antio xidant and lipo xygenase inhibitory activity. Bioorg. Med. \nChem. Lett. 2010, 20, 3889-3892.  \n \n(40) Ostrov, D. A.; Hern\u00e1ndez Prada, J. A.; Corsino, P. E.; Finton, K. A.; Le, N.; Rowe, T. C. Discovery \nof novel DNA gyrase inhibitors by high-throughput virtual screening. Antimicrob.  Agents Chemother.  \n2007, 51, 3688-3698.  \n (41) Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.; Hong, S.  C.; \nTsay, S.-C.; Hsu, M.-H.; Hwu, J. R. Structure-activity relationship of new anti-Hepatitis C virus agents: \nheterobicycle-coumarin conjugates . J. Med. Chem. 2009, 52, 1486-1490.  \n (42) Kostova, I. Coumarins as inhibitors of HIV reverse trans criptase. Current HIV Res. 2006, 4, 347-\n363.  \n (43) C himenti, F.; Bizzarri, B.; Bolasco, A.; Secci, D.; C himenti, P.; Granese, A.; Carradori, S .; \nRivanera, D.; Zicari, A.; Scaltrito, M. M .; Sisto, F. Synthesis, selective anti -Helicobacter pylori activity, \nand cytotoxicity of novel N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides . Bioorg. Med. Chem. \nLett. 2010, 20, 4922-4926.  \n301 \n(44) C hilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S .; Poletto, G.; Mazzorana, M.; \nZagotto, G.; Uriarte, E.; Guiotto, A.; Meggio, F.; Moro, S. Coumarin as attractive casein kinase 2 (CK2) \ninhibitor scaffold: an integrate approa ch to elucidate the putative binding motif and explain structure -\nactivity relationships. J. Med. Chem. 2008, 51, 752-759.  \n (45) Timonen, J. M .; Nieminen, R. M .; Sareila, O.; Vainiotalo, P.; Moilanen, E.; Aulaskari, P. H. \nSynthesis and anti-inflammatory effects of a series of novel 7 -hydroxycoumarin derivatives. Eur. J. \nMed. Chem. 2011, 46, 3845-3850. \n \n(46) Garino, C.; Tomita, T.; Pietrancosta, N.; Laras, Y.; Rosas, R. Naphthyl and coumarinyl \nbiarylpiperazine derivatives as highly potent human \u03b2 -secretase inhibitors. Design, synthesis, and \nenzymatic BACE-1 and cell assays. J. Med. Chem. 2006, 49, 4275-4285.  (47) Rendenbach, B.; Weifenba ch, H.; Teschendorf, H. J. Preparation of 7-(arylalkoxy)coumarins as \ncentral nervous system agents . Patent D E 3834861 A1, 1990, (BASF AG). \n \n(48) Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; S ummo, L.; De Marco, A.; Rose, S.; Jenner, P.; \nTesta, B. Lipophilicity plays a major role in mod ulating the inhibition of monoamine o xidase B by 7 -\nsubstituted coumarins. Chem. Biodivers.  2006, 3, 134-149.  \n (49) Secci, D.; Carradori, S .; Bolasco, A.; Chimenti, P.; Y\u00e1\u00f1ez, M.; Ortuso, F.; Alcaro, S. Synthesis and \nselective human monoamine oxidase inhibition of 3-carbonyl, 3-acyl, and 3-carboxyhydrazido coumarin \nderivatives. Eur. J. Med. Chem. 2011, 46, 4846-4852.   (50) Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; \nSalvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a novel class of \npotent coumarin monoamine oxidase B inhibitors: development and biop harmacological profiling of 7 -\n[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl] -2H-chromen-2-one methanes ulfonate (NW-1772) as a \nhighly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. J. Med. Chem. \n2009, 52, 6685-6706. \n (51) Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizarri, B.; Granese, A.; Carradori, S .; Y\u00e1\u00f1ez, \nM.; Orallo, F.; Ortuso, F.; Alcaro, S. Synthesis, molecular modeling, and selective inhibitory activity \n302against human monoamine oxidases of 3-carboxamido -7-substituted coumarins. J. Med. Chem. 2009, \n52, 1935-1942.  \n \n(52) Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A. D.; Soto-Otero, R.; M\u00e9ndez-\u00c1lvarez, \nE.; Carotti, A. Structural Insights into Monoamine Oxidase Inhibitory Potency and Selectivity of 7-\nSubstituted Coumarins from Ligand- and Target-Based Approaches. J. Med.Chem. 2006, 49, 4912-\n4925. \n \n(53) Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; S ummo, L.; De Marco, A.; Rose, S.; Jenner, P.; \nTesta, B. Lipophilicity plays a major role in mod ulating the inhibition of monoamine o xidase B by 7 -\nsubstituted coumarins. Chem. Biodivers.  2006, 3, 134-149. \n (54) Santana, L.; Orallo, F.; Vi\u00f1a, D.; Matos, M.J.; Q uezada, E.; Ya\u00f1ez, M.; Vilar, S.; Uriarte, E. Use of \n6-substituted 3-phenylcoumarins as sele ctive monoamine oxidase B inhibitors for treating \nneurodcegenerative diseases and obesity and preparation of new derivatives . Spain. (2010), ES 2343347 \nA1 20100728.   (55) Matos, M. J .; Vi\u00f1a, D.; Q uezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; Santana, L.; Uriarte, E . A \nnew series of 3-phenylcoumarins as potent and sele ctive M AO-B inhibitors. Bioorg. Med. Chem. Lett. \n2009, 19, 3268-3270. \n (56) Matos, M. J .; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and evaluation of \n6-methyl-3-phenylcoumarins as potent and sele ctive M AO-B inhibitors. Bioorg. Med. Chem. Lett. 2009, \n19, 5053-5055.  (57) Matos, M. J .; Ter\u00e1n, C.; P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. Synthesis and Study \nof a Series of 3-Arylcoumarins as Potent and Selective Monoamine Oxidase B Inhibitors . J. Med. Chem. \n2011, 54, 7127-7137. \n (58) Matos, M. J .; V\u00e1zquez-Rodriguez, S.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. M AO inhibitory activity \nmodulation: 3-phenylcoumarins versus 3-benzoylcoumarins. Bioorg. Med. Chem. Lett. 2011, 21, 4224-\n4227.  (59) Vi\u00f1a, D.; Matos, M. J .; Y\u00e1\u00f1ez, M.; Santana, L.; Uriarte, E. 3-Substituted coumarins as dual \n303inhibitors of AChE and MAO for the treatment of Alzheimer\u00b4s disease. Med. Chem. Commun. 2012, 3, \n213-218. \n \n(60) Matos, M. J .; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E. New halogenated 3-\nphenylcoumarins as potent and sele ctive M AO-B inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 5157-\n5160. \n \n(61) Vi\u00f1a, D.; Matos, M. J .; Ferino, G.; Cadoni, E.; Laguna, R.; Borges, F.; Uriarte, E.; Santana, L. 8 -\nSubstituted-3-arylcoumarins as Potent and Selective M AO-B Inhibitors: Synt hesis, Pharmacological \nEvaluation and Do cking Studies . ChemMedChem 2012, 7, 464-470. \n \n(62) Delogu, G.; Picciau, C .; Ferino, G.; Quezada, E.; Podda, G.; Uriarte, E.; Vi\u00f1a, D. Synthesis, human \nmonoamine oxidase inhibitory activity and molecular docking studies of 3-h eteroarylcoumarin \nderivatives. Eur. J. Med. Chem. 2011, 49, 1147-1152. \n \n(63) Serra, S.; Ferino, G.; Matos, M. J .; V\u00e1zquez-Rodr\u00edguez, S.; Delogu, G.; Vi\u00f1a, D.;  Cadoni, E.; \nSantana, L.; Uriarte, E. Hydroxycoumarins as sele ctive M AO-B inhibitors. Bioorg. Med. Chem. Lett. \n2012, 22, 258-261. \n (64) Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: safety and future. \nNeurotoxicology  2004, 25, 11-20. \n \n(65) Hub\u00e1lek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castaganoli, N .; Edmondson, D. E. \nDemonstration of isole ucine 199 as a structural determinant for the selective inhibition of human \nmonoamine oxidase B by specifi c reversible inhibitors. J. Biol. Chem . 2005, 280, 16761-15766. \n (66) Son, S-Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukih ara, T. Stucture of human \nmonoamine oxidase A at 2.2 \u00c5 resolution: the control of opening t he entry for substrates/in hibitors. \nProc. Natl. Acad. Sci. U. S. A. 2008, 105, 5739-5744.  (67) Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D. E.; Mattevi, A.  \nStructures of human monoamine oxidase B complex es with selective noncovalent inhibitors: safinamide \nand coumarin analogs . J. Med. Chem . 2007, 50, 5848-5852. \n \n304(68) Prendergast, P. T. Use of flavones, coumarins and related compounds to treat infe ctions PCT Int. \nAppl. (2001), WO 2001003681 A2 20010118.  \n \n(69) Y\u00e1\u00f1ez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effe cts of cis and trans-resveratrol on \nnoradrenaline and 5 -hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. \nRes. Comm.  2006, 344, 688-695. \n (70) Clark, D. E. Rapid calculation of polar mole cular surfa ce area and its application to the prediction \nof transport phenomena. 2 . Prediction of blood-brain barrier penetration.  J. Pharm. Sci. 1999, 88, 815-\n821.  \n \n(71) Abraham, M. H.; Tak\u00e1cs-Nov\u00e1k, K.; Mitchell, R. C. On the partition of amp holytes: application to \nblood-brain distribution. J. Pharm. Sci. 1997, 86, 310-315.  \n \n(72) RCSB Protein Data Bank: http://www.rcsb.org/ (Accessed Jun 2012) \n \n(73) Rishton, G. M.; LaBonte, K.; Williams, A. J .; Kassam, K.; Kolovanov, E. Computational \napproaches to the prediction of blood-brain barrier permeability: A comparative analysis of central \nnervous system drugs versus secretase inhibitors for Alzheimer' s disease . Curr. Opin. Drug Discov.  \nDevel. 2006, 9, 303-313. \n (74) Katritzky, A. R.; Kuanar, M .; Slavov, S.; Dobchev, D. A.; Fara, D. C .; Karelson, M.; Acree, W. E. \nJr.; Solov' ev, V. P.; Varnek, A. Correlation of blood -brain penetration using structural descriptors . \nBioorg. Med. Chem. 2006, 14, 4888-4917.  (75) LigPrep, version 2.5, Schr\u00f6dinger, LLC, New York, NY, 2011.  \n(76) Maestro, version 9.2, Schr\u00f6dinger, LLC, New York, NY, 2011. \n (77) M OE software, version 2011.10; C hemical Computing Group, Inc., 2011. Available: \nwww.chemcomp.com/ \n (78) QM-Polarized Ligand Docking protocol; Glide version 5.7, Jaguar version 7.8, QSite version 5.7, \nSchr\u00f6dinger, LLC, New York, NY, 2011. \n305 \n(79) Glide, version 5 .7, Schr\u00f6dinger, LLC, New York, NY, 2011. \n306Table of Contents Graphic \n \n307Synthesis and adenosine receptor s binding affinities of a series 1 \nof 3-aryl coumarin s 2 \n 3 \nMaria Jo\u00e3o Matos,a,b,* Veronika Hogger,b Alexandra Gaspar,a Sonja Kachler,c Fernanda 4 \nBorges,a Eugenio Uriarte,b Lourdes Santanab and Karl-Norbert Klotzc 5 \naCIQUP/Departamento de Qu\u00edmica  e Bioqu\u00edmica,  Faculdade  de Ci\u00eancias,  Universidade  do Porto,  4169- 6 \n007Porto,  Portugal  7 \nbDepartamento  de Qu\u00edmica  Org\u00e1nica,  Facultad de Farmacia,  Universidad de Santiago de Compostela,  8 \n15782, Santiago de Compostela,  Spain  9 \ncInstitut  f\u00fcr Pharmakologie  und Toxikologie,  Universit \u00e4t W\u00fcrzburg,  97078 W\u00fcrzburg,  Germany  10 \n 11 \ne-mails : mariajoao .correiapinto@rai .usc.es, veroni kahogger@web .de, ale xandrangaspar@gmail .com, 12 \nsonja.kachler@ toxi.uni-wuerzburg.de, mfernandamborges@gmail .com, e ugenio.uriarte@ usc.es, 13 \nlourdes.santana@ usc.es, klotz@toxi.uni-wuerzburg.de 14 \n 15 \n* Corresponding a uthor: To whom corresponden ce should be addressed . Phone: +34 981 563100.  Fax: 16 \n+34 981 5449 12. E-mail: mariajoao .correiapinto@rai .usc.es 17 \n 18 \nAbstract 19 \n 20 \nObjectives In the present communication we report the synthesis, pharmacological 21 \nevaluation, theoretical evaluation of ADME properties, and SAR study of a selected 22 \nseries of 3-arylcoumarins (compounds 1-9). Adenosine receptors (ARs) binding activity 23 \nand selectivity of t he synthesized compounds 1-9 were evaluated in this stu dy. Different 24 \nsubstituents were introd uced in both benzene rings of the evaluated s caffold, at 25 \npositions 6 and 3\u2019 or 4\u2019 of t he moiety. The lack of data on the 3-arylcoumarin scaffold 26 \nencouraged us to explore the ARs\u2019 binding activity of a selected series of derivatives . 27 \nMethods A new series of coumarins (compounds 1-9) were synthesized and evaluated 28 \nby radioligand binding studies towards adenosine receptors.  29 \nKey findings Analyzing t he experimental data it can be observed t hat neit her the simple 30 \n3-arylcoumarin, nor the 4\u2019-nitro derivatives presented dete ctable binding affinity for t he 31 \nevaluated receptors. Although, most of the other substituted derivatives have good 32 \nbinding affinity profiles, especially against the hA1/hA3 or only hA 3 AR.  33 \nConclusions The most remarkable derivative is compound 2, presenting t he best 34 \naffinity for hA 3 AR (K i = 2,680 nM) and signifi cant selectivity for t his subtype.  35 \nKeywords 3-Arylcoumarins; adenosine receptors binding a ctivity; ADME properties ; 36 \nSAR study. 37 \n 38 \nIntroduction 39 \n 40 \nAdenosine receptors (ARs) are G- protein-coupled receptors that exert a huge number of 41 \nphysiological activities through a ctivation of four different receptor subtypes: A1, A2A, 42 \n309A2B and A 3.[1] ARs are distrib uted throughout a wide variety of tiss ues in mammalian 43 \nsystems and regulate diverse physiological f unctions by modulating cell signalling, 44 \nbeing activated by the endogenous agonist adenosine and blo cked by natural 45 \nantagonists .[2,3] During the last years, the search for agonist and antagonist ligands 46 \nbinding to individual AR subtypes has been intensified, as t he role of t hese receptors in 47 \ndrug discovery is continuously expanding.[4-6] Most of the AR antagonists are promising 48 \nnew drug candidates for a n umber of pathological processes such as inflammation 49 \n(A3),[5] heart and renal failure (A1),[7] or neurological disorders li ke Parkinson\u00b4s [8,9] and 50 \nAlzheimer\u2019s diseases (A2A and/or A1).[10] In particular A3 AR, the most recently 51 \nidentified s ubtype, has been the subject of intensive resear ch during the last decade as a 52 \npotential therapeutic target in preventing ischemic damage in the brain and heart.[11] In 53 \naddition, as the A3 AR is expressed in relatively high densities in the lung, liver, 54 \nneutrophils, macrophages and glial cells, it can encompass an important role in 55 \ninflammation, immunosuppression and cell growth.[12] Therefore, A3 AR ligands can 56 \nhave therapeutic potential against cancer, hepatitis, myocardial is chemia, rheumatoid 57 \narthritis or ophthalmic diseases .[13] More recently, an involvement of A3 AR in 58 \nneuroprotection was also proposed.[14] However, the mixed A3-mediated 59 \nprotective/damaging effect remains enigmatic and has to be clarified. Therefore, 60 \nadditional studies must be performed to verify t he modulating effect of the A3 AR 61 \nagonists and antagonists in ne urodegenerative diseases . As a consequence, numerous A3 62 \nAR agonists and antagonists have been developed and investigated for t heir potential 63 \ntherapeutic applications in diseases w here the A 3 AR seems to have a positive role. 64 \nOf the large number of compounds exerting high potency and selectivity towards ARs, 65 \nthe xanthine and adenine scaffolds  have been used to develop the so-called classical AR 66 \nantagonists . In the search for nonclassical AR ligands, novel str uctures have recently 67 \nbeen discovered. Examples are the quinolinone derivatives (F igure 1 \u2013 I), recogni zed as 68 \nputative A1, A2A and A 2B AR ligands.[15] Based on these findings, and taken into 69 \nconsideration that the coumarin nucleus can be a non -nitrogen aromatic bioisoster 70 \nscaffold, it was fo und to be relevant to explore it in the design of novel AR antagonists. 71 \nOur interest in this new scaffold was also motivated by t he structure similarity between 72 \nthe coumarin skeleton and chromone scaffolds (Figure 1 \u2013 II), previously described as 73 \nAR antagonists t hat present a particular selectivity for t he A3 and A 2A AR subtypes.[16-74 \n18] Among them, our attention was fo cused on the 3-arylcoumarin ring system (Figure 1 75 \n\u2013 III), which has never been proposed as a s caffold for AR ligands.  The recent findings, 76 \nand the lack of data on the 3-arylcoumarin scaffold encouraged us to e xplore the ARs\u2019 77 \nbinding activity of a selected series of derivatives . 78 \n 79 \n(Figure 1) 80 \n 81 \nFigure 1. Examples of nonclassical AR ligands. Q uinolinone derivatives (I), chromone 82 \nderivatives (II) and 3-arylcoumarin derivatives (III). 83 \n 84 \nCoumarins are an important class of ben zopyrone heterocyclic compounds, of nat ural or 85 \nsynthetic origin, associated with remarkable pharmacological activities . [19,20] Diverse 86 \n310biological properties, s uch as antioxidant, anti-HIV, anticancer, anti-inflammatory, 87 \nantimicrobial, vasorela xant or enzymatic inhibitory agents, have been ascribed to this 88 \ntype of structure. [19-33] The fused heterocyclic framework of coumarins has been widely 89 \nused as a archetype for the synthesis of a wide variety of analog ues suitable to perform 90 \nstructure-activity relationship st udies intended to improve their biological 91 \nproperties.[19,20] In the last few years our research group has been engaged in the 92 \nsynthesis of new biologically active coumarins. In particular, the 3-arylcoumarin 93 \nscaffold has been a focal point of o ur recent studies demonstrating t heir importance as 94 \nmonoamine oxidase (MAO) inhibitors.[27-36 ] Different synthetic strategies can be used to 95 \nobtain the arylcoumarin scaffold. The principal one is the construction of the coumarin 96 \nnucleus by condensation: cyclization -type reactions . The classical Perkin condensation 97 \nis perhaps t he most direct and simple method  known for the preparation of t hese 98 \nmolecules.[23] Some variations of t his methodology are des cribed in the chemistry 99 \nsection below. 100 \nIn the present communication we report the synthesis, pharmacological evaluation, 101 \ntheoretical evaluation of ADME properties and S AR study of a selected series of 3- 102 \narylcoumarins (compounds 1-9). Adenosine receptors (ARs) binding activity and 103 \nselectivity of t he synthesized compounds 1-9  were evaluated in this study.  104 \n 105 \nMaterial s and M ethods 106 \n 107 \nChemistry 108 \n 109 \nCompounds 1-9 were effi ciently synthesized according to t he synthetic strategy outlined 110 \nin Scheme 1. Perkin condensation of different commercially available ortho- 111 \nhydroxybenzaldehydes with a conveniently substituted arylacetic a cid, using N,N\u2019- 112 \ndicyclohexylcarbodiimide (DCC) as dehydrating agent,[28,29,32] afforded t he 3- 113 \narylcoumarins 1-3.[37-39] In fact, these reaction conditions have been also fo und to be 114 \nappropriate when t he reagents en compass in t heir str ucture met hyl, methoxyl, ethoxyl or 115 \nhalogen groups. However, in t he case of the hydroxyl substituents, these groups must be 116 \npreviously protected by acetylation . Therefore, compound 4 was obtained starting from 117 \nthe 2,5-dihydroxybenzaldehyde and the 4 -methylphenylacetic a cid, using potassium 118 \nacetate in acetic anhydride, under refl ux, for 16 hours. Acetylation of the hydroxyl 119 \ngroups and pyrone ring closure occurred simultaneously.[40] Nitro-substituted 120 \ncompounds 5 and 6[41,42] were obtained via other modified Perkin conditions, using a 121 \nsubstituted ortho-hydroxybenzaldehyde and 4 -nitrophenylacetic a cid, in presen ce of 122 \nNaH in acetic anhydride, for 20 hours.[43] Compounds 7 and 8[32] were obtained by 123 \nacidic hydrolysis of t he respective methoxy/acetoxy derivatives 3 and 4, using hydriodic 124 \nacid 57% in the presence of acetic a cid and acetic anhydride.[29] Finally, the Williamson 125 \nreaction of the hydroxycoumarin 8 with chloroacetone, under refl ux of a cetone for 16 126 \nhours, gave the corresponding et her 9.[32] 127 \n 128 \n(Scheme 1) 129 \n 130 \n311Scheme 1 . Reagents and conditions: (a) DCC, DMSO, 110 \u00baC, 24 h; (b) CH3CO 2K, 131 \nAc2O, reflux, 16 h; (c) NaH, Ac2O, r.t., 20 h; (d) HI, AcOH, Ac2O, 110 \u00baC, 5 h; (e) 132 \nchloroacetone, K 2CO3, acetone, refl ux, 16 h. 133 \n 134 \nMelting points were determined using a Reichert Kofler thermopan or in capillary tubes 135 \non a B\u00fcchi 510 apparatus and are uncorrected. 1H and 13C NMR spectra were recorded 136 \non a Bruker AMX spectrometer at 300 and 75.47 MHz, respectively, using TMS as 137 \ninternal standard (chemical shifts in \u03b4 values, J in Hz). Mass spectra were obtained 138 \nusing a Hewlett-Packard 5988A spectrometer . Elemental analyses were performed using 139 \na Perkin-Elmer 240B microanalyser and were wit hin \u00b10.4% of calculated values in all 140 \ncases. Silica gel (Merck 60, 230\u201300 mesh) was used for flas h chromatography (FC). 141 \nAnalytical thin layer chromatography (TLC) was performed on plates pre coated with 142 \nsilica gel (Merck 60 F254, 0.25 mm). The purity of compounds was assessed by high 143 \nperformance liquid chromatography ( HPLC) coupled at diode array detector (DAD) on 144 \na Thermo Quest Spectrasystem (Thermo Fisher Scientific, Waltham, MA) equipped 145 \nwith a P4000 pump, an UV6000 UV-Vis diode array detector, and an SN4000 interface 146 \nto be operated via a personal computer. Instrument software ChromQuest 5.0 (Thermo 147 \nFisher Scientific, Waltham, MA) was used for data acquisition. Different analytical 148 \ncolumns and mobile phases (all solvents were HPLC grade) were tested. The mobile 149 \nphase was H2O:CH3CN=70:30 and an Eclipse xdb C18 column (5 \u03bcm particle size, 0.46 150 \nmm i.d., 25 cm length; Agilent Technologies) was used. The purity of the compounds  151 \nwas found to be higher than 95%.  152 \n 153 \nSynthetic methodologies 154 \n 155 \nGeneral procedure for t he preparation of 3-phenylcoumarins 1-3. A conveniently 156 \nsubstituted ortho-hydroxybenzaldehyde (7.34 mmol) and the corresponding 157 \nphenylacetic a cid (9.18 mmol) were dissolved in dimet hyl sulfoxide (15 mL). N,N\u2019- 158 \nDicyclohexylcarbodiimide (11.46 mmol) was added, and t he mixture was heated in an 159 \noil bath at 110 \u00baC for 24 h. After reaction, ice (100 mL) and acetic a cid (10 mL) were 160 \nadded to the mixture. The reaction was kept at room temperature for 2 h, and then 161 \nextracted with ether (3 x 25 mL).  The organic layer was washed with sodium 162 \nbicarbonate solution (50 mL, 5%) and then water (20 mL). The solvent was evaporated 163 \nunder vacuum, and the dry residue was purified by FC (hexane/ethyl acetate 9:1) to give 164 \nthe products 1 (mp 131-132 \u00baC)[37], 2 (mp 139-140 \u00baC)[38] or 3 (mp 98-99 \u00baC )[32,39] as 165 \nbeige powders, in yields of 70 %, 65% and 75%, respectively.  166 \n 167 \nSynthesis of 6-acetoxy-3-(4\u2019-methylphenyl)coumarin (4). Compound 4 was synt hesized 168 \nunder anhydrous conditions, using material previously dried at 60 \u00baC for at least 12 h 169 \nand at 300 \u00baC during few minutes immediately before use. A solution containing 170 \nanhydrous CH 3CO 2K (2.94 mmol), the 4-methylphenylacetic a cid derivative (1.67 171 \nmmol) and the 2,5-dihydroxybenzaldehyde (1.67 mmol), in Ac 2O (1.2 mL) was 172 \nprepared and refl uxed (138 \u00baC) for 16 h. The reaction mixture was cooled, ne utralized 173 \nwith 10% a queous NaHCO 3, and extracted (3 x 30 mL) with EtOAc. The organic layers 174 \n312were combined, was hed with distilled water, dried (anhydrous Na 2SO 4), and evaporated 175 \nunder reduced pressure. The product was purified by recrystallization in EtOH and 176 \ndried, to afford 4 as a beige powder .  177 \n 178 \nSynthesis of 3-(4\u2019-nitrophenyl)coumarins 5 and 6. To a dry 100-mL round bottomed 179 \nflask t he conveniently substituted ortho-hydroxybenzaldehyde (42.5 mmol), 4\u2019- 180 \nnitrophenylacetic a cid (42.5 mmol) and acetic anhydride (40.1 mL, 0.43 mol) were 181 \nadded. Then, sodium hydride (60% dispersion in mineral oil ) (42.5 mmol) was added in 182 \nsmall aliquots. After the dissolution of the reagents, an instantaneous (after 2 -5 minutes) 183 \nprecipitation process was observed. The reaction mixture was stirred for 20 h and then 7 184 \nmL of water were added . After the addition of 4 3 mL acetic a cid, the mixture was 185 \ncooled to 4 \u00baC for 4 h. The res ulting precipitate was filtered and was hed with cold 186 \nglacial acetic a cid. The acetic a cid was then removed as an azeotrope upon addition of 187 \n250 mL toluene and rotary evaporation to dryness . The process was repeated t hree 188 \ntimes. The final resid ue was dried under vacuum and purified by FC (hexane/ethyl 189 \nacetate 9:1) to give the products 5 (mp 100-101 \u00baC )[41] or 6 (mp 103-104 \u00baC )[42] as beige 190 \npowders, in yields of 61% and 64%, respectively. 191 \n 192 \nSynthesis of 6-hydroxy-3-phenylcoumarins 7 and 8. A solution of the 6- 193 \nmethoxy/acetoxy substituted 3-phenylcoumarin (3 or 4, 0.50 mmol) in acetic a cid (5 194 \nmL) and acetic anhydride (5 mL) at 0 \u00baC, was obtained . Hydriodic a cid 57% (10 mL) 195 \nwas then added dropwise . The mixture was stirred at 110 \u00baC for 5 h. The solvent was 196 \nevaporated under vacuum and the dry residue was purified by CH 3CN crystallization to 197 \ngive 7 or 8 (mp 214-215 \u00baC)[32] as beige powders, in yields of 55% and 61%, 198 \nrespectively.  199 \n 200 \nSynthesis of 3-(4\u2019-methylphenyl)-6-(2-oxopropoxy)coumarin (9). To a suspension of 201 \nanhydrous K2CO3 (0.25 mmol) and the 6-hydroxy-3-(4\u2019-methylphenyl)coumarin (8, 202 \n0.13 mmol), in anhydrous acetone (3 mL), chloroacetone (0.25 mmol) was added. The 203 \nsuspension was stirred, at refl ux temperature, for 16 h. The mixture was cooled, and the 204 \nprecipitate was recovered by filtration and was hed with anhydrous acetone (3 x 40 mL). 205 \nThe solvent was evaporated under vacuum, and the dry resid ue was purified by FC 206 \n(hexane/ethyl acetate 85:15) to give compound 9 (mp 128-129 \u00baC )[32] as a beige powder, 207 \nin a yield of 74 %. 208 \n 209 \nBiological assays 210 \n 211 \nThe adenosine binding affinity of compounds 1-9 for the human AR subtypes hA1, 212 \nhA2A, hA2B and hA 3, expressed in Chinese Hamster Ovary (CHO) cells, was determined 213 \nin radioligand competition experiments.[44-47] In the binding affinity assay, it is 214 \nmeasured the competition of ligands for spe cific binding of [3H]CCPA binding at hA 1 215 \nARs; specifi c binding of [3H]NECA binding at hA 2A ARs; and specifi c binding of 216 \n[3H]HEMADO at hA 3 ARs. The res ults were expressed as K i (dissociation constants ), 217 \nwhich were calculated with t he program SC TFIT, and given as geometric means of at 218 \n313least three experiments, including 95 % confidence intervals.[46] Due to the lack of a 219 \nsuitable radioligand for hA2B receptor in binding assay, t he potency of antagonists at 220 \nhA2B receptor was determined instead by in hibition of NECA- stimulated adenylyl 221 \ncyclase activity with increasing concentrations of antagonist .[44,45] As a result, cAMP 222 \n(cyclic adenosine monop hosphate) production was inhibited in a concentration- 223 \ndependent fashion, and IC 50 and K i values, respectively, were determined.   224 \n 225 \nADME properties 226 \n 227 \nThe preliminary data for an ADME profile analysis was calculated using the 228 \nMolinspiration property calculation program.[48] 229 \n 230 \nStatistical Analysis 231 \n 232 \nKi (dissociation constants ) values (Table 1) are reported as geometric means of three 233 \nindependent experiments with each tested concentration of compounds measured in 234 \nduplicates. Ki were calculated with t he program SC TFIT. As an interval estimate for t he 235 \ndissociation constants 95% confidence intervals are given in parentheses.  236 \n 237 \nResults 238 \n 239 \nStructural Identification 240 \n 241 \n6-Acetoxy-3-(4\u2019-methylphenyl)coumarin (4): Yield 61%. Mp 146-147 oC; 1H NMR \u03b4 242 \nppm (CDCl 3-300 MHz): 2.38 (3H, s, CH 3), 2.44 (3H, s, CH 3), 7.24-7.32 (4H, m, H-2\u2019, 243 \nH-3\u2019, H-5\u2019, H-6\u2019), 7.40 (1H, dd, J = 8 .7, 2.7 Hz, H-7), 7.63 (2H, d, J = 8 .6 Hz, H-5, H- 244 \n8), 7.77 (1H, s, H-4). 13C NMR \u03b4 ppm (CDCl 3-75 MHz): 21.1, 21.3, 117.4, 119.9, 245 \n120.2, 124.6, 128.4, 129.1, 129.2, 131.5, 138.4, 138.4, 139.2, 146.7, 150.9, 169.3. MS 246 \n(ESI): 295 (M+H+, 20), 294 (M+, 100). Anal. Calcd for C 18H14O4: C, 73.46; H, 4.79. 247 \nFound: C, 73.41; H, 4.74. 248 \n 249 \n6-Hydroxy-3-(3\u2019-methylphenyl)coumarin (7): Yield 55%. Mp 132-3 oC; 1H NMR \u03b4 250 \nppm (CDCl 3-300 MHz): 2.24 (3H, s, CH 3), 6.97-7.29 (4H, m, H-5, H-7, H-4\u2019, H-6\u2019), 251 \n7.31-7.33 (2H, m, H-2\u2019, H-5\u2019), 7.48 (1H, d, J = 8 .8 Hz, H-8), 8.11 (1H, s, H-4), 9.82 252 \n(1H, s, OH). 13C NMR \u03b4 ppm (CDCl 3-75 MHz): 25.2, 113.2, 117.4, 120.4, 126.6, 127.5, 253 \n128.7, 129.8, 130.2, 135.4, 138.0, 141.1, 147.0, 154.5, 160.6, 169.8. MS (ESI): 253 254 \n(M+H+, 15), 252 (M+, 100). Anal. Calcd for C 16H12O3: C, 76.18; H, 4.79. Found: C, 255 \n76.15; H, 4.76. 256 \n 257 \nBiological results 258 \n 259 \nThe data from radioligand binding e xperiments for compounds 1-9 is summarized in 260 \nTable 1. Details for pharmacological experiments were previo usly described in 261 \nmaterials and methods and in references 44-47. 262 \n314 263 \nTable 1 . Affinity (Ki) to bind human A1 and A 3 ARs expressed in CHO cells of 264 \ncoumarins 1-9, in radioligand binding assays . 265 \n 266 \n(Table 1) 267 \n 268 \nOne of the important requirements for a mole cule to be a good dr ug candidate is the 269 \nability to cross membranes. Also, associated with t his characteristic, a molecule must 270 \npossess t he appropriate ADME properties. To better understand the overall properties of 271 \nthe synthesized coumarins, preliminary data for an ADME profile analysis were carried 272 \nout. The lipophilicity, expressed as the octanol/water partition coeffi cient (represented 273 \nas logP), was calculated using the Molinspiration property calculation program (Table 274 \n2).[48] Therefore, a t heoretical prediction of ADME properties of all compounds was 275 \ncarried out and is described by different parameters (Table 2).[49,50] 276 \n 277 \nTable 2. Structural properties of t he coumarin derivatives 1-9.a  278 \n 279 \n(Table 2) 280 \n 281 \nDiscussion  282 \n 283 \nCompounds 1-9 were synthesized and tested for t heir in vitro binding affinity against 284 \nhuman AR subtypes hA1, hA2A, hA2B and hA 3, expressed in CHO cells. In the present 285 \ncommunication, st udies of t he effe ct on the binding affinity by the presence of different 286 \nsubstituents in the 3-arylcoumarin scaffold, at positions 3\u2019, 4\u2019 and 6, were performed.  287 \nSince the 3-arylcoumarin scaffold never been described as AR ligand, we were 288 \nencouraged to explore the ARs\u2019 binding activity of a selected series of derivatives. The 289 \nexperimental data s how that all th e 3-arylcoumarin derivatives have no detectable 290 \nbinding affinity to hA 2A and hA2B ARs (Ki > 30,000 \u2013 100,000 nM). Compound 1, the 291 \nnon-substituted 3-arylcoumarin, presents no binding affinity for any of the evaluated 292 \nreceptors (Ki > 30,000 nM). The introduction of electron donating gro ups in both 293 \nphenyl rings (methyl groups at positions 6 and 4\u2019) afforded compound 2, the most 294 \ninteresting compound of this series with a K i at the hA3 AR of 2,680 nM. The structural 295 \nmodification of coumarin 1 results in significant affinity and sele ctivity for hA 3 ARs. 296 \nThe interesting result found for compound 2 was inspiring for the development of new 297 \nhA3 AR selective ligands. The changing of the methyl group of the phenyl substituent 298 \nfor a strong electron withdrawing nitro gro up led to compound 5, which displays no 299 \nbinding affinity for any of AR subtypes. The presence of a nitro group at that position 300 \ndoesn' t seem to be compatible with receptor binding, as confirmed by the data obtained 301 \nwith compound 6. As the presence of a methyl group at position 4\u2019 seems to be 302 \nimportant for t he binding affinity, compou nds 4, 8 and 9 were synthesized and studied. 303 \nFor compound 8, with a hydroxyl group at position 6, a decrease in the selectivity was 304 \nobserved, although t he affinity data for both hA1 and hA3 ARs were interesting (Ki = 305 \n3157,900 and K i = 4,910 nM, respectively). Compound 4, with an acetoxy group in the 306 \nsame position of t he coumarin skeleton, is a selective compound, with good binding 307 \naffinity for t he hA3 AR (Ki = 7,280 nM). Finally, the presence of a 2 -oxopropoxy group 308 \n(compound 9) in the previously mentioned position of t he coumarin moiety led also to a 309 \nnoteworthy hA 3 AR ligand (K i = 4,680 nM).  310 \nTo complete the present st udy, the methyl group at 4\u2019 position (present in the best 311 \ncompound of the series -compound 2) was transposed to position 3\u2019 (compounds 3 and 312 \n7). In the case of compound 7, as previously described for compound 8, the presence of 313 \na hydroxyl group at position 6 has a strong influence on the selectivity and affinity 314 \ntowards hA1 and hA 3 ARs (Ki = 9,250 nM and K i = 14,600 nM, respectively). 315 \nCompound 3 with a methyl group at position 3\u2019 of the 3-aryl ring is a selective hA3 AR 316 \nligand (Ki = 5,050 nM), similar to the other non-hydroxylated 4\u2019-methyl derivatives. In 317 \nfact, the protection of the hydroxyl groups forming ether (compound 3) or ester 318 \n(compounds 4 and 9) derivatives results in an increase in hA3 selectivity. 319 \nFrom these preliminary results one can conclude that t he presence of the methyl group 320 \nin the aryl substituent will provide an important strategy to improve t he AR binding 321 \naffinity of coumarin-based ligands . In addition, chemical changes at position 6 are 322 \nimportant for mod ulating the selectivity of compounds against hA 1/hA3 or hA 3 ARs. 323 \nMoreover, due to the demonstrated importance of the 3-arylcoumarins as MAO 324 \ninhibitors, t hese AR ligands can be f urther developed to give improvements in bot h ARs 325 \nactivity and ARs vs MAO selectivity. Also, since A3 AR ligands are involved in 326 \nneurodegenerative diseases, t his study can be an encouragement for the development of 327 \nmultitarget drugs as AR ligands and M AO inhibitors. Compound 2, presenting t he 328 \nbetter hA3 affinity/selectivity of t his series, was previously described as M AO-B 329 \nselective inhibitor, with an IC 50 of 308 pM. This compound is one of the best MAO-B 330 \ninhibitors des cribed by our research group. This is an additional data to consider this 331 \ncompound an excellent candidate for f uture st udies in the field of neurodegenerative 332 \ndiseases . 333 \nFinally, analyzing the obtained theoretical res ults, it can be observed t hat no violations 334 \nof Lipinski\u2019s rule (molecular weight, logP, number of hydrogen donors and acceptors) 335 \nwere fo und for the des cribed coumarins. Also, TPSA, described to be a predictive 336 \nindicator of membrane penetration, is also fo und to be positive for t hese drug 337 \ncandidates. 338 \n 339 \nConclusions 340 \n 341 \nIn the current study, a series of 3-arylcoumarin derivatives were synt hesized and 342 \nevaluated as p utative adenosine receptor ligands. A detailed analysis of t he experimental 343 \nresults allows us to conclude that the affinity and/or selectivity of t he synthesized 344 \ncoumarins is influenced by the presence and the nature of t he substituents at positions 345 \n3\u2019, 4\u2019 and 6 of t he 3-arylcoumarin scaffold . The experimental data s how that neither the 346 \nsimple 3-arylcoumarin nor the 4\u2019 -nitro derivatives presented detectable binding affinity 347 \nfor the evaluated receptors. Although, most of the other substituted derivatives have 348 \ngood binding affinity profiles, especially against the hA1/hA3 or only hA 3 AR. In 349 \n316general, one can conclude t hat the presence of a met hyl gro up at positions 3\u2019 or 4\u2019 of t he 350 \n3-aryl ring is important for t he binding affinity. Fulfilling this condition, the presence of 351 \na methyl, methoxy, acetoxy or 2-oxopropoxy groups at position 6 of the scaffold, res ults 352 \nin a noticeable affinity and sele ctivity for hA3 AR. The presence of a hydroxyl group at 353 \nposition 6 gives rise to non-selective ligands binding to bot h hA1 and hA 3 ARs. This 354 \nstudy demonstrates t hat 3-arylcoumarin is an interesting s caffold for the design of novel 355 \nARs ligands. Accordingly, compound 2 (Ki hA3 AR = 2,680 nM), which is also a very 356 \ninteresting MAO-B selective inhibitor, can be considered t he lead for the design and 357 \nsynthesis of new hA3 AR coumarin-based selective ligands. This compound, as all 358 \ncompounds in this series, is in a ccordance wit h the Lipinski\u2019s rule. Therefore, the 359 \nversatility of t he synthetic routes and the substitution variability of these coumarins 360 \nallow proposing t hem as privileged multitarget scaffolds for drug discovery in the field 361 \nof neurodegenerative diseases . 362 \n 363 \nAcknow ledgement  364 \n 365 \nPartial financial support from Ministerio de Sanidad y Cons umo (PS09/00501), Xunta 366 \nde Galicia (PGIDIT09CSA030203PR) and Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia 367 \n(projects PTDC/QUI/70359/2006 and PTDC/QUI-QUI/113687/2009) is gratef ully 368 \nacknowledged . M .J. Matos (SFRH/BD/61262/2009), A. Gaspar 369 \n(SFRH/BD/43531/2008) and F. Borges (SFRH/BSAB/1090/2010) thank FCT grants. 370 \n 371 \nReferen ces and notes 372 \n 373 \n1. Fredholm et al. International Union of Pharmacology. XXV. Nomenclature and 374 \nclassifi cation of adenosine re ceptors. Pharm. Rev. 2001; 53: 527-552. 375 \n2. Klotz KN. Adenosine receptors and t heir ligands. Naunyn-Schmiedebergs  Arch. 376 \nPharmacol. 2000; 362: 382-391. 377 \n3. Baraldi PG et al. A(3) adenosine receptor ligands: history and perspe ctives. Med. 378 \nRes. Rev. 2000; 20: 103-128.  379 \n4. Kim Y et al.  Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine 380 \nderivatives as allosteri c modulators of the A3 adenosine receptor. J. Med. Chem. 381 \n2009; 52: 2098-2108. 382 \n5. Lopes LV et al. Adenosine and related dr ugs in brain diseases: present and f uture 383 \nin clinical trials.  Curr. Top. Med. Chem. 2011; 11: 1087-1101. 384 \n6. El-Tayeb A et al. Development of Polar Adenosine A2A Receptor Agonists for 385 \nInflammatory Bowel Disease: Synergism wit h A2B Antagonists . ACS Med. Chem. 386 \nLett. 2011; 2: 890-895. 387 \n7. Shah RH et al. Adenosine1 re ceptor antagonism: a new t herapeutic approach for 388 \nthe treatment of decompensated heart failure.  Cardiol. Rev. 2009; 17: 125-131. 389 \n8. Shook BC et al. Design and characterization of optimized adenosine A 2A/A1 390 \nreceptor antagonists for t he treatment of Parkinson' s disease. J. Med. Chem. 2012; 391 \n55: 1402-1417. 392 \n3179. Armentero T et al. Past, present and f uture of A(2A) adenosine receptor 393 \nantagonists in t he therapy of Parkinson' s disease. Pharmacol. Ther. 2011; 1 32: 394 \n280-299. 395 \n10. Stone TW et al. Adenosine receptors and ne urological disease: neuroprotection 396 \nand neurodegeneration. Handb. Exp. Pharmacol. 2009; 193: 535-587. 397 \n11. Luan F et al. Affinity prediction on A3 adenosine receptor antagonists: the 398 \nchemometric approa ch. Bioorg. Med. Chem. 2011; 19: 6853-6859. 399 \n12. Gessi S et al.  The A3 adenosine receptor: an enigmatic player in cell biology.  400 \nPharmacol. Ther. 2008; 117: 123-140. 401 \n13. Fishman, P et al. Pharmacological and therapeutic effe cts of A3 adenosine 402 \nreceptor agonists . Drug Discov. Today 2012; 17: 359-366. 403 \n14. Colotta V et al.  New 2 -arylpyrazolo[3,4-c]quinoline derivatives as potent and 404 \nselective human A3 adenosine receptor antagonists . Synthesis, pharmacological 405 \nevaluation, and ligand -receptor modeling st udies. J. Med. Chem. 2007; 50: 4061- 406 \n4074. 407 \n15. Mosti L et al. Q uinolinedione nucleus as a novel s caffold for A1 and A2 A 408 \nadenosine receptor antagonists . Med. Chem. Res. 2008; 17: 587-603. 409 \n16. Langmead CJ et al. Identification of novel adenosine A(2A) receptor antagonists 410 \nby virtual screening. J. Med. Chem. 2012; 55: 1904-1909. 411 \n17. Gaspar A et al. Discovery of novel A 3 adenosine receptor ligands based on 412 \nchromone scaffold. Bioch. Pharm. 2012; 84: 21-29.  413 \n18. Gaspar A et al. In search for new chemical entities as adenosine receptor ligands: 414 \ndevelopment of agents based on ben zo-\u03b3-pyrone skeleton. Eur. J. Med. Chem. 415 \n2012; 54: 914-918. 416 \n19. Borges F et al. Simple Coumarins: Privileged Scaffolds in Medi cinal Chemistry. 417 \nFront. Med. Chem. 2009; 4: 2 3-85.  418 \n20. Borges F et al. Simple coumarins and analogues in medicinal chemistry: 419 \noccurrence, synthesis and biologi cal activity. Curr. Med. Chem. 2005; 12: 887- 420 \n916. 421 \n21. Belluti F et al. Design, synthesis and anticancer activities of stilbene -coumarin 422 \nhybrid compounds: Identification of novel proapoptoti c agents.  Bioorg. Med. 423 \nChem. 2010; 18: 3 543-3550. 424 \n22. Roussaki M et al. A novel synthesis of 3-aryl coumarins and evaluation of their 425 \nantioxidant and lipoxygenase inhibitory activity. Bioorg. Med. Chem. Lett. 2010; 426 \n20: 3889-3892. 427 \n23. Neyts J et al . Structure-activity relationship of new anti-hepatitis C virus agents: 428 \nheterobicycle-coumarin conjugates . J. Med. Chem. 2009; 52: 1486-1490.  429 \n24. Kostova I. Coumarins as inhibitors of HIV reverse trans criptase. Curr. HIV Res. 430 \n2006; 4: 347-363.  431 \n25. Pisani L et al. Discovery of a novel class of potent coumarin monoamine o xidase 432 \nB inhibitors: development and biop harmacological profiling of 7 -[(3- 433 \nchlorobenzyl)oxy]-4-[(methylamino)-methyl] -2H-chromen-2-one 434 \nmethanes ulfonate (NW-1772) as a highly potent, selective, reversible, and orally 435 \nactive monoamine oxidase B inh ibitor. J. Med. Chem. 2009; 52: 6685-6706. 436 \n31826. Matos MJ et al. New halogenated phenylcoumarins as tyrosinase in hibitors. 437 \nBioorg. Med. Chem. Lett. 2011; 21: 3342-3345.  438 \n27. Vi\u00f1a D et al. 3-Substituted Coumarins as Dual Inhibitors of AChE and MAO for 439 \nthe Treatment of Alzheimer\u00b4s Disease . MedChemComm 2011; 3: 213\u2013218. 440 \n28. Matos MJ et al. A new series of 3-ph enylcoumarins as potent and sele ctive M AO- 441 \nB inhibitors. Bioorg. Med. Chem. Lett. 2009; 19: 3268-3270. 442 \n29. Matos MJ et al. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as 443 \npotent and selective M AO-B inhibitors. Bioorg. Med. Chem. Lett. 2009; 1 9: 5053- 444 \n5055. 445 \n30. Matos MJ et al. Halogenated 3-phenylco umarins as potent and sele ctive M AO-B 446 \ninhibitors. Bioorg. Med. Chem. Lett. 2010; 20: 5157-5160. 447 \n31. Delogu G et al. Synthesis, human monoamine oxidase inhibitory activity and 448 \nmolecular docking studies of 3-heteroarylcoumarin derivatives. Eur. J. Med. 449 \nChem. 2011; 49: 1147-1152. 450 \n32. Matos MJ et al. Synthesis and Study of a Series of 3-Arylcoumarins as Potent and 451 \nSelective Monoamine Oxidase B Inhibitors. J. Med. Chem. 2011; 54: 7127-7137. 452 \n33. Serra S et al. Hydroxycoumarins as sele ctive M AO-B inhibitors. Bioorg. Med. 453 \nChem. Lett. 2012; 22: 258-261. 454 \n34. Secci D et al. Synthesis and sele ctive human monoamine oxidase inhibition of 3- 455 \ncarbonyl, 3-acyl, and 3-carbox yhydrazido coumarin derivatives. Eur. J. Med. 456 \nChem. 2011; 46: 4846-52. 457 \n35. Chimenti F et al. Synt hesis, Molecular Modeling, and Sele ctive Inhibitory 458 \nActivity against Human Monoamine Oxidases of 3- Carboxamido -7-Substituted 459 \nCoumarins. J. Med. Chem. 2009; 52: 1935-1942. 460 \n36. Chimenti F et al.  Inhibition of monoamine o xidases by coumarin -3-acyl 461 \nderivatives: biological activity and computational study. Bioorg. Med. Chem. Lett. 462 \n2004; 14: 3697-3703. 463 \n37. Singer LA et al. Stereoselectivity in hydrogen atom transfer to equilibrated 464 \nisomeric vinyl radicals. J. Am. Chem. Soc. 1966; 88: 5213-5219. 465 \n38. Natarajan M et al . Synthesis of 3-arylco umarins, thiacoumarins and carbostyrils . 466 \nIndian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1984; 23: 529-534. 467 \n39. Piazzi L et al.  Extensive S AR and computational studies of 3-{4- 468 \n[(benzylmethylamino)methyl]phenyl} -6,7-dimethoxy-2H-2-chromenone 469 \n(AP223 8) derivatives. J. Med. Chem. 2007; 50: 4250-4254.  470 \n40. Kabeya L et al. Inhibition of horseradis h peroxidase catalytic a ctivity by new 3- 471 \nphenylcoumarin derivatives: Synt hesis and structure-activity relationships. 472 \nBioorg. Med. Chem. 2007; 15: 1516-1524. 473 \n41. Kremky E. Chromatographic method for the separation and identifi cation of some 474 \ncoumarin derivatives. Organika 1979; 159-163. 475 \n42. Ulrich H et al. Decarboxylation of \u03b1-nitrophenylcinnamic a cids. J. Org. Chem. 476 \n1966; 31: 4146-4149. 477 \n43. Girouard S et al. Synt hesis and characterization of dimaleimide fl uorogens 478 \ndesigned for specifi c labeling of proteins . J. Am.  Chem. Soc. 2005; 127: 559-566.  479 \n44. Klotz KN et al. Comparative pharmacology of human adenosine receptor 480 \n319subtypes - characterization of stably transfected receptors in CHO cells. N-S Arch. 481 \nPharmacol. 1997; 357: 1-9. 482 \n45. Klotz KN et al. [ 3H]HEMADO-a novel tritiated agonist selective for the human 483 \nadenosine A3 receptor. Eur. J. Pharmacol. 2007; 556: 14-18. 484 \n46. Cheng YC et al. Relationship between t he inhibition constant (K1) and the 485 \nconcentration of in hibitor which causes 50 per cent inhibition (I50) of an 486 \nenzymatic reaction. Biochem. Pharmacol. 1973; 22: 3099-3108. 487 \n47. De Lean A et al. Validation and statistical analysis of a computer modeling 488 \nmethod for quantitative analysis of radioligand binding data for mi xtures of 489 \npharmacological receptor subtypes.  Mol. Pharmacol. 1982; 21: 5-16. 490 \n48. M cheminformatics, Bratislava, Slovak Republic, 491 \nhttp://www.molinspiration.com/services/properties.html (2009).  492 \n49. Lipinski CA et al. Experimental and computational approa ches to estimate 493 \nsolubility and permeability in drug discovery and development settings . Adv. 494 \nDrug Deliv. Rev. 1997; 23 : 3-25. 495 \n50. Ertl P al. Fast calculation of molecular polar surfa ce area as a sum of fragment 496 \nbased contributions and its appli cation to the prediction of drug transport 497 \nproperties. J. Med. Chem. 2000; 43: 3714-3717. 498 \n499 \n320Table 1 500 \n 501 \nCompounds hA 1 hA 3 S electivity \n R R1 K i (nM) K i (nM) hA 1/hA 3 \n1 H H > 30,000 > 30,000 - \n2 CH3 4\u2019-CH 3 > 30,000 2,680 \n(1,440-5,010) > 11.2 \n3 OCH 3 3\u2019-CH 3 > 30,000 5,050 \n(3,670-7,000) > 5.9 \n4 OCOCH 3 4\u2019-CH 3 > 30,000 7,280 \n(4,130-12,800) > 4.1 \n5 CH3 4\u2019-NO 2 > 30,000 > 30,000 - \n6 OCH 3 4\u2019-NO 2 > 100,000 > 100,000 - \n7 OH 3\u2019-CH 3 9,250 \n(8,270-10,300) 14,600 \n(13,400-15,900) 0.6 \n8 OH 4\u2019-CH 3 7,900 \n(4,080-15,300) 4,910 \n(3,970-6,070 1.6 \n9 OCH 2COCH 3 4\u2019-CH 3 > 30,000 4,680 \n(3,870-5,660) > 6.4 \nThese results are average results of three experiments.  502 \n 503 \n504 \n321Table 2 505 \n  506 \nCompounds \nlogP Molecular \nweight \n(g/mol) TPSA \n(\u00c52) n-OH \nacceptors n-\nOHNH \ndonors Volume \n(\u00c53)  R      R 1 \n1 H H 3.74 222.24 30.211 2 0 200.00 \n2 CH3 4\u2019-CH 3 4.61 250.30 30.21 2 0 233.12 \n3 OCH 3 3\u2019-CH 3 4.19 2 66.30 39.44 3 0 242.10 \n4 OCOCH 3 4\u2019-CH 3 3.71 294.31 56.52 4 0 261.08 \n5 CH3 4\u2019-NO 2 4.12 281.27 76.03 5 0 239.89 \n6 OCH 3 4\u2019-NO 2 3.73 2 97.27 85.27 6 0 248.88 \n7 OH 3\u2019-CH 3 3.66 252.27 50.44 3 1 224.57 \n8 OH 4\u2019-CH 3 3.68 252.27 50.44 3 1 224.57 \n9 OCH 2COCH 3 4\u2019-CH 3 3.76 308.33 5 6.52 4 0 277.89 \na TPSA, topologi cal polar surfa ce area; n -OH, number of hydrogen bond acceptors; n - 507 \nOHNH, number of hydrogen bond donors. The data was determined wit h 508 \nMolinspiration calculation software .[45] 509 \n 510 \n511 \n322Graphical Abstract 512 \n 513 \nIn the present communication we report t he synt hesis, 514 \npharmacological eval uation, t heoretic al eval uation of 515 \nADME properties and S AR study of a  selected series of 3- 516 \narylcoumarins (compou nds 1-9). Adenosine re ceptors 517 \n(ARs) binding a ctivity and sele ctivity of t he synthesized 518 \ncompou nds 1-9 were eval uated in t his study. Most of t he 519 \nsubstitu ted derivatives have good binding affinity profiles, 520 \nespec ially against th e hA1/hA3 or only hA3 AR. The most 521 \nremarkable derivative is compou nd 2, presenting t he best 522 \naffinity for hA3 AR (Ki = 2,680 nM ) and signifi cant 523 \nselectivity for th is subtype.  524 \n 525 \n323Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a089 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a06. ConclusionesCumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a091 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n\u00fc\uf0fc Effective and versatile synthetic methodologies for the preparation of large \nseries of compounds were developed. The new compounds incorporate in a \nsingle structure the coumarin and stilbene cores , or the coumarin core and \ndifferent groups such as ester s, amides or carbamates. The  methodologies for \nthe synthesis of the coumarin and 3-arylcoumarin skeletons involved Perkin, \nmodified -Perkin and palladium-coupling reactions.  Modifications of these \nskeletons were carried out  using simple and safe methods , involving different \nreactions such as bromination, amination, reduction, etherification, acylation, \nhydrolysis, etc.. \n \u00fc\uf0fc All the compounds were obtained in good yields, with the desired degree of \npurity and in sufficient quantity for the biological and/or physicochemical tests.  \n \u00fc\uf0fc All the compounds were characterized by melting point, mass spectra, \n1H \nNMR, 13C NMR, DEPT and elemental analysis. IR and/or X-ray have further \ncharacterized some of the derivatives . \n \u00fc\uf0fc Many of the tested compounds showed a high degre e of potency and \nselectivity inhibiting in vitro the MAO-B isoform (IC\n50 in nano-picoMolar range), \nwithout modifying the enzymatic activity against MAO -A. In particular the 3-(3'-\nbromophenyl)-6-methylcoumarin proved to be more than 6000 times more active (IC\n50 = 134.04 pM) and over 200 times more selective than selegiline.  \n \u00fc\uf0fc Some of the derivatives have presented a  moderate inhibitory activity against  \nAChE. Others proved to be ligands of one or more of the four adenosine \nreceptors. Other derivatives have also shown activity against tyrosinase. \nParticularly the 3-amino -7-hydroxycoumarin proved to inhibit the tyrosine 8  \ntimes more than the  umbelliferone. Simple coumarins and 3 -nitro-substituted-\narylcoumarins presented antibacterial pr operties. In particular the 3 -(3'-\nmethylphenyl) -6-nitrocoumarin presented a MIC against S. aureus of 8 \u00b5g/mL. \nMany of the studied derivatives presented low oxidation potential , high ORAC-\nFL and an excellent ability to trap hydroxyl radicals. In particular, 3-(4'-\n327Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a092 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0hydroxyphenyl)-8-hydroxycoumarin presented an ORAC -FL value of 13.5 , in \naddition to  a low oxidation potential and 100% of hydroxyl radicals trapping.  \n \n\u00fc\uf0fc All these studies are the result of interesting collaborations with different \ngroups in different national and foreign uni versities. Without the joint effort these \nprojects would not be possible and the results presented in this report have not \nbeen achieved. The work is necessarily interdisciplinary.  \n \n \n \n \n   \n \n   \n \n   \n \n   \n \n  \n \n \n   \n328Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a093 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n7. Bibliograf\u00edaCumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a095 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0 \n                                            \n1 Somberg, J.C. The Evolving Drug Discovery Process, The Drug Discovery \nProcess: Increasing Efficiency and Cost Effectiveness. In: Wellington, P.G.; Lasagna, L.; Banakar, U.V.; Dekker, M. (Eds), New York, 1996. \n2 Pizzi, R. Salving with Science. The Pharmaceutical Century: Ten Decades of \nDrug Discovery Supplement to American Chemical Society, 2000. \n3 Tsinopoulos, C.; McCarthy, I. An Evolutionary Classification of the Strategies \nfor Drug Discovery. Manufacturing C omplexity Network Conference; \nCambridge, 2002. \n4 Rotella, D.P. ACS Med. Chem. Lett. 2012, 3, 172.  \n5 Lowe, D.B. ACS Med. Chem. Lett. 2012, 3, 3. \n6 Reitz, A.B. ACS Med. Chem. Lett. 2012, 3, 80.  \n7 Kontogiorgis, C.; Hadjipavlou-Litina, D. J. Enzyme Inhib. Med.  Chem. 2003, \n18, 63.  \n8 Ribeiro, C.; Kaplan, M. Quim. Nova 2002, 25, 533.  \n9 Murray, R.D.H. Nat. Prod. Rep. 1995, 12, 477.  \n10 Proen\u00e7a da Cunha A. Farmacognosia e Fitoqu\u00edmica. Lisboa: Funda\u00e7\u00e3o \nCaloust Gulbenkian; 2005.  \n11 Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. Front. Med. \nChem. 2009, 4, 23-85. \n12 Accame, M. Panorama Actual Med. 2000, 24, 432.  \n13 De Surya, K.; Richard, A. Synthesis 2005, 8, 1231.  \n14 Hoult, J.R.S.; Pay\u00e1, M. Gen. Pharmacol. 1996, 27, 713.  \n15 Santana, L.; Uriarte, E.; Roleira, F.; Milhazes, N.; Borges, F. Curr. Med. \nChem. 2004, 11, 3239.  \n16 Riveiro, M.E.; De Kimpe, N.; Moglioni, A.; V\u00e1zquez, R.; Monczor, F.; Shayo, \nC.; Davio, C. Curr. Med. Chem. 2010, 17, 1325.  \n17 Frizler, M.; Mertens, M.D.; G\u00fctschow, M. Bioorg. Med. Chem. Lett. 2012, 22, \n7715.  \n18 Campos-Toimil, M.; Orallo, F.; Santana, L.; Uriarte, E. Bioorg. Med. Chem.  \n2002, 12, 783.  \n19 Fr\u00e9d\u00e9rick, R.; Robert, S.; Charlier, C.; Ruyck, J.; Wouters, J.; Pirotte, B.; \nMasereel, B.; Pochet, L. J. Med. Chem. 2005, 48, 7592.  \n331Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a096 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n20 Manolov, I.; Dankev, N.D. Eur. J. Med. Chem. 1995, 30, 531.  \n21 Emanuel-Giota, A.A.; Fylaktakidou, K.C.; Hadjipavlou -Litina, D.J.; Litinas, \nK.E.; Nicolaides, D.N. J. Heterocycl. Chem. 2001, 38, 717.  \n22 Delgado, G.; Olivares, M.S.; Chavez, M.I.; Ramirez -Apan, T.; Linares, E.; \nBye, R.; Espinosa-Garcia, F.J. J. Nat. Prod. 2001, 64, 861.  \n23 Kaneko, T.; Baba, N.; Matsuo, M. Cytotechnology 2001, 35, 43.  \n24 Khode, S.; Maddi, V.; Aragade, P.; Palkar, M.; Ronad, P.K.; Mamledesai, S.; \nThippeswamy, A.H.M.; Satyanarayana, D. Eur. J. Med. Chem. 2009, 44, 1682.  \n25 Xiao, C.; Luo, X. -Y.; Li, D.-J.; Lu, H.; Liu, Z.-Q.; Song, Z.-G.; Jin, Y.-H. Eur. J. \nMed. Chem.  2012, 53, 159.  \n26 Kostova, I.; Bhatia, S.; Grigorov, P.; Balkansky, S.; Parmar, V.S.; Prasad, \nA.K.; Saso, L. Curr. Med. Chem. 2011, 18, 3929.  \n27 Fais, A.; Corda, M.; Era, B.; Fadda, M.; Matos, M.J.; Quezada, E.; Santana, \nL.; Picciau, C.; Podda, G.; Delogu, G. Molecules 2009, 14, 2514.  \n28 Masamoto, Y.; Murata, Y.; Baba, K.; Shimoishi, Y.; Tada, M.; Takahata, K. \nBiol. Pharm. Bull. 2004, 27, 422.  \n29 Xie, L.; Takeuchi, Y.; Cosentino, L.M.; Lee, K.H. J. Med. Chem. 1999, 42, \n2662.  \n30 De Clercq, E. Med. Res. Rev. 2000, 20, 323.  \n31 Bedoya, L.; Beltran, M.; Sancho, R.; Olmedo, D.A.; del Olmo, E.; Lopez -\nPerez, J.L.; San Feliciano, A. Bioorg. Med. Chem. Lett.  2005, 15, 4447.  \n32 Xie, L.; Yu, D.; Wild, C.; Allaway, G.; Turpin, J.; Smith, P.C.; Lee, K.  J. Med. \nChem. 2004, 47, 756.  \n33 Neyts, J.; De Clercq, E.; Singha, R.; Chang, Y.H.; Das, A.R.; Chakraborty, \nS.K.; Hong, S.C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J.R. J. Med. Chem.  2009, 52, \n1486.  \n34 Hwu, J.R.; Singha, R.; Hong, S.C.; Chang, Y.H.; Das, A.R.; Vliegen, I.; De \nClercq, E.; Neyts, J. Antiviral Res. 2008, 77 , 157.  \n35 Hwu, J.R.; Lin, S.-Y.; Tsay, S.-C.; De Clercq, E.; Leyssen, P.; Neyts, J. J. \nMed. Chem. 2011, 54, 2114.  \n36 Xie, L.; Takeuchi, Y.; Cosentino, L.M.; Lee, K. -H. J. Med. Chem. 1999, 42, \n2662.  \n332Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a097 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n37 Ganina, O.G.; Daras, E.; Bourgarel-Rey, V.; Peyrot, V.; Andresyuk, A.N.; \nFinet, J.-P.; Fedorov, A.Y.; Beletskaya, I.P.; Combes, S. Bioorg. Med. Chem. \nLett. 2008, 16, 8806.  \n38 Combes, S.; Barbier, P.; Douillard, S.; McLeer -Florin, A.; Bourgarel-Rey, V.; \nPierson, J.-T.; Fedorov, A.Y.; Finet, J.-P.; Boutonnat, J.; Peyrot, V. J. Med. \nChem. 2011, 54, 3153.  \n39 Zhao, H.; Donnelly, A.C.; Kusuma, B.R.; Brandt, G.E.L.; Brown, D.; Rajewski, \nR.A.; Vielhauer, G.; Holzbeierlein, J.; Cohen, M.S.; Blagg, B.S.J. J. Med. Chem. \n2011, 54, 3839.  \n40 Zhao, H.; Yan, B.; Peterson, L.B.; Blagg, B.S.J. ACS Med. Chem. Lett.  2012, \n3, 327.  \n41 Hooper, D.C.; Wolfson, J.S.; McHugh, G.L.; Winters, M.B.; Swartz, M.N. \nAntimicrob. Agents Chemother.  1982, 22, 662.  \n42 Bradbury, B.J.; Pucci, M.J. Curr. Opin. Pharmacol.  2008, 8, 574.  \n43 Debeljak, Z.; Skrbo, A.; Jasprica, I.; Mornar, A.; Plecko, V.; Banjanac, M.; \nMedic -Saric, M. J. Chem. Inf. Model. 2007, 47, 918.  \n44 Rachakonda, S.; Cartee, L. Curr. Med. Chem. 2004, 11, 775.  \n45 Periers, A.M. Tetrahedron Lett.  2000, 41, 867.  \n46 Sardari, S. Bioorg. Med. Chem. 1999, 7, 1933.  \n47 Li, B.; Pai, R.; Di, M.; Aiello, D.; Barnes, M.H.; Butler, M.M; Tashjian, T.F.; \nPeet, N.P.; Bowlin, T.L.; Moir, D.T. J. Med. Chem. 2012, 55, 10896.  \n48 (a) Patrick, L.; Ferroud, D.; Klich, M.; Dupuis-Hamelin, C.; Mauvais, P.; \nLassaigne,  P.; Bonnefoy, A.; Musicki, B. Bioorg. Med. Chem. Lett.  1999, 9, \n2079. (b) Nathan, C. Nature 2004, 431, 899. (c) Hoettecke, N.; Rotzoll, S.; \nAlbrecht, U.; Lalk, M; Fischer, C.; Langer, P. Bioorg. Med. Chem.  2008, 16, \n10319. (d) Shi, Y.; Zhou, C. Bioorg. Med. Chem. Lett. 2011, 21, 956.  \n49 Sabry, N.M.; Mohamed, H.M.; Khattab, E.S.A.E.H.; Motlaq, S.S.; El-Agrody, \nA.M. Eur. J. Med. Chem. 2011, 46, 765.  \n50 (a) Patel, D.; Kumari, P.; Patel, N. J. Chem. Pharm. Res. 2010, 2, 84. (b) \nPatel, D.; Kumari, P.; Patel, N. Arch. Appl. Sci. Res. 2010, 2, 68.  \n51 Daly, J.W.; Spande, T.F.; Garrafo, H.M. J. Nat. Prod. 2005, 68, 1556.  \n52 Patel, K.; Karthikeyan, C.; Moorthy, N.S.N.; Deora, .S.; Solomon, V.R.; Lee, \nH.; Trivedi, P. Med. Chem. Res. 2012, 21, 1780.  \n333Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a098 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n53 Jeyachandran, M.; Ramesh, P.; Sriram, D.; Senthilkumar, P.; Yogeeswari, P. \nBioorg. Med. Chem. Lett. 2012,  22, 4807.  \n54 Upadhyay, K.; Manvar, A.; Rawal, K.; Joshi, S.; Trivedi, J.; Chaniyara, R.; \nShah, A. Chem. Bio. Drug Des. 2012, 80, 1003. \n55 Orallo, F.; \u00c1lvarez, E.; Cami\u00f1a, M; Leiro, J.M.; G\u00f3mez, E.; Fern\u00e1ndez, P. Mol. \nPharmacol. 2002, 61, 294.  \n56 Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.; Poletto, G.; \nMazzorana, M.; Zagotto, G; Uriarte, E.; Guiotto, A.; Pinna, L.; Meggio, F.; Moro, \nS. J. Med. Chem. 2008, 51, 752.  \n57 Garino, C.; Tomita, T.; Pietrancosta, N.; Laras, Y.; Rosas, R.; Herbette, G.; \nMaigret, B.; Quelever, G.; Iwatsubo, T.; Kraus, J. J. Med. Chem. 2006, 49, \n4275.  \n58 Germer, S.; Hauer, H.; Koch, E.; Schoetz, K. WO2006002918, 2006. \n59 Zhou, X.; Wang, X.; Wang, T.; Kong, L.; Xiang, T. Bioorg. Med. Chem. 2008, \n16, 8011.  \n60 Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; \nRecanatini, M.; Andrisano, V.; Rampa, A. Bioorg. Med. Chem. Lett.  2008, 18, \n423.  \n61 Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; \nCarradori, S.; Y\u00e1nez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. J. Med. Chem. 2009, \n52, 1935.  \n62 Br\u00fchulmann, C.; Ooms, F.; Carrupt, P.A.; Testa, B.; Catto, M.; Leonetti, F.; \nAltomare, C.; Carotti, A. J. Med. Chem. 2001, 44, 3195.  \n63 Rendenbach-Muller, B.; Schlecker, R.; Traut, M.; Weifenbach, H. Bioorg. \nMed. Chem. Lett. 1994, 4, 1195.  \n64 Marchi, A.; Castilho, M.; Nascimento, P.; Archanjo, F.; Del Ponte, G.; Oliva, \nG.; Pupo, M. Bioorg. Med. Chem. 2004, 12, 4823.  \n65 Moskvina, V.S.; Khilya, V.P. Chem. Nat. Comp.  2008, 44, 16.  \n66 Singh, P.R.; Singh, De V.U.; Samant, S.D. Synlett 2004, 11, 1909.  \n67 Quezada, E.; Delogu, G.; Vi\u00f1a, D.; Santana, L.; Podda, G.; Matos, M.J.; \nPicciau, C. Helv. Chim. Acta 2009, 92, 1309.  \n68 Brady, W.T.; Shieh, C.H. J. Heterocycl. Chem. 1984, 21, 1337.  \n69 Sabitha, G.; Rao, A.V. Syn. Commun. 1987, 17, 341.  \n334Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a099 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n70 Roman, J.; Kozhkov, V.; Larock, R.C. J. Org. Chem . 2003, 68, 6314.  \n71 Eicher, T.; Schneider, V. Synthesis 1989, 5, 372.  \n72 Hans, N.; Singhi, M.; Sharma, V.; Grover, S.K. Indian J. Chem., Sect. B 1996, \n35B, 1159.  \n73 Phansalkar, M.; Deshmukh, K.; Kelkar, S.; Wadia, M. Indian J. Chem., Sect. \nB 1987, 26B, 562.  \n74 Mohanty, S.; Makrandi, J.K.; Grover, S.K. Indian J. Chem., Sect. B 1989, \n28B, 766.  \n75 Pankajkumar, R.S.; Devendrapratap, U.S.; Shriniwas, D.S. Synlett 2004, 11, \n1909.  \n76 Sethna, S.M.; Shah, N.M . Chem. Rev., 1945, 36, 1. \n77 Tuanli, Y.; Dawei, Y.; Larock, R.C. J. Org. Chem. 2005, 70, 9985.  \n78 Bogdal, D. J. Chem. Research (S) 1998, 468.  \n79 Hoz, A.; Moreno, A.; V\u00e1zquez, E. Synlett 1999, 5, 608.  \n80 Kidwai, M.; Kumar, P. J. Chem. Research (S) 1997, 178.  \n81 Bose, P.; Banerji, J. Indian J. Chem., Sect. B 1990, 29B, 422.  \n82 Chandrasekhar, S.; Karri, P. Tetrahedron Lett. 2006, 47, 2249.  \n83 Kasprzyk, H.; Kinastowski, S. React. Kinet. Catal. Lett.  2002, 77, 3. \n84 (a) Rosen, T. The Perkin Reaction. In Comprehensive Organic Synthesis, \nVolume 2 Additions to C-X \u03c0-Bonds, Part 2, 1st ed.; Trost, B.M., Fleming, I., \nHeathcock, C.H., (Eds), Pergamon Press: Oxford, 1991. (b) K\u00fcrti, L.; Czak\u00f3, B. \nStrategic Applications of named Reactions in Organic Synthesis \u2013 Background \nand Detailed Mechanisms. Hayhurst, J., Ed., Elsevier Inc.: Amsterdam, 2005. \n85 Leiro, J.; \u00c1lvarez, E.; Arranz, J.A.; Laguna, R.; Uriarte, E.; Orallo, F. J. \nLeukoc. Biol. 2004, 75, 1156.  \n86 Orsini, F.; Pelizzoni, F.; Verotta, L.; Aburjai, T. J. Nat. Prod. 1997, 60, 1082.  \n87 Orallo, F. Biological Effects of Cis- versus Trans-Resveratrol, in: Aggarwal, \nB.B.; Shishodia, S. (Eds), Resveratrol in Health and Disease , CRC Press, Boca \nRaton, USA, 2005. \n88 Yu, C.; Shin, Y.; Chow, A.; Li, Y.; Kosmeder, J.; Lee, Y.; Hirschelman, W.; \nPezzuto, J.; Mehta, R.; Breemen, R. Pharm. Res. 2002, 19, 1907.  \n89 Langcake, P.; Pryce, R.J. Physiol. Plant Pathol. 1976, 9, 77.  \n90 Siemann, E.H.; Creasy, L.L. Am. J. Enol. Vitic. 1992, 43, 49.  \n335Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a0100 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n91 Renaud, S.; De Lorgeril, M. Lancet 1992, 339, 1523.  \n92 Leger, A.S.; Cochrane, A.L.; Moore, F. Lancet 1979, 1, 1017.  \n93 Wenzel, E.; Soldo, T.; Erbersdobler, H.; Somoza, V. Mol. Butr. Food Res. \n2005, 49 , 482.  \n94 Andrus, M.; Liu. J. Tetrahedron Lett. 2006, 47, 5811.  \n95 Magrone, T.; Jirillo, E. Curr. Top. Med. Chem. 2011, 11, 1780.  \n96 Orsini, F.; Verotta, L.; Lecchi, M.; Restano, R.; Curia, G.; Redaelli, E.; Wanke, \nE. J. Nat. Prod. 2004, 67, 421.  \n97 Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A.; Lin, C.; Hamel, \nE. J. Med. Chem. 1991, 34, 2579.  \n98 Wang, Z.R.; Huang, Y.Z.; Zou, J.C.; Cao, K.J.; Xu, Y.N.; Wu, J.M. Int. J. Mol. \nMed.  2002, 9, 77.  \n99 Kovacic, P.; Somanathan, R. Oxid. Med. Cell. Longev. 2010, 3, 86.  \n100 Roberti, M.; Pizzirani, D.; Simoni, D.; Rondanin, R.; Baruchello, R.; Bonora, \nC.; Buscemi, F.; Grimaudo, S.; Tolomeo, M. J. Med. Chem. 2003, 46, 3546.  \n101 Y\u00e1nez, M.; Fraiz, N.; Cano, E.; Orallo, F. Biochem. Biophys. Res. Commun.  \n2006, 344, 688.  \n102 Rocha-Gonz\u00e1lez, H.I.; Ambriz-Tututi, M.; Granados-Soto, V. Neurosci. Ther. \n2008, 14, 234.  \n103 Torres-Lopez, J.E.; Ortiz, M.I.; Castaneda-Hernandez, G.; Alonso-Lopez, R.; \nAsomoza-Espinosa, R.; Grandos-Soto, V. Life Sci. 2002, 70, 1669.  \n104 Jang, D.S.; Kang, B.S.; Ryu, S.Y.; Chang, I.M.; Min, K.R.; Kim, Y. Biochem. \nPharmacol. 1999, 57, 705.  \n105 Qian, Y.-P.; Cai, Y.-J.; Fan, G.-J.; Wei, Q.-Y.; Yang, J.; Zheng, L.-F.; Li, X.-\nZ.; Fang, J.-G.; Zhou, B. J. Med. Chem. 2009, 52, 1963.  \n106 Fan, G. -J.; Liu, X.-D.; Qian, Y.-P.; Shang, Y.-J.; Li, X.-Z.; Fang, J.-G.; Jin, X.-\nL.; Zhou, B. Bioorg. Med. Chem.  2009, 17, 2360.   \n107 Rastija, V.; Medi\u0107-\u0160ari\u0107, M. Eur. J. Med. Chem. 2009, 44, 400.  \n108 Hoshino, J.; Park, E.-J.; Kondratyuk, T.P.; Marler, L.; Pezzuto, J.M.; van \nBreemen, R.B.; Mo, S.; Li, Y.; Cushman, M. J. Med. Chem. 2010, 53, 5033.  \n109 Androutsopoulos, V.P.; Ruparelia, K.C.; Papakyriakou, A.; Filippakis, H.; \nTsatsakis, A.M.; Spandidos, D.A. Eur. J. Med. Chem. 2011, 46, 2586.  \n336Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a0101 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n110 Zhang, W.; Sviripa, V.; Kril, L.M.; Chen, X.; Yu, T.; Shi, J.; Rychahou, P.; \nEvers, B.M.; Watt, D.S.; Liu, C. J. Med. Chem. 2011, 54, 1288.  \n111 Lu, J.; Li, C.; Chai, Y.F.; Yang, D.Y.; Sun, C.R. Bioorg. Med. Chem. Lett.  \n2012, 22, 5744.  \n112 Novick, P.A.; Lopes, D.H.; Branson, K.M.; Esteras-Chopo,  A.; Graef, I.A.; \nBitan, G.; Pande, V.S. J. Med. Chem.  2012,  55, 3002.  \n113 Vlok, N.; Malan, S.F.; Castagnoli Jr., N.; Bergh, J.J.; Petzer, J.P. Bioorg. \nMed. Chem.  2006, 14, 3512.  \n114 Van der Walt, E.M.; Milczek, E.M.; Malan, S.F.; Edmondson, D.E.; \nCastagnoli Jr., N.; Bergh, J.J.; Petzer, J.P. Bioorg. Med. Chem. Lett.  2009, 19, \n2509.  \n115 Cui, M.; Li, Z.; Tang, R.; Jia, H.; Liu, B. Eur. J. Med. Chem. 2011, 46, 2908.  \n116 Kung, H.F. ACS Med. Chem. Lett.  2012,  3, 265. \n117 Zhu, Y.; Xiao, K.; Ma, L.; Xiong, B.; Fu, Y.; Yu, H.; Wang, W.; Wang, X.; Hu, \nD.; Peng, H.; Li, J.; Gong, Q.; Chai, Q.; Tang, X.; Zang, H.; Li, J.; Shen, J. \nBioorg. Med. Chem.  2009, 17, 1600.   \n118 Scarpini, E.; Scheltens, P.; Feldman, H. Lancet Neurol.  2003, 2, 539.  \n119 Geldenhuys, W.J.; Van der Schyf, C.J. Curr. Med. Chem. 2013, 20, 1662.  \n120 Factor, S. Neurotherapeutics 2008, 5, 164.  \n121 Li, X.; Sundquist, J.; Hwang, H.; Sundquist. K. J. Neurol. 2008, 255, 31.  \n122 Petzer, J.; Castagnoli, N.; Schwarzschild, M.; Chen, J.; Van der Schyf, C. \nNeurotherap. 2009, 6, 141.  \n123 Allain, H.; Bentu\u00e9-Ferrer, D.; Akwa, Y. Prog. Neurobiol.  2008, 84, 25.  \n124 Voss, T.; Ravina, B. Curr. Neurol. Neurosci. Rep.  2008, 8, 304.  \n125 Nagatsu, T.; Sawada, M. Parkinsonism & Related Disorders  2009, 15, 53.  \n126 Catto, M.; Nicolotti, O.; Leonetti, F.; Carotti, A.; Favia, A.; Soto-Otero, R.; \nM\u00e9ndez -\u00c1lvarez, E.; Carotti, A. J. Med. Chem. 2006, 49, 4912.  \n127 Carotti, A.; Altomare, C.; Catto, M.; Gnerre, C.; Summo, L.; De Marco, A.; \nRose, S.; Jenner, P.; Testa, B. Chem. & Biod. 2006, 3, 134.  \n128 Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki -Ikola, O.; \nPalm, R. Neurology 2006, 66, 1200.  \n129 Guay, D.  Am. J. Geriatr. Pharmacother. 2006, 4, 330.  \n337Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a0102 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n130 Piazzi, L.; Cavalli, A.; Belluti, F.; Bisi, A.; Gobbi, S.; Rizzo, S.; Bartolini, M.; \nAndrisano, V.; Recanatini, M.; Rampa, A. J. Med. Chem. 2007, 50, 4250.  \n131 Youdim, M.B.H.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004, 111, 1455.  \n132 Weinstock, M. CNS Drugs 1999, 12, 307.  \n133 Orhan, I.E.; Orhan, G.; Gurkas, E. Mini -Rev . Med. Chem.  2011, 11, 836.  \n134 Cesura, A.M.; Pletscher, A. Prog. Drug Res. 1992, 38, 171.  \n135 Riederer, P.; Danielczyk, W.; Grunblatt, E. Neurotoxicology 2004, 25, 271.  \n136 Le\u00f3n, R.;  Marco-Contelles, J. Curr. Med. Chem. 2011, 18, 552.  \n137 Samadi, A.; R\u00edos, C.; Bolea, I.; Chioua, M.; Iriepa, I.; Moraleda, I.; Bartolini, \nM.; Andrisano, V.; G\u00e1lvez, E.; Valderas, C.; Unzeta, M.; Marco-Contelles, J. \nEur. J. Med. Chem. 2012, 52, 251 . \n138 Fern\u00e1ndez-Bachiller, M.I.; P\u00e9rez, C.; Monjas, L.; Rademann, J.; Rodr\u00edguez -\nFranco, M.I. J. Med. Chem. 2012, 55, 1303.  \n139 Huang, L.; Lu, C.; Sun, Y.; Mao, F.; Luo,Z.; Su, T.; Jiang, H.; Shan, W.; Li, X. \nJ. Med. Chem. 2012, 55, 8483.  \n140 Zheng, H.; Fridkin, M.; Youdim, M.B. Mini Rev. Med. Chem. 2012, 12, 364.  \n141 Zheng, H .; Amit, T.; Bar-Am, O.; Fridkin, M.; Youdim, M.B.; Mandel, S.A. J. \nAlzheimers Dis. 2012, 30, 1. \n142 Nagatsu, T. Neurotoxicology 2004, 25,11.  \n143 Binda, C.; Wang, J.; Pisano, L.; Caccia, C.; Carotti, A.; Salvati, P.; \nEdmondson, D.; Mattevi, A. J. Med. Chem. 2007, 50, 5848.  \n144 Dostert, P.; Strolin Benedetti, M.; Jafre, M. Monoamine Oxidase: Basic and \nClinical Frontiers; Kamijo, K.; Usdin, E.; Nagausu, T. (Eds), Excerpta Medica: \nAmsterdam, 1982. \n145 Singer, T.P.; Monoamine oxidases. In Chemistry and Biochemistry of \nFlavoenzymes (II). Muller , F., Ed.; CRC Press: London, 1991, pp 437 -470.  \n146 Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Graneses, A.; Befani, O.; \nTurini, P.; Alcaro, S.; Ortuso, F. Bioorg. Med. Chem. Lett. 2004, 14, 3697.  \n147 Grimsby, J.; Lan, N.C.; Neve, R.; Chen, K.; Shih, J.C.  J. Neurochem.  1990, \n55, 1166.  \n148 Petzer, J.P.; Castagnoli, N.J.; Schwarzschild, M.A.; Chen, J.F.; Van der \nSchyf, C.J. Neurotherapeutics 2009, 6, 141.  \n149 Ramsay, R. Curr. Top. Med. Chem. 2012, 12, 2189.  \n338Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a0103 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n150 Geha, R. M.; Rebrin, I.; Chen, K.; Shih, J.C. J. Biol. Chem. 2001, 276, 9877.  \n151 Johnston, J.P. Biochem. Pharmacol. 1968, 17, 1285.  \n152 De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. \nProc. Natl. Acad. Sci. U.S.A. 2005, 102, 12684.  \n153 Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A. \nNat. Struct. Biol. 2002, 9, 22.  \n154 Ma, J.; Yoshimura, M.; Yamashita, E.; Nakagawa, A.; Ito, A.; Tsukihara, T. J. \nMol. Biol. 2004, 338, 103.  \n155 Rudorfer, M.V.; Potter, V.Z. Drugs 1989, 37, 713.  \n156 Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A. \nProc. Natl. Acad. Sci. U.S.A. 2003, 100, 9750.  \n157 Yamada, M.; Yasuhara, H. Neurotoxicology 2004, 25, 11.  \n158 Harfenist, M.; Joyner, C.; Mize, P.; White, H. J. Med. Chem. 1994, 37, 2085.  \n159 Riederer, P.; Lachenmayer, L.; Laux, G. Curr. Med. Chem. 2004, 11, 2033.  \n160 Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B.H. Prog. Neurobiol.  2010, \n92, 330.  \n161 Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, \nBiochemistry 2009, 48, 4220.  \n162 Harfenist, H.; Heuseur, D.J.; Joyner, C.T.; Batchelor, J.F.; White, H.L. J. \nMed. Chem.  1996,  39, 1857.  \n163 Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.; Altomare, C.; \nCarotti, A.; Testa, B. J. Med. Chem. 2000, 43, 4747.  \n164 Leegwater -Kim, J.; Bortan, E. Clin. Interv. Aging 2010, 5, 149.  \n165 Youdim, M.B.; Collins, G.G.; Sandler, M.; Bevan, A.B.; Pare, C.M.; \nNicholson, W.J. Nature 1972, 236, 225.  \n166 Kadir, H.A.; Knowles, C.O. Gen. Pharmacol. 1981, 12, 239.  \n167 Rendenbach, B.; Weifenbach, H.; Teschendorf, H.J. Ger. Offen. (1990), DE \n3834861 A1 19900419.  \n168 Patil, P.O.; Bari, S.B.; Firke, S.D.; Deshmukh, P.K.; Donda, S.T.; Patil, D.A. \nBioorg. Med. Chem.  2013, 21, 2434.  \n169 Kong, L.D.; Tan, R.X.; Woo, A.Y. Cheng, C.H. Pharmacol. Toxicol. 2001, 88, \n75. \n339Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a0104 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n170 Carotti, A.; Carrieri, A.; Chimichi, S.; Boccalini, M.; Cosimelli, B.; Gnerre, C.; \nCarotti, A.; Carrupt, P.-A.; Testa, B. Bioorg. Med. Chem. Lett. 2002, 12, 3551.  \n171 Matos, M.J.; Vi\u00f1a, D.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L. Curr. \nTop. Med. Chem . 2012, 12, 2210.  \n172 Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, \nM.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; \nCarotti, A. J. Med. Chem. 2009, 52, 6685.  \n173 Rendenbach-M\u00fcller, B.; Bulrich, K.; Weifenbach, H. Eur. Pat. Appl. (1994), \nEP 594036 A1 19940427.  \n174 Ferino, G.; Vilar, S.; Matos, M.J.; Uriarte, E.; Cadoni, E. Curr. Top. Med. \nChem. 2012, 12, 2145.  \n175 Begala, M.; Delogu, G.; Maccioni, E.; Podda. G.; Tocco, G.; Quezada, E.; \nUriarte, E.; Fedrigo, M.A.; Favretto, D.; Traldi, P. Rapid Comm. Mass Spectr.  \n2001, 15, 1000.  \n176 Vilar, S.; Quezada, E.; Santana, L.; Uriarte, E.; Y\u00e1nez, M.; Fraiz, N.; Alcaide, \nC.; Cano, E.; Orallo, F. Bioorg. Med. Chem. Lett.  2006, 16, 257.  \n177 Vilar, S.; Quezada, E.; Alcaide, C.; Orallo, F.; Santana, L.; Uriarte, E. QSAR \nComb. Sci. 2007, 26, 317.  \n178 Santana, L.; Gonz\u00e1lez-D\u00edaz, H.; Quezada, E.; Uriarte, E.; Y\u00e1nez, M.; Vi\u00f1a, \nD.; Orallo, F. J. Med. Chem. 2008, 51, 6740.  \n179 Santana, L.; Uriarte, E.; Gonz\u00e1lez-D\u00edaz, H.; Zagotto, G.; Soto-Otero, R.; \nM\u00e9ndez -\u00c1lvarez, E. J. Med. Chem. 2006, 49, 1149.  \n180 Kamat, S.; D\u00b4Souza, A.; Paknikar, S.; Beauchamp, P. J. Chem. Research \n(S) 2002, 242.  \n181 Perkin, W.H. J. Chem. Soc. 1868, 21, 53.  \n182 Matos, M.J.; Vi\u00f1a, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E.  Bioorg. \nMed. Chem. Lett. 2009, 19, 5053.  \n183 Girouard, S.; Houle, M. -H.; Grandbois, A.; Keillor, J.W.; Michnick, S.W. J. \nAm. Chem. Soc. 2005, 127, 559.  \n184 Matos, M.J.; Vazquez-Rodriguez, S.; Borges, F.; Santana, L.; Uriarte, E. \nTetrahedron Lett. 2011, 52, 1225.  \n185 Hansen, J.B.; Bjerring, P. J. Med. Chem. 1985, 28, 1001.  \n186 Hoirie, T.; Tominaga, H. J. Med. Chem. 1991, 34, 2169.  \n340Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \t\r \u00a0105 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n187 Fraginals, R.; Schaeffer, M. J. Med. Chem., 1991, 34, 1024.  \n188 Wang, L.; Jing, H.; Bu, X.; Chang, T.; Jin, L.; Liang, Y. Cat. Comm. 2007, 8, \n80. \n189 Larock, R.C. Comprehensive Organic Transformations: A guide to \nFunctional Group Protection; Wiley-VCH: New York, 1997. \n190 Butler, A; Walker, J.V. Chem. Rev . 1993, 93, 1937.  \n191 Kajigaeshi, S.; Kakinami, T.; Okamoto, T.; Nakamura, H.; Fujikama, M. Bull. \nChem. Soc. Jpn. 1987, 60, 4187.  \n192 Bisarya, S.C.; Rao, R. Syn. Commun. 1993, 23, 779.  \n193 Konishi, H.; Aritomi, K.; Okano, T.; Kiji, J. Bull. Chem. Soc. Jpn. 1989, 62, \n591. \n194 Das, B.; Venkateswarlu, K.; Krishnaiah, M.; Holla, H. Tetrahedron Lett.  2006, \n47, 8693.  \n195 Sarma, J.; Nagaraju, A.; Majumdar, K.; Samuel, P.; Das, I.; Roy, S.; McGhie, \nA. J. Chem. Soc., Perkin Trans. 2 2000, 1119.  \n196 Xiao, S.; Yi, T.; Li, F.; Huang, C. Tetrahedron Lett . 2005, 46, 9009.  \n197 Xie, L.; Yu, D.; Wild, C.; Allaway, G.; Turpin, J.; Simth, P.C.; Lee, K. J. Med. \nChem. 2004, 47, 756.  \n198 Matos, M.J.; Delogu, G.; Podda, G.; Santana, L; Uriarte, E. Helvetica \nChimica Acta 2009, 92, 1309.  \n199 Matos, M.J.; Delogu, G.; Podda, G.; Santana, L.; Uriarte, E. Synthesis 2010 \n16, 2763.  \n200 Hartwig, J.F. Modern Arene Chemistry, Astruc, D. ; Ed.: Wiley-VCH: \nWeinheim, 2002, pp 107.  \n201 Netherton, M.R.; Fu, G.C. Org. Lett. 2001, 3, 4295.  \n202 Liu, X.; Barry, M.; Tsou, H. Tetrahedron Lett. 2007, 48, 8409.  \n203 Matos, M.J.; Gaspar, A.; Borges, F.; Uriarte, E.; Santana, L. Org. Prep. Proc. \nInter. 2012, 44, 522.  \n204 Dalla Via, L.; Uriarte, E.; Santana, L.; Magno, S.M.; Gia, O. ARKIVOC 2004, \n5, 131.  \n205 Matos, M.J.; Ter\u00e1n, C.; P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. \nJ. Med. Chem. 2011, 54, 7127.  \n341Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica  2013 \n \n \t\r \u00a0106 \t\r \u00a0\n\t\r \u00a0 \t\r \u00a0                                                                                                                                \n206 Matos, M.J.; Vi\u00f1a, D.; Quezada, E.; Picciau, C.; Delogu, G.; Orallo, F.; \nSantana, L.; Uriarte, E. Bioorg. Med. Chem. Lett. 2009, 19, 3268.  \n207 Matos, M.J.; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; Uriarte, E.  Bioorg. \nMed. Chem. Lett.  2010, 20, 5157.  \n208 Vi\u00f1a, D.; Matos, M.J.; Ferino, G.; Cadoni, E.; Laguna, R.; Borges, F.; Uriarte, \nE.; Santana, L. ChemMedChem  2012, 7, 464.  \n209 Janeiro, P.; Matos, M.J.; Santana, L.; Uriarte, E.; Oliveira-Brett, A.M. J. \nElectroanal. Chem.  2013, 689, 243.  \n210 Matos, M.J.; P\u00e9rez-Cruz, F.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, \nL.; Borges, F.; Olea -Azar, C. Bioorg. Med. Chem.  2013, in press \n211 Vi\u00f1a, D.; Matos, M.J.; Y\u00e1\u00f1ez, M.; Santana, L.; Uriarte, E. Med. Chem. \nCommun. 2012, 3, 213.  \n212 Matos, M.J.; Vilar, S.; Gonzalez-Franco, R.M.; Uriarte, E.; Santana, L.; \nFriedman, C.; Tatonetti, N.P.; Vi\u00f1a, D.; Fontenla, J.A. Eur. J. Med. Chem. 2013, \n63, 151 . \n213 Matos, M.J.; Gaspar, A.; Kachler, S.; Klotz, K.-N.; Borges, F.; Santana, L.; \nUriarte, E. J. Pharm. Pharmac. 2012, 65, 30.  \n214 Matos, M.J.; Vazquez-Rodriguez, S.; Santana, L.; Uriarte, E.; Fuentes-Edfuf, \nC.; Santos Y.; Mu\u00f1oz-Crego, A. Med. Chem.  2012, 8, 1140.  \n215 Matos, M.J.; Vazquez-Rodriguez, S.; Santana, L.; Uriarte, E.; Fuentes-Edfuf, \nC.; Santos, Y.; Mu\u00f1oz-Crego, A. Molecules 2013, 18, 1394.  \n216 Matos, M.J.; Santana, L.; Uriarte, E.; Serra, S.; Corda, M.; Fadda, M.B.; Era, \nB.; Fais, A. J. Pharm. Pharmacol. 2012, 64, 742.  \n217 Matos, M.J.; Santana, L.; Uriarte, E.; Delogu, G.; Corda, M.; Fadda, M.B.; \nEra, B.; Fais, A. Bioorg. Med. Chem. Lett.  2011, 21, 3342.  \n218 Schr\u00f6dinger Suite, in, Schr\u00f6dinger, LLC, New York, NY, USA.  \n219 Matos, M.J.; Uriarte, E.; Santana, L.; Vilar, S. J. Mol. Struct. 2013, 1041, \n144. \n \n342", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}